<SEC-DOCUMENT>0001739940-26-000043.txt : 20260430
<SEC-HEADER>0001739940-26-000043.hdr.sgml : 20260430
<ACCEPTANCE-DATETIME>20260430114707
ACCESSION NUMBER:		0001739940-26-000043
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		113
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260430
DATE AS OF CHANGE:		20260430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cigna Group
		CENTRAL INDEX KEY:			0001739940
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		ORGANIZATION NAME:           	02 Finance
		EIN:				824991898
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38769
		FILM NUMBER:		26921753

	BUSINESS ADDRESS:	
		STREET 1:		900 COTTAGE GROVE ROAD
		CITY:			BLOOMFIELD
		STATE:			CT
		ZIP:			06002
		BUSINESS PHONE:		8602266000

	MAIL ADDRESS:	
		STREET 1:		900 COTTAGE GROVE ROAD
		CITY:			BLOOMFIELD
		STATE:			CT
		ZIP:			06002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cigna Corp
		DATE OF NAME CHANGE:	20181221

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Halfmoon Parent, Inc.
		DATE OF NAME CHANGE:	20180508
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ci-20260331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c9afa-b9b6-7bff-8807-e603b8e89aeb,g:b1b37cb4-a013-41e0-9774-54a06c55ff7f,d:9262e6da8fb24f8e98f20abd6e5292a7-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ci="http://www.thecignagroup.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ci-20260331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-2">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-3">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-4">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-5">0001739940</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" scale="0" id="f-322">2</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="ci:AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid" id="f-323"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="ci:AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid" id="f-324"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="INF" name="ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding" format="ixt:fixed-zero" scale="6" id="f-325">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="INF" name="ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding" format="ixt:fixed-zero" scale="6" id="f-326">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="INF" name="ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted" format="ixt:fixed-zero" scale="6" id="f-327">&#8212;</ix:nonFraction><ix:nonNumeric contextRef="c-52" name="us-gaap:DebtInstrumentMaturityDate" id="f-328">2030-04-30</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-329">3</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-54" xsi:nil="true" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" id="f-330"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="us-gaap:DerivativeGainLossOnDerivativeNet" id="f-331"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:DerivativeGainLossOnDerivativeNet" id="f-332"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" id="f-333"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" id="f-334"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" id="f-335"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" id="f-336"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-55" xsi:nil="true" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" id="f-337"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-56" xsi:nil="true" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" id="f-338"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="ci:ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue" id="f-339"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="ci:ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue" id="f-340"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" id="f-341"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" id="f-342"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" id="f-343"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" id="f-344"></ix:nonFraction><ix:nonNumeric contextRef="c-57" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-345">448</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:fixed-zero" scale="0" id="f-346">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-347">124,732</ix:nonFraction><ix:nonNumeric contextRef="c-8" name="us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-378">http://fasb.org/us-gaap/2025#AccountsPayableCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-9" name="us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" id="f-379">http://fasb.org/us-gaap/2025#AccountsPayableCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-9" name="us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-380">http://fasb.org/us-gaap/2025#AccountsPayableCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-8" name="us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" id="f-381">http://fasb.org/us-gaap/2025#AccountsPayableCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" id="f-979">http://fasb.org/us-gaap/2025#NetInvestmentIncome http://www.thecignagroup.com/20260331#NetInvestmentGainLoss</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" id="f-980">http://fasb.org/us-gaap/2025#NetInvestmentIncome http://www.thecignagroup.com/20260331#NetInvestmentGainLoss</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList" id="f-981">http://www.thecignagroup.com/20260331#OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ci-20260331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ci:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="reinsurer"><xbrli:measure>ci:reinsurer</xbrli:measure></xbrli:unit><xbrli:unit id="position"><xbrli:measure>ci:position</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ci:OperatingResultsOfCertainNonstrategicBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceRelatedAssessmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ci:DavidCordaniMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ci:DavidCordaniMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">ci:TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ci:DavidCordaniMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">ci:TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DividendsAxis">ci:R2026Q2DividendsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-22</xbrli:startDate><xbrli:endDate>2026-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2026125Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2026125Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:AllSegmentsExcludingCignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:AllSegmentsExcludingCignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:AllSegmentsExcludingCignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:CompletionFactorsAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:CompletionFactorsAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:MedicalCostTrendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:MedicalCostTrendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LifeAndAnnuityInsuranceProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LifeAndAnnuityInsuranceProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">ci:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">ci:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ReinsurerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskSecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ci:CededCreditCollateralizationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:InvestmentGradeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:InvestmentGradeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:BelowInvestmentGradeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:BelowInvestmentGradeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociLiabilityForFuturePolicyBenefitParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociLiabilityForFuturePolicyBenefitParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ci:EmployeeSeveranceAndOtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ci:EmployeeSeveranceAndOtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ci:EmployeeSeveranceAndOtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ci:AssetImpairmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:RetirementAndLifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:RetirementAndLifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:NetworkPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:NetworkPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:HomeDeliveryAndSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:HomeDeliveryAndSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:EmployerInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:EmployerInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:StopLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:StopLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:IndividualAndFamilyPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:IndividualAndFamilyPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:InternationalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:InternationalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:GuaranteeObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:GuaranteeObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ci:DavidCordaniMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">ci:TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ci:DavidCordaniMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">ci:TradingArrangementStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-144 f-145" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-318 f-319 f-320 f-321" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/></ix:resources></ix:header></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1126"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span id="id873c8c4382242f3904c068faef8b2ac_2184"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><img src="ci-20260331_g1.jpg" alt="cignagroup_logo_color_pos_rgb_600ppi.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:112px" id="i-1"/></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">FORM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-6">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-7">&#9746;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-8">March&#160;31, 2026</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-9">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the transition period from _____ to _____</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-10">001-38769</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-11">The Cigna Group</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-12">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-13">82-4991898</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-14">900 Cottage Grove Road</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-15">Bloomfield</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-16">Connecticut</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-17">06002</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-18">860</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-19">226-6000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Not Applicable</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-20">Common Stock, Par Value $0.01</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-21">CI</ix:nonNumeric></span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">New York Stock Exchange</ix:nonNumeric>, Inc.</span></div></td></tr></table></div><div style="margin-bottom:10pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-23">Yes</ix:nonNumeric> &#9744; No</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-24">Yes</ix:nonNumeric> &#9744; No</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.951%"><tr><td style="width:1.0%"/><td style="width:37.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-25">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-26">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-27">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#9744; </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#9744; Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9746;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">No</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of April&#160;24, 2026, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-29">264,532,404</ix:nonFraction> shares of the issuer's Common Stock were outstanding.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1129"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span id="i39f73b35fc0f41548dca30fcea73b9b2_83"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">THE CIGNA GROUP</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.305%"><tr><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1132">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1132">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1135">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1135">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_307">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_307">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_310">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_310">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_313">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_313">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_316">Consolidated Statements of Changes in Total Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_316">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_325">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_325">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_337">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_337">8</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1138">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1138">27</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1141">Quantitative and Qualitative Disclosures </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1141">A</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1141">bout Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1141">40</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1144">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1144">40</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1147">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1147">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1150">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1150">41</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1153">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1153">41</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1156">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1156">41</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1159">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1159">41</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1162">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1162">42</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1165">SIGNATURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_1165">43</a></span></div></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As used herein, the term "Company" refers to one or more of The Cigna Group and its consolidated subsidiaries.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1132"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span id="ie3543d30ffa3481195764a49788008e7_33"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Part I. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FINANCIAL INFORMATION</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1135"></div><div><span id="ibaeba14035244a4eab79c1de9f9715ce_32"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">FINANCIAL STATEMENTS</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_307"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.955%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.096%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="i5aef62a17a56464aa301ada0ffeea05e_0-0-1-10-1517267"></span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">The Cigna Group</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Income</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unaudited</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-30">54,037</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-31">48,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-32">9,812</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-33">12,736</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Fees and other revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-34">4,443</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-35">3,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-36">202</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-37">238</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL REVENUES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-38">68,494</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-39">65,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Benefits and expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-40">54,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-41">48,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs and other benefit expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="f-42">7,924</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="f-43">10,498</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-44">3,722</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-45">4,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-46">390</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-47">422</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL BENEFITS AND EXPENSES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-48">66,136</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-49">63,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income from operations</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-50">2,358</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-51">1,971</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-52">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-53">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of businesses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-54">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-55">41</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment gains (losses)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:NetInvestmentGainLoss" scale="6" id="f-56">258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:NetInvestmentGainLoss" scale="6" id="f-57">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income before income taxes</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-58">2,270</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-59">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL INCOME TAXES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-60">409</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-61">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net income</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-62">1,861</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-63">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-64">207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-65">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">SHAREHOLDERS' NET INCOME</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-66">1,654</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-67">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income per share</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-68">6.30</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-69">4.88</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-70">6.26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-71">4.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_310"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.679%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="i3078e62632cf46b784c75a8fad61f7db_0-0-1-5-1517267"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">The Cigna Group<br/>Consolidated Statements of Comprehensive Income</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unaudited</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-72">1,861</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-73">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized depreciation on securities and derivatives</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" scale="6" id="f-74">129</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" scale="6" id="f-75">100</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net long-duration insurance and contractholder liabilities measurement adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" scale="6" id="f-76">635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" scale="6" id="f-77">168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net translation (depreciation) appreciation on foreign currencies</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" scale="6" id="f-78">35</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" scale="6" id="f-79">13</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement benefits liability adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-80">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-81">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-82">792</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-83">249</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-84">1,069</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-85">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net income attributable to other noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="f-86">207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="f-87">86</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">SHAREHOLDERS' COMPREHENSIVE INCOME</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-88">862</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-89">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_313"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="i03ea40c29cdc4751901fce733e707812_0-0-1-4-1517267"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">The Cigna Group<br/>Consolidated Balance Sheets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unaudited</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of <br/>December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-90">7,040</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-91">7,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-92">812</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-93">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-94">26,607</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-95">28,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-96">5,831</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-97">7,338</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-98">2,742</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-99">2,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-100">43,032</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-101">47,814</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-102">18,902</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-103">18,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance recoverables</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:ReinsuranceRecoverablesNonCurrent" format="ixt:num-dot-decimal" scale="6" id="f-104">4,073</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:ReinsuranceRecoverablesNonCurrent" format="ixt:num-dot-decimal" scale="6" id="f-105">4,103</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-106">3,704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-107">3,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-108">45,534</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-109">44,924</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-110">27,318</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-111">28,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-112">3,253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-113">2,885</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Separate account assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:SeparateAccountAssetAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-114">7,450</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:SeparateAccountAssetAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-115">7,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-116">153,266</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-117">157,919</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current insurance and contractholder liabilities</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-118">6,455</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-119">5,710</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:PharmacyAndServiceCostsPayable" format="ixt:num-dot-decimal" scale="6" id="f-120">25,763</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:PharmacyAndServiceCostsPayable" format="ixt:num-dot-decimal" scale="6" id="f-121">30,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-122">9,879</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-123">10,659</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:AccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-124">8,980</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:AccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-125">9,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-126">1,529</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:DebtCurrent" scale="6" id="f-127">592</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-128">52,606</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-129">56,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-current insurance and contractholder liabilities</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-130">9,777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-131">9,938</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-132">6,851</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-133">7,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-134">4,769</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-135">4,238</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-136">29,371</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-137">30,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Separate account liabilities</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:SeparateAccountsLiability" format="ixt:num-dot-decimal" scale="6" id="f-138">7,450</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:SeparateAccountsLiability" format="ixt:num-dot-decimal" scale="6" id="f-139">7,511</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-140">110,824</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-141">116,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Contingencies &#8212; Note 14</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-8" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-142"></ix:nonFraction></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-9" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-143"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-144">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-145">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-146">31,914</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-147">31,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-148">3,598</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-149">2,806</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-150">49,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-151">47,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Treasury stock, at cost</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-152">35,216</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-153">35,140</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-154">42,210</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-155">41,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-156">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-157">161</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-158">42,442</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-159">41,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-160">153,266</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-161">157,919</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Par value per share, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-162"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-163">0.01</ix:nonFraction></ix:nonFraction>; shares issued, <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-164">406</ix:nonFraction>&#160;million as of March&#160;31, 2026 and <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-165">405</ix:nonFraction> million as of December&#160;31, 2025; authorized shares, <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-166"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-167">600</ix:nonFraction></ix:nonFraction> million.</span></ix:footnote></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_316"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:115%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="if4d2a29e199542308c55e92df7449577_0-0-1-10-1517267"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">The Cigna Group</span></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Changes in Total Equity</span></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unaudited</span></td></tr><tr><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Shareholders'<br/>Equity</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-168">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-169">31,790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-170">2,806</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-171">47,865</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-172">35,140</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-173">41,713</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-174">161</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-175">41,874</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Effects of issuing stock for employee benefit plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-176">127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-177">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-178">51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-179">51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-180">792</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-181">792</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-182">792</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-183">1,654</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-184">1,654</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="f-185">207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-186">1,861</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Common dividends declared (per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-187">1.56</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-188">413</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-189">413</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-190">413</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-191">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-192">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-193">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-194">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Other transactions impacting noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-195">3</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-196">3</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-197">136</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-198">139</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at March 31, 2026</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-199">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-200">31,914</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-201">3,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-202">49,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-203">35,216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-204">42,210</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-205">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-206">42,442</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="27" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Shareholders'<br/>Equity</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-207">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-208">31,288</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-209">2,341</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-210">43,519</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-211">31,437</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-212">41,033</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-213">210</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-214">41,243</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Effect of issuing stock for employee benefit plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-215">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-216">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-217">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-218">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-219">249</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-220">249</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-221">249</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-222">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-223">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="f-224">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-225">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Common dividends declared (per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-226">1.51</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-227">408</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-228">408</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-229">408</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-231">1,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-232">1,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-233">1,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Other transactions impacting noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="ci:NoncontrollingInterestOtherChanges" format="ixt:fixed-zero" scale="6" id="f-234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="ci:NoncontrollingInterestOtherChanges" format="ixt:fixed-zero" scale="6" id="f-235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-236">108</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-237">108</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at March 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-238">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-239">31,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-240">2,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-241">44,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-242">33,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-243">40,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-244">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-245">40,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_325"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div><span id="i5584f4d639754b5fa99db6ec0c6e0adc_166"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">The Cigna Group</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Consolidated Statements of Cash Flows</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.430%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unaudited</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-246">1,861</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-247">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-248">650</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-249">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Investment (gains) losses, net</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:NetInvestmentGainLoss" scale="6" id="f-250">258</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:NetInvestmentGainLoss" scale="6" id="f-251">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income tax benefit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="f-252">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="f-253">216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of businesses</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-254">11</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-255">41</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net changes in assets and liabilities, net of non-operating effects:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-256">2,152</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-257">2,205</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="f-258">1,507</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="f-259">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance recoverable and Other assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInReinsuranceRecoverable" scale="6" id="f-260">104</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IncreaseDecreaseInReinsuranceRecoverable" scale="6" id="f-261">219</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Insurance liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" scale="6" id="f-262">739</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-263">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs payable</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable" format="ixt:num-dot-decimal" scale="6" id="f-264">4,570</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable" scale="6" id="f-265">135</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and Accrued expenses and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" scale="6" id="f-266">988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-267">1,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-268">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-269">260</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">NET CASH PROVIDED BY OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-270">1,131</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-271">1,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Proceeds from investments sold:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities and equity securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:ProceedsFromSaleOfDebtAndEquitySecurities" scale="6" id="f-272">54</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:ProceedsFromSaleOfDebtAndEquitySecurities" scale="6" id="f-273">94</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Investment maturities and repayments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities and equity securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" scale="6" id="f-274">185</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" scale="6" id="f-275">222</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromCollectionOfLoansReceivable" scale="6" id="f-276">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ProceedsFromCollectionOfLoansReceivable" scale="6" id="f-277">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other sales, maturities and repayments (primarily short-term and other long-term investments)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="f-278">426</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="f-279">331</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Investments purchased or originated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities and equity securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:PaymentsToAcquireDebtAndEquitySecurities" scale="6" id="f-280">362</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:PaymentsToAcquireDebtAndEquitySecurities" scale="6" id="f-281">952</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireMortgageNotesReceivable" scale="6" id="f-282">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PaymentsToAcquireMortgageNotesReceivable" scale="6" id="f-283">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other (primarily short-term and other long-term investments)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="f-284">557</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="f-285">475</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment purchases, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:PaymentsForProceedsFromPropertyPlantAndEquipment" scale="6" id="f-286">267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:PaymentsForProceedsFromPropertyPlantAndEquipment" scale="6" id="f-287">327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Divestitures, net of cash sold</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="f-288">20</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:num-dot-decimal" scale="6" id="f-289">2,346</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Renewable energy tax credit equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="f-290">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="f-291">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-292">5</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-293">1</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-294">637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-295">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Deposits and interest credited to contractholder deposit funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdditionsToContractHoldersFunds" scale="6" id="f-296">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AdditionsToContractHoldersFunds" scale="6" id="f-297">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Withdrawals and benefit payments from contractholder deposit funds</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:WithdrawalFromContractHoldersFunds" scale="6" id="f-298">99</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:WithdrawalFromContractHoldersFunds" scale="6" id="f-299">64</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net change in short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:ProceedsFromRepaymentsOfOtherShortTermDebt" scale="6" id="f-300">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:ProceedsFromRepaymentsOfOtherShortTermDebt" scale="6" id="f-301">891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-302">550</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-303">700</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-304">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-305">1,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-306">57</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-307">69</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Common stock dividend paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-308">417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-309">412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-310">158</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-311">211</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">NET CASH USED IN FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-312">1,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-313">3,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Effect of foreign currency rate changes on cash, cash equivalents and restricted cash </span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-314">9</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-315">9</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-316">656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-317">555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash January 1,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-318">7,736</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-319">8,931</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash March 31, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-320">7,080</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-321">8,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Restricted cash and cash equivalents were reported in other long-term investments and Other assets.</span></ix:footnote></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_337"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">THE CIGNA GROUP</span></div><div style="margin-bottom:10pt;text-align:center"><span id="i3c4cf6f19fc440de8c603751b97371e7_57"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) </span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:20pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.277%"><tr><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.030%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Note Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Footnote</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">B</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">USINESS AND</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">APITAL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"> S</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">TRUCTURE</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_352">Description of Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_352">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_355">Summary of Significant Accounting Policies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_355">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_385">Accounts Receivable, Net</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_385">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_412">Supplier Finance Program</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_412">11</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_478">Earnings Per Share</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_478">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_502">Debt</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_502">11</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">NSURANCE</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"> I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">NFORMATION</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_6055">Insurance and Contractholder Liabilities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_6055">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_640">Reinsurance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_640">14</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">NVESTMENTS</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_664">Investments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_664">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_772">Fair Value Measurements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_772">18</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_844">Accumulated Other Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_844">21</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">W</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">ORKFORCE</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"> M</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">ANAGEMENT AND</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"> C</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">OMPENSATION</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_847">Strategic Optimization Program</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_847">22</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">OMPLIANCE</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">, R</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">EGULATION AND</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"> C</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">ONTINGENCIES</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_880">Income Taxes</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_880">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_913">Contingencies and Other Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_913">22</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">R</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">ESULTS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"> D</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">ETAILS</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_928">Segment Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9262e6da8fb24f8e98f20abd6e5292a7_928">23</a></span></div></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_352"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-348" escape="true"><div style="margin-bottom:10pt"><span id="ib641022b45dc4b2381a2a2ff76bff34d_3012"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8211; Description of Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Powered by our dedicated people and valued brands, we advance our mission to improve the health and vitality of those we serve. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. The majority of these products and services are offered through employers and other entities, such as governmental and nongovernmental organizations, unions and associations. Certain subsidiaries also offer health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A full description of our segments follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Evernorth Health Services</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services, such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cigna Healthcare</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:700;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as for individual and family plan customers. International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare also included the Medicare Advantage and related businesses until the divestiture of such businesses to Health Care Services Corporation ("HCSC") on March 19, 2025 ("HCSC transaction").</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> comprises the remainder of our business operations, which includes certain continuing business (corporate-owned life insurance ("COLI")), as well as run-off and other non-strategic businesses. Our run-off businesses include the (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013; (ii) settlement annuity business; and (iii) individual life insurance and annuity and retirement benefits businesses, which were sold through reinsurance agreements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.</span></div></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_355"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-349" continuedAt="f-349-1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt"><span id="iad4ff92f8b8243cd96f4a641a7625340_743"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8211; Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-350" continuedAt="f-350-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain goodwill and other intangible assets amounts in the Consolidated Balance Sheet have been reclassified as of March 31, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.</span></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_358"></div><ix:continuation id="f-350-1" continuedAt="f-350-2"><ix:continuation id="f-349-1" continuedAt="f-349-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">These interim Consolidated Financial Statements are unaudited but include all adjustments (including normal recurring adjustments) necessary, in the opinion of management, for a fair statement of financial position and results of operations for the periods reported. The interim Consolidated Financial Statements and Notes should be read in conjunction with the Consolidated Financial Statements and Notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K"). The Company has not included certain footnote disclosures that would substantially duplicate the disclosures contained in its 2025 Form </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-350-2"><ix:continuation id="f-349-2" continuedAt="f-349-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">10-K, unless the information in those disclosures materially changed or is required by GAAP. The preparation of interim Consolidated Financial Statements necessarily relies heavily on estimates. This and other factors, including the seasonal nature of portions of the health care and related benefits business, as well as competitive and other market conditions, call for caution in estimating full-year results based on interim results of operations.</span></div></ix:continuation></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_361"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-351" continuedAt="f-351-1" escape="true"><ix:continuation id="f-349-3" continuedAt="f-349-4"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_370"></div><ix:continuation id="f-351-1"><ix:continuation id="f-349-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">The Company's 2025 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. There are no updates to significant accounting pronouncements recently adopted that have occurred since the Company filed its 2025 Form 10-K. There are no incremental significant accounting pronouncements recently issued and not yet adopted that are expected to impact our operations or financial statements beyond those described in the Company's 2025 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"> The Company continues to progress with its adoption plans, with no significant updates since the 2025 Form 10-K.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_385"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="f-352" continuedAt="f-352-1" escape="true"><div><span id="iab9e5d6c7f8041278eb36290adebc81f_13"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8211; Accounts Receivable, Net</span></div></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_391"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="f-353" escape="true"><ix:continuation id="f-352-1" continuedAt="f-352-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included within Accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Noninsurance customer receivables</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" format="ixt:num-dot-decimal" scale="6" id="f-354">13,797</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" format="ixt:num-dot-decimal" scale="6" id="f-355">14,707</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical manufacturers receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:PharmaceuticalManufacturerReceivable" format="ixt:num-dot-decimal" scale="6" id="f-356">10,914</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:PharmaceuticalManufacturerReceivable" format="ixt:num-dot-decimal" scale="6" id="f-357">12,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Insurance customer receivables</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:InsuranceCustomerReceivables" format="ixt:num-dot-decimal" scale="6" id="f-358">1,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:InsuranceCustomerReceivables" format="ixt:num-dot-decimal" scale="6" id="f-359">1,385</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="f-360">244</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="f-361">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-362">26,607</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-363">28,768</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_394"></div><ix:continuation id="f-352-2" continuedAt="f-352-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These accounts receivable are reported net of our allowances of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-8" name="ci:AllowanceForReceivablesCurrent" scale="9" id="f-364">7.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-8" name="ci:AllowanceForReceivablesCurrent" scale="9" id="f-365">6.8</ix:nonFraction> billion as of March&#160;31, 2026 and December&#160;31, 2025, respectively. These allowances include contractual allowances for certain rebates receivable with pharmaceutical manufacturers and certain accounts receivable from third-party payors, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses, and other non-credit adjustments.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_397"></div><ix:continuation id="f-352-3" continuedAt="f-352-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's allowance for current expected credit losses was $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-366">228</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-367">199</ix:nonFraction> million as of March&#160;31, 2026 and December&#160;31, 2025, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_403"></div><ix:continuation id="f-352-4" continuedAt="f-352-5"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Accounts Receivable Factoring Facilities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company maintains uncommitted factoring facilities with a total capacity of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-8" name="ci:AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity" scale="9" id="f-368">2.0</ix:nonFraction> billion under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. In the first quarter of 2026, the Company entered into a new accounts receivable factoring facility with an initial two-year term, in addition to the previously established accounts receivable factoring facility outlined in Note 3 to the Consolidated Financial Statements included in the Company's 2025 Form 10-K (together, the "Facilities"). The Facilities automatically renew and are subject to automatic <ix:nonNumeric contextRef="c-1" name="ci:AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm" format="ixt-sec:durwordsen" id="f-369">one-year</ix:nonNumeric> renewal terms following the expiration of the initial term unless terminated by either party. The transactions under the Facilities are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with the Facilities are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under the Facilities are reflected in Interest expense and other in the Consolidated Statements of Income.</span></div></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_6373"></div><ix:continuation id="f-352-5"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We sold receivables under the Facilities of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="ci:AccountsReceivableUncommittedFactoringFacilitiesAmountSold" scale="9" id="f-370">0.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-8" name="ci:AccountsReceivableUncommittedFactoringFacilitiesAmountSold" scale="9" id="f-371">1.4</ix:nonFraction> billion for the three months ended March&#160;31, 2026 and 2025, respectively. For the three months ended March&#160;31, 2026 and 2025, factoring fees paid were not material. As of March&#160;31, 2026 and December&#160;31, 2025, all sold accounts receivable had been collected. As of March&#160;31, 2026, all collections have been remitted to the financial institution. As of December&#160;31, 2025, there were $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-8" name="ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted" scale="9" id="f-372">0.4</ix:nonFraction> billion of collections that had not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.</span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_412"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SupplierFinanceProgramTextBlock" id="f-373" continuedAt="f-373-1" escape="true"><div style="margin-top:10pt"><span id="ia7fc84917c564cad9c9383247302640f_12"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8211; Supplier Finance Program</span></div></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_415"></div><ix:continuation id="f-373-1" continuedAt="f-373-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require. </span></div></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_421"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-373-2">As of March&#160;31, 2026 and December&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-8" name="us-gaap:SupplierFinanceProgramObligation" scale="9" id="f-374"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-8" name="us-gaap:SupplierFinanceProgramObligationCurrent" scale="9" id="f-375">1.3</ix:nonFraction></ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-8" name="us-gaap:SupplierFinanceProgramObligation" scale="9" id="f-376"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-8" name="us-gaap:SupplierFinanceProgramObligationCurrent" scale="9" id="f-377">1.6</ix:nonFraction></ix:nonFraction>&#160;billion, respectively, of the Company's outstanding payment obligations were confirmed as valid within the Program by the financial institution and are reflected in <span style="-sec-ix-hidden:f-378"><span style="-sec-ix-hidden:f-379"><span style="-sec-ix-hidden:f-380"><span style="-sec-ix-hidden:f-381">Accounts payable</span></span></span></span> in the Consolidated Balance Sheets. The amounts confirmed as valid for both periods are predominately associated with one supplier.</ix:continuation> </span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_478"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-382" continuedAt="f-382-1" escape="true"><div style="margin-top:10pt"><span id="i70b43112ac3247a498e319c771b05e87_13"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 &#8211; Earnings Per Share</span></div></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_484"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-383" continuedAt="f-383-1" escape="true"><ix:continuation id="f-382-1" continuedAt="f-382-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted earnings per share were computed as follows:</span></div></ix:continuation></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_490"></div><ix:continuation id="f-383-1"><ix:continuation id="f-382-2" continuedAt="f-382-3"><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.238%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands, dollars in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' net income</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-384">1,654</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-385">1,654</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-386">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-387">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-388">262,746</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-389">262,746</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-390">270,867</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-391">270,867</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Common stock equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-392">1,271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-393">1,271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-394">2,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-395">2,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total shares</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-396">262,746</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-397">1,271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-398">264,017</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-399">270,867</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-400">2,086</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-401">272,953</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Earnings per share</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-402">6.30</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ci:EarningsPerShareEffectOfDilution" scale="0" id="f-403">0.04</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-404">6.26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-405">4.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="ci:EarningsPerShareEffectOfDilution" scale="0" id="f-406">0.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-407">4.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_496"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-408" escape="true"><ix:continuation id="f-382-3" continuedAt="f-382-4"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.955%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.096%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-409">2.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-410">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_5892"></div><ix:continuation id="f-382-4" continuedAt="f-382-5"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On <ix:nonNumeric contextRef="c-62" name="us-gaap:DividendsPayableDateDeclaredDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="f-411">April&#160;22, 2026</ix:nonNumeric>, the Board of Directors of The Cigna Group (the "Board") declared the second quarter cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-412">1.56</ix:nonFraction> per share of The Cigna Group common stock to be paid on <ix:nonNumeric contextRef="c-62" name="us-gaap:DividendPayableDateToBePaidDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="f-413">June&#160;18, 2026</ix:nonNumeric> to shareholders of record on <ix:nonNumeric contextRef="c-62" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en" id="f-414">June&#160;4, 2026</ix:nonNumeric>. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by the Board and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.</span></div></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_499"></div><ix:continuation id="f-382-5"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company held approximately <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-415">141.4</ix:nonFraction> million shares of common stock in treasury as of March&#160;31, 2026, <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-416">141.1</ix:nonFraction> million shares as of December&#160;31, 2025 and <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-417">134.1</ix:nonFraction> million shares as of March&#160;31, 2025.</span></div></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_502"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-418" continuedAt="f-418-1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt"><span id="i94555fdb495846a18fe0238b309c6410_11"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8211; Debt</span></div></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_508"></div><ix:continuation id="f-418-1" continuedAt="f-418-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term and Long-Term Debt. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026, the Company repaid $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-419">550</ix:nonFraction> million <ix:nonFraction unitRef="number" contextRef="c-64" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-420">1.250</ix:nonFraction>% senior notes that matured in March 2026. For more information regarding our short-term and long-term debt, see Note 7 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_520"></div><ix:continuation id="f-418-2" continuedAt="f-418-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revolving Credit Agreement.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> The Company maintains a $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="f-421">6.5</ix:nonFraction> billion, <ix:nonNumeric contextRef="c-52" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-422">five-year</ix:nonNumeric> revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for additional <ix:nonNumeric contextRef="c-52" name="ci:DebtInstrumentExtensionTerm" format="ixt-sec:durwordsen" id="f-423">one-year</ix:nonNumeric> periods, subject to consent of the banks (the "Credit Agreement"). Our Credit Agreement provides us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of March&#160;31, 2026, there was <ix:nonFraction unitRef="usd" contextRef="c-66" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-424">no</ix:nonFraction> outstanding balance under the Credit Agreement.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_526"></div><ix:continuation id="f-418-3" continuedAt="f-418-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Paper. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="f-425">6.5</ix:nonFraction> billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was <ix:nonFraction unitRef="usd" contextRef="c-67" decimals="INF" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="f-426">no</ix:nonFraction> commercial paper balance as of March&#160;31, 2026.</span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_535"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-418-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Expense. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense on long-term and short-term debt was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="f-427">357</ix:nonFraction> million for the three months ended March&#160;31, 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="f-428">362</ix:nonFraction> million for the three months ended March&#160;31, 2025.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_6055"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="f-429" continuedAt="f-429-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8211; <span id="i360bb05418cb4cd3be784b1eac3699f5_700"></span>Insurance and Contractholder Liabilities</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Account Balances &#8211; Insurance and Contractholder Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="f-430" continuedAt="f-430-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance and contractholder liabilities were comprised of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unpaid claims and claim expenses</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="f-431">4,856</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" scale="6" id="f-432">64</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-433">4,920</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="f-434">4,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" scale="6" id="f-435">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-436">4,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-437">4,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" scale="6" id="f-438">152</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" scale="6" id="f-439">164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="f-440">316</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" scale="6" id="f-441">167</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" scale="6" id="f-442">176</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="f-443">343</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="f-444">366</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Future policy benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" scale="6" id="f-445">37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" scale="6" id="f-446">148</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" scale="6" id="f-447">185</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" scale="6" id="f-448">38</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" scale="6" id="f-449">153</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" scale="6" id="f-450">191</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" scale="6" id="f-451">192</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" scale="6" id="f-452">139</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-453">3,008</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="6" id="f-454">3,147</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" scale="6" id="f-455">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-456">3,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="6" id="f-457">3,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="6" id="f-458">3,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Contractholder deposit funds</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:PolicyholderContractDepositCurrent" scale="6" id="f-459">329</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:PolicyholderContractDepositNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-460">5,701</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PolicyholderContractDeposits" format="ixt:num-dot-decimal" scale="6" id="f-461">6,030</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:PolicyholderContractDepositCurrent" scale="6" id="f-462">336</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:PolicyholderContractDepositNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-463">5,778</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:PolicyholderContractDeposits" format="ixt:num-dot-decimal" scale="6" id="f-464">6,114</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:PolicyholderContractDeposits" format="ixt:num-dot-decimal" scale="6" id="f-465">6,251</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:MarketRiskBenefitLiabilityAmountCurrent" scale="6" id="f-466">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:MarketRiskBenefitLiabilityAmountNoncurrent" scale="6" id="f-467">647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:MarketRiskBenefitLiabilityAmount" scale="6" id="f-468">675</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:MarketRiskBenefitLiabilityAmountCurrent" scale="6" id="f-469">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:MarketRiskBenefitLiabilityAmountNoncurrent" scale="6" id="f-470">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:MarketRiskBenefitLiabilityAmount" scale="6" id="f-471">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:MarketRiskBenefitLiabilityAmount" scale="6" id="f-472">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Unearned premiums</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:UnearnedPremiumsCurrent" scale="6" id="f-473">914</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:UnearnedPremiumsNoncurrent" scale="6" id="f-474">45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:UnearnedPremiums" scale="6" id="f-475">959</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:UnearnedPremiumsCurrent" scale="6" id="f-476">822</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:UnearnedPremiumsNoncurrent" scale="6" id="f-477">40</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:UnearnedPremiums" scale="6" id="f-478">862</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:UnearnedPremiums" scale="6" id="f-479">838</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total insurance and contractholder liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-480">6,455</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-481">9,777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:InsuranceAndContractholderLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-482">16,232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-483">5,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-484">9,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:InsuranceAndContractholderLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-485">15,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="ci:InsuranceAndContractholderLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-486">16,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_6079"></div><ix:continuation id="f-429-1" continuedAt="f-429-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Insurance and contractholder liabilities expected to be paid within one year are classified as current. </span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_565"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><ix:continuation id="f-429-2" continuedAt="f-429-3"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Unpaid Claims and Claim Expenses &#8211; Cigna Healthcare</span></ix:continuation></div><ix:continuation id="f-429-3" continuedAt="f-429-4"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" id="f-487" escape="true">This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.</ix:nonNumeric> </span></div></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_571"></div><ix:continuation id="f-429-4" continuedAt="f-429-5"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-8" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" scale="9" id="f-488">4.7</ix:nonFraction> billion as of March&#160;31, 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-8" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" scale="9" id="f-489">4.4</ix:nonFraction> billion as of March&#160;31, 2025.</span></div><ix:continuation id="f-430-1"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:74.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-490">4,241</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-491">5,018</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="f-492">147</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="ci:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" scale="6" id="f-493">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, net</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-494">4,094</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-495">4,859</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-496">7,852</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-497">10,606</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-498">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-499">222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="f-500">7,664</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="f-501">10,384</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Paid costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="f-502">4,119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="f-503">6,078</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="f-504">2,859</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="f-505">3,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-506">6,978</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-507">9,550</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Divestiture and other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther" format="ixt:fixed-zero" scale="6" id="f-508">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther" format="ixt:num-dot-decimal" scale="6" id="f-509">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance, net</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-510">4,780</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-511">4,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Add: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="f-512">140</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="f-513">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-514">4,920</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-515">4,508</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_6096"></div><ix:continuation id="f-429-5" continuedAt="f-429-6"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes unpaid claims amounts classified as liabilities of businesses held for sale prior to the completion of the HCSC transaction. As of December&#160;31, 2024, includes $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" scale="6" id="f-516">983</ix:nonFraction> million classified as liabilities of businesses held for sale.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_6107"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-429-6" continuedAt="f-429-7"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 8 to the Consolidated Financial Statements for additional information on reinsurance.</span></div></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_574"></div><ix:continuation id="f-429-7" continuedAt="f-429-8"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" id="f-517" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:53.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.889%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Actual completion factors and other</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-518">96</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-519">0.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-520">96</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-521">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical cost trend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-522">92</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-523">0.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-524">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-525">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total favorable variance</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-526">188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-527">0.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-528">222</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-529">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2025.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2024.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Favorable prior year development in both years primarily reflects lower than expected utilization of medical services as compared to our assumptions.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_580"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><ix:continuation id="f-429-8" continuedAt="f-429-9"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Future Policy Benefits</span></ix:continuation></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_595"></div><ix:continuation id="f-429-9" continuedAt="f-429-10"><ix:nonNumeric contextRef="c-1" name="us-gaap:LiabilityForFuturePolicyBenefitActivityTableTextBlock" id="f-530" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest accretion rate </span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" scale="-2" id="f-531">5.64</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" scale="-2" id="f-532">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current discount rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" scale="-2" id="f-533">5.39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" scale="-2" id="f-534">5.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average duration </span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-85" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration" format="ixt-sec:duryear" id="f-535">10.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-86" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration" format="ixt-sec:duryear" id="f-536">10.8</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FuturePolicyBenefitsLiabilityPolicy" id="f-537" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">'</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_598"></div><ix:continuation id="f-429-10" continuedAt="f-429-11"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Future policy benefits include deferred profit liability of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability" scale="6" id="f-538">348</ix:nonFraction> million as of March&#160;31, 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability" scale="6" id="f-539">359</ix:nonFraction>&#160;million as of March&#160;31, 2025. Future policy benefits excluding deferred profit liability were $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-8" name="ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" scale="9" id="f-540">2.8</ix:nonFraction>&#160;billion as of March&#160;31, 2026, $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-8" name="ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" scale="9" id="f-541">2.9</ix:nonFraction>&#160;billion as of December&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-8" name="ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" scale="9" id="f-542">3.0</ix:nonFraction>&#160;billion as of March&#160;31, 2025, and $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-8" name="ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" scale="9" id="f-543">2.9</ix:nonFraction>&#160;billion as of December&#160;31, 2024. Undiscounted expected future policy benefits were $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" scale="9" id="f-544">4.1</ix:nonFraction>&#160;billion as of March&#160;31, 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" scale="9" id="f-545">4.3</ix:nonFraction>&#160;billion as of March&#160;31, 2025. As of March&#160;31, 2026 and March&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" scale="9" id="f-546">0.8</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" scale="9" id="f-547">0.9</ix:nonFraction>&#160;billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.</span></div></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_607"></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><ix:continuation id="f-429-11" continuedAt="f-429-12"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Contractholder Deposit Funds</span></ix:continuation></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_613"></div><ix:continuation id="f-429-12" continuedAt="f-429-13"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Contractholder deposit fund liabilities within Other Operations were $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-8" name="us-gaap:PolicyholderContractDeposits" scale="9" id="f-548">6.0</ix:nonFraction> billion as of March&#160;31, 2026, $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-8" name="us-gaap:PolicyholderContractDeposits" scale="9" id="f-549"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-8" name="us-gaap:PolicyholderContractDeposits" scale="9" id="f-550">6.1</ix:nonFraction></ix:nonFraction> billion as of December&#160;31, 2025 and $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-8" name="us-gaap:PolicyholderContractDeposits" scale="9" id="f-551"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-8" name="us-gaap:PolicyholderContractDeposits" scale="9" id="f-552">6.3</ix:nonFraction></ix:nonFraction> billion as of both March&#160;31, 2025 and December&#160;31, 2024. Approximately <ix:nonFraction unitRef="number" contextRef="c-8" decimals="2" name="ci:PolicyholderContractBalancePercentReinsuredExternally" scale="-2" id="f-553">37</ix:nonFraction>% of the balance is reinsured externally. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_619"></div><ix:continuation id="f-429-13" continuedAt="f-429-14"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2026, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were <ix:nonFraction unitRef="number" contextRef="c-8" decimals="4" name="us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate" scale="-2" id="f-554">3.19</ix:nonFraction>%, $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-8" name="us-gaap:PolicyholderAccountBalanceNetAmountAtRisk" scale="9" id="f-555">2.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-8" name="us-gaap:CashSurrenderValueDuePolicyholdersAmount" scale="9" id="f-556">2.8</ix:nonFraction> billion, respectively. The comparative amounts as of March&#160;31, 2025 were <ix:nonFraction unitRef="number" contextRef="c-51" decimals="4" name="us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate" scale="-2" id="f-557">3.20</ix:nonFraction>%, $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-8" name="us-gaap:PolicyholderAccountBalanceNetAmountAtRisk" scale="9" id="f-558">2.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-8" name="us-gaap:CashSurrenderValueDuePolicyholdersAmount" scale="9" id="f-559">2.8</ix:nonFraction> billion, respectively. More than <ix:nonFraction unitRef="number" contextRef="c-88" decimals="2" name="ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" scale="-2" id="f-560"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" scale="-2" id="f-561">99</ix:nonFraction></ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-8" name="us-gaap:PolicyholderFunds" scale="9" id="f-562">3.8</ix:nonFraction> billion liability as of March&#160;31, 2026 and the $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-8" name="us-gaap:PolicyholderFunds" scale="9" id="f-563">4.0</ix:nonFraction> billion liability as of March&#160;31, 2025 not reinsured externally is for contracts with guaranteed interest rates of <ix:nonFraction unitRef="number" contextRef="c-90" decimals="2" name="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating" scale="-2" id="f-564"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="2" name="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating" scale="-2" id="f-565">3</ix:nonFraction></ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating" scale="-2" id="f-566"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating" scale="-2" id="f-567">4</ix:nonFraction></ix:nonFraction>%, and approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-8" name="us-gaap:PolicyholderFunds" scale="9" id="f-568"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-8" name="us-gaap:PolicyholderFunds" scale="9" id="f-569">1.2</ix:nonFraction></ix:nonFraction> billion as of both period ends represented contracts with policies at the guarantee. At these same period ends, $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-8" name="us-gaap:PolicyholderFunds" scale="9" id="f-570">1.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-8" name="us-gaap:PolicyholderFunds" scale="9" id="f-571">1.2</ix:nonFraction> billion was <ix:nonFraction unitRef="number" contextRef="c-98" decimals="3" name="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" scale="-4" id="f-572"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="3" name="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" scale="-4" id="f-573">50</ix:nonFraction></ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-100" decimals="3" name="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" scale="-4" id="f-574"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="3" name="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" scale="-4" id="f-575">150</ix:nonFraction></ix:nonFraction> basis points ("bps") above the guarantee, and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-8" name="us-gaap:PolicyholderFunds" scale="9" id="f-576"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-8" name="us-gaap:PolicyholderFunds" scale="9" id="f-577">1.6</ix:nonFraction></ix:nonFraction> billion as of both March&#160;31, 2026 and March&#160;31, 2025 represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. As of both March&#160;31, 2026 and March&#160;31, 2025, more than <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" scale="-2" id="f-578"><ix:nonFraction unitRef="number" contextRef="c-103" decimals="2" name="ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" scale="-2" id="f-579">90</ix:nonFraction></ix:nonFraction>% of these contracts have actual cash values of at least 110% of the guaranteed cash value.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_625"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><ix:continuation id="f-429-14" continuedAt="f-429-15"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Market Risk Benefits</span></ix:continuation></div><ix:continuation id="f-429-15" continuedAt="f-429-16"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities for market risk benefits ("MRBs") consist of variable annuity reinsurance contracts in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within <ix:nonNumeric contextRef="c-1" name="ci:AnnuitizationElectionPeriod" format="ixt-sec:durday" id="f-580">30</ix:nonNumeric> days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_631"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketRiskBenefitActivityTableTextBlock" id="f-581" escape="true"><ix:continuation id="f-429-16" continuedAt="f-429-17"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Market risk benefits activity was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"/><td style="width:74.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" scale="6" id="f-582">674</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" scale="6" id="f-583">785</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" scale="6" id="f-584">714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" scale="6" id="f-585">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to expected run-off</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" scale="6" id="f-586">6</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" scale="6" id="f-587">4</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to capital markets versus expected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" scale="6" id="f-588">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" scale="6" id="f-589">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to policyholder behavior versus expected</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" scale="6" id="f-590">5</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" format="ixt:fixed-zero" scale="6" id="f-591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" scale="6" id="f-592">716</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" scale="6" id="f-593">878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Nonperformance risk (own credit risk), end of period</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" scale="6" id="f-594">41</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" scale="6" id="f-595">48</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" scale="6" id="f-596">675</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" scale="6" id="f-597">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Reinsured market risk benefit, end of period</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance" scale="6" id="f-598">715</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance" scale="6" id="f-599">876</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_634"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" id="f-600" escape="true"><ix:continuation id="f-429-17"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 8 to the Consolidated Financial Statements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions, excludes impact of reinsurance ceded)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net amount at risk</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" format="ixt:num-dot-decimal" scale="6" id="f-601">1,194</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" format="ixt:num-dot-decimal" scale="6" id="f-602">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Average attained age of contractholders (weighted by exposure)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-106" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" format="ixt-sec:duryear" id="f-603">77.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-107" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" format="ixt-sec:duryear" id="f-604">77.0</ix:nonNumeric> years</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_640"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReinsuranceTextBlock" id="f-605" continuedAt="f-605-1" escape="true"><div style="margin-bottom:10pt"><span id="id20be86505734bd88680a83a2a1e6585_624"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 8 &#8211; Reinsurance</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk. </span></div></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_649"></div><ix:continuation id="f-605-1" continuedAt="f-605-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. <ix:nonNumeric contextRef="c-1" name="us-gaap:ReinsuranceAccountingPolicy" id="f-606" continuedAt="f-606-1" escape="true">The Company reviews its reinsurance arrangements and establishes reserves against the recoverables primarily for expected credit losses.</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_652"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock" id="f-607" escape="true"><ix:continuation id="f-605-2" continuedAt="f-605-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's reinsurance recoverables as of March&#160;31, 2026 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.903%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Collateral Provisions Exist That May Mitigate Risk of Credit Loss </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">No Collateral</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Ongoing operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">A- equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" format="ixt:fixed-zero" scale="6" id="f-608">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-609">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-610">227</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-611">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">BBB- to BBB+ equivalent current credit ratings</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" format="ixt:fixed-zero" scale="6" id="f-612">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" format="ixt:fixed-zero" scale="6" id="f-613">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-614">64</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-615">64</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-616">81</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-617">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-618">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-619">85</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition, disposition or run-off activities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">BBB+ equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-620">280</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" format="ixt:num-dot-decimal" scale="6" id="f-621">2,810</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-622">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" format="ixt:num-dot-decimal" scale="6" id="f-623">3,116</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" format="ixt:fixed-zero" scale="6" id="f-624">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-625">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-626">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-627">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables before market risk benefits</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-628">361</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" format="ixt:num-dot-decimal" scale="6" id="f-629">2,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" scale="6" id="f-630">319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ReinsuranceRecoverablesGross" format="ixt:num-dot-decimal" scale="6" id="f-631">3,502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for uncollectible reinsurance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ReinsuranceRecoverablesAllowance" scale="6" id="f-632">22</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance" scale="6" id="f-633">715</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ReinsuranceRecoverables" format="ixt:num-dot-decimal" scale="6" id="f-634">4,195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Certified by a nationally recognized statistical ratings organization ("NRSRO").</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Comprised of <ix:nonFraction unitRef="reinsurer" contextRef="c-123" decimals="INF" name="ci:ReinsuranceRecoverablesNumberOfReinsurers" format="ixt-sec:numwordsen" scale="0" id="f-635">six</ix:nonFraction> reinsurers, of which <ix:nonFraction unitRef="number" contextRef="c-131" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-636">77</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">is held by <ix:nonFraction unitRef="reinsurer" contextRef="c-132" decimals="INF" name="ci:ReinsuranceRecoverablesNumberOfReinsurers" format="ixt-sec:numwordsen" scale="0" id="f-637">two</ix:nonFraction> reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:ReinsuranceRecoverables" scale="6" id="f-638">122</ix:nonFraction> million of current reinsurance recoverables that are reported in Other current assets.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_655"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-605-3">The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. <ix:continuation id="f-606-1">Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 7 to the Consolidated Financial Statements.</ix:continuation> Berkshire reinsured <ix:nonFraction unitRef="number" contextRef="c-134" decimals="INF" name="us-gaap:ReinsuranceRetentionPolicyReinsuredRiskPercentage" scale="-2" id="f-639">100</ix:nonFraction>% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit, with approximately $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-8" name="ci:CededReinsuranceAgreementCoverageLimitAmountRemaining" scale="9" id="f-640">3.0</ix:nonFraction> billion remaining as of March&#160;31, 2026. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit. As of both March&#160;31, 2026 and 2025, market risk benefits (shown in the table net of nonperformance risk as of March&#160;31, 2026) were predominantly reinsured by Berkshire, which is rated AA+ by an NRSRO. As of March&#160;31, 2026, approximately <ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-641">100</ix:nonFraction>% of the Berkshire recoverable is secured by assets in a trust.</ix:continuation> </span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_664"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-642" continuedAt="f-642-1" escape="true"><div style="margin-bottom:10pt"><span id="iffda1ddb399742d1a8a04892fba27ddb_14"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 &#8211; Investments</span></div></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_667"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" id="f-643" escape="true"><ix:continuation id="f-642-1" continuedAt="f-642-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's investments by category and current or long-term classification:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-644">453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-645">7,859</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-646">8,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-647">691</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-648">7,671</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-649">8,362</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-650">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-651">3,641</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-652">3,669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-653">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-654">3,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-655">3,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-656">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-657">1,220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-658">1,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-659">86</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-660">1,147</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-661">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Policy loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-662">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-663">1,024</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-664">1,024</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-666">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-667">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-668">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-669">5,158</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-670">5,158</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-672">5,037</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-673">5,037</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-674">279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="6" id="f-675">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:Investments" scale="6" id="f-676">279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-677">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="6" id="f-678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:Investments" scale="6" id="f-679">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-680">812</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-681">18,902</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-682">19,714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-683">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-684">18,471</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-685">19,527</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_673"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><ix:continuation id="f-642-2" continuedAt="f-642-3"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Investment Portfolio</span></ix:continuation></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_676"></div><ix:continuation id="f-642-3" continuedAt="f-642-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_682"></div><ix:continuation id="f-642-4" continuedAt="f-642-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-686" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of March&#160;31, 2026:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="f-687">674</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="f-688">566</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-689">3,842</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-690">3,783</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-691">2,017</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-692">1,969</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-693">1,956</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-694">1,766</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" scale="6" id="f-695">250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" scale="6" id="f-696">228</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-697">8,739</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-698">8,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.</span></div></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_685"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="f-699" escape="true"><ix:continuation id="f-642-5" continuedAt="f-642-6"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Appreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-700">220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-701">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-702">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-703">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-704">230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-705">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-706">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-707">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-708">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-709">25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-710">452</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-711">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-712">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-713">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-714">452</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-715">7,793</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" scale="6" id="f-716">135</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-717">121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-718">402</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-719">7,377</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-720">250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-721">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-722">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-723">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-724">228</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-725">8,739</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" scale="6" id="f-726">135</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-727">145</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-728">437</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-729">8,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-730">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-732">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-733">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-734">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-735">24</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-737">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-739">25</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-740">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-741">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-742">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-743">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-744">456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-745">7,704</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" scale="6" id="f-746">137</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-747">175</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-748">332</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-749">7,410</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-750">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-751">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-752">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-753">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-754">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-755">8,660</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" scale="6" id="f-756">137</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-757">206</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-758">367</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-759">8,362</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="padding-right:36pt"><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_688"></div><ix:continuation id="f-642-6" continuedAt="f-642-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-760" continuedAt="f-760-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Review of Declines in Fair Value. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-761" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">One year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-762">1,674</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-763">1,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-764">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-159" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-765">609</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-766">384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" scale="6" id="f-767">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-768">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-160" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-769">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-770">276</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" scale="6" id="f-771">283</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-772">7</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-161" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-773">632</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-774">120</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" scale="6" id="f-775">125</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-776">5</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-162" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-777">239</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">More than one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-778">2,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-779">3,146</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-780">389</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-159" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="f-781">743</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-782">3,044</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-783">3,382</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-784">338</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-160" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="f-785">799</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-786">128</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" scale="6" id="f-787">143</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-788">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-161" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="f-789">82</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-790">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" scale="6" id="f-791">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-792">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-162" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="f-793">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-794">4,835</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-795">5,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-796">437</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-8" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="f-797">2,066</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-798">3,733</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-799">4,100</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-800">367</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-9" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="f-801">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_694"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-642-7" continuedAt="f-642-8"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equity Securities</span></div><ix:nonNumeric contextRef="c-1" name="ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" id="f-802" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the values of the Company's equity security investments: </span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-803">101</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-804">85</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-805">78</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-806">92</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-807">6,893</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="f-808">3,584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-809">6,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="f-810">3,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-811">6,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-812">3,669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-813">6,870</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-814">3,556</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_700"></div><ix:continuation id="f-642-8" continuedAt="f-642-9"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Mortgage Loans</span></div></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_706"></div><ix:continuation id="f-642-9" continuedAt="f-642-10"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high-quality, primarily completed and substantially leased operating properties.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_712"></div><ix:continuation id="f-760-1" continuedAt="f-760-2"><ix:continuation id="f-642-10" continuedAt="f-642-11"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company regularly evaluates and monitors credit risk from the initial mortgage loan underwriting and throughout the investment holding period. The annual portfolio review performed in the second quarter of 2025 confirmed ongoing strong overall credit quality in line with the previous year's results. For more information on the Company's accounting policies and methodologies regarding these investments, see Note 11 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_715"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock" id="f-815" escape="true"><ix:continuation id="f-642-11" continuedAt="f-642-12"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.890%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Below 60%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-816">393</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-817">2.13</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-818">355</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-166" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-819">2.13</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">60% to 79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-820">694</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-821">1.79</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-822">694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-170" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-823">1.81</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">80% to 100%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-824">185</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-172" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-825">0.92</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-826">184</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-174" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-827">0.79</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-828">1,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-176" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-829">1.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-176" decimals="2" name="ci:FinancingReceivableCreditQualityLoanToValueRatio" scale="-2" id="f-830">71</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-831">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-178" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-832">1.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-178" decimals="2" name="ci:FinancingReceivableCreditQualityLoanToValueRatio" scale="-2" id="f-833">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_721"></div><ix:continuation id="f-642-12" continuedAt="f-642-13"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Long-Term Investments</span></div><ix:nonNumeric contextRef="c-1" name="ci:ScheduleOfOtherLongTermInvestmentsTableTextBlock" id="f-834" escape="true"><ix:continuation id="f-760-2" continuedAt="f-760-3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. </span></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-760-3">Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other.</ix:continuation> The following table provides the carrying value information for these investments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-835">1,993</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-836">1,895</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-837">2,961</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-838">2,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:OtherLongTermInvestments" scale="6" id="f-839">204</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-6" name="us-gaap:OtherLongTermInvestments" scale="6" id="f-840">194</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-841">5,158</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-842">5,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_736"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><ix:continuation id="f-642-13" continuedAt="f-642-14"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Derivative Financial Instruments</span></ix:continuation></div><ix:continuation id="f-642-14" continuedAt="f-642-15"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt. The Company also has derivative instruments associated with certain equity securities; see Note 12A to the Consolidated Financial Statements in the Company&#8217;s 2025 Form 10-K for further information.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_742"></div><ix:continuation id="f-642-15" continuedAt="f-642-16"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2026, the notional value of interest rate swap contracts increased to $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-843">3.5</ix:nonFraction> billion compared with $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-844">3.2</ix:nonFraction> billion as of December&#160;31, 2025. There were no other material changes to the Company's individual derivative hedging strategies during the three months ended March&#160;31, 2026. <ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-845" escape="true">Please refer to the Company's 2025 Form 10-K for further discussion of the types of derivative financial instruments and associated accounting policies.</ix:nonNumeric> The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of March&#160;31, 2026 and December&#160;31, 2025. The gross fair values of our derivative financial instruments are presented in Note 10 to the Consolidated Financial Statements. </span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_751"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><ix:continuation id="f-642-16" continuedAt="f-642-17"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Investment Gains and Losses</span></ix:continuation></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_760"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-642-17">Net investment gains (losses) before income taxes were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:NetInvestmentGainLoss" scale="6" id="f-846">258</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2026 versus $(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:NetInvestmentGainLoss" scale="6" id="f-847">2</ix:nonFraction>)&#160;million for the three months ended March&#160;31, 2025. Investment results increased primarily due to fair value changes of derivative instruments associated with certain equity securities. These amounts exclude investment gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders.</ix:continuation> </span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_772"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-848" continuedAt="f-848-1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt"><span id="i1597debdc6cf41409a9c5b168712b46e_14"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 &#8211; Fair Value Measurements </span></div></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_778"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-849" continuedAt="f-849-1" escape="true"><ix:continuation id="f-848-1" continuedAt="f-848-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For a description of the policies, methods and assumptions that are used to estimate fair value and determine the fair value hierarchy for each class of financial instruments, see Note 12 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_781"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><ix:continuation id="f-848-2" continuedAt="f-848-3"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Financial Assets and Financial Liabilities Carried at Fair Value</span></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-850" escape="true"><ix:continuation id="f-848-3" continuedAt="f-848-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides information about the Company's investment and derivative financial assets and liabilities carried at fair value on a recurring basis. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets at fair value</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-851">108</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-852">105</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-853">122</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-854">122</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-855">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-857">230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-858">227</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-859">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-861">25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-862">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-863">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-864">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-865">25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-866">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-867">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-869">442</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-870">446</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-871">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-872">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-873">452</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-874">456</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-875">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-877">7,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-878">7,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-879">271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-880">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-881">7,377</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-882">7,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-883">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-885">195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-886">206</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-887">33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-888">38</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-889">228</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-890">244</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-891">108</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-892">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-893">7,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-894">7,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-895">314</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-896">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-897">8,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-898">8,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-899">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-900">54</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-901">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-902">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-903">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-904">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-905">85</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-906">92</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-907">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-908">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:OtherShortTermInvestments" scale="6" id="f-909">279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-6" name="us-gaap:OtherShortTermInvestments" scale="6" id="f-910">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-911">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="us-gaap:OtherShortTermInvestments" scale="6" id="f-913">279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:OtherShortTermInvestments" scale="6" id="f-914">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-915">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-917">97</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-918">68</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="f-919">1,173</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-920">923</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="f-921">1,270</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-922">991</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities at fair value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-923">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-925">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-926">22</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-927">343</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-928">354</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-929">351</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-930">376</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Excludes certain equity securities that have no readily determinable fair value.</span></div></ix:continuation></ix:nonNumeric><div style="text-indent:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_787"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-849-1" continuedAt="f-849-2"><ix:continuation id="f-848-4" continuedAt="f-848-5"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 3 Financial Assets and Financial Liabilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_793"></div><ix:continuation id="f-848-5" continuedAt="f-848-6"><div style="margin-bottom:10pt"><ix:continuation id="f-849-2" continuedAt="f-849-3"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Information about Debt Securities. </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-849-3" continuedAt="f-849-4">The significant unobservable input used to value our corporate and government debt securities, and mortgage and other asset-backed securities, is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-931" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.101%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Adjustment Range (Weighted Average by Quantity) as of</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Fair value in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-932">280</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-933">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-245" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-934">10</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-246" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-935">920</ix:nonFraction> (<ix:nonFraction unitRef="number" contextRef="c-247" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-936">135</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-248" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-937">60</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-249" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-938">920</ix:nonFraction> (<ix:nonFraction unitRef="number" contextRef="c-250" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-939">175</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-940">33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-941">38</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-253" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-942">115</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-254" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-943">340</ix:nonFraction> (<ix:nonFraction unitRef="number" contextRef="c-255" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-944">160</ix:nonFraction>) </span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-256" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-945">105</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-257" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-946">350</ix:nonFraction> (<ix:nonFraction unitRef="number" contextRef="c-258" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-947">160</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-948">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-949">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Level 3 debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-950">314</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-951">325</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_6290"></div><ix:continuation id="f-848-6" continuedAt="f-848-7"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Information about Derivative Instruments. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">See Note 12A to the Consolidated Financial Statements in the Company&#8217;s 2025 Form 10-K for further information regarding our Level 3 derivative instruments.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_796"></div><ix:continuation id="f-848-7" continuedAt="f-848-8"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value</span></div><ix:nonNumeric contextRef="c-1" name="ci:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="f-952" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="f-953">896</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-954">417</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) included in Shareholders' net income</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="f-955">258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="f-956">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Losses) gains included in Other comprehensive loss</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="f-957">3</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="f-958">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Purchases, sales and settlements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="f-959">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="f-960">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="f-961">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="f-962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="f-963">2</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="f-964">31</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total purchases, sales and settlements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" scale="6" id="f-965">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" scale="6" id="f-966">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Transfers into / (out of) Level 3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="f-967">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="f-968">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="f-969">38</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="f-970">30</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total transfers into / (out of) Level 3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="f-971">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="f-972">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="6" id="f-973">1,146</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="f-974">373</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:FairValueAssetRecurringBasisStillHeldRealizedGainLoss" scale="6" id="f-975">258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:FairValueAssetRecurringBasisStillHeldRealizedGainLoss" scale="6" id="f-976">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="6" id="f-977">3</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="6" id="f-978">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="f-849-4" continuedAt="f-849-5"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Total gains and losses included in Shareholders' net income in the table above are reflected in the Consolidated Statements of Income as <span style="-sec-ix-hidden:f-979">Net investment gains/losses</span> and as <span style="-sec-ix-hidden:f-980">Net investment income/losses</span>. Gains and losses included in Other comprehensive loss, net of tax, in the table above are reflected in <span style="-sec-ix-hidden:f-981">Net unrealized depreciation on securities and derivatives</span> in the Consolidated Statements of Comprehensive Income.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-848-8" continuedAt="f-848-9"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-849-5" continuedAt="f-849-6">Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads.</ix:continuation> Transfers between Level 2 and Level 3 during 2026 and 2025 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Level 3 Financial Assets and Financial Liabilities above for more information.</span></div></ix:continuation><div id="i9262e6da8fb24f8e98f20abd6e5292a7_799"></div><ix:continuation id="f-848-9" continuedAt="f-848-10"><ix:nonNumeric contextRef="c-1" name="us-gaap:PolicyholderAccountsPolicy" id="f-982" continuedAt="f-982-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-982-1" continuedAt="f-982-2">The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows.</ix:continuation> The separate account activity for the three months ended March&#160;31, 2026 and 2025 was primarily driven by changes in the market values of the underlying separate account investments.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_805"></div><ix:nonNumeric contextRef="c-1" name="ci:FairValueOfSeparateAccountAssetsTableTextBlock" id="f-983" escape="true"><ix:continuation id="f-848-10" continuedAt="f-848-11"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Fair values of Separate account assets were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Guaranteed separate accounts (see Note 14)</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-984">238</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-985">247</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-986">332</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-987">330</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="f-988">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="f-989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-990">570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-991">577</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-992">262</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-993">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-994">5,766</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-995">5,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-996">167</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-997">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-998">6,195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-999">6,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-1000">500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-1001">518</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-1002">6,098</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-1003">6,099</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-1004">167</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-1005">209</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-1006">6,765</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-1007">6,826</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts priced at net asset value as a practical expedient </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-1008">662</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="f-1009">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-1010">7,427</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-1011">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Non-guaranteed separate accounts include $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-8" name="us-gaap:SeparateAccountAssets" scale="9" id="f-1012">3.7</ix:nonFraction> billion as of March&#160;31, 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-8" name="us-gaap:SeparateAccountAssets" scale="9" id="f-1013">3.8</ix:nonFraction> billion</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">as of December&#160;31, 2025 in assets supporting the Company's pension plans, including $<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-8" name="us-gaap:SeparateAccountAssets" scale="9" id="f-1014">0.1</ix:nonFraction> billion classified in Level 3 as of March&#160;31, 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-8" name="us-gaap:SeparateAccountAssets" scale="9" id="f-1015">0.2</ix:nonFraction> billion</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">as of December&#160;31, 2025. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.</span></div></ix:continuation></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_817"></div><div><span><br/></span></div><ix:continuation id="f-848-11" continuedAt="f-848-12"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-982-2">Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans.</ix:continuation> Activity, including transfers into and out of Level 3, was not material for the three months ended March&#160;31, 2026 or 2025. </span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_823"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><ix:continuation id="f-849-6" continuedAt="f-849-7"><ix:continuation id="f-848-12" continuedAt="f-848-13"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Assets and Liabilities Measured at Fair Value under Certain Conditions</span></ix:continuation></ix:continuation></div><ix:continuation id="f-848-13" continuedAt="f-848-14"><ix:continuation id="f-849-7"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">For the three months ended March&#160;31, 2026 and 2025, impairments recognized requiring the assets and liabilities described above to be measured at fair value were not material. Observable price changes for equity securities with no readily determinable fair value were not material for the three months ended March&#160;31, 2026 or March&#160;31, 2025.</span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_826"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><ix:continuation id="f-848-14" continuedAt="f-848-15"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Fair Value Disclosures for Financial Instruments Not Carried at Fair Value</span></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="f-1016" escape="true"><ix:continuation id="f-848-15"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.045%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Fair Value Hierarchy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet" format="ixt:num-dot-decimal" scale="6" id="f-1017">1,227</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet" format="ixt:num-dot-decimal" scale="6" id="f-1018">1,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet" format="ixt:num-dot-decimal" scale="6" id="f-1019">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet" format="ixt:num-dot-decimal" scale="6" id="f-1020">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, including current maturities, excluding finance leases</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1021">28,838</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1022">30,783</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1023">29,907</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1024">31,352</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_844"></div><ix:nonNumeric contextRef="c-1" name="ci:AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" id="f-1025" continuedAt="f-1025-1" escape="true"><div style="margin-bottom:10pt"><span id="i863307f831dc42769ca918fef181998a_940"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 11 &#8211; Accumulated Other Comprehensive Income (Loss)</span></div></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_3298534889672"></div><ix:continuation id="f-1025-1" continuedAt="f-1025-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Accumulated Other Comprehensive Income (Loss) ("AOCI") includes net unrealized appreciation/depreciation on securities and derivatives, change in discount rate and instrument-specific credit risk for certain long-duration insurance contractholder liabilities (see Note 7 to the Consolidated Financial Statements), foreign currency translation, and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-1026" escape="true">Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_6321"></div><ix:continuation id="f-1025-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Shareholders' other comprehensive loss, net of tax, for the three months ended March 31, 2026 and March 31, 2025 is primarily attributable to the change in discount rates for certain long-duration liabilities and unrealized changes in the market values of securities and derivatives, including the impacts from unconsolidated entities reported on the equity method. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1027" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the components of AOCI were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:81.122%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.790%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Securities and derivatives</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1028">594</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1029">832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (depreciation) on securities and derivatives, before reclassification, net of tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1030">44</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1031">49</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1032">133</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1033">134</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1034">1</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1035">9</ix:nonFraction>), respectively</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1036">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1037">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss), net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1038">129</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1039">100</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1040">465</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1041">732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net long-duration insurance and contractholder liabilities measurement adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1042">2,329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1043">2,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1044">214</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1045">33</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1046">636</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1047">108</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to Shareholders' net income, net of tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="f-1048">&#8212;</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1049">16</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1050">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1051">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in discount rate for certain long-duration liabilities, net of tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="f-1052">214</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="f-1053">49</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1054">636</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1055">164</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="f-1056">&#8212;</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1057">1</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1058">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1059">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss), net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1060">635</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1061">168</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1062">2,964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1063">2,206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1064">127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1065">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net translation of foreign currencies, before reclassification, net of tax benefit (expense) of $<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1066">2</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1067">6</ix:nonFraction>), respectively</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1068">35</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1069">13</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1070">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1071">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Postretirement benefits liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1072">944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1073">937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1074">2</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1075">2</ix:nonFraction>), respectively</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1076">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1077">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1078">937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1079">931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1080">2,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1081">2,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive (loss), net of tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="f-1082">257</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="f-1083">82</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1084">792</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1085">249</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1086">3,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1087">2,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_847"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-1088" continuedAt="f-1088-1" escape="true"><div style="margin-bottom:10pt"><span id="ida55c25e8fb54e10816a26583a743776_1349"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 12 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Strategic Optimization Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2025, the Company commenced an enterprise-wide initiative to evolve our business and deliver a more efficient and improved experience for our patients, providers and customers. The Company expects that the program will continue through 2028 and is continuing to evaluate additional opportunities to improve the overall efficiency and effectiveness of our operations. The program includes severance and other employee costs, asset impairments and accelerated asset amortization, and the operating results of certain small non-strategic businesses that we plan to discontinue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2026, we reported total costs of $<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1089">380</ix:nonFraction> million pre-tax ($<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-6" name="ci:RestructuringChargesNetOfTaxExpense" scale="6" id="f-1090">290</ix:nonFraction> million after-tax) associated with this initiative, compared with $<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1091">215</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-6" name="ci:RestructuringChargesNetOfTaxExpense" scale="6" id="f-1092">163</ix:nonFraction> million after-tax) for the three months ended March&#160;31, 2025. The total costs for the three months ended March&#160;31, 2026 included $<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1093">377</ix:nonFraction> million, pre-tax in Selling, general and administrative expenses, which was primarily associated with severance ($<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1094">337</ix:nonFraction> million). The total costs for the three months ended March&#160;31, 2025 included $<ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1095">198</ix:nonFraction> million, pre-tax in Selling, general and administrative expenses, which was primarily associated with severance ($<ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1096">171</ix:nonFraction> million). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Program-to-date total costs of $<ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-1097">1,129</ix:nonFraction> million pre-tax ($<ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-6" name="ci:RestructuringChargesNetOfTaxExpense" scale="6" id="f-1098">855</ix:nonFraction> million after-tax) included $<ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1099">993</ix:nonFraction> million in Selling, general and administrative expenses, which were primarily associated with severance ($<ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1100">715</ix:nonFraction> million) and asset impairments ($<ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1101">101</ix:nonFraction> million). The remainder of the total program costs reflects the operating results of certain non-strategic businesses. We expect substantially all of the accrued liability to be paid by the end of 2026. See Note 15 to the Consolidated Financial Statements for further details of the strategic optimization program by segment.</span></div></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_6125"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-1102" escape="true"><ix:continuation id="f-1088-1"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2025</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-1103">140</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2026 charges</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1104">337</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2026 payments</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-1105">75</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2026</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-1106">402</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_880"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1107" continuedAt="f-1107-1" escape="true"><div><span id="if8a7d32f2f9a48df9d2560389dd78819_12"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 13 &#8211; Income Taxes</span></div></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_904"></div><div style="margin-bottom:10pt;margin-top:10pt"><ix:continuation id="f-1107-1" continuedAt="f-1107-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense. </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1107-2">The <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1108">18.0</ix:nonFraction>% effective tax rate for the three months ended March&#160;31, 2026 was higher than the <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1109">14.5</ix:nonFraction>% rate for the three months ended March&#160;31, 2025 primarily due to the absence of a benefit related to the</ix:continuation> HCSC transaction. </span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_913"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1110" continuedAt="f-1110-1" escape="true"><div style="margin-bottom:10pt"><span id="iac22c09659494a23aa923ff1c0be1036_2784"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 14 &#8211; Contingencies and Other Matters</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" id="f-1111" continuedAt="f-1111-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Financial Guarantees: Retiree and Life Insurance Benefits</span></ix:nonNumeric></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1111-1" continuedAt="f-1111-2">The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.</ix:continuation> As of March&#160;31, 2026, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-6" name="us-gaap:GuaranteeObligationsMaximumExposure" scale="6" id="f-1112"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-6" name="us-gaap:GuaranteeObligationsLiquidationProceeds" scale="6" id="f-1113">390</ix:nonFraction></ix:nonFraction> million. <ix:continuation id="f-1111-2" continuedAt="f-1111-3">An additional liability is established if management believes that the Company will be required to make payments under the guarantees;</ix:continuation> there were <ix:nonFraction unitRef="usd" contextRef="c-339" decimals="INF" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" format="ixt:fixed-zero" scale="6" id="f-1114">no</ix:nonFraction> additional liabilities required for these guarantees, net of reinsurance, as of March&#160;31, 2026. <ix:continuation id="f-1111-3" continuedAt="f-1111-4">Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.</ix:continuation></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><ix:continuation id="f-1111-4" continuedAt="f-1111-5"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Certain Other Guarantees</span></ix:continuation></div><ix:continuation id="f-1111-5" continuedAt="f-1111-6"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company had indemnification obligations as of March&#160;31, 2026 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. </span></div></ix:continuation></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1110-1" continuedAt="f-1110-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1111-6">The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="c-341" decimals="INF" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" format="ixt:fixed-zero" scale="0" id="f-1115">no</ix:nonFraction> recorded liabilities for these indemnification obligations as of March&#160;31, 2026.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Guaranty Fund Assessments</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the three months ended March&#160;31, 2026.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_919"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><ix:continuation id="f-1110-2" continuedAt="f-1110-3"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Legal and Regulatory Matters</span></ix:continuation></div><ix:continuation id="f-1110-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_928"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1116" continuedAt="f-1116-1" escape="true"><div style="margin-bottom:10pt"><span id="ia0e64411f920407abbeb7bfa2e95bbb4_620"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 15 &#8211; Segment Information</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-1117" continuedAt="f-1117-1" escape="true">Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chair and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to each segment and assessing its performance.</ix:nonNumeric></span></div><ix:continuation id="f-1117-1" continuedAt="f-1117-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. </span></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1117-2">The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.</ix:continuation> </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not report total assets by segment because this is not a metric used by the CODM to allocate resources or evaluate segment performance.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_934"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="ci:ScheduleOfSpecialItemsTableTextBlock" id="f-1118" escape="true"><ix:continuation id="f-1116-1" continuedAt="f-1116-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:65.427%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.377%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Strategic optimization program</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(primarily Selling, general and administrative expenses)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1119">380</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-6" name="ci:RestructuringChargesNetOfTaxExpense" scale="6" id="f-1120">290</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1121">215</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-6" name="ci:RestructuringChargesNetOfTaxExpense" scale="6" id="f-1122">163</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Integration and transaction-related costs</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(Selling, general and administrative expenses)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-1123">35</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:TransactionRelatedCostsAfterTax" scale="6" id="f-1124">27</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-1125">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:TransactionRelatedCostsAfterTax" scale="6" id="f-1126">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Deferred tax expenses, net</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(Income taxes, less amount attributable to noncontrolling interests)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SpecialItemChargeBenefitTaxMatters" format="ixt:fixed-zero" scale="6" id="f-1127">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SpecialItemChargeBenefitTaxMattersAfterTax" scale="6" id="f-1128">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:SpecialItemChargeBenefitTaxMatters" format="ixt:fixed-zero" scale="6" id="f-1129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:SpecialItemChargeBenefitTaxMattersAfterTax" scale="6" id="f-1130">17</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Gain) on sale of businesses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:fixed-zero" scale="6" id="f-1131">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax" scale="6" id="f-1132">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" scale="6" id="f-1133">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax" scale="6" id="f-1134">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Benefits) associated with litigation matters</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(Selling, general and administrative expenses)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-1135">11</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitAfterTaxLitigation" scale="6" id="f-1136">8</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-1137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:SpecialItemChargeBenefitAfterTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-1138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total impact from special items</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity" scale="6" id="f-1139">404</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity" scale="6" id="f-1140">322</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity" scale="6" id="f-1141">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="ci:SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity" scale="6" id="f-1142">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_469"></div><ix:continuation id="f-1116-2" continuedAt="f-1116-3"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Integration and Transaction-Related Costs. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March&#160;31, 2026 and March&#160;31, 2025 the Company incurred transaction-related costs, as shown in the table above, associated with the HCSC transaction. These costs incurred consisted primarily of post-closing technology activities to separate the divested systems; fees for legal, advisory and other professional services; and certain employment-related costs.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_940"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1143" continuedAt="f-1143-1" escape="true"><ix:continuation id="f-1116-3" continuedAt="f-1116-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Summarized segment financial information was as follows:</span></div></ix:continuation></ix:nonNumeric><div id="i9262e6da8fb24f8e98f20abd6e5292a7_949"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:115%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-1144" continuedAt="f-1144-1" escape="true"><ix:continuation id="f-1143-1" continuedAt="f-1143-2"><ix:continuation id="f-1116-4" continuedAt="f-1116-5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2026</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1145">58,206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1146">10,039</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="ci:NonInvestmentRevenue" scale="6" id="f-1147">47</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:fixed-zero" scale="6" id="f-1148">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1149">68,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" scale="6" id="f-1150">211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1151">1,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" scale="6" id="f-1152">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1153">1,526</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-1154">25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-1155">103</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-1156">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-1157">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-1158">202</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1159">58,442</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1160">11,454</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-1161">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1162">1,522</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1163">68,494</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net investment results from certain equity method investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:NetInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-1164">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" sign="-" name="ci:NetInvestmentGainsLossesEquityMethodInvestments" scale="6" id="f-1165">23</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="ci:NetInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-1166">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="ci:NetInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-1167">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:NetInvestmentGainsLossesEquityMethodInvestments" scale="6" id="f-1168">23</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-1169">58,442</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-1170">11,477</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="ci:SegmentRevenues" scale="6" id="f-1171">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-6" sign="-" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-1172">1,522</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-1173">68,517</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-1174">55,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="f-1175">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:fixed-zero" scale="6" id="f-1176">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="f-1177">7,664</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" format="ixt:num-dot-decimal" scale="6" id="f-1178">1,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" format="ixt:num-dot-decimal" scale="6" id="f-1179">2,301</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1180">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1181">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" scale="6" id="f-1182">226</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1183">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1184">1,466</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1185">1,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1186">27</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" sign="-" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1187">404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1188">2,603</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1189">1,561</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1190">1,481</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1191">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1192">796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1193">2,270</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-1194">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1195">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1196">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1197">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-1198">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-1199">261</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" sign="-" name="ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-1200">29</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-1201">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-1202">3</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-1203">235</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1204">388</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1205">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1206">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1207">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1208">390</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Strategic optimization program</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1209">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1210">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1211">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1212">360</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1213">380</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-1214">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-1215">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-1216">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-1217">35</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-1218">35</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Benefits) associated with litigation matters</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-1219">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-1220">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-1221">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-1222">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-1223">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1224">1,466</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1225">1,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1226">27</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" sign="-" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1227">404</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1228">2,603</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other segment information</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-1229">560</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-1230">83</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-1231">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-1232">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-1233">650</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation></ix:nonNumeric></div><ix:continuation id="f-1144-1" continuedAt="f-1144-2"><ix:continuation id="f-1143-2" continuedAt="f-1143-3"><ix:continuation id="f-1116-5" continuedAt="f-1116-6"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. </span></div></ix:continuation></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_952"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1116-6" continuedAt="f-1116-7"><ix:continuation id="f-1144-2" continuedAt="f-1144-3"><ix:continuation id="f-1143-3" continuedAt="f-1143-4"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1234">52,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1235">13,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-6" name="ci:NonInvestmentRevenue" scale="6" id="f-1236">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:fixed-zero" scale="6" id="f-1237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1238">65,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1239">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1240">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" scale="6" id="f-1241">12</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1242">2,891</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-1243">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-1244">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-1245">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-1246">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-1247">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1248">53,681</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1249">14,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-1250">175</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1251">2,886</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1252">65,502</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ci:NetInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-1253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:NetInvestmentGainsLossesEquityMethodInvestments" scale="6" id="f-1254">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="ci:NetInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-1255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="ci:NetInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-1256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:NetInvestmentGainsLossesEquityMethodInvestments" scale="6" id="f-1257">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-1258">53,681</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-1259">14,482</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="ci:SegmentRevenues" scale="6" id="f-1260">175</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-6" sign="-" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-1261">2,886</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-1262">65,452</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-1263">51,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="f-1264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:fixed-zero" scale="6" id="f-1265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="f-1266">10,385</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" format="ixt:num-dot-decimal" scale="6" id="f-1267">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" format="ixt:num-dot-decimal" scale="6" id="f-1268">2,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="f-1269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1270">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" scale="6" id="f-1271">102</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1273">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1274">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-1275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" sign="-" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1276">411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1277">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1278">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1279">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1280">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1281">804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1282">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-1283">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-1287">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-1288">4</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-1289">47</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" sign="-" name="ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-1290">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-1291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-1292">48</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1293">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1294">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1297">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Integration and transaction-related costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-1298">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-1299">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-1300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-1301">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-1302">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Strategic optimization program</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1303">21</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-1304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1305">17</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1306">177</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-1307">215</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Gain) on sale of businesses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" scale="6" id="f-1308">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" scale="6" id="f-1309">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:fixed-zero" scale="6" id="f-1310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:fixed-zero" scale="6" id="f-1311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" scale="6" id="f-1312">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1313">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1314">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-1315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" sign="-" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1316">411</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1317">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other segment information</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-1318">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-1319">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-1320">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-1321">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-1322">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.</span></div></ix:continuation></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><ix:continuation id="f-1144-3" continuedAt="f-1144-4"><ix:continuation id="f-1143-4" continuedAt="f-1143-5"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"><ix:continuation id="f-1144-4"><ix:continuation id="f-1143-5">Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.</ix:continuation></ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_958"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-1323" escape="true"><ix:continuation id="f-1116-7" continuedAt="f-1116-8"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from external customers includes Pharmacy revenues, Premiums, and Fees and other revenues. The following table presents these revenues by product, premium and service type:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.011%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Products (Pharmacy revenues) (ASC 606)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Network revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1324">31,080</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1325">28,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Home delivery and specialty revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1326">19,788</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1327">18,937</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1328">3,426</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1329">3,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Evernorth Health Services</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1330">54,294</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1331">50,226</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1332">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1333">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and eliminations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1334">257</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1335">1,606</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Pharmacy revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1336">54,037</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1337">48,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Insurance premiums (ASC 944)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Employer insured</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1338">4,996</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1339">4,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1340">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1341">2,363</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Stop loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1342">2,116</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1343">1,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Individual and Family Plans</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1344">873</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1345">859</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1346">507</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1347">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1348">8,492</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1349">11,650</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">International Health</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1350">1,113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1351">978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Cigna Healthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1352">9,605</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1353">12,628</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1354">53</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1355">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and eliminations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1356">154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1357">27</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Premiums</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1358">9,812</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1359">12,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Services (Fees) (ASC 606) and other revenues</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1360">4,123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1361">3,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1362">1,746</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1363">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1364">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1365">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and eliminations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1366">1,423</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1367">1,312</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Fees and other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1368">4,443</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1369">3,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from external customers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1370">68,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1371">65,264</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other revenues for the three months ended March&#160;31, 2026 and 2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">were $<ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1372">159</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1373">162</ix:nonFraction> million, respectively.</span></div></ix:continuation></ix:nonNumeric><div style="text-indent:9pt"><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_964"></div><ix:continuation id="f-1116-8"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial and performance guarantees. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-1374" escape="true">Evernorth Health Services may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period, and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period.</ix:nonNumeric> Historically, adjustments to original estimates have not been material. This guarantee liability was $<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-8" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="9" id="f-1375">2.0</ix:nonFraction> billion as of March&#160;31, 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-8" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="9" id="f-1376">1.8</ix:nonFraction> billion as of December&#160;31, 2025.</span></div></ix:continuation><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1138"></div><div><span id="i7d396a193e50446482d18fa9d63f9252_14"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_106"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A") is intended to provide information to assist you in better understanding and evaluating our financial condition as of March&#160;31, 2026 compared with December&#160;31, 2025 and our results of operations for the three months ended March&#160;31, 2026 compared with the same period last year, and is intended to help you understand the ongoing trends in our business. We encourage you to read this MD&amp;A in conjunction with our Consolidated Financial Statements included in Part I, Item 1 in this Form 10-Q and our Annual Report on Form 10-K for the year ended December&#160;31, 2025 ("2025 Form 10-K"). In particular, we encourage you to refer to the "Risk Factors" contained in Part I, Item 1A in our 2025 Form 10-K.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_109"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unless otherwise indicated, financial information in this MD&amp;A is presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). See Note 2 to the Consolidated Financial Statements in our 2025 Form 10-K for additional information regarding the Company's significant accounting policies and see Note 2 to the Consolidated Financial </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Statements in this Form 10-Q for updates to those policies resulting from adopting new accounting guidance, if any. The preparation of interim consolidated financial statements necessarily relies heavily on estimates. This and certain other factors call for caution in estimating full-year results based on interim results of operations. In some of our financial tables in this MD&amp;A, we present either percentage changes or "N/M" when those changes are so large as to become not meaningful. Changes in percentages are expressed in basis points ("bps").</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_118"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In this MD&amp;A, our consolidated measures "adjusted income from operations," earnings per share on that same basis and "adjusted revenues" are not determined in accordance with GAAP and should not be viewed as substitutes for the most directly comparable GAAP measures of "shareholders' net income," "earnings per share" and "total revenues." We also use pre-tax adjusted income (loss) from operations and adjusted revenues to measure the results of our segments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability. We define adjusted income (loss) from operations as shareholders' net income (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See the below Financial Highlights section for a reconciliation of consolidated adjusted income from operations to shareholders' net income. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See the below Financial Highlights section for a reconciliation of consolidated adjusted revenues to total revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">See Note 15 to the Consolidated Financial Statements for additional discussion of these metrics and a reconciliation of income (loss) before income taxes to pre-tax adjusted income (loss) from operations, as well as a reconciliation of Total revenues to adjusted revenues. Note 15 to the Consolidated Financial Statements also explains that segment revenues include both external revenues and sales between segments that are eliminated in Corporate. Ratios presented in the segment discussion exclude the same items as adjusted revenues and pre-tax adjusted income (loss) from operations.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_121"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy, and strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of developing inflationary and interest rate pressures; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions and their expected benefits; and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in Part I, Item 1A - "Risk Factors" in our 2025 Form 10-K, discussed in Part II, Item 7 - "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2025 Form 10-K, and as described from time to time in our future reports filed with the Securities and Exchange Commission.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_124"></div><div style="margin-bottom:10pt"><span id="i598a8e67993643b996f1fe04bbd9ef94_408"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">EXECUTIVE OVERVIEW</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. For further information on our business and strategy, see Part I, Item 1 - "Business" in our 2025 Form 10-K. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_127"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Financial Highlights</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_130"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.720%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Results of Operations (GAAP basis)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="18" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">54,037</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">48,633&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">9,812</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Fees and other revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,443</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,895&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,494</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,502&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">54,100</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">48,398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs and other benefit expenses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,924</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10,498&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,722</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">390</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total benefits and expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">66,136</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">63,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Income from operations</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,358</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of businesses</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment gains (losses)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,270</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,861</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,654</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">18.0</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_133"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of Shareholders' Net Income (GAAP) to Adjusted Income from Operations</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,654</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment (gains) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(235)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(233)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">390</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">315</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Strategic optimization program</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">380</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">290</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Integration and transaction-related costs</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Deferred tax expenses, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Gain) on sale of businesses</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Benefits) associated with litigation matters</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total special items</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">322</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted income from operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,058</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.</span></div><div style="text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:68.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of Shareholders' Net Income (GAAP) to Adjusted Income from Operations</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Diluted earnings per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6.26</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4.85&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment (gains) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(0.89)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(0.88)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.48</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.19</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Strategic optimization program</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.44</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.10</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Integration and transaction-related costs</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.13</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.10</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Deferred tax expenses, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.06</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Gain) on sale of businesses</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(0.01)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Benefits) associated with litigation matters</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total special items</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.53</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.22</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted income from operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7.79</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6.74&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_136"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.886%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial highlights by segment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="18" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted revenues by segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Evernorth Health Services</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">53,681&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">11,477</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate, net of eliminations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,522)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,517</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,452&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,494</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,502&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,654</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted income from operations</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,058</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Earnings per share (diluted)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' net income</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6.26</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4.85&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted income from operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7.79</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjusted income (loss) from operations by segment</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Evernorth Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,466</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,514</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate, net of eliminations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(404)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated pre-tax adjusted income from operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,603</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Income attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">226</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment gains </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">235</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(390)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,270</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_151"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Commentary: Three Months Ended March 31, 2026 versus Three Months Ended March 31, 2025</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The commentary presented below, and the segment commentaries that follow, compare results for the three months ended March&#160;31, 2026 with results for the three months ended March&#160;31, 2025. Commentary regarding percentage changes (or bps) and dollar variances represents the driver's impact on the overall category.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_157"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shareholders' net income </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">increased 25%, primarily reflecting higher adjusted income from operations in Cigna Healthcare, as well as Evernorth Health Services. See discussion of segment results in the "Segment Reporting" section.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted income from operations. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">See discussion of segment results in the "Segment Reporting" section.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">increased 11%, primarily reflecting changes in claims composition (defined in the "Segment Reporting" section) within our Pharmacy Benefit Services operating segment.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Premiums</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> decreased 23%, primarily driven by the impact of the HCSC transaction (defined in the "Segment Reporting" section) (-30%), offset primarily by higher premium rates within our ongoing U.S. Healthcare businesses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fees and other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">increased 14%, primarily reflecting growth in fee-based services within our Pharmacy Benefit Services operating segment.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net investment income</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> decreased 15%, primarily due to lower average assets, due to the impact of the HCSC transaction.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy and other service costs </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">increased 12%, primarily reflecting changes in claims composition within our Pharmacy Benefit Services operating segment.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Medical costs and other benefit expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">decreased 25%, primarily driven by the impact of the HCSC transaction (-32%), offset primarily by higher medical costs within our ongoing U.S. Healthcare businesses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Selling, general and administrative ("SG&amp;A") expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> decreased 12%, primarily impacted by the HCSC transaction.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Investment results </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">increased, primarily due to fair value changes of derivative instruments associated with certain equity securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The effective tax rate</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> increased, primarily due to the absence of a benefit related to the HCSC transaction.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_175"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">S<span id="i9e035d4c37684caa8376e337b13fdfdb_21"></span>EGMENT REPORTING</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_178"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Evernorth Health Services Segment</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Evernorth Health Services</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">includes our Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives. As described in the MD&amp;A</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">introduction, the performance of Evernorth Health Services is measured using adjusted revenues and pre-tax adjusted income (loss) from operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Key Factors Affecting Segment Performance</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The key factors that impact the segment's revenues and income from operations are claims volume, claims composition and client- and customer-focused initiatives. Specialty and Care Services revenues are also impacted by customer and client growth. These key factors are discussed further below. See Note 2 to the Consolidated Financial Statements in our 2025 Form 10-K for additional information on revenue and cost recognition policies for this segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Key factors that impact both Pharmacy Benefit Services and Specialty and Care Services:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Pharmacy claim volume (also referred to as utilization) relates to processing prescription claims filled by retail pharmacies in our network and dispensing prescription claims from our home delivery and specialty pharmacies, along with other claims. Pharmacy claim volume is impacted by new clients or organic customer growth through the expansion of existing clients or through the loss of customers and business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The composition of claims generally considers the types of drugs, including the mix of claims among branded and higher priced specialty drugs compared to generic or biosimilar alternatives. We manage pharmaceutical manufacturer increases in prices through programs designed to reduce drug spend, providing positive impacts on our clients, our customers and us. Changes to claims mix, including types of drugs, distribution methods, pharmaceutical manufacturer prices (including government programs) and alternative uses of drugs within our formularies continue to be a significant driver of our revenues and income from operations in the current environment. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The business continues to evolve amid changing legislative, regulatory, and client dynamics, including our business model plans announced in October 2025. The Company has undertaken certain client- and customer-focused initiatives, which include proactive renewals or extensions of large client contracts, investments to support the recently announced rebate-free model, and multi-stakeholder recontracting efforts (including affordability-related contract changes and responses to government programs such as the Inflation Reduction Act). These initiatives are intended to support long-term growth, reduce medication costs, and enhance transparency and are expected to impact income from operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Key factors that impact Specialty and Care Services:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Customer and client growth, both organic and new business, and key strategic relationships in our Specialty and Care Services business generally results in increased revenues and income from operations (also referred to as growth). This includes client movement in our specialty pharmacy, specialty distribution services, virtual care, benefits management and behavioral health services as we expand our businesses.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_181"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.122%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.719%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial Summary</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">53,681&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income from operations </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,466</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax margin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">SG&amp;A expense ratio </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.8</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">See Note 15 to the Consolidated Financial Statements for reconciliation of adjusted revenues and pre-tax adjusted income from operations to Total revenues and Income before income taxes, respectively. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Pre-tax margin is calculated as pre-tax adjusted income from operations divided by adjusted revenues.</span></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">SG&amp;A expense ratio is calculated as segment selling, general and administrative expenses divided by adjusted revenues. See Note 15 to the Consolidated Financial Statements for further details.</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_184"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In this selected financial information, we present adjusted revenues and pre-tax income from operations by our two operating segments, Pharmacy Benefit Services and Specialty and Care Services. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.886%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Selected Financial Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars and adjusted scripts in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy Benefit Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">33,002</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">29,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Specialty and Care Services</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">25,440</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">23,939&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total adjusted revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">53,681&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy Benefit Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Specialty and Care Services</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,072</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total pre-tax adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,466</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pharmacy claim volume </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">527</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Non-specialty network prescriptions filled through 90-day programs and home delivery prescriptions are counted as three claims. All other network and specialty prescriptions are counted as one claim.</span></div><div style="text-indent:4.5pt"><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_187"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended March 31, 2026 versus Three Months Ended March 31, 2025</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Commentary in parentheses regarding percentage changes (or bps) represents the driver's impact on the overall category.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted revenues</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> increased 9%, primarily reflecting an increase due to claims composition in Pharmacy Benefit Services (+7%) and higher claims volume from customer growth in Specialty and Care Services (+2%).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pre-tax adjusted income from operations </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">increased 2%, primarily reflecting growth in Specialty and Care Services (+13%), partially offset by client- and customer-focused initiatives in Pharmacy Benefits Services (-8%) and a decrease in claims volume in Pharmacy Benefit Services (-3%).</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">SG&amp;A expense ratio </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">decreased 10 bps, primarily reflecting higher adjusted revenues as discussed above.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_193"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Cigna Healthcare Segment</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Cigna Healthcare includes our U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. As described in the MD&amp;A introduction, performance of the Cigna Healthcare segment is measured using adjusted revenues and pre-tax adjusted income from operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On March 19, 2025, the Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses within the U.S. Healthcare operating segment (the "HCSC transaction"). </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Key Factors Affecting Segment Performance </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The key factors that impact the segment's revenues and income from operations include revenue growth, customer growth, medical cost trend, the medical care ratio ("MCR") and the SG&amp;A expense ratio. These key factors are discussed further below. See Note 2 to the Consolidated Financial Statements in our 2025 Form 10-K for additional information on revenue and cost recognition policies for this segment.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Revenue growth includes increases to premium rates in consideration of anticipated medical cost increases, customer growth driven by new clients and customers, and increased fee revenue from the expansion of products and services to existing clients and customers, including solutions provided by Evernorth Health Services.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Higher medical costs (also referred to as higher medical cost trend) are impacted by utilization (the quantity of medical services consumed by our customers), unit costs (the cost per medical service) and mix of services. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">MCR represents medical costs as a percentage of premiums for our segment's insured businesses, and it is impacted by medical cost trend and premium rates. Affordability initiatives that serve to mitigate medical cost inflation also impact the MCR. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">The SG&amp;A expense ratio represents the segment's selling, general and administrative expenses divided by adjusted revenues.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_196"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.582%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial Summary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">11,477</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,482&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income from operations </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,514</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax margin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">13.2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical care ratio</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">79.8</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">SG&amp;A expense ratio </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">See Note 15 to the Consolidated Financial Statements for reconciliation of adjusted revenues and pre-tax adjusted income from operations to Total revenues and Income before income taxes, respectively. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Pre-tax margin is calculated as pre-tax adjusted income from operations divided by adjusted revenues.</span></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">SG&amp;A expense ratio is calculated as segment selling, general and administrative expenses divided by adjusted revenues. See Note 15 to the Consolidated Financial Statements for further details.</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_199"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2026 versus Three Months Ended March 31, 2025</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Commentary regarding percentage changes (or bps) and dollar variances represents the driver's impact on the overall category.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">decreased 21%, or $3,005 million, primarily due to the impact of the HCSC transaction (-$3,850 million), partially offset by higher premiums within employer insured (+$308 million) and stop loss (+$248 million), primarily reflecting premium rate increases.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pre-tax adjusted income from operations </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">increased</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">18%, or $227 million, primarily due to higher contributions from U.S. Healthcare, reflecting improved margins in both the U.S. Employer and Individual and Family Plans businesses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">medical care ratio </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">decreased 240 bps, due to the impact of the HCSC transaction.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">SG&amp;A expense ratio </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">increased 60 bps, primarily due to the impact of the HCSC transaction (+170 bps), partially offset by expense management efficiencies (-70 bps) and revenue growth outpacing volume-related expenses within the ongoing businesses (-60 bps).</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_205"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Medical Customers</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Medical customers include individuals who meet any of the following criteria: (i) are covered under a medical insurance policy, managed care arrangement or administrative services agreement issued by Cigna Healthcare; (ii) have access to the Cigna Healthcare provider network for covered services under their medical plan; or (iii) have medical claims that are administered by Cigna Healthcare.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.886%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare Medical Customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of <br/>March 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,493</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,645&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">International Health </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,241</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Insured</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,734</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,872&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">14,130</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13,719&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">International Health </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">470</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Administrative services only</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">14,600</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,171&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">18,334</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18,043&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">International Health excludes medical customers served by less than 100%-owned subsidiaries, as well as certain customers served by our third-party administrator.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total medical customers increased 2%, primarily due to customer growth within the Middle Market and Select market segments (+3% and +1%, respectively), partially offset by a decrease in National Accounts segment customers (-2%).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unpaid Claims and Claim Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our unpaid claims and claim expenses liability increased to $4,920 million as of March&#160;31, 2026 from $4,241 million as of December&#160;31, 2025, primarily due to stop loss seasonality.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_208"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Operations</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Other Operations includes corporate-owned life insurance ("COLI"), the Company's run-off operations and other non-strategic businesses. As described in the MD&amp;A introduction, performance of Other Operations is measured using adjusted revenues and pre-tax adjusted income from operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.538%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:4.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.580%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial Summary</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income from operations</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax margin</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">22.5</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2026 versus Three Months Ended March 31, 2025</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">decreased and</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> Pre-tax adjusted income from operations </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">increased, primarily driven by the discontinuation of certain small non-strategic businesses.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_214"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.886%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial Summary</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted loss from operations</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(404)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended March 31, 2026 versus Three Months Ended March 31, 2025</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pre-tax adjusted loss from operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> decreased, primarily due to lower interest expense.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_223"></div><div><span id="idbe0413b51404b4db57b70c1875cbcc1_36"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">LIQUIDITY AND CAPITAL RESOURCES</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_229"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidity</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's cash requirements generally consist of pharmacy, medical and other benefit costs; operating and capital expenditures primarily for employee compensation and benefits, information technology, and facilities costs; purchases of investment securities; income taxes; debt service; and payment of declared dividends. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Liquidity requirements are generally met by maintaining appropriate levels of cash, cash equivalents and short-term investments; using cash flows from operating activities; matching durations of investments to estimated durations for the related liabilities; selling investments; and using proceeds from issuing debt and common stock.</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_232"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Cash flows for the three months ended March 31 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.708%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,131</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,920&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(637)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,141)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(3,681)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following discussion explains variances in the various categories of cash flows for the three months ended March&#160;31, 2026 compared with the same period in 2025. </span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_238"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities consist principally of cash receipts and disbursements for pharmacy revenues and costs, premiums and medical costs, fees, investment income, taxes, and other expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash flows decreased for the three months ended March&#160;31, 2026, primarily due to the unfavorable net cash flow impact related to the Inflation Reduction Act, lower insurance liabilities, and the timing of pharmaceutical manufacturer receivables. These decreases are partially offset by the favorable timing of noninsurance customer receivables and accounts receivable factoring settlements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cash used in investing activities reflects the absence of the net proceeds from the HCSC transaction.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in net cash used in financing activities in 2026 is primarily driven by the absence of share repurchases as well as lower debt repayments.</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_241"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Capital Resources</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our capital resources consist primarily of cash, cash equivalents and investments maintained at regulated subsidiaries required to underwrite insurance risks, cash flows from operating activities, our commercial paper program, revolving credit facility, and the issuance of long-term debt and equity securities. Our businesses generate significant cash flows from operations, some of which is </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">subject to regulatory restrictions relative to the amount and timing of dividend payments to the parent company. Dividends received from U.S.-regulated subsidiaries were $0.5 billion for the three months ended March&#160;31, 2026 and 2025. Non-regulated subsidiaries also generate significant cash flows from operating activities, which are typically available immediately to the parent company for general corporate purposes. </span></div><div style="margin-bottom:12pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Funds Available</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Paper Program</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> There was no commercial paper outstanding balance as of March&#160;31, 2026.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revolving Credit Agreement. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our revolving credit agreement provides us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed above. See Note 6 to the Consolidated Financial Statements for further information on our credit agreement and commercial paper program. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2026, we had $6.5 billion of undrawn committed capacity under our revolving credit agreement (these amounts are available for general corporate purposes, including providing liquidity support for our commercial paper program), $6.5&#160;billion of remaining capacity under our commercial paper program, and $7.3 billion in cash and short-term investments, approximately $1.1 billion of which was held by the parent company or certain non-regulated subsidiaries.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our debt-to-capitalization ratio (calculated as Short-term debt and Long-term debt ("Total debt") as a percentage of Total shareholders' equity and Total debt ("Total capitalization")) was 42.3% and 43.0% as of March&#160;31, 2026 and December&#160;31, 2025, respectively. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We actively monitor our debt obligations and engage in issuance and repayment activities as needed in accordance with our capital management strategy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Subsidiary Borrowings. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the sources of liquidity discussed above, the parent company can borrow an additional $1.4 billion from its subsidiaries without further approvals as of March&#160;31, 2026.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Regulatory Restrictions. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Dividends from our insurance, Health Maintenance Organization ("HMO") and certain foreign subsidiaries are subject to regulatory restrictions. See Note 20 to the Consolidated Financial Statements in our 2025 Form 10-K for additional information regarding these restrictions. Most of the Evernorth Health Services segment operations are not subject to regulatory restrictions regarding dividends and therefore provide significant financial flexibility to The Cigna Group.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Use of Capital Resources</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our capital resources are directed towards several areas, including (i) investing in capital expenditures (primarily related to technology to support innovative solutions for our clients and customers), providing the capital necessary to maintain or improve the financial strength ratings of subsidiaries, and repaying debt and funding pension obligations if necessary; (ii) paying dividends to shareholders; (iii) considering acquisitions and investments that are strategically and economically advantageous; and (iv) returning capital to shareholders through share repurchases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Short-Term and Long-Term Debt. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">See Note 6 to the Consolidated Financial Statements for further information regarding changes to our short-term and long-term debt. The Company may, from time to time, repay or repurchase debt in advance of maturities when it deems appropriate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Capital Expenditures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Capital expenditures for property, equipment and computer software were $0.3 billion in both the three months ended March&#160;31, 2026 and 2025. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Dividends</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by our Board of Directors ("Board") and our Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. See Note 5 to the Consolidated Financial Statements for further information regarding future dividend declarations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company maintains a share repurchase program authorized by our Board, under which it may repurchase shares of its common stock from time to time. There were no share repurchases during the three months ended March&#160;31, 2026, compared with repurchases of 5.0 million shares for approximately $1.5 billion during the three months ended March&#160;31, 2025. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_250"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Risks to Liquidity and Capital Resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Risks to our liquidity and capital resources outlook include cash projections that may not be realized, and the demand for funds could exceed available cash if our ongoing businesses experience unexpected shortfalls in earnings or we experience material adverse effects from one or more risks or uncertainties described more fully in the "Risk Factors" section in our 2025 Form 10-K. </span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_256"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Guarantees and Contractual Obligations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We are contingently liable for various contractual obligations and financial and other guarantees entered into in the ordinary course of business. See Note 14 to the Consolidated Financial Statements for discussion of various guarantees. </span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_259"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2026, there were no material changes to the guarantees and contractual obligations set forth in our 2025 Form 10-K.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_265"></div><div style="margin-bottom:10pt"><span id="i58870937e7cc446db905f140d6181896_874"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect reported amounts and related disclosures in the Consolidated Financial Statements. Management considers an accounting estimate to be critical if:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">it requires assumptions to be made that were uncertain at the time the estimate was made; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in the estimate or different estimates that could have been selected could have a material effect on our consolidated results of operations or financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Management has discussed how critical accounting estimates are developed and selected with the Audit and Compliance Committee of our Board, and the Audit and Compliance Committee has reviewed the disclosures presented in our 2025 Form 10-K. We regularly evaluate items that may impact critical accounting estimates.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_268"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our most critical accounting estimates, as well as the effect of hypothetical changes in material assumptions used to develop each estimate, are described in our 2025 Form 10-K. As of March&#160;31, 2026, there were no significant changes to the critical accounting estimates from what was reported in our 2025 Form 10-K.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_280"></div><div style="margin-bottom:10pt"><span id="i467f5443aa7a4f0393eb3b99cb39b716_6287"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INVESTMENT ASSETS</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding our investment assets is included in Notes 9, 10 and 11 to the Consolidated Financial Statements. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Investment Outlook</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Investment results will be driven largely by market conditions that are not reasonably predictable. We believe that the vast majority of our investments will continue to perform under their contractual terms. We manage the portfolio for long-term economics; therefore, we expect to hold a significant portion of these assets for the long term. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The below discussion addresses the strategies and risks associated with our various classes of investment assets. See Part I, Item 1A - "Risk Factors" in our 2025 Form 10-K for additional information regarding risks associated with our investment portfolio.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Debt Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The carrying value of our debt securities portfolio decreased from $8.4&#160;billion as of December&#160;31, 2025 to $8.3&#160;billion as of March&#160;31, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio remains in a net unrealized depreciation position due to generally increasing interest rates over the past few years. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2026, $7.3&#160;billion, or 88%, of the debt securities in our investment portfolio were investment grade (Baa and above, or equivalent) and the remaining $1.0&#160;billion were below investment grade. The majority of the bonds that are below investment grade were rated at the higher end of the non-investment-grade spectrum. These quality characteristics have not materially changed since the prior year and remain consistent with our investment strategy. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Commercial Mortgage Loans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2026, our $1.3&#160;billion commercial mortgage loan portfolio consisted of approximately 40 fixed-rate loans. Given the quality and diversity of the underlying real estate, positive debt service coverage, loan-to-value ratio and significant borrower cash invested in the property generally ranging between 30% and 40%, we remain confident that the vast majority of borrowers will </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">continue to perform as expected under their contract terms. For further discussion of the results and changes in key credit quality indicators, see Note 9 to the Consolidated Financial Statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Office sector fundamentals are weak but have begun to stabilize for higher-quality assets. Our commercial mortgage loan portfolio has approximately 25% exposure to office properties. Although future losses remain possible due to further credit deterioration, we do not expect these losses to have a material unfavorable effect on our results of operations, financial condition or liquidity.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Other Long-Term Investments</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments of $5.2 billion as of March&#160;31, 2026 included investments in securities limited partnerships and real estate limited partnerships, direct investments in real estate joint ventures, and other deposit activity that is required to support various insurance and health services businesses. These limited partnership entities typically invest in mezzanine debt or equity of privately held companies and equity real estate. Given our subordinate position in the capital structure of these underlying entities, we assume a higher level of risk for higher expected returns. To mitigate risk, these investments are diversified by industry sector or property type and geographic region.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We expect continued volatility in private equity and real estate fund performance going forward as fair market valuations are adjusted to reflect market and portfolio transactions. Less than 4% of our other long-term investments are exposed to real estate in the office sector.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Unconsolidated Subsidiary Investments Portfolio</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We participate in an insurance joint venture in China with a 50% ownership interest. We account for this joint venture under the equity method of accounting. Our 50% share of the investment portfolio supporting the joint venture's liabilities was approximately $19.1 billion as of March&#160;31, 2026. These investments were comprised of approximately 70% debt securities, including government and corporate debt diversified by issuer, industry and geography; 20% equities, including mutual funds, equity securities and private equity partnerships; and 10% long-term deposits and policy loans. We continuously review the joint venture's investment strategy and its execution. There were no investments with a material unrealized loss as of March&#160;31, 2026. See Note 14 to the Consolidated Financial Statements in our 2025 Form 10-K for additional information regarding unconsolidated subsidiaries.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_283"></div><div style="margin-bottom:10pt"><span id="if882fc915957417583b028a9a8674c9e_15"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">MARKET RISK</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_286"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our assets and liabilities include financial instruments subject to the risk of potential losses from adverse changes in market rates and prices. Our primary market risk exposure is interest rate risk. We encourage you to read this in conjunction with "Market Risk &#8211; Financial Instruments" included in the MD&amp;A section in our 2025 Form 10-K. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2026, there was no material change in our risk exposure as reported in our 2025 Form 10-K. </span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1141"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i9fe3f415c1b94e4dbd0f1d104014ee88_296"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Information responsive to this item is contained under the caption "Market Risk" in Item 2 above, Management's Discussion and Analysis of Financial Condition and Results of Operations, and is incorporated herein by reference.</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1144"></div><div style="margin-bottom:10pt"><span id="i0b95f61df3be44c1b3d01bb4453b18af_35"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 4. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">CONTROLS AND PROCEDURES</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_991"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Based on an evaluation of the effectiveness of The Cigna Group's disclosure controls and procedures conducted under the supervision and with the participation of The Cigna Group's management (including The Cigna Group's Chief Executive Officer and Chief Financial Officer), The Cigna Group's Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, The Cigna Group's disclosure controls and procedures are effective to ensure that information required to be disclosed by The Cigna Group in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to The Cigna Group's management (including The Cigna Group's Chief Executive Officer and Chief Financial Officer) as appropriate to allow timely decisions regarding required disclosure.</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_997"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Change in Internal Control over Financial Reporting</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">There have been no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2026 that have materially affected, or are reasonably likely to materially affect, The Cigna Group's internal control over financial reporting. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1147"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="iec37c2956eb345e588c4db739177b011_30"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Part II. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1150"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i11cc9f11d87543b5a14fa0ba9058f9ce_176"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The information contained under "Legal and Regulatory Matters" in Note 14 to the Consolidated Financial Statements is incorporated herein by reference.</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1153"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span id="if22a1f787baf46aea28c2a03ed651579_273"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A - "Risk Factors" in our Annual Report on Form 10-K for the year ended December&#160;31, 2025.</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1156"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i0b2dec755c7d407b9c021d5843330d6f_9"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_91"></div><div style="margin-bottom:12pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about The Cigna Group share repurchase activity for the quarter ended March&#160;31, 2026:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Total # of shares purchased</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Average price paid per share</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1) (3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Total # of shares purchased as part of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">publicly announced program</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Approximate dollar value of shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">that may yet be purchased as part</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">of publicly announced program </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">January 1 - 31, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">621</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">271.97</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">February 1 - 28, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">247,549</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">287.54</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">March 1 - 31, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">20,230</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">276.51</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">268,400</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">286.67</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Includes shares tendered by employees under the Company's equity compensation plans as follows: 1) payment of taxes on vesting of restricted stock (grants and units) and strategic performance shares and 2) payment of the exercise price and taxes for certain stock options exercised. Employees tendered 621 shares in January, 247,549 shares in February and 20,230 shares in March 2026.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Additionally, the Company maintains a share repurchase program authorized by the Board. Under this program, the Company may repurchase shares from time to time, depending on market conditions and alternate uses of capital. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through Rule 10b5-1 plans, open market purchases, each in compliance with Rule 10b-18 under the Exchange Act, or privately negotiated transactions. The program may be suspended or discontinued at any time and does not have an expiration date.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">The average price paid per share and approximate dollar value of shares exclude the impact of excise tax.</span></div><div><span><br/></span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1159"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i16f0e1fe2862453b9293549863747686_29"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1003"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rule 10b5-1 Plan Elections </span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1012"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2026, the following 10b5-1 director and officer trading plan arrangement <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1377"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1378"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1379">change</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> occurred:</span></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1015"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">1.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt"><ix:nonNumeric contextRef="c-57" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1380" escape="true">On <ix:nonNumeric contextRef="c-57" name="ecd:TrdArrAdoptionDate" id="f-1381">February&#160;6, 2026</ix:nonNumeric>, <ix:nonNumeric contextRef="c-57" name="ecd:TrdArrIndName" id="f-1382">David Cordani</ix:nonNumeric>, <ix:nonNumeric contextRef="c-57" name="ecd:TrdArrIndTitle" id="f-1383">Chair and Chief Executive Officer of The Cigna Group</ix:nonNumeric>, <ix:nonNumeric contextRef="c-57" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1384">adopted</ix:nonNumeric> a 10b5-1 plan. Mr. Cordani's plan provides for (i) the sale of shares of The Cigna Group common stock issuable upon vesting of performance awards (the actual number of shares depends on actual performance achieved and may range from 0% to 200% of the <ix:nonFraction unitRef="shares" contextRef="c-408" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1385">62,366</ix:nonFraction> shares subject to the awards at the target level of performance), net of shares withheld to satisfy applicable tax obligations; and (ii) the exercise of up to <ix:nonFraction unitRef="shares" contextRef="c-409" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1386">212,543</ix:nonFraction> vested stock options and the associated sale of shares of The Cigna Group common stock acquired upon exercise to cover the exercise price, applicable tax obligations and fees and 50% of the resulting net shares acquired upon exercise (such limitation reflecting The Cigna Group stock ownership guidelines), through <ix:nonNumeric contextRef="c-57" name="ecd:TrdArrExpirationDate" id="f-1387">April&#160;30, 2027</ix:nonNumeric>.</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934 and the Company's policies regarding insider transactions.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1162"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:10pt"><span id="i842070d9b2fa4a6d810996fccfdb9c99_40"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EXHIBITS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Method of Filing</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739940/000173994023000020/exh_31xrestatedxcharter.htm">Restated Certificate of Incorporation of The Cigna Group</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 3.1 to the Quarterly Report on Form 10-Q for the period ended June 30, 2023 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739940/000095015923000019/ex3-3.htm">Amended and Restated By-laws of The Cigna Group</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 3.3 to the Current Report on Form 8-K on February 13, 2023 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101.htm">Offer Letter for David Cordani dated February 25, 2026</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102.htm">Offer Letter for Brian Evanko dated February 25, 2026</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103.htm">Form of The Cigna Group Long-Term Incentive Plan (the &#8220;Cigna LTIP&#8221;): Nonqualified Stock Option Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit104.htm">Form of Cigna LTIP: Strategic Performance Share Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit105.htm">Form of Cigna LTIP: Restricted Stock Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit106.htm">Form of Cigna LTIP: Covenant Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit107.htm">Form of Cigna LTIP: Strategic Performance Share Grant Agreement for David Cordani</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_31126q1.htm">Certification of Chief Executive Officer of The Cigna Group pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_31226q1.htm">Certification of Chief Financial Officer of The Cigna Group pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_32126q1.htm">Certification of Chief Executive Officer of The Cigna Group pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_32226q1.htm">Certification of Chief Financial Officer of The Cigna Group pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from The Cigna Group Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2026, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Consolidated Statements of Income; (ii) the Consolidated Statements of Comprehensive Income; (iii) the Consolidated Balance Sheets; (iv) the Consolidated Statements of Total Equity; (v) the Consolidated Statements of Cash Flows; and (vi) the Notes to the Consolidated Financial Statements</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">* Indicates a management contract or compensatory plan or arrangement. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><div id="i9262e6da8fb24f8e98f20abd6e5292a7_1165"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:20pt;text-align:center"><span id="ia85ee1db33ce42b1943e70f683dca059_210"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Date: April&#160;30, 2026</span></div><div style="margin-bottom:10pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.888%"><tr><td style="width:1.0%"/><td style="width:2.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.675%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">THE CIGNA GROUP</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ann M. Dennison</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ann M. Dennison</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Authorized Signatory)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt;text-align:right"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ib24fd5606d714361817d89ebe3a1f157_1"></div><div style="min-height:108pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:12.00pt">Eric Wiseman</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:9.00pt">Lead Independent Director </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">February 25, 2026</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">David Cordani</font></div><div style="padding-right:-36pt"><font><br></font></div><div style="padding-right:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Dear David&#58;</font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-right:0.9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">I am pleased to confirm that the Board of Directors has approved the following changes to your compensation package effective July 1, 2026 (the &#8220;Effective Date&#8221;), in connection with the assumption of your role as Executive Chair of The Cigna Group&#58; </font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-left:18pt;padding-right:0.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Base Salary &#8211; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Your base salary will increase to a pre-tax annualized rate of $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> 1,000,000</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-left:18pt;padding-right:0.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Annual Incentive &#8211; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Your annual incentive target will be $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> 2,000,000 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and will be pro-rated for 2026 (payout in 2027) based on the Effective Date. As you know, the annual incentive is typically paid in the first quarter of the year following the performance year and is not considered earned until the paid.</font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-left:18pt;padding-right:0.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Long-Term Incentive &#8211; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You will continue to be eligible for annual long-term incentive awards, subject to the approval of the Board of Directors. Grants will are typically awarded in the first quarter each year.  </font></div><div style="padding-right:0.75pt"><font><br></font></div><div style="padding-right:0.75pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Your stock ownership guideline will continue to be eight times your base salary.&#160;</font></div><div style="padding-right:0.75pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Your employment will remain as an at-will employee, meaning that you or the Company has the right to terminate your employment relationship at any time for any reason or no reason. The changes above have no impact on previously awarded bonuses, stock options, restricted stock or SPS grants.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">As an executive of the company, your compensation will be subject to any future program changes.</font></div><div style="padding-right:-36pt"><font><br></font></div><div style="padding-right:-30.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">David, congratulations on your new role. I look forward to continuing to partner with you.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Sincerely,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Eric Wiseman</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Eric Wiseman</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.787%"><tr><td style="width:1.0%"></td><td style="width:15.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">cc&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">K. Stevens</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">N. Ryan</font></td></tr></table></div><div style="height:22.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ib668defc70fc419ebdc0939b3d375d78_1"></div><div style="min-height:107.28pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:12.00pt">David M. Cordani</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:9.00pt">Chairman and CEO</font></div><div><font><br></font></div><div style="margin-bottom:3pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">February 25, 2026</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Brian Evanko</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:10pt;padding-right:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Dear Brian&#58;</font></div><div style="margin-bottom:6pt;padding-right:0.7pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">I am pleased to confirm that the Board of Directors has approved the following changes to your compensation package effective July 1, 2026 (the &#8220;Effective Date&#8221;), in connection with the assumption of your role as the next Chief Executive Officer of The Cigna Group&#58; </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; Your base salary will increase to a pre-tax annualized rate of $1,300,000.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Annual Incentive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; Your annual incentive target will increase to $ 2,600,000 and will be pro-rated for 2026 (payout in 2027) based on the Effective Date. As you know, the annual incentive is typically paid in the first quarter of the year following the performance year and is not considered earned until the paid.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Long-Term Incentive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; Your annual long-term incentive target will increase to $ 15,100,000. Grants are typically awarded in the first quarter each year, may vary from 0 to 150% of target based on individual performance and potential, and consist of the following three components&#58;</font></div><div><font><br></font></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.61pt">Stock Options &#8211; Options typically vest over a three- year period and expire no later than 10 years after grant. The annual target is $ 2,265,000.</font></div><div style="text-indent:4.5pt"><font><br></font></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.61pt">Restricted Stock &#8211; Restricted stock typically vests over a three-year period. The annual target is $ 3,775,000.</font></div><div style="text-indent:4.5pt"><font><br></font></div><div style="margin-bottom:11pt;padding-left:31.7pt;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.81pt">Strategic Performance Shares (SPS) &#8211; SPS awards are typically paid or vested three years after the beginning of the performance period. Awards are not considered earned until the date paid or vested. The annual target is $ 9,060,000.</font></div><div style="margin-bottom:10pt;padding-right:0.7pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">NEW TOTAL ANNUAL COMPENSATION OPPORTUNITY&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">$</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> 19,000,000</font></div><div style="margin-bottom:10pt;padding-right:0.7pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Transitional Equity Awards.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The following one-time additional long-term incentive awards with an aggregate grant date target value of $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> 3,500,000</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> will be awarded to you subject to your assumption of the CEO role on July 1, 2026&#58;</font></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:5.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A stock option award with a grant date value of $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> 525,000</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:5.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A restricted stock award with a grant date value of $ </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">875,000</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:5.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">An SPS award for the 2026-2028 performance period with a grant date value of $ </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2,100,000</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#59; shares earned (paid) in 2029 on the regular cycle date per the plan&#8217;s formula.</font></div><div style="margin-bottom:10pt;padding-right:0.7pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Your stock ownership guideline will be eight times your base salary.&#160;As you know, each executive has five years from the date they become subject to the stock ownership guidelines to meet the guideline.</font></div><div style="height:22.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:107.28pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Your employment will remain as an at-will employee, meaning that you or the Company has the right to terminate your employment relationship at any time for any reason or no reason. The changes above have no impact on previously awarded bonuses, stock options, restricted stock or SPS grants.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">As an executive of the company, your compensation will be subject to any future program changes.</font></div><div style="padding-right:-30.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Brian, congratulations on your new role. I look forward to continuing to partner with you.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Sincerely,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; David M. Cordani</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">David M. Cordani</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.787%"><tr><td style="width:1.0%"></td><td style="width:15.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">cc&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">K. Stevens</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">N. Ryan</font></td></tr></table></div><div style="height:22.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i54ba832a05a84b93b91ea2a70dd4af83_1"></div><div style="min-height:50.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Cigna Group</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cigna Long-Term Incentive Plan&#58;  Nonqualified Stock Option Grant Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Cigna Group (&#8220;Cigna&#8221;) has granted you the option to purchase the number of shares of Cigna Common Stock set forth below in this Option Grant Agreement (&#8220;Option Grant&#8221;) under the Cigna Long-Term Incentive Plan (&#8220;Plan&#8221;).  The date of your Option Grant (&#8220;Grant Date&#8221;), the dates on which your Option Grant is scheduled to vest (&#8220;Vesting Dates&#8221;) and the date on which it is scheduled to expire (&#8220;Expiration Date&#8221;) are also indicated below. The award is subject to the provisions of the Plan and the Terms and Conditions below.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The award of Options pursuant to this Nonqualified Stock Option Grant is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">expressly conditioned</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> on your acceptance of the terms and conditions of this Option Grant and of the attached Confidentiality, Non-Competition and Non-Solicitation Agreement (or, with respect to Cigna company employment in California, the attached Confidentiality and Non-Solicitation Agreement) (as applicable, the &#8220;Covenant Agreement&#8221;).  You should carefully read all the terms and conditions of this Option Grant and the attached Covenant Agreement and be sure you understand what they say and what your responsibilities and obligations are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">before you click on the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to acknowledge and agree to this Option Grant.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you are not willing to agree to all of the Option Grant and Covenant Agreement terms and conditions, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">do not accept the Option Grant and do not click the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> for the Option Grant Acknowledgment and Agreement.  If you do not accept the Option Grant, you will not receive the benefits of the Option Grant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you do </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">click on the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, you are accepting and agreeing to all of the terms and conditions of this Option Grant and the Covenant Agreement, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Participant&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Type&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Plan Name&#58;  Cigna Long-Term Incentive Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Date&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Expiration Date&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Total Options Granted&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Option Price&#58;  (USD)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Vesting Schedule&#58; Please refer to Appendix&#58;  Vesting Schedule on the last page of this document</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition to this Nonqualified Stock Option Grant and the attached Covenant Agreement, you should also read the Plan Document and Key Contacts and Reference Materials document (attached to the Plan) and indicate that you have done so and agree to the terms of all documents attached to this Option Grant by checking the appropriate box in the online grant acceptance process.  The Key Contacts and Reference Materials document contains information on how to get important stock award information (such as the Plan Prospectus, Tax Considerations and Cigna's Securities Transactions and Insider Trading Policy) and whom to contact if you have questions.</font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Please be aware that the Cigna Securities Transactions and Insider Trading Policy places restrictions on your transactions in Cigna securities and requires certain Cigna employees to obtain advance permission from the Corporate Secretary before executing transactions in Cigna securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you have questions about your award, please contact Cigna Shareholder Services by email at </font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> or by phone at 215.761.3516.</font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Important Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  Option Grant and Covenant Agreement Acknowledgment and Agreement</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">By clicking on the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ACCEPT</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> button, I&#58;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Acknowledge and represent to Cigna that I have&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;received the Option Grant, the Terms and Conditions of the Option Grant and the Covenant Agreement&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;read and understand their terms and conditions, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions&#59; and </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;received answers to any questions I had about the Option Grant, the Terms and Conditions of the Option Grant and the Covenant Agreement and their respective terms and conditions, including the applicable restrictive covenants. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Scroll down for the TERMS AND CONDITIONS of the Option Grant.</font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">TERMS AND CONDITIONS OF YOUR &#91;YEAR&#93; GRANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">OF A NONQUALIFIED STOCK OPTION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">These Terms and Conditions are an important part of your grant of a nonqualified stock option (Option) from The Cigna Group (Cigna).  The terms of your Option are in (a) the electronic Option Grant Agreement above, (b) these Terms and Conditions, (c) the Covenant Agreement, and (d) the applicable Plan provisions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Certain words in this document with first letters capitalized are defined in the Option Grant Agreement above, these Terms and Conditions, or Article 2 of the Plan. This grant is void if you are not an employee of Cigna or a Subsidiary (a Cigna company) on the Grant Date. </font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The Option</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Option gives you the right to buy a certain number of shares of Cigna Common Stock (Shares) during the Option Period (described in paragraph 2) at the Option Price.  Your Option Grant Agreement lists the number of Shares and your Option Price.  To buy the Shares at the Option Price, you must exercise the Option.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Option Period&#59; Vesting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;You can exercise the Option only during the Option Period.  The Option becomes exercisable, or &#8220;vests,&#8221; on the first day of the Option Period and expires on the last day of the Option Period.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Option Period for the Shares (or for a portion of the Shares) starts on the applicable Vesting Date as shown in the Appendix&#58; Vesting Schedule.  The Appendix contains the Vesting Schedule for the Option.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Option Period for all the Shares ends, and the Option will expire, at 5&#58;00 p.m. Philadelphia time on the Expiration Date, or, if you have a Termination prior to that time, then the Option Period will end, and the Option will expire, as described under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Early Expiration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> in paragraph 4.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Unless the Option vests early or continues to vest under paragraph 3 below, any portion of the Option that is not vested and exercisable as of the date of your Termination shall be immediately and automatically forfeited.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Early or Continued Vesting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Option may vest earlier than the dates listed on the Appendix or continue to vest after your Termination date, as described here.  If your Termination occurs before the Option vests under the Vesting Schedule set forth on the Appendix, the Option will vest on your Termination date or continue to vest after your Termination date (as applicable), but only if your Termination is described in this paragraph 3 or as otherwise determined by the Committee.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Option will fully vest on your Termination date if your Termination is due to death or Disability or a Termination Upon a Change of Control.   </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Option </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">may continue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to vest following your Termination due to Early Retirement or Retirement if&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">The date of Termination due to your Early Retirement or Retirement is at least six (6) months after the Grant Date, provided that this requirement may be waived by (i) Cigna's Senior Human Resources Officer in certain limited and unanticipated circumstances, or (ii) with respect to the CEO or any executive officer who is subject to the requirements of Section 16(a) of the Exchange Act (&#8220;Executive Officer&#8221;), the Committee&#59;   </font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">You will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> be receiving severance pay from any Cigna company (whether under any severance benefit plan or any contract, agreement or arrangement)&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">You continue to comply with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period&#59; and </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">The Committee or its designee (including Cigna&#8217;s Senior Human Resources Officer) approves the continued vesting before your Termination.</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you want to be considered for continued vesting when you retire, you should review the &#8220;Ready to Retire&#8221; page on HR Central for more information or contact Cigna Shareholder Services (</font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) if you have questions.  You must submit your consideration request far enough in advance of your retirement so there is time to process your request.  </font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">A Termination resulting from a Cigna divestiture, outsourcing or other business transaction where you become employed by the buyer, vendor or other entity involved in the transaction will not constitute a Retirement or Early Retirement under this paragraph 3(b).  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Option </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">will continue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to vest for a period of twelve (12) months following the date of your Involuntary Termination as if you had remained employed for such twelve (12) month period.  For example, if the date of your Involuntary Termination is June 1, 2026 you will vest in any portion of the Option scheduled to vest on or before June 1, 2027 on the otherwise scheduled Vesting Date.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The continued vesting described in this paragraph 3(c) is subject to (and contingent upon) your ongoing compliance with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">A Termination resulting from a Cigna divestiture, outsourcing or other business transaction where you become employed by the buyer, vendor or other entity involved in the transaction will not constitute an Involuntary Termination under this paragraph 3(c).  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;If approved by (1) Cigna's Senior Human Resources Officer or his or her designee, or (2) the Committee (with respect to the CEO or any Executive Officer) before your Termination, your Option </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">may continue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to vest following your Termination if you (i) continue to provide services to Cigna as a consultant or contractor, and (ii) continue to comply with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The continued vesting period, if any, under this paragraph 3(d) shall be equal to the period of your continued services to Cigna as a consultant or contractor.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Unless otherwise determined by the Committee, the continued vesting period described in this paragraph 3(d) will immediately cease on the date that you stop providing services to Cigna as a consultant or contractor, regardless of the reason your consulting or contracting services terminated.   The foregoing notwithstanding, if your consulting or contracting services end due to your death or Disability, the Option will vest on the date that your services terminate.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;For avoidance of doubt, the continued vesting described in paragraphs 3(b), 3(c) and 3(d) above is expressly subject to (and contingent upon) your ongoing compliance with the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.  If a Violation (as defined below) occurs or is discovered following your Termination, then, in addition to any other remedies available to Cigna under this Option </font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Agreement or the Covenant Agreement, any then outstanding portion of this Option (whether vested or unvested) shall be immediately and automatically cancelled and forfeited.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Early Expiration upon Termination&#59; Exceptions</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Upon your Termination (other than a Termination for Cause), the Option will expire on the earlier of the Grant Expiration Date or ninety (90) days after your Termination date </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">unless </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">one of the exceptions described in paragraph 4(b) through (f) applies.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If (1) your Termination is because of your death, Disability or Retirement (only if approved under paragraph 3(b) above), and (2) you will not be receiving severance pay from any Cigna company (whether under any severance benefit plan or any contract, agreement or arrangement), then the Option will expire at 5&#58;00 p.m. Philadelphia time on the Expiration Date.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If your Termination is because of your Early Retirement (only if approved under paragraph 3(b) above), and you will not be receiving severance pay from any Cigna company (whether under any severance benefit plan or any contract, agreement or arrangement), the Option will expire at 5&#58;00 p.m. Philadelphia time on&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The earlier of the Expiration Date or the third anniversary of your Termination date&#59; or </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The Expiration Date if, within six months before your Termination date, you were a member of the Executive Leadership Team (ELT).</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;If your Termination is an Involuntary Termination, the Option will expire on the earlier of (1) the Expiration Date or (2) ninety (90) days after the first anniversary of your Termination date.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;If your Termination is Upon a Change of Control (of The Cigna Group), the Option will expire on the earlier of the Expiration Date or the third anniversary of your Termination date.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The Option will expire immediately upon your Termination for Cause.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Exercising the Option&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Cigna may limit your rights to exercise the Option and to sell any Shares you acquire by exercising the Option.  Your rights are subject to the terms of Cigna's Securities Transactions and Insider Trading Policy, and Cigna reserves the right, for any reason at any time, to suspend or delay action on any request you make to exercise the Option or sell the Shares.  To comply with legal requirements, Cigna may restrict the method by which you exercise the Option.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If, because of limitations imposed by applicable law, you cannot exercise the Option before it expires, then the Option will not expire on the date described in paragraph 4.  Instead, the Option Period will be extended temporarily until the earlier of (1) ten business days after the first date on which the Option again becomes exercisable without the limitations or (2) 5&#58;00 p.m. Philadelphia time on the Expiration Date.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;To exercise all or part of the Option, you must (1) complete and submit any required Option exercise form or electronic exercise instructions and (2) pay the Option Price and any required tax withholding.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;You may pay the Option Price with cash.  If you pay with cash, you must also pay any applicable withholding tax liability in cash before Shares will be deposited in your Stock Account or delivered to you.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;If you are a Cigna company employee when you exercise the Option, you may pay the Option Price with Shares that are in your Stock Account if&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;you first purchased the shares on the open market&#59; or</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;at least six months have elapsed after the&#58; </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A) &#160;&#160;&#160;&#160;grant date, if you received the shares as a grant of unrestricted Shares&#59; </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(B) &#160;&#160;&#160;&#160;vesting date, if you received them as a grant of Restricted Stock&#59; or </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(C) &#160;&#160;&#160;&#160;purchase date, if you bought them through a previous option exercise.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You will not be allowed to pay the Option Price with Shares if Cigna in its sole discretion determines that it would risk adverse tax or accounting consequences as a result. If you are not a Cigna company employee when you exercise the Option, or if your beneficiary or estate exercises the Option, the Option Price cannot be paid in shares of stock.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;If you pay the Option Price in Shares&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;You must exercise the Option for at least 50 Shares.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If there are not at least 50 Shares underlying the Option, you must exercise the Option for all the Shares.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;You must pay any applicable tax-withholding obligation.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cigna reserves the right to withhold from the Shares you purchase enough Shares to meet all or part of any applicable tax-withholding obligation.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If you are an Executive Officer when you exercise the Option, you may satisfy part of the withholding obligation by remitting to Cigna Shares you have owned for at least six months as of the date the withholding obligation arises.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;You may pay the Option Price through a cashless exercise of the Option.  Cigna reserves the right to change the rules that apply to cashless exercises, or end your ability to do a cashless exercise, at any time.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Book-Entry Shares</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cigna (or a custodian appointed by Cigna) will hold any Shares you, your beneficiary or estate acquire upon exercise of the Option in book-entry form in a Stock Account.  That is, a record of Share ownership will be kept electronically.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Conditions of Grant</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;By accepting the grant, you are agreeing&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;to the Inventions provision in paragraph 7(b)&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;to the restrictions contained in the attached Covenant Agreement and in paragraph 7(c)(2) below (such restrictions collectively, the &#8220;Promises&#8221;)&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">notify Cigna</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> if you accept an offer to perform services for any individual or entity while you are subject to the non-competition Promise under the Covenant Agreement.  Such notice shall be provided by email to </font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">noncompete&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> within 10 days of your acceptance of the offer and shall identify the individual or entity and your anticipated start date&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">disclose the terms of the Promises</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (including, without limitation, the Promises related to non-solicitation and non-competition) and the consequences of a Violation (as defined below) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">to any individual or entity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> for whom you perform services during the 12 month period immediately following your Termination&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;not to engage in any activity that would constitute a Violation (as defined below).</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You understand and agree that the conditions of the grant set forth in this paragraph 7(a) are a material part of the inducement for Cigna's granting you the Option and essential pre-conditions to your eligibility to exercise any rights associated with the Option and retain any benefit from exercising the Option. </font></div><div style="margin-bottom:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The award of Options pursuant to this Nonqualified Stock Option Grant is expressly conditioned on your acceptance of the terms and conditions of this Option Grant and of the attached Covenant Agreement.  If you </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">decide to accept</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> this Nonqualified Stock Option Grant, you are accepting and agreeing to all of the terms and conditions of this Option Grant and of the attached Covenant Agreement, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions.</font></div><div style="margin-bottom:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You should review the terms of this Option Grant and the Covenant Agreement carefully to ensure that you understand what they say and what your responsibilities and obligations are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">before you click on the accept button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to acknowledge and agree to this Option Grant.   </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (b) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inventions </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;You hereby assign and promise to assign to Cigna companies or their designee, all your right, title, and interest in and to any and all current and future Inventions.  You acknowledge that all original works of authorship which you make (whether alone or jointly with others) within the scope of your Cigna company employment and which are protectable by copyright are &#8220;works made for hire,&#8221; as defined in the United States Copyright Act.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;You agree to (i) maintain and make available adequate current records, including electronic records, notes, sketches and drawings, of all Inventions you make, and (ii) disclose such Inventions in writing upon request. These records will remain the property of Cigna companies.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;If in the course of your Cigna company employment, you incorporate a Prior Invention into any Cigna company work product, you grant Cigna companies a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to use the Prior Invention as part of or in connection with the work product. Within 45 days after the date of this grant, you agree to notify Cigna Shareholder Services (</font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) of any Prior Inventions that you are not assigning under this paragraph 7(b).</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;&#8220;Inventions&#8221; means any and all inventions, original works of authorship, developments, concepts, sales methods, improvements, trade secrets, or similar intellectual property, whether or not patentable or registrable under copyright or similar laws, that relate to any Cigna company&#8217;s current or proposed business, work products or research and development which you have or will solely or jointly conceive, develop, reduce to practice, or fix during your Cigna company employment.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;&#8220;Prior Inventions&#8221; means all inventions, original works of authorship, developments, concepts, sales methods, improvements, trade secrets or similar intellectual property, whether or not patentable or registrable under copyright or similar laws, that relate to any Cigna company&#8217;s current or proposed business, work products or research and development which you conceived, developed, reduced to practice or fixed before your Cigna company employment and which belong to you. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Violation</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You will engage in a &#8220;Violation&#8221; if, directly or indirectly, you engage in any willful misconduct as described in paragraph 7(c)(1) below or you break any of the Promises.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Willful</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Misconduct</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;You have a Termination initiated by a Cigna company because you engaged in conduct that constitutes a gross violation of Cigna's Code of Ethics and Principles of Conduct or other employment policies.  </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;You do anything else while an employee of any Cigna company that is not discovered by the company until after your Termination and that would, if you had still been employed at the time of the discovery, be reason for your Termination for willful misconduct, as described above. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Promise to Assist with Patent and Copyright Registrations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">  </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.74pt">You Promise that, during your Cigna company employment and after your Termination, you will assist Cigna companies, should they request and at Cigna&#8217;s expense, to secure their rights (including any copyrights, patents, trademarks or other intellectual property rights) in or relating to the Inventions in any and all countries, including by&#58;</font></div><div style="margin-bottom:6pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;disclosing to Cigna Companies all pertinent information and data&#59; and</font></div><div style="margin-bottom:6pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;executing all applications, assignments or other instruments necessary to apply for and obtain these rights and assign them to Cigna companies.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consequences of a Violation&#58; Payment to Cigna</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Important&#58; This paragraph 8 is not Cigna's only remedy for a Violation.  Cigna may seek any additional legal or equitable remedy, including as described in the Covenant Agreement.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If you engage in any Violation at any time, Cigna will cancel any part of the Option you have not yet exercised.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You must immediately make the Payment described in paragraph 8(c) to Cigna in the manner described in paragraph 8(d) if&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;You engage in a Violation of the non-competition or non-solicitation restrictions of the Covenant Agreement&#59; or</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;You engage in a Violation described in paragraph 7(c)(1) (willful misconduct) or any other Violation (e.g. you disclose Cigna company Confidential Information in violation of the Covenant Agreement) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">at any time</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Payment requirement applies only to the parts of the Option, if any, that you exercise during the 24-month period prior to the date of your Termination and thereafter.  &#8220;Payment&#8221; means the amount equal to&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;the number of Shares you acquire when you exercise the Option&#59; </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;multiplied by </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;the excess of (A) the Fair Market Value on the date you exercise the Option over (B) the Option Price&#59; </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;plus </font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;the total amount of all dividends, if any, paid on those Shares through the date of the Payment.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Cigna will recover the Payment from you by any means permitted by applicable law, at the sole discretion of Cigna management, including but not limited to any or all of the following methods&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;If you have any Shares in a Stock Account or in any other account in book-entry form when a Violation occurs, Cigna will take back from you the whole number of Shares that has a total Fair Market Value as of the date of the Violation up to, but not more than, the Payment amount.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Cigna will, to the extent permitted by applicable law, reduce&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;The amount of any payments that any Cigna company owes you for any reason (including without limit any payments owed to you under any nonqualified retirement, deferred compensation or other plan or arrangement) by </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;The Payment amount.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This reduction will not occur until the date a future payment to you is due.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Cigna will send you a written notice and demand for all or part of any Payment amount.  Within 30 days after you receive that notice and demand, you must make the Payment to Cigna.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;If you were an Executive Officer at any time during the 24-month period before the date of a Violation of the Covenant Agreement, the Committee will have the sole discretion to waive your obligation to make all or any part of the Payment (described in this paragraph 8) and to impose conditions on any waiver.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;If you are in Career Band 6 or higher on your Termination date but </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> subject to paragraph 8(e)(1) above, Cigna's Restrictive Covenant Review Committee will have the sole discretion to waive your obligation to make all or any part of the Payment (described in this paragraph 8) and to impose conditions on any waiver.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Otherwise, Cigna's Senior Human Resources Officer, or his or her designee, will have the sole discretion to waive your obligation to make all or any part of the Payment and to impose conditions on any waiver.  </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Determinations of the Committee, the Restrictive Covenant Review Committee, or Cigna's Senior Human Resources Officer (or his or her designee), will be final and binding on all parties.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consequences of a Violation&#58; Designation of Cigna as Agent and Attorney-in-Fact for Inventions</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You agree that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If Cigna Companies are unable to obtain your signature on any instruments needed to secure their rights in or relating to the Inventions pursuant to paragraph 7(c)(2)(A)&#59; then</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You hereby appoint Cigna companies and their duly authorized officers as your agents and attorneys in fact to act for and on your behalf to execute and file any documents and take other actions as may be necessary for Cigna companies to secure those rights.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreeing to Assume Risks</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cigna, its stock plan administrator and its transfer agent will try to process your stock transaction requests in a timely manner&#59; however, Cigna makes no promises or guarantees to you relating to the market price of the Shares or to the time it may take to act on your request to exercise the Option, or sell the Shares.  By accepting this Option grant&#58;</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;You acknowledge that the action you request may not be completed until several days after you submit it.    </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You agree to assume the risks, including the risk that the market price of the Shares may change, related to delays described in paragraph 10(a)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.02pt">Between the time you submit an Option exercise form and the time your Option is actually exercised&#59; and </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.02pt">Between the time you ask for any Shares to be sold and the time your Shares are actually sold.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Applicable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Law</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You understand and agree that, except as otherwise provided in the Covenant Agreement, the terms and conditions of this Option Grant and all determinations made under the Nonqualified Stock Option Grant Agreement, the Plan, and these Terms and Conditions will be interpreted under the laws of the State of Delaware, without regard to its conflict of laws rule.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, the terms and conditions of the Covenant Agreement and all determinations made under the Covenant Agreement will be interpreted under applicable state law as set forth in the Covenant Agreement. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Arbitration </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Except as otherwise provided in the Covenant Agreement, if you have an agreement with Cigna to arbitrate employment related disputes, you agree to resolve any disputes relating to this Nonqualified Stock Option Grant through arbitration. </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Acceptance</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">If you disagree with any of these Terms and Conditions, or the terms and conditions of the Covenant Agreement, YOU MUST NOT ACCEPT THE OPTION GRANT. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> If you sign the Option grant or the Covenant Agreement, or acknowledge your acceptance electronically or otherwise, you will be&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Agreeing to all the terms and conditions of the Option grant and of the Covenant Agreement, including the Inventions provision in paragraph 7(b) and all of the Promises&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Warranting and representing to Cigna that you are, and will remain, in full compliance with all applicable terms and conditions&#59; </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;Authorizing Cigna to recover the Payment described in paragraph 8 and to seek any other available remedy pursuant to the Covenant Agreement if you engage in a Violation&#59; and  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Appointing Cigna as your agent and attorney-in-fact to secure rights with respect to Inventions if unable to obtain your signature as described in paragraph 9.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Year&#93; US Option Grant Agreement including Terms and Conditions</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>exhibit104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ib06623c4a6a74d5aaa764bfb5956fcca_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.4</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Cigna Group</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cigna Long-Term Incentive Plan&#58;  Strategic Performance Share Grant Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Cigna Group (&#8220;Cigna&#8221;) has granted you the number of strategic performance shares set forth below in this Strategic Performance Share Grant Agreement (&#8220;Strategic Performance Share Grant&#8221; or &#8220;Grant&#8221;) under the Cigna Long-Term Incentive Plan (&#8220;Plan&#8221;).  The date of your Strategic Performance Share Grant (&#8220;Grant Date&#8221;) is also indicated below. The award is subject to the provisions of the Plan and the Terms and Conditions below.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The award of Shares pursuant to this Strategic Performance Share Grant is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">expressly conditioned</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> on your acceptance of the terms and conditions of this Grant and of the attached Confidentiality, Non-Competition and Non-Solicitation Agreement (or with respect to Cigna company employment in California, the attached Confidentiality and Non-Solicitation Agreement) (as applicable, the &#8220;Covenant Agreement&#8221;).  You should carefully read all the terms and conditions of this Strategic Performance Share Grant and the attached Covenant Agreement and be sure you understand what they say and what your responsibilities and obligations are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">before you click on the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to acknowledge and agree to this Grant.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you are not willing to agree to all of the Grant and Covenant Agreement terms and conditions, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">do not accept the Grant and do not click the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> for the Strategic Performance Share Grant Acknowledgment and Agreement.  If you do not accept the Grant, you will not receive the benefits of the Grant. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you do </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">click on the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, you are accepting and agreeing to all of the terms and conditions of this Strategic Performance Share Grant and the Covenant Agreement, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Participant&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Type&#58;   </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Plan Name&#58;  Cigna Long-Term Incentive Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Date&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Total Granted&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Price&#58;  (USD)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Vesting Schedule</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.911%"><tr><td style="width:1.0%"></td><td style="width:63.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Shares Granted</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Approximate Vest Date</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Please Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> The date shown in the Vesting Schedule chart above is not your actual vesting date.  It is an approximation of the expected vesting date and is provided due to systems requirements. In accordance with the Terms and Conditions of your Strategic Performance Share Grant, the actual vesting date will be determined by the People Resources Committee of the Board of Directors.</font></div><div><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition to this Strategic Performance Share Grant and the attached Covenant Agreement, you should also read the Plan Document and Key Contacts and Reference Materials document (attached to the Plan) and indicate that you have done so and agree to the terms of all documents attached to this Grant by checking the appropriate box in the online grant acceptance process.  The Key Contacts and Reference Materials document contains information on how to get important award information (such as the Plan Prospectus, Tax Considerations and Cigna's Securities Transactions and Insider Trading Policy) and whom to contact if you have questions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Please be aware that the Cigna Securities Transactions and Insider Trading Policy places restrictions on your transactions in Cigna securities and requires certain Cigna employees to obtain advance permission from the Corporate Secretary before executing transactions in Cigna securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you have questions about your award, please contact Cigna Shareholder Services by email at </font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> or by phone at 215.761.3516.</font></div><div><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Important Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  Strategic Performance Share Grant and Covenant Agreement Acknowledgment and Agreement</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">By clicking on the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ACCEPT</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> button, I&#58;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Acknowledge and represent to Cigna that I have&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;received the Strategic Performance Share Grant, the Terms and Conditions of the Strategic Performance Share Grant and the Covenant Agreement&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;read and understand their terms and conditions, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions&#59; and </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;received answers to any questions I had about the Grant, the Terms and Conditions of the Grant and the Covenant Agreement and their terms and conditions, including the applicable restrictive covenants. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Scroll down for the TERMS AND CONDITIONS of the Strategic Performance Share Grant.</font></div><div><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">TERMS AND CONDITIONS OF YOUR &#91;YEAR&#93; GRANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">OF STRATEGIC PERFORMANCE SHARES</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">These Terms and Conditions are an important part of your grant of Strategic Performance Shares from The Cigna Group (Cigna).  The terms of your Strategic Performance Share grant are in&#58; (a) the electronic Strategic Performance Share Grant Agreement above, (b) these Terms and Conditions (including Schedule 1), (c) the Covenant Agreement, and (d) the Cigna Long-Term Incentive Plan (Plan).  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Certain words in this document with first letters capitalized are defined in the Strategic Performance Share Grant Agreement above, these Terms and Conditions or Article 2 of the Plan.  This grant is void if you are not an employee of Cigna or a Subsidiary (a Cigna company) on the Grant Date.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Strategic Performance Shares&#59; Performance Period</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Each Strategic Performance Share (Performance Share) represents a conditional right to receive one share of Cigna Common Stock (Share), subject to the performance, vesting and payment provisions described below. The Performance Period applicable to your award is January 1, &#91;____&#93; to December 31, &#91;____&#93; (the Performance Period). </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restrictions</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Performance Shares are subject to certain Restrictions from the Grant Date until the Payment Date described in paragraph 4.  The Restrictions are&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;You cannot sell or transfer the Performance Shares to anyone&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Unless an exception applies (described in paragraph 4) or unless otherwise determined by the Committee, you will forfeit (lose your right to) your unvested Performance Shares and all related rights immediately upon your Termination&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Of the Performance Shares awarded to you (Shares Awarded), the number of Performance Shares, if any, that you earn and for which you may receive payment (Shares Earned) is subject to the performance criteria described in Schedule 1.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Article 11 of the Plan describes these Restrictions in more detail.  In addition to these Restrictions, you must also comply with all the terms and conditions of this grant and the Covenant Agreement. </font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Performance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Shares Earned </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Schedule 1 specifies the performance criteria applicable to your Shares Awarded. Except as provided in paragraph 4, after the end of the Performance Period, the Committee shall determine whether and to what extent these performance criteria have been achieved for purposes of determining the Vesting Percentage applicable to your Performance Shares (Shares Earned Percentage). </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any Shares Awarded that are not Shares Earned after giving effect to the Committee&#8217;s determinations under this paragraph 3 shall terminate and become null and void immediately following such determinations.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Eligibility for Payment</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as described in paragraph 4(b) and subject to paragraph 4(c) and paragraph 3, the Restrictions on the Performance Shares will end (your Performance Shares will vest) on the Payment Date described in paragraph 5, but only if you remain continuously employed </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by a Cigna company until the Payment Date and comply with all the terms and conditions of this grant and the Covenant Agreement.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Notwithstanding paragraph 4(a) and subject to paragraph 4(c) and paragraph 3, if your Termination is before the Payment Date&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;Your Performance Shares will vest upon your Termination if it is a Termination Upon a Change of Control. If your Performance Shares vest under this paragraph 4(b)(1), the Shares Earned Percentage shall be 100%.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;Your Performance Shares will vest upon your Termination if it is due to your death or Disability. If your Performance Shares vest under this paragraph 4(b)(2), the Shares Earned Percentage shall be 100%. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;Your Performance Shares </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">may</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">continue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to vest following your Termination due to your Early Retirement or Retirement if&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;The date of Termination due to your Early Retirement or Retirement is at least six (6) months after the Grant Date, provided that this requirement may be waived by (i) Cigna's Senior Human Resources Officer in certain limited and unanticipated circumstances, or (ii) with respect to the CEO or any executive officer who is subject to the requirements of Section 16(a) of the Exchange Act (&#8220;Executive Officer&#8221;), the Committee&#59;  </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;You will </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> be receiving severance pay from any Cigna company (whether under any severance benefit plan or any contract, agreement or arrangement)&#59;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(iii)&#160;&#160;&#160;&#160;You continue to comply with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period&#59; and </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(iv)&#160;&#160;&#160;&#160;The Committee or its designee (including Cigna&#8217;s Senior Human Resources Officer) approves the continued vesting before your Termination.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If you want to be considered for continued vesting when you retire, you should review the &#8220;Ready to Retire&#8221; page on HR Central for more information or contact Cigna Shareholder Services (</font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) if you have questions.  You must submit your consideration request far enough in advance of your retirement so there is time to process your request.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A Termination resulting from a Cigna divestiture, outsourcing or other business transaction where you become employed by the buyer, vendor or other entity involved in the transaction will not constitute a Retirement or Early Retirement under this paragraph 4(b)(3).  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If your Performance Shares continue to vest under this paragraph 4(b)(3), the Performance Shares will be prorated based on the amount of time you were employed by a Cigna company during the applicable Performance Period prior to, and inclusive of, your Early Retirement or Retirement date and then the Shares Earned Percentage shall be determined by the Committee under paragraph 3(a) above and applied.    </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;Your Performance Shares </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">continue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to vest following your Termination if your Termination is an Involuntary Termination that occurs within twelve (12) months of the Approximate Vest Date for the Performance Shares described in the Strategic Performance Share Grant Agreement above.  For example, if the date of your Involuntary Termination is June 1, 2027 you will vest in any Performance Shares scheduled to be paid on or before June 1, 2028 on the otherwise scheduled Payment Date.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Unless otherwise determined by the Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, if your Performance Shares continue to vest under this paragraph 4(b)(4), the Performance Shares will be prorated based on the amount of time you were employed by a Cigna company during the applicable Performance Period prior to, and inclusive of, the date of your Involuntary Termination and then the Shares Earned Percentage shall be determined by the Committee under paragraph 3(a) above and applied.  Subject to Section 15.2(b) of the Plan, The Cigna Group&#8217;s Shareholder Services team shall have the authority to determine the extent of proration if you were not employed by a Cigna company for the entire Performance Period.            </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The continued vesting described in this paragraph 4(b)(4) is subject to (and contingent upon) your ongoing compliance with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A Termination resulting from a Cigna divestiture, outsourcing or other business transaction where you become employed by the buyer, vendor or other entity involved in the transaction will not constitute an Involuntary Termination under this paragraph 4(b)(4).  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;If approved by (1) Cigna's Senior Human Resources Officer or his or her designee, or (2) the Committee (with respect to the CEO or any Executive Officer) before your Termination, your Shares </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">may continue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to vest following your Termination if you (i) continue to provide services to Cigna as a consultant or contractor, and (ii) continue to comply with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.   </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If your Performance Shares continue to vest under this paragraph 4(b)(5), the Shares Earned Percentage shall be determined by the Committee under paragraph 3(a) above.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The continued vesting period, if any, under this paragraph 4(b)(5) shall be equal to the period of your continued services to Cigna as a consultant or contractor.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Unless otherwise determined by the Committee, the continued vesting period described in this paragraph 4(b)(5) will immediately cease on the date that you stop providing services to Cigna as a consultant or contractor, regardless of the reason your consulting or contracting services terminated.   The foregoing notwithstanding, if your consulting or contracting services to Cigna terminate upon one of the events described in paragraph 4(b)(2) above, the Performance Shares will vest on the date that your services terminate.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; (6)&#160;&#160;&#160;&#160;For avoidance of doubt, the continued vesting described in paragraphs 4(b)(3), 4(b)(4) and 4(b)(5) above is expressly subject to (and contingent upon) your ongoing compliance with the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.  If a </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Violation (as defined below) occurs or is discovered following your Termination, then, in addition to any other remedies available to Cigna under this Grant or the Covenant Agreement, any then unvested Performance Shares shall be immediately and automatically forfeited.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;You must comply in all respects with the terms and conditions of this Grant and the Covenant Agreement.   </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Payment</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as provided in paragraph 5(b) and 5(c), below, your vested Shares Earned under this grant will be paid in the year following the close of the Performance Period on the date within such year specified by the Committee (Payment Date). </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any Performance Shares that vest on account of your Termination due to death or Disability will be paid during the 90 day period immediately following your Termination due to death or Disability to you (or to your estate, in the case of death).  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Any Performance Shares that vest on account of your Termination Upon a Change of Control will be paid during the 30 day period immediately following your Termination Upon a Change of Control.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;For each Share Earned that vests, Cigna will make payment by issuing one Share as of the Payment Date.  Until the Shares are issued to you, you will not be a Cigna shareholder, not have the right to vote the Shares, and not receive actual dividends.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Taxes </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 17.7 of the Plan shall apply to any tax withholding that may be required by law for Performance Shares or Shares.  Upon the vesting or payment of any Performance Share, Cigna reserves the right to withhold enough newly-issued Shares to cover all or part of any applicable tax withholding.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Book-Entry Shares&#59; Sale of Shares</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Upon payment of the Shares as described in paragraph 5, Cigna (or a custodian appointed by Cigna) will hold your Shares in book-entry form in a Stock Account.  That is, a record of your Share ownership will be kept electronically.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You may generally sell or transfer the Shares at any time, but your right to sell the Shares may be limited by Cigna.  This right is subject to the terms of Cigna's Securities Transactions and Insider Trading Policy, and Cigna reserves the right, for any reason at any time, to suspend or delay action on any request you make to sell the Shares.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Conditions of Grant</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;By accepting the grant, you are agreeing&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1) &#160;&#160;&#160;&#160;to the Inventions provision in paragraph 8(b)&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;to the restrictions contained in the attached Covenant Agreement and in paragraph 8(c)(2) below (such restrictions collectively, the &#8220;Promises&#8221;)&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">notify Cigna</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> if you accept an offer to perform services for any individual or entity while you are subject to the non-competition Promise under the Covenant Agreement.  Such notice shall be provided by email to </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt"><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">noncompete&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> within 10 days of your acceptance of the offer and shall identify the individual or entity and your anticipated start date&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">disclose the terms of the Promises</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (including, without limitation, the Promises related to non-solicitation and non-competition) and the consequences of a Violation (as defined below) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">to any individual or entity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> for whom you perform services during the 12 month period immediately following your Termination&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;not to engage in any activity that would constitute a Violation (as defined below). &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You understand and agree that the conditions of the grant set forth in this paragraph 8(a) are a material part of the inducement for Cigna's granting you the Performance Shares and essential pre-conditions to your eligibility to exercise any rights associated with the Grant and retain any benefit from the vesting of the Performance Shares and issuance of the Shares. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The award of Shares pursuant to this Strategic Performance Share Grant is expressly conditioned on your acceptance of the terms and conditions of this Grant and of the attached Covenant Agreement.  If you </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">decide to accept this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Strategic Performance Share Grant, you are accepting and agreeing to all of the terms and conditions of this Grant and of the attached Covenant Agreement, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You should review the terms of this Grant and the Covenant Agreement carefully to ensure that you understand what they say and what your responsibilities and obligations are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">before you click on the accept button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to acknowledge and agree to this Grant. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inventions </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;You hereby assign and promise to assign to Cigna companies or their designee, all your right, title, and interest in and to any and all current and future Inventions.  You acknowledge that all original works of authorship which you make (whether alone or jointly with others) within the scope of your Cigna company employment and which are protectable by copyright are &#8220;works made for hire,&#8221; as defined in the United States Copyright Act.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;You agree to (i) maintain and make available adequate current records, including electronic records, notes, sketches and drawings, of all Inventions you make, and (ii) disclose such Inventions in writing upon request. These records will remain the property of Cigna companies.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;If in the course of your Cigna company employment, you incorporate a Prior Invention into any Cigna company work product, you grant Cigna companies a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to use the Prior Invention as part of or in connection with the work product. Within 45 days after the date of this grant, you agree to notify Cigna Shareholder Services (</font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) of any Prior Inventions that you are not assigning under this paragraph 8(b).</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Inventions&#8221; means any and all inventions, original works of authorship, developments, concepts, sales methods, improvements, trade secrets, or similar intellectual property, whether or not patentable or registrable under copyright or similar laws, that relate to any Cigna company&#8217;s current or proposed business, </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">work products or research and development which you have or will solely or jointly conceive, develop, reduce to practice, or fix during your Cigna company employment.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;&#8220;Prior Inventions&#8221; means all inventions, original works of authorship, developments, concepts, sales methods, improvements, trade secrets or similar intellectual property, whether or not patentable or registrable under copyright or similar laws, that relate to any Cigna company&#8217;s current or proposed business, work products or research and development which you conceived, developed, reduced to practice or fixed before your Cigna company employment and which belong to you.   </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Violation</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You will engage in a &#8220;Violation&#8221; if, directly or indirectly, you engage in any willful misconduct as described in paragraph 8(c)(1) below or you break any of the &#8220;Promises&#8221;.</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Willful</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Misconduct</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;You have a Termination initiated by a Cigna company because you engaged in conduct that constitutes a gross violation of Cigna's Code of Ethics and Principles of Conduct or other employment policies.</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;You do anything else while an employee of any Cigna company that is not discovered by the company until after your Termination and that would, if you had still been employed at the time of the discovery, be reason for your Termination for willful misconduct, as described above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Promise to Assist with Patent and Copyright Registrations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;You Promise that, during your Cigna company employment and after your Termination, you will assist Cigna companies, should they request and at Cigna's expense, to secure their rights (including any copyrights, patents, trademarks or other intellectual property rights) in or relating to the Inventions in any and all countries, including by&#58; </font></div><div style="margin-bottom:6pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">disclosing to Cigna Companies all pertinent information and data&#59; and</font></div><div style="margin-bottom:6pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">executing all applications, assignments or other instruments necessary to apply for and obtain these rights and assign them to Cigna companies.   </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consequences of a Violation&#58; Payment to Cigna</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Important&#58; This paragraph 9 is not Cigna's only remedy for a Violation.  Cigna may seek any additional legal or equitable remedy, including as described in the Covenant Agreement.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If you engage in any Violation at any time&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;You will immediately forfeit all unvested Performance Shares&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;No payment will be made for any Performance Shares that have vested under paragraph 4(b) if the Violation occurs before the applicable Payment Date.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You must immediately make the Payment described in paragraph 9(c) to Cigna in the manner described in paragraph 9(d) if&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;You engage in a Violation of the non-competition or non-solicitation restrictions of the Covenant Agreement&#59; or</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;You engage in a Violation described in paragraph 8(c)(1) (willful misconduct) or any other Violation (e.g. you disclose Cigna company Confidential Information in violation of the Covenant Agreement) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">at any time</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#8220;Payment&#8221; is the value you realize from any Performance Shares that are paid under paragraph 5 during the 12-month period prior to the date of your Termination and thereafter.  The Payment will equal&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The number of Performance Shares that are paid during the applicable period&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;multiplied by </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The Fair Market Value of the Shares issued on the Payment Date for those Performance Shares&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;plus </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The total amount of all actual dividends, if any, paid to you on those Shares through the date of the Payment described in paragraph 9(d).  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Cigna will recover the Payment from you by any means permitted by applicable law, at the sole discretion of Cigna management, including but not limited to any or all of the following methods&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;If you have any Shares in a Stock Account or in any other account in book-entry form when a Violation occurs, Cigna will take back from you the whole number of Shares that has a total Fair Market Value as of the date of the Violation up to, but not more than, the Payment amount.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Cigna will, to the extent permitted by applicable law, reduce&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;The amount of any payments that any Cigna company owes you for any reason (including without limit any payments owed to you under any nonqualified retirement, deferred compensation or other plan or arrangement) by </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;The Payment amount.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This reduction will not occur until the date a future payment to you is due.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Cigna will send you a written notice and demand for all or part of any Payment amount.  Within 30 days after you receive that notice and demand, you must make the Payment to Cigna.</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;If you were an Executive Officer at any time during the 24-month period before the date of a Violation of the Covenant Agreement, the Committee will have the sole discretion to waive your obligation to make all or any part of the Payment (described in this paragraph 9) and to impose conditions on any waiver.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;If you are in Career Band 6 or higher on your Termination date but </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> subject to paragraph 9(e)(1) above, Cigna's Restrictive Covenant Review Committee will have the sole discretion to waive your obligation to make all or any part of the Payment (described in this paragraph 9) and to impose conditions on any waiver.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Otherwise, Cigna's Senior Human Resources Officer, or his or her designee, will have the sole discretion to waive your obligation to make all or any part of the Payment and to impose conditions on any waiver.  </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Determinations of the Committee, the Restrictive Covenant Review Committee, or Cigna's Senior Human Resources Officer (or his or her designee), will be final and binding on all parties.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consequences of a Violation&#58; Designation of Cigna as Agent and Attorney-in-Fact for Inventions</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You agree that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If Cigna Companies are unable to obtain your signature on any instruments needed to secure their rights in or relating to the Inventions pursuant to paragraph 8(c)(2)(A)&#59; then</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You hereby appoint Cigna companies and their duly authorized officers as your agents and attorneys in fact to act for and on your behalf to execute and file any documents and take other actions as may be necessary for Cigna companies to secure those rights.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreeing to Assume Risks</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cigna, its stock plan administrator and its transfer agent will try to process your stock transaction requests in a timely manner&#59; however, Cigna makes no promises or guarantees to you relating to the market price of the Shares or to the time it may take to act on your request to sell the Shares.  By accepting this Strategic Performance Share grant&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;You acknowledge that the action you request may not be completed until several days after you submit it.    </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You agree to assume the risks, including the risk that the market price of the Shares may change, related to delays described in paragraph 11(a) between the time you ask for any Shares to be sold and the time your Shares are actually sold.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Applicable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Law</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You understand and agree that, except as otherwise provided in the Covenant Agreement, the terms and conditions of this Strategic Performance Share Grant and all determinations made under the Strategic Performance Share Grant Agreement, the Plan, and these Terms and Conditions will be interpreted under the laws of the State of Delaware, without regard to its conflict of laws rule. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, the terms and conditions of the Covenant Agreement and all determinations made under the Covenant Agreement will be interpreted under applicable state law as set forth in the Covenant Agreement. </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Arbitration </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Except as otherwise provided in the Covenant Agreement, if you have an agreement with Cigna to arbitrate employment-related disputes, you agree to resolve any disputes relating to this Strategic Performance Share Grant through arbitration. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Acceptance</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">If you disagree with any of these Terms and Conditions, or the terms and conditions of the Covenant Agreement, YOU MUST NOT ACCEPT THE STRATEGIC PERFORMANCE SHARE GRANT. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> If you sign the Strategic Performance Share grant, or the Covenant Agreement, or acknowledge your acceptance electronically or otherwise, you will be&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Agreeing to all the terms and conditions of the Strategic Performance Share grant and of the Covenant Agreement, including the Inventions provision in paragraph 8(b) and all of the Promises&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Warranting and representing to Cigna that you are, and will remain, in full compliance with all applicable terms and conditions&#59; </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;Authorizing Cigna to recover the Payment described in paragraph 9 and to seek any other available remedy pursuant to the Covenant Agreement, if you engage in a Violation&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Appointing Cigna as your agent and attorney-in-fact to secure rights with respect to Inventions if unable to obtain your signature as described in paragraph 10.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Year&#93; US SPS Grant Agreement including Terms and Condition</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>exhibit105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i096320b8e0f140f6a3acc5c99be7d092_1"></div><div style="min-height:72pt;width:100%"><div style="padding-left:180pt;text-align:right;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.5</font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Cigna Group</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cigna Long-Term Incentive Plan&#58;  Restricted Stock Grant Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Cigna Group (&#8220;Cigna&#8221;) has granted you the number of shares of restricted stock of Cigna set forth below in this Restricted Stock Grant Agreement (&#8220;Restricted Stock Grant&#8221; or &#8220;Grant&#8221;) under the Cigna Long-Term Incentive Plan (&#8220;Plan&#8221;).  The date of your Restricted Stock Grant (&#8220;Grant Date&#8221;) and the dates on which your Grant is scheduled to vest (&#8220;Vesting Dates&#8221;) are also indicated below. The award is subject to the provisions of the Plan and the Terms and Conditions below.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The award of Shares pursuant to this Restricted Stock Grant is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">expressly conditioned</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> on your acceptance of the terms and conditions of this Grant and of the attached Confidentiality, Non-Competition and Non-Solicitation Agreement (or, with respect to Cigna company employment in California, the attached Confidentiality and Non-Solicitation Agreement) (as applicable, the &#8220;Covenant Agreement&#8221;).  You should carefully read all the terms and conditions of this Restricted Stock Grant and the attached Covenant Agreement and be sure you understand what they say and what your responsibilities and obligations are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">before you click on the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to acknowledge and agree to this Grant.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you are not willing to agree to all of the Grant and Covenant Agreement terms and conditions, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">do not accept the Grant and do not click the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> for the Restricted Stock Grant Acknowledgment and Agreement.  If you do not accept the Grant, you will not receive the benefits of the Grant. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you do</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> click on the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, you are accepting and agreeing to all of the terms and conditions of this Restricted Stock Grant and the Covenant Agreement, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Participant&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Type&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Plan Name&#58;  Cigna Long-Term Incentive Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Date&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Total Granted&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Price&#58;  (USD)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Vesting Schedule&#58; Please refer to Appendix&#58;  Vesting Schedule on the last page of this document</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition to this Restricted Stock Grant and the attached Covenant Agreement, you should also read the Plan Document and Key Contacts and Reference Materials document (attached to the Plan) and indicate that you have done so and agree to the terms of all documents attached to this Grant by checking the appropriate box in the online grant acceptance process.  The Key Contacts and Reference Materials document contains information on how to get important stock award information (such as the Plan Prospectus, Tax Considerations and Cigna's Securities Transactions and Insider Trading Policy) and whom to contact if you have questions.</font></div><div><font><br></font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Please be aware that the Cigna Securities Transactions and Insider Trading Policy places restrictions on your transactions in Cigna securities and requires certain Cigna employees to obtain advance permission from the Corporate Secretary before executing transactions in Cigna securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you have questions about your award, please contact Cigna Shareholder Services by email at </font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> or by phone at 215.761.3516.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Important Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  Restricted Stock Grant and Covenant Agreement Acknowledgment and Agreement</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">By clicking on the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> ACCEPT</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> button, I&#58;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Acknowledge and represent to Cigna that I have&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;received the Restricted Stock Grant, the Terms and Conditions of the Restricted Stock Grant and the Covenant Agreement&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;read and understand their terms and conditions, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions&#59; and </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;received answers to any questions I had about the Grant, the Terms and Conditions of the Grant and the Covenant Agreement and their respective terms and conditions, including the applicable restrictive covenants. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Scroll down for the TERMS AND CONDITIONS of the Restricted Stock Grant.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">TERMS AND CONDITIONS OF YOUR &#91;YEAR&#93;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">RESTRICTED STOCK GRANT</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">These Terms and Conditions are an important part of your grant of Restricted Stock from The Cigna Group (Cigna).  The terms of your Restricted Stock grant are in&#58; (a) the electronic Restricted Stock Grant Agreement above, (b) these Terms and Conditions, (c) the Covenant Agreement and (d) the applicable Plan provisions.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Certain words in this document with first letters capitalized are defined in the Restricted Stock Grant Agreement above, these Terms and Conditions or Article 2 of the Plan.  This grant is void if you are not an employee of Cigna or a Subsidiary (a Cigna company) on the Grant Date.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock&#59; Restrictions</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Shares of Restricted Stock (Shares) are regular shares of Cigna Common Stock, but they are subject to certain Restrictions.  The Restrictions are&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;You cannot sell or transfer the Shares to anyone during the Restricted Period&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Unless an exception applies or unless otherwise determined by the Committee or its designee, you will forfeit (lose your right to) the Shares if you have a Termination during the Restricted Period.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Article 7 of the Plan describes these Restrictions in more detail.  In addition, you must also comply with all the other terms and conditions of this grant and the Covenant Agreement. </font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted Period&#59; Vesting</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Restricted Period starts on the Grant Date and ends on the Vesting Date.  The Restrictions on the Shares will end (your Shares will vest) on the applicable Vesting Date subject to the terms and conditions of this grant and the Covenant Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Your Shares will vest in accordance with the Vesting Schedule set forth on the Appendix to this Restricted Stock Grant Agreement.  Your vesting date may be earlier than the Vesting Date(s) shown on the Appendix (see paragraph 3).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Unless otherwise determined by the Committee or its designee, your Shares will vest on the applicable Vesting Date if you are on a leave of absence on such date.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Early or Continued Vesting</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In certain situations your vesting date may be earlier than the Vesting Dates described in the Appendix or your Shares will continue to vest after your Termination date&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Shares will vest upon your Termination if it is a Termination Upon a Change of Control or is due to your death or Disability.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Shares </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">may</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">continue </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to vest following your Termination if&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;It is due to your Early Retirement or Retirement&#59; </font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2) &#160;&#160;&#160;&#160;The date of Termination due to your Early Retirement or Retirement is at least six (6) months after the Grant Date, provided that this requirement may be waived by (i) Cigna's Senior Human Resources Officer in certain limited and unanticipated circumstances, or (ii) with respect to the CEO or any executive officer who is subject to the requirements of Section 16(a) of the Exchange Act (&#8220;Executive Officer&#8221;), the Committee&#59;  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;You will </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> be receiving severance pay from any Cigna company (whether under any severance benefit plan or any contract, agreement or arrangement)&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(4)  &#160;&#160;&#160;&#160;You continue to comply with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period&#59; and </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The Committee or its designee (including Cigna&#8217;s Senior Human Resources Officer) approves the continued vesting before your Termination.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If you want to be considered for continued vesting when you retire, you should review the &#8220;Ready to Retire&#8221; page on HR Central for more information or contact Cigna Shareholder Services (</font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> if you have questions.  You must submit your consideration request far enough in advance of your retirement so there is time to process your request.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A Termination resulting from a Cigna divestiture, outsourcing or other business transaction where you become employed by the buyer, vendor or other entity involved in the transaction will not constitute a Retirement or Early Retirement under this paragraph 3(b).  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If your Termination is an Involuntary Termination, you will continue to vest in the Shares for a period of twelve (12) months following the date of your Involuntary Termination as if you had remained employed for such twelve (12) month period.  For example, if the date of your Involuntary Termination is June 1, 2026 you will vest in any Shares scheduled to vest on or before June 1, 2027 on the otherwise scheduled Vesting Date.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The continued vesting described in this paragraph 3(c) is subject to (and contingent upon) your ongoing compliance with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A Termination resulting from a Cigna divestiture, outsourcing or other business transaction where you become employed by the buyer, vendor or other entity involved in the transaction will not constitute an Involuntary Termination under this paragraph 3(c).  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;If approved by (1) Cigna's Senior Human Resources Officer or his or her designee, or (2) the Committee (with respect to the CEO or any Executive Officer) before your Termination, your Shares </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">may continue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to vest following your Termination if you (i) continue to provide services to Cigna as a consultant or contractor, and (ii) continue to comply with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The continued vesting period, if any, under this paragraph 3(d) shall be equal to the period of your continued services to Cigna as a consultant or contractor.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unless otherwise determined by the Committee, the continued vesting period described in this paragraph 3(d) will immediately cease on the date that you stop providing services to Cigna as a consultant or contractor, regardless of the reason your consulting or contracting services terminated.   The foregoing notwithstanding, if your consulting or contracting services to Cigna end due to your death or Disability, the shares will vest on the date your services end.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (e)&#160;&#160;&#160;&#160;For avoidance of doubt, the continued vesting described in paragraphs 3(b), 3(c) and 3(d) above is expressly subject to (and contingent upon) your ongoing compliance with the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.  If a Violation (as defined below) occurs or is discovered following your Termination, then, in addition to any other remedies available to Cigna under this Restricted Stock Grant or the Covenant Agreement, any then unvested Shares shall be immediately and automatically forfeited.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights&#59; Dividends </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;You have the right to vote the Shares.  If you forfeit a Share, you will also forfeit the right to vote the Share.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You have the right to receive dividends on the Shares.  Dividends paid on the Shares during the Restricted Period will be held by Cigna.  Subject to the forfeiture provisions of paragraph 4(c) and except as set forth below, your right to receive accumulated dividends on a Share will vest on the scheduled Vesting Date for the Share described in the Appendix (Scheduled Vesting Date).  Once a Share vests, your right to future dividends on the Share, and the method of payment, will be the same as for any other Cigna shareholder.</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If your Termination qualifies for early vesting under paragraph 3(a) above, your right to receive accumulated dividends on a Share will vest upon your Termination date (instead of on the Scheduled Vesting Date).  For avoidance of doubt, if you have a Termination before the Scheduled Vesting Date as described in paragraphs 3(b)-(d) above, your right to receive accumulated dividends on a Share will vest on the Scheduled Vesting Date </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">unless </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the Share is otherwise forfeited before the Scheduled Vesting Date. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If you forfeit a Share, you will also forfeit the right to any accumulated and future dividends related to the Share.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Vested accumulated dividends, less applicable taxes withheld, will be paid to you in a lump sum within 70 days after the Scheduled Vesting Date.    If your Termination qualifies for early vesting under paragraph 3(a) above, vested accumulated dividends, less applicable taxes withheld, will be paid to you in a lump sum within 70 days after your Termination.  Cigna will not pay any interest on the accumulated dividends.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Taxes at Vesting</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">When the Shares vest or there is otherwise a taxable event, you must satisfy any required tax withholding obligation.  Cigna reserves the right to withhold enough Shares to cover all or part of any applicable tax withholding.  However, if section 83(b) of the Code applies to you and you make a timely election under that provision, you must make an immediate cash payment to satisfy any required tax withholding obligation. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Please note that a taxable event with respect to the Shares may occur prior to the applicable Vesting Date for such Shares if you continue to vest in the Shares following your Termination pursuant to paragraph 3 above and there is no longer a &#8220;substantial risk of forfeiture&#8221; under section 83(a)(1) of the Code.  For example, if you continue to vest in the Shares pursuant to your Retirement under paragraph 3(b), any Shares that remain unvested on the date that you are no longer subject to a &#8220;substantial risk of forfeiture&#8221; (typically, the date you are no longer subject to a non-compete restriction) will immediately become taxable and Cigna reserves the right to withhold enough Shares to cover all or part of any applicable tax withholding under this paragraph 5.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Book-Entry Shares&#59; Sale of Shares</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Cigna (or a custodian appointed by Cigna) will hold your Shares before and after vesting in book-entry form in a Stock Account.  That is, a record of your Share ownership will be kept electronically.    </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You may generally sell or transfer vested Shares at any time, but your right to sell the Shares after they vest may be limited by Cigna.  This right is subject to the terms of Cigna's Securities Transactions and Insider Trading Policy, and Cigna reserves the right, for any reason at any time, to suspend or delay action on any request you make to sell the Shares.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Conditions of Grant</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;By accepting the grant, you are agreeing&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1) &#160;&#160;&#160;&#160;to the Inventions provision in paragraph 7(b)&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;to the restrictions contained in the attached Covenant Agreement and in paragraph 7(c)(2) below (such restrictions collectively, the &#8220;Promises&#8221;)&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">notify Cigna</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> if you accept an offer to perform services for any individual or entity while you are subject to the non-competition Promise under the Covenant Agreement.  Such notice shall be provided by email to </font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">noncompete&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> within 10 days of your acceptance of the offer and shall identify the individual or entity and your anticipated start date&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">disclose the terms of the Promises</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (including, without limitation, the Promises related to non-solicitation and non-competition) and the consequences of a Violation </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">to any individual or entity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> for whom you perform services during the 12 month period immediately following your Termination&#59; and </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;not to engage in any activity that would constitute a Violation (as defined below).  &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You understand and agree that the conditions of the grant set forth in this paragraph 7(a) are a material part of the inducement for Cigna's granting you the Shares and essential pre-conditions to your eligibility to exercise any rights associated with the Shares and retain any benefit from the vesting of the Shares.  </font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The award of Shares pursuant to this Restricted Stock Grant is expressly conditioned on your acceptance of the terms and conditions of this Grant and of the attached Covenant Agreement.  If you </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">decide to accept </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this Restricted Stock Grant, you are accepting and agreeing to all of the terms and conditions of this Grant and of the attached Covenant Agreement, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You should review the terms of this Grant and the Covenant Agreement carefully to ensure that you understand what they say and what your responsibilities and obligations are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">before you click on the accept button </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to acknowledge and agree to this Grant.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inventions </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;You hereby assign and promise to assign to Cigna companies or their designee, all your right, title, and interest in and to any and all current and future Inventions.  You acknowledge that all original works of authorship which you make (whether alone or jointly with others) within the scope of your Cigna company employment and which are protectable by copyright are &#8220;works made for hire,&#8221; as defined in the United States Copyright Act.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;You agree to (i) maintain and make available adequate current records, including electronic records, notes, sketches and drawings, of all Inventions you make, and (ii) disclose such Inventions in writing upon request. These records will remain the property of Cigna companies.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;If in the course of your Cigna company employment, you incorporate a Prior Invention into any Cigna company work product, you grant Cigna companies a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to use the Prior Invention as part of or in connection with the work product. Within 45 days after the date of this grant, you agree to notify Cigna Shareholder Services (</font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) of any Prior Inventions that you are not assigning under this paragraph 7(b).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Inventions&#8221; means any and all inventions, original works of authorship, developments, concepts, sales methods, improvements, trade secrets, or similar intellectual property, whether or not patentable or registrable under copyright or similar laws, that relate to any Cigna company&#8217;s current or proposed business, work products or research and development which you have or will solely or jointly conceive, develop, reduce to practice, or fix during your Cigna company employment.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;&#8220;Prior Inventions&#8221; means all inventions, original works of authorship, developments, concepts, sales methods, improvements, trade secrets or similar intellectual property, whether or not patentable or registrable under copyright or similar laws, that relate to any Cigna company&#8217;s current or proposed business, work products or research and development which you conceived, developed, reduced to practice or fixed before your Cigna company employment and which belong to you. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Violation</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You will engage in a &#8220;Violation&#8221; if, directly or indirectly, you engage in any willful misconduct as described in paragraph 7(c)(1) below, or you break any of the Promises.   </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Willful</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Misconduct</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58; </font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;You have a Termination initiated by a Cigna company because you engaged in conduct that constitutes a gross violation of Cigna's Code of Ethics and Principles of Conduct or other employment policies.</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;You do anything else while an employee of any Cigna company that is not discovered by the company until after your Termination and that would, if you had still been employed at the time of the discovery, be reason for your Termination for willful misconduct, as described above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Promise to Assist with Patent and Copyright Registrations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;You Promise that, during your Cigna company employment and after your Termination, you will assist Cigna companies, should they request and at Cigna's expense, to secure their rights (including any copyrights, patents, trademarks or other intellectual property rights) in or relating to the Inventions in any and all countries, including by&#58; </font></div><div style="margin-bottom:6pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">disclosing to Cigna companies all pertinent information and data&#59; and</font></div><div style="margin-bottom:6pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">executing all applications, assignments or other instruments necessary to apply for and obtain these rights and assign them to Cigna companies.   </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consequences of a Violation&#58; Payment to Cigna</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Important&#58; This paragraph 8 is not Cigna's only remedy for a Violation.  Cigna may seek any additional legal or equitable remedy, including as described in the Covenant Agreement.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;You will immediately forfeit all unvested Shares if you engage in any Violation at any time.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You must immediately make the Payment described in paragraph 8(c) to Cigna in the manner described in paragraph 8(d) if&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;You engage in a Violation of the non-competition or non-solicitation restrictions of the Covenant Agreement&#59; or</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;You engage in a Violation described in paragraph 7(c)(1) (willful misconduct) or any other Violation (e.g. you disclose Cigna company Confidential Information in violation of the Covenant Agreement) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">at any time</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#8220;Payment&#8221; is the value you realize from any Shares that vest during the 12-month period prior to the date of your Termination and thereafter.  The Payment will equal&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The number of Shares that vest during the applicable period&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;multiplied by </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The Fair Market Value of those Shares on their Vesting Date&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;plus </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The total amount of all dividends, if any, paid to you on those Shares through the date of the Payment.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Cigna will recover the Payment from you by any means permitted by applicable law, at the sole discretion of Cigna management, including but not limited to any or all of the following methods&#58;</font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;If you have any Shares in a Stock Account or in any other account in book-entry form when a Violation occurs, Cigna will take back from you the whole number of Shares that has a total Fair Market Value as of the date of the Violation up to, but not more than, the Payment amount.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Cigna will, to the extent permitted by applicable law, reduce&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;The amount of any payments that any Cigna company owes you for any reason (including without limit any payments owed to you under any nonqualified retirement, deferred compensation or other plan or arrangement) by </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;The Payment amount.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This reduction will not occur until the date a future payment to you is due.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Cigna will send you a written notice and demand for all or part of any Payment amount.  Within 30 days after you receive that notice and demand, you must make the Payment to Cigna.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;If you were an Executive Officer at any time during the 24-month period before the date of a Violation of the Covenant Agreement, the Committee will have the sole discretion to waive your obligation to make all or any part of the Payment (described in this paragraph 8) and to impose conditions on any waiver.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;If you are in Career Band 6 or higher on your Termination date but </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> subject to paragraph 8(e)(1) above, Cigna's Restrictive Covenant Review Committee will have the sole discretion to waive your obligation to make all or any part of the Payment (described in this paragraph 8) and to impose conditions on any waiver.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Otherwise, Cigna's Senior Human Resources Officer, or his or her designee, will have the sole discretion to waive your obligation to make all or any part of the Payment and to impose conditions on any waiver.  </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Determinations of the Committee, the Restrictive Covenant Review Committee, or Cigna's Senior Human Resources Officer (or his or her designee), will be final and binding on all parties.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consequences of a Violation&#58; Designation of Cigna as Agent and Attorney-in-Fact for Inventions</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You agree that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If Cigna Companies are unable to obtain your signature on any instruments needed to secure their rights in or relating to the Inventions pursuant to paragraph 7(c)(2)(A)&#59; then</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You hereby appoint Cigna companies and their duly authorized officers as your agents and attorneys in fact to act for and on your behalf to execute and file any documents and take other actions as may be necessary for Cigna companies to secure those rights.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreeing to Assume Risks</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cigna, its stock plan administrator and its transfer agent will try to process your stock transaction requests in a timely manner&#59; however, Cigna makes no promises or guarantees to you relating to the market price of the Shares or to the time it may take to act on your request to sell the Shares.  By accepting this Restricted Stock grant&#58;</font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;You acknowledge that the action you request may not be completed until several days after you submit it.    </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You agree to assume the risks, including the risk that the market price of the Shares may change, related to delays described in paragraph 10(a) between the time you ask for any Shares to be sold and the time your Shares are actually sold.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Applicable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Law</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You understand and agree that, except as otherwise provided in the Covenant Agreement, the terms and conditions of this Restricted Stock Grant and all determinations made under the Restricted Stock Grant Agreement, the Plan, and these Terms and Conditions will be interpreted under the laws of the State of Delaware, without regard to its conflict of laws rule.  </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, the terms and conditions of the Covenant Agreement and all determinations made under the Covenant Agreement will be interpreted under applicable state law as set forth in the Covenant Agreement.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Arbitration &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Except as otherwise provided in the Covenant Agreement, if you have an agreement with Cigna to arbitrate employment-related disputes, you agree to resolve any disputes relating to this Restricted Stock Grant through arbitration. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Acceptance</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">If you disagree with any of these Terms and Conditions or the terms and conditions of the Covenant Agreement, YOU MUST NOT ACCEPT THE RESTRICTED STOCK GRANT. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> If you sign the Restricted Stock Grant or the Covenant Agreement, or acknowledge your acceptance electronically or otherwise, you will be&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Agreeing to all the terms and conditions of the Restricted Stock Grant and of the Covenant Agreement, including the Inventions provision in paragraph 7(b) and all of the Promises&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Warranting and representing to Cigna that you are, and will remain, in full compliance with all applicable terms and conditions&#59; </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;Authorizing Cigna to recover the Payment described in paragraph 8 and to seek any other available remedy pursuant to the Covenant Agreement, if you engage in a Violation&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Appointing Cigna as your agent and attorney-in-fact to secure rights with respect to Inventions if unable to obtain your signature as described in paragraph 9.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Year&#93; US RSG Grant Agreement including Terms and Conditions</font></div><div><font><br></font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>exhibit106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i76feb07bd2134ca18e7f13fd7b948596_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.6</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e7e6e6;border-bottom:2pt double #000000;border-left:2pt double #000000;border-right:2pt double #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">THE CIGNA GROUP</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CONFIDENTIALITY, NON-COMPETITION AND</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">NON-SOLICITATION AGREEMENT </font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In consideration of The Cigna Group and&#47;or its affiliates, subsidiaries, successors, assigns, or related companies or entities (collectively the &#8220;Company&#8221;) employing me, compensating me, providing me with access to Confidential Information, and&#47;or access to the Company's customers and clients and the opportunity to develop and maintain relationships and goodwill with them, and&#47;or other good and valuable consideration, the adequacy, sufficiency and receipt of which is hereby acknowledged, and intending to be legally bound, the undersigned employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(&#8220;Employee&#8221;) enters into this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Confidentiality, Non-Competition and Non-Solicitation Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;Agreement&#8221;). Employee acknowledges and agrees that the provisions of this Agreement are part of and a condition of Employee&#8217;s employment with the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Section 1&#160;&#160;&#160;&#160;Confidentiality, Non-Solicitation &#38; Non-Competition</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt;text-decoration:underline">Confidentiality, Non-Disclosure and Non-Use Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">. </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Employee agrees that all records and Confidential Information obtained by Employee as a result of Employee&#8217;s employment with the Company, whether original, duplicated, computerized, memorized, handwritten, or in any other form, and all information contained therein or derived therefrom, are confidential and the sole and exclusive property of the Company. Employee understands and agrees that the business of the Company and the nature of Employee&#8217;s employment will require Employee to have access to Confidential Information of and about the Company, its business, its prospects, and its Customers. During Employee&#8217;s employment and thereafter, Employee will not use Confidential Information or remove any such records or information from the premises or computer systems of the Company except for the sole purpose of conducting business on behalf of the Company. Employee further agrees that during Employee&#8217;s employment and thereafter, Employee will not, without express consent of the Company, divulge or disclose this Confidential Information to any third party other than for the purposes of performing Employee&#8217;s job duties with the Company, and under no circumstances will Employee reveal or permit this information to become known by any competitor of the Company. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.20pt">(b)&#160;&#160;&#160;&#160;Employee agrees not to use or attempt to use any Confidential Information on behalf of any person or entity other than the Company, or in any manner which may injure or cause loss or may be calculated to injure or cause loss, whether directly or indirectly, to the Company. If at any time over the last two years of Employee&#8217;s employment with the Company, Employee&#8217;s position included access to Confidential Information as described above, specifically related to the Company&#8217;s procurement of prescription drugs, Employee understands and agrees that Employee&#8217;s subsequent employment with a pharmaceutical manufacturer, distributor or supplier (&#8220;Pharmaceutical Entity&#8221;) would create a substantial risk of use and&#47;or disclosure of Confidential Information with which Employee has been or will be entrusted during Employee&#8217;s employment with the Company. Specifically, Employee agrees that the disclosure of such Confidential Information to the Company&#8217;s pharmacy benefits management competitors with which one may negotiate in the course of employment with such Pharmaceutical Entity, would cause immediate and irreparable harm to the Company. In light of this risk of disclosure under such circumstances, and in recognition of the severity of harm that would result from such disclosure, Employee acknowledges and agrees that the Company will be entitled to immediate injunctive relief to prevent Employee from disclosing any such Confidential Information in the course of Employee&#8217;s employment with any such Pharmaceutical Entity. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.20pt">(c)&#160;&#160;&#160;&#160;During Employee&#8217;s employment, Employee will not make, use, or permit to be used, any materials of any nature relating to any matter within the scope of the business of the Company or concerning any of its dealings or affairs other than for the benefit of the Company. Employee will not, after the termination of Employee&#8217;s employment, use or permit to be used any such materials and shall return same in accordance with Section 1.2 below. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.20pt">(d)&#160;&#160;&#160;&#160;Employee will promptly notify the Company if Employee becomes aware of or suspects any unauthorized use or disclosure of Confidential Information by Employee or anyone else, whether intentional or accidental.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#0b0b0b;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement, pursuant to United States federal law as set forth in 18 USC Section 1833(b), Employee understands that Employee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of any Confidential Information that is a trade secret that is made&#58; (1) confidentially to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. If Employee files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Employee may disclose such trade secret to Employee&#8217;s attorney and use the trade secret information in related court proceedings, provided that Employee files any document containing the trade secret information under seal and does not disclose the trade secret, except pursuant to court order.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Nothing contained in this Agreement restricts or limits Employee&#8217;s right to discuss or disclose information about unlawful acts in the workplace, at work-related events, or between Company employees or the Company and Employee, such as harassment, discrimination, retaliation, sexual assault, or any other conduct that Employee has reason to believe is unlawful, nor does this Agreement prohibit Employee from discussing Employee&#8217;s employment or reporting possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor, the Occupational Safety and Health Administration, the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or state or local government agency. This Agreement does not prohibit Employee from discussing the terms and conditions of Employee&#8217;s employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including but not limited to &#8220;whistleblower&#8221; statutes or other similar provisions that protect such disclosure.  This Agreement also does not prohibit Employee from disclosing or discussing conduct or the existence of a settlement involving conduct relating to a dispute&#58; (1) involving a nonconsensual sexual act or sexual contact, as such terms are defined in section 2246 or title 18, United States Code, or similar applicable tribal or state law&#59; or (2) relating to conduct that is alleged to constitute sexual harassment under applicable federal, tribal, or state law.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section&#160;1.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt;text-decoration:underline">Return of Information, Records and Materials</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Employee agrees that upon termination of Employee&#8217;s employment with the Company or at the request of the Company at any time, Employee will immediately deliver to the Company all property of the Company, including without limitation all equipment owned or leased by the Company, and all documents, information, records, materials, and copies thereof in any form, that are related in any way to the Company or its business, or which are otherwise referred to in Section 1.1 above and as defined in Section 1.9 below. Employee understands that this includes, but is not limited </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to, delivery to the Company of all documents, memoranda, notes, records, data, computer programs, disks, data contained on hard drives or other computer or electronic storage media, or reports (and all copies thereof) made or compiled by, delivered to, or otherwise acquired by Employee concerning, containing or embodying any Confidential Information. </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section&#160;1.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt;text-decoration:underline">Non-Competition Covenant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Employee agrees that, during the Restricted Period and in any Restricted Area, Employee will not, directly or indirectly by assisting, provide services to a Competitor of the Company. Employee&#8217;s agreement not to provide such services to a Competitor applies regardless of whether Employee does so as an employee, owner, partner, principal, advisor, independent contractor, consultant, agent, officer, director, investor, or shareholder. Notwithstanding the foregoing, Employee&#8217;s ownership of less than 1% of the outstanding shares of a publicly traded company that constitutes a Competitor will not be deemed to be providing services to such Competitor solely by virtue of owning such shares. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Employee agrees that during the Restricted Period, Employee will not, directly or indirectly, work on a Company account on behalf of a Customer or Business Partner or serve as the representative of a Business Partner or Customer for such Business Partner&#8217;s or Customer&#8217;s relationship with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">During the Restricted Period, if a representative of the Company requests that Employee identify the company or business to which Employee will be or is providing services, or with which Employee will be or is employed, and requests that Employee provide information about the services that Employee is or will be providing to such entity, Employee will provide the Company with a written statement containing such information with sufficient detail to allow the Company to independently assess whether Employee is or will be in violation of this Agreement. Such statement must be delivered to the Company's senior director of Executive Compensation or his or her authorized delegate via personal delivery, email or overnight delivery within five calendar days of Employee&#8217;s receipt of such request.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Notwithstanding the foregoing, where applicable, this Section 1.3 will apply only to the extent permissible under (i) the ABA Model Rules of Professional Conduct&#8217;s provisions regarding restrictions on the right to practice law, and&#47;or (ii) any applicable state counterpart similarly addressing restrictions on the right to practice law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section&#160;1.4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt;text-decoration:underline">Non-Solicitation&#47;Interference - Employees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Employee acknowledges that the Company has a legitimate protectable interest in maintaining a stable and undisrupted workforce. Employee agrees that during the Restricted Period, Employee will not, directly or indirectly, on behalf of himself&#47;herself, or on behalf of any other person, entity, or organization, employ, solicit for employment, recruit, or otherwise seek to employ or retain the services of any employee or contractor of the Company, or in any way assist or facilitate any such employment, solicitation, or retention effort. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Employee agrees that during the Restricted Period, Employee will not, directly or indirectly, engage in any conduct intended or reasonably calculated to induce or urge any employee or contractor of the Company to discontinue, in whole or in part, his&#47;her employment relationship or engagement with the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The restrictions in this Section apply only to those employees or contractors of the Company with whom Employee worked or whom Employee supervised or about whom Employee obtained non-public information, in each case at any time during the twenty-four months preceding termination of Employee&#8217;s employment with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section&#160;1.5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt;text-decoration:underline">Non-Solicitation&#47;Interference - Customers or Business Partners</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Customers &#47; Business Partners</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">During the Restricted Period, Employee will not, directly or indirectly, solicit any Customer or Business Partner for the purpose of (A) providing or selling services or goods and products of a nature being provided or sold by the Company, or (B) entering into or seeking to enter into any contract or other arrangement with any Customer or Business Partner for the performance or sale of services or goods and products of a nature being provided or sold by the Company. Employee&#8217;s agreement &#8220;not to solicit&#8221; as set forth in this Section 1.5(a) means that Employee will not, directly or indirectly, initiate any contact or communication with any Customer or Business Partner for the purpose of soliciting, inviting, encouraging, recommending or requesting any Customer or Business Partner to do business with Employee and&#47;or a Competitor in connection with the performance or sale of services or goods and products of a nature being provided or sold by the Company or take a position where Employee would likely engage in such prohibited solicitation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">During the Restricted Period, Employee will not, directly or indirectly, engage in any conduct intended or reasonably calculated to induce or urge any Customer or Business Partner to discontinue, in whole or in part, its patronage or business relationship with the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">During the Restricted Period, Employee will not, directly or indirectly, accept any business from, provide services to, or do any business with, any Customer or Business Partner in connection with the performance or sale of services or goods and products of a nature being provided or sold by the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Employee acknowledges that as a result of Employee&#8217;s employment with the Company, Employee will be acting as a representative of the Company and will be using the Company&#8217;s assets and resources, and will be benefiting from the Company&#8217;s goodwill, name recognition, reputation, and experience in regard to these Customers and Business Partners, and Employee will gain Confidential Information about these Customers and Business Partners, and consequently, the covenants set forth above are reasonable and necessary to protect the Company&#8217;s legitimate business interests. Employee agrees that the covenants in this Section will apply to all Customers and Business Partners, even if the identity of certain Customers and Business Partners of the Company may be publicly known, and even if Employee knew or had previous dealings with one or more such Customers or Business Partners prior to Employee&#8217;s employment with the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section&#160;1.6</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt;text-decoration:underline">Injunctive Relief&#59; Expedited Discovery</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">In the event that Employee breaches or threatens to breach, or the Company reasonably believes Employee is about to breach, any of the restrictive covenants in this Agreement, the Company will be entitled to injunctive relief as well as an equitable accounting of all earnings, profits and other benefits arising from violation of this Agreement, which rights shall be cumulative and in addition to any other rights or remedies to which the Company may be entitled in law or equity. Employee agrees that the Company will suffer immediate and irreparable harm and that money damages will not be adequate to compensate the Company or to preserve the status quo. Therefore, Employee consents to the issuance of a temporary restraining order and other injunctive relief necessary to enforce this Agreement. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Employee agrees that the duration of any injunction will be increased in an amount equal to any period of time during which Employee failed to comply with the covenants contained in this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Employee and the Company agree that any application for temporary restraining order and&#47;or temporary or preliminary injunctive relief must be adjudicated exclusively in a court of competent jurisdiction, even if Employee and the Company are parties to an arbitration agreement that otherwise includes disputes under this Agreement. Employee agrees that the injunctive relief to which Employee consents above, under the circumstances addressed in this Section 1.6(c), must be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">granted by a court of competent jurisdiction pending arbitration on the merits in order to preserve the status quo pending such arbitration.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Employee agrees that in any proceeding alleging breach of this Agreement (whether in court or in arbitration), the Company and Employee each have the right to engage in deposition and document discovery, and the Company has the right to conduct forensic examination(s) of any computers and&#47;or electronic devices in Employee&#8217;s possession or control, if the Company reasonably believes such devices contain Confidential Information or other Company property. The Company and Employee further agree that in connection with any application for injunctive relief to enforce this Agreement (including without limitation any application for temporary and&#47;or preliminary injunctive relief), the foregoing discovery must be conducted on an expedited basis, including expedited document and deposition discovery. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;If any dispute under this Agreement is subject to resolution by arbitration under an agreement or program agreed to by Employee and the Company, Employee understands and agrees that Employee&#8217;s agreement to engage in expedited discovery as outlined in Section 1.6(d) is an essential term of the parties&#8217; arbitration agreement, and these provisions are intended to supplement and modify any applicable arbitration rules which may be incorporated into any arbitration agreement that is applicable to the dispute. Accordingly, Employee and the Company request that any court of competent jurisdiction order such expedited discovery in order to enforce the parties&#8217; arbitration agreement as written and in accordance with its terms. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section&#160;1.7</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt;text-decoration:underline">Notice of Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Employee agrees that Employee will tell any prospective new employer, partner in a business venture, investors and&#47;or any entity seeking to engage Employee&#8217;s services, prior to accepting employment, engagement as a consultant or contractor, or engaging in a business venture, that this Agreement exists, and further, Employee agrees to provide a true and correct copy of this Agreement to any such individual or entity prior to accepting any such employment or entering into any such engagement or business venture. Employee further authorizes the Company to provide a copy of this Agreement to any such entity(ies) or individual(s).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section&#160;1.8</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt;text-decoration:underline">Modification &#38; Severability&#59; Other Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If any section, provision, paragraph, phrase, word, and&#47;or line (collectively &#8220;Provision&#8221;) of this Agreement is held to be unenforceable, then this Agreement will be deemed amended to the extent necessary to render the otherwise unenforceable Provision, and the rest of the Agreement, valid and enforceable. If a court declines to amend this Agreement as provided herein, the invalidity or unenforceability of any Provision of this Agreement will not affect the validity or enforceability of the remaining Provisions, which must be enforced as if the offending Provision had not been included in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section&#160;1.9</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Business Partner&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> means a vendor, healthcare provider, supplier, manufacturer, agency, broker, regional marketing director, employee benefit plan or trust, hospital, hospital system, long-term care facility, and&#47;or pharmaceutical manufacturer with whom the Company has a business relationship, provided that Employee had business-related contact with the Business Partner in the last twenty-four months of employment with the Company or had access to non-public information </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 5 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">regarding such Business Partner during such period because of Employee&#8217;s employment relationship with the Company. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means any person, entity or organization engaged (or about to become engaged or preparing to become engaged) in a business similar to, or that competes with, the business of the Company, including without limitation any person or organization that provides any product or service that is similar to or competes with any product or service which has been offered or provided by the Company at any time during the twenty-four months preceding Employee&#8217;s termination of employment. The term &#8220;Competitor&#8221; specifically includes without limitation any person, entity or organization that provides any of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.13pt">pharmacy benefits management (&#34;PBM&#34;), including&#58; (a) the administration of pharmacy benefits for businesses, government agencies and health plans&#59; (b) mail order pharmacy&#59; (c) specialty pharmacy&#59; (d) prescription drug claims processing or formulary development or administration&#59; (e) the procurement of prescription drugs at a negotiated rate for dispensing&#59; and (f) Medicare Part D services&#59; </font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.08pt">pharmaceutical products and ancillary services, including specialty pharmaceutical products and support services and the provision of related pharmacy consulting, data management services and medical supplies&#59; </font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.03pt">prescription infusion drugs and related services (&#34;Infusion&#34;)&#59; </font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.63pt">insurance (&#34;Insurance&#34;) including&#58; (a) health, medical, dental, life, travel and accident insurance coverages, plans, programs, products and services&#59; (b) managed health care products and services&#59; (c) dental, vision, workers' compensation and employee assistance program products and services&#59; (d) wellness products and services to employers, government agencies, health plans, other businesses or third party payers&#59; (e) supplemental insurance products and services&#59; (f) administrative services provided to benefit plans&#59; and&#47;or (g) other voluntary products that are excepted benefits under HIPAA&#59; </font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">population health management products and services (&#34;Health Management&#34;)&#59; </font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.63pt">medical benefits management (&#8220;MBM&#8221;), including&#58; (a) the design or commercialization of software that uses natural language processing or clinical judgment to perform clinical order appropriateness determination&#59; (b) risk adjustment&#47;medical coding&#59; (c) clinical registry reporting services&#59; (d) prospective healthcare utilization management review&#59; and (e) utilization review or other management services relating to, or assumption of financial risk (including insurance risk) with respect to any clinical or other area entered into by the Company during the period of Employee&#8217;s employment&#59; </font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.58pt">behavioral health, care delivery, and care enablement products and services, including primary home care, worksite care, and virtual care products and services&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">health care related data and advanced analytics and applied innovation products and services&#59;</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.63pt">the administration of (i) &#8212; (viii) above (&#34;Administration&#34;)&#59; </font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">audit reviews or other consulting or advisory services with respect to any relationship between the Company and any third party, including its customers, vendors, suppliers and drug </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 6 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">manufacturers, as to a subject matter which is the same as or similar to subject matters with respect to which Employee provided services to the Company during the last twenty-four months of Employee&#8217;s employment with the Company, or about which Employee had access to Confidential Information during the last twenty-four months of Employee&#8217;s employment with the Company&#59; and&#47;or</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.63pt">any other product or service the Company was actively preparing to offer or provide during the last twenty-four months of Employee&#8217;s employment with the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> means all confidential and&#47;or proprietary information and trade secrets that are not generally known to the public, in any form, whether oral, written, computerized or otherwise, regarding the Company, including but not limited to&#58; computer code generated or developed by the Company&#59; software or programs and related documentation&#59; strategic compilations and analysis&#59; strategic processes&#59; business or financial methods, practices and plans&#59; non-public costs and prices&#59; operating margins&#59; marketing, merchandising and selling techniques and information&#59; customer lists and information&#59; prospective customer lists and information&#59; provider lists and information&#59; vendor, supplier, and business partner lists and information&#59; details of customer agreements&#59; pricing arrangements with pharmaceutical manufacturers, distributors or suppliers including but not limited to any discounts and&#47;or rebates&#59; pricing arrangements with insurance clients and customers&#59; pharmacy reimbursement rates&#59; premium information&#59; payment rates&#59; contractual forms&#59; expansion strategies&#59; real estate strategies&#59; operating strategies&#59; sources of supply&#59; patient records&#59; business plans&#59; other financial, commercial, business or technical information related to the Company and confidential information of third parties which is given to the Company pursuant to an obligation or agreement to keep such information </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">confidential.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Customer&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> means a customer (person or entity) or prospective customer (person or entity), provided that Employee had business-related contact with the customer or prospective customer in the last twenty-four months of employment with the Company or had access to non-public information regarding such customer or prospective customer during such period because of Employee&#8217;s employment relationship with the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Restricted Area&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> refers to (i) those states, districts and territories of the United States in which the Company conducts its business&#59; and (ii) any other countries in which the Company conducts its business. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Restricted Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> refers to the duration of Employee&#8217;s employment with the Company, plus the two-year period immediately following the termination of Employee&#8217;s employment with the Company for any reason. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Section 2&#160;&#160;&#160;&#160;Additional Terms</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Choice of Law, Jurisdiction &#38; Venue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">This Agreement will be governed by, construed, interpreted, and its validity determined under the law of the State, Province or Territory of Employee&#8217;s last assigned work location for the Company, without regard to such jurisdiction&#8217;s conflicts of laws principles. Such law will govern regardless of the court or arbitration forum in which a dispute may be adjudicated. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Employee and the Company agree that the exclusive and mandatory venue for adjudicating any disputes under this Agreement is the federal court or state (or provincial or territorial, as the case may be) court having original jurisdiction for the location in which Employee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 7 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">last worked for the Company. Employee and the Company consent to jurisdiction in such court for such purpose, and Employee consents to service of process by mail in respect of any such suit, action or proceeding. Employee and the Company further agree not to file any action relating in any way to this Agreement in any court other than as specified in this Section. Notwithstanding any of the foregoing, if any dispute under this Agreement is subject to resolution by arbitration under an agreement or program agreed to by Employee and the Company, then such arbitration will be the sole and exclusive venue for adjudicating such disputes, other than any requests for a temporary restraining order and&#47;or a temporary or preliminary injunction pending arbitration, which are reserved exclusively for adjudication in court pursuant to Section 1.6 above even in otherwise arbitrable disputes. </font></div><div style="margin-bottom:1pt;margin-top:0.5pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section 2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:0.55pt;margin-top:0.45pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.65pt">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.65pt;padding-left:23.8pt">In the event Employee receives a subpoena, deposition notice, interview request, or other process or order to testify or produce Confidential Information or any other information or property of the Company, Employee must promptly&#58; (i) notify the Company of the item, document, or information sought by such subpoena, deposition notice, interview request, or other process or order&#59; (ii) furnish the Company with a copy of said subpoena, deposition notice, interview request, or other process or order&#59; and (iii) provide reasonable cooperation with respect to any procedure that the Company may initiate to protect Confidential Information or other interests. If the Company objects to the subpoena, deposition notice, interview request, process, or order, Employee will cooperate to ensure that there is no disclosure until the court or other applicable entity has ruled upon the objection, and then only in accordance with the ruling so made. If no objection is made despite a reasonable opportunity to do so, Employee may comply with the subpoena, deposition, notice, interview request, or other process or order provided that Employee has fulfilled the above obligations.</font></div><div style="margin-bottom:1.55pt;margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1.3pt;margin-top:0.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.65pt">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.65pt;padding-left:23.18pt">Employee will cooperate fully with the Company, its affiliates, and their legal counsel in connection with any action, proceeding, or dispute arising out of matters with which Employee was directly or indirectly involved while serving as an employee of the Company, its predecessors, subsidiaries or affiliates. This cooperation includes, but is not limited to, meeting with, and providing information to, the Company and its legal counsel, maintaining the confidentiality of any past or future privileged communications with the Company&#8217;s legal counsel (outside and in-house), and Employee making himself or herself available to testify truthfully by affidavit, in depositions, or in any other forum on behalf of the Company. The Company agrees to reimburse Employee for any reasonable and necessary out-of-pocket costs associated with Employee&#8217;s cooperation.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section 2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Binding Effect and Assignability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement is be binding upon and inures to the benefit of the parties and their respective heirs, personal representatives, successors, assigns, affiliated entities, and any party-in-interest. Employee agrees that, should the Company be acquired by, merge with, or otherwise combine with another corporation or business entity, the surviving entity will have all rights to enforce the terms of this Agreement as if it were the Company itself enforcing the Agreement. Employee further agrees that this Agreement may be enforced against Employee by any Company affiliate, without the need for any formal assignment of this Agreement.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Employee may not assign this Agreement. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 8 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section 2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">No Waiver of Rights&#59; Amendment&#59; Other Agreements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">A waiver by the Company of the breach of any of the provisions of this Agreement by Employee will not be deemed a waiver of any subsequent breach, nor will recourse to any remedy hereunder be deemed a waiver of any other or further relief or remedy provided for herein. No waiver will be effective unless made in writing and signed by an officer of the Company. This Agreement can only be amended or modified in a writing signed by both parties. Any subsequent change(s) in Employee&#8217;s duties, salary, compensation, or benefits will not affect the validity or scope of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement does not supersede or replace any prior agreements between the parties, including but limited to any prior agreements that provide for restriction(s) on post-employment conduct. Any and all such prior Agreements remain in full force and effect, according to their terms, and to the extent enforceable under applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section 2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Employee and the Company agree that in any legal proceeding to enforce this Agreement, the prevailing party will be entitled to reimbursement of its actual costs and expenses, including without limitation reasonable attorneys&#8217; fees, costs, and disbursements. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">State-Specific Modifications</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Employee is directed to Exhibit A for state-specific modifications to the terms of this Agreement, as may be applicable to Employee. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">EMPLOYEE CERTIFIES THAT EMPLOYEE HAS READ AND UNDERSTANDS THIS AGREEMENT AND THE RESTRICTIONS CONTAINED IN SECTION 1, AND HAS HAD AN OPPORTUNITY TO CONSULT WITH LEGAL COUNSEL PRIOR TO SIGNING. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">EMPLOYEE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> UNDERSTAND</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">S</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> THAT </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">EMPLOYEE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> SHOULD CONSULT WITH AN ATTORNEY PRIOR TO SIGNING THIS AGREEMENT. EMPLOYEE ACKNOWLEDGES THAT THIS AGREEMENT MAY BE ACCEPTED AND AGREED TO ELECTRONICALLY BY EMPLOYEE, AND THAT AN ELECTRONIC COPY, HARD COPY OR ACKNOWLEDGMENT IS AS ENFORCEABLE AS AN ORIGINAL. EMPLOYEE ACKNOWLEDGES THAT EMPLOYEE HAS ACCESS TO A PAPER COPY OF THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">THE CIGNA GROUP</font></div><div style="margin-bottom:13.2pt;padding-left:2.77pt;padding-right:30.27pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Kari Knight Stevens</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">The Cigna Group</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EVP, Chief Human Resources Officer</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;DATE&#93;</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EMPLOYEE</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;Via Electronic Acceptance&#93;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><br> </font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 9 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">STATE SPECIFIC MODIFICATIONS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(AS APPLICABLE)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">For District of Columbia Employees Only</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The modifications in this section apply to Employee if Employee performs a majority of Employee&#8217;s work in the District of Columbia or is based in the District of Columbia and does not perform the majority of Employee&#8217;s work in any other jurisdiction.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Employee is a &#8220;covered employee&#8221; as defined in D.C. Code &#167; 32-581.01(6), Section 1.3 will not apply to Employee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If Employee is a &#8220;highly compensated employee&#8221; as defined in D.C. Code &#167; 32-581.01(1), then&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Employee acknowledges that Employee received a copy of the Agreement in writing at least 14 days before Employee began employment with the Company, if Employee is a new employee of the Company&#59; or if Employee was already employed by the Company at the time Employee was asked to sign the Agreement, at least 14 days before Employee was required to sign the Agreement.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Employee acknowledges receipt of the following notice&#58; &#8220;The District&#8217;s Ban on Non-Compete Agreements Amendments Act of 2020 limits use of non-compete agreements.  It allows employers to request non-compete agreements from highly compensated employees, as that term is defined in the Ban on Non-Compete Agreements Amendments Act of 2020, under certain conditions. The Company has determined that you are a highly compensated employee.  For more information about the Ban on Non-Compete Agreements Amendment Act of 2020, contact the District of Columbia Department of Employment Services (DOES).&#8221;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">For Massachusetts Employees Only</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The modifications in this section apply to Employee if Employee is, or if Employee has been for at least 30 days immediately preceding the date of termination of Employee&#8217;s employment, a resident of or employed in Massachusetts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Employee acknowledges that Employee has a right to consult with an attorney prior to signing this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If Employee entered into this Agreement after beginning employment with the Company, Employee acknowledges that Employee has been provided at least ten (10) business days before the Agreement is to be effective to consider this Agreement.  If Employee entered into this Agreement in connection with the beginning of employment, Employee acknowledges that Employee received the Agreement by the earlier of a formal offer of employment or 10 business days before the beginning of Employee&#8217;s employment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 10 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.3 of this Agreement is replaced with&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:4.25pt">   </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Non-Competition Covenant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">.</font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Employee agrees that, during the Restricted Period and in any Restricted Area, Employee will not, directly or indirectly by assisting, provide services to a Competitor of the Company. Employee&#8217;s agreement not to provide such services to a Competitor applies regardless of whether Employee does so as an employee, owner, partner, principal, advisor, independent contractor, consultant, agent, officer, director, investor, or shareholder.  Notwithstanding the foregoing, Employee&#8217;s ownership of less than 1% of the outstanding shares of a publicly traded company that constitutes a Competitor will not be deemed to be providing services to such Competitor solely by virtue of owning such shares. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">During the Restricted Period, if a representative of the Company requests that Employee identify the company or business to which Employee will be or is providing services, or with which Employee will be or is employed, and requests that Employee provide information about the services that Employee is or will be providing to such entity, Employee will provide the Company with a written statement containing such information with sufficient detail to allow the Company to independently assess whether Employee is or will be in violation of this Agreement. Such statement must be delivered to the Company's senior director of Executive Compensation or his or her authorized delegate via personal delivery, email or overnight delivery within five calendar days of Employee&#8217;s receipt of such request. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Unless Employee is laid off or involuntarily terminated by the Company without Cause, and provided Company does not waive the non-compete restrictions set forth in Section 1.3, in consideration for Employee&#8217;s compliance with the covenants made in Section 1.3 of this Agreement, Company agrees to pay Employee garden leave payments during the 12-month period immediately following the termination of Employee&#8217;s employment, which will be paid as follows&#58; (i) Company will pay Employee fifty percent (50%) of Employee&#8217;s highest annualized base salary (not including any bonus payments) within the preceding two (2) years of employment with Company, to be paid in substantially equal installments during such 12-month period (the &#8220;Garden Leave Payments&#8221;)&#59; (ii) the Garden Leave Payments will be paid through payroll on regular payroll dates, and will be subject to all applicable withholdings&#59; and (iii) unless Company decides to waive the non-competition restrictions contained in this Section 1.3 on or before commencement of the post-employment portion of the Restricted Period, Company will not unilaterally fail or refuse to make such payments. Employee acknowledges that Employee would not otherwise be entitled to receive the foregoing consideration absent Employee&#8217;s agreement to fully comply with the obligations contained in this Section 1.3. For the avoidance of doubt, the payments described in this Section 1.3(c) apply only to the non-competition covenants contained in Section 1.3, but have no applicability to, and are not a condition of, enforcement of the covenants contained in Sections 1.1, 1.2, 1.4, and 1.5. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">At any time prior to commencement of the post-employment portion of the Restricted Period, Company has the option and the right to waive the non-competition restrictions contained in this Section 1.3. If Company does so, then Company will have no obligation to make any further Garden Leave Payments under Section 1.3(c), other than what may be owed to Employee on a pro-rata basis for any portion of the 12-month period following termination </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 11 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of employment during which Employee was complying with the restrictions of Section 1.3 prior to Company notifying Employee of its waiver. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The restrictions contained in this Section 1.3 will not apply in the event Employee is (i) laid off, or (ii) involuntarily terminated by the Company without Cause, and in either such event there shall correspondingly be no obligation on the part of Company to make any Garden Leave Payments. In the event of a termination for Cause (as defined below), however, this Section 1.3 will remain in full force and effect to the same extent as it would if Employee resigned voluntarily. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">Notwithstanding the foregoing, where applicable, this Section 1.3 will apply only to the extent permissible under (i) the ABA Model Rules of Professional Conduct&#8217;s provisions regarding restrictions on the right to practice law, and&#47;or (ii) any applicable state counterpart similarly addressing restrictions on the right to practice law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.6(b) of the Agreement does not apply to Employee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any of the following&#58; (i) an unsatisfactory level of performance&#59; (ii) a violation of any legal or contractual obligation to the Company&#59; (iii) non-compliance with Company policies or procedures, including without limitation Cigna's Code of Ethics and Principles of Conduct&#59; (iv) engagement in any activity resulting in an employee being not bondable as determined by Cigna under its (or its successor&#8217;s) fidelity bond&#59; (v) the conviction of a felony involving fraud or dishonesty directed against the Company&#59; or (vi) any willful act or failure to act that adversely affects the business of the Company in any material respect. For purposes of this definition, &#8220;unsatisfactory level of performance&#8221; means a serious performance failure or infraction, including, without limitation, serious conduct and attendance failures, subject to formal discipline or corrective action up to and including immediate termination. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The definition of &#8220;Restricted Period&#8221; in Section 1.9 of the Agreement is replaced with&#58; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> refers to the duration of Employee&#8217;s employment with the Company, plus the one-year period immediately following the termination of Employee&#8217;s employment with the Company for any reason&#59; provided, however, that in the event Employee breaches a fiduciary duty to the Company, or unlawfully takes the Company&#8217;s property, then the Restricted Period will be extended for the duration of the two-year period immediately following the termination of Employee&#8217;s employment with the Company for any reason. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.1 of the Agreement is replaced with&#58;  &#8220;This Agreement will be governed by and construed according to the laws of the Commonwealth of Massachusetts. Employee consents to the personal jurisdiction of the court located in the county in which Employee resides as of the date of Employee&#8217;s termination of employment and the business litigation session of the Superior Court in Suffolk County, Massachusetts with respect to all matters arising out of or related to this Agreement.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Cigna Group and the Company entity with which Employee is employed represent, and Employee acknowledges, that&#58; (1) both are parties to this Agreement&#59; and (2) the individual who has executed this Agreement above  is authorized to and does execute this Agreement on behalf of the Company entity with which Employee is employed. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">- 12 -</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>8
<FILENAME>exhibit107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i24390c6d0708427a89df1a05815174c1_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.7</font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Cigna Group</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cigna Long-Term Incentive Plan&#58;  Strategic Performance Share Grant Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Cigna Group (&#8220;Cigna&#8221;) has granted you the number of strategic performance shares set forth below in this Strategic Performance Share Grant Agreement (&#8220;Strategic Performance Share Grant&#8221; or &#8220;Grant&#8221;) under the Cigna Long-Term Incentive Plan (&#8220;Plan&#8221;).  The date of your Strategic Performance Share Grant (&#8220;Grant Date&#8221;) is also indicated below. The award is subject to the provisions of the Plan and the Terms and Conditions below.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The award of Shares pursuant to this Strategic Performance Share Grant is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">expressly conditioned</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> on your acceptance of the terms and conditions of this Grant and of the attached Confidentiality, Non-Competition and Non-Solicitation Agreement (or with respect to Cigna company employment in California, the attached Confidentiality and Non-Solicitation Agreement) (as applicable, the &#8220;Covenant Agreement&#8221;).  You should carefully read all the terms and conditions of this Strategic Performance Share Grant and the attached Covenant Agreement and be sure you understand what they say and what your responsibilities and obligations are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">before you click on the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to acknowledge and agree to this Grant.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you are not willing to agree to all of the Grant and Covenant Agreement terms and conditions, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">do not accept the Grant and do not click the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> for the Strategic Performance Share Grant Acknowledgment and Agreement.  If you do not accept the Grant, you will not receive the benefits of the Grant. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you do </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">click on the ACCEPT button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, you are accepting and agreeing to all of the terms and conditions of this Strategic Performance Share Grant and the Covenant Agreement, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and  litigation cooperation and intellectual property assignment and assistance provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Participant&#58;  David M. Cordani</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Type&#58;  RSU</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Plan Name&#58;  Cigna Long-Term Incentive Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Date&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Total Granted&#58;  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Grant Price&#58;  (USD)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Vesting Schedule</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.009%"><tr><td style="width:1.0%"></td><td style="width:63.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Shares Granted</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Approximate Vest Date</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Please Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> The date shown in the Vesting Schedule chart above is not your actual vesting date.  It is an approximation of the expected vesting date and is provided due to systems requirements. In accordance with the Terms and Conditions of your Strategic Performance Share Grant, the actual vesting date will be determined by the People Resources Committee of the Board of Directors.</font></div><div><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition to this Strategic Performance Share Grant and the attached Covenant Agreement, you should also read the Plan Document and Key Contacts and Reference Materials document (attached to the Plan) and indicate that you have done so and agree to the terms of all documents attached to this Grant by checking the appropriate box in the online grant acceptance process.  The Key Contacts and Reference Materials document contains information on how to get important award information (such as the Plan Prospectus, Tax Considerations and Cigna's Securities Transactions and Insider Trading Policy) and whom to contact if you have questions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Please be aware that the Cigna Securities Transactions and Insider Trading Policy places restrictions on your transactions in Cigna securities and requires certain Cigna employees to obtain advance permission from the Corporate Secretary before executing transactions in Cigna securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If you have questions about your award, please contact Cigna Shareholder Services by email at </font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> or by phone at 215.761.3516.</font></div><div><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Important Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  Strategic Performance Share Grant and Covenant Agreement Acknowledgment and Agreement</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">By clicking on the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ACCEPT</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> button, I&#58;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Acknowledge and represent to Cigna that I have&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;received the Strategic Performance Share Grant, the Terms and Conditions of the Strategic Performance Share Grant and the Covenant Agreement&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;read and understand their terms and conditions, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions&#59; and </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;received answers to any questions I had about the Grant, the Terms and Conditions of the Grant and the Covenant Agreement and their terms and conditions, including the applicable restrictive covenants. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Scroll down for the TERMS AND CONDITIONS of the Strategic Performance Share Grant.</font></div><div><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">TERMS AND CONDITIONS OF YOUR &#91;YEAR&#93; GRANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">OF STRATEGIC PERFORMANCE SHARES</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">These Terms and Conditions are an important part of your grant of Strategic Performance Shares from The Cigna Group (Cigna).  The terms of your Strategic Performance Share grant are in&#58; (a) the electronic Strategic Performance Share Grant Agreement above, (b) these Terms and Conditions (including Schedule 1), (c) the Covenant Agreement, and (d) the Cigna Long-Term Incentive Plan (Plan).  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Certain words in this document with first letters capitalized are defined in the Strategic Performance Share Grant Agreement above, these Terms and Conditions or Article 2 of the Plan.  This grant is void if you are not an employee of Cigna or a Subsidiary (a Cigna company) on the Grant Date.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Strategic Performance Shares&#59; Performance Period</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Each Strategic Performance Share (Performance Share) represents a conditional right to receive one share of Cigna Common Stock (Share), subject to the performance, vesting and payment provisions described below. The Performance Period applicable to your award is January 1, &#91;____&#93; to December 31, &#91;____&#93; (the Performance Period). </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restrictions</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Performance Shares are subject to certain Restrictions from the Grant Date until the Payment Date described in paragraph 4.  The Restrictions are&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;You cannot sell or transfer the Performance Shares to anyone&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Unless an exception applies (described in paragraph 4) or unless otherwise determined by the Committee, you will forfeit (lose your right to) your unvested Performance Shares and all related rights immediately upon your Termination&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Of the Performance Shares awarded to you (Shares Awarded), the number of Performance Shares, if any, that you earn and for which you may receive payment (Shares Earned) is subject to the performance criteria described in Schedule 1.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Article 11 of the Plan describes these Restrictions in more detail.  In addition to these Restrictions, you must also comply with all the terms and conditions of this grant and the Covenant Agreement. </font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Performance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Shares Earned </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Schedule 1 specifies the performance criteria applicable to your Shares Awarded. Except as provided in paragraph 4, after the end of the Performance Period, the Committee shall determine whether and to what extent these performance criteria have been achieved for purposes of determining the Vesting Percentage applicable to your Performance Shares (Shares Earned Percentage). </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any Shares Awarded that are not Shares Earned after giving effect to the Committee&#8217;s determinations under this paragraph 3 shall terminate and become null and void immediately following such determinations.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Eligibility for Payment</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as described in paragraph 4(b) and subject to paragraph 4(c) and paragraph 3, the Restrictions on the Performance Shares will end (your Performance Shares will vest) on the Payment Date described in paragraph 5, but only if you remain continuously employed by a </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cigna company until the Payment Date and comply with all the terms and conditions of this grant and the Covenant Agreement.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Notwithstanding paragraph 4(a) and subject to paragraph 4(c) and paragraph 3, if your Termination is before the Payment Date&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;Your Performance Shares will vest upon your Termination if it is a Termination Upon a Change of Control. If your Performance Shares vest under this paragraph 4(b)(1), the Shares Earned Percentage shall be 100%.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;Your Performance Shares will vest upon your Termination if it is due to your death or Disability. If your Performance Shares vest under this paragraph 4(b)(2), the Shares Earned Percentage shall be 100%. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;Your Performance Shares will continue to vest following your Termination due to your Early Retirement or Retirement if&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;The date of Termination due to your Early Retirement or Retirement is at least twelve (12) months after the Grant Date&#59;  </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;You will </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> be receiving severance pay from any Cigna company (whether under any severance benefit plan or any contract, agreement or arrangement)&#59; and</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(iii)&#160;&#160;&#160;&#160;You continue to comply with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period. </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A Termination resulting from a Cigna divestiture, outsourcing or other business transaction where you become employed by the buyer, vendor or other entity involved in the transaction will not constitute a Retirement or Early Retirement under this paragraph 4(b)(3).  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If your Performance Shares continue to vest under this paragraph 4(b)(3), the Shares Earned Percentage shall be determined by the Committee under paragraph 3(a) above and applied.    </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;Your Performance Shares </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">continue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to vest following your Termination if your Termination is an Involuntary Termination that occurs within twelve (12) months of the Approximate Vest Date for the Performance Shares described in the Strategic Performance Share Grant Agreement above.  For example, if the date of your Involuntary Termination is June 1, 2027 you will vest in any Performance Shares scheduled to be paid on or before June 1, 2028 on the otherwise scheduled Payment Date.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Unless otherwise determined by the Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, if your Performance Shares continue to vest under this paragraph 4(b)(4), the Performance Shares will be prorated based on the amount of time you were employed by a Cigna company during the applicable Performance Period prior to, and inclusive of, the date of your Involuntary Termination and then the Shares Earned Percentage shall be determined by the Committee under paragraph 3(a) above and applied.  Subject to Section 15.2(b) of the Plan, The Cigna Group&#8217;s Shareholder Services team shall have the authority to determine the extent of proration if you were not employed by a Cigna company for the entire Performance Period.            </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The continued vesting described in this paragraph 4(b)(4) is subject to (and contingent upon) your ongoing compliance with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A Termination resulting from a Cigna divestiture, outsourcing or other business transaction where you become employed by the buyer, vendor or other entity involved in the transaction will not constitute an Involuntary Termination under this paragraph 4(b)(4).  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;If approved by (1) Cigna's Senior Human Resources Officer or his or her designee, or (2) the Committee (with respect to the CEO or any Executive Officer) before your Termination, your Shares </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">may continue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to vest following your Termination if you (i) continue to provide services to Cigna as a consultant or contractor, and (ii) continue to comply with the terms and conditions of the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.   </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If your Performance Shares continue to vest under this paragraph 4(b)(5), the Shares Earned Percentage shall be determined by the Committee under paragraph 3(a) above.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The continued vesting period, if any, under this paragraph 4(b)(5) shall be equal to the period of your continued services to Cigna as a consultant or contractor.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Unless otherwise determined by the Committee, the continued vesting period described in this paragraph 4(b)(5) will immediately cease on the date that you stop providing services to Cigna as a consultant or contractor, regardless of the reason your consulting or contracting services terminated.   The foregoing notwithstanding, if your consulting or contracting services to Cigna terminate upon one of the events described in paragraph 4(b)(2) above, the Performance Shares will vest on the date that your services terminate.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; (6)&#160;&#160;&#160;&#160;For avoidance of doubt, the continued vesting described in paragraphs 4(b)(3), 4(b)(4) and 4(b)(5) above is expressly subject to (and contingent upon) your ongoing compliance with the Covenant Agreement and any other restrictive covenant agreement(s) applicable to you during the continued vesting period.  If a Violation (as defined below) occurs or is discovered following your Termination, then, in addition to any other remedies available to Cigna under this Grant or the Covenant Agreement, any then unvested Performance Shares shall be immediately and automatically forfeited.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;You must comply in all respects with the terms and conditions of this Grant and the Covenant Agreement.   </font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Payment</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as provided in paragraph 5(b) and 5(c), below, your vested Shares Earned under this grant will be paid in the year following the close of the Performance Period on the date within such year specified by the Committee (Payment Date). </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any Performance Shares that vest on account of your Termination due to death or Disability will be paid during the 90 day period immediately following your Termination due to death or Disability to you (or to your estate, in the case of death).  </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Any Performance Shares that vest on account of your Termination Upon a Change of Control will be paid during the 30 day period immediately following your Termination Upon a Change of Control.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;For each Share Earned that vests, Cigna will make payment by issuing one Share as of the Payment Date.  Until the Shares are issued to you, you will not be a Cigna shareholder, not have the right to vote the Shares, and not receive actual dividends.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Taxes </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 17.7 of the Plan shall apply to any tax withholding that may be required by law for Performance Shares or Shares.  Upon the vesting or payment of any Performance Share, Cigna reserves the right to withhold enough newly-issued Shares to cover all or part of any applicable tax withholding.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Book-Entry Shares&#59; Sale of Shares</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Upon payment of the Shares as described in paragraph 5, Cigna (or a custodian appointed by Cigna) will hold your Shares in book-entry form in a Stock Account.  That is, a record of your Share ownership will be kept electronically.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You may generally sell or transfer the Shares at any time, but your right to sell the Shares may be limited by Cigna.  This right is subject to the terms of Cigna's Securities Transactions and Insider Trading Policy, and Cigna reserves the right, for any reason at any time, to suspend or delay action on any request you make to sell the Shares.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Conditions of Grant</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;By accepting the grant, you are agreeing&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1) &#160;&#160;&#160;&#160;to the Inventions provision in paragraph 8(b)&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;to the restrictions contained in the attached Covenant Agreement and in paragraph 8(c)(2) below (such restrictions collectively, the &#8220;Promises&#8221;)&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">notify Cigna</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> if you accept an offer to perform services for any individual or entity while you are subject to the non-competition Promise under the Covenant Agreement.  Such notice shall be provided by email to </font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">noncompete&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> within 10 days of your acceptance of the offer and shall identify the individual or entity and your anticipated start date&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">disclose the terms of the Promises</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (including, without limitation, the Promises related to non-solicitation and non-competition) and the consequences of a Violation (as defined below) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">to any individual or entity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> for whom you perform services during the 12 month period immediately following your Termination&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;not to engage in any activity that would constitute a Violation (as defined below). &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You understand and agree that the conditions of the grant set forth in this paragraph 8(a) are a material part of the inducement for Cigna's granting you the Performance Shares and essential pre-conditions to your eligibility to exercise any rights associated with the Grant and retain any benefit from the vesting of the Performance Shares and issuance of the Shares. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The award of Shares pursuant to this Strategic Performance Share Grant is expressly conditioned on your acceptance of the terms and conditions of this Grant and of the attached Covenant Agreement.  If you </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">decide to accept this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Strategic Performance Share Grant, you </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">are accepting and agreeing to all of the terms and conditions of this Grant and of the attached Covenant Agreement, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You should review the terms of this Grant and the Covenant Agreement carefully to ensure that you understand what they say and what your responsibilities and obligations are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">before you click on the accept button</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to acknowledge and agree to this Grant. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inventions </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;You hereby assign and promise to assign to Cigna companies or their designee, all your right, title, and interest in and to any and all current and future Inventions.  You acknowledge that all original works of authorship which you make (whether alone or jointly with others) within the scope of your Cigna company employment and which are protectable by copyright are &#8220;works made for hire,&#8221; as defined in the United States Copyright Act.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;You agree to (i) maintain and make available adequate current records, including electronic records, notes, sketches and drawings, of all Inventions you make, and (ii) disclose such Inventions in writing upon request. These records will remain the property of Cigna companies.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;If in the course of your Cigna company employment, you incorporate a Prior Invention into any Cigna company work product, you grant Cigna companies a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to use the Prior Invention as part of or in connection with the work product. Within 45 days after the date of this grant, you agree to notify Cigna Shareholder Services (</font><font style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">shareholderservices&#64;evernorth.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) of any Prior Inventions that you are not assigning under this paragraph 8(b).</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;&#8220;Inventions&#8221; means any and all inventions, original works of authorship, developments, concepts, sales methods, improvements, trade secrets, or similar intellectual property, whether or not patentable or registrable under copyright or similar laws, that relate to any Cigna company&#8217;s current or proposed business, work products or research and development which you have or will solely or jointly conceive, develop, reduce to practice, or fix during your Cigna company employment.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;&#8220;Prior Inventions&#8221; means all inventions, original works of authorship, developments, concepts, sales methods, improvements, trade secrets or similar intellectual property, whether or not patentable or registrable under copyright or similar laws, that relate to any Cigna company&#8217;s current or proposed business, work products or research and development which you conceived, developed, reduced to practice or fixed before your Cigna company employment and which belong to you.   </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Violation</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You will engage in a &#8220;Violation&#8221; if, directly or indirectly, you engage in any willful misconduct as described in paragraph 8(c)(1) below or you break any of the &#8220;Promises&#8221;.</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Willful</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Misconduct</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;You have a Termination initiated by a Cigna company because you engaged in conduct that constitutes a gross violation of Cigna's Code of Ethics and Principles of Conduct or other employment policies.</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;You do anything else while an employee of any Cigna company that is not discovered by the company until after your Termination and that would, if you had still been employed at the time of the discovery, be reason for your Termination for willful misconduct, as described above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Promise to Assist with Patent and Copyright Registrations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;You Promise that, during your Cigna company employment and after your Termination, you will assist Cigna companies, should they request and at Cigna's expense, to secure their rights (including any copyrights, patents, trademarks or other intellectual property rights) in or relating to the Inventions in any and all countries, including by&#58; </font></div><div style="margin-bottom:6pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">disclosing to Cigna Companies all pertinent information and data&#59; and</font></div><div style="margin-bottom:6pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">executing all applications, assignments or other instruments necessary to apply for and obtain these rights and assign them to Cigna companies.   </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consequences of a Violation&#58; Payment to Cigna</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Important&#58; This paragraph 9 is not Cigna's only remedy for a Violation.  Cigna may seek any additional legal or equitable remedy, including as described in the Covenant Agreement.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If you engage in any Violation at any time&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;You will immediately forfeit all unvested Performance Shares&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;No payment will be made for any Performance Shares that have vested under paragraph 4(b) if the Violation occurs before the applicable Payment Date.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You must immediately make the Payment described in paragraph 9(c) to Cigna in the manner described in paragraph 9(d) if&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;You engage in a Violation of the non-competition or non-solicitation restrictions of the Covenant Agreement&#59; or</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;You engage in a Violation described in paragraph 8(c)(1) (willful misconduct) or any other Violation (e.g. you disclose Cigna company Confidential Information in violation of the Covenant Agreement) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">at any time</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#8220;Payment&#8221; is the value you realize from any Performance Shares that are paid under paragraph 5 during the 12-month period prior to the date of your Termination and thereafter.  The Payment will equal&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The number of Performance Shares that are paid during the applicable period&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;multiplied by </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The Fair Market Value of the Shares issued on the Payment Date for those Performance Shares&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;plus </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The total amount of all actual dividends, if any, paid to you on those Shares through the date of the Payment described in paragraph 9(d).  </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Cigna will recover the Payment from you by any means permitted by applicable law, at the sole discretion of Cigna management, including but not limited to any or all of the following methods&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;If you have any Shares in a Stock Account or in any other account in book-entry form when a Violation occurs, Cigna will take back from you the whole number of Shares that has a total Fair Market Value as of the date of the Violation up to, but not more than, the Payment amount.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Cigna will, to the extent permitted by applicable law, reduce&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;The amount of any payments that any Cigna company owes you for any reason (including without limit any payments owed to you under any nonqualified retirement, deferred compensation or other plan or arrangement) by </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;The Payment amount.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This reduction will not occur until the date a future payment to you is due.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Cigna will send you a written notice and demand for all or part of any Payment amount.  Within 30 days after you receive that notice and demand, you must make the Payment to Cigna.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;If you were an Executive Officer at any time during the 24-month period before the date of a Violation of the Covenant Agreement, the Committee will have the sole discretion to waive your obligation to make all or any part of the Payment (described in this paragraph 9) and to impose conditions on any waiver.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;If you are in Career Band 6 or higher on your Termination date but </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> subject to paragraph 9(e)(1) above, Cigna's Restrictive Covenant Review Committee will have the sole discretion to waive your obligation to make all or any part of the Payment (described in this paragraph 9) and to impose conditions on any waiver.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Otherwise, Cigna's Senior Human Resources Officer, or his or her designee, will have the sole discretion to waive your obligation to make all or any part of the Payment and to impose conditions on any waiver.  </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Determinations of the Committee, the Restrictive Covenant Review Committee, or Cigna's Senior Human Resources Officer (or his or her designee), will be final and binding on all parties.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consequences of a Violation&#58; Designation of Cigna as Agent and Attorney-in-Fact for Inventions</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You agree that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If Cigna Companies are unable to obtain your signature on any instruments needed to secure their rights in or relating to the Inventions pursuant to paragraph 8(c)(2)(A)&#59; then</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You hereby appoint Cigna companies and their duly authorized officers as your agents and attorneys in fact to act for and on your behalf to execute and file any documents and take other actions as may be necessary for Cigna companies to secure those rights.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreeing to Assume Risks</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cigna, its stock plan administrator and its transfer agent will try to process your stock transaction requests in a timely manner&#59; however, Cigna makes no promises or guarantees to you relating to the market price of the Shares or to the time it may take to act on your request to sell the Shares.  By accepting this Strategic Performance Share grant&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;You acknowledge that the action you request may not be completed until several days after you submit it.    </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You agree to assume the risks, including the risk that the market price of the Shares may change, related to delays described in paragraph 11(a) between the time you ask for any Shares to be sold and the time your Shares are actually sold.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Applicable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Law</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">You understand and agree that, except as otherwise provided in the Covenant Agreement, the terms and conditions of this Strategic Performance Share Grant and all determinations made under the Strategic Performance Share Grant Agreement, the Plan, and these Terms and Conditions will be interpreted under the laws of the State of Delaware, without regard to its conflict of laws rule. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, the terms and conditions of the Covenant Agreement and all determinations made under the Covenant Agreement will be interpreted under applicable state law as set forth in the Covenant Agreement. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Arbitration </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Except as otherwise provided in the Covenant Agreement, if you have an agreement with Cigna to arbitrate employment-related disputes, you agree to resolve any disputes relating to this Strategic Performance Share Grant through arbitration. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Acceptance</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">If you disagree with any of these Terms and Conditions, or the terms and conditions of the Covenant Agreement, YOU MUST NOT ACCEPT THE STRATEGIC PERFORMANCE SHARE GRANT. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> If you sign the Strategic Performance Share grant, or the Covenant Agreement, or acknowledge your acceptance electronically or otherwise, you will be&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Agreeing to all the terms and conditions of the Strategic Performance Share grant and of the Covenant Agreement, including the Inventions provision in paragraph 8(b) and all of the Promises&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Warranting and representing to Cigna that you are, and will remain, in full compliance with all applicable terms and conditions&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;Authorizing Cigna to recover the Payment described in paragraph 9 and to seek any other available remedy pursuant to the Covenant Agreement, if you engage in a Violation&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Appointing Cigna as your agent and attorney-in-fact to secure rights with respect to Inventions if unable to obtain your signature as described in paragraph 10.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Year&#93; US SPS Grant Agreement including Terms and Condition</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>exh_31126q1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i1291cd88745947e88d89843b20e500f9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, DAVID M. CORDANI, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of The Cigna Group&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:43.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;&#160;&#160;April&#160;30, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David M. Cordani</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Chief Executive Officer of The Cigna Group</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>exh_31226q1.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ic7d52f7beb8a483c98e92467b910a3c7_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, ANN M. DENNISON, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of The Cigna Group&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:62.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;&#160;&#160;April&#160;30, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ann M. Dennison</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>exh_32126q1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i341bff554ba24abfb6d2cf55d81c362f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer of </font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Cigna Group pursuant to 18 U.S.C. Section 1350</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I certify that, to the best of my knowledge and belief, the Quarterly Report on Form 10-Q of The Cigna Group for the fiscal period ending March&#160;31, 2026 (the &#8220;Report&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of The Cigna Group.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:right;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.365%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David M. Cordani</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">David M. Cordani</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Chief Executive Officer of The Cigna Group</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;30, 2026</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>exh_32226q1.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="id304093b80da4a539675f376924a464b_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Financial Officer of</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Cigna Group pursuant to 18 U.S.C. Section 1350</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I certify that, to the best of my knowledge and belief, the Quarterly Report on Form 10-Q of The Cigna Group for the fiscal period ending March&#160;31, 2026 (the &#8220;Report&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of The Cigna Group.</font></div><div style="margin-bottom:12pt;text-align:right;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.621%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ann M. Dennison</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ann M. Dennison</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;30, 2026</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>ci-20260331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c9afa-b9b6-7bff-8807-e603b8e89aeb,g:b1b37cb4-a013-41e0-9774-54a06c55ff7f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ci="http://www.thecignagroup.com/20260331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.thecignagroup.com/20260331">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ci-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ci-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ci-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ci-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.thecignagroup.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome">
        <link:definition>9952151 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>9952152 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.thecignagroup.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952153 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952154 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinTotalEquity" roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity">
        <link:definition>9952155 - Statement - Consolidated Statements of Changes in Total Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinTotalEquityParenthetical" roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical">
        <link:definition>9952156 - Statement - Consolidated Statements of Changes in Total Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952157 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.thecignagroup.com/role/DescriptionofBusiness">
        <link:definition>9952158 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952159 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNet" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNet">
        <link:definition>9952160 - Disclosure - Accounts Receivable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplierFinanceProgram" roleURI="http://www.thecignagroup.com/role/SupplierFinanceProgram">
        <link:definition>9952161 - Disclosure - Supplier Finance Program</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.thecignagroup.com/role/EarningsPerShare">
        <link:definition>9952162 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.thecignagroup.com/role/Debt">
        <link:definition>9952163 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilities" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities">
        <link:definition>9952164 - Disclosure - Insurance and Contractholder Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Reinsurance" roleURI="http://www.thecignagroup.com/role/Reinsurance">
        <link:definition>9952165 - Disclosure - Reinsurance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.thecignagroup.com/role/Investments">
        <link:definition>9952166 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.thecignagroup.com/role/FairValueMeasurements">
        <link:definition>9952167 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>9952168 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicOptimizationProgram" roleURI="http://www.thecignagroup.com/role/StrategicOptimizationProgram">
        <link:definition>9952169 - Disclosure - Strategic Optimization Program</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.thecignagroup.com/role/IncomeTaxes">
        <link:definition>9952170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherMatters" roleURI="http://www.thecignagroup.com/role/ContingenciesandOtherMatters">
        <link:definition>9952171 - Disclosure - Contingencies and Other Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.thecignagroup.com/role/SegmentInformation">
        <link:definition>9952172 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetPolicies" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetPolicies">
        <link:definition>9955512 - Disclosure - Accounts Receivable, Net (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerSharePolicies" roleURI="http://www.thecignagroup.com/role/EarningsPerSharePolicies">
        <link:definition>9955513 - Disclosure - Earnings Per Share (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesPolicies" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesPolicies">
        <link:definition>9955514 - Disclosure - Insurance and Contractholder Liabilities (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsurancePolicies" roleURI="http://www.thecignagroup.com/role/ReinsurancePolicies">
        <link:definition>9955515 - Disclosure - Reinsurance (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsPolicies" roleURI="http://www.thecignagroup.com/role/InvestmentsPolicies">
        <link:definition>9955516 - Disclosure - Investments (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasuresandDisclosuresPolicies" roleURI="http://www.thecignagroup.com/role/FairValueMeasuresandDisclosuresPolicies">
        <link:definition>9955517 - Disclosure - Fair Value Measures and Disclosures (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossPolicies" roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossPolicies">
        <link:definition>9955518 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesPolicies" roleURI="http://www.thecignagroup.com/role/IncomeTaxesPolicies">
        <link:definition>9955519 - Disclosure - Income Taxes (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesPolicies" roleURI="http://www.thecignagroup.com/role/CommitmentandContingenciesPolicies">
        <link:definition>9955520 - Disclosure - Commitment and Contingencies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingPolicies" roleURI="http://www.thecignagroup.com/role/SegmentReportingPolicies">
        <link:definition>9955521 - Disclosure - Segment Reporting (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetTables" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetTables">
        <link:definition>9955522 - Disclosure - Accounts Receivable, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplierFinanceProgramTables" roleURI="http://www.thecignagroup.com/role/SupplierFinanceProgramTables">
        <link:definition>9955523 - Disclosure - Supplier Finance Program (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.thecignagroup.com/role/EarningsPerShareTables">
        <link:definition>9955524 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesTables" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables">
        <link:definition>9955525 - Disclosure - Insurance and Contractholder Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceTables" roleURI="http://www.thecignagroup.com/role/ReinsuranceTables">
        <link:definition>9955526 - Disclosure - Reinsurance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.thecignagroup.com/role/InvestmentsTables">
        <link:definition>9955527 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsTables">
        <link:definition>9955528 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>9955529 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicOptimizationProgramTables" roleURI="http://www.thecignagroup.com/role/StrategicOptimizationProgramTables">
        <link:definition>9955530 - Disclosure - Strategic Optimization Program (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.thecignagroup.com/role/SegmentInformationTables">
        <link:definition>9955531 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessSegmentInformationDetails" roleURI="http://www.thecignagroup.com/role/DescriptionofBusinessSegmentInformationDetails">
        <link:definition>9955532 - Disclosure - Description of Business - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetAmountsDetails" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails">
        <link:definition>9955533 - Disclosure - Accounts Receivable, Net - Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetAllowancesDetails" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAllowancesDetails">
        <link:definition>9955534 - Disclosure - Accounts Receivable, Net - Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetFactoringFacilityDetails" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails">
        <link:definition>9955535 - Disclosure - Accounts Receivable, Net - Factoring Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplierFinanceProgramDetails" roleURI="http://www.thecignagroup.com/role/SupplierFinanceProgramDetails">
        <link:definition>9955536 - Disclosure - Supplier Finance Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareBasicandDilutedEarningsPerShareDetails" roleURI="http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails">
        <link:definition>9955537 - Disclosure - Earnings Per Share - Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAntidilutiveOptionsDetails" roleURI="http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails">
        <link:definition>9955538 - Disclosure - Earnings Per Share - Anti-dilutive Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDividendsDetails" roleURI="http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails">
        <link:definition>9955539 - Disclosure - Earnings Per Share - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSharesofCommonStockHeldinTreasuryDetails" roleURI="http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails">
        <link:definition>9955540 - Disclosure - Earnings Per Share - Shares of Common Stock Held in Treasury (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDebtRepaymentDetails" roleURI="http://www.thecignagroup.com/role/DebtDebtRepaymentDetails">
        <link:definition>9955541 - Disclosure - Debt - Debt Repayment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtRevolvingCreditAgreementandCommercialPaperDetails" roleURI="http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails">
        <link:definition>9955542 - Disclosure - Debt - Revolving Credit Agreement and Commercial Paper (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.thecignagroup.com/role/DebtInterestExpenseDetails">
        <link:definition>9955543 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesAccountBalancesDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails">
        <link:definition>9955544 - Disclosure - Insurance and Contractholder Liabilities - Account Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesAccountBalancesDetails_1" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1">
        <link:definition>9955544 - Disclosure - Insurance and Contractholder Liabilities - Account Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails">
        <link:definition>9955545 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails">
        <link:definition>9955546 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails">
        <link:definition>9955547 - Disclosure - Insurance and Contractholder Liabilities - Future Policy Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails">
        <link:definition>9955548 - Disclosure - Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails">
        <link:definition>9955549 - Disclosure - Insurance and Contractholder Liabilities - Market Risk Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails">
        <link:definition>9955550 - Disclosure - Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceReinsuranceRecoverablesDetails" roleURI="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails">
        <link:definition>9955551 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceVariableAnnuityReinsuranceAgreementDetails" roleURI="http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails">
        <link:definition>9955552 - Disclosure - Reinsurance - Variable Annuity Reinsurance Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInvestmentsbyCategoryDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails">
        <link:definition>9955553 - Disclosure - Investments - Investments by Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails">
        <link:definition>9955554 - Disclosure - Investments - Investments by Category, Including Disposal Groups (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails_1" roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails_1">
        <link:definition>9955554 - Disclosure - Investments - Investments by Category, Including Disposal Groups (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails">
        <link:definition>9955555 - Disclosure - Investments - Debt Securities by Contractual Maturity Periods (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails">
        <link:definition>9955556 - Disclosure - Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails">
        <link:definition>9955557 - Disclosure - Investments - Summary of Debt Securities with a Decline in Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails_1" roleURI="http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails_1">
        <link:definition>9955557 - Disclosure - Investments - Summary of Debt Securities with a Decline in Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsEquitySecuritiesDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails">
        <link:definition>9955558 - Disclosure - Investments - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsCommercialMortgageLoansDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails">
        <link:definition>9955559 - Disclosure - Investments - Commercial Mortgage Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsOtherLongTermInvestmentsDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails">
        <link:definition>9955560 - Disclosure - Investments - Other Long-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDerivativeFinancialInstrumentsDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails">
        <link:definition>9955561 - Disclosure - Investments - Derivative Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsComponentsofNetInvestmentIncomeLossesDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails">
        <link:definition>9955562 - Disclosure - Investments - Components of Net Investment Income/Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInvestmentGainsandLossesDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentGainsandLossesDetails">
        <link:definition>9955563 - Disclosure - Investments - Investment Gains and Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails">
        <link:definition>9955564 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails">
        <link:definition>9955565 - Disclosure - Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails">
        <link:definition>9955566 - Disclosure - Fair Value Measurements - Information about Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails">
        <link:definition>9955567 - Disclosure - Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSeparateAccountsDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails">
        <link:definition>9955568 - Disclosure - Fair Value Measurements - Separate Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails">
        <link:definition>9955569 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails">
        <link:definition>9955570 - Disclosure - Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>9955571 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicOptimizationProgramDetails" roleURI="http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails">
        <link:definition>9955572 - Disclosure - Strategic Optimization Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.thecignagroup.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955573 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherMattersDetails" roleURI="http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails">
        <link:definition>9955574 - Disclosure - Contingencies and Other Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSpecialItemChargesBenefitsDetails" roleURI="http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails">
        <link:definition>9955575 - Disclosure - Segment Information - Special Item Charges (Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSummarizedSegmentFinancialInformationDetails" roleURI="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails">
        <link:definition>9955576 - Disclosure - Segment Information - Summarized Segment Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSummarizedSegmentFinancialInformationDetails_1" roleURI="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails_1">
        <link:definition>9955576 - Disclosure - Segment Information - Summarized Segment Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuefromExternalCustomersDetails" roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails">
        <link:definition>9955577 - Disclosure - Segment Information - Revenue from External Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationFinancialandPerformanceGuaranteesDetails" roleURI="http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails">
        <link:definition>9955578 - Disclosure - Segment Information - Financial and Performance Guarantees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ci_NetInvestmentGainLoss" abstract="false" name="NetInvestmentGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" abstract="false" name="OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" abstract="false" name="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ReinsuranceRecoverablesNonCurrent" abstract="false" name="ReinsuranceRecoverablesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SeparateAccountAssetAtCarryingValue" abstract="false" name="SeparateAccountAssetAtCarryingValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesCurrent" abstract="false" name="InsuranceAndContractholderLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PharmacyAndServiceCostsPayable" abstract="false" name="PharmacyAndServiceCostsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccruedExpensesAndOtherLiabilities" abstract="false" name="AccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesNoncurrent" abstract="false" name="InsuranceAndContractholderLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NoncontrollingInterestOtherChanges" abstract="false" name="NoncontrollingInterestOtherChanges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_TemporaryEquityOtherComprehensiveIncomeLoss" abstract="false" name="TemporaryEquityOtherComprehensiveIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" abstract="false" name="IncreaseDecreaseInPharmacyAndServiceCostsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ProceedsFromSaleOfDebtAndEquitySecurities" abstract="false" name="ProceedsFromSaleOfDebtAndEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" abstract="false" name="ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PaymentsToAcquireDebtAndEquitySecurities" abstract="false" name="PaymentsToAcquireDebtAndEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PaymentsForProceedsFromPropertyPlantAndEquipment" abstract="false" name="PaymentsForProceedsFromPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ProceedsFromRepaymentsOfOtherShortTermDebt" abstract="false" name="ProceedsFromRepaymentsOfOtherShortTermDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" abstract="false" name="AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ci_InsuranceUnearnedPremiumsPolicyTextBlock" abstract="false" name="InsuranceUnearnedPremiumsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ci_ContractholderDepositFundsPolicyPolicyTextBlock" abstract="false" name="ContractholderDepositFundsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" abstract="false" name="EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" abstract="false" name="ScheduleOfOtherLongTermInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" abstract="false" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ci_FairValueOfSeparateAccountAssetsTableTextBlock" abstract="false" name="FairValueOfSeparateAccountAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ci_ScheduleOfSpecialItemsTableTextBlock" abstract="false" name="ScheduleOfSpecialItemsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" abstract="false" name="NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PharmaceuticalManufacturerReceivable" abstract="false" name="PharmaceuticalManufacturerReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InsuranceCustomerReceivables" abstract="false" name="InsuranceCustomerReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AllowanceForReceivablesCurrent" abstract="false" name="AllowanceForReceivablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ContractualAllowancePharmaceuticalManufacturersReceivables" abstract="false" name="ContractualAllowancePharmaceuticalManufacturersReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ContractualAllowanceNoninsuranceCustomerReceivables" abstract="false" name="ContractualAllowanceNoninsuranceCustomerReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity" abstract="false" name="AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm" abstract="false" name="AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold" abstract="false" name="AccountsReceivableUncommittedFactoringFacilitiesAmountSold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid" abstract="false" name="AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding" abstract="false" name="AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted" abstract="false" name="AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" abstract="false" name="SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EarningsPerShareEffectOfDilution" abstract="false" name="EarningsPerShareEffectOfDilution" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ci_R2026Q2DividendsMember" abstract="true" name="R2026Q2DividendsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_SeniorNotesIssuedSeptember2025Member" abstract="true" name="SeniorNotesIssuedSeptember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_A1000Million4.500NotesDueSeptember2030Member" abstract="true" name="A1000Million4.500NotesDueSeptember2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_A1250Million4.875NotesDueSeptember2032Member" abstract="true" name="A1250Million4.875NotesDueSeptember2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_A1500Million5.250NotesDueJanuary2036Member" abstract="true" name="A1500Million5.250NotesDueJanuary2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_A750Million6.000NotesDueJanuary2056Member" abstract="true" name="A750Million6.000NotesDueJanuary2056Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_NotesDue2026125Member" abstract="true" name="NotesDue2026125Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" abstract="false" name="ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate" abstract="false" name="DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ci_RevolvingCreditAgreementApril2025Member" abstract="true" name="RevolvingCreditAgreementApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_DebtInstrumentExtensionTerm" abstract="false" name="DebtInstrumentExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" abstract="false" name="LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesTable" abstract="true" name="InsuranceAndContractholderLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_CignaHealthcareMember" abstract="true" name="CignaHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_AllSegmentsExcludingCignaHealthcareMember" abstract="true" name="AllSegmentsExcludingCignaHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_EvernorthMember" abstract="true" name="EvernorthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesLineItems" abstract="true" name="InsuranceAndContractholderLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" abstract="true" name="InsuranceAndContractholderLiabilitiesCurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" abstract="false" name="LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PolicyholderContractDepositCurrent" abstract="false" name="PolicyholderContractDepositCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MarketRiskBenefitLiabilityAmountCurrent" abstract="false" name="MarketRiskBenefitLiabilityAmountCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_UnearnedPremiumsCurrent" abstract="false" name="UnearnedPremiumsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" abstract="true" name="InsuranceAndContractholderLiabilitiesNoncurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" abstract="false" name="LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PolicyholderContractDepositNoncurrent" abstract="false" name="PolicyholderContractDepositNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MarketRiskBenefitLiabilityAmountNoncurrent" abstract="false" name="MarketRiskBenefitLiabilityAmountNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_UnearnedPremiumsNoncurrent" abstract="false" name="UnearnedPremiumsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesAbstract" abstract="true" name="InsuranceAndContractholderLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilities" abstract="false" name="InsuranceAndContractholderLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" abstract="true" name="MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" abstract="false" name="ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CompletionFactorsAndOtherMember" abstract="true" name="CompletionFactorsAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_MedicalCostTrendMember" abstract="true" name="MedicalCostTrendMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" abstract="false" name="LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" abstract="false" name="LiabilityForFuturePolicyBenefitsDeferredProfitLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" abstract="false" name="LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" abstract="true" name="PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_PolicyholderContractBalancePercentReinsuredExternally" abstract="false" name="PolicyholderContractBalancePercentReinsuredExternally" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" abstract="false" name="PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" abstract="false" name="PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_AnnuitizationElectionPeriod" abstract="false" name="AnnuitizationElectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" abstract="false" name="MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" abstract="false" name="MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" abstract="false" name="NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" abstract="true" name="CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" abstract="true" name="CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" abstract="true" name="NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" abstract="true" name="NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" abstract="true" name="NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" abstract="true" name="NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_OngoingOperationsMember" abstract="true" name="OngoingOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_AcquisitionDispositionRunoffActivitiesMember" abstract="true" name="AcquisitionDispositionRunoffActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" abstract="true" name="CededCreditRiskSecuredContractuallyRequiredFairValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" abstract="true" name="CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" abstract="true" name="LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember" abstract="true" name="ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_ReinsuranceRecoverablesNumberOfReinsurers" abstract="false" name="ReinsuranceRecoverablesNumberOfReinsurers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" abstract="true" name="BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" abstract="true" name="MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_CededCreditCollateralizationRiskMember" abstract="true" name="CededCreditCollateralizationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" abstract="false" name="CededReinsuranceAgreementCoverageLimitAmountRemaining" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ShortTermAndLongTermInvestmentsAbstract" abstract="true" name="ShortTermAndLongTermInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationInvestments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InvestmentsCreditRatingAxis" abstract="true" name="InvestmentsCreditRatingAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_InvestmentsCreditRatingDomain" abstract="true" name="InvestmentsCreditRatingDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_InvestmentGradeMember" abstract="true" name="InvestmentGradeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_BelowInvestmentGradeMember" abstract="true" name="BelowInvestmentGradeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ShieldsHealthSolutionsMember" abstract="true" name="ShieldsHealthSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" abstract="true" name="EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" abstract="false" name="EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" abstract="true" name="EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" abstract="false" name="EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LtvLessThan60PercentMember" abstract="true" name="LtvLessThan60PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_Ltv60To79PercentMember" abstract="true" name="Ltv60To79PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_LtvGreaterThan100PercentMember" abstract="true" name="LtvGreaterThan100PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" abstract="false" name="FinancingReceivableCreditQualityDebtServiceCoverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ci_FinancingReceivableCreditQualityLoanToValueRatio" abstract="false" name="FinancingReceivableCreditQualityLoanToValueRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" abstract="false" name="UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_CommitmentsToContributeAdditionalEquityAndCapital" abstract="false" name="CommitmentsToContributeAdditionalEquityAndCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InvestmentIncomeAndGainsAndLossesAbstract" abstract="true" name="InvestmentIncomeAndGainsAndLossesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_CashCashEquivalentsAndShortTermInvestmentsMember" abstract="true" name="CashCashEquivalentsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" abstract="false" name="InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DividendsReceivableImpairmentLoss" abstract="false" name="DividendsReceivableImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesClassifiedInLevel3Percentage" abstract="false" name="DebtSecuritiesClassifiedInLevel3Percentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_CorporateAndGovernmentDebtSecuritiesMember" abstract="true" name="CorporateAndGovernmentDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_UnobservableInputsDevelopedByCompanyMember" abstract="true" name="UnobservableInputsDevelopedByCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_MeasurementInputLiquidityMember" abstract="true" name="MeasurementInputLiquidityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_MeasurementInputEquityPriceVolatilityMember" abstract="true" name="MeasurementInputEquityPriceVolatilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_MeasurementInputInterVariableCorrelationAssumptionMember" abstract="true" name="MeasurementInputInterVariableCorrelationAssumptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss" abstract="false" name="FairValueAssetRecurringBasisStillHeldRealizedGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SeparateAccountGuaranteedSeparateAccountsMember" abstract="true" name="SeparateAccountGuaranteedSeparateAccountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_SeparateAccountNonGuaranteedSeparateAccountsMember" abstract="true" name="SeparateAccountNonGuaranteedSeparateAccountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_SeparateAccountAssetsMember" abstract="true" name="SeparateAccountAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_VillageMDMember" abstract="true" name="VillageMDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue" abstract="false" name="ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" abstract="true" name="AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" abstract="true" name="AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_EmployeeSeveranceAndOtherRestructuringMember" abstract="true" name="EmployeeSeveranceAndOtherRestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_AssetImpairmentsMember" abstract="true" name="AssetImpairmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_OperatingResultsOfCertainNonstrategicBusinessesMember" abstract="true" name="OperatingResultsOfCertainNonstrategicBusinessesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_StrategicOptimizationProgramMember" abstract="true" name="StrategicOptimizationProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_RestructuringChargesNetOfTaxExpense" abstract="false" name="RestructuringChargesNetOfTaxExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_RetirementAndLifeInsuranceContractsMember" abstract="true" name="RetirementAndLifeInsuranceContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_LitigationMattersAndRegulatoryMattersMember" abstract="true" name="LitigationMattersAndRegulatoryMattersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_OrganizationalEfficiencyPlanMember" abstract="true" name="OrganizationalEfficiencyPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_SpecialItemsBeforeTaxAbstract" abstract="true" name="SpecialItemsBeforeTaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_TransactionRelatedCosts" abstract="false" name="TransactionRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemChargeBenefitTaxMatters" abstract="false" name="SpecialItemChargeBenefitTaxMatters" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" abstract="false" name="SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemChargeBenefitBeforeTaxLitigation" abstract="false" name="SpecialItemChargeBenefitBeforeTaxLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemsIncreaseDecreaseToRevenues" abstract="false" name="SpecialItemsIncreaseDecreaseToRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" abstract="false" name="SpecialItemChargesDebtExtinguishmentCostsBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" abstract="false" name="SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity" abstract="false" name="SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemsAfterTaxAbstract" abstract="true" name="SpecialItemsAfterTaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_TransactionRelatedCostsAfterTax" abstract="false" name="TransactionRelatedCostsAfterTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemChargeBenefitTaxMattersAfterTax" abstract="false" name="SpecialItemChargeBenefitTaxMattersAfterTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" abstract="false" name="SpecialItemGainLossOnSaleOfBusinessNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemChargeBenefitAfterTaxLitigation" abstract="false" name="SpecialItemChargeBenefitAfterTaxLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax" abstract="false" name="SpecialItems.IncreaseDecreaseToRevenuesAfterTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" abstract="false" name="SpecialItemChargesDebtExtinguishmentCostsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" abstract="false" name="SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity" abstract="false" name="SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CorporateAndEliminationsMember" abstract="true" name="CorporateAndEliminationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_NonInvestmentRevenue" abstract="false" name="NonInvestmentRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NetInvestmentGainsLossesEquityMethodInvestments" abstract="false" name="NetInvestmentGainsLossesEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SegmentRevenues" abstract="false" name="SegmentRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" abstract="false" name="SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" abstract="false" name="OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" abstract="false" name="AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" abstract="true" name="PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" abstract="false" name="IncomeLossAttributableToNoncontrollingInterestBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries" abstract="false" name="NetInvestmentGainLossIncludingEquityMethodSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_UnitedStatesHealthcareMember" abstract="true" name="UnitedStatesHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_InternationalHealthMember" abstract="true" name="InternationalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_NetworkPharmacyMember" abstract="true" name="NetworkPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_HomeDeliveryAndSpecialtyMember" abstract="true" name="HomeDeliveryAndSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_OtherPharmacyMember" abstract="true" name="OtherPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_EmployerInsuredMember" abstract="true" name="EmployerInsuredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_StopLossMember" abstract="true" name="StopLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_IndividualAndFamilyPlansMember" abstract="true" name="IndividualAndFamilyPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_OtherHealthcareMember" abstract="true" name="OtherHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_ServiceFeesAndOtherRevenuesMember" abstract="true" name="ServiceFeesAndOtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_ServiceFeesMember" abstract="true" name="ServiceFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_DavidCordaniMember" abstract="true" name="DavidCordaniMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember" abstract="true" name="TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember" abstract="true" name="TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember" abstract="true" name="TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_TradingArrangementStockOptionsMember" abstract="true" name="TradingArrangementStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>ci-20260331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c9afa-b9b6-7bff-8807-e603b8e89aeb,g:b1b37cb4-a013-41e0-9774-54a06c55ff7f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019c9afa-bfed-746a-80fc-4ce6514e3d10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-7d8f-bf1a-87fcba181c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_019c9afa-bfed-746a-80fc-4ce6514e3d10" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-7d8f-bf1a-87fcba181c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c9afa-bfed-7e94-9abd-9d617672d51d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_019c9afa-bfed-746a-80fc-4ce6514e3d10" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019c9afa-bfed-7e94-9abd-9d617672d51d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019c9afa-bfed-7171-8e2e-3b7f1750f291" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019c9afa-bfed-72e6-82ad-905d21b71f71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019c9afa-bfed-7171-8e2e-3b7f1750f291" xlink:to="loc_us-gaap_Revenues_019c9afa-bfed-72e6-82ad-905d21b71f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-7baa-997c-aa6bb5cea712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019c9afa-bfed-7171-8e2e-3b7f1750f291" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-7baa-997c-aa6bb5cea712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-7e12-a6a4-865c804e7c77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-bfed-70d1-a91e-fb0442ea4464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-7e12-a6a4-865c804e7c77" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-bfed-70d1-a91e-fb0442ea4464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-bfed-7b91-9419-5f2bc928b730" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-7e12-a6a4-865c804e7c77" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-bfed-7b91-9419-5f2bc928b730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c9afa-bfed-78cc-9280-fd23240ac2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-7e12-a6a4-865c804e7c77" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c9afa-bfed-78cc-9280-fd23240ac2f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-bfed-7427-8d85-604a19dfa4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-7e12-a6a4-865c804e7c77" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-bfed-7427-8d85-604a19dfa4b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c9afa-bfed-73f2-a0f4-0b9f0edb9ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019c9afa-bfed-758c-a817-c72a465ae1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019c9afa-bfed-73f2-a0f4-0b9f0edb9ac4" xlink:to="loc_us-gaap_ProfitLoss_019c9afa-bfed-758c-a817-c72a465ae1c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019c9afa-bfed-7f6c-9777-f54ef26e5d82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019c9afa-bfed-73f2-a0f4-0b9f0edb9ac4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019c9afa-bfed-7f6c-9777-f54ef26e5d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-76a4-992b-9a3778286031" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLoss_019c9afa-bfed-79f8-a1d2-409e66b340e2" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-76a4-992b-9a3778286031" xlink:to="loc_ci_NetInvestmentGainLoss_019c9afa-bfed-79f8-a1d2-409e66b340e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019c9afa-bfed-795a-b28d-9b0e02ed6161" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-76a4-992b-9a3778286031" xlink:to="loc_us-gaap_OperatingIncomeLoss_019c9afa-bfed-795a-b28d-9b0e02ed6161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-bfed-769e-97c5-1271f0b21ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-76a4-992b-9a3778286031" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-bfed-769e-97c5-1271f0b21ba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_019c9afa-bfed-7aab-ac0a-9a3ab81bd40c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-76a4-992b-9a3778286031" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_019c9afa-bfed-7aab-ac0a-9a3ab81bd40c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-bfed-7df8-8cd5-cf7d8af2e1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-76a4-992b-9a3778286031" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-bfed-7df8-8cd5-cf7d8af2e1d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019c9afa-bfed-7c3c-b038-04c688a86807" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-bfed-797a-beec-c38de51a34e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_019c9afa-bfed-7c3c-b038-04c688a86807" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-bfed-797a-beec-c38de51a34e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_019c9afa-bfed-739f-b7ec-91e4ef93adc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_019c9afa-bfed-7c3c-b038-04c688a86807" xlink:to="loc_us-gaap_PremiumsEarnedNet_019c9afa-bfed-739f-b7ec-91e4ef93adc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_019c9afa-bfed-712f-9ff9-ece085a7f54b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_019c9afa-bfed-7c3c-b038-04c688a86807" xlink:to="loc_us-gaap_NetInvestmentIncome_019c9afa-bfed-712f-9ff9-ece085a7f54b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7460-bfd4-7e730933dfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_019c9afa-bfed-7477-afe0-9180aef38b99" xlink:href="ci-20260331.xsd#ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7460-bfd4-7e730933dfc8" xlink:to="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_019c9afa-bfed-7477-afe0-9180aef38b99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_019c9afa-bfed-70b6-8be7-7cb088d0539f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7460-bfd4-7e730933dfc8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_019c9afa-bfed-70b6-8be7-7cb088d0539f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_019c9afa-bfed-71b5-883a-fac6a5ce3661" xlink:href="ci-20260331.xsd#ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7460-bfd4-7e730933dfc8" xlink:to="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_019c9afa-bfed-71b5-883a-fac6a5ce3661" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_019c9afa-bfed-737c-b86e-f3365d8fc11f" xlink:href="ci-20260331.xsd#ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7460-bfd4-7e730933dfc8" xlink:to="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_019c9afa-bfed-737c-b86e-f3365d8fc11f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c9afa-bfed-7caa-814d-203222098e03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-76b5-8751-fe9538c2d5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c9afa-bfed-7caa-814d-203222098e03" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-76b5-8751-fe9538c2d5ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_019c9afa-bfed-72bc-93b5-fc6c427e63a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c9afa-bfed-7caa-814d-203222098e03" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_019c9afa-bfed-72bc-93b5-fc6c427e63a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-77cd-bc9a-9fb6e8f8ee7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019c9afa-bfed-7e77-a63d-f470eabc24ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-77cd-bc9a-9fb6e8f8ee7e" xlink:to="loc_us-gaap_ProfitLoss_019c9afa-bfed-7e77-a63d-f470eabc24ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7c72-8126-44a0e541f70f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-77cd-bc9a-9fb6e8f8ee7e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7c72-8126-44a0e541f70f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c9afa-bfed-74d2-9e5d-95eafbd47acf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7c1e-a32d-91bc17549594" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c9afa-bfed-74d2-9e5d-95eafbd47acf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7c1e-a32d-91bc17549594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019c9afa-bfed-7e8c-a68c-587a0bded668" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c9afa-bfed-74d2-9e5d-95eafbd47acf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019c9afa-bfed-7e8c-a68c-587a0bded668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019c9afa-bfed-7744-81a0-cf99aa74b72a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c9afa-bfed-74d2-9e5d-95eafbd47acf" xlink:to="loc_us-gaap_Liabilities_019c9afa-bfed-7744-81a0-cf99aa74b72a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c9afa-bfed-7db5-8de4-f909882fdd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019c9afa-bfed-73f3-ab9d-56cf031156d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019c9afa-bfed-7db5-8de4-f909882fdd1d" xlink:to="loc_us-gaap_CommonStockValue_019c9afa-bfed-73f3-ab9d-56cf031156d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019c9afa-bfed-7153-a23d-b38f4b641bca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019c9afa-bfed-7db5-8de4-f909882fdd1d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019c9afa-bfed-7153-a23d-b38f4b641bca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-79cb-8284-7ae27ad11058" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019c9afa-bfed-7db5-8de4-f909882fdd1d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-79cb-8284-7ae27ad11058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019c9afa-bfed-7695-88ce-283c4c79b786" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019c9afa-bfed-7db5-8de4-f909882fdd1d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019c9afa-bfed-7695-88ce-283c4c79b786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_019c9afa-bfed-7a05-a3bf-435d7d71e645" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019c9afa-bfed-7db5-8de4-f909882fdd1d" xlink:to="loc_us-gaap_TreasuryStockValue_019c9afa-bfed-7a05-a3bf-435d7d71e645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7cde-8645-b34864c3e42f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019c9afa-bfed-7b33-bc32-2f49a84a97ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7cde-8645-b34864c3e42f" xlink:to="loc_us-gaap_AccountsPayableCurrent_019c9afa-bfed-7b33-bc32-2f49a84a97ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_019c9afa-bfed-74dd-b6ac-20ae96d1b2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7cde-8645-b34864c3e42f" xlink:to="loc_us-gaap_DebtCurrent_019c9afa-bfed-74dd-b6ac-20ae96d1b2cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-bfed-77c1-9519-8fd3ca72103c" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7cde-8645-b34864c3e42f" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-bfed-77c1-9519-8fd3ca72103c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyAndServiceCostsPayable_019c9afa-bfed-75c5-92cf-cc4a7551cf3b" xlink:href="ci-20260331.xsd#ci_PharmacyAndServiceCostsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7cde-8645-b34864c3e42f" xlink:to="loc_ci_PharmacyAndServiceCostsPayable_019c9afa-bfed-75c5-92cf-cc4a7551cf3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccruedExpensesAndOtherLiabilities_019c9afa-bfed-70db-a485-41e32feb9dc2" xlink:href="ci-20260331.xsd#ci_AccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7cde-8645-b34864c3e42f" xlink:to="loc_ci_AccruedExpensesAndOtherLiabilities_019c9afa-bfed-70db-a485-41e32feb9dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c9afa-bfed-70e1-a31d-f684ee62a33f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7cde-8645-b34864c3e42f" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c9afa-bfed-70e1-a31d-f684ee62a33f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019c9afa-bfed-719f-a4d8-8c9169e35907" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019c9afa-bfed-7a63-aef7-05556a56822f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c9afa-bfed-719f-a4d8-8c9169e35907" xlink:to="loc_us-gaap_OtherAssetsCurrent_019c9afa-bfed-7a63-aef7-05556a56822f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019c9afa-bfed-7d10-83bb-eecb40cff0db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c9afa-bfed-719f-a4d8-8c9169e35907" xlink:to="loc_us-gaap_InventoryNet_019c9afa-bfed-7d10-83bb-eecb40cff0db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_019c9afa-bfed-7658-8dea-eb4ba0f0fc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c9afa-bfed-719f-a4d8-8c9169e35907" xlink:to="loc_us-gaap_ShortTermInvestments_019c9afa-bfed-7658-8dea-eb4ba0f0fc9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfed-7c4d-842a-c1e013a38281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c9afa-bfed-719f-a4d8-8c9169e35907" xlink:to="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfed-7c4d-842a-c1e013a38281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c9afa-bfed-7dfd-8546-6376d3bb29cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c9afa-bfed-719f-a4d8-8c9169e35907" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c9afa-bfed-7dfd-8546-6376d3bb29cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c9afa-bfed-7bbc-9fc0-596c646737fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c9afa-bfed-719f-a4d8-8c9169e35907" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c9afa-bfed-7bbc-9fc0-596c646737fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7ed2-9330-6386f598d0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c9afa-bfed-723b-ac2a-80b5eb0cea11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7ed2-9330-6386f598d0b5" xlink:to="loc_us-gaap_StockholdersEquity_019c9afa-bfed-723b-ac2a-80b5eb0cea11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_019c9afa-bfed-7019-84b8-faeb06b8722a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7ed2-9330-6386f598d0b5" xlink:to="loc_us-gaap_MinorityInterest_019c9afa-bfed-7019-84b8-faeb06b8722a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019c9afa-bfed-7e37-98d0-7d11e00bb50d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7117-a0cb-506ea5bcf04d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019c9afa-bfed-7e37-98d0-7d11e00bb50d" xlink:to="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7117-a0cb-506ea5bcf04d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-bfed-7195-b07a-e73809038aa0" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019c9afa-bfed-7e37-98d0-7d11e00bb50d" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-bfed-7195-b07a-e73809038aa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019c9afa-bfed-7d5e-ab2a-a06c9d63ae0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019c9afa-bfed-7e37-98d0-7d11e00bb50d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019c9afa-bfed-7d5e-ab2a-a06c9d63ae0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019c9afa-bfed-738a-aeaf-514a2a2cfb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019c9afa-bfed-7e37-98d0-7d11e00bb50d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019c9afa-bfed-738a-aeaf-514a2a2cfb6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_019c9afa-bfed-70f0-8bd9-b23160777f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019c9afa-bfed-7e37-98d0-7d11e00bb50d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_019c9afa-bfed-70f0-8bd9-b23160777f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability_019c9afa-bfed-7bb1-9b1f-0956749abe87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019c9afa-bfed-7e37-98d0-7d11e00bb50d" xlink:to="loc_us-gaap_SeparateAccountsLiability_019c9afa-bfed-7bb1-9b1f-0956749abe87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019c9afa-bfed-792c-b59f-a43f3375eaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019c9afa-bfed-786c-bb66-edb4835b0900" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c9afa-bfed-792c-b59f-a43f3375eaa1" xlink:to="loc_us-gaap_AssetsCurrent_019c9afa-bfed-786c-bb66-edb4835b0900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_019c9afa-bfed-78be-a867-eff66791a930" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c9afa-bfed-792c-b59f-a43f3375eaa1" xlink:to="loc_us-gaap_LongTermInvestments_019c9afa-bfed-78be-a867-eff66791a930" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesNonCurrent_019c9afa-bfed-7a85-848d-c3cd512896f9" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverablesNonCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c9afa-bfed-792c-b59f-a43f3375eaa1" xlink:to="loc_ci_ReinsuranceRecoverablesNonCurrent_019c9afa-bfed-7a85-848d-c3cd512896f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_019c9afa-bfed-78b6-8479-6c85b22b38b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c9afa-bfed-792c-b59f-a43f3375eaa1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_019c9afa-bfed-78b6-8479-6c85b22b38b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_019c9afa-bfed-79e1-89f0-07c8d1b900e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c9afa-bfed-792c-b59f-a43f3375eaa1" xlink:to="loc_us-gaap_Goodwill_019c9afa-bfed-79e1-89f0-07c8d1b900e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019c9afa-bfed-7f4e-bce2-dc11c5ce9b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c9afa-bfed-792c-b59f-a43f3375eaa1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019c9afa-bfed-7f4e-bce2-dc11c5ce9b6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019c9afa-bfed-7a90-8ff2-039e1f6f0bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c9afa-bfed-792c-b59f-a43f3375eaa1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019c9afa-bfed-7a90-8ff2-039e1f6f0bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetAtCarryingValue_019c9afa-bfed-7931-a063-33a786bea5bc" xlink:href="ci-20260331.xsd#ci_SeparateAccountAssetAtCarryingValue"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c9afa-bfed-792c-b59f-a43f3375eaa1" xlink:to="loc_ci_SeparateAccountAssetAtCarryingValue_019c9afa-bfed-7931-a063-33a786bea5bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c9afa-bfed-79be-ae97-fca056ddd57e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7f64-8f1d-91ea62f1c38a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c9afa-bfed-79be-ae97-fca056ddd57e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7f64-8f1d-91ea62f1c38a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7930-a69a-b611df2e9a78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c9afa-bfed-79be-ae97-fca056ddd57e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7930-a69a-b611df2e9a78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7971-89bd-7428b46c363e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c9afa-bfed-79be-ae97-fca056ddd57e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7971-89bd-7428b46c363e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c9afa-bfed-7e95-97d2-e42e899c13eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c9afa-bfed-79be-ae97-fca056ddd57e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c9afa-bfed-7e95-97d2-e42e899c13eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_019c9afa-bfed-76f3-88fc-32cd9882240a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_019c9afa-bfed-76f3-88fc-32cd9882240a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_019c9afa-bfed-7dbd-bc8a-51b0c53e7a3f" xlink:href="ci-20260331.xsd#ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_019c9afa-bfed-7dbd-bc8a-51b0c53e7a3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_019c9afa-bfed-751d-9648-929bb7aa43f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_019c9afa-bfed-751d-9648-929bb7aa43f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019c9afa-bfed-781f-9253-05f90e506e45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019c9afa-bfed-781f-9253-05f90e506e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_019c9afa-bfed-760e-aab3-ec8492eb7ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_019c9afa-bfed-760e-aab3-ec8492eb7ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019c9afa-bfed-7717-a253-98c6f97cf39f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_us-gaap_ProfitLoss_019c9afa-bfed-7717-a253-98c6f97cf39f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_019c9afa-bfed-7f84-9209-cac5f2520bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_019c9afa-bfed-7f84-9209-cac5f2520bcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_019c9afa-bfed-7afe-9074-26c44282430f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_019c9afa-bfed-7afe-9074-26c44282430f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLoss_019c9afa-bfed-7e5f-bba8-fb085e9361ef" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLoss"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_ci_NetInvestmentGainLoss_019c9afa-bfed-7e5f-bba8-fb085e9361ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_019c9afa-bfed-7dba-a2a1-c05182722878" xlink:href="ci-20260331.xsd#ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_019c9afa-bfed-7dba-a2a1-c05182722878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_019c9afa-bfed-7d65-8927-3c1a14ba8f74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInReinsuranceRecoverable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_019c9afa-bfed-7d65-8927-3c1a14ba8f74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_019c9afa-bfed-7da4-bd10-5ef9903ab148" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_019c9afa-bfed-7da4-bd10-5ef9903ab148" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-bfed-7bac-b361-bbc844a9850d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7407-be12-bd53f89cce2a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-bfed-7bac-b361-bbc844a9850d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_019c9afa-bfed-7a7a-b97a-beb28755c6cd" xlink:href="ci-20260331.xsd#ci_ProceedsFromRepaymentsOfOtherShortTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_019c9afa-bfed-7a7a-b97a-beb28755c6cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019c9afa-bfed-75a6-a9cd-9776616c0554" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019c9afa-bfed-75a6-a9cd-9776616c0554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_019c9afa-bfed-7f68-bbfc-f27e2ee94174" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_019c9afa-bfed-7f68-bbfc-f27e2ee94174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019c9afa-bfed-78d7-943f-821bb25ba8db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019c9afa-bfed-78d7-943f-821bb25ba8db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WithdrawalFromContractHoldersFunds_019c9afa-bfed-7e1e-91ba-736043505267" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WithdrawalFromContractHoldersFunds"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_WithdrawalFromContractHoldersFunds_019c9afa-bfed-7e1e-91ba-736043505267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c9afa-bfed-7a43-bf7d-c916063193f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c9afa-bfed-7a43-bf7d-c916063193f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_019c9afa-bfed-70e9-b09e-7cb292dc6136" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_019c9afa-bfed-70e9-b09e-7cb292dc6136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019c9afa-bfed-7e1d-900f-a9fcf929220e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019c9afa-bfed-7e1d-900f-a9fcf929220e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionsToContractHoldersFunds_019c9afa-bfed-7e6d-b22a-2155c7e9b3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionsToContractHoldersFunds"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_AdditionsToContractHoldersFunds_019c9afa-bfed-7e6d-b22a-2155c7e9b3a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_019c9afa-bfed-71fb-8448-8f9a82a0f5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_019c9afa-bfed-71fb-8448-8f9a82a0f5e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_019c9afa-bfed-723e-95ca-84e6741da6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_019c9afa-bfed-723e-95ca-84e6741da6e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_019c9afa-bfed-76f4-bc62-d329c2e59805" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-7a90-a790-d5def8b1841d" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_019c9afa-bfed-76f4-bc62-d329c2e59805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities_019c9afa-bfed-788c-b468-a21da7414af7" xlink:href="ci-20260331.xsd#ci_ProceedsFromSaleOfDebtAndEquitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities_019c9afa-bfed-788c-b468-a21da7414af7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019c9afa-bfed-7913-8fea-8d255dc653c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019c9afa-bfed-7913-8fea-8d255dc653c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_019c9afa-bfed-70b5-9692-9e4225350791" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_019c9afa-bfed-70b5-9692-9e4225350791" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_019c9afa-bfed-7ce6-a496-b12af1b71ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_019c9afa-bfed-7ce6-a496-b12af1b71ce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_019c9afa-bfed-7ad0-9b7c-1d059adfed27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_019c9afa-bfed-7ad0-9b7c-1d059adfed27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable_019c9afa-bfed-7d8d-9f3f-d8b2d72ba7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMortgageNotesReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable_019c9afa-bfed-7d8d-9f3f-d8b2d72ba7a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_019c9afa-bfed-7500-9547-dd44d07c3214" xlink:href="ci-20260331.xsd#ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_019c9afa-bfed-7500-9547-dd44d07c3214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_019c9afa-bfed-7d30-85cd-7f1ca32f91a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_019c9afa-bfed-7d30-85cd-7f1ca32f91a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_019c9afa-bfed-728e-9316-a80f283c0127" xlink:href="ci-20260331.xsd#ci_PaymentsToAcquireDebtAndEquitySecurities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_019c9afa-bfed-728e-9316-a80f283c0127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_019c9afa-bfed-7158-8d6a-a9e3b1515e19" xlink:href="ci-20260331.xsd#ci_PaymentsForProceedsFromPropertyPlantAndEquipment"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_019c9afa-bfed-7158-8d6a-a9e3b1515e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_019c9afa-bfed-7a59-9635-0b4b49a88422" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_019c9afa-bfed-7a59-9635-0b4b49a88422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_019c9afa-bfed-77d7-8d6c-bb359cb73aea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7f4d-b884-f9e9a63e2868" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_019c9afa-bfed-77d7-8d6c-bb359cb73aea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#AccountsReceivableNetAmountsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfee-7b53-9511-4e2f0a788c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivables_019c9afa-bfee-7462-b036-4009cda61a31" xlink:href="ci-20260331.xsd#ci_InsuranceCustomerReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfee-7b53-9511-4e2f0a788c4b" xlink:to="loc_ci_InsuranceCustomerReceivables_019c9afa-bfee-7462-b036-4009cda61a31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturerReceivable_019c9afa-bfee-73d6-868e-cb64216704ca" xlink:href="ci-20260331.xsd#ci_PharmaceuticalManufacturerReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfee-7b53-9511-4e2f0a788c4b" xlink:to="loc_ci_PharmaceuticalManufacturerReceivable_019c9afa-bfee-73d6-868e-cb64216704ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_019c9afa-bfee-745a-abb2-f0d4f490a074" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfee-7b53-9511-4e2f0a788c4b" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_019c9afa-bfee-745a-abb2-f0d4f490a074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_019c9afa-bfee-796a-a729-2ad9dd123b5e" xlink:href="ci-20260331.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfee-7b53-9511-4e2f0a788c4b" xlink:to="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_019c9afa-bfee-796a-a729-2ad9dd123b5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#EarningsPerShareBasicandDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019c9afa-c0ae-7fc2-8576-53ffc47a9fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019c9afa-c0ae-7989-9d6a-652936f13b35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_019c9afa-c0ae-7fc2-8576-53ffc47a9fc6" xlink:to="loc_us-gaap_EarningsPerShareBasic_019c9afa-c0ae-7989-9d6a-652936f13b35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EarningsPerShareEffectOfDilution_019c9afa-c0ae-735b-a229-58c062b93240" xlink:href="ci-20260331.xsd#ci_EarningsPerShareEffectOfDilution"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_019c9afa-c0ae-7fc2-8576-53ffc47a9fc6" xlink:to="loc_ci_EarningsPerShareEffectOfDilution_019c9afa-c0ae-735b-a229-58c062b93240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c9afa-c0ae-77a9-8838-b2e78e386260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_019c9afa-c0ae-7c4b-a366-09ba79f670a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c9afa-c0ae-77a9-8838-b2e78e386260" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_019c9afa-c0ae-7c4b-a366-09ba79f670a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c9afa-c0ae-7dfe-a4d3-93c56707c902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c9afa-c0ae-77a9-8838-b2e78e386260" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c9afa-c0ae-7dfe-a4d3-93c56707c902" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#DebtRevolvingCreditAgreementandCommercialPaperDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature_019c9afa-c0ae-7457-947b-3dbe7de5f21f" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c9afa-c0ae-7740-bd0c-7426c86b6eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature_019c9afa-c0ae-7457-947b-3dbe7de5f21f" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c9afa-c0ae-7740-bd0c-7426c86b6eb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_019c9afa-c0ae-739b-808b-cb19e29d9944" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature_019c9afa-c0ae-7457-947b-3dbe7de5f21f" xlink:to="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_019c9afa-c0ae-739b-808b-cb19e29d9944" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-72e8-9629-2ce0d73d4d36" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_019c9afa-c0af-7226-a9ee-e7647a8d3f33" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-72e8-9629-2ce0d73d4d36" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_019c9afa-c0af-7226-a9ee-e7647a8d3f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrent_019c9afa-c0af-7a74-87b3-1dbfc012a44c" xlink:href="ci-20260331.xsd#ci_PolicyholderContractDepositNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-72e8-9629-2ce0d73d4d36" xlink:to="loc_ci_PolicyholderContractDepositNoncurrent_019c9afa-c0af-7a74-87b3-1dbfc012a44c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_019c9afa-c0af-7781-8f1b-5b90601c2abe" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-72e8-9629-2ce0d73d4d36" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_019c9afa-c0af-7781-8f1b-5b90601c2abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_019c9afa-c0af-77dc-82a2-122d641c808e" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-72e8-9629-2ce0d73d4d36" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_019c9afa-c0af-77dc-82a2-122d641c808e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrent_019c9afa-c0af-7cee-bc39-92c62e3e6164" xlink:href="ci-20260331.xsd#ci_UnearnedPremiumsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-72e8-9629-2ce0d73d4d36" xlink:to="loc_ci_UnearnedPremiumsNoncurrent_019c9afa-c0af-7cee-bc39-92c62e3e6164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount_019c9afa-c0af-7928-8039-9bcaea6fc64d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_019c9afa-c0af-7d5d-bf4e-76253674d322" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_MarketRiskBenefitLiabilityAmount_019c9afa-c0af-7928-8039-9bcaea6fc64d" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_019c9afa-c0af-7d5d-bf4e-76253674d322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_019c9afa-c0af-706d-8f21-3801eee32225" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_MarketRiskBenefitLiabilityAmount_019c9afa-c0af-7928-8039-9bcaea6fc64d" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_019c9afa-c0af-706d-8f21-3801eee32225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums_019c9afa-c0af-7ae1-b0fc-83af274415b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnearnedPremiums"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrent_019c9afa-c0af-7d8c-b769-e6232f9a0ec1" xlink:href="ci-20260331.xsd#ci_UnearnedPremiumsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_UnearnedPremiums_019c9afa-c0af-7ae1-b0fc-83af274415b5" xlink:to="loc_ci_UnearnedPremiumsNoncurrent_019c9afa-c0af-7d8c-b769-e6232f9a0ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrent_019c9afa-c0af-748a-a42e-6ac867faf6d6" xlink:href="ci-20260331.xsd#ci_UnearnedPremiumsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_UnearnedPremiums_019c9afa-c0af-7ae1-b0fc-83af274415b5" xlink:to="loc_ci_UnearnedPremiumsCurrent_019c9afa-c0af-748a-a42e-6ac867faf6d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-708c-a41f-b028006607e5" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrent_019c9afa-c0af-79fc-babb-31dd86ba0757" xlink:href="ci-20260331.xsd#ci_PolicyholderContractDepositCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-708c-a41f-b028006607e5" xlink:to="loc_ci_PolicyholderContractDepositCurrent_019c9afa-c0af-79fc-babb-31dd86ba0757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_019c9afa-c0af-79b7-acf1-6be98f6b846e" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-708c-a41f-b028006607e5" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_019c9afa-c0af-79b7-acf1-6be98f6b846e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_019c9afa-c0af-7904-86ba-cfde9331ffac" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-708c-a41f-b028006607e5" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_019c9afa-c0af-7904-86ba-cfde9331ffac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_019c9afa-c0af-79da-948f-12650ddc2d67" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-708c-a41f-b028006607e5" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_019c9afa-c0af-79da-948f-12650ddc2d67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrent_019c9afa-c0af-7c0d-bd1c-4c5dda580756" xlink:href="ci-20260331.xsd#ci_UnearnedPremiumsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-708c-a41f-b028006607e5" xlink:to="loc_ci_UnearnedPremiumsCurrent_019c9afa-c0af-7c0d-bd1c-4c5dda580756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7a8c-b3db-3c63601bd058" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrent_019c9afa-c0af-7bef-998d-7cac3ee578d0" xlink:href="ci-20260331.xsd#ci_PolicyholderContractDepositNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7a8c-b3db-3c63601bd058" xlink:to="loc_ci_PolicyholderContractDepositNoncurrent_019c9afa-c0af-7bef-998d-7cac3ee578d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrent_019c9afa-c0af-7fe4-80da-4abf1132917e" xlink:href="ci-20260331.xsd#ci_PolicyholderContractDepositCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7a8c-b3db-3c63601bd058" xlink:to="loc_ci_PolicyholderContractDepositCurrent_019c9afa-c0af-7fe4-80da-4abf1132917e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-78e2-ac52-ad5e04b8835c" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums_019c9afa-c0af-75a0-9947-aba2b1ea5b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnearnedPremiums"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-78e2-ac52-ad5e04b8835c" xlink:to="loc_us-gaap_UnearnedPremiums_019c9afa-c0af-75a0-9947-aba2b1ea5b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7fb5-9eb4-c46891183c73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-78e2-ac52-ad5e04b8835c" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7fb5-9eb4-c46891183c73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-750a-af60-755068a6d993" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-78e2-ac52-ad5e04b8835c" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-750a-af60-755068a6d993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount_019c9afa-c0af-764a-acf9-4dd84d7605a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-78e2-ac52-ad5e04b8835c" xlink:to="loc_us-gaap_MarketRiskBenefitLiabilityAmount_019c9afa-c0af-764a-acf9-4dd84d7605a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7cd8-8c29-b5bdbe06f0da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-78e2-ac52-ad5e04b8835c" xlink:to="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7cd8-8c29-b5bdbe06f0da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7436-9743-1b858842d3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_019c9afa-c0af-7f5c-9ea8-b6a578312289" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7436-9743-1b858842d3f0" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_019c9afa-c0af-7f5c-9ea8-b6a578312289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_019c9afa-c0af-7d08-b7a7-a285fe47f0ad" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7436-9743-1b858842d3f0" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_019c9afa-c0af-7d08-b7a7-a285fe47f0ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-7764-81d4-15d082189fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_019c9afa-c0af-7b56-967e-075b36249526" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-7764-81d4-15d082189fd8" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_019c9afa-c0af-7b56-967e-075b36249526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_019c9afa-c0af-7adc-92d0-5a523f462e92" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-7764-81d4-15d082189fd8" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_019c9afa-c0af-7adc-92d0-5a523f462e92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-7242-b5f7-c43edc9c10d6" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-72a0-8632-6e4e769a9994" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-7242-b5f7-c43edc9c10d6" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-72a0-8632-6e4e769a9994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-7d49-9930-0b9a9a41bbc1" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-7242-b5f7-c43edc9c10d6" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-7d49-9930-0b9a9a41bbc1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c0af-7bc0-a43e-a5e458aff8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c0af-73a7-9826-b34eff43dbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c0af-7bc0-a43e-a5e458aff8ad" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c0af-73a7-9826-b34eff43dbcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7293-9140-97e4805353e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c0af-7bc0-a43e-a5e458aff8ad" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7293-9140-97e4805353e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_019c9afa-c0af-7c7f-892c-fb50ef839297" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_019c9afa-c0af-7857-b05b-d8f232db5901" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_019c9afa-c0af-7c7f-892c-fb50ef839297" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_019c9afa-c0af-7857-b05b-d8f232db5901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_019c9afa-c0af-7cef-bcc5-48a59e1c81f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_019c9afa-c0af-7c7f-892c-fb50ef839297" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_019c9afa-c0af-7cef-bcc5-48a59e1c81f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c0af-71db-a0ec-2eb821bd94b8" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c0af-738d-8f08-88821b12a8ea" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c0af-71db-a0ec-2eb821bd94b8" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c0af-738d-8f08-88821b12a8ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c0af-71d3-809f-b89ee65bdb4f" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c0af-71db-a0ec-2eb821bd94b8" xlink:to="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c0af-71d3-809f-b89ee65bdb4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_019c9afa-c0af-7c15-b160-174be56350a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7b3b-8545-c3c186caa08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_019c9afa-c0af-7c15-b160-174be56350a5" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7b3b-8545-c3c186caa08e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-71fd-a954-fa7c3133173e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_019c9afa-c0af-7c15-b160-174be56350a5" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-71fd-a954-fa7c3133173e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-7100-ad01-531614d896b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_019c9afa-c0af-7607-b583-194099333274" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-7100-ad01-531614d896b3" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_019c9afa-c0af-7607-b583-194099333274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_019c9afa-c0af-7899-bfb2-9c166584883c" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-7100-ad01-531614d896b3" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_019c9afa-c0af-7899-bfb2-9c166584883c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_019c9afa-c0af-75ed-907a-db3a7020bfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_019c9afa-c0af-7cff-9daf-2b807298cf70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_019c9afa-c0af-75ed-907a-db3a7020bfaa" xlink:to="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_019c9afa-c0af-7cff-9daf-2b807298cf70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_019c9afa-c0af-7dbe-b5e4-3b3d9b4e1ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_019c9afa-c0af-75ed-907a-db3a7020bfaa" xlink:to="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_019c9afa-c0af-7dbe-b5e4-3b3d9b4e1ad1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#ReinsuranceReinsuranceRecoverablesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables_019c9afa-c0af-793d-8f72-97c05f55a716" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesGross_019c9afa-c0af-75e3-ae0d-f2ef0231ede9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverablesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ReinsuranceRecoverables_019c9afa-c0af-793d-8f72-97c05f55a716" xlink:to="loc_us-gaap_ReinsuranceRecoverablesGross_019c9afa-c0af-75e3-ae0d-f2ef0231ede9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesAllowance_019c9afa-c0af-768b-b27f-d86fe5052785" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverablesAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ReinsuranceRecoverables_019c9afa-c0af-793d-8f72-97c05f55a716" xlink:to="loc_us-gaap_ReinsuranceRecoverablesAllowance_019c9afa-c0af-768b-b27f-d86fe5052785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-714f-bbd8-beb29a8ab6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ReinsuranceRecoverables_019c9afa-c0af-793d-8f72-97c05f55a716" xlink:to="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-714f-bbd8-beb29a8ab6aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsInvestmentsbyCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_019c9afa-c16c-7d94-8940-b079231f84ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-758d-9bbe-5ecd25f2b4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_019c9afa-c16c-7d94-8940-b079231f84ce" xlink:to="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-758d-9bbe-5ecd25f2b4c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_019c9afa-c16c-789c-bb28-2d4102ae3df4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_019c9afa-c16c-7d94-8940-b079231f84ce" xlink:to="loc_us-gaap_LongTermInvestments_019c9afa-c16c-789c-bb28-2d4102ae3df4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7684-9f87-6a8e50b0c44c" xlink:href="ci-20260331.xsd#ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7a73-bfec-5f9a8d87e5de" xlink:href="ci-20260331.xsd#ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7684-9f87-6a8e50b0c44c" xlink:to="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7a73-bfec-5f9a8d87e5de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7f2a-b749-b3e4a0c81e45" xlink:href="ci-20260331.xsd#ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7684-9f87-6a8e50b0c44c" xlink:to="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7f2a-b749-b3e4a0c81e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7359-80fe-9cf6f7840348" xlink:href="ci-20260331.xsd#ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_019c9afa-c16c-7d8b-a46e-c0a35887791b" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7359-80fe-9cf6f7840348" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_019c9afa-c16c-7d8b-a46e-c0a35887791b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_019c9afa-c16c-7bc3-8c2b-651a94dc1819" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7359-80fe-9cf6f7840348" xlink:to="loc_us-gaap_LongTermInvestments_019c9afa-c16c-7bc3-8c2b-651a94dc1819" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_019c9afa-c16c-77a8-89e3-395d56fa7be9" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_019c9afa-c16c-7b24-98cd-ce2cfa5bef87" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_019c9afa-c16c-77a8-89e3-395d56fa7be9" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_019c9afa-c16c-7b24-98cd-ce2cfa5bef87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_019c9afa-c16c-7937-ab7b-3da6e819e8d7" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_019c9afa-c16c-77a8-89e3-395d56fa7be9" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_019c9afa-c16c-7937-ab7b-3da6e819e8d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-732e-b50e-6b4fd5bacffc" xlink:href="ci-20260331.xsd#ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_019c9afa-c16c-7b8a-bb3f-e560668bea27" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-732e-b50e-6b4fd5bacffc" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_019c9afa-c16c-7b8a-bb3f-e560668bea27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-71ce-ace3-060fce98c88f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-732e-b50e-6b4fd5bacffc" xlink:to="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-71ce-ace3-060fce98c88f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails_1" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7cff-abdb-23be6d838dd7" xlink:href="ci-20260331.xsd#ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_019c9afa-c16c-769c-a7be-c21391a2da31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7cff-abdb-23be6d838dd7" xlink:to="loc_us-gaap_Investments_019c9afa-c16c-769c-a7be-c21391a2da31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_019c9afa-c16c-7bc4-8170-257d9217c144" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7cff-abdb-23be6d838dd7" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_019c9afa-c16c-7bc4-8170-257d9217c144" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-7800-bbaf-6c5f37bcbf73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_019c9afa-c16c-7481-8ae0-9b4e4f2e5e23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-7800-bbaf-6c5f37bcbf73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_019c9afa-c16c-7481-8ae0-9b4e4f2e5e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_019c9afa-c16c-70dc-a456-48c3572c0919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-7800-bbaf-6c5f37bcbf73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_019c9afa-c16c-70dc-a456-48c3572c0919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c9afa-c16c-7bd6-b021-5e107d7d6891" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-7800-bbaf-6c5f37bcbf73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c9afa-c16c-7bd6-b021-5e107d7d6891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c9afa-c16c-7b73-9eb9-56435c7fc6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-7800-bbaf-6c5f37bcbf73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c9afa-c16c-7b73-9eb9-56435c7fc6a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_019c9afa-c16c-7f63-8670-faa87025a131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-7800-bbaf-6c5f37bcbf73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_019c9afa-c16c-7f63-8670-faa87025a131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7349-97bd-62ffa05327f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_019c9afa-c16c-7523-a724-bb1641f233d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7349-97bd-62ffa05327f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_019c9afa-c16c-7523-a724-bb1641f233d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c9afa-c16c-7d47-a452-e99580e05e98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7349-97bd-62ffa05327f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c9afa-c16c-7d47-a452-e99580e05e98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_019c9afa-c16c-7a4c-aebf-81d4ffd763f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7349-97bd-62ffa05327f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_019c9afa-c16c-7a4c-aebf-81d4ffd763f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_019c9afa-c16c-786c-937f-3529d6f17dce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7349-97bd-62ffa05327f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_019c9afa-c16c-786c-937f-3529d6f17dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c9afa-c16c-7983-a5c3-6202809ad36b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7349-97bd-62ffa05327f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c9afa-c16c-7983-a5c3-6202809ad36b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019c9afa-c16c-7a80-8c69-aa21d368b545" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_019c9afa-c16c-7c3a-bf48-4bf7af7a38af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019c9afa-c16c-7a80-8c69-aa21d368b545" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_019c9afa-c16c-7c3a-bf48-4bf7af7a38af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_019c9afa-c16c-7538-b27f-0815f746e8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019c9afa-c16c-7a80-8c69-aa21d368b545" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_019c9afa-c16c-7538-b27f-0815f746e8ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c9afa-c16c-75ff-a00c-411ce5d7f2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019c9afa-c16c-72b0-85e2-e1230ff28df4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c9afa-c16c-75ff-a00c-411ce5d7f2a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019c9afa-c16c-72b0-85e2-e1230ff28df4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019c9afa-c16c-769d-a75c-32c03b31012b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c9afa-c16c-75ff-a00c-411ce5d7f2a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019c9afa-c16c-769d-a75c-32c03b31012b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c9afa-c16c-7969-8120-7b481db4b271" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019c9afa-c16c-735a-b430-c39a439cf76b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c9afa-c16c-7969-8120-7b481db4b271" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019c9afa-c16c-735a-b430-c39a439cf76b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019c9afa-c16c-750a-ae10-6a2b69ab5199" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c9afa-c16c-7969-8120-7b481db4b271" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019c9afa-c16c-750a-ae10-6a2b69ab5199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_019c9afa-c16c-75aa-b200-333921451760" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019c9afa-c16c-7cde-a6cc-efecf2dd6d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_019c9afa-c16c-75aa-b200-333921451760" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019c9afa-c16c-7cde-a6cc-efecf2dd6d9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019c9afa-c16c-71c7-92e0-4504d161fbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_019c9afa-c16c-75aa-b200-333921451760" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019c9afa-c16c-71c7-92e0-4504d161fbf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c16c-7582-835a-11f7e309feed" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c9afa-c16c-7ec8-8138-507c3d3348a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c16c-7582-835a-11f7e309feed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c9afa-c16c-7ec8-8138-507c3d3348a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c9afa-c16c-75ab-a31c-fe5ff30656e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c16c-7582-835a-11f7e309feed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c9afa-c16c-75ab-a31c-fe5ff30656e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_019c9afa-c16c-7ec1-9c52-05df0eb1c728" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019c9afa-c16c-71f7-8262-c12b46abddf9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_019c9afa-c16c-7ec1-9c52-05df0eb1c728" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019c9afa-c16c-71f7-8262-c12b46abddf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019c9afa-c16c-76c4-884b-a8f57b88db32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_019c9afa-c16c-7ec1-9c52-05df0eb1c728" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019c9afa-c16c-76c4-884b-a8f57b88db32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails_1" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c16c-7701-bafe-9497f65f9dd6" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_019c9afa-c16c-796d-bb68-7f861276d279" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c16c-7701-bafe-9497f65f9dd6" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_019c9afa-c16c-796d-bb68-7f861276d279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_019c9afa-c16c-74b0-a754-af717476451a" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c16c-7701-bafe-9497f65f9dd6" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_019c9afa-c16c-74b0-a754-af717476451a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_019c9afa-c16c-7bfb-84fc-f2c0579351af" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c16c-7c04-ae4d-b92471d557ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_019c9afa-c16c-7bfb-84fc-f2c0579351af" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c16c-7c04-ae4d-b92471d557ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019c9afa-c16c-7fe7-b014-4d33a6292c46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_019c9afa-c16c-7bfb-84fc-f2c0579351af" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019c9afa-c16c-7fe7-b014-4d33a6292c46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_019c9afa-c16c-7171-8162-10ac3bb31ffa" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_019c9afa-c16c-73da-be02-2718b8e7ba94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_019c9afa-c16c-7171-8162-10ac3bb31ffa" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_019c9afa-c16c-73da-be02-2718b8e7ba94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_019c9afa-c16c-7845-84f6-3b1cb2ef83da" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_019c9afa-c16c-7171-8162-10ac3bb31ffa" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_019c9afa-c16c-7845-84f6-3b1cb2ef83da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsComponentsofNetInvestmentIncomeLossesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_019c9afa-c16c-73bd-9d67-851d0bf3b0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_019c9afa-c16c-7ed0-9c0e-5bcf4c015c63" xlink:href="ci-20260331.xsd#ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetInvestmentIncome_019c9afa-c16c-73bd-9d67-851d0bf3b0b4" xlink:to="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_019c9afa-c16c-7ed0-9c0e-5bcf4c015c63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_019c9afa-c16c-712d-8626-e34b8e6e9e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetInvestmentIncome_019c9afa-c16c-73bd-9d67-851d0bf3b0b4" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_019c9afa-c16c-712d-8626-e34b8e6e9e7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_019c9afa-c16d-70b7-aa46-17d529b73f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_019c9afa-c16d-76cf-8e36-8225b3a5ec4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_019c9afa-c16d-70b7-aa46-17d529b73f6d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_019c9afa-c16d-76cf-8e36-8225b3a5ec4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_019c9afa-c16d-7e94-b417-e394f56998fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_019c9afa-c16d-70b7-aa46-17d529b73f6d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_019c9afa-c16d-7e94-b417-e394f56998fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_019c9afa-c16d-7846-914f-a9be712cf919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_019c9afa-c16d-70b7-aa46-17d529b73f6d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_019c9afa-c16d-7846-914f-a9be712cf919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_019c9afa-c16d-77f6-a4cc-4e6cffef19e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_019c9afa-c16d-71aa-a2b2-c66a1383cf36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_019c9afa-c16d-77f6-a4cc-4e6cffef19e1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_019c9afa-c16d-71aa-a2b2-c66a1383cf36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_019c9afa-c16d-73dd-b89d-28cb7c82ffd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_019c9afa-c16d-77f6-a4cc-4e6cffef19e1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_019c9afa-c16d-73dd-b89d-28cb7c82ffd8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-c22b-7ef5-b331-89d85b42435b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_019c9afa-c22b-7983-b150-4921450a1328" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-c22b-7ef5-b331-89d85b42435b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_019c9afa-c22b-7983-b150-4921450a1328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_019c9afa-c22b-7865-8482-13e8efbf0b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-c22b-7ef5-b331-89d85b42435b" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_019c9afa-c22b-7865-8482-13e8efbf0b70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_019c9afa-c22b-7c16-b79f-647906af4a10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_019c9afa-c22b-7a7f-be85-c08672d3d2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_019c9afa-c22b-7c16-b79f-647906af4a10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_019c9afa-c22b-7a7f-be85-c08672d3d2ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_019c9afa-c22b-7283-bbee-b1bbb3f18091" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_019c9afa-c22b-7c16-b79f-647906af4a10" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_019c9afa-c22b-7283-bbee-b1bbb3f18091" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationSpecialItemChargesBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-7764-acef-29f9827e294d" xlink:href="ci-20260331.xsd#ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c2d7-7b58-8963-d22b78b66edd" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-7764-acef-29f9827e294d" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c2d7-7b58-8963-d22b78b66edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-763f-b69c-196a025767b5" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-7764-acef-29f9827e294d" xlink:to="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-763f-b69c-196a025767b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-793c-95dd-639ad0e3ee66" xlink:href="ci-20260331.xsd#ci_SpecialItemsIncreaseDecreaseToRevenues"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-7764-acef-29f9827e294d" xlink:to="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-793c-95dd-639ad0e3ee66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-72f0-b4fb-5752ef91e52d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-7764-acef-29f9827e294d" xlink:to="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-72f0-b4fb-5752ef91e52d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c2d7-7e1b-bc2c-cc64b4ada300" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitTaxMatters"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-7764-acef-29f9827e294d" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c2d7-7e1b-bc2c-cc64b4ada300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7a2e-8d4f-62a774654b4c" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-7764-acef-29f9827e294d" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7a2e-8d4f-62a774654b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-78a3-b703-29c37b59f843" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-7764-acef-29f9827e294d" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-78a3-b703-29c37b59f843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-773a-9856-300b2808c9f8" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-7764-acef-29f9827e294d" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-773a-9856-300b2808c9f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-73bf-a6e7-a9f414e454bb" xlink:href="ci-20260331.xsd#ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_019c9afa-c2d7-729c-bf34-876c21f72a42" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-73bf-a6e7-a9f414e454bb" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_019c9afa-c2d7-729c-bf34-876c21f72a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax_019c9afa-c2d7-7711-9d22-97bc57ad8102" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitTaxMattersAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-73bf-a6e7-a9f414e454bb" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax_019c9afa-c2d7-7711-9d22-97bc57ad8102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_019c9afa-c2d7-717e-b0d0-bc59b3ac3e88" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-73bf-a6e7-a9f414e454bb" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_019c9afa-c2d7-717e-b0d0-bc59b3ac3e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation_019c9afa-c2d7-7e3b-ad18-2532e44841d4" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitAfterTaxLitigation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-73bf-a6e7-a9f414e454bb" xlink:to="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation_019c9afa-c2d7-7e3b-ad18-2532e44841d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c2d7-7c95-b463-ba87abb8eb23" xlink:href="ci-20260331.xsd#ci_RestructuringChargesNetOfTaxExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-73bf-a6e7-a9f414e454bb" xlink:to="loc_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c2d7-7c95-b463-ba87abb8eb23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax_019c9afa-c2d7-738b-8ccb-f3f3f1e3cf6d" xlink:href="ci-20260331.xsd#ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-73bf-a6e7-a9f414e454bb" xlink:to="loc_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax_019c9afa-c2d7-738b-8ccb-f3f3f1e3cf6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCostsAfterTax_019c9afa-c2d7-7049-b063-861c6ded641e" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCostsAfterTax"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-73bf-a6e7-a9f414e454bb" xlink:to="loc_ci_TransactionRelatedCostsAfterTax_019c9afa-c2d7-7049-b063-861c6ded641e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_019c9afa-c2d7-7f13-a42a-9b59819cfbdb" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-73bf-a6e7-a9f414e454bb" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_019c9afa-c2d7-7f13-a42a-9b59819cfbdb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationSummarizedSegmentFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-736d-bb7a-e183645a2e51" xlink:href="ci-20260331.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:to="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-736d-bb7a-e183645a2e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries_019c9afa-c2d7-7bf4-9a0b-1202c8de80bb" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:to="loc_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries_019c9afa-c2d7-7bf4-9a0b-1202c8de80bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_019c9afa-c2d7-7677-9ddb-0627a927bfce" xlink:href="ci-20260331.xsd#ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:to="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_019c9afa-c2d7-7677-9ddb-0627a927bfce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7e14-b48c-54e3355898e0" xlink:href="ci-20260331.xsd#ci_SpecialItemsIncreaseDecreaseToRevenues"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:to="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7e14-b48c-54e3355898e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-752c-a52a-5de29dacd258" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-752c-a52a-5de29dacd258" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-7c6d-aefc-a952d63c4868" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:to="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-7c6d-aefc-a952d63c4868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-7b5e-8ef4-dba3c8e1bc7b" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:to="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-7b5e-8ef4-dba3c8e1bc7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-c2d7-76da-bfa9-a1e5915376a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-c2d7-76da-bfa9-a1e5915376a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7192-beda-f0e99fa0194c" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7192-beda-f0e99fa0194c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-7c42-bf18-30c41636c1a1" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7fd4-ac52-00d87f4591a3" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-7c42-bf18-30c41636c1a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019c9afa-c2d7-745a-955d-3a48d0d76713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SegmentRevenues_019c9afa-c2d7-7d8b-af89-6926ad84a775" xlink:href="ci-20260331.xsd#ci_SegmentRevenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_019c9afa-c2d7-745a-955d-3a48d0d76713" xlink:to="loc_ci_SegmentRevenues_019c9afa-c2d7-7d8b-af89-6926ad84a775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainsLossesEquityMethodInvestments_019c9afa-c2d7-7768-9369-04f69ca22601" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainsLossesEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_019c9afa-c2d7-745a-955d-3a48d0d76713" xlink:to="loc_ci_NetInvestmentGainsLossesEquityMethodInvestments_019c9afa-c2d7-7768-9369-04f69ca22601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7a11-95a8-9dac913afa25" xlink:href="ci-20260331.xsd#ci_SpecialItemsIncreaseDecreaseToRevenues"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_019c9afa-c2d7-745a-955d-3a48d0d76713" xlink:to="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7a11-95a8-9dac913afa25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7740-9498-dfe1033c7961" xlink:href="ci-20260331.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax_019c9afa-c2d7-7449-997e-9fc84696fca2" xlink:href="ci-20260331.xsd#ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7740-9498-dfe1033c7961" xlink:to="loc_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax_019c9afa-c2d7-7449-997e-9fc84696fca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-c2d7-7e00-879a-684e91a887ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7740-9498-dfe1033c7961" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-c2d7-7e00-879a-684e91a887ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric_019c9afa-c2d7-7d2e-bdb7-01336aa3033f" xlink:href="ci-20260331.xsd#ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7740-9498-dfe1033c7961" xlink:to="loc_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric_019c9afa-c2d7-7d2e-bdb7-01336aa3033f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SegmentRevenues_019c9afa-c2d7-7e07-9f66-d1e6b05fedaa" xlink:href="ci-20260331.xsd#ci_SegmentRevenues"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7740-9498-dfe1033c7961" xlink:to="loc_ci_SegmentRevenues_019c9afa-c2d7-7e07-9f66-d1e6b05fedaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-c2d7-7cd2-859e-f97c7bcf1759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7740-9498-dfe1033c7961" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-c2d7-7cd2-859e-f97c7bcf1759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-c2d7-7530-b0f4-1f4e99d63093" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7740-9498-dfe1033c7961" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-c2d7-7530-b0f4-1f4e99d63093" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails_1" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationSummarizedSegmentFinancialInformationDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019c9afa-c2d7-7475-af49-2319a665c2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-74d0-8945-3b355b1a9a3d" xlink:href="ci-20260331.xsd#ci_NonInvestmentRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_019c9afa-c2d7-7475-af49-2319a665c2c2" xlink:to="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-74d0-8945-3b355b1a9a3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_019c9afa-c2d7-7b19-9b58-bd7ba8cbc032" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_019c9afa-c2d7-7475-af49-2319a665c2c2" xlink:to="loc_us-gaap_NetInvestmentIncome_019c9afa-c2d7-7b19-9b58-bd7ba8cbc032" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationRevenuefromExternalCustomersDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-758f-bd17-8530316f857e" xlink:href="ci-20260331.xsd#ci_NonInvestmentRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_019c9afa-c2d7-7048-bf80-eb6d725db99f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-758f-bd17-8530316f857e" xlink:to="loc_us-gaap_PremiumsEarnedNet_019c9afa-c2d7-7048-bf80-eb6d725db99f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-c2d7-7574-bc85-78a7388f741f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-758f-bd17-8530316f857e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-c2d7-7574-bc85-78a7388f741f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>ci-20260331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c9afa-b9b6-7bff-8807-e603b8e89aeb,g:b1b37cb4-a013-41e0-9774-54a06c55ff7f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019c9afa-bfed-7127-95c4-2ea198e5d1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_StatementTable_019c9afa-bfed-7127-95c4-2ea198e5d1e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-bfed-7565-85e1-ba5b29cb35b1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019c9afa-bfed-7127-95c4-2ea198e5d1e3" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-bfed-7565-85e1-ba5b29cb35b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-bfed-7565-85e1-ba5b29cb35b1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-bfed-7565-85e1-ba5b29cb35b1" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-bfed-7565-85e1-ba5b29cb35b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-bfed-7dcb-9e0d-11e29311f0db" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-bfed-7565-85e1-ba5b29cb35b1" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-bfed-7dcb-9e0d-11e29311f0db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019c9afa-bfed-7b8d-a42b-eb99c20dbe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-bfed-7dcb-9e0d-11e29311f0db" xlink:to="loc_us-gaap_ProductMember_019c9afa-bfed-7b8d-a42b-eb99c20dbe6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_019c9afa-bfed-755e-8ed9-50e00e2bef54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-bfed-7dcb-9e0d-11e29311f0db" xlink:to="loc_us-gaap_ServiceMember_019c9afa-bfed-755e-8ed9-50e00e2bef54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-bfed-74fc-8534-492c3229220a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-bfed-74fc-8534-492c3229220a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_019c9afa-bfed-70c7-af09-ba8b87fa5a73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:to="loc_us-gaap_PremiumsEarnedNet_019c9afa-bfed-70c7-af09-ba8b87fa5a73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_019c9afa-bfed-74cc-afc3-3659f129a90c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:to="loc_us-gaap_NetInvestmentIncome_019c9afa-bfed-74cc-afc3-3659f129a90c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019c9afa-bfed-793b-8ec1-cbd0051c0d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:to="loc_us-gaap_Revenues_019c9afa-bfed-793b-8ec1-cbd0051c0d8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BenefitsLossesAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-bfed-7716-bb8a-99f13fcb5d85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-bfed-7716-bb8a-99f13fcb5d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-bfed-7723-8b11-578a54c69d74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-bfed-7723-8b11-578a54c69d74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c9afa-bfed-79f1-b244-66f55bd1546b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c9afa-bfed-79f1-b244-66f55bd1546b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-bfed-75e0-aaa3-b03abc6a11cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-bfed-75e0-aaa3-b03abc6a11cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-73a5-b3c7-0717a49acfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-73a5-b3c7-0717a49acfcf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019c9afa-bfed-73ba-92d0-fdcf3ebea7de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_OperatingIncomeLoss_019c9afa-bfed-73ba-92d0-fdcf3ebea7de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-bfed-7488-834e-a98c98d90b74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-bfed-7488-834e-a98c98d90b74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-bfed-78fb-bd35-8b510555b3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-bfed-78fb-bd35-8b510555b3a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_019c9afa-bfed-7104-90e3-bf6f65b86508" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_019c9afa-bfed-7104-90e3-bf6f65b86508" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLoss_019c9afa-bfed-7199-80cb-8123d4116ef4" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_ci_NetInvestmentGainLoss_019c9afa-bfed-7199-80cb-8123d4116ef4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-7340-aca8-6fdfa051e76a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-7340-aca8-6fdfa051e76a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c9afa-bfed-78c3-925d-30b71e910da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019c9afa-bfed-78c3-925d-30b71e910da1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019c9afa-bfed-7132-9256-f5826941de7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_ProfitLoss_019c9afa-bfed-7132-9256-f5826941de7d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019c9afa-bfed-7ace-a987-1af87b71a351" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019c9afa-bfed-7ace-a987-1af87b71a351" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c9afa-bfed-7ea7-855c-5fe3c56e7796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_NetIncomeLoss_019c9afa-bfed-7ea7-855c-5fe3c56e7796" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c9afa-bfed-76f8-a843-1af789ecf569" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_019c9afa-bfed-76f8-a843-1af789ecf569" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019c9afa-bfed-739c-aa87-8283afc116aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-bfed-76f8-a843-1af789ecf569" xlink:to="loc_us-gaap_EarningsPerShareBasic_019c9afa-bfed-739c-aa87-8283afc116aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019c9afa-bfed-7ae3-8da2-7c3b9287a77d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-bfed-76f8-a843-1af789ecf569" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019c9afa-bfed-7ae3-8da2-7c3b9287a77d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedStatementsofChangesinTotalEquity"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019c9afa-bfed-7c85-96d6-e53e8d3a5af5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019c9afa-bfed-7137-8a4d-59365886fec3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7c85-96d6-e53e8d3a5af5" xlink:to="loc_us-gaap_StatementTable_019c9afa-bfed-7137-8a4d-59365886fec3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-bfed-7e7e-839a-7535fd753a11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019c9afa-bfed-7137-8a4d-59365886fec3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-bfed-7e7e-839a-7535fd753a11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019c9afa-bfed-7e7e-839a-7535fd753a11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-bfed-7e7e-839a-7535fd753a11" xlink:to="loc_us-gaap_EquityComponentDomain_019c9afa-bfed-7e7e-839a-7535fd753a11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019c9afa-bfed-7f57-821d-940bf2edec96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-bfed-7e7e-839a-7535fd753a11" xlink:to="loc_us-gaap_EquityComponentDomain_019c9afa-bfed-7f57-821d-940bf2edec96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019c9afa-bfed-7f57-821d-940bf2edec96" xlink:to="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019c9afa-bfed-7057-baaa-947ecff0eb58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:to="loc_us-gaap_CommonStockMember_019c9afa-bfed-7057-baaa-947ecff0eb58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019c9afa-bfed-7b66-80d8-37f84c5b7854" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019c9afa-bfed-7b66-80d8-37f84c5b7854" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-bfed-7b67-b701-f775c90d4ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-bfed-7b67-b701-f775c90d4ed8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019c9afa-bfed-7426-9a51-85f635e4117c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:to="loc_us-gaap_RetainedEarningsMember_019c9afa-bfed-7426-9a51-85f635e4117c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019c9afa-bfed-7f5b-b53f-2067a93fc35a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019c9afa-bfed-7f5b-b53f-2067a93fc35a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_019c9afa-bfed-7217-8edd-4fbbea1c08aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019c9afa-bfed-7f57-821d-940bf2edec96" xlink:to="loc_us-gaap_NoncontrollingInterestMember_019c9afa-bfed-7217-8edd-4fbbea1c08aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7c85-96d6-e53e8d3a5af5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7b20-ade2-3559a7856a24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7b20-ade2-3559a7856a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019c9afa-bfed-72aa-83a1-e5a4d5723864" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019c9afa-bfed-72aa-83a1-e5a4d5723864" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-78e3-b03b-6db392113e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-78e3-b03b-6db392113e9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_019c9afa-bfed-7ed5-b946-9655d22b4b80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_019c9afa-bfed-7ed5-b946-9655d22b4b80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_019c9afa-bfed-796f-b310-8ee2025397b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_DividendsCommonStockCash_019c9afa-bfed-796f-b310-8ee2025397b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c9afa-bfed-72ac-83b3-c79eef640bff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c9afa-bfed-72ac-83b3-c79eef640bff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoncontrollingInterestOtherChanges_019c9afa-bfed-7669-bd67-c084c34b98c4" xlink:href="ci-20260331.xsd#ci_NoncontrollingInterestOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_ci_NoncontrollingInterestOtherChanges_019c9afa-bfed-7669-bd67-c084c34b98c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7c79-ad4b-41c1268090ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7c85-96d6-e53e8d3a5af5" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_019c9afa-bfed-7005-8610-9c6478fe101f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_019c9afa-bfed-7005-8610-9c6478fe101f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncomeLoss_019c9afa-bfed-7f8c-b04a-beccf4e25a45" xlink:href="ci-20260331.xsd#ci_TemporaryEquityOtherComprehensiveIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:to="loc_ci_TemporaryEquityOtherComprehensiveIncomeLoss_019c9afa-bfed-7f8c-b04a-beccf4e25a45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_019c9afa-bfed-7b92-ace3-5595037b9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_019c9afa-bfed-7b92-ace3-5595037b9e17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_019c9afa-bfed-7428-84ff-ac89cb328497" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#EarningsPerShareAntidilutiveOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c9afa-c0ae-7fc0-b9fe-6b3f3e91889a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c9afa-c0ae-7806-b210-4e88c1b0ca20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c9afa-c0ae-7fc0-b9fe-6b3f3e91889a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c9afa-c0ae-7806-b210-4e88c1b0ca20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c9afa-c0ae-7327-9c89-6b4560d26485" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c9afa-c0ae-7806-b210-4e88c1b0ca20" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c9afa-c0ae-7327-9c89-6b4560d26485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c9afa-c0ae-7327-9c89-6b4560d26485_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c9afa-c0ae-7327-9c89-6b4560d26485" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c9afa-c0ae-7327-9c89-6b4560d26485_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c9afa-c0ae-739e-b14b-f7ff4534c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c9afa-c0ae-7327-9c89-6b4560d26485" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c9afa-c0ae-739e-b14b-f7ff4534c73f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019c9afa-c0ae-7020-9da8-880fb1677b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c9afa-c0ae-739e-b14b-f7ff4534c73f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019c9afa-c0ae-7020-9da8-880fb1677b7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019c9afa-c0ae-75e7-b764-a385b34ad06d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c9afa-c0ae-7fc0-b9fe-6b3f3e91889a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019c9afa-c0ae-75e7-b764-a385b34ad06d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#EarningsPerShareDividendsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableTable_019dbbc5-3865-7bad-bc71-e367103b972c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:to="loc_us-gaap_DividendsPayableTable_019dbbc5-3865-7bad-bc71-e367103b972c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAxis_019dbbc5-3865-7230-8ba1-2baa71fa48ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DividendsPayableTable_019dbbc5-3865-7bad-bc71-e367103b972c" xlink:to="loc_us-gaap_DividendsAxis_019dbbc5-3865-7230-8ba1-2baa71fa48ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain_019dbbc5-3865-7230-8ba1-2baa71fa48ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DividendsAxis_019dbbc5-3865-7230-8ba1-2baa71fa48ff" xlink:to="loc_us-gaap_DividendsDomain_019dbbc5-3865-7230-8ba1-2baa71fa48ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain_019dbbc5-3865-718d-847e-3e55a15087bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DividendsAxis_019dbbc5-3865-7230-8ba1-2baa71fa48ff" xlink:to="loc_us-gaap_DividendsDomain_019dbbc5-3865-718d-847e-3e55a15087bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_R2026Q2DividendsMember_019dbbc5-3865-7fb6-9e14-57bd70b867fd" xlink:href="ci-20260331.xsd#ci_R2026Q2DividendsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsDomain_019dbbc5-3865-718d-847e-3e55a15087bf" xlink:to="loc_ci_R2026Q2DividendsMember_019dbbc5-3865-7fb6-9e14-57bd70b867fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019dbbc5-3865-7a04-b184-16c9c70196b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DividendsPayableTable_019dbbc5-3865-7bad-bc71-e367103b972c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019dbbc5-3865-7a04-b184-16c9c70196b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019dbbc5-3865-7a04-b184-16c9c70196b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019dbbc5-3865-7a04-b184-16c9c70196b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019dbbc5-3865-7a04-b184-16c9c70196b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019dbbc5-3865-73fa-8cba-6e81735946df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019dbbc5-3865-7a04-b184-16c9c70196b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019dbbc5-3865-73fa-8cba-6e81735946df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019dbbc5-3865-7457-8f63-8b030da8ab42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019dbbc5-3865-73fa-8cba-6e81735946df" xlink:to="loc_us-gaap_SubsequentEventMember_019dbbc5-3865-7457-8f63-8b030da8ab42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_019dbbc5-3865-7aa2-a9df-94c262af4c97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:to="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_019dbbc5-3865-7aa2-a9df-94c262af4c97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_019dbbc5-3865-74ed-855f-95fe9cde6688" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_019dbbc5-3865-74ed-855f-95fe9cde6688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_019dbbc5-3865-7ef5-8b0e-c0c4a6594461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:to="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_019dbbc5-3865-7ef5-8b0e-c0c4a6594461" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_019dbbc5-3865-799b-8a21-2259a65ca1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:to="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_019dbbc5-3865-799b-8a21-2259a65ca1c1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtDebtRepaymentDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#DebtDebtRepaymentDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/DebtDebtRepaymentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-7944-9703-b425c6504137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-7944-9703-b425c6504137" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7599-b51d-773888142cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-7944-9703-b425c6504137" xlink:to="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7599-b51d-773888142cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7599-b51d-773888142cf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7599-b51d-773888142cf0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7599-b51d-773888142cf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7b1c-b42a-33e0dd29025d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7599-b51d-773888142cf0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7b1c-b42a-33e0dd29025d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:href="ci-20260331.xsd#ci_SeniorNotesIssuedSeptember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7b1c-b42a-33e0dd29025d" xlink:to="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A1000Million4.500NotesDueSeptember2030Member_019c9afa-c0ae-79af-bc31-d62445c15abb" xlink:href="ci-20260331.xsd#ci_A1000Million4.500NotesDueSeptember2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:to="loc_ci_A1000Million4.500NotesDueSeptember2030Member_019c9afa-c0ae-79af-bc31-d62445c15abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A1250Million4.875NotesDueSeptember2032Member_019c9afa-c0ae-7598-ad50-cc39313bfd16" xlink:href="ci-20260331.xsd#ci_A1250Million4.875NotesDueSeptember2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:to="loc_ci_A1250Million4.875NotesDueSeptember2032Member_019c9afa-c0ae-7598-ad50-cc39313bfd16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A1500Million5.250NotesDueJanuary2036Member_019c9afa-c0ae-7fee-8a56-4217389c1fd3" xlink:href="ci-20260331.xsd#ci_A1500Million5.250NotesDueJanuary2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:to="loc_ci_A1500Million5.250NotesDueJanuary2036Member_019c9afa-c0ae-7fee-8a56-4217389c1fd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A750Million6.000NotesDueJanuary2056Member_019c9afa-c0ae-74ab-bf80-624b49268bee" xlink:href="ci-20260331.xsd#ci_A750Million6.000NotesDueJanuary2056Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:to="loc_ci_A750Million6.000NotesDueJanuary2056Member_019c9afa-c0ae-74ab-bf80-624b49268bee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2026125Member_019d3132-92b8-7e46-a2fa-be8569454569" xlink:href="ci-20260331.xsd#ci_NotesDue2026125Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7b1c-b42a-33e0dd29025d" xlink:to="loc_ci_NotesDue2026125Member_019d3132-92b8-7e46-a2fa-be8569454569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019c9afa-c0ae-7ed2-9f2a-051a2c64f72a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-7944-9703-b425c6504137" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019c9afa-c0ae-7ed2-9f2a-051a2c64f72a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019c9afa-c0ae-7ed2-9f2a-051a2c64f72a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019c9afa-c0ae-7ed2-9f2a-051a2c64f72a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019c9afa-c0ae-7ed2-9f2a-051a2c64f72a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019c9afa-c0ae-760d-b43e-f6de3d3ade2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019c9afa-c0ae-7ed2-9f2a-051a2c64f72a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019c9afa-c0ae-760d-b43e-f6de3d3ade2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_019c9afa-c0ae-7207-be3f-64925c358a61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019c9afa-c0ae-760d-b43e-f6de3d3ade2d" xlink:to="loc_us-gaap_SeniorNotesMember_019c9afa-c0ae-7207-be3f-64925c358a61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_019c9afa-c0ae-7e11-81ce-842ac103b279" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_019c9afa-c0ae-7e11-81ce-842ac103b279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_019c9afa-c0ae-71f7-aa6e-b0561bf256cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_019c9afa-c0ae-71f7-aa6e-b0561bf256cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019c9afa-c0ae-76c5-8da3-64a91811453e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019c9afa-c0ae-76c5-8da3-64a91811453e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_019c9afa-c0ae-78a7-b0f6-dcebd1f5e199" xlink:href="ci-20260331.xsd#ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_019c9afa-c0ae-78a7-b0f6-dcebd1f5e199" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate_019c9afa-c0ae-73fe-bf79-23870803a069" xlink:href="ci-20260331.xsd#ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate_019c9afa-c0ae-73fe-bf79-23870803a069" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#DebtRevolvingCreditAgreementandCommercialPaperDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7092-98ac-224f6a4f0e21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:to="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7092-98ac-224f6a4f0e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7092-98ac-224f6a4f0e21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7092-98ac-224f6a4f0e21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7092-98ac-224f6a4f0e21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-729f-89a2-759e1965bcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7092-98ac-224f6a4f0e21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-729f-89a2-759e1965bcd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAgreementApril2025Member_019c9afa-c0ae-7427-a9cb-64fb85dc6468" xlink:href="ci-20260331.xsd#ci_RevolvingCreditAgreementApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-729f-89a2-759e1965bcd7" xlink:to="loc_ci_RevolvingCreditAgreementApril2025Member_019c9afa-c0ae-7427-a9cb-64fb85dc6468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019c9afa-c0ae-7b88-9449-424a683ad749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:to="loc_us-gaap_CreditFacilityAxis_019c9afa-c0ae-7b88-9449-424a683ad749" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7b88-9449-424a683ad749_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_019c9afa-c0ae-7b88-9449-424a683ad749" xlink:to="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7b88-9449-424a683ad749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7f17-8bd4-36fd80a7ad81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_019c9afa-c0ae-7b88-9449-424a683ad749" xlink:to="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7f17-8bd4-36fd80a7ad81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_019dd492-23b7-7885-9bde-e0b18181cf47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7f17-8bd4-36fd80a7ad81" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_019dd492-23b7-7885-9bde-e0b18181cf47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_019c9afa-c0ae-7673-b457-44eaed3077e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7f17-8bd4-36fd80a7ad81" xlink:to="loc_us-gaap_LetterOfCreditMember_019c9afa-c0ae-7673-b457-44eaed3077e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019c9afa-c0ae-7dfb-9d2f-25c10b3426dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7f17-8bd4-36fd80a7ad81" xlink:to="loc_us-gaap_CommercialPaperMember_019c9afa-c0ae-7dfb-9d2f-25c10b3426dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019dd491-7a35-78b9-bbf7-7273abe7292c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019dd491-7a35-78b9-bbf7-7273abe7292c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019dd491-7a35-78b9-bbf7-7273abe7292c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019dd491-7a35-78b9-bbf7-7273abe7292c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019dd491-7a35-78b9-bbf7-7273abe7292c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019dd491-7a35-707b-88fe-ce276497f1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019dd491-7a35-78b9-bbf7-7273abe7292c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019dd491-7a35-707b-88fe-ce276497f1ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019dd491-d5bc-7eeb-8ed3-1073b06f4869" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019dd491-7a35-707b-88fe-ce276497f1ea" xlink:to="loc_us-gaap_LineOfCreditMember_019dd491-d5bc-7eeb-8ed3-1073b06f4869" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c9afa-c0ae-7cfe-b6e0-31f855124fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c9afa-c0ae-7cfe-b6e0-31f855124fd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_019c9afa-c0ae-702a-b115-e0833f419455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_DebtInstrumentTerm_019c9afa-c0ae-702a-b115-e0833f419455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_019dd52b-a723-713d-8dcf-af7a9a065c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_019dd52b-a723-713d-8dcf-af7a9a065c1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentExtensionTerm_019c9afa-c0ae-7269-a3a6-1205048bdd5d" xlink:href="ci-20260331.xsd#ci_DebtInstrumentExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_ci_DebtInstrumentExtensionTerm_019c9afa-c0ae-7269-a3a6-1205048bdd5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_019c9afa-c0ae-7bbe-a4ce-b597119a898d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_LineOfCredit_019c9afa-c0ae-7bbe-a4ce-b597119a898d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_019c9afa-c0ae-70e1-831f-0e1b500a6655" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_019c9afa-c0ae-70e1-831f-0e1b500a6655" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature_019c9afa-c0ae-7b5f-a95c-64fd3f6e753d" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature_019c9afa-c0ae-7b5f-a95c-64fd3f6e753d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_019c9afa-c0ae-75f9-9fca-47ca81dcca51" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_019c9afa-c0ae-75f9-9fca-47ca81dcca51" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_019c9afa-c0ae-710c-8b80-8b69aa7abd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_CommercialPaper_019c9afa-c0ae-710c-8b80-8b69aa7abd7c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CommercialPaperAverageRatePaid_019c9afa-c0ae-70ae-9e4f-60c7571f5b85" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CommercialPaperAverageRatePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_srt_CommercialPaperAverageRatePaid_019c9afa-c0ae-70ae-9e4f-60c7571f5b85" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c0af-7c28-91ee-0b3d3a34df77" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable_019c9afa-c0af-7bbc-a4ec-925c6ea0c7ac" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c0af-7c28-91ee-0b3d3a34df77" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesTable_019c9afa-c0af-7bbc-a4ec-925c6ea0c7ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7a87-bc53-df38c3b7b91d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_019c9afa-c0af-7bbc-a4ec-925c6ea0c7ac" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7a87-bc53-df38c3b7b91d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-7a87-bc53-df38c3b7b91d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7a87-bc53-df38c3b7b91d" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-7a87-bc53-df38c3b7b91d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-7515-96c3-b4ce35e247dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7a87-bc53-df38c3b7b91d" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-7515-96c3-b4ce35e247dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c0af-780e-8a9c-4ca79fd84385" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-7515-96c3-b4ce35e247dd" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c0af-780e-8a9c-4ca79fd84385" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllSegmentsExcludingCignaHealthcareMember_019c9afa-c0af-77b7-a554-c78accd9b150" xlink:href="ci-20260331.xsd#ci_AllSegmentsExcludingCignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-7515-96c3-b4ce35e247dd" xlink:to="loc_ci_AllSegmentsExcludingCignaHealthcareMember_019c9afa-c0af-77b7-a554-c78accd9b150" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_019c9afa-c0af-7ff2-a3dd-17af15c2ae62" xlink:href="ci-20260331.xsd#ci_EvernorthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_AllSegmentsExcludingCignaHealthcareMember_019c9afa-c0af-77b7-a554-c78accd9b150" xlink:to="loc_ci_EvernorthMember_019c9afa-c0af-7ff2-a3dd-17af15c2ae62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c0af-7fe7-88fd-59a65a3c3bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_AllSegmentsExcludingCignaHealthcareMember_019c9afa-c0af-77b7-a554-c78accd9b150" xlink:to="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c0af-7fe7-88fd-59a65a3c3bf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c0af-7c28-91ee-0b3d3a34df77" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_019c9afa-c0af-7a7f-99a5-7d6adcd4c8fb" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_019c9afa-c0af-7a7f-99a5-7d6adcd4c8fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_019c9afa-c0af-7d78-bde6-5ed503fc69b6" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_019c9afa-c0af-7d78-bde6-5ed503fc69b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrent_019c9afa-c0af-75ca-91a4-45dcadd8fb85" xlink:href="ci-20260331.xsd#ci_PolicyholderContractDepositCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_PolicyholderContractDepositCurrent_019c9afa-c0af-75ca-91a4-45dcadd8fb85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_019c9afa-c0af-77a0-9c1c-47d7447fadfe" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_019c9afa-c0af-77a0-9c1c-47d7447fadfe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrent_019c9afa-c0af-7c01-ae18-59b649ea5c59" xlink:href="ci-20260331.xsd#ci_UnearnedPremiumsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_UnearnedPremiumsCurrent_019c9afa-c0af-7c01-ae18-59b649ea5c59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-7b48-a62e-b676d6f608fc" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-7b48-a62e-b676d6f608fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c0af-7c28-91ee-0b3d3a34df77" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_019c9afa-c0af-70f6-904c-f320018dd108" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_019c9afa-c0af-70f6-904c-f320018dd108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_019c9afa-c0af-7884-a32c-02c2944707b5" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_019c9afa-c0af-7884-a32c-02c2944707b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrent_019c9afa-c0af-7297-989e-46723d3b5158" xlink:href="ci-20260331.xsd#ci_PolicyholderContractDepositNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_PolicyholderContractDepositNoncurrent_019c9afa-c0af-7297-989e-46723d3b5158" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_019c9afa-c0af-76b1-8638-2758d3727417" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_019c9afa-c0af-76b1-8638-2758d3727417" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrent_019c9afa-c0af-7fac-ab12-6a9ea0078ef2" xlink:href="ci-20260331.xsd#ci_UnearnedPremiumsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_UnearnedPremiumsNoncurrent_019c9afa-c0af-7fac-ab12-6a9ea0078ef2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-73b1-95dc-0d00975dc9c4" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-73b1-95dc-0d00975dc9c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c0af-7c28-91ee-0b3d3a34df77" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7dd7-91eb-441f06e7224d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7dd7-91eb-441f06e7224d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-72d4-ae64-8e4e3b50e730" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-72d4-ae64-8e4e3b50e730" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7995-a3c4-2e24ac13ae80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7995-a3c4-2e24ac13ae80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount_019c9afa-c0af-7eb9-b314-b54f97eaca4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_us-gaap_MarketRiskBenefitLiabilityAmount_019c9afa-c0af-7eb9-b314-b54f97eaca4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums_019c9afa-c0af-7456-8a6f-dcf46c373ace" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnearnedPremiums"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_us-gaap_UnearnedPremiums_019c9afa-c0af-7456-8a6f-dcf46c373ace" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-7bb7-abe5-7f38de8ffd78" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-7bb7-abe5-7f38de8ffd78" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-7e44-b682-5601ba61f604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-7e44-b682-5601ba61f604" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7aac-b2ca-2c47195f4e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7aac-b2ca-2c47195f4e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-7aac-b2ca-2c47195f4e40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7aac-b2ca-2c47195f4e40" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-7aac-b2ca-2c47195f4e40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-7f7a-ad54-76624ee3dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7aac-b2ca-2c47195f4e40" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-7f7a-ad54-76624ee3dbe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c0af-76ce-8ad5-50dc545dcd4a" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-7f7a-ad54-76624ee3dbe2" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c0af-76ce-8ad5-50dc545dcd4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c0af-7b89-ba58-29fab8cf4d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c0af-7b89-ba58-29fab8cf4d7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c0af-7b89-ba58-29fab8cf4d7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c0af-7b89-ba58-29fab8cf4d7e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c0af-7b89-ba58-29fab8cf4d7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c0af-79d1-a43b-c46a09421f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c0af-7b89-ba58-29fab8cf4d7e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c0af-79d1-a43b-c46a09421f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_019c9afa-c0af-76ee-9bc4-ab70dcf7a647" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c0af-79d1-a43b-c46a09421f3a" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_019c9afa-c0af-76ee-9bc4-ab70dcf7a647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c0af-72b7-89b0-ac9d5b69b3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c0af-72b7-89b0-ac9d5b69b3b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c0af-72b7-89b0-ac9d5b69b3b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c0af-72b7-89b0-ac9d5b69b3b8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c0af-72b7-89b0-ac9d5b69b3b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c0af-736e-b75c-d73c2d42db00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c0af-72b7-89b0-ac9d5b69b3b8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c0af-736e-b75c-d73c2d42db00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_019c9afa-c0af-792f-be02-a88b09f8c271" xlink:href="ci-20260331.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c0af-736e-b75c-d73c2d42db00" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_019c9afa-c0af-792f-be02-a88b09f8c271" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_019c9afa-c0af-7357-b58a-c36998d0b857" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-7e44-b682-5601ba61f604" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_019c9afa-c0af-7357-b58a-c36998d0b857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-7e44-b682-5601ba61f604" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7db8-95f9-35a6648c7367" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7db8-95f9-35a6648c7367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c0af-76ce-880c-0ee9014ed96b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c0af-76ce-880c-0ee9014ed96b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c0af-75db-a8d2-b39912560b56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c0af-75db-a8d2-b39912560b56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c0af-7850-a559-4b98920565c2" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c0af-7850-a559-4b98920565c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c0af-7f2a-b405-3bed9554ca78" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c0af-7f2a-b405-3bed9554ca78" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c0af-7fbe-921f-a77bd1a5443a" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c0af-7fbe-921f-a77bd1a5443a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c0af-79e1-ab2f-defa4cbd9405" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c0af-79e1-ab2f-defa4cbd9405" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-79c8-8dfd-d0ee52d8cef2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c0af-79e1-ab2f-defa4cbd9405" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-79c8-8dfd-d0ee52d8cef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-740d-ad89-b95bb8670d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c0af-79e1-ab2f-defa4cbd9405" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-740d-ad89-b95bb8670d6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_019c9afa-c0af-7466-820a-1b95f8e5d89b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c0af-79e1-ab2f-defa4cbd9405" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_019c9afa-c0af-7466-820a-1b95f8e5d89b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c0af-798d-aa1a-a14e2ad66824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c0af-798d-aa1a-a14e2ad66824" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_019c9afa-c0af-7e20-8257-9cd021d55fde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c0af-798d-aa1a-a14e2ad66824" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_019c9afa-c0af-7e20-8257-9cd021d55fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_019c9afa-c0af-7f20-b2d4-b219be0d75d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c0af-798d-aa1a-a14e2ad66824" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_019c9afa-c0af-7f20-b2d4-b219be0d75d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_019c9afa-c0af-7098-a1f1-d699eb380e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c0af-798d-aa1a-a14e2ad66824" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_019c9afa-c0af-7098-a1f1-d699eb380e2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther_019c9afa-c0af-788e-b703-59cce73bc5f3" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther_019c9afa-c0af-788e-b703-59cce73bc5f3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c0af-7f33-9c77-fdc041bdf372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c0af-7aeb-ab3e-b170158bf3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-76a2-b790-e345fa94d572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c0af-7154-894d-e02d28631186" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c0af-7ac8-9015-38ab35bdd344" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c0af-7fe7-a317-ea8bbd2f5765" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-78dc-81eb-379e8eaa4e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-78dc-81eb-379e8eaa4e8f" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-750c-9f0c-1dd02c73c016" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7ab9-a0e9-85824da5cf10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-750c-9f0c-1dd02c73c016" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7ab9-a0e9-85824da5cf10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-724d-9d0c-797bd30cecbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7ab9-a0e9-85824da5cf10" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-724d-9d0c-797bd30cecbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-724d-9d0c-797bd30cecbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-724d-9d0c-797bd30cecbc" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-724d-9d0c-797bd30cecbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-72ac-a6d5-d3e308208ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-724d-9d0c-797bd30cecbc" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-72ac-a6d5-d3e308208ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c0af-7b3f-be4e-689b652b987d" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-72ac-a6d5-d3e308208ccf" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c0af-7b3f-be4e-689b652b987d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventAxis_019c9afa-c0af-7bd4-a98a-ce6af6ba0ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncatastrophicEventAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7ab9-a0e9-85824da5cf10" xlink:to="loc_us-gaap_NoncatastrophicEventAxis_019c9afa-c0af-7bd4-a98a-ce6af6ba0ae0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventDomain_019c9afa-c0af-7bd4-a98a-ce6af6ba0ae0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncatastrophicEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NoncatastrophicEventAxis_019c9afa-c0af-7bd4-a98a-ce6af6ba0ae0" xlink:to="loc_us-gaap_NoncatastrophicEventDomain_019c9afa-c0af-7bd4-a98a-ce6af6ba0ae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventDomain_019c9afa-c0af-7ae9-9e72-28758d483c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncatastrophicEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NoncatastrophicEventAxis_019c9afa-c0af-7bd4-a98a-ce6af6ba0ae0" xlink:to="loc_us-gaap_NoncatastrophicEventDomain_019c9afa-c0af-7ae9-9e72-28758d483c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CompletionFactorsAndOtherMember_019c9afa-c0af-74ee-a289-d1afdd297d56" xlink:href="ci-20260331.xsd#ci_CompletionFactorsAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncatastrophicEventDomain_019c9afa-c0af-7ae9-9e72-28758d483c6c" xlink:to="loc_ci_CompletionFactorsAndOtherMember_019c9afa-c0af-74ee-a289-d1afdd297d56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicalCostTrendMember_019c9afa-c0af-73bf-88ce-5a4ea6978f5e" xlink:href="ci-20260331.xsd#ci_MedicalCostTrendMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncatastrophicEventDomain_019c9afa-c0af-7ae9-9e72-28758d483c6c" xlink:to="loc_ci_MedicalCostTrendMember_019c9afa-c0af-73bf-88ce-5a4ea6978f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_019c9afa-c0af-774f-9c23-b075ff5ec34b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-750c-9f0c-1dd02c73c016" xlink:to="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_019c9afa-c0af-774f-9c23-b075ff5ec34b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7cb7-a96d-122b4d42cb01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_019c9afa-c0af-774f-9c23-b075ff5ec34b" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7cb7-a96d-122b4d42cb01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_019c9afa-c0af-7c95-9c83-24502778eb87" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_019c9afa-c0af-774f-9c23-b075ff5ec34b" xlink:to="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_019c9afa-c0af-7c95-9c83-24502778eb87" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_019c9afa-c0af-7283-837a-a5d6acf32a74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitActivityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_019c9afa-c0af-7283-837a-a5d6acf32a74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-75a2-9839-53c6d3934ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_019c9afa-c0af-7283-837a-a5d6acf32a74" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-75a2-9839-53c6d3934ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-75a2-9839-53c6d3934ed6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-75a2-9839-53c6d3934ed6" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-75a2-9839-53c6d3934ed6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-77f5-b565-f90615a4feff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-75a2-9839-53c6d3934ed6" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-77f5-b565-f90615a4feff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c0af-7e53-bc7e-dcdc713c6576" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-77f5-b565-f90615a4feff" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c0af-7e53-bc7e-dcdc713c6576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c0af-715b-ae03-45f2ab5327fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-77f5-b565-f90615a4feff" xlink:to="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c0af-715b-ae03-45f2ab5327fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c0af-70f1-8c99-6848c0f4085c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_019c9afa-c0af-7283-837a-a5d6acf32a74" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c0af-70f1-8c99-6848c0f4085c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-70f1-8c99-6848c0f4085c_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-70f1-8c99-6848c0f4085c" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-70f1-8c99-6848c0f4085c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a77-8ed8-e7a6695d9fec" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-70f1-8c99-6848c0f4085c" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a77-8ed8-e7a6695d9fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeAndAnnuityInsuranceProductLineMember_019c9afa-c0af-77be-8dc6-c10e26526d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LifeAndAnnuityInsuranceProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a77-8ed8-e7a6695d9fec" xlink:to="loc_us-gaap_LifeAndAnnuityInsuranceProductLineMember_019c9afa-c0af-77be-8dc6-c10e26526d3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_019c9afa-c0af-751b-86ae-f1ca8c5d9b98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_019c9afa-c0af-751b-86ae-f1ca8c5d9b98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_019c9afa-c0af-7c9e-abb7-97e80f283faa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_019c9afa-c0af-7c9e-abb7-97e80f283faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_019c9afa-c0af-7c85-a120-5a6387da44f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_019c9afa-c0af-7c85-a120-5a6387da44f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_019c9afa-c0af-7033-85fd-640e38c356c2" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_019c9afa-c0af-7033-85fd-640e38c356c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_019c9afa-c0af-744b-b4e6-4998cf325761" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_019c9afa-c0af-744b-b4e6-4998cf325761" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-7dfe-99cf-d14772a5b192" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-7dfe-99cf-d14772a5b192" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_019c9afa-c0af-7453-8567-58341531b8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_019c9afa-c0af-7453-8567-58341531b8ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-7d7f-83fb-2093d5bb6dea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-7d7f-83fb-2093d5bb6dea" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c9afa-c0af-73da-8604-d30d77793e8a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:to="loc_srt_RangeAxis_019c9afa-c0af-73da-8604-d30d77793e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c9afa-c0af-73da-8604-d30d77793e8a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019c9afa-c0af-73da-8604-d30d77793e8a" xlink:to="loc_srt_RangeMember_019c9afa-c0af-73da-8604-d30d77793e8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c9afa-c0af-7ec3-945c-5137149aee57" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019c9afa-c0af-73da-8604-d30d77793e8a" xlink:to="loc_srt_RangeMember_019c9afa-c0af-7ec3-945c-5137149aee57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c9afa-c0af-7d0a-86f1-7d209760f2f7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c9afa-c0af-7ec3-945c-5137149aee57" xlink:to="loc_srt_MinimumMember_019c9afa-c0af-7d0a-86f1-7d209760f2f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c9afa-c0af-724c-85d6-cf6a70cf3057" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c9afa-c0af-7ec3-945c-5137149aee57" xlink:to="loc_srt_MaximumMember_019c9afa-c0af-724c-85d6-cf6a70cf3057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_019c9afa-c0af-73c4-b8b5-d7114a1e9973" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_019c9afa-c0af-73c4-b8b5-d7114a1e9973" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_019c9afa-c0af-73c4-b8b5-d7114a1e9973_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_019c9afa-c0af-73c4-b8b5-d7114a1e9973" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_019c9afa-c0af-73c4-b8b5-d7114a1e9973_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_019c9afa-c0af-780a-a441-bbb906731dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_019c9afa-c0af-73c4-b8b5-d7114a1e9973" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_019c9afa-c0af-780a-a441-bbb906731dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_019c9afa-c0af-7e1b-b7c7-b60bd3983ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_019c9afa-c0af-780a-a441-bbb906731dae" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_019c9afa-c0af-7e1b-b7c7-b60bd3983ac4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_019c9afa-c0af-740e-b0e8-51ba71c2f810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_019c9afa-c0af-740e-b0e8-51ba71c2f810" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-740e-b0e8-51ba71c2f810_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_019c9afa-c0af-740e-b0e8-51ba71c2f810" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-740e-b0e8-51ba71c2f810_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-7487-aafe-751a03645a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_019c9afa-c0af-740e-b0e8-51ba71c2f810" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-7487-aafe-751a03645a32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_019c9afa-c0af-7f86-9f96-229304dfe3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-7487-aafe-751a03645a32" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_019c9afa-c0af-7f86-9f96-229304dfe3ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_019c9afa-c0af-7335-807d-01973a73dc07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-7487-aafe-751a03645a32" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_019c9afa-c0af-7335-807d-01973a73dc07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_019c9afa-c0af-70ba-9f10-c06bc19030ef" xlink:href="ci-20260331.xsd#ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-7487-aafe-751a03645a32" xlink:to="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_019c9afa-c0af-70ba-9f10-c06bc19030ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7761-bc60-773645b9f64e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7761-bc60-773645b9f64e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractBalancePercentReinsuredExternally_019c9afa-c0af-7e78-95e1-af9a1bfc96bb" xlink:href="ci-20260331.xsd#ci_PolicyholderContractBalancePercentReinsuredExternally"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_ci_PolicyholderContractBalancePercentReinsuredExternally_019c9afa-c0af-7e78-95e1-af9a1bfc96bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_019c9afa-c0af-7c95-88fb-8626651f6954" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_019c9afa-c0af-7c95-88fb-8626651f6954" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_019c9afa-c0af-7794-8656-a4c7db0853cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceNetAmountAtRisk"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_019c9afa-c0af-7794-8656-a4c7db0853cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount_019c9afa-c0af-7162-99d3-896ea2dc4c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashSurrenderValueDuePolicyholdersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount_019c9afa-c0af-7162-99d3-896ea2dc4c0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_019c9afa-c0af-778d-be7a-b5a601ef8169" xlink:href="ci-20260331.xsd#ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_019c9afa-c0af-778d-be7a-b5a601ef8169" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderFunds_019c9afa-c0af-78f2-8324-0462abfb92bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderFunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderFunds_019c9afa-c0af-78f2-8324-0462abfb92bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_019c9afa-c0af-764c-8c38-0d26e516a861" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_019c9afa-c0af-764c-8c38-0d26e516a861" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_019c9afa-c0af-7bd4-985f-5f3838ecf866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_019c9afa-c0af-7bd4-985f-5f3838ecf866" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_019c9afa-c0af-7bba-8c5f-e024e12dc988" xlink:href="ci-20260331.xsd#ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_019c9afa-c0af-7bba-8c5f-e024e12dc988" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_019c9afa-c0af-7c06-876e-5aedbed65ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_019c9afa-c0af-7c06-876e-5aedbed65ae8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7ec3-9c6f-e80cf912c55b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_019c9afa-c0af-7c06-876e-5aedbed65ae8" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7ec3-9c6f-e80cf912c55b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7ec3-9c6f-e80cf912c55b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7ec3-9c6f-e80cf912c55b" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7ec3-9c6f-e80cf912c55b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7e1b-8ead-25eebac7d949" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7ec3-9c6f-e80cf912c55b" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7e1b-8ead-25eebac7d949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember_019c9afa-c0af-739a-a268-7298e0512fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableAnnuityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7e1b-8ead-25eebac7d949" xlink:to="loc_us-gaap_VariableAnnuityMember_019c9afa-c0af-739a-a268-7298e0512fe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_019c9afa-c0af-7fe0-aa2f-ac5665ca3137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_019c9afa-c0af-7fe0-aa2f-ac5665ca3137" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_019c9afa-c0af-7baf-87b5-254656638b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_019c9afa-c0af-7baf-87b5-254656638b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_019c9afa-c0af-7f54-a1c0-326cc1019523" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_019c9afa-c0af-7f54-a1c0-326cc1019523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_019c9afa-c0af-7315-a998-ece08349ce30" xlink:href="ci-20260331.xsd#ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:to="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_019c9afa-c0af-7315-a998-ece08349ce30" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#ReinsuranceReinsuranceRecoverablesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_019c9afa-c0af-7834-a0c7-cfd891a74f4a" xlink:href="ci-20260331.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_019c9afa-c0af-7834-a0c7-cfd891a74f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7834-a0c7-cfd891a74f4a_default" xlink:href="ci-20260331.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_019c9afa-c0af-7834-a0c7-cfd891a74f4a" xlink:to="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7834-a0c7-cfd891a74f4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7666-a3ce-4ee9ac6d383e" xlink:href="ci-20260331.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_019c9afa-c0af-7834-a0c7-cfd891a74f4a" xlink:to="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7666-a3ce-4ee9ac6d383e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_019c9afa-c0af-793d-bc1c-049f5fe59519" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7666-a3ce-4ee9ac6d383e" xlink:to="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_019c9afa-c0af-793d-bc1c-049f5fe59519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_019c9afa-c0af-76d0-86cf-b6c1ed377058" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_019c9afa-c0af-793d-bc1c-049f5fe59519" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_019c9afa-c0af-76d0-86cf-b6c1ed377058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_019c9afa-c0af-7b46-9c62-9377b33f96f5" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7666-a3ce-4ee9ac6d383e" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_019c9afa-c0af-7b46-9c62-9377b33f96f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_019c9afa-c0af-7a4e-aa63-304698cc22c6" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7666-a3ce-4ee9ac6d383e" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_019c9afa-c0af-7a4e-aa63-304698cc22c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7b7b-9edf-c1add3f4226c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7b7b-9edf-c1add3f4226c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7b7b-9edf-c1add3f4226c_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7b7b-9edf-c1add3f4226c" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7b7b-9edf-c1add3f4226c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-74af-b403-a1d786a76327" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7b7b-9edf-c1add3f4226c" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-74af-b403-a1d786a76327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OngoingOperationsMember_019c9afa-c0af-78dc-a0a1-cdfa340e07fd" xlink:href="ci-20260331.xsd#ci_OngoingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-74af-b403-a1d786a76327" xlink:to="loc_ci_OngoingOperationsMember_019c9afa-c0af-78dc-a0a1-cdfa340e07fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AcquisitionDispositionRunoffActivitiesMember_019c9afa-c0af-7ec4-ad04-30ef9cc44c34" xlink:href="ci-20260331.xsd#ci_AcquisitionDispositionRunoffActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-74af-b403-a1d786a76327" xlink:to="loc_ci_AcquisitionDispositionRunoffActivitiesMember_019c9afa-c0af-7ec4-ad04-30ef9cc44c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-788b-9c72-42fca8b0ee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-788b-9c72-42fca8b0ee5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-788b-9c72-42fca8b0ee5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-788b-9c72-42fca8b0ee5a" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-788b-9c72-42fca8b0ee5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-778a-88f9-ad87f8e53b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-788b-9c72-42fca8b0ee5a" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-778a-88f9-ad87f8e53b1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-7a4e-a2a0-a540229748ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskSecuredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-778a-88f9-ad87f8e53b1b" xlink:to="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-7a4e-a2a0-a540229748ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_019c9afa-c0af-728a-8b75-a6179f17c5ef" xlink:href="ci-20260331.xsd#ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-7a4e-a2a0-a540229748ae" xlink:to="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_019c9afa-c0af-728a-8b75-a6179f17c5ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_019c9afa-c0af-7153-a0bc-409325badd9e" xlink:href="ci-20260331.xsd#ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-7a4e-a2a0-a540229748ae" xlink:to="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_019c9afa-c0af-7153-a0bc-409325badd9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskUnsecuredMember_019c9afa-c0af-72e9-a858-03735896005f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskUnsecuredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-778a-88f9-ad87f8e53b1b" xlink:to="loc_us-gaap_CededCreditRiskUnsecuredMember_019c9afa-c0af-72e9-a858-03735896005f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-7623-b68e-e3d4871a0e09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-7623-b68e-e3d4871a0e09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7623-b68e-e3d4871a0e09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-7623-b68e-e3d4871a0e09" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7623-b68e-e3d4871a0e09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7496-a49c-662b942fd483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-7623-b68e-e3d4871a0e09" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7496-a49c-662b942fd483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_019c9afa-c0af-7906-a96d-961bca238e04" xlink:href="ci-20260331.xsd#ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7496-a49c-662b942fd483" xlink:to="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_019c9afa-c0af-7906-a96d-961bca238e04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76cb-8838-673b951dfe76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76cb-8838-673b951dfe76" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-76cb-8838-673b951dfe76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76cb-8838-673b951dfe76" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-76cb-8838-673b951dfe76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-7fa8-b01f-e08588417151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76cb-8838-673b951dfe76" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-7fa8-b01f-e08588417151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsurerConcentrationRiskMember_019c9afa-c0af-7d4e-9148-a7f8eacce2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsurerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-7fa8-b01f-e08588417151" xlink:to="loc_us-gaap_ReinsurerConcentrationRiskMember_019c9afa-c0af-7d4e-9148-a7f8eacce2ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_019c9afa-c0af-7a9a-aeef-955077be81a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_019c9afa-c0af-7a9a-aeef-955077be81a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019c9afa-c0af-7a9a-aeef-955077be81a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019c9afa-c0af-7a9a-aeef-955077be81a2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019c9afa-c0af-7a9a-aeef-955077be81a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019c9afa-c0af-71ba-a92e-ef64e2dda8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019c9afa-c0af-7a9a-aeef-955077be81a2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019c9afa-c0af-71ba-a92e-ef64e2dda8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_019c9afa-c0af-7a0d-9359-74558fe18d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019c9afa-c0af-71ba-a92e-ef64e2dda8f5" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_019c9afa-c0af-7a0d-9359-74558fe18d7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-73eb-958d-67badb4c5ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-73eb-958d-67badb4c5ee5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-73eb-958d-67badb4c5ee5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-73eb-958d-67badb4c5ee5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-73eb-958d-67badb4c5ee5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7ce7-8753-ab476df27e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-73eb-958d-67badb4c5ee5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7ce7-8753-ab476df27e4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember_019c9afa-c0af-77ea-a364-cbcdd9f52bb7" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7ce7-8753-ab476df27e4a" xlink:to="loc_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember_019c9afa-c0af-77ea-a364-cbcdd9f52bb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesGross_019c9afa-c0af-7aec-b0f6-2dc236bcdb84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverablesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_ReinsuranceRecoverablesGross_019c9afa-c0af-7aec-b0f6-2dc236bcdb84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesAllowance_019c9afa-c0af-7b00-a3ef-b53b6acab1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverablesAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_ReinsuranceRecoverablesAllowance_019c9afa-c0af-7b00-a3ef-b53b6acab1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-7d29-a894-8d035a603f92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-7d29-a894-8d035a603f92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables_019c9afa-c0af-7fb4-8487-d88c86457a77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_ReinsuranceRecoverables_019c9afa-c0af-7fb4-8487-d88c86457a77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesNumberOfReinsurers_019c9afa-c0af-726d-9f01-4b2e1a363831" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverablesNumberOfReinsurers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_ci_ReinsuranceRecoverablesNumberOfReinsurers_019c9afa-c0af-726d-9f01-4b2e1a363831" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019c9afa-c0af-7ee7-a3f3-a64dcd91f29f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019c9afa-c0af-7ee7-a3f3-a64dcd91f29f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#ReinsuranceVariableAnnuityReinsuranceAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-72aa-90ed-c8c37280f8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-72aa-90ed-c8c37280f8b1" xlink:to="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c0af-780c-947e-9dc700814fd3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c0af-780c-947e-9dc700814fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-780c-947e-9dc700814fd3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-780c-947e-9dc700814fd3" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-780c-947e-9dc700814fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a59-aff8-5e7704723ad5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-780c-947e-9dc700814fd3" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a59-aff8-5e7704723ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember_019c9afa-c0af-7d4b-9392-b60cccccd70d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableAnnuityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a59-aff8-5e7704723ad5" xlink:to="loc_us-gaap_VariableAnnuityMember_019c9afa-c0af-7d4b-9392-b60cccccd70d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-78e7-919a-7113e436999b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-78e7-919a-7113e436999b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-78e7-919a-7113e436999b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-78e7-919a-7113e436999b" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-78e7-919a-7113e436999b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7281-9df4-7a3a3f696783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-78e7-919a-7113e436999b" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7281-9df4-7a3a3f696783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_019c9afa-c0af-7964-b8b1-ee28ad81fac6" xlink:href="ci-20260331.xsd#ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7281-9df4-7a3a3f696783" xlink:to="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_019c9afa-c0af-7964-b8b1-ee28ad81fac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-7cf2-bb5c-4f2b73d48c52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-7cf2-bb5c-4f2b73d48c52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-7cf2-bb5c-4f2b73d48c52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-7cf2-bb5c-4f2b73d48c52" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-7cf2-bb5c-4f2b73d48c52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-794e-9f1c-705a3627d0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-7cf2-bb5c-4f2b73d48c52" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-794e-9f1c-705a3627d0ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-72c3-b093-98c47fa31356" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskSecuredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-794e-9f1c-705a3627d0ae" xlink:to="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-72c3-b093-98c47fa31356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-79fe-9943-d34aa41cddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-79fe-9943-d34aa41cddc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-79fe-9943-d34aa41cddc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-79fe-9943-d34aa41cddc9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-79fe-9943-d34aa41cddc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7684-8b56-878b30c4378f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-79fe-9943-d34aa41cddc9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7684-8b56-878b30c4378f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_019c9afa-c0af-7d89-8bf8-2398cf22aaef" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7684-8b56-878b30c4378f" xlink:to="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_019c9afa-c0af-7d89-8bf8-2398cf22aaef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76ad-919c-8d9b5dd7f61a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76ad-919c-8d9b5dd7f61a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-76ad-919c-8d9b5dd7f61a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76ad-919c-8d9b5dd7f61a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-76ad-919c-8d9b5dd7f61a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-72c5-a210-caea1627b85a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76ad-919c-8d9b5dd7f61a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-72c5-a210-caea1627b85a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditCollateralizationRiskMember_019c9afa-c0af-716b-95bd-8195ac53aece" xlink:href="ci-20260331.xsd#ci_CededCreditCollateralizationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-72c5-a210-caea1627b85a" xlink:to="loc_ci_CededCreditCollateralizationRiskMember_019c9afa-c0af-716b-95bd-8195ac53aece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage_019c9afa-c0af-7112-a7a7-38f86a4a80cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-72aa-90ed-c8c37280f8b1" xlink:to="loc_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage_019c9afa-c0af-7112-a7a7-38f86a4a80cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_019c9afa-c0af-70af-8857-40dbc027cd56" xlink:href="ci-20260331.xsd#ci_CededReinsuranceAgreementCoverageLimitAmountRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-72aa-90ed-c8c37280f8b1" xlink:to="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_019c9afa-c0af-70af-8857-40dbc027cd56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019c9afa-c0af-7cd4-9814-7173d889f8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-72aa-90ed-c8c37280f8b1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019c9afa-c0af-7cd4-9814-7173d889f8ee" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsInvestmentsbyCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7eb9-a483-d85ac9f672e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7a90-a507-c7384f1e7d84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7eb9-a483-d85ac9f672e7" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7a90-a507-c7384f1e7d84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7946-8690-8543557537f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7a90-a507-c7384f1e7d84" xlink:to="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7946-8690-8543557537f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7946-8690-8543557537f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7946-8690-8543557537f7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7946-8690-8543557537f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7946-8690-8543557537f7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-763c-acf1-5cdba2114966" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-763c-acf1-5cdba2114966" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-7583-8d41-4a96e34cb5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-7583-8d41-4a96e34cb5e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_019c9afa-c16c-71c4-aa1d-10ff88fb137e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_MortgagesMember_019c9afa-c16c-71c4-aa1d-10ff88fb137e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-74be-a52f-a46fb0b521c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-74be-a52f-a46fb0b521c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-7d2f-8107-371597b63f93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-7d2f-8107-371597b63f93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_019c9afa-c16c-7241-85cc-a1b31b480989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_019c9afa-c16c-7241-85cc-a1b31b480989" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-7289-ac21-dcf6e9c6bc60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7eb9-a483-d85ac9f672e7" xlink:to="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-7289-ac21-dcf6e9c6bc60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_019c9afa-c16c-76b2-87fc-8e541587533a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7eb9-a483-d85ac9f672e7" xlink:to="loc_us-gaap_LongTermInvestments_019c9afa-c16c-76b2-87fc-8e541587533a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_019c9afa-c16c-7d69-8add-9f39e3c4c9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7eb9-a483-d85ac9f672e7" xlink:to="loc_us-gaap_Investments_019c9afa-c16c-7d69-8add-9f39e3c4c9fa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7d80-a499-4c0495bff1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7d80-a499-4c0495bff1ed" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c6a-811b-1f2b7381afeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:to="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c6a-811b-1f2b7381afeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7c6a-811b-1f2b7381afeb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c6a-811b-1f2b7381afeb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7c6a-811b-1f2b7381afeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c6a-811b-1f2b7381afeb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7804-99eb-b7157c6cccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7804-99eb-b7157c6cccf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-73a9-b495-51d439be7612" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-73a9-b495-51d439be7612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_019c9afa-c16c-7d27-854c-a35163f5a81a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_MortgagesMember_019c9afa-c16c-7d27-854c-a35163f5a81a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-71fb-840b-11d9e4256c75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-71fb-840b-11d9e4256c75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-76b1-99fe-01d05676677f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-76b1-99fe-01d05676677f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_019c9afa-c16c-73ed-b4ca-6703c853379f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_019c9afa-c16c-73ed-b4ca-6703c853379f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c16c-74e4-90b9-6df11ec1049e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c16c-74e4-90b9-6df11ec1049e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c16c-74e4-90b9-6df11ec1049e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c16c-74e4-90b9-6df11ec1049e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c16c-74e4-90b9-6df11ec1049e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c16c-745a-9a51-064335ca5b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c16c-74e4-90b9-6df11ec1049e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c16c-745a-9a51-064335ca5b9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_019c9afa-c16c-7bd3-965e-4fb5c3c48707" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c16c-745a-9a51-064335ca5b9b" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_019c9afa-c16c-7bd3-965e-4fb5c3c48707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c16c-7983-9f65-5d7b9966f2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c16c-7983-9f65-5d7b9966f2ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c16c-7983-9f65-5d7b9966f2ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c16c-7983-9f65-5d7b9966f2ae" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c16c-7983-9f65-5d7b9966f2ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c16c-798e-b7e7-0e263cda1811" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c16c-7983-9f65-5d7b9966f2ae" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c16c-798e-b7e7-0e263cda1811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_019c9afa-c16c-7c87-8669-4470db6b8c0c" xlink:href="ci-20260331.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c16c-798e-b7e7-0e263cda1811" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_019c9afa-c16c-7c87-8669-4470db6b8c0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c16c-7f55-9bcd-0ff0e052e9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7d80-a499-4c0495bff1ed" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c16c-7f55-9bcd-0ff0e052e9bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-77c5-8004-bab8bd6d5085" xlink:href="ci-20260331.xsd#ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c16c-7f55-9bcd-0ff0e052e9bb" xlink:to="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-77c5-8004-bab8bd6d5085" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_019c9afa-c16c-7cf3-af62-b26736b446fd" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c16c-7f55-9bcd-0ff0e052e9bb" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_019c9afa-c16c-7cf3-af62-b26736b446fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-738c-90c7-46bc5ee8704f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c16c-7f55-9bcd-0ff0e052e9bb" xlink:to="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-738c-90c7-46bc5ee8704f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_019c9afa-c16c-7052-8c2d-0168a06c13ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7d80-a499-4c0495bff1ed" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_019c9afa-c16c-7052-8c2d-0168a06c13ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-750a-9be3-4a35e7bb66a5" xlink:href="ci-20260331.xsd#ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_019c9afa-c16c-7052-8c2d-0168a06c13ea" xlink:to="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-750a-9be3-4a35e7bb66a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_019c9afa-c16c-7ad1-80de-f9440d58194b" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_019c9afa-c16c-7052-8c2d-0168a06c13ea" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_019c9afa-c16c-7ad1-80de-f9440d58194b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_019c9afa-c16c-7051-84e7-248c978f8d11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_019c9afa-c16c-7052-8c2d-0168a06c13ea" xlink:to="loc_us-gaap_LongTermInvestments_019c9afa-c16c-7051-84e7-248c978f8d11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c16c-7415-9133-ccd841465951" xlink:href="ci-20260331.xsd#ci_ShortTermAndLongTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7d80-a499-4c0495bff1ed" xlink:to="loc_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c16c-7415-9133-ccd841465951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7957-88a3-60d2855bc3f2" xlink:href="ci-20260331.xsd#ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c16c-7415-9133-ccd841465951" xlink:to="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7957-88a3-60d2855bc3f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_019c9afa-c16c-7c28-b52d-7c5283fca9e1" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c16c-7415-9133-ccd841465951" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_019c9afa-c16c-7c28-b52d-7c5283fca9e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_019c9afa-c16c-7e07-9b33-f526c6f0f8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c16c-7415-9133-ccd841465951" xlink:to="loc_us-gaap_Investments_019c9afa-c16c-7e07-9b33-f526c6f0f8ba" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-70e2-bbb5-fb3cf191b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-70e2-bbb5-fb3cf191b86d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-77ef-a20f-b5aec9f05c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-70e2-bbb5-fb3cf191b86d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-77ef-a20f-b5aec9f05c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-77ef-a20f-b5aec9f05c0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-77ef-a20f-b5aec9f05c0c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-77ef-a20f-b5aec9f05c0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-77ef-a20f-b5aec9f05c0c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019c9afa-c16c-71d8-81ce-30749f0be3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019c9afa-c16c-71d8-81ce-30749f0be3b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_019c9afa-c16c-7518-bd61-576fdac6a208" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_019c9afa-c16c-7518-bd61-576fdac6a208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_019c9afa-c16c-788a-8311-34a851721d72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_019c9afa-c16c-788a-8311-34a851721d72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019c9afa-c16c-70c7-b6a8-bf04858da77b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019c9afa-c16c-70c7-b6a8-bf04858da77b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7091-ae5b-23102f6d0e94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7091-ae5b-23102f6d0e94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7eca-a4e6-13a75aa1a508" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7eca-a4e6-13a75aa1a508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_019c9afa-c16c-7dc1-b8fc-2a0b0478fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_019c9afa-c16c-7dc1-b8fc-2a0b0478fa5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019c9afa-c16c-72a3-b452-e29318d48e34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019c9afa-c16c-72a3-b452-e29318d48e34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019c9afa-c16c-7372-8d3e-b47a13114de2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019c9afa-c16c-7372-8d3e-b47a13114de2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-7bc1-be2a-9de6abe7b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-7bc1-be2a-9de6abe7b9dc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-737a-a06c-951efe8217f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-7b31-8c10-e31e3cf11efb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-737a-a06c-951efe8217f4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-7b31-8c10-e31e3cf11efb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingAxis_019c9afa-c16c-7012-b6bb-ed7b287fda15" xlink:href="ci-20260331.xsd#ci_InvestmentsCreditRatingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-7b31-8c10-e31e3cf11efb" xlink:to="loc_ci_InvestmentsCreditRatingAxis_019c9afa-c16c-7012-b6bb-ed7b287fda15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingDomain_019c9afa-c16c-7012-b6bb-ed7b287fda15_default" xlink:href="ci-20260331.xsd#ci_InvestmentsCreditRatingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ci_InvestmentsCreditRatingAxis_019c9afa-c16c-7012-b6bb-ed7b287fda15" xlink:to="loc_ci_InvestmentsCreditRatingDomain_019c9afa-c16c-7012-b6bb-ed7b287fda15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingDomain_019c9afa-c16c-776f-8e77-7d8af36cf5ae" xlink:href="ci-20260331.xsd#ci_InvestmentsCreditRatingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ci_InvestmentsCreditRatingAxis_019c9afa-c16c-7012-b6bb-ed7b287fda15" xlink:to="loc_ci_InvestmentsCreditRatingDomain_019c9afa-c16c-776f-8e77-7d8af36cf5ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentGradeMember_019c9afa-c16c-71c8-9f68-e189bf91819f" xlink:href="ci-20260331.xsd#ci_InvestmentGradeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InvestmentsCreditRatingDomain_019c9afa-c16c-776f-8e77-7d8af36cf5ae" xlink:to="loc_ci_InvestmentGradeMember_019c9afa-c16c-71c8-9f68-e189bf91819f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BelowInvestmentGradeMember_019c9afa-c16c-7fad-afbe-d721ba615127" xlink:href="ci-20260331.xsd#ci_BelowInvestmentGradeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InvestmentsCreditRatingDomain_019c9afa-c16c-776f-8e77-7d8af36cf5ae" xlink:to="loc_ci_BelowInvestmentGradeMember_019c9afa-c16c-7fad-afbe-d721ba615127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7ca5-b7ad-9dfa577091c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-7b31-8c10-e31e3cf11efb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7ca5-b7ad-9dfa577091c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7ca5-b7ad-9dfa577091c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7ca5-b7ad-9dfa577091c5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7ca5-b7ad-9dfa577091c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7f57-bc3a-9ce70c0cc813" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7ca5-b7ad-9dfa577091c5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7f57-bc3a-9ce70c0cc813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7633-90f6-587ad97d423d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7f57-bc3a-9ce70c0cc813" xlink:to="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7633-90f6-587ad97d423d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-737a-a06c-951efe8217f4" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019c9afa-c16c-7573-a2a4-815669706dec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019c9afa-c16c-7573-a2a4-815669706dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_019c9afa-c16c-7545-bc5a-c786b3ca3dca" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_019c9afa-c16c-7545-bc5a-c786b3ca3dca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019c9afa-c16c-7d23-bb87-77fe13fbf035" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019c9afa-c16c-7d23-bb87-77fe13fbf035" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_019c9afa-c16c-7c7d-be88-c602e5071a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_019c9afa-c16c-7c7d-be88-c602e5071a94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-737a-a06c-951efe8217f4" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019c9afa-c16c-72a8-860d-4b7db0219fee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019c9afa-c16c-72a8-860d-4b7db0219fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_019c9afa-c16c-7e83-91bf-572c6ea4755e" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_019c9afa-c16c-7e83-91bf-572c6ea4755e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019c9afa-c16c-7f0d-a4e1-7602d5b0437d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019c9afa-c16c-7f0d-a4e1-7602d5b0437d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_019c9afa-c16c-7e92-b3e5-5e2ed2747795" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_019c9afa-c16c-7e92-b3e5-5e2ed2747795" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-737a-a06c-951efe8217f4" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c9afa-c16c-7d84-a520-0dab00c9cf64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c9afa-c16c-7d84-a520-0dab00c9cf64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c16c-7234-813e-44935b974e60" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c16c-7234-813e-44935b974e60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c9afa-c16c-7124-b1bc-6f2f5becd5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c9afa-c16c-7124-b1bc-6f2f5becd5dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019c9afa-c16c-72ff-9a84-d55d75727251" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019c9afa-c16c-72ff-9a84-d55d75727251" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7ec0-9bcc-463c0ecbd3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7f77-94e8-958b599814fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7ec0-9bcc-463c0ecbd3cb" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7f77-94e8-958b599814fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16c-7185-b3f2-bb94eb11e3b8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7f77-94e8-958b599814fb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16c-7185-b3f2-bb94eb11e3b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16c-7185-b3f2-bb94eb11e3b8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16c-7185-b3f2-bb94eb11e3b8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16c-7185-b3f2-bb94eb11e3b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16c-73b8-a3d6-b6a670c87ebe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16c-7185-b3f2-bb94eb11e3b8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16c-73b8-a3d6-b6a670c87ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShieldsHealthSolutionsMember_019c9afa-c16c-7e82-b724-8b9ee941656c" xlink:href="ci-20260331.xsd#ci_ShieldsHealthSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16c-73b8-a3d6-b6a670c87ebe" xlink:to="loc_ci_ShieldsHealthSolutionsMember_019c9afa-c16c-7e82-b724-8b9ee941656c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-72a2-86ad-e46157e96c34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7f77-94e8-958b599814fb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-72a2-86ad-e46157e96c34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-72a2-86ad-e46157e96c34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-72a2-86ad-e46157e96c34" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-72a2-86ad-e46157e96c34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-747a-9a05-805dcfcc30b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-72a2-86ad-e46157e96c34" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-747a-9a05-805dcfcc30b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_019c9afa-c16c-7ce4-9488-4ee7158ead99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-747a-9a05-805dcfcc30b3" xlink:to="loc_us-gaap_PreferredStockMember_019c9afa-c16c-7ce4-9488-4ee7158ead99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c16c-7f66-8b2c-5d1b0b635821" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7ec0-9bcc-463c0ecbd3cb" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c16c-7f66-8b2c-5d1b0b635821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_019c9afa-c16c-7269-bc0b-cd9d58ac20e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c16c-7f66-8b2c-5d1b0b635821" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_019c9afa-c16c-7269-bc0b-cd9d58ac20e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_019c9afa-c16c-729e-a719-ca6a01ff84df" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c16c-7f66-8b2c-5d1b0b635821" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_019c9afa-c16c-729e-a719-ca6a01ff84df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_019c9afa-c16c-7d29-8b4a-164c9c2daf98" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c16c-7f66-8b2c-5d1b0b635821" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_019c9afa-c16c-7d29-8b4a-164c9c2daf98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c16c-73e8-9cb7-6f40086cf1b3" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7ec0-9bcc-463c0ecbd3cb" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c16c-73e8-9cb7-6f40086cf1b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c16c-7ba9-abf7-419f0c9a83a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c16c-73e8-9cb7-6f40086cf1b3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c16c-7ba9-abf7-419f0c9a83a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019c9afa-c16c-727b-bbe7-4c646304be68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c16c-73e8-9cb7-6f40086cf1b3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019c9afa-c16c-727b-bbe7-4c646304be68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_019c9afa-c16c-7095-914b-f27ddf7435a5" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c16c-73e8-9cb7-6f40086cf1b3" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_019c9afa-c16c-7095-914b-f27ddf7435a5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsCommercialMortgageLoansDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7fff-9ddb-1af2c28e7110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7fff-9ddb-1af2c28e7110" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c9afa-c16c-79ea-846c-880e6dea5785" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c9afa-c16c-79ea-846c-880e6dea5785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c9afa-c16c-79ea-846c-880e6dea5785_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c9afa-c16c-79ea-846c-880e6dea5785" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c9afa-c16c-79ea-846c-880e6dea5785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c9afa-c16c-7cb4-bfac-f913bb7abeed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c9afa-c16c-79ea-846c-880e6dea5785" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c9afa-c16c-7cb4-bfac-f913bb7abeed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_019c9afa-c16c-7b0c-9f69-5f1b538c3de8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c9afa-c16c-7cb4-bfac-f913bb7abeed" xlink:to="loc_us-gaap_RealEstateLoanMember_019c9afa-c16c-7b0c-9f69-5f1b538c3de8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_019c9afa-c16c-7027-9f67-f66d152abdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_019c9afa-c16c-7027-9f67-f66d152abdcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_019c9afa-c16c-7027-9f67-f66d152abdcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_019c9afa-c16c-7027-9f67-f66d152abdcc" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_019c9afa-c16c-7027-9f67-f66d152abdcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_019c9afa-c16c-7299-a0f3-60c967e55701" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_019c9afa-c16c-7027-9f67-f66d152abdcc" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_019c9afa-c16c-7299-a0f3-60c967e55701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPortfolioSegmentMember_019c9afa-c16c-77d3-9f60-88a1f53579d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPortfolioSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_019c9afa-c16c-7299-a0f3-60c967e55701" xlink:to="loc_us-gaap_CommercialPortfolioSegmentMember_019c9afa-c16c-77d3-9f60-88a1f53579d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueAxis_019c9afa-c16c-7e24-97cf-0078753903c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoanToValueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:to="loc_us-gaap_LoanToValueAxis_019c9afa-c16c-7e24-97cf-0078753903c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7e24-97cf-0078753903c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoanToValueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LoanToValueAxis_019c9afa-c16c-7e24-97cf-0078753903c5" xlink:to="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7e24-97cf-0078753903c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7ca5-95f9-bc659dc50f07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoanToValueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LoanToValueAxis_019c9afa-c16c-7e24-97cf-0078753903c5" xlink:to="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7ca5-95f9-bc659dc50f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LtvLessThan80PercentMember_019c9afa-c16c-72a1-bc4e-d3902edb589a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LtvLessThan80PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7ca5-95f9-bc659dc50f07" xlink:to="loc_us-gaap_LtvLessThan80PercentMember_019c9afa-c16c-72a1-bc4e-d3902edb589a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvLessThan60PercentMember_019c9afa-c16c-7aba-b164-6b5c2e483bea" xlink:href="ci-20260331.xsd#ci_LtvLessThan60PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LtvLessThan80PercentMember_019c9afa-c16c-72a1-bc4e-d3902edb589a" xlink:to="loc_ci_LtvLessThan60PercentMember_019c9afa-c16c-7aba-b164-6b5c2e483bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_Ltv60To79PercentMember_019c9afa-c16c-741e-8656-843622f0559a" xlink:href="ci-20260331.xsd#ci_Ltv60To79PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LtvLessThan80PercentMember_019c9afa-c16c-72a1-bc4e-d3902edb589a" xlink:to="loc_ci_Ltv60To79PercentMember_019c9afa-c16c-741e-8656-843622f0559a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Ltv80To100PercentMember_019c9afa-c16c-7298-b4fb-179a2bd1646b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Ltv80To100PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7ca5-95f9-bc659dc50f07" xlink:to="loc_us-gaap_Ltv80To100PercentMember_019c9afa-c16c-7298-b4fb-179a2bd1646b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvGreaterThan100PercentMember_019c9afa-c16c-77cf-95e8-275354fb0faf" xlink:href="ci-20260331.xsd#ci_LtvGreaterThan100PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7ca5-95f9-bc659dc50f07" xlink:to="loc_ci_LtvGreaterThan100PercentMember_019c9afa-c16c-77cf-95e8-275354fb0faf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c9afa-c16c-7471-80d8-19566db04993" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:to="loc_srt_RangeAxis_019c9afa-c16c-7471-80d8-19566db04993" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c9afa-c16c-7471-80d8-19566db04993_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019c9afa-c16c-7471-80d8-19566db04993" xlink:to="loc_srt_RangeMember_019c9afa-c16c-7471-80d8-19566db04993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c9afa-c16c-796d-b58b-7d017c278d6b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019c9afa-c16c-7471-80d8-19566db04993" xlink:to="loc_srt_RangeMember_019c9afa-c16c-796d-b58b-7d017c278d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_019c9afa-c16c-7f77-a530-f7505f44267f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c9afa-c16c-796d-b58b-7d017c278d6b" xlink:to="loc_srt_WeightedAverageMember_019c9afa-c16c-7f77-a530-f7505f44267f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_019c9afa-c16c-7091-ace4-fdb8d536c7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7fff-9ddb-1af2c28e7110" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_019c9afa-c16c-7091-ace4-fdb8d536c7ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_019c9afa-c16c-7d1f-8f0b-60cd38f0bbc0" xlink:href="ci-20260331.xsd#ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7fff-9ddb-1af2c28e7110" xlink:to="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_019c9afa-c16c-7d1f-8f0b-60cd38f0bbc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio_019c9afa-c16c-7a33-8d30-767dcc54adab" xlink:href="ci-20260331.xsd#ci_FinancingReceivableCreditQualityLoanToValueRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7fff-9ddb-1af2c28e7110" xlink:to="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio_019c9afa-c16c-7a33-8d30-767dcc54adab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsOtherLongTermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7bcb-8b41-e163212742d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7bcb-8b41-e163212742d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c58-8a6a-471cb0485839" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7bcb-8b41-e163212742d6" xlink:to="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c58-8a6a-471cb0485839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7c58-8a6a-471cb0485839_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c58-8a6a-471cb0485839" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7c58-8a6a-471cb0485839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d02-a876-a15a3804ad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c58-8a6a-471cb0485839" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d02-a876-a15a3804ad9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateInvestmentMember_019c9afa-c16c-78ee-acb2-74b7401c7585" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d02-a876-a15a3804ad9c" xlink:to="loc_us-gaap_RealEstateInvestmentMember_019c9afa-c16c-78ee-acb2-74b7401c7585" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_019c9afa-c16c-7f0c-96b1-4fced1e3e33e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d02-a876-a15a3804ad9c" xlink:to="loc_srt_PartnershipInterestMember_019c9afa-c16c-7f0c-96b1-4fced1e3e33e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_019c9afa-c16c-7810-ac98-6ae2df6b85b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d02-a876-a15a3804ad9c" xlink:to="loc_us-gaap_OtherInvestmentsMember_019c9afa-c16c-7810-ac98-6ae2df6b85b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_019c9afa-c16c-7413-bdd5-e74fd6bafacb" xlink:href="ci-20260331.xsd#ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:to="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_019c9afa-c16c-7413-bdd5-e74fd6bafacb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_019c9afa-c16c-7430-8ee2-89533f41f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_019c9afa-c16c-7430-8ee2-89533f41f5e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_019c9afa-c16c-7239-834f-9551106fcfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:to="loc_us-gaap_OtherLongTermInvestments_019c9afa-c16c-7239-834f-9551106fcfdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital_019c9afa-c16c-7075-8a62-9b2f2926aba8" xlink:href="ci-20260331.xsd#ci_CommitmentsToContributeAdditionalEquityAndCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:to="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital_019c9afa-c16c-7075-8a62-9b2f2926aba8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsDerivativeFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:to="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_019c9afa-c16c-707e-ba08-036db5cda375" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:to="loc_us-gaap_HedgingDesignationAxis_019c9afa-c16c-707e-ba08-036db5cda375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_019c9afa-c16c-707e-ba08-036db5cda375_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_019c9afa-c16c-707e-ba08-036db5cda375" xlink:to="loc_us-gaap_HedgingDesignationDomain_019c9afa-c16c-707e-ba08-036db5cda375_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_019c9afa-c16c-70e9-a832-94278f6237dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_019c9afa-c16c-707e-ba08-036db5cda375" xlink:to="loc_us-gaap_HedgingDesignationDomain_019c9afa-c16c-70e9-a832-94278f6237dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_019c9afa-c16c-7339-a70a-708434b2f864" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_019c9afa-c16c-70e9-a832-94278f6237dd" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_019c9afa-c16c-7339-a70a-708434b2f864" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_019c9afa-c16c-7c99-ba0a-62985137627f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_019c9afa-c16c-7c99-ba0a-62985137627f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_019c9afa-c16c-7c99-ba0a-62985137627f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_019c9afa-c16c-7c99-ba0a-62985137627f" xlink:to="loc_us-gaap_HedgingRelationshipDomain_019c9afa-c16c-7c99-ba0a-62985137627f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_019c9afa-c16c-7feb-a8d5-ef9c758a441c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_019c9afa-c16c-7c99-ba0a-62985137627f" xlink:to="loc_us-gaap_HedgingRelationshipDomain_019c9afa-c16c-7feb-a8d5-ef9c758a441c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_019c9afa-c16c-7e5a-9282-d40896e91a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_019c9afa-c16c-7feb-a8d5-ef9c758a441c" xlink:to="loc_us-gaap_FairValueHedgingMember_019c9afa-c16c-7e5a-9282-d40896e91a2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_019c9afa-c16c-753f-a2e2-c3471a90c845" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_019c9afa-c16c-7feb-a8d5-ef9c758a441c" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_019c9afa-c16c-753f-a2e2-c3471a90c845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_019c9afa-c16c-772e-bbb2-57d4269a715e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_019c9afa-c16c-772e-bbb2-57d4269a715e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019c9afa-c16c-772e-bbb2-57d4269a715e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019c9afa-c16c-772e-bbb2-57d4269a715e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019c9afa-c16c-772e-bbb2-57d4269a715e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019c9afa-c16c-7317-b4e5-58f9473158f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019c9afa-c16c-772e-bbb2-57d4269a715e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019c9afa-c16c-7317-b4e5-58f9473158f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_019c9afa-c16c-7cb8-8719-dd18a41fd0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_019c9afa-c16c-7317-b4e5-58f9473158f6" xlink:to="loc_us-gaap_CurrencySwapMember_019c9afa-c16c-7cb8-8719-dd18a41fd0d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_019c9afa-c16c-7f26-a9d1-54fe1ac4175f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_019c9afa-c16c-7317-b4e5-58f9473158f6" xlink:to="loc_us-gaap_InterestRateSwapMember_019c9afa-c16c-7f26-a9d1-54fe1ac4175f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_019c9afa-c16c-72a4-8f7a-f32ab325a36b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_019c9afa-c16c-72a4-8f7a-f32ab325a36b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_019c9afa-c16c-7203-bb92-302f65228541" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_019c9afa-c16c-7203-bb92-302f65228541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_019c9afa-c16c-7620-b2b5-4fa7f3bca948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_019c9afa-c16c-7620-b2b5-4fa7f3bca948" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_019c9afa-c16c-7821-a1e9-55fedb1c44c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_019c9afa-c16c-7821-a1e9-55fedb1c44c4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsComponentsofNetInvestmentIncomeLossesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_019c9afa-c16c-78cc-844a-d6862c0a0e23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_019c9afa-c16c-78cc-844a-d6862c0a0e23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7695-931a-275c207f5908" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_019c9afa-c16c-78cc-844a-d6862c0a0e23" xlink:to="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7695-931a-275c207f5908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7695-931a-275c207f5908_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7695-931a-275c207f5908" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7695-931a-275c207f5908_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7695-931a-275c207f5908" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-743a-bb37-440a2d9cdcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-743a-bb37-440a2d9cdcd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-76fe-b97b-201a95583895" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-76fe-b97b-201a95583895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_019c9afa-c16c-7318-abd2-2be4cd0f9047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_us-gaap_MortgagesMember_019c9afa-c16c-7318-abd2-2be4cd0f9047" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-7e45-aab4-e283c64f5be1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-7e45-aab4-e283c64f5be1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-751f-9a10-e24cdb538ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-751f-9a10-e24cdb538ff1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember_019c9afa-c16c-721d-8f4c-d4140c27d83e" xlink:href="ci-20260331.xsd#ci_CashCashEquivalentsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember_019c9afa-c16c-721d-8f4c-d4140c27d83e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_019c9afa-c16c-7fa3-957b-f6d6a336a986" xlink:href="ci-20260331.xsd#ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:to="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_019c9afa-c16c-7fa3-957b-f6d6a336a986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_019c9afa-c16c-707c-b3c1-5cac6bb545f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_019c9afa-c16c-707c-b3c1-5cac6bb545f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_019c9afa-c16c-7233-8d33-b701e5afd0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:to="loc_us-gaap_NetInvestmentIncome_019c9afa-c16c-7233-8d33-b701e5afd0f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DividendsReceivableImpairmentLoss_019c9afa-c16c-7cfe-a08d-297456baf50a" xlink:href="ci-20260331.xsd#ci_DividendsReceivableImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:to="loc_ci_DividendsReceivableImpairmentLoss_019c9afa-c16c-7cfe-a08d-297456baf50a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16c-7283-be1a-12715da78c30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16c-7283-be1a-12715da78c30" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7f83-8702-f8aa4f2d978a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7f83-8702-f8aa4f2d978a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7f83-8702-f8aa4f2d978a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7f83-8702-f8aa4f2d978a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7f83-8702-f8aa4f2d978a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7f83-8702-f8aa4f2d978a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019c9afa-c16c-7fee-bf5c-5269498890f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019c9afa-c16c-7fee-bf5c-5269498890f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_019c9afa-c16c-73bd-96bd-e374b43d6e69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_019c9afa-c16c-73bd-96bd-e374b43d6e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_019c9afa-c16c-7eb7-82aa-f81bab9eae5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_019c9afa-c16c-7eb7-82aa-f81bab9eae5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019c9afa-c16c-7ae9-bdbf-a881f14640ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019c9afa-c16c-7ae9-bdbf-a881f14640ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7368-b831-e1cc0d303cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7368-b831-e1cc0d303cf7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember_019c9afa-c16c-7675-a4cc-fbd257dde873" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_DerivativeMember_019c9afa-c16c-7675-a4cc-fbd257dde873" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-7525-a959-1ed7f324ec03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-7525-a959-1ed7f324ec03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7525-a959-1ed7f324ec03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-7525-a959-1ed7f324ec03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7525-a959-1ed7f324ec03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7f78-b020-2a1d865f4351" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-7525-a959-1ed7f324ec03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7f78-b020-2a1d865f4351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019c9afa-c16c-7ace-8837-1119e4749002" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7f78-b020-2a1d865f4351" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019c9afa-c16c-7ace-8837-1119e4749002" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16c-79c8-9f2c-6ca2aac806fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7f78-b020-2a1d865f4351" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16c-79c8-9f2c-6ca2aac806fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16c-72a7-ad59-08f38a0ef8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7f78-b020-2a1d865f4351" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16c-72a7-ad59-08f38a0ef8b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77c2-8a2e-e30140ca6d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77c2-8a2e-e30140ca6d0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-77c2-8a2e-e30140ca6d0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77c2-8a2e-e30140ca6d0e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-77c2-8a2e-e30140ca6d0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-751b-ac21-c73ab35aa415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77c2-8a2e-e30140ca6d0e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-751b-ac21-c73ab35aa415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_019c9afa-c16c-7370-aad0-706f276f77d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-751b-ac21-c73ab35aa415" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_019c9afa-c16c-7370-aad0-706f276f77d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16c-7283-be1a-12715da78c30" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c9afa-c16c-752c-8ba8-bb70f2f3b96d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c9afa-c16c-752c-8ba8-bb70f2f3b96d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c16c-74cc-a647-1be230b81d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c16c-74cc-a647-1be230b81d33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_019c9afa-c16c-7c20-8fca-8915b1088097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:to="loc_us-gaap_OtherShortTermInvestments_019c9afa-c16c-7c20-8fca-8915b1088097" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_019c9afa-c16c-7758-be07-8ec0f6ef9d39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:to="loc_us-gaap_DerivativeAssets_019c9afa-c16c-7758-be07-8ec0f6ef9d39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019c9afa-c16c-75f9-9320-797f9ff85db6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16c-7283-be1a-12715da78c30" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019c9afa-c16c-75f9-9320-797f9ff85db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_019c9afa-c16c-7317-be8c-fd102d898271" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019c9afa-c16c-75f9-9320-797f9ff85db6" xlink:to="loc_us-gaap_DerivativeLiabilities_019c9afa-c16c-7317-be8c-fd102d898271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesClassifiedInLevel3Percentage_019c9afa-c16c-707e-8e45-72aee3e5cbc4" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesClassifiedInLevel3Percentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16c-7283-be1a-12715da78c30" xlink:to="loc_ci_DebtSecuritiesClassifiedInLevel3Percentage_019c9afa-c16c-707e-8e45-72aee3e5cbc4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16c-7a4a-9790-009cee6ed01e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16c-7a4a-9790-009cee6ed01e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7fee-887f-a81f2a5a4233" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7fee-887f-a81f2a5a4233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7fee-887f-a81f2a5a4233_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7fee-887f-a81f2a5a4233" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7fee-887f-a81f2a5a4233_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-781b-aee3-295548b3007c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7fee-887f-a81f2a5a4233" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-781b-aee3-295548b3007c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7be9-b4e7-1220f91dbb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-781b-aee3-295548b3007c" xlink:to="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7be9-b4e7-1220f91dbb3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndGovernmentDebtSecuritiesMember_019c9afa-c16c-7fd7-904c-454686fbdd71" xlink:href="ci-20260331.xsd#ci_CorporateAndGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7be9-b4e7-1220f91dbb3d" xlink:to="loc_ci_CorporateAndGovernmentDebtSecuritiesMember_019c9afa-c16c-7fd7-904c-454686fbdd71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7ad4-a66b-cb4e4feb89c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7be9-b4e7-1220f91dbb3d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7ad4-a66b-cb4e4feb89c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_019c9afa-c16c-748d-9a5a-f5e984040bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7be9-b4e7-1220f91dbb3d" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_019c9afa-c16c-748d-9a5a-f5e984040bd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16c-74e7-91fa-a0ce10dcb918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16c-74e7-91fa-a0ce10dcb918" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16c-74e7-91fa-a0ce10dcb918_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16c-74e7-91fa-a0ce10dcb918" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16c-74e7-91fa-a0ce10dcb918_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16c-7118-a1d7-e13d714ca0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16c-74e7-91fa-a0ce10dcb918" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16c-7118-a1d7-e13d714ca0bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnobservableInputsDevelopedByCompanyMember_019c9afa-c16c-7eb0-b233-b6d5d0986db3" xlink:href="ci-20260331.xsd#ci_UnobservableInputsDevelopedByCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16c-7118-a1d7-e13d714ca0bf" xlink:to="loc_ci_UnobservableInputsDevelopedByCompanyMember_019c9afa-c16c-7eb0-b233-b6d5d0986db3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77a4-b0e5-d7915fb0237f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77a4-b0e5-d7915fb0237f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-77a4-b0e5-d7915fb0237f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77a4-b0e5-d7915fb0237f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-77a4-b0e5-d7915fb0237f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-7b63-bdd7-5edffc056dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77a4-b0e5-d7915fb0237f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-7b63-bdd7-5edffc056dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_019c9afa-c16c-7078-b19e-3de249c27ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-7b63-bdd7-5edffc056dae" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_019c9afa-c16c-7078-b19e-3de249c27ae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-706a-93e6-5320c39655c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-706a-93e6-5320c39655c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-706a-93e6-5320c39655c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-706a-93e6-5320c39655c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-706a-93e6-5320c39655c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-72b5-ab49-2f7ce34141fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-706a-93e6-5320c39655c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-72b5-ab49-2f7ce34141fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16c-78b0-8be0-05a7f7958bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-72b5-ab49-2f7ce34141fb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16c-78b0-8be0-05a7f7958bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c9afa-c16c-7859-b6a1-9b5a92477476" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_srt_RangeAxis_019c9afa-c16c-7859-b6a1-9b5a92477476" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c9afa-c16c-7859-b6a1-9b5a92477476_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019c9afa-c16c-7859-b6a1-9b5a92477476" xlink:to="loc_srt_RangeMember_019c9afa-c16c-7859-b6a1-9b5a92477476_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c9afa-c16c-71df-8348-4223050c687f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019c9afa-c16c-7859-b6a1-9b5a92477476" xlink:to="loc_srt_RangeMember_019c9afa-c16c-71df-8348-4223050c687f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c9afa-c16c-7413-986b-d29a5f15fd9c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c9afa-c16c-71df-8348-4223050c687f" xlink:to="loc_srt_MinimumMember_019c9afa-c16c-7413-986b-d29a5f15fd9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c9afa-c16c-713c-b79b-a8ed9185cc2c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c9afa-c16c-71df-8348-4223050c687f" xlink:to="loc_srt_MaximumMember_019c9afa-c16c-713c-b79b-a8ed9185cc2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_019c9afa-c16c-71ab-ba0e-d7f3cd9b690f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c9afa-c16c-71df-8348-4223050c687f" xlink:to="loc_srt_WeightedAverageMember_019c9afa-c16c-71ab-ba0e-d7f3cd9b690f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16c-7e9e-885e-ee3c3a2b6f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16c-7e9e-885e-ee3c3a2b6f3d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16c-7e9e-885e-ee3c3a2b6f3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16c-7e9e-885e-ee3c3a2b6f3d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16c-7e9e-885e-ee3c3a2b6f3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16c-7f74-86d6-7555c795df9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16c-7e9e-885e-ee3c3a2b6f3d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16c-7f74-86d6-7555c795df9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputLiquidityMember_019c9afa-c16c-7b22-8d36-30fee007d4e6" xlink:href="ci-20260331.xsd#ci_MeasurementInputLiquidityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16c-7f74-86d6-7555c795df9a" xlink:to="loc_ci_MeasurementInputLiquidityMember_019c9afa-c16c-7b22-8d36-30fee007d4e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_019c9afa-c16c-7e86-831f-1faec1502a71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16c-7a4a-9790-009cee6ed01e" xlink:to="loc_us-gaap_MarketableSecurities_019c9afa-c16c-7e86-831f-1faec1502a71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_019c9afa-c16c-7681-b4da-c2dec8c4e56f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16c-7a4a-9790-009cee6ed01e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_019c9afa-c16c-7681-b4da-c2dec8c4e56f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16d-7ae3-99f8-7e55373d1ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16d-7ae3-99f8-7e55373d1ddf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16d-7386-b9f6-abd5385ddfce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:to="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16d-7386-b9f6-abd5385ddfce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16d-7386-b9f6-abd5385ddfce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16d-7386-b9f6-abd5385ddfce" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16d-7386-b9f6-abd5385ddfce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16d-7143-9b0a-625d28709c90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16d-7386-b9f6-abd5385ddfce" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16d-7143-9b0a-625d28709c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_019c9afa-c16d-7b98-9c95-7fdb4d928f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16d-7143-9b0a-625d28709c90" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_019c9afa-c16d-7b98-9c95-7fdb4d928f4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7d8c-9fff-c58121526aff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7d8c-9fff-c58121526aff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7d8c-9fff-c58121526aff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7d8c-9fff-c58121526aff" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7d8c-9fff-c58121526aff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7726-899a-d603d0f78a68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7d8c-9fff-c58121526aff" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7726-899a-d603d0f78a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7e7d-8ab0-4aa05b7e64b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7726-899a-d603d0f78a68" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7e7d-8ab0-4aa05b7e64b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16d-79c6-a169-c1788ea13213" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16d-79c6-a169-c1788ea13213" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-79c6-a169-c1788ea13213_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16d-79c6-a169-c1788ea13213" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-79c6-a169-c1788ea13213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16d-79c6-a169-c1788ea13213" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_019c9afa-c16d-76d8-8821-055a7f75b07f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_019c9afa-c16d-76d8-8821-055a7f75b07f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputEquityPriceVolatilityMember_019c9afa-c16d-71d3-97df-12c8c9396f25" xlink:href="ci-20260331.xsd#ci_MeasurementInputEquityPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:to="loc_ci_MeasurementInputEquityPriceVolatilityMember_019c9afa-c16d-71d3-97df-12c8c9396f25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputInterVariableCorrelationAssumptionMember_019c9afa-c16d-7746-ab39-fbfecab89ca7" xlink:href="ci-20260331.xsd#ci_MeasurementInputInterVariableCorrelationAssumptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:to="loc_ci_MeasurementInputInterVariableCorrelationAssumptionMember_019c9afa-c16d-7746-ab39-fbfecab89ca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputEntityCreditRiskMember_019c9afa-c16d-7db9-923c-8cfb312b64c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputEntityCreditRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:to="loc_us-gaap_MeasurementInputEntityCreditRiskMember_019c9afa-c16d-7db9-923c-8cfb312b64c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019c9afa-c16d-71cb-823e-a1f333233356" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019c9afa-c16d-71cb-823e-a1f333233356" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_019c9afa-c16d-7825-8f60-9929e1b7c5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetLiabilityNetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16d-7ae3-99f8-7e55373d1ddf" xlink:to="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_019c9afa-c16d-7825-8f60-9929e1b7c5eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsSeparateAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16d-7d11-bd11-94ea1f1799f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16d-7d11-bd11-94ea1f1799f4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7bbd-8133-8efa298bc608" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7bbd-8133-8efa298bc608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7bbd-8133-8efa298bc608_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7bbd-8133-8efa298bc608" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7bbd-8133-8efa298bc608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7912-a6ab-6b47eebd46ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7bbd-8133-8efa298bc608" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7912-a6ab-6b47eebd46ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c16d-73cb-a368-6f2600936ada" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7912-a6ab-6b47eebd46ac" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c16d-73cb-a368-6f2600936ada" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019c9afa-c16d-7748-bd02-41be8ab280a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c16d-73cb-a368-6f2600936ada" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019c9afa-c16d-7748-bd02-41be8ab280a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16d-71fe-a4f4-062c0be9010f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c16d-73cb-a368-6f2600936ada" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16d-71fe-a4f4-062c0be9010f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7740-98bf-798efda37c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c16d-73cb-a368-6f2600936ada" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7740-98bf-798efda37c7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_019c9afa-c16d-71b5-bb30-7e5b5dad9382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7912-a6ab-6b47eebd46ac" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_019c9afa-c16d-71b5-bb30-7e5b5dad9382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_019c9afa-c16d-782d-a8d1-e445e5dd02d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_019c9afa-c16d-782d-a8d1-e445e5dd02d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_019c9afa-c16d-782d-a8d1-e445e5dd02d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_019c9afa-c16d-782d-a8d1-e445e5dd02d7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_019c9afa-c16d-782d-a8d1-e445e5dd02d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_019c9afa-c16d-7060-b92e-ad0361faafa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_019c9afa-c16d-782d-a8d1-e445e5dd02d7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_019c9afa-c16d-7060-b92e-ad0361faafa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_019c9afa-c16d-710b-98bd-0a7ee18b1149" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_019c9afa-c16d-7060-b92e-ad0361faafa7" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_019c9afa-c16d-710b-98bd-0a7ee18b1149" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryAxis_019c9afa-c16d-7746-a7b2-fef8ea42d6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountAssetCategoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryAxis_019c9afa-c16d-7746-a7b2-fef8ea42d6ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c16d-7746-a7b2-fef8ea42d6ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis_019c9afa-c16d-7746-a7b2-fef8ea42d6ae" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c16d-7746-a7b2-fef8ea42d6ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c16d-74df-9814-87687fd34af4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis_019c9afa-c16d-7746-a7b2-fef8ea42d6ae" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c16d-74df-9814-87687fd34af4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountGuaranteedSeparateAccountsMember_019c9afa-c16d-743b-a80f-c4dff0710768" xlink:href="ci-20260331.xsd#ci_SeparateAccountGuaranteedSeparateAccountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c16d-74df-9814-87687fd34af4" xlink:to="loc_ci_SeparateAccountGuaranteedSeparateAccountsMember_019c9afa-c16d-743b-a80f-c4dff0710768" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountNonGuaranteedSeparateAccountsMember_019c9afa-c16d-7eaf-9c98-6fc1490fbe3d" xlink:href="ci-20260331.xsd#ci_SeparateAccountNonGuaranteedSeparateAccountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c16d-74df-9814-87687fd34af4" xlink:to="loc_ci_SeparateAccountNonGuaranteedSeparateAccountsMember_019c9afa-c16d-7eaf-9c98-6fc1490fbe3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_019c9afa-c16d-73a6-8e76-378e0af8da2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_019c9afa-c16d-73a6-8e76-378e0af8da2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_019c9afa-c16d-73a6-8e76-378e0af8da2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_019c9afa-c16d-73a6-8e76-378e0af8da2b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_019c9afa-c16d-73a6-8e76-378e0af8da2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_019c9afa-c16d-7e68-bac8-aa2b8c3a818b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_019c9afa-c16d-73a6-8e76-378e0af8da2b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_019c9afa-c16d-7e68-bac8-aa2b8c3a818b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsMember_019c9afa-c16d-79e1-bb40-6dfa644d5a24" xlink:href="ci-20260331.xsd#ci_SeparateAccountAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_019c9afa-c16d-7e68-bac8-aa2b8c3a818b" xlink:to="loc_ci_SeparateAccountAssetsMember_019c9afa-c16d-79e1-bb40-6dfa644d5a24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_019c9afa-c16d-776f-8d2d-d85c7dcf5761" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16d-7d11-bd11-94ea1f1799f4" xlink:to="loc_us-gaap_SeparateAccountAssets_019c9afa-c16d-776f-8d2d-d85c7dcf5761" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_019c9afa-c16d-7864-8f4f-ed66657badae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16d-7d11-bd11-94ea1f1799f4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_019c9afa-c16d-7864-8f4f-ed66657badae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7318-8090-4774c2946705" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7318-8090-4774c2946705" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16d-745c-bb80-449343c32bdc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7318-8090-4774c2946705" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16d-745c-bb80-449343c32bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16d-745c-bb80-449343c32bdc_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16d-745c-bb80-449343c32bdc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16d-745c-bb80-449343c32bdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16d-77a9-bcfa-28ce5d0aab5c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16d-745c-bb80-449343c32bdc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16d-77a9-bcfa-28ce5d0aab5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_VillageMDMember_019c9afa-c16d-711e-9178-42d92ca599c6" xlink:href="ci-20260331.xsd#ci_VillageMDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16d-77a9-bcfa-28ce5d0aab5c" xlink:to="loc_ci_VillageMDMember_019c9afa-c16d-711e-9178-42d92ca599c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_019c9afa-c16d-7f00-9346-985916049078" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_019c9afa-c16d-7f00-9346-985916049078" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue_019c9afa-c16d-717d-b82f-1bc300dcd859" xlink:href="ci-20260331.xsd#ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:to="loc_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue_019c9afa-c16d-717d-b82f-1bc300dcd859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_019c9afa-c16d-7aa5-be16-5f8401c3a8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_019c9afa-c16d-7aa5-be16-5f8401c3a8a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_019c9afa-c16d-7489-b989-63e2d1a93a61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_019c9afa-c16d-7489-b989-63e2d1a93a61" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7619-bd7c-61b9354a53f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7a4c-b271-4ad7f122315d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7619-bd7c-61b9354a53f9" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7a4c-b271-4ad7f122315d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_019c9afa-c16d-7f12-b015-ce73bdc08203" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7a4c-b271-4ad7f122315d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_019c9afa-c16d-7f12-b015-ce73bdc08203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c16d-7f12-b015-ce73bdc08203_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_019c9afa-c16d-7f12-b015-ce73bdc08203" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c16d-7f12-b015-ce73bdc08203_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019c9afa-c16d-78a9-94f9-e100bbf35349" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_019c9afa-c16d-7f12-b015-ce73bdc08203" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019c9afa-c16d-78a9-94f9-e100bbf35349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c16d-727d-9e77-7a0344020dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019c9afa-c16d-78a9-94f9-e100bbf35349" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c16d-727d-9e77-7a0344020dd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019c9afa-c16d-79a2-8752-0299d1db443f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c16d-727d-9e77-7a0344020dd0" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019c9afa-c16d-79a2-8752-0299d1db443f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_019c9afa-c16d-7587-9f42-5e49b4cf27e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c16d-727d-9e77-7a0344020dd0" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_019c9afa-c16d-7587-9f42-5e49b4cf27e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7e49-be1c-43a8059416df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7a4c-b271-4ad7f122315d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7e49-be1c-43a8059416df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7e49-be1c-43a8059416df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7e49-be1c-43a8059416df" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7e49-be1c-43a8059416df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7ef0-a68c-9009293a7e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7e49-be1c-43a8059416df" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7ef0-a68c-9009293a7e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16d-75fe-b96d-b7e679b72513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7ef0-a68c-9009293a7e3a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16d-75fe-b96d-b7e679b72513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7a09-9294-27b7d823d3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7ef0-a68c-9009293a7e3a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7a09-9294-27b7d823d3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_019c9afa-c16d-75b1-9ab1-d791cda83b28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7619-bd7c-61b9354a53f9" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_019c9afa-c16d-75b1-9ab1-d791cda83b28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_019c9afa-c16d-7f46-8835-603c549baf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7619-bd7c-61b9354a53f9" xlink:to="loc_us-gaap_LongTermDebtFairValue_019c9afa-c16d-7f46-8835-603c549baf5b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019c9afa-c22b-7fd4-afc2-46e1dbb8352f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019c9afa-c22b-7e6e-a43a-f5c069c5a78c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019c9afa-c22b-7fd4-afc2-46e1dbb8352f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019c9afa-c22b-7e6e-a43a-f5c069c5a78c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-c22b-7f68-b294-fcecd583166c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019c9afa-c22b-7e6e-a43a-f5c069c5a78c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-c22b-7f68-b294-fcecd583166c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019c9afa-c22b-7f68-b294-fcecd583166c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-c22b-7f68-b294-fcecd583166c" xlink:to="loc_us-gaap_EquityComponentDomain_019c9afa-c22b-7f68-b294-fcecd583166c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019c9afa-c22b-7fc4-a543-75fc2d18da59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-c22b-7f68-b294-fcecd583166c" xlink:to="loc_us-gaap_EquityComponentDomain_019c9afa-c22b-7fc4-a543-75fc2d18da59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019c9afa-c22b-7fc4-a543-75fc2d18da59" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_019c9afa-c22b-7fd1-8625-47df33e51da4" xlink:href="ci-20260331.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:to="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_019c9afa-c22b-7fd1-8625-47df33e51da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7a9a-a909-fec42bacea3e" xlink:href="ci-20260331.xsd#ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:to="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7a9a-a909-fec42bacea3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_019c9afa-c22b-75b9-a57e-cfa2c0dacb63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7a9a-a909-fec42bacea3e" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_019c9afa-c22b-75b9-a57e-cfa2c0dacb63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7ac6-bd0d-e8a504596e00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7a9a-a909-fec42bacea3e" xlink:to="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7ac6-bd0d-e8a504596e00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_019c9afa-c22b-70ca-865e-05913abe83e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_019c9afa-c22b-70ca-865e-05913abe83e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_019c9afa-c22b-72b6-b755-c115a7eeaff9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_019c9afa-c22b-72b6-b755-c115a7eeaff9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c22b-7ed8-af59-9f14a3a78f30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019c9afa-c22b-7fd4-afc2-46e1dbb8352f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c22b-7ed8-af59-9f14a3a78f30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_019c9afa-c22b-70d4-b0e1-8c0bc8fc3bde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c22b-7ed8-af59-9f14a3a78f30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_019c9afa-c22b-70d4-b0e1-8c0bc8fc3bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_019c9afa-c22b-7107-b666-5cb9ebd64f84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c22b-7ed8-af59-9f14a3a78f30" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_019c9afa-c22b-7107-b666-5cb9ebd64f84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_019c9afa-c22b-7876-bce3-c14d25053315" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c22b-7ed8-af59-9f14a3a78f30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_019c9afa-c22b-7876-bce3-c14d25053315" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019c9afa-c22b-7fd4-afc2-46e1dbb8352f" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c22b-7b51-bdf7-729682528df9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c22b-7b51-bdf7-729682528df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_019c9afa-c22b-765d-831b-81218ca12554" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_019c9afa-c22b-765d-831b-81218ca12554" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_019c9afa-c22b-7864-ab62-535338bfb7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_019c9afa-c22b-7864-ab62-535338bfb7f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-c22b-70b6-a9ea-a733450b157a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-c22b-70b6-a9ea-a733450b157a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c22b-74c1-a837-c0d452dba039" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#StrategicOptimizationProgramDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c22b-7ff1-a184-d7c9c8ed70bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c22b-7682-90ee-beda48cc5521" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c22b-7ff1-a184-d7c9c8ed70bf" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c22b-7682-90ee-beda48cc5521" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_019c9afa-c22b-7047-988f-c21c05c5ffe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c22b-7682-90ee-beda48cc5521" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_019c9afa-c22b-7047-988f-c21c05c5ffe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_019c9afa-c22b-7047-988f-c21c05c5ffe1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_019c9afa-c22b-7047-988f-c21c05c5ffe1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_019c9afa-c22b-7047-988f-c21c05c5ffe1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_019c9afa-c22b-78f2-a7aa-e3d82e033761" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_019c9afa-c22b-7047-988f-c21c05c5ffe1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_019c9afa-c22b-78f2-a7aa-e3d82e033761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c22b-773a-9eeb-10a35298dc68" xlink:href="ci-20260331.xsd#ci_EmployeeSeveranceAndOtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_019c9afa-c22b-78f2-a7aa-e3d82e033761" xlink:to="loc_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c22b-773a-9eeb-10a35298dc68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_019c9afa-c22b-73b9-be76-3ceecb53233d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c22b-773a-9eeb-10a35298dc68" xlink:to="loc_us-gaap_EmployeeSeveranceMember_019c9afa-c22b-73b9-be76-3ceecb53233d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetImpairmentsMember_019c9afa-c22b-768d-9922-f777da80082c" xlink:href="ci-20260331.xsd#ci_AssetImpairmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c22b-773a-9eeb-10a35298dc68" xlink:to="loc_ci_AssetImpairmentsMember_019c9afa-c22b-768d-9922-f777da80082c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_019c9afa-c22b-7b53-97fc-ffa6c4127c43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c22b-773a-9eeb-10a35298dc68" xlink:to="loc_us-gaap_OtherRestructuringMember_019c9afa-c22b-7b53-97fc-ffa6c4127c43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingResultsOfCertainNonstrategicBusinessesMember_019c9afa-c22b-7b62-a390-bdd74783e35a" xlink:href="ci-20260331.xsd#ci_OperatingResultsOfCertainNonstrategicBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_019c9afa-c22b-78f2-a7aa-e3d82e033761" xlink:to="loc_ci_OperatingResultsOfCertainNonstrategicBusinessesMember_019c9afa-c22b-7b62-a390-bdd74783e35a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_019c9afa-c22b-7fac-aeff-41754864bf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c22b-7682-90ee-beda48cc5521" xlink:to="loc_us-gaap_RestructuringPlanAxis_019c9afa-c22b-7fac-aeff-41754864bf7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c9afa-c22b-7fac-aeff-41754864bf7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c9afa-c22b-7fac-aeff-41754864bf7a" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c9afa-c22b-7fac-aeff-41754864bf7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c9afa-c22b-74b6-9260-d5524762fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c9afa-c22b-7fac-aeff-41754864bf7a" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c9afa-c22b-74b6-9260-d5524762fc9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StrategicOptimizationProgramMember_019c9afa-c22b-7b7f-b885-d102266d22db" xlink:href="ci-20260331.xsd#ci_StrategicOptimizationProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c9afa-c22b-74b6-9260-d5524762fc9d" xlink:to="loc_ci_StrategicOptimizationProgramMember_019c9afa-c22b-7b7f-b885-d102266d22db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c22b-7ff1-a184-d7c9c8ed70bf" xlink:to="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019c9afa-c22b-7078-8339-1aafe58f03b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:to="loc_us-gaap_RestructuringReserve_019c9afa-c22b-7078-8339-1aafe58f03b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c9afa-c22b-7eb1-b67e-020f4bf2604c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:to="loc_us-gaap_RestructuringCharges_019c9afa-c22b-7eb1-b67e-020f4bf2604c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_019c9afa-c22b-75a5-917e-7695813b4112" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:to="loc_us-gaap_PaymentsForRestructuring_019c9afa-c22b-75a5-917e-7695813b4112" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019c9afa-c22b-7af8-9782-a991743c101e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c22b-71ea-bbc4-7653b506cd35" xlink:href="ci-20260331.xsd#ci_RestructuringChargesNetOfTaxExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c22b-7ff1-a184-d7c9c8ed70bf" xlink:to="loc_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c22b-71ea-bbc4-7653b506cd35" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#ContingenciesandOtherMattersDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:href="ci-20260331.xsd#ci_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:href="ci-20260331.xsd#ci_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-7ec0-96cd-87b39060afc8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-7ec0-96cd-87b39060afc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-7ec0-96cd-87b39060afc8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-7ec0-96cd-87b39060afc8" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-7ec0-96cd-87b39060afc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-7c60-9097-1c22f6fb615c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-7ec0-96cd-87b39060afc8" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-7c60-9097-1c22f6fb615c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RetirementAndLifeInsuranceContractsMember_019c9afa-c2d7-7aef-84e1-dcc658750269" xlink:href="ci-20260331.xsd#ci_RetirementAndLifeInsuranceContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-7c60-9097-1c22f6fb615c" xlink:to="loc_ci_RetirementAndLifeInsuranceContractsMember_019c9afa-c2d7-7aef-84e1-dcc658750269" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_019c9afa-c2d7-74f1-9700-ba1a72e6f980" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_019c9afa-c2d7-74f1-9700-ba1a72e6f980" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c2d7-74f1-9700-ba1a72e6f980_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_019c9afa-c2d7-74f1-9700-ba1a72e6f980" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c2d7-74f1-9700-ba1a72e6f980_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c2d7-724e-b63c-b682ababe2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_019c9afa-c2d7-74f1-9700-ba1a72e6f980" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c2d7-724e-b63c-b682ababe2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeMember_019c9afa-c2d7-76dc-a5cc-183ea95be5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c2d7-724e-b63c-b682ababe2a7" xlink:to="loc_us-gaap_FinancialGuaranteeMember_019c9afa-c2d7-76dc-a5cc-183ea95be5ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_019c9afa-c2d7-73a1-a176-b128779aa624" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c2d7-724e-b63c-b682ababe2a7" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_019c9afa-c2d7-73a1-a176-b128779aa624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7524-ab3b-7c31376f3384" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7524-ab3b-7c31376f3384" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-7524-ab3b-7c31376f3384_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7524-ab3b-7c31376f3384" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-7524-ab3b-7c31376f3384_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-78eb-9be0-b516f15d95d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7524-ab3b-7c31376f3384" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-78eb-9be0-b516f15d95d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRelatedAssessmentsMember_019c9afa-c2d7-70ab-8120-d57b0ede1e66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceRelatedAssessmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-78eb-9be0-b516f15d95d8" xlink:to="loc_us-gaap_InsuranceRelatedAssessmentsMember_019c9afa-c2d7-70ab-8120-d57b0ede1e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LitigationMattersAndRegulatoryMattersMember_019c9afa-c2d7-73e8-8957-c1da35f36c21" xlink:href="ci-20260331.xsd#ci_LitigationMattersAndRegulatoryMattersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-78eb-9be0-b516f15d95d8" xlink:to="loc_ci_LitigationMattersAndRegulatoryMattersMember_019c9afa-c2d7-73e8-8957-c1da35f36c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_019c9afa-c2d7-7baa-ab16-fbd38a1575fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_019c9afa-c2d7-7baa-ab16-fbd38a1575fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLiquidationProceeds_019c9afa-c2d7-7603-8785-1fee90fe7d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsLiquidationProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_us-gaap_GuaranteeObligationsLiquidationProceeds_019c9afa-c2d7-7603-8785-1fee90fe7d8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_019c9afa-c2d7-7db6-a85d-5da7e5d36d15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_019c9afa-c2d7-7db6-a85d-5da7e5d36d15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_019c9afa-c2d7-7e42-9bcf-74df88ffeb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_019c9afa-c2d7-7e42-9bcf-74df88ffeb4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c9afa-c2d7-7d0c-bcc8-ef4b4f216127" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c9afa-c2d7-7d0c-bcc8-ef4b4f216127" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationSpecialItemChargesBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c2d7-7431-8a40-52fb2d69cecb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c2d7-7203-9dcd-b497a7fbdbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c2d7-7431-8a40-52fb2d69cecb" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c2d7-7203-9dcd-b497a7fbdbd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-71cc-b2b0-121d517e2b26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c2d7-7203-9dcd-b497a7fbdbd0" xlink:to="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-71cc-b2b0-121d517e2b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-71cc-b2b0-121d517e2b26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-71cc-b2b0-121d517e2b26" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-71cc-b2b0-121d517e2b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-7cc5-b914-b43f2a01821d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-71cc-b2b0-121d517e2b26" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-7cc5-b914-b43f2a01821d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StrategicOptimizationProgramMember_019c9afa-c2d7-7d7e-8103-6043b7f6e581" xlink:href="ci-20260331.xsd#ci_StrategicOptimizationProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-7cc5-b914-b43f2a01821d" xlink:to="loc_ci_StrategicOptimizationProgramMember_019c9afa-c2d7-7d7e-8103-6043b7f6e581" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanMember_019c9afa-c2d7-796b-a274-5f7644fadbd8" xlink:href="ci-20260331.xsd#ci_OrganizationalEfficiencyPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-7cc5-b914-b43f2a01821d" xlink:to="loc_ci_OrganizationalEfficiencyPlanMember_019c9afa-c2d7-796b-a274-5f7644fadbd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:href="ci-20260331.xsd#ci_SpecialItemsBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c2d7-7431-8a40-52fb2d69cecb" xlink:to="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-7c28-b63b-b5af2e62da95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-7c28-b63b-b5af2e62da95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-71fa-917b-87a34e9b2fa9" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-71fa-917b-87a34e9b2fa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c2d7-779b-ab70-a37aae98aeea" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitTaxMatters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c2d7-779b-ab70-a37aae98aeea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7145-8fb6-652caedddd0f" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7145-8fb6-652caedddd0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-7da2-af43-a71b06d84da3" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-7da2-af43-a71b06d84da3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7647-8256-9f966cdb5a70" xlink:href="ci-20260331.xsd#ci_SpecialItemsIncreaseDecreaseToRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7647-8256-9f966cdb5a70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-7f2c-8097-3685237ab577" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-7f2c-8097-3685237ab577" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c2d7-7df8-a554-97694996623e" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c2d7-7df8-a554-97694996623e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-75ff-9550-021135450cc4" xlink:href="ci-20260331.xsd#ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-75ff-9550-021135450cc4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:href="ci-20260331.xsd#ci_SpecialItemsAfterTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c2d7-7431-8a40-52fb2d69cecb" xlink:to="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c2d7-7e7b-b98c-f98350c70487" xlink:href="ci-20260331.xsd#ci_RestructuringChargesNetOfTaxExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c2d7-7e7b-b98c-f98350c70487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCostsAfterTax_019c9afa-c2d7-789d-8827-816d2acc1d7e" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCostsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_TransactionRelatedCostsAfterTax_019c9afa-c2d7-789d-8827-816d2acc1d7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax_019c9afa-c2d7-774e-94c7-131224f70a04" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitTaxMattersAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax_019c9afa-c2d7-774e-94c7-131224f70a04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_019c9afa-c2d7-77e0-afae-444ca7a7e5f1" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_019c9afa-c2d7-77e0-afae-444ca7a7e5f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation_019c9afa-c2d7-701b-a5d4-6b0c63f287cb" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitAfterTaxLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation_019c9afa-c2d7-701b-a5d4-6b0c63f287cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax_019c9afa-c2d7-7012-8657-d874c67595f8" xlink:href="ci-20260331.xsd#ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax_019c9afa-c2d7-7012-8657-d874c67595f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_019c9afa-c2d7-7f7e-bca7-e33322b37a75" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_019c9afa-c2d7-7f7e-bca7-e33322b37a75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_019c9afa-c2d7-7987-aec6-b28e6cf72b6c" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_019c9afa-c2d7-7987-aec6-b28e6cf72b6c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-761f-a700-9762fe856e02" xlink:href="ci-20260331.xsd#ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-761f-a700-9762fe856e02" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationSummarizedSegmentFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-7c20-b018-850cd9e88ca8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:to="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-7c20-b018-850cd9e88ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7c20-b018-850cd9e88ca8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-7c20-b018-850cd9e88ca8" xlink:to="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7c20-b018-850cd9e88ca8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7481-969c-bafe72ae0cb5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-7c20-b018-850cd9e88ca8" xlink:to="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7481-969c-bafe72ae0cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_019c9afa-c2d7-7332-9162-e62cfacbe133" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7481-969c-bafe72ae0cb5" xlink:to="loc_us-gaap_OperatingSegmentsMember_019c9afa-c2d7-7332-9162-e62cfacbe133" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-7f16-b731-d2b25d4c3c43" xlink:href="ci-20260331.xsd#ci_CorporateAndEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7481-969c-bafe72ae0cb5" xlink:to="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-7f16-b731-d2b25d4c3c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_019c9afa-c2d7-7983-85b2-5c242828a2df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-7f16-b731-d2b25d4c3c43" xlink:to="loc_us-gaap_CorporateNonSegmentMember_019c9afa-c2d7-7983-85b2-5c242828a2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_019c9afa-c2d7-75d4-8ae4-8b7e94dac30a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-7f16-b731-d2b25d4c3c43" xlink:to="loc_us-gaap_IntersegmentEliminationMember_019c9afa-c2d7-75d4-8ae4-8b7e94dac30a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7d45-8168-6cdcc795c618" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7d45-8168-6cdcc795c618" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7d45-8168-6cdcc795c618_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7d45-8168-6cdcc795c618" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7d45-8168-6cdcc795c618_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c2d7-796d-a5c2-b636953d96d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7d45-8168-6cdcc795c618" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c2d7-796d-a5c2-b636953d96d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_019c9afa-c2d7-7f07-8744-59e1b989cb07" xlink:href="ci-20260331.xsd#ci_EvernorthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-796d-a5c2-b636953d96d3" xlink:to="loc_ci_EvernorthMember_019c9afa-c2d7-7f07-8744-59e1b989cb07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c2d7-7e29-82c5-3e0e3760975a" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-796d-a5c2-b636953d96d3" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c2d7-7e29-82c5-3e0e3760975a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c2d7-7e07-aae0-40441240d2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-796d-a5c2-b636953d96d3" xlink:to="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c2d7-7e07-aae0-40441240d2ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-78b2-8f13-f028b7148c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:to="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-78b2-8f13-f028b7148c8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-78b2-8f13-f028b7148c8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-78b2-8f13-f028b7148c8d" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-78b2-8f13-f028b7148c8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-73b0-afe7-1dac786a2f43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-78b2-8f13-f028b7148c8d" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-73b0-afe7-1dac786a2f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StrategicOptimizationProgramMember_019c9afa-c2d7-70cc-9c51-7efd1aa4e6ab" xlink:href="ci-20260331.xsd#ci_StrategicOptimizationProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-73b0-afe7-1dac786a2f43" xlink:to="loc_ci_StrategicOptimizationProgramMember_019c9afa-c2d7-70cc-9c51-7efd1aa4e6ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanMember_019c9afa-c2d7-7a24-8bd6-3c38a476cace" xlink:href="ci-20260331.xsd#ci_OrganizationalEfficiencyPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-73b0-afe7-1dac786a2f43" xlink:to="loc_ci_OrganizationalEfficiencyPlanMember_019c9afa-c2d7-7a24-8bd6-3c38a476cace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-7168-b71d-8ebf9707de6b" xlink:href="ci-20260331.xsd#ci_NonInvestmentRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-7168-b71d-8ebf9707de6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_019c9afa-c2d7-7571-8aac-a3977bc4b526" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_NetInvestmentIncome_019c9afa-c2d7-7571-8aac-a3977bc4b526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019c9afa-c2d7-76a2-a2b3-fda7f331e746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_Revenues_019c9afa-c2d7-76a2-a2b3-fda7f331e746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainsLossesEquityMethodInvestments_019c9afa-c2d7-7030-b551-a86abbfcaea9" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainsLossesEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_NetInvestmentGainsLossesEquityMethodInvestments_019c9afa-c2d7-7030-b551-a86abbfcaea9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7ddc-93ed-29a8f3ca2927" xlink:href="ci-20260331.xsd#ci_SpecialItemsIncreaseDecreaseToRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7ddc-93ed-29a8f3ca2927" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SegmentRevenues_019c9afa-c2d7-7246-bf84-8b94f24f56be" xlink:href="ci-20260331.xsd#ci_SegmentRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_SegmentRevenues_019c9afa-c2d7-7246-bf84-8b94f24f56be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-c2d7-78db-acab-1b3366791e97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-c2d7-78db-acab-1b3366791e97" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-c2d7-7b94-b8ed-04fbb1ae5b23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-c2d7-7b94-b8ed-04fbb1ae5b23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric_019c9afa-c2d7-7f94-83cf-420d9757d967" xlink:href="ci-20260331.xsd#ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric_019c9afa-c2d7-7f94-83cf-420d9757d967" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-c2d7-7bb4-acc1-69f4116b0099" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-c2d7-7bb4-acc1-69f4116b0099" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax_019c9afa-c2d7-7785-bdf9-ffe9edd509ae" xlink:href="ci-20260331.xsd#ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax_019c9afa-c2d7-7785-bdf9-ffe9edd509ae" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7b0d-9c6d-fab12180aff9" xlink:href="ci-20260331.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7b0d-9c6d-fab12180aff9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7209-91c6-688c1ab6c044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7209-91c6-688c1ab6c044" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:href="ci-20260331.xsd#ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_019c9afa-c2d7-74d3-90e7-09cef4501354" xlink:href="ci-20260331.xsd#ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:to="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_019c9afa-c2d7-74d3-90e7-09cef4501354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries_019c9afa-c2d7-7125-8357-0fa472f5cc94" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:to="loc_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries_019c9afa-c2d7-7125-8357-0fa472f5cc94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-c2d7-7966-8ef9-44c6cab452db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-c2d7-7966-8ef9-44c6cab452db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:href="ci-20260331.xsd#ci_SpecialItemsBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:to="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-7499-ab28-8f11fc1b8eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-7499-ab28-8f11fc1b8eb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-7044-b18f-d9a6e731f82b" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-7044-b18f-d9a6e731f82b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-732a-a704-f6523cef3e3a" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-732a-a704-f6523cef3e3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7b4c-879f-211846d53fb1" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7b4c-879f-211846d53fb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c2d7-71be-a50f-0fcd0ac9e6ac" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitTaxMatters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c2d7-71be-a50f-0fcd0ac9e6ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7ed3-baa9-51018a3454b8" xlink:href="ci-20260331.xsd#ci_SpecialItemsIncreaseDecreaseToRevenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-7544-bca8-1c0aee257a68" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-7544-bca8-1c0aee257a68" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c2d7-7b4d-a2bb-902678a7b93e" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c2d7-7b4d-a2bb-902678a7b93e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-71d1-94e5-8ccf9ad900e4" xlink:href="ci-20260331.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019c9afa-c2d7-7ea8-a147-b35642d9d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019c9afa-c2d7-7ea8-a147-b35642d9d6c6" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationRevenuefromExternalCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c2d7-78cf-8e2e-5f58968d41df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c2d7-78cf-8e2e-5f58968d41df" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-748b-8ef3-925db73be66b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:to="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-748b-8ef3-925db73be66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-748b-8ef3-925db73be66b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-748b-8ef3-925db73be66b" xlink:to="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-748b-8ef3-925db73be66b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7ec0-a906-56fce355346e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-748b-8ef3-925db73be66b" xlink:to="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7ec0-a906-56fce355346e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_019c9afa-c2d7-75ff-95db-6d6b6c5200c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7ec0-a906-56fce355346e" xlink:to="loc_us-gaap_OperatingSegmentsMember_019c9afa-c2d7-75ff-95db-6d6b6c5200c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-78ee-b176-043ec95d7daf" xlink:href="ci-20260331.xsd#ci_CorporateAndEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7ec0-a906-56fce355346e" xlink:to="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-78ee-b176-043ec95d7daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_019c9afa-c2d7-7687-b134-1b4c984df516" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-78ee-b176-043ec95d7daf" xlink:to="loc_us-gaap_CorporateNonSegmentMember_019c9afa-c2d7-7687-b134-1b4c984df516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_019c9afa-c2d7-70f3-b503-43a3697374b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-78ee-b176-043ec95d7daf" xlink:to="loc_us-gaap_IntersegmentEliminationMember_019c9afa-c2d7-70f3-b503-43a3697374b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7333-9804-dc52d78fd08a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7333-9804-dc52d78fd08a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7333-9804-dc52d78fd08a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7333-9804-dc52d78fd08a" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7333-9804-dc52d78fd08a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7eaa-8215-6c9656a1776c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7333-9804-dc52d78fd08a" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7eaa-8215-6c9656a1776c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_019c9afa-c2d7-7a40-baa2-212d94ab3922" xlink:href="ci-20260331.xsd#ci_EvernorthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7eaa-8215-6c9656a1776c" xlink:to="loc_ci_EvernorthMember_019c9afa-c2d7-7a40-baa2-212d94ab3922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c2d7-79d1-831b-946e3c56f3b0" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7eaa-8215-6c9656a1776c" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c2d7-79d1-831b-946e3c56f3b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c2d7-7989-931d-a541cd4a66a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7eaa-8215-6c9656a1776c" xlink:to="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c2d7-7989-931d-a541cd4a66a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_019c9afa-c2d7-7ab0-bae8-0373eb4009bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:to="loc_us-gaap_SubsegmentsAxis_019c9afa-c2d7-7ab0-bae8-0373eb4009bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_019c9afa-c2d7-7ab0-bae8-0373eb4009bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_019c9afa-c2d7-7ab0-bae8-0373eb4009bd" xlink:to="loc_us-gaap_SubsegmentsDomain_019c9afa-c2d7-7ab0-bae8-0373eb4009bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_019c9afa-c2d7-7406-88d5-15ad0b4bea55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_019c9afa-c2d7-7ab0-bae8-0373eb4009bd" xlink:to="loc_us-gaap_SubsegmentsDomain_019c9afa-c2d7-7406-88d5-15ad0b4bea55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnitedStatesHealthcareMember_019c9afa-c2d7-75bc-aae7-fc466244a1e6" xlink:href="ci-20260331.xsd#ci_UnitedStatesHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_019c9afa-c2d7-7406-88d5-15ad0b4bea55" xlink:to="loc_ci_UnitedStatesHealthcareMember_019c9afa-c2d7-75bc-aae7-fc466244a1e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalHealthMember_019c9afa-c2d7-7875-bb79-e334b1e1ed5c" xlink:href="ci-20260331.xsd#ci_InternationalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_019c9afa-c2d7-7406-88d5-15ad0b4bea55" xlink:to="loc_ci_InternationalHealthMember_019c9afa-c2d7-7875-bb79-e334b1e1ed5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-797c-a478-6af969c76ebe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-797c-a478-6af969c76ebe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-797c-a478-6af969c76ebe_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-797c-a478-6af969c76ebe" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-797c-a478-6af969c76ebe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-79c8-8604-527add133736" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-797c-a478-6af969c76ebe" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-79c8-8604-527add133736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019c9afa-c2d7-777e-8ee6-66a75d77c3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-79c8-8604-527add133736" xlink:to="loc_us-gaap_ProductMember_019c9afa-c2d7-777e-8ee6-66a75d77c3ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetworkPharmacyMember_019c9afa-c2d7-79fa-a9d5-cd8fac828a24" xlink:href="ci-20260331.xsd#ci_NetworkPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_019c9afa-c2d7-777e-8ee6-66a75d77c3ff" xlink:to="loc_ci_NetworkPharmacyMember_019c9afa-c2d7-79fa-a9d5-cd8fac828a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HomeDeliveryAndSpecialtyMember_019c9afa-c2d7-7cb5-9269-d98ef58e1f25" xlink:href="ci-20260331.xsd#ci_HomeDeliveryAndSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_019c9afa-c2d7-777e-8ee6-66a75d77c3ff" xlink:to="loc_ci_HomeDeliveryAndSpecialtyMember_019c9afa-c2d7-7cb5-9269-d98ef58e1f25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherPharmacyMember_019c9afa-c2d7-77b2-8b0e-2daaceb22e39" xlink:href="ci-20260331.xsd#ci_OtherPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_019c9afa-c2d7-777e-8ee6-66a75d77c3ff" xlink:to="loc_ci_OtherPharmacyMember_019c9afa-c2d7-77b2-8b0e-2daaceb22e39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-79c8-8604-527add133736" xlink:to="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmployerInsuredMember_019c9afa-c2d7-7df8-918e-c967c87255c5" xlink:href="ci-20260331.xsd#ci_EmployerInsuredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:to="loc_ci_EmployerInsuredMember_019c9afa-c2d7-7df8-918e-c967c87255c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageMember_019c9afa-c2d7-7a72-a5d4-9ef9b9ca567d" xlink:href="ci-20260331.xsd#ci_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:to="loc_ci_MedicareAdvantageMember_019c9afa-c2d7-7a72-a5d4-9ef9b9ca567d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StopLossMember_019c9afa-c2d7-7fb3-86ab-73f25c2db972" xlink:href="ci-20260331.xsd#ci_StopLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:to="loc_ci_StopLossMember_019c9afa-c2d7-7fb3-86ab-73f25c2db972" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndividualAndFamilyPlansMember_019c9afa-c2d7-79e0-b254-6d7718381d96" xlink:href="ci-20260331.xsd#ci_IndividualAndFamilyPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:to="loc_ci_IndividualAndFamilyPlansMember_019c9afa-c2d7-79e0-b254-6d7718381d96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherHealthcareMember_019c9afa-c2d7-71ce-be03-3628ccdcd6e3" xlink:href="ci-20260331.xsd#ci_OtherHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:to="loc_ci_OtherHealthcareMember_019c9afa-c2d7-71ce-be03-3628ccdcd6e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_019c9afa-c2d7-7353-979a-3005e2490689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-79c8-8604-527add133736" xlink:to="loc_us-gaap_ServiceMember_019c9afa-c2d7-7353-979a-3005e2490689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ServiceFeesAndOtherRevenuesMember_019c9afa-c2d7-779e-babc-d5497da800e1" xlink:href="ci-20260331.xsd#ci_ServiceFeesAndOtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_019c9afa-c2d7-7353-979a-3005e2490689" xlink:to="loc_ci_ServiceFeesAndOtherRevenuesMember_019c9afa-c2d7-779e-babc-d5497da800e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ServiceFeesMember_019c9afa-c2d7-7238-a8ff-19ea7a24ea5d" xlink:href="ci-20260331.xsd#ci_ServiceFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ServiceFeesAndOtherRevenuesMember_019c9afa-c2d7-779e-babc-d5497da800e1" xlink:to="loc_ci_ServiceFeesMember_019c9afa-c2d7-7238-a8ff-19ea7a24ea5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_019c9afa-c2d7-7c5b-8d58-c6b107fc3ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ServiceFeesAndOtherRevenuesMember_019c9afa-c2d7-779e-babc-d5497da800e1" xlink:to="loc_us-gaap_ServiceOtherMember_019c9afa-c2d7-7c5b-8d58-c6b107fc3ea4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-c2d7-7fa3-bca1-706eeab1584e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c2d7-78cf-8e2e-5f58968d41df" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-c2d7-7fa3-bca1-706eeab1584e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_019c9afa-c2d7-7d8f-be47-696a0b6252b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c2d7-78cf-8e2e-5f58968d41df" xlink:to="loc_us-gaap_PremiumsEarnedNet_019c9afa-c2d7-7d8f-be47-696a0b6252b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-7190-aaee-2ccc01ed1f4f" xlink:href="ci-20260331.xsd#ci_NonInvestmentRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c2d7-78cf-8e2e-5f58968d41df" xlink:to="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-7190-aaee-2ccc01ed1f4f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationFinancialandPerformanceGuaranteesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_019c9afa-c2d7-76cc-8f4d-47d6414b42ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_019c9afa-c2d7-70d4-9eb5-55733f03c54f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c9afa-c2d7-76cc-8f4d-47d6414b42ed" xlink:to="loc_us-gaap_LossContingenciesTable_019c9afa-c2d7-70d4-9eb5-55733f03c54f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-77f2-a67f-204ed1ec74ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019c9afa-c2d7-70d4-9eb5-55733f03c54f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-77f2-a67f-204ed1ec74ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c2d7-77f2-a67f-204ed1ec74ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-77f2-a67f-204ed1ec74ae" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c2d7-77f2-a67f-204ed1ec74ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7b3a-b12f-99e80f04b1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-77f2-a67f-204ed1ec74ae" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7b3a-b12f-99e80f04b1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_019c9afa-c2d7-778e-8570-8d9038ddb856" xlink:href="ci-20260331.xsd#ci_EvernorthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7b3a-b12f-99e80f04b1ba" xlink:to="loc_ci_EvernorthMember_019c9afa-c2d7-778e-8570-8d9038ddb856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7ccd-b188-633ce98914a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019c9afa-c2d7-70d4-9eb5-55733f03c54f" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7ccd-b188-633ce98914a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-7ccd-b188-633ce98914a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7ccd-b188-633ce98914a0" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-7ccd-b188-633ce98914a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-7717-bfed-399fb3ca218e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7ccd-b188-633ce98914a0" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-7717-bfed-399fb3ca218e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMember_019c9afa-c2d7-7d7a-a9b2-587f213e14c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-7717-bfed-399fb3ca218e" xlink:to="loc_us-gaap_GuaranteeObligationsMember_019c9afa-c2d7-7d7a-a9b2-587f213e14c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c9afa-c2d7-7582-96f7-5b5a8a593e29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c9afa-c2d7-76cc-8f4d-47d6414b42ed" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c9afa-c2d7-7582-96f7-5b5a8a593e29" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DavidCordaniMember_019c9afa-b9b7-7182-99ea-07eeaa00b23f" xlink:href="ci-20260331.xsd#ci_DavidCordaniMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ci_DavidCordaniMember_019c9afa-b9b7-7182-99ea-07eeaa00b23f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember_019c9afa-bb3a-7af7-a3f4-f3ec03044df3" xlink:href="ci-20260331.xsd#ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember_019c9afa-bb3a-7af7-a3f4-f3ec03044df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember_019c9afa-bbe4-7c07-9507-1ab94aa8322e" xlink:href="ci-20260331.xsd#ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember_019c9afa-bbe4-7c07-9507-1ab94aa8322e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember_019c9afa-bd3b-76bb-9334-e999f009ea53" xlink:href="ci-20260331.xsd#ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember_019c9afa-bd3b-76bb-9334-e999f009ea53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementStockOptionsMember_019c9afa-ba8b-7f4c-95a1-1fcddc8af876" xlink:href="ci-20260331.xsd#ci_TradingArrangementStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_ci_TradingArrangementStockOptionsMember_019c9afa-ba8b-7f4c-95a1-1fcddc8af876" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_NetInvestmentIncome" xlink:type="arc" order="691"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLoss_019c9afa-b9b7-77f6-9308-79feee789962" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_ci_NetInvestmentGainLoss_019c9afa-b9b7-77f6-9308-79feee789962" xlink:type="arc" order="692"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_019c9afa-b9b7-7a0f-acc1-49e73420d2fd" xlink:href="ci-20260331.xsd#ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_019c9afa-b9b7-7a0f-acc1-49e73420d2fd" xlink:type="arc" order="81"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>ci-20260331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c9afa-b9b6-7bff-8807-e603b8e89aeb,g:b1b37cb4-a013-41e0-9774-54a06c55ff7f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ci_InvestmentGradeMember_019c9afa-c42c-7a48-bd14-9bfbcf36d281_terseLabel_en-US" xlink:label="lab_ci_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment grade</link:label>
    <link:label id="lab_ci_InvestmentGradeMember_label_en-US" xlink:label="lab_ci_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Grade [Member]</link:label>
    <link:label id="lab_ci_InvestmentGradeMember_documentation_en-US" xlink:label="lab_ci_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments that connote investment grade.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentGradeMember" xlink:href="ci-20260331.xsd#ci_InvestmentGradeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InvestmentGradeMember" xlink:to="lab_ci_InvestmentGradeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_019c9afa-c542-7693-948d-7d0d8eb9a806_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_019c9afa-c4bc-7b58-b373-257b3ade6f7f_negatedLabel_en-US" xlink:label="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Income) loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_label_en-US" xlink:label="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss Attributable To Noncontrolling Interest Before Tax</link:label>
    <link:label id="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_documentation_en-US" xlink:label="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of pre-tax income (loss) attributable to noncontrolling interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:href="ci-20260331.xsd#ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:to="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c42c-7811-822d-a5e1880219e0_terseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMatters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expenses (benefits)</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c42c-7ba9-b4e5-59ba9f361cb4_verboseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMatters" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expenses</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMatters_label_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMatters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item Charge Benefit Tax Matters</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMatters_documentation_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMatters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Item Charge Benefit Tax Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMatters" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitTaxMatters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargeBenefitTaxMatters" xlink:to="lab_ci_SpecialItemChargeBenefitTaxMatters" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_019c9afa-c4bd-702d-9bda-e813783e3a30_totalLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:to="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c42c-7ad5-8508-bf59e1e16be5_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities, Noncurrent [Abstract]</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock_019c9afa-c5bb-7ee5-9ba6-50939d05c09d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Amount of Risk by Product and Guarantee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019c9afa-c42c-782b-a1eb-89ff4103963d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_019c9afa-c4bd-7266-a2ae-6de2661920c5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnobservableInputsDevelopedByCompanyMember_019c9afa-c4bc-799d-adc6-8ecc21c3a154_terseLabel_en-US" xlink:label="lab_ci_UnobservableInputsDevelopedByCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Priced by the Company</link:label>
    <link:label id="lab_ci_UnobservableInputsDevelopedByCompanyMember_label_en-US" xlink:label="lab_ci_UnobservableInputsDevelopedByCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unobservable Inputs Developed By Company [Member]</link:label>
    <link:label id="lab_ci_UnobservableInputsDevelopedByCompanyMember_documentation_en-US" xlink:label="lab_ci_UnobservableInputsDevelopedByCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant unobservable inputs used in pricing Level 3 securities that were developed directly by the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnobservableInputsDevelopedByCompanyMember" xlink:href="ci-20260331.xsd#ci_UnobservableInputsDevelopedByCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnobservableInputsDevelopedByCompanyMember" xlink:to="lab_ci_UnobservableInputsDevelopedByCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OngoingOperationsMember_019c9afa-c4bc-7181-be9f-453e1c63f311_terseLabel_en-US" xlink:label="lab_ci_OngoingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ongoing operations</link:label>
    <link:label id="lab_ci_OngoingOperationsMember_label_en-US" xlink:label="lab_ci_OngoingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ongoing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OngoingOperationsMember" xlink:href="ci-20260331.xsd#ci_OngoingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OngoingOperationsMember" xlink:to="lab_ci_OngoingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_019c9afa-c38f-7062-8682-847d0b5b0ebf_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CededCreditCollateralizationRiskMember_019c9afa-c542-70ed-be86-1cfc68ea9869_terseLabel_en-US" xlink:label="lab_ci_CededCreditCollateralizationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateralization risk</link:label>
    <link:label id="lab_ci_CededCreditCollateralizationRiskMember_label_en-US" xlink:label="lab_ci_CededCreditCollateralizationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Credit Collateralization Risk [Member]</link:label>
    <link:label id="lab_ci_CededCreditCollateralizationRiskMember_documentation_en-US" xlink:label="lab_ci_CededCreditCollateralizationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration risk related to collateralization of a specified benchmark, such as reinsurance recoverables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditCollateralizationRiskMember" xlink:href="ci-20260331.xsd#ci_CededCreditCollateralizationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CededCreditCollateralizationRiskMember" xlink:to="lab_ci_CededCreditCollateralizationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019c9afa-c42c-7446-b624-d1060d690102_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NonInvestmentRevenue_019c9afa-c38f-744a-aaf7-ad2d008e1d4c_verboseLabel_en-US" xlink:label="lab_ci_NonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from customers</link:label>
    <link:label id="lab_ci_NonInvestmentRevenue_019c9afa-c38f-7632-ae78-ed08f9ecaf61_totalLabel_en-US" xlink:label="lab_ci_NonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from external customers</link:label>
    <link:label id="lab_ci_NonInvestmentRevenue_label_en-US" xlink:label="lab_ci_NonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Investment Revenue</link:label>
    <link:label id="lab_ci_NonInvestmentRevenue_documentation_en-US" xlink:label="lab_ci_NonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue excluding net investment income and realized investment results.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue" xlink:href="ci-20260331.xsd#ci_NonInvestmentRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NonInvestmentRevenue" xlink:to="lab_ci_NonInvestmentRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_019c9afa-c5bb-70fe-9979-cf98dcc6e2c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures, net of cash sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_019c9afa-c38f-7b21-867d-66c3c9e2b98e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures for Financial Instruments Not Carried at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c5bb-7268-b422-3f93b35912f0_periodStartLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Less: Reinsurance, including held for sale liabilities</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c5bb-753b-b00c-e0afbebd2e33_periodEndLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Add: Reinsurance, including held for sale liabilities</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:to="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_019c9afa-c4bd-79f9-b955-d8863055edf4_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum guarantee exposure</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_019c9afa-c42c-7b34-90a2-5847fd8dbf71_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c542-7496-99c0-e55395070103_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_019c9afa-c4bd-7e40-9400-79a21f219286_terseLabel_en-US" xlink:label="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BBB+ equivalent and higher current ratings</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_label_en-US" xlink:label="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nationally Recognized Statistical Rating Organizations (NRSRO), BBB+ Or Higher [Member]</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_documentation_en-US" xlink:label="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nationally Recognized Statistical Rating Organizations (NRSRO), BBB+ Or Higher</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:to="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_019c9afa-c42c-72af-808f-fc33b3db8e88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePortfolioSegmentDomain_019c9afa-c543-7d18-bc34-e25dc7220933_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Receivable Portfolio Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePortfolioSegmentDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable Portfolio Segment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="lab_us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CommitmentsAndContingenciesLineItems_019c9afa-c543-7f11-a969-640d94a8c140_terseLabel_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesLineItems" xlink:href="ci-20260331.xsd#ci_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems" xlink:to="lab_ci_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_019c9afa-c38f-73e6-9e6f-e588906cc00c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_019c9afa-c42c-7d80-a571-0d6bd4ad1c49_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019c9afa-c42c-7bb7-a4ea-8cec826732ed_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_019c9afa-c42c-7809-8257-2dfd2dbc4d4e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c9afa-c543-791e-9d66-43b014cf7835_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_019c9afa-c4bd-7e46-83ce-3445c6e8ba02_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Common dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019c9afa-c4bc-7490-8fd1-750612000f53_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c4bc-743e-8d86-e24f97b40b8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c543-7d44-ad07-010571af30eb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_019c9afa-c4bd-7fa9-8243-c5e197b2ae98_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SeparateAccountGuaranteedSeparateAccountsMember_019c9afa-c42c-7a0b-a3bd-cf351f24569e_terseLabel_en-US" xlink:label="lab_ci_SeparateAccountGuaranteedSeparateAccountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate Account, Guaranteed Separate Accounts</link:label>
    <link:label id="lab_ci_SeparateAccountGuaranteedSeparateAccountsMember_label_en-US" xlink:label="lab_ci_SeparateAccountGuaranteedSeparateAccountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Separate Account, Guaranteed Separate Accounts [Member]</link:label>
    <link:label id="lab_ci_SeparateAccountGuaranteedSeparateAccountsMember_documentation_en-US" xlink:label="lab_ci_SeparateAccountGuaranteedSeparateAccountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Separate Account, Guaranteed Separate Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountGuaranteedSeparateAccountsMember" xlink:href="ci-20260331.xsd#ci_SeparateAccountGuaranteedSeparateAccountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SeparateAccountGuaranteedSeparateAccountsMember" xlink:to="lab_ci_SeparateAccountGuaranteedSeparateAccountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_019c9afa-c42c-7d3d-971e-cac72ba6692f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableAnnuityMember_019c9afa-c4bd-7f2a-b76c-a3357c12daad_terseLabel_en-US" xlink:label="lab_us-gaap_VariableAnnuityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Annuity</link:label>
    <link:label id="lab_us-gaap_VariableAnnuityMember_label_en-US" xlink:label="lab_us-gaap_VariableAnnuityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Annuity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableAnnuityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableAnnuityMember" xlink:to="lab_us-gaap_VariableAnnuityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c542-77e0-9215-d77f3062555e_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019c9afa-c38f-72d2-81a4-533f59b70ca6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c38f-71d3-a0b4-2cd7aaa197a0_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain" xlink:to="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019c9afa-c542-760a-867b-fb17cffb6f98_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c9afa-c38f-70b8-8f6b-b46bb29f5d28_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_019c9afa-c543-7450-a9cf-b0f3fdf223c8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_019c9afa-c42c-7cf0-be67-91d9be799931_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c42c-77cf-b54e-ca40a6c142b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Receivable, Credit Quality Indicator [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Credit Quality Indicator [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:to="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c42c-7748-926b-4b2d80b89b65_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019c9afa-c4bc-705d-bba9-60ca3928f443_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_019c9afa-c5bb-7b33-a12d-500cb13fe2ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c38f-7f0b-88fe-dc2f265f85e6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_019c9afa-c4bd-7e25-94b2-2c063d68965d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_019c9afa-c4bc-7131-846a-e47873304ea5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_019c9afa-c543-78ff-9e30-1695479b7e74_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_019c9afa-c543-7da2-99ce-3aeaf995fdd3_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_019c9afa-c42c-77b1-b4b6-463b9204b3a8_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_TemporaryEquityOtherComprehensiveIncomeLoss_019c9afa-c42c-7564-bb3e-50652ba17cf4_netLabel_en-US" xlink:label="lab_ci_TemporaryEquityOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_ci_TemporaryEquityOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_ci_TemporaryEquityOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_ci_TemporaryEquityOtherComprehensiveIncomeLoss_documentation_en-US" xlink:label="lab_ci_TemporaryEquityOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The portion of other comprehensive income or(loss) attributable to temporary equity interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncomeLoss" xlink:href="ci-20260331.xsd#ci_TemporaryEquityOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_TemporaryEquityOtherComprehensiveIncomeLoss" xlink:to="lab_ci_TemporaryEquityOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AcquisitionDispositionRunoffActivitiesMember_019c9afa-c38f-7ad4-b6a1-257c461ebe47_terseLabel_en-US" xlink:label="lab_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition, disposition or run-off activities</link:label>
    <link:label id="lab_ci_AcquisitionDispositionRunoffActivitiesMember_label_en-US" xlink:label="lab_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition Disposition Runoff Activities [Member]</link:label>
    <link:label id="lab_ci_AcquisitionDispositionRunoffActivitiesMember_documentation_en-US" xlink:label="lab_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products related to acquisition, disposition or runoff activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:href="ci-20260331.xsd#ci_AcquisitionDispositionRunoffActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:to="lab_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesTable_019c9afa-c38f-715e-8559-94b4d3e5283e_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities [Table]</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesTable_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019c9afa-c4bd-7727-bb24-3009afc02ca9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_019c9afa-c542-7565-b2f5-a4d9ef16acbf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation of foreign currencies</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_019c9afa-c42c-7118-ae00-6d45d3db423d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CorporateAndGovernmentDebtSecuritiesMember_019c9afa-c38f-7785-8850-7d05e673c53f_terseLabel_en-US" xlink:label="lab_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_ci_CorporateAndGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate And Government Debt Securities [Member]</link:label>
    <link:label id="lab_ci_CorporateAndGovernmentDebtSecuritiesMember_documentation_en-US" xlink:label="lab_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This category includes information about debt securities that are issued by either a domestic or foreign corporate business entity with a promise of repayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:href="ci-20260331.xsd#ci_CorporateAndGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:to="lab_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_019c9afa-c38f-7acd-81ea-a7e17d154086_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019c9afa-c42c-7d5e-ab4a-74ec3df3e6b8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitLiabilityAmount_019c9afa-c4bd-78fd-8503-a43788f52dd7_totalLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitLiabilityAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Market risk benefits</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitLiabilityAmount_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitLiabilityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Liability, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitLiabilityAmount" xlink:to="lab_us-gaap_MarketRiskBenefitLiabilityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019c9afa-c542-7682-a775-9c4809ff997e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c9afa-c4bc-799d-ad79-89d5e5698b05_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Financing Receivable [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Financing Receivable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c42c-75d2-91a4-0ce0481bbc9c_negatedLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) on sale of businesses</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_label_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item, Gain (Loss) On Sale Of Business, Before Taxes</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_documentation_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Item, Gain (Loss) On Sale Of Business, Before Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:to="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_019c9afa-c4bc-7b9c-a436-eb3ce0bc66dd_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis" xlink:to="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019c9afa-c42c-7182-b68f-231649b7e0ab_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c38f-7dae-922e-96b86c6303e5_terseLabel_en-US" xlink:label="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in instrument-specific credit risk for market risk benefits</link:label>
    <link:label id="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_label_en-US" xlink:label="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Market Risk Benefit, Instrument-Specific Credit Risk, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:to="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_019c9afa-c42c-705a-984a-24ecc758eef0_terseLabel_en-US" xlink:label="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noninsurance customer receivables</link:label>
    <link:label id="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_label_en-US" xlink:label="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable</link:label>
    <link:label id="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_documentation_en-US" xlink:label="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivables due from customers that are not under insurance contracts. These include pharmacy sales and fees due from employer clients.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:href="ci-20260331.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:to="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_019c9afa-c4bd-7799-bcbf-7c884f2fa6ed_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative gain (loss) recognized in the income statement</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_019c9afa-c42c-7c7a-899f-00ef27d0989b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderContractDepositCurrent_019c9afa-c4bd-74c1-9fc2-ebe20615ae26_terseLabel_en-US" xlink:label="lab_ci_PolicyholderContractDepositCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractholder deposit funds, current</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositCurrent_label_en-US" xlink:label="lab_ci_PolicyholderContractDepositCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Contract Deposit, Current</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositCurrent_documentation_en-US" xlink:label="lab_ci_PolicyholderContractDepositCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Policyholder Contract Deposit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrent" xlink:href="ci-20260331.xsd#ci_PolicyholderContractDepositCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderContractDepositCurrent" xlink:to="lab_ci_PolicyholderContractDepositCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_019c9afa-c4bd-71ab-bba1-81c995633bae_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_019c9afa-c4bc-7539-8b03-b8f7920f0fc7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undiscounted expected future policy benefits</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit, Expected Future Policy Benefit, Undiscounted, before Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c9afa-c542-7b24-871e-2a0f21c50441_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Financing Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Financing Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_019c9afa-c38f-765b-a200-5084b76dd4f0_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Current Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:to="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019c9afa-c543-721b-991c-d75263faff8b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables_019c9afa-c4bd-775e-b1ed-d03cef7e54b9_terseLabel_en-US" xlink:label="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">contractual allowances for third-party payor noninsurance customer receivables</link:label>
    <link:label id="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables_label_en-US" xlink:label="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Allowance, Noninsurance Customer Receivables</link:label>
    <link:label id="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables_documentation_en-US" xlink:label="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of contractual allowances from third-party payors based upon the contractual payment terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:href="ci-20260331.xsd#ci_ContractualAllowanceNoninsuranceCustomerReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:to="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019c9afa-c38f-77dc-a481-42e1dda287bc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">TOTAL INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c542-798e-8b98-98051ae248b4_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestmentsAbstract_019c9afa-c542-75cd-b382-f85189caf457_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments purchased or originated:</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract" xlink:to="lab_us-gaap_PaymentsToAcquireInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019c9afa-c38f-75ec-9a9d-61f12d987bed_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019c9afa-c38f-7d4a-9bad-4de9c4e5b658_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Ltv80To100PercentMember_019c9afa-c42c-7422-a9c2-1cf5c970f5d1_terseLabel_en-US" xlink:label="lab_us-gaap_Ltv80To100PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">80% to 100%</link:label>
    <link:label id="lab_us-gaap_Ltv80To100PercentMember_label_en-US" xlink:label="lab_us-gaap_Ltv80To100PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt-to-Value Ratio, 80 to 100 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Ltv80To100PercentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Ltv80To100PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Ltv80To100PercentMember" xlink:to="lab_us-gaap_Ltv80To100PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_019c9afa-c38f-7ac2-b9e9-aacf6c187173_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_TransactionRelatedCosts_019c9afa-c4bc-7294-a730-73ef8e839a5c_verboseLabel_en-US" xlink:label="lab_ci_TransactionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Integration and transaction-related costs</link:label>
    <link:label id="lab_ci_TransactionRelatedCosts_019c9afa-c4bc-7c30-a20f-cbd83a4767c9_terseLabel_en-US" xlink:label="lab_ci_TransactionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Integration and transaction-related costs</link:label>
    <link:label id="lab_ci_TransactionRelatedCosts_label_en-US" xlink:label="lab_ci_TransactionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Related Costs</link:label>
    <link:label id="lab_ci_TransactionRelatedCosts_documentation_en-US" xlink:label="lab_ci_TransactionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-tax transaction-related costs primarily consisting of fees for legal, advisory and other professional services, as well as employee costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_TransactionRelatedCosts" xlink:to="lab_ci_TransactionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_019c9afa-c543-7701-80dd-fbfd67613f0f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c38f-741a-8b0b-98de0c7f0c88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_019c9afa-c42c-7456-b37e-8a1d8a867abf_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis]</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis" xlink:to="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_019c9afa-c542-7033-b99c-4a14d0526c83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative gain (loss) recognized in other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_019c9afa-c4bc-79e5-a664-6dca5fd815bc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ScheduleOfSpecialItemsTableTextBlock_019c9afa-c42c-722c-bfc3-0df38d8f1bb4_terseLabel_en-US" xlink:label="lab_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Special Items</link:label>
    <link:label id="lab_ci_ScheduleOfSpecialItemsTableTextBlock_label_en-US" xlink:label="lab_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Special Items [Table Text Block]</link:label>
    <link:label id="lab_ci_ScheduleOfSpecialItemsTableTextBlock_documentation_en-US" xlink:label="lab_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of pre- and after-tax amounts reported as special items, attributable to the parent. Special items are amounts that management does not believe are representative of underlying results of operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:href="ci-20260331.xsd#ci_ScheduleOfSpecialItemsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:to="lab_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c5bb-7a96-979e-4bf928d187ba_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incurred costs related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CorporateAndEliminationsMember_019c9afa-c42c-7b34-ad36-70f07436999a_terseLabel_en-US" xlink:label="lab_ci_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate and Eliminations</link:label>
    <link:label id="lab_ci_CorporateAndEliminationsMember_label_en-US" xlink:label="lab_ci_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate And Eliminations [Member]</link:label>
    <link:label id="lab_ci_CorporateAndEliminationsMember_documentation_en-US" xlink:label="lab_ci_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reflects amounts not allocated to other segments, such as net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment operations), interest on uncertain tax positions, certain litigation matters, intersegment eliminations, compensation cost for stock options, expense associated with its frozen pension plans, certain corporate project and overhead costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndEliminationsMember" xlink:href="ci-20260331.xsd#ci_CorporateAndEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CorporateAndEliminationsMember" xlink:to="lab_ci_CorporateAndEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_019c9afa-c4bc-7f20-891c-59bdf511b6bb_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification obligations</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeparateAccountAssetCategoryAxis_019c9afa-c4bd-7e1d-b122-8ac105fde384_terseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountAssetCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate Account Asset Category [Axis]</link:label>
    <link:label id="lab_us-gaap_SeparateAccountAssetCategoryAxis_label_en-US" xlink:label="lab_us-gaap_SeparateAccountAssetCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Separate Account Asset Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountAssetCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis" xlink:to="lab_us-gaap_SeparateAccountAssetCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PharmaceuticalManufacturerReceivable_019c9afa-c42c-7c0f-966a-58394eb4059d_terseLabel_en-US" xlink:label="lab_ci_PharmaceuticalManufacturerReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmaceutical manufacturer receivables</link:label>
    <link:label id="lab_ci_PharmaceuticalManufacturerReceivable_label_en-US" xlink:label="lab_ci_PharmaceuticalManufacturerReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmaceutical Manufacturer Receivable</link:label>
    <link:label id="lab_ci_PharmaceuticalManufacturerReceivable_documentation_en-US" xlink:label="lab_ci_PharmaceuticalManufacturerReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivables due from pharmaceutical manufacturers related to rebate contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturerReceivable" xlink:href="ci-20260331.xsd#ci_PharmaceuticalManufacturerReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PharmaceuticalManufacturerReceivable" xlink:to="lab_ci_PharmaceuticalManufacturerReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_019c9afa-c543-7f45-8247-c55457797d03_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019c9afa-c4bd-7b9f-9e93-df6c92b42304_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Optimization Program</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NetInvestmentGainLoss_019c9afa-c42c-7cca-a262-6c10317e0b60_terseLabel_en-US" xlink:label="lab_ci_NetInvestmentGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment gains (losses)</link:label>
    <link:label id="lab_ci_NetInvestmentGainLoss_019c9afa-c42c-7404-95f4-6dceb91774cd_negatedLabel_en-US" xlink:label="lab_ci_NetInvestmentGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Investment (gains) losses, net</link:label>
    <link:label id="lab_ci_NetInvestmentGainLoss_label_en-US" xlink:label="lab_ci_NetInvestmentGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Gain Loss</link:label>
    <link:label id="lab_ci_NetInvestmentGainLoss_documentation_en-US" xlink:label="lab_ci_NetInvestmentGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains (losses) based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLoss" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NetInvestmentGainLoss" xlink:to="lab_ci_NetInvestmentGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019c9afa-c543-750f-bca8-c389d6c002cd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_019c9afa-c543-7bcb-a080-786d8160db9b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskSecuredMember_019c9afa-c5bb-763e-843a-3d76177029c2_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskSecuredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskSecuredMember_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskSecuredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Secured [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskSecuredMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskSecuredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskSecuredMember" xlink:to="lab_us-gaap_CededCreditRiskSecuredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c9afa-c42c-756f-bf29-7ea29b43be55_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c38f-7b9f-8212-1e1495aba3d3_periodStartLabel_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, net, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c38f-7721-a42c-79bf7b224ac4_periodEndLabel_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, net, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:to="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtInstrumentExtensionTerm_019c9afa-c5bb-78ee-8546-891ce877e233_terseLabel_en-US" xlink:label="lab_ci_DebtInstrumentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit agreement term extension</link:label>
    <link:label id="lab_ci_DebtInstrumentExtensionTerm_label_en-US" xlink:label="lab_ci_DebtInstrumentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Extension Term</link:label>
    <link:label id="lab_ci_DebtInstrumentExtensionTerm_documentation_en-US" xlink:label="lab_ci_DebtInstrumentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentExtensionTerm" xlink:href="ci-20260331.xsd#ci_DebtInstrumentExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtInstrumentExtensionTerm" xlink:to="lab_ci_DebtInstrumentExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-c4bd-7d89-ba3d-444b6afaaf88_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CASH PROVIDED BY OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_019c9afa-c543-7ece-af95-e897ee07f8a4_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_019c9afa-c543-740b-9250-d28e59cba1a4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments per Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c42c-7171-8003-e04626610c07_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesAbstract_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities [Abstract]</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesAbstract_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_019c9afa-c4bc-7bf1-9770-30b6a136fcc4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit agreement term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c42c-7f57-9edd-8edd445652a6_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c42c-7619-84ea-3355b68d8293_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_019c9afa-c542-76b9-a178-d144ebd1119a_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_019c9afa-c42c-7984-8440-5497ad0bd68a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SegmentRevenues_019c9afa-c542-7c19-bfc9-50be12f3b693_terseLabel_en-US" xlink:label="lab_ci_SegmentRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted revenues</link:label>
    <link:label id="lab_ci_SegmentRevenues_label_en-US" xlink:label="lab_ci_SegmentRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Revenues</link:label>
    <link:label id="lab_ci_SegmentRevenues_documentation_en-US" xlink:label="lab_ci_SegmentRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total revenues less realized investment gains from equity method subsidiaries, special items and other reconciling items determined by management.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SegmentRevenues" xlink:href="ci-20260331.xsd#ci_SegmentRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SegmentRevenues" xlink:to="lab_ci_SegmentRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_019c9afa-c42c-7a44-ae16-8918ca0036b2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c5bb-720f-a932-29876070c36a_terseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountAssetCategoryDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate Account Asset Category [Domain]</link:label>
    <link:label id="lab_us-gaap_SeparateAccountAssetCategoryDomain_label_en-US" xlink:label="lab_us-gaap_SeparateAccountAssetCategoryDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Separate Account Asset Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain" xlink:to="lab_us-gaap_SeparateAccountAssetCategoryDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019c9afa-c4bc-7c63-9244-97c855b1c370_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid_019c9afa-c38f-761c-a538-658ca6828d6e_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Factoring fees paid, uncommitted factoring facilities</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facilities, Factoring Fees Paid</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Factoring fees paid under uncommitted Account Receivable factoring facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock_019c9afa-c42c-79c3-a416-dfc2d5b11354_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Market Risk Benefit</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:to="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_019c9afa-c4bc-743e-8be0-dac63ff8feaf_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Pharmacy revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_019c9afa-c38f-7ebe-bf73-01e872b2e4a2_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net amount at risk</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Net Amount at Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceNetAmountAtRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk" xlink:to="lab_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_019c9afa-c5bb-7728-a237-015687c0c8cc_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock_019c9afa-c542-7be5-a265-07ab5adaef81_terseLabel_en-US" xlink:label="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unearned Premium</link:label>
    <link:label id="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock_label_en-US" xlink:label="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance, Unearned Premiums [Policy Text Block]</link:label>
    <link:label id="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock_documentation_en-US" xlink:label="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance, Unearned Premiums</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:href="ci-20260331.xsd#ci_InsuranceUnearnedPremiumsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:to="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_019c9afa-c38f-7426-9c36-c95263439bb7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment term (in months)</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Payment Timing, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramPaymentTimingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:to="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-c38f-7bce-8610-cf8044fc1fe7_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical costs and other benefit expenses</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019c9afa-c38f-7707-9bb8-cf8eb0e8bb29_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_019c9afa-c4bc-7f49-ba4c-fdc3a23f2e0c_terseLabel_en-US" xlink:label="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net long-duration insurance and contractholder liabilities measurement adjustments</link:label>
    <link:label id="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_label_en-US" xlink:label="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent</link:label>
    <link:label id="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_documentation_en-US" xlink:label="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:href="ci-20260331.xsd#ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:to="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c9afa-c543-76f4-9977-af1f2ddd06dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_019c9afa-c4bc-7d43-8ac1-6d38240d1ca4_verboseLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total of incurred but not reported liabilities plus expected claim development on reported claims and reported claims in process</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense Excluding Physician Incentives And Other Expenses</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the total liability for incurred but not reported claims plus expected claim development on reported claims, including reported claims in process. Excludes amounts due for physician incentives and other medical care expenses and services payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019c9afa-c543-7a86-9edf-cb6a5cfafe50_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c4bc-7409-adbe-72011a1bc7fe_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One year or less</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less Than 12 Months [Abstract]</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less Than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LtvLessThan80PercentMember_019c9afa-c38f-7222-81b8-dcd99d062836_terseLabel_en-US" xlink:label="lab_us-gaap_LtvLessThan80PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than 80 percent</link:label>
    <link:label id="lab_us-gaap_LtvLessThan80PercentMember_label_en-US" xlink:label="lab_us-gaap_LtvLessThan80PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt-to-Value Ratio, Less than 80 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LtvLessThan80PercentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LtvLessThan80PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LtvLessThan80PercentMember" xlink:to="lab_us-gaap_LtvLessThan80PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeparateAccountAssets_019c9afa-c38f-7d81-9e3e-9dd20996b2bb_terseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate account assets</link:label>
    <link:label id="lab_us-gaap_SeparateAccountAssets_label_en-US" xlink:label="lab_us-gaap_SeparateAccountAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Separate Account Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeparateAccountAssets" xlink:to="lab_us-gaap_SeparateAccountAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_019c9afa-c4bc-7c68-8903-63fcfe3faf30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common stock dividend paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_019c9afa-c4bc-7fcc-8277-8fc0ddfd479d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total amount paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PaymentsToAcquireDebtAndEquitySecurities_019c9afa-c42c-7d9c-b2f9-5f947ed92d63_negatedLabel_en-US" xlink:label="lab_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Debt securities and equity securities</link:label>
    <link:label id="lab_ci_PaymentsToAcquireDebtAndEquitySecurities_label_en-US" xlink:label="lab_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Debt And Equity Securities</link:label>
    <link:label id="lab_ci_PaymentsToAcquireDebtAndEquitySecurities_documentation_en-US" xlink:label="lab_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Debt And Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:href="ci-20260331.xsd#ci_PaymentsToAcquireDebtAndEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:to="lab_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_019c9afa-c4bc-7c66-8b46-922618a5db6d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskTable_019c9afa-c4bd-753b-89ab-93fa7f62118e_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk [Table]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskTable_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskTable" xlink:to="lab_us-gaap_CededCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_019c9afa-c38f-7dca-9c02-17fb5164a9e9_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_019c9afa-c38f-7e20-96c7-7c654d59a397_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019c9afa-c38f-7c0c-9185-46218ec46718_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c38f-77e0-99da-6e8900bb8ef0_totalLabel_en-US" xlink:label="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Investments including held for sale assets</link:label>
    <link:label id="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20260331.xsd#ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c543-729c-8f5d-f5adb41a0e6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CommercialPaperAverageRatePaid_019c9afa-c542-7979-921a-770a4080b45d_terseLabel_en-US" xlink:label="lab_srt_CommercialPaperAverageRatePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper average interest rate</link:label>
    <link:label id="lab_srt_CommercialPaperAverageRatePaid_label_en-US" xlink:label="lab_srt_CommercialPaperAverageRatePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Average Rate Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CommercialPaperAverageRatePaid" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CommercialPaperAverageRatePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CommercialPaperAverageRatePaid" xlink:to="lab_srt_CommercialPaperAverageRatePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_BelowInvestmentGradeMember_019c9afa-c42c-752b-b3a6-a325549d08c9_terseLabel_en-US" xlink:label="lab_ci_BelowInvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Below investment grade</link:label>
    <link:label id="lab_ci_BelowInvestmentGradeMember_label_en-US" xlink:label="lab_ci_BelowInvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Below Investment Grade [Member]</link:label>
    <link:label id="lab_ci_BelowInvestmentGradeMember_documentation_en-US" xlink:label="lab_ci_BelowInvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments that connote non-investment grade.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BelowInvestmentGradeMember" xlink:href="ci-20260331.xsd#ci_BelowInvestmentGradeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_BelowInvestmentGradeMember" xlink:to="lab_ci_BelowInvestmentGradeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_019c9afa-c42c-75c9-b976-a6360e334999_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock_019c9afa-c42c-717d-ac55-54c936361c6b_terseLabel_en-US" xlink:label="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values of Separate Account Assets</link:label>
    <link:label id="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock_label_en-US" xlink:label="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Separate Account Assets [Table Text Block]</link:label>
    <link:label id="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclose the aggregate fair value of separate account assets, by fair value level.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:href="ci-20260331.xsd#ci_FairValueOfSeparateAccountAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:to="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList_019c9afa-c38f-724f-b80c-6d3534e4937d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_019c9afa-c4bc-747a-b36f-0fa2f03c55c7_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityOtherChanges_019c9afa-c4bd-7977-8019-c366bcaa9989_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other transactions impacting noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityOtherChanges_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Other Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityOtherChanges" xlink:to="lab_us-gaap_TemporaryEquityOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_019c9afa-c42c-7f7c-aedc-f18a7f5b32ce_terseLabel_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt extinguishment costs (gains), after-tax</link:label>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_label_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item Charges Debt Extinguishment Costs Net Of Tax</link:label>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_documentation_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Item Charges Debt Extinguishment Costs Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:to="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_019c9afa-c4bc-7467-b2f1-253459ed5d6f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Net income attributable to other noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c38f-75d1-8a22-84a98df53b74_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than one year</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months Or Longer [Abstract]</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months Or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_019c9afa-c5bb-775c-b8c7-e212396383e2_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage_019c9afa-c542-7998-b64c-bbe47bb10095_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinsurance, Reinsured Risk, Percentage</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance, Reinsured Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage" xlink:to="lab_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_019c9afa-c543-70f1-8a2b-21a830fdbec5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019c9afa-c543-7adf-9214-40e19e185400_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskLineItems_019c9afa-c42c-7f29-8471-91b5f2d0267c_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskLineItems_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskLineItems" xlink:to="lab_us-gaap_CededCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_019c9afa-c4bd-7206-997c-c236e3decfa6_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL REVENUES</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c42c-7585-82a5-85727bbe8661_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost [Abstract]</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:to="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c42c-7d17-956f-6b27981cb593_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_019c9afa-c42c-764a-bf85-845a5ebdd16c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency Swap</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock_019c9afa-c543-7aa5-ba0d-dd69c042af54_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable Credit Quality Indicators [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock" xlink:to="lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_019c9afa-c42c-73b6-812c-b0a3a1f086ea_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total incurred</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c42c-7e0d-9958-1d141a7f7142_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019c9afa-c543-7fca-8188-a91ee3a26039_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ServiceFeesMember_019c9afa-c543-7fcb-865d-4e4eabafe5ee_terseLabel_en-US" xlink:label="lab_ci_ServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees</link:label>
    <link:label id="lab_ci_ServiceFeesMember_label_en-US" xlink:label="lab_ci_ServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service, Fees [Member]</link:label>
    <link:label id="lab_ci_ServiceFeesMember_documentation_en-US" xlink:label="lab_ci_ServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service, Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ServiceFeesMember" xlink:href="ci-20260331.xsd#ci_ServiceFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ServiceFeesMember" xlink:to="lab_ci_ServiceFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss_019c9afa-c4bc-70ea-ad61-d82801dddcc8_terseLabel_en-US" xlink:label="lab_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date</link:label>
    <link:label id="lab_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss_label_en-US" xlink:label="lab_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Still Held, Realized Gain (Loss)</link:label>
    <link:label id="lab_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss_documentation_en-US" xlink:label="lab_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents total gains or losses for the period (realized and unrealized), arising from assets included in income attributable to instruments held at the reporting date, measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in earnings or resulted in a change in asset value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss" xlink:href="ci-20260331.xsd#ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss" xlink:to="lab_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_019c9afa-c542-7890-9eff-1dff38b12682_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionsToContractHoldersFunds_019c9afa-c4bc-7ffd-8845-8fbfb7f19602_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionsToContractHoldersFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and interest credited to contractholder deposit funds</link:label>
    <link:label id="lab_us-gaap_AdditionsToContractHoldersFunds_label_en-US" xlink:label="lab_us-gaap_AdditionsToContractHoldersFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to Contract Holders Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionsToContractHoldersFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionsToContractHoldersFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionsToContractHoldersFunds" xlink:to="lab_us-gaap_AdditionsToContractHoldersFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital_019c9afa-c4bd-79d3-925b-06b84ed91bdc_terseLabel_en-US" xlink:label="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded commitments</link:label>
    <link:label id="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital_label_en-US" xlink:label="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments To Contribute Additional Equity And Capital</link:label>
    <link:label id="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital_documentation_en-US" xlink:label="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment commitments of estimated payments required under contractual arrangements diversified by issuer, property type and geographic regions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:href="ci-20260331.xsd#ci_CommitmentsToContributeAdditionalEquityAndCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:to="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_019c9afa-c4bc-744a-8385-20063362f9c2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MedicareAdvantageMember_019c9afa-c42c-7eca-8673-7a8fd6cffba9_terseLabel_en-US" xlink:label="lab_ci_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_ci_MedicareAdvantageMember_label_en-US" xlink:label="lab_ci_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageMember" xlink:href="ci-20260331.xsd#ci_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MedicareAdvantageMember" xlink:to="lab_ci_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_VillageMDMember_019c9afa-c42c-7212-a3ba-8be91e255875_terseLabel_en-US" xlink:label="lab_ci_VillageMDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VillageMD</link:label>
    <link:label id="lab_ci_VillageMDMember_label_en-US" xlink:label="lab_ci_VillageMDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VillageMD [Member]</link:label>
    <link:label id="lab_ci_VillageMDMember_documentation_en-US" xlink:label="lab_ci_VillageMDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VillageMD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_VillageMDMember" xlink:href="ci-20260331.xsd#ci_VillageMDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_VillageMDMember" xlink:to="lab_ci_VillageMDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoanToValueDomain_019c9afa-c42c-73ab-b339-0156454f6456_terseLabel_en-US" xlink:label="lab_us-gaap_LoanToValueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt-to-Value [Domain]</link:label>
    <link:label id="lab_us-gaap_LoanToValueDomain_label_en-US" xlink:label="lab_us-gaap_LoanToValueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt-to-Value [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoanToValueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoanToValueDomain" xlink:to="lab_us-gaap_LoanToValueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_019c9afa-c42c-771a-a300-0301f72ebdcc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment maturities and repayments:</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpenses_019c9afa-c42c-7c5c-bfe8-4d1057b91a0a_totalLabel_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL BENEFITS AND EXPENSES</link:label>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpenses_label_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benefits, Losses and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses" xlink:to="lab_us-gaap_BenefitsLossesAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019c9afa-c5bb-771c-b5ba-e9a97e781994_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CompletionFactorsAndOtherMember_019c9afa-c4bc-7986-b20e-4ef107b0e2cf_terseLabel_en-US" xlink:label="lab_ci_CompletionFactorsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actual completion factors and other</link:label>
    <link:label id="lab_ci_CompletionFactorsAndOtherMember_label_en-US" xlink:label="lab_ci_CompletionFactorsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Completion Factors And Other [Member]</link:label>
    <link:label id="lab_ci_CompletionFactorsAndOtherMember_documentation_en-US" xlink:label="lab_ci_CompletionFactorsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amounts relating to actual claims emerging differently from assumptions about claim payment speed used to set reserves, as well as other factors impacting prior year reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CompletionFactorsAndOtherMember" xlink:href="ci-20260331.xsd#ci_CompletionFactorsAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CompletionFactorsAndOtherMember" xlink:to="lab_ci_CompletionFactorsAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_019c9afa-c42c-736e-b439-1f5691634695_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_019c9afa-c42c-759d-9bba-20917ef99437_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Including Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_019c9afa-c542-79ce-a596-9beb7a3cdd92_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract" xlink:to="lab_us-gaap_LongTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ServiceFeesAndOtherRevenuesMember_019c9afa-c4bc-7cbb-8a10-dac6a62bc498_terseLabel_en-US" xlink:label="lab_ci_ServiceFeesAndOtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service, Fees And Other Revenues [Member]</link:label>
    <link:label id="lab_ci_ServiceFeesAndOtherRevenuesMember_label_en-US" xlink:label="lab_ci_ServiceFeesAndOtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service, Fees And Other Revenues [Member]</link:label>
    <link:label id="lab_ci_ServiceFeesAndOtherRevenuesMember_documentation_en-US" xlink:label="lab_ci_ServiceFeesAndOtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service, Fees And Other Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ServiceFeesAndOtherRevenuesMember" xlink:href="ci-20260331.xsd#ci_ServiceFeesAndOtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ServiceFeesAndOtherRevenuesMember" xlink:to="lab_ci_ServiceFeesAndOtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c42c-77de-8a73-4b26c9822da3_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c42c-748a-9173-90ffe4b65b75_totalLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities Noncurrent</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c42c-7e79-92dd-3f1954b03371_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c42c-7a01-b5e6-0e9fb363f04f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019c9afa-c4bd-73be-ab9e-a4b7e438fd81_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">allowances for current expected credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c38f-7b93-98bb-13805221f13c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c4bd-7f42-b54d-120e2ff74b02_periodStartLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Less: Reinsurance and other amounts recoverable</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c4bd-755f-85a4-58a5e3862819_periodEndLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Add: Reinsurance and other amounts recoverable</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverable for Unpaid Claims and Claims Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:to="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_019c9afa-c4bc-7e34-aaf1-ac9f867e743f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other sales, maturities and repayments (primarily short-term and other long-term investments)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_019c9afa-c38f-7210-b2e9-c987c5d79386_terseLabel_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Debt Service Coverage Ratio</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_label_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Credit Quality Debt Service Coverage Ratio</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_documentation_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Receivable, Credit Quality Debt Service Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:href="ci-20260331.xsd#ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:to="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_019c9afa-c42c-78ff-901d-d5d1a6fd25ff_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SeparateAccountNonGuaranteedSeparateAccountsMember_019c9afa-c42c-72f4-b3cf-6ed93d126545_terseLabel_en-US" xlink:label="lab_ci_SeparateAccountNonGuaranteedSeparateAccountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate Account, Non-Guaranteed Separate Accounts</link:label>
    <link:label id="lab_ci_SeparateAccountNonGuaranteedSeparateAccountsMember_label_en-US" xlink:label="lab_ci_SeparateAccountNonGuaranteedSeparateAccountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Separate Account, Non-Guaranteed Separate Accounts [Member]</link:label>
    <link:label id="lab_ci_SeparateAccountNonGuaranteedSeparateAccountsMember_documentation_en-US" xlink:label="lab_ci_SeparateAccountNonGuaranteedSeparateAccountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Separate Account, Non-Guaranteed Separate Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountNonGuaranteedSeparateAccountsMember" xlink:href="ci-20260331.xsd#ci_SeparateAccountNonGuaranteedSeparateAccountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SeparateAccountNonGuaranteedSeparateAccountsMember" xlink:to="lab_ci_SeparateAccountNonGuaranteedSeparateAccountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_019c9afa-c543-78dd-b0a3-d38b83e5ed7c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-for-Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_A1000Million4.500NotesDueSeptember2030Member_019c9afa-c42c-7d62-8961-2c8e9e351136_terseLabel_en-US" xlink:label="lab_ci_A1000Million4.500NotesDueSeptember2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.500% Notes due September 2030</link:label>
    <link:label id="lab_ci_A1000Million4.500NotesDueSeptember2030Member_label_en-US" xlink:label="lab_ci_A1000Million4.500NotesDueSeptember2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$1,000 million, 4.500% Notes Due September 2030 [Member]</link:label>
    <link:label id="lab_ci_A1000Million4.500NotesDueSeptember2030Member_documentation_en-US" xlink:label="lab_ci_A1000Million4.500NotesDueSeptember2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$1,000 million, 4.500% Notes Due September 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A1000Million4.500NotesDueSeptember2030Member" xlink:href="ci-20260331.xsd#ci_A1000Million4.500NotesDueSeptember2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_A1000Million4.500NotesDueSeptember2030Member" xlink:to="lab_ci_A1000Million4.500NotesDueSeptember2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_019c9afa-c4bc-769a-a12e-3ccad3a6546f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current discount rate</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit, Current Weighted-Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c42c-7394-a59d-5f491327da64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:to="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember_label_en-US" xlink:label="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Target Level [Member]</link:label>
    <link:label id="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember_documentation_en-US" xlink:label="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Target Level</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember" xlink:href="ci-20260331.xsd#ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember" xlink:to="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c9afa-c38f-739d-b3e5-6945f6cab77f_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock equivalents</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_A1500Million5.250NotesDueJanuary2036Member_019c9afa-c42c-725d-99cf-39fc2cf2ad29_terseLabel_en-US" xlink:label="lab_ci_A1500Million5.250NotesDueJanuary2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.250% Notes due January 2036</link:label>
    <link:label id="lab_ci_A1500Million5.250NotesDueJanuary2036Member_label_en-US" xlink:label="lab_ci_A1500Million5.250NotesDueJanuary2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$1,500 million, 5.250% Notes Due January 2036 [Member]</link:label>
    <link:label id="lab_ci_A1500Million5.250NotesDueJanuary2036Member_documentation_en-US" xlink:label="lab_ci_A1500Million5.250NotesDueJanuary2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$1,500 million, 5.250% Notes Due January 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A1500Million5.250NotesDueJanuary2036Member" xlink:href="ci-20260331.xsd#ci_A1500Million5.250NotesDueJanuary2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_A1500Million5.250NotesDueJanuary2036Member" xlink:to="lab_ci_A1500Million5.250NotesDueJanuary2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_019c9afa-c42c-7676-85ed-82521301a75e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019c9afa-c543-7448-bcd2-d8bc3af00de8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_019c9afa-c543-79cd-8ab3-d1da3e18b4b6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid claims classified as liabilities of business held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liability for Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_019c9afa-c4bc-7ee1-a709-a93659f4bd95_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, including current maturities, excluding finance leases</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_019c9afa-c42c-755b-bcad-8551db828075_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_019c9afa-c42c-7018-a125-759c9cfae493_negatedLabel_en-US" xlink:label="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property and equipment purchases, net</link:label>
    <link:label id="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For (Proceeds From) Property, Plant, And Equipment</link:label>
    <link:label id="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For (Proceeds From) Property, Plant, And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:href="ci-20260331.xsd#ci_PaymentsForProceedsFromPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:to="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_019c9afa-c38f-78d0-8161-4ee62b392c61_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_019c9afa-c4bc-7c30-9283-5bc2b63f4e3b_totalLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_Investments_019c9afa-c4bc-7e07-bc58-bff86a71afd8_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c42c-74f4-bd0e-8d42d80e0bb3_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance and Contractholder Liabilities [Line Items]</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesLineItems_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance and Contractholder Liabilities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019c9afa-c38f-796e-9848-9f963679340f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019c9afa-c4bc-7c45-bf54-059c7c3d34d3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Appreciation</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_019c9afa-c42c-75c1-b35a-42da64b78d48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for debt extinguishment</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_019c9afa-c42c-78dc-97dc-6868786cc306_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_019c9afa-c4bd-7259-a014-cad21296ca82_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_019c9afa-c4bd-713f-9adb-0afd34be536d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_019c9afa-c543-7e20-95d6-ff9efdd6b8cf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_019c9afa-c543-7280-a740-979a7b45aa69_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Insurance and Contractholder Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019c9afa-c38f-713a-b0a9-ef370f3efc5e_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_019c9afa-c42c-7970-a643-9e3a25e5119c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax_019c9afa-c4bc-7fd4-8cd3-8ab892952741_terseLabel_en-US" xlink:label="lab_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Income attributable to noncontrolling interests</link:label>
    <link:label id="lab_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax_label_en-US" xlink:label="lab_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segment Items, Income (Loss) Attributable To Noncontrolling Interests, Before Tax</link:label>
    <link:label id="lab_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax_documentation_en-US" xlink:label="lab_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Segment Items, Income (Loss) Attributable To Noncontrolling Interests, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" xlink:href="ci-20260331.xsd#ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" xlink:to="lab_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c38f-7c2c-813e-e6b894e59356_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c9afa-c543-7b96-9964-1147b4f08bb9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c42c-79a5-91ec-0c3b109d0176_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_019c9afa-c4bd-7342-9074-7327f5e1163e_terseLabel_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average attained age of contractholders (weighted by exposure)</link:label>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_label_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Amount at Risk by Product and Guarantee, Weighted Average Attained Age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" xlink:to="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c9afa-c42c-73f5-b6dd-ebb84335eca8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_019c9afa-c4bd-7acc-be61-67478c57fd65_terseLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid claims and claim expenses, current</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Current</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries_019c9afa-c38f-74fb-9072-2f592f30f395_negatedLabel_en-US" xlink:label="lab_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net realized investment (gains) losses</link:label>
    <link:label id="lab_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries_label_en-US" xlink:label="lab_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Gain Loss Including Equity Method Subsidiaries</link:label>
    <link:label id="lab_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries_documentation_en-US" xlink:label="lab_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains (losses), including those from equity method subsidiaries, based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:to="lab_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_019c9afa-c4bc-79d4-97c6-df7cded78387_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_019c9afa-c543-70b2-acdd-1385adaf747c_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member" xlink:to="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_019c9afa-c542-7de2-8678-556a02b2dee3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock_019c9afa-c38f-7591-9800-880e35320ef5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Policy Benefit Activity</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_019c9afa-c42c-7278-9efe-5b0274ae7b12_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Issues</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019c9afa-c38f-78c8-ae36-2c6657a6f11c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_019c9afa-c42c-7d7a-b9b6-40863a0c1aa3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DavidCordaniMember_label_en-US" xlink:label="lab_ci_DavidCordaniMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">David Cordani [Member]</link:label>
    <link:label id="lab_ci_DavidCordaniMember_documentation_en-US" xlink:label="lab_ci_DavidCordaniMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">David Cordani</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DavidCordaniMember" xlink:href="ci-20260331.xsd#ci_DavidCordaniMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DavidCordaniMember" xlink:to="lab_ci_DavidCordaniMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c542-7f0a-a797-21a6fe70a55c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_019c9afa-c42c-79b1-b5e7-57ce8cf77b9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_019c9afa-c42c-7188-bbd2-1474a5bf8542_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c543-77e0-85a8-5d91e63ef10c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_019c9afa-c38f-7ed9-b0b8-fba9f2a271c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative gain (loss) reclassified from other comprehensive income into shareholders' net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_019c9afa-c42c-78bd-a9cb-762dd68e285e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InvestmentsCreditRatingDomain_019c9afa-c4bc-7324-b9d2-c15d59635e3b_terseLabel_en-US" xlink:label="lab_ci_InvestmentsCreditRatingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Credit Rating [Domain]</link:label>
    <link:label id="lab_ci_InvestmentsCreditRatingDomain_label_en-US" xlink:label="lab_ci_InvestmentsCreditRatingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Credit Rating [Domain]</link:label>
    <link:label id="lab_ci_InvestmentsCreditRatingDomain_documentation_en-US" xlink:label="lab_ci_InvestmentsCreditRatingDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingDomain" xlink:href="ci-20260331.xsd#ci_InvestmentsCreditRatingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InvestmentsCreditRatingDomain" xlink:to="lab_ci_InvestmentsCreditRatingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019c9afa-c543-72ef-8fa0-23a02054b49f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PartnershipInterestMember_019c9afa-c42c-705a-a391-e08d956f0c85_terseLabel_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities partnerships</link:label>
    <link:label id="lab_srt_PartnershipInterestMember_label_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PartnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PartnershipInterestMember" xlink:to="lab_srt_PartnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_019c9afa-c4bc-7204-ae48-407bf4b22e86_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected_019c9afa-c4bd-73f8-b16c-898dae328da4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes due to policyholder behavior versus expected</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) from Actual Policyholder Behavior Different from Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" xlink:to="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_019c9afa-c4bc-7b24-9023-af6c0a5dcc0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c542-7baf-944a-9d2551feed45_terseLabel_en-US" xlink:label="lab_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_ShortTermAndLongTermInvestmentsAbstract_label_en-US" xlink:label="lab_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term And Long-Term Investments [Abstract]</link:label>
    <link:label id="lab_ci_ShortTermAndLongTermInvestmentsAbstract_documentation_en-US" xlink:label="lab_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-Term And Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:href="ci-20260331.xsd#ci_ShortTermAndLongTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:to="lab_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_019c9afa-c542-79b1-8e3f-4598951f4532_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_019c9afa-c543-7c3e-b664-c633370bccad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_019c9afa-c42c-79e2-88e9-1d5659fc0fae_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PharmacyAndServiceCostsPayable_019c9afa-c4bc-733a-89bd-a0527c9597bf_terseLabel_en-US" xlink:label="lab_ci_PharmacyAndServiceCostsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmacy and other service costs payable</link:label>
    <link:label id="lab_ci_PharmacyAndServiceCostsPayable_label_en-US" xlink:label="lab_ci_PharmacyAndServiceCostsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmacy And Service Costs Payable</link:label>
    <link:label id="lab_ci_PharmacyAndServiceCostsPayable_documentation_en-US" xlink:label="lab_ci_PharmacyAndServiceCostsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reflects amounts due to pharmacies for prescriptions filled through our retail network of pharmacies. Also includes amounts due to clients for their portion of rebates that must be contractually shared.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyAndServiceCostsPayable" xlink:href="ci-20260331.xsd#ci_PharmacyAndServiceCostsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PharmacyAndServiceCostsPayable" xlink:to="lab_ci_PharmacyAndServiceCostsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_019c9afa-c42c-7fad-b976-d7cee19946d9_terseLabel_en-US" xlink:label="lab_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in discount rate for certain long-duration liabilities</link:label>
    <link:label id="lab_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_label_en-US" xlink:label="lab_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Liability for Future Policy Benefit, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember" xlink:to="lab_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_019c9afa-c38f-7900-9038-24efb94983eb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019c9afa-c4bd-72dc-9c23-e6685eea7675_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies and Other Matters</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c9afa-c42c-7761-b9a9-93ee7e5534bb_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_019c9afa-c42c-7ad4-9936-c84dd0119f75_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_019c9afa-c543-70ef-9a96-92512fc51ac2_terseLabel_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) required to adjust future policy benefits for settlement annuities</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_label_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Required To Adjust Future Policy Benefits</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_documentation_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents total gains or losses for the period (realized and unrealized), arising from assets measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in gains or losses required to adjust future policy benefits for settlement annuities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:href="ci-20260331.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:to="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_019c9afa-c543-7c54-837c-2473c47396e8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c38f-7793-b326-3f4771f5d278_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit Activity [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit, Activity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_019c9afa-c42c-7ac0-aeb8-3ec9d1c73806_totalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019c9afa-c4bc-7359-be1e-5f67dfb512b2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_019c9afa-c4bc-72c9-9571-035f986b05ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019c9afa-c42c-7d19-b8d2-3ebb9b99b71d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c9afa-c4bc-74f9-9954-7e600974ba85_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c42c-7a03-a02c-8d2013a1eee5_verboseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Charges (benefits) associated with litigation matters</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c42c-709a-9fc3-51e72339264b_terseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Benefits) charges associated with litigation matters</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation_label_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item Charge (Benefit) Before Tax Litigation</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation_documentation_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:to="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019c9afa-c42c-7d70-950c-baa178ef36bc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_019c9afa-c42c-7b5e-b880-50f418d8a422_terseLabel_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BBB- to BBB+ equivalent current credit ratings</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_label_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), BBB- To BBB+ Rating [Member]</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_documentation_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), BBB- To BBB+ Rating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:to="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019c9afa-c543-7fb0-b751-974fb2358992_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_019c9afa-c4bc-79c5-ad12-ec777a9cab32_terseLabel_en-US" xlink:label="lab_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskUnsecuredMember_019c9afa-c4bd-71fd-bdf8-a0b1e77dd16a_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskUnsecuredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No Collateral</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskUnsecuredMember_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskUnsecuredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Unsecured [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskUnsecuredMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskUnsecuredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskUnsecuredMember" xlink:to="lab_us-gaap_CededCreditRiskUnsecuredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_019c9afa-c4bc-7c0f-ac91-eb72753b4ea1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c543-76cc-b2c8-0c851207926d_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskCollateralizationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Collateralization [Domain]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskCollateralizationDomain_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskCollateralizationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Collateralization [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain" xlink:to="lab_us-gaap_CededCreditRiskCollateralizationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember_019c9afa-c4bc-7447-8d0a-6c3ca4ff348e_terseLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverables, Gross, Acquisition Disposition Runoff Activities, Nationally Recognized Statistical Rating Organizations, BBB+ Or Higher</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember_label_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverables, Gross, Acquisition Disposition Runoff Activities, Nationally Recognized Statistical Rating Organizations, BBB+ Or Higher [Member]</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember_documentation_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverables, Gross, Acquisition Disposition Runoff Activities, Nationally Recognized Statistical Rating Organizations, BBB+ Or Higher</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember" xlink:to="lab_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther_019c9afa-c38f-700c-ba2e-d9c7c94273b8_terseLabel_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Divestiture and other</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther_label_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Divestiture and Other</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther_documentation_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of decrease (increase) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the divesture and/or re-segmentation of business unit(s). Includes, but is not limited to, claims which have been incurred but not reported.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther" xlink:to="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_019c9afa-c42c-76d1-8162-598717024032_terseLabel_en-US" xlink:label="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining overall limit under reinsurance agreement</link:label>
    <link:label id="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_label_en-US" xlink:label="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Reinsurance Agreement, Coverage Limit, Amount Remaining</link:label>
    <link:label id="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_documentation_en-US" xlink:label="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount remaining of overall limit to claims covered under ceded reinsurance agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:href="ci-20260331.xsd#ci_CededReinsuranceAgreementCoverageLimitAmountRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:to="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c42c-7710-9985-2f4103290e28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_019c9afa-c42c-7785-abe0-81d9e22ea084_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 to 0399 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member" xlink:to="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_019c9afa-c42c-7256-9e5d-c3864df2e608_terseLabel_en-US" xlink:label="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leverage ratio covenant</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_label_en-US" xlink:label="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility Debt To Adjusted Capital Ratio Covenant</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_documentation_en-US" xlink:label="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The debt-to adjusted capital ratio which the Company must not exceed in accordance with the terms of the line of credit facility agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:to="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyLoansMember_019c9afa-c4bc-72d2-9be2-5fe3f69c61c9_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policy loans</link:label>
    <link:label id="lab_us-gaap_PolicyLoansMember_019c9afa-c4bc-7b2b-bd97-23bf1a3c3c92_verboseLabel_en-US" xlink:label="lab_us-gaap_PolicyLoansMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Policy loans</link:label>
    <link:label id="lab_us-gaap_PolicyLoansMember_label_en-US" xlink:label="lab_us-gaap_PolicyLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policy Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyLoansMember" xlink:to="lab_us-gaap_PolicyLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c543-7d09-8c45-25073554215a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c543-78a8-a3e0-38f16a1f46b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c543-74e6-bb17-c4e3e8cf2fce_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c4bd-7341-9fed-9b5c68947050_negatedTotalLabel_en-US" xlink:label="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total impact from special items, pre-tax</link:label>
    <link:label id="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item Gain Or Loss Before Tax Attributable To Reporting Entity</link:label>
    <link:label id="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_documentation_en-US" xlink:label="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sum of before-tax tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity" xlink:href="ci-20260331.xsd#ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity" xlink:to="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_019c9afa-c42c-79e1-8e23-70e6dcfe493a_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial mortgage loans</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage Loans on Real Estate, Commercial and Consumer, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:to="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019c9afa-c42c-71f0-b247-e307e68dd827_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_019c9afa-c4bc-7ea1-9ef2-2e949e649920_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_019c9afa-c4bc-702c-a82a-77b19bf95dfb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_019c9afa-c542-7a97-a330-be1afcc927a5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_019c9afa-c42c-7391-8cf0-b6eebfbd9d0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_019c9afa-c543-7b22-9337-de486131f86c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c4bd-76d5-b474-6620487087c4_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskReinsurerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Reinsurer [Domain]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskReinsurerDomain_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskReinsurerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurer, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain" xlink:to="lab_us-gaap_CededCreditRiskReinsurerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-c42c-74f6-87b5-59b6836d72c5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c42c-7207-bacd-0bf7e3acbca7_terseLabel_en-US" xlink:label="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net long-duration insurance and contractholder liabilities measurement adjustments</link:label>
    <link:label id="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_label_en-US" xlink:label="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Parent [Member]</link:label>
    <link:label id="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_documentation_en-US" xlink:label="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AOCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:href="ci-20260331.xsd#ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:to="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c38f-720d-96ac-4cf63c580a83_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c38f-711c-8296-b4cdda5f49e1_totalLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrent_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities Current</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrent_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LifeAndAnnuityInsuranceProductLineMember_019c9afa-c38f-7da6-9343-e83761121909_terseLabel_en-US" xlink:label="lab_us-gaap_LifeAndAnnuityInsuranceProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Life and annuity insurance products</link:label>
    <link:label id="lab_us-gaap_LifeAndAnnuityInsuranceProductLineMember_label_en-US" xlink:label="lab_us-gaap_LifeAndAnnuityInsuranceProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Life and Annuity Insurance Product Line [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeAndAnnuityInsuranceProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LifeAndAnnuityInsuranceProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LifeAndAnnuityInsuranceProductLineMember" xlink:to="lab_us-gaap_LifeAndAnnuityInsuranceProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_019c9afa-c4bd-7b39-aaa1-71f4b86685dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019c9afa-c4bc-7dc3-90ea-6a8926cf61a7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019c9afa-c542-7a41-81a3-89ccb280bc58_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_019c9afa-c42c-7001-a197-8aadd59815e2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantee liability</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_019c9afa-c42c-7db8-8756-5ba1e6038fc9_netLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Guarantee liability</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_019c9afa-c4bc-7097-a3e5-d4009501ba10_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c543-7340-bbe3-6ec4dfdffbf6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c4bc-722e-9779-12c656d04b39_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoanToValueAxis_019c9afa-c542-7c9b-823c-fbeef272bb07_terseLabel_en-US" xlink:label="lab_us-gaap_LoanToValueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt-to-Value [Axis]</link:label>
    <link:label id="lab_us-gaap_LoanToValueAxis_label_en-US" xlink:label="lab_us-gaap_LoanToValueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt-to-Value [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoanToValueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoanToValueAxis" xlink:to="lab_us-gaap_LoanToValueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_019c9afa-c4bc-7e41-b977-e50787c32813_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Nonperformance risk (own credit risk), end of period</link:label>
    <link:label id="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_label_en-US" xlink:label="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Market Risk Benefit, Instrument-Specific Credit Risk, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" xlink:to="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesClassifiedInLevel3Percentage_019c9afa-c4bc-79bd-9088-65ddcb5aedd3_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesClassifiedInLevel3Percentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of debt securities classified in Level 3</link:label>
    <link:label id="lab_ci_DebtSecuritiesClassifiedInLevel3Percentage_label_en-US" xlink:label="lab_ci_DebtSecuritiesClassifiedInLevel3Percentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Classified In Level 3 Percentage</link:label>
    <link:label id="lab_ci_DebtSecuritiesClassifiedInLevel3Percentage_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesClassifiedInLevel3Percentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Classified In Level 3 Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesClassifiedInLevel3Percentage" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesClassifiedInLevel3Percentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesClassifiedInLevel3Percentage" xlink:to="lab_ci_DebtSecuritiesClassifiedInLevel3Percentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature_019c9afa-c4bd-7c1e-9ecc-76ce36f87ed0_totalLabel_en-US" xlink:label="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Maximum total commitment</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature_label_en-US" xlink:label="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Including Accordion Feature</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature_documentation_en-US" xlink:label="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Including Accordion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature" xlink:to="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_019c9afa-c38f-7eeb-b66c-4f43c153ace6_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_StrategicOptimizationProgramMember_019c9afa-c38f-7868-9302-c97f6e4d9a68_terseLabel_en-US" xlink:label="lab_ci_StrategicOptimizationProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Optimization Program</link:label>
    <link:label id="lab_ci_StrategicOptimizationProgramMember_label_en-US" xlink:label="lab_ci_StrategicOptimizationProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Optimization Program [Member]</link:label>
    <link:label id="lab_ci_StrategicOptimizationProgramMember_documentation_en-US" xlink:label="lab_ci_StrategicOptimizationProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic Optimization Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StrategicOptimizationProgramMember" xlink:href="ci-20260331.xsd#ci_StrategicOptimizationProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_StrategicOptimizationProgramMember" xlink:to="lab_ci_StrategicOptimizationProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c542-7376-bfd5-d0371403b0e6_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:to="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LitigationMattersAndRegulatoryMattersMember_019c9afa-c543-7613-b007-3ccd30803330_terseLabel_en-US" xlink:label="lab_ci_LitigationMattersAndRegulatoryMattersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Matters and Regulatory Matters</link:label>
    <link:label id="lab_ci_LitigationMattersAndRegulatoryMattersMember_label_en-US" xlink:label="lab_ci_LitigationMattersAndRegulatoryMattersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Matters And Regulatory Matters [Member]</link:label>
    <link:label id="lab_ci_LitigationMattersAndRegulatoryMattersMember_documentation_en-US" xlink:label="lab_ci_LitigationMattersAndRegulatoryMattersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Matters And Regulatory Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LitigationMattersAndRegulatoryMattersMember" xlink:href="ci-20260331.xsd#ci_LitigationMattersAndRegulatoryMattersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LitigationMattersAndRegulatoryMattersMember" xlink:to="lab_ci_LitigationMattersAndRegulatoryMattersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_019c9afa-c42c-7e1e-be69-5bda4cef3391_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_019c9afa-c542-70ba-b529-1fd67326f7b2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding balances</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SeparateAccountAssetAtCarryingValue_019c9afa-c42c-779a-b478-cb3dd9ccc450_terseLabel_en-US" xlink:label="lab_ci_SeparateAccountAssetAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate account assets</link:label>
    <link:label id="lab_ci_SeparateAccountAssetAtCarryingValue_label_en-US" xlink:label="lab_ci_SeparateAccountAssetAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Separate Account Asset, At Carrying Value</link:label>
    <link:label id="lab_ci_SeparateAccountAssetAtCarryingValue_documentation_en-US" xlink:label="lab_ci_SeparateAccountAssetAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Separate Account Asset, At Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetAtCarryingValue" xlink:href="ci-20260331.xsd#ci_SeparateAccountAssetAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SeparateAccountAssetAtCarryingValue" xlink:to="lab_ci_SeparateAccountAssetAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock_019c9afa-c4bc-7e79-a585-d4d07f899620_terseLabel_en-US" xlink:label="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractholder Deposit Funds</link:label>
    <link:label id="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractholder Deposit Funds, Policy [Policy Text Block]</link:label>
    <link:label id="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an entity's accounting policy for contractholder deposit funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:href="ci-20260331.xsd#ci_ContractholderDepositFundsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:to="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent_019c9afa-c38f-784c-9c2c-58173015d9bd_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market risk benefits, non-current</link:label>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent_label_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Liability, Amount, Noncurrent</link:label>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Liability, Amount, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:to="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019c9afa-c42c-7448-852a-6b293100a291_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019c9afa-c42c-7d44-8dde-e7cd8d170a6c_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Earnings per share, diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CommitmentsAndContingenciesTable_019c9afa-c543-7c20-8165-d445c4d8e0af_terseLabel_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesTable" xlink:href="ci-20260331.xsd#ci_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CommitmentsAndContingenciesTable" xlink:to="lab_ci_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_019c9afa-c542-7fad-80c0-ad2da3e9c76b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c38f-7eff-b4d2-a982a5cb6261_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance [Table]</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceTable_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceTable" xlink:to="lab_us-gaap_PolicyholderAccountBalanceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsAxis_019c9afa-c38f-7a50-9974-a4e1f90adcc3_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends [Axis]</link:label>
    <link:label id="lab_us-gaap_DividendsAxis_label_en-US" xlink:label="lab_us-gaap_DividendsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsAxis" xlink:to="lab_us-gaap_DividendsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceAccountingPolicy_019c9afa-c4bc-72db-8a3f-feb6abdbf902_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinsurance</link:label>
    <link:label id="lab_us-gaap_ReinsuranceAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceAccountingPolicy" xlink:to="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_019c9afa-c42c-71b8-9466-e53caabe0c14_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_019c9afa-c542-7db1-8685-5f12e32c664c_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountsPolicy_019c9afa-c543-7d8c-b4b8-c734e3c9b937_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate Accounts</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountsPolicy" xlink:to="lab_us-gaap_PolicyholderAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskAxis_019c9afa-c4bd-75ca-b319-2b1e5c313e98_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Reinsurer [Axis]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskAxis_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurer, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskAxis" xlink:to="lab_us-gaap_CededCreditRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_019c9afa-c4bc-7f19-bcf7-b6f935a5ce20_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incurred and Paid Claims Development</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Duration Insurance Contracts, Claims Development [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember_019c9afa-c543-728b-b6d6-80c98d9878f0_verboseLabel_en-US" xlink:label="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments and cash</link:label>
    <link:label id="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Cash Equivalents And Short Term Investments [Member]</link:label>
    <link:label id="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate of cash, cash equivalents and short-term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:href="ci-20260331.xsd#ci_CashCashEquivalentsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:to="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverables_019c9afa-c4bc-7c1c-819c-aae41a1447ef_totalLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverables" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total reinsurance recoverables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverables_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverables, Including Reinsurance Premium Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverables" xlink:to="lab_us-gaap_ReinsuranceRecoverables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePortfolioSegmentAxis_019c9afa-c38f-7eab-b311-88604cb543b6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Receivable Portfolio Segment [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePortfolioSegmentAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable Portfolio Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="lab_us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_A750Million6.000NotesDueJanuary2056Member_019c9afa-c4bc-7c66-96b8-0da25e0f3775_terseLabel_en-US" xlink:label="lab_ci_A750Million6.000NotesDueJanuary2056Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.000% Notes due January 2056</link:label>
    <link:label id="lab_ci_A750Million6.000NotesDueJanuary2056Member_label_en-US" xlink:label="lab_ci_A750Million6.000NotesDueJanuary2056Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$750 million, 6.000% Notes Due January 2056 [Member]</link:label>
    <link:label id="lab_ci_A750Million6.000NotesDueJanuary2056Member_documentation_en-US" xlink:label="lab_ci_A750Million6.000NotesDueJanuary2056Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$750 million, 6.000% Notes Due January 2056</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A750Million6.000NotesDueJanuary2056Member" xlink:href="ci-20260331.xsd#ci_A750Million6.000NotesDueJanuary2056Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_A750Million6.000NotesDueJanuary2056Member" xlink:to="lab_ci_A750Million6.000NotesDueJanuary2056Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_019c9afa-c42c-76dd-989b-5fafc146664e_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due</link:label>
    <link:label id="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_label_en-US" xlink:label="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit Reinsurance Recoverable After Allowance And Related Balances [Member]</link:label>
    <link:label id="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market risk benefit reinsurance recoverable, including IBNR and outstanding claims, less premiums due.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:to="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c9afa-c4bd-7f5c-94c3-9b3106e060c9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_019c9afa-c543-74b7-b156-bf04efe68a8e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InvestmentsCreditRatingAxis_019c9afa-c5bb-71ca-8d8e-d16ad496af36_terseLabel_en-US" xlink:label="lab_ci_InvestmentsCreditRatingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Credit Rating [Axis]</link:label>
    <link:label id="lab_ci_InvestmentsCreditRatingAxis_label_en-US" xlink:label="lab_ci_InvestmentsCreditRatingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Credit Rating [Axis]</link:label>
    <link:label id="lab_ci_InvestmentsCreditRatingAxis_documentation_en-US" xlink:label="lab_ci_InvestmentsCreditRatingAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by credit rating of debt and securities investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingAxis" xlink:href="ci-20260331.xsd#ci_InvestmentsCreditRatingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InvestmentsCreditRatingAxis" xlink:to="lab_ci_InvestmentsCreditRatingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsDomain_019c9afa-c38f-7900-b22d-2f6367adacee_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends [Domain]</link:label>
    <link:label id="lab_us-gaap_DividendsDomain_label_en-US" xlink:label="lab_us-gaap_DividendsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDomain" xlink:to="lab_us-gaap_DividendsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_019c9afa-c42c-7812-81df-2f98a7442dc8_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019c9afa-c4bc-7968-b9bc-dd99b5cc2b16_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Debt Securities with a Decline in Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-c4bd-7df9-aa05-cec300e47231_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_019c9afa-c543-744f-9a2a-beccf0710c44_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign government</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock_019c9afa-c4bc-7eeb-a976-0c5839b3f79f_terseLabel_en-US" xlink:label="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock_label_en-US" xlink:label="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Text Block]</link:label>
    <link:label id="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock_documentation_en-US" xlink:label="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclousre of the changes in the componenets of other comprehensive income/loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:href="ci-20260331.xsd#ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:to="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_019c9afa-c38f-7db3-a252-086197a5c861_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember" xlink:to="lab_us-gaap_OtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_019c9afa-c4bc-734b-9c5b-e6a369404362_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic optimization program costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_019c9afa-c4bc-7623-a5f1-29dbd8286058_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic optimization program</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_019c9afa-c5bb-77dd-b0ad-85240671eb22_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c42c-79f1-ade6-360277f1029c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019c9afa-c5bb-7610-b152-cf6d34fad4e1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_019c9afa-c42c-7368-a4cf-6f68154b4fe1_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with no readily determinable fair value</link:label>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_label_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Amortized Cost</link:label>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:to="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_019c9afa-c42c-7dc8-9f35-2c0c0004131c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments by category and current or long-term classification</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Holdings, Schedule of Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:to="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_019c9afa-c543-7f95-91d8-d73ef6db6078_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MeasurementInputEquityPriceVolatilityMember_019c9afa-c38f-740b-b116-72d481a1ce2a_terseLabel_en-US" xlink:label="lab_ci_MeasurementInputEquityPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Volatility</link:label>
    <link:label id="lab_ci_MeasurementInputEquityPriceVolatilityMember_label_en-US" xlink:label="lab_ci_MeasurementInputEquityPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Equity Price Volatility [Member]</link:label>
    <link:label id="lab_ci_MeasurementInputEquityPriceVolatilityMember_documentation_en-US" xlink:label="lab_ci_MeasurementInputEquityPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Equity Price Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputEquityPriceVolatilityMember" xlink:href="ci-20260331.xsd#ci_MeasurementInputEquityPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MeasurementInputEquityPriceVolatilityMember" xlink:to="lab_ci_MeasurementInputEquityPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_019c9afa-c5bb-7172-9ab5-73fbb5acdf80_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c4bd-79d0-8c0b-3062ab77e612_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Revenue from External Customer, Product and Service [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c9afa-c4bd-7630-be30-213ee2d2831a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputEntityCreditRiskMember_019c9afa-c38f-78c0-aab4-9070c93301a1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputEntityCreditRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchaser credit spread</link:label>
    <link:label id="lab_us-gaap_MeasurementInputEntityCreditRiskMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputEntityCreditRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Entity Credit Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputEntityCreditRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputEntityCreditRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputEntityCreditRiskMember" xlink:to="lab_us-gaap_MeasurementInputEntityCreditRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_019c9afa-c42c-7710-8aa0-38e270f8f077_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_019c9afa-c42c-754f-bb89-d3ac513f5c25_terseLabel_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Amount at Risk, by Product and Guarantee [Table]</link:label>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_label_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Amount at Risk, by Product and Guarantee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable" xlink:to="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-c38f-79d3-ac30-482aadb70991_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-c38f-7286-bd27-af1620ebc8b7_terseLabel_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefits and expenses</link:label>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benefits, Losses and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BenefitsLossesAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:to="lab_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019c9afa-c38f-7e0c-b54b-142a992bfe34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Depreciation</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019c9afa-c38f-7ca1-956c-7e40e5598519_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds on issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019c9afa-c42c-7da1-b2c7-46f5265f064e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_019c9afa-c42c-71fa-9ceb-222cb525653d_terseLabel_en-US" xlink:label="lab_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmacy and other service costs payable</link:label>
    <link:label id="lab_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_label_en-US" xlink:label="lab_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Pharmacy And Service Costs Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" xlink:href="ci-20260331.xsd#ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" xlink:to="lab_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019c9afa-c38f-76db-aa2d-3f8de8204c88_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Depreciation</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReinsuranceRecoverablesNumberOfReinsurers_019c9afa-c42c-7f8d-925b-5c659ba69aad_terseLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesNumberOfReinsurers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reinsurers</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesNumberOfReinsurers_label_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesNumberOfReinsurers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverables, Number Of Reinsurers</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesNumberOfReinsurers_documentation_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesNumberOfReinsurers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverables, Number Of Reinsurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesNumberOfReinsurers" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverablesNumberOfReinsurers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReinsuranceRecoverablesNumberOfReinsurers" xlink:to="lab_ci_ReinsuranceRecoverablesNumberOfReinsurers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_019c9afa-c543-725e-87a7-2305cb3262bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_019c9afa-c38f-7c8f-b4b1-230608d45c03_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_019c9afa-c38f-778e-be81-be8a4d61aa1b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_019c9afa-c542-750e-aac8-9403ab20c327_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_019c9afa-c542-72f1-af12-60c0646a2b18_totalLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c9afa-c4bc-7698-9c82-f4625dbde3ac_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Unrealized Depreciation</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_019c9afa-c42c-70b9-9079-9c60d8067865_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income distributions</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_019c9afa-c38f-7f85-b599-6994b7caec8a_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred profit liability included in future policy benefits</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Future Policy Benefits, Deferred Profit Liability</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Future Policy Benefits, Deferred Profit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019c9afa-c4bc-7b09-ad28-e200c3208c48_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive options</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceRelatedAssessmentsMember_019c9afa-c38f-7107-900b-e52471c023ef_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceRelatedAssessmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guaranty Fund Assessments</link:label>
    <link:label id="lab_us-gaap_InsuranceRelatedAssessmentsMember_label_en-US" xlink:label="lab_us-gaap_InsuranceRelatedAssessmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance-related Assessments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRelatedAssessmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceRelatedAssessmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRelatedAssessmentsMember" xlink:to="lab_us-gaap_InsuranceRelatedAssessmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c4bd-72b1-8636-6627df180849_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialGuaranteeMember_019c9afa-c42c-73b3-b856-5086f999f0f0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Guarantees</link:label>
    <link:label id="lab_us-gaap_FinancialGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_FinancialGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Guarantee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialGuaranteeMember" xlink:to="lab_us-gaap_FinancialGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-c38f-7e88-8e1a-d1adee9aac49_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CASH USED IN FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AllSegmentsExcludingCignaHealthcareMember_019c9afa-c4bc-70f2-86a4-c68d5755ec73_terseLabel_en-US" xlink:label="lab_ci_AllSegmentsExcludingCignaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ci_AllSegmentsExcludingCignaHealthcareMember_label_en-US" xlink:label="lab_ci_AllSegmentsExcludingCignaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Segments Excluding Cigna Healthcare [Member]</link:label>
    <link:label id="lab_ci_AllSegmentsExcludingCignaHealthcareMember_documentation_en-US" xlink:label="lab_ci_AllSegmentsExcludingCignaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Segments Excluding Cigna Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllSegmentsExcludingCignaHealthcareMember" xlink:href="ci-20260331.xsd#ci_AllSegmentsExcludingCignaHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AllSegmentsExcludingCignaHealthcareMember" xlink:to="lab_ci_AllSegmentsExcludingCignaHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OperatingResultsOfCertainNonstrategicBusinessesMember_019c9afa-c38f-79e4-9053-8d2a0c22da60_terseLabel_en-US" xlink:label="lab_ci_OperatingResultsOfCertainNonstrategicBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating results of certain non-strategic businesses</link:label>
    <link:label id="lab_ci_OperatingResultsOfCertainNonstrategicBusinessesMember_label_en-US" xlink:label="lab_ci_OperatingResultsOfCertainNonstrategicBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Results Of Certain Nonstrategic Businesses [Member]</link:label>
    <link:label id="lab_ci_OperatingResultsOfCertainNonstrategicBusinessesMember_documentation_en-US" xlink:label="lab_ci_OperatingResultsOfCertainNonstrategicBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Results Of Certain Non-strategic Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingResultsOfCertainNonstrategicBusinessesMember" xlink:href="ci-20260331.xsd#ci_OperatingResultsOfCertainNonstrategicBusinessesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OperatingResultsOfCertainNonstrategicBusinessesMember" xlink:to="lab_ci_OperatingResultsOfCertainNonstrategicBusinessesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_019c9afa-c4bd-75c6-a0f8-0702bb6ffeec_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashSurrenderValueDuePolicyholdersAmount_019c9afa-c4bc-72ce-ae9f-974c23469578_terseLabel_en-US" xlink:label="lab_us-gaap_CashSurrenderValueDuePolicyholdersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash surrender value</link:label>
    <link:label id="lab_us-gaap_CashSurrenderValueDuePolicyholdersAmount_label_en-US" xlink:label="lab_us-gaap_CashSurrenderValueDuePolicyholdersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Cash Surrender Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashSurrenderValueDuePolicyholdersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount" xlink:to="lab_us-gaap_CashSurrenderValueDuePolicyholdersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_019c9afa-c4bc-765b-9df3-2700fcf5701f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmacy and other service costs</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_019c9afa-c543-75d7-b93b-92d6213cffa2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_019c9afa-c543-7d20-887d-628d1da23867_terseLabel_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Axis]</link:label>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_label_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Axis]</link:label>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_documentation_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:href="ci-20260331.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:to="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitPolicyTextBlock_019c9afa-c38f-7a93-ab8d-0115428bcbdc_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Risk Benefits</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:to="lab_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligation_019c9afa-c42c-7d6d-a99d-2d245ea5e7a2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding payment obligations, supplier finance program</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligation_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligation" xlink:to="lab_us-gaap_SupplierFinanceProgramObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInvestmentExpense_019c9afa-c4bc-79a3-b645-f68319274cd1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less investment expenses</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInvestmentExpense_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Investment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019c9afa-c542-70fb-82d8-837220396b89_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_019c9afa-c38f-7ca5-9b68-23e4c050749f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsLiquidationProceeds_019c9afa-c543-713b-b580-676dddbf1e34_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLiquidationProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets maintained by employers (minimum)</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsLiquidationProceeds_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLiquidationProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Liquidation Proceeds, Monetary Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLiquidationProceeds" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsLiquidationProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsLiquidationProceeds" xlink:to="lab_us-gaap_GuaranteeObligationsLiquidationProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_019c9afa-c42c-7a6e-9a90-4fd655cd26cd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeMember_019c9afa-c42c-749b-8b50-e7575d5a159d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeMember_label_en-US" xlink:label="lab_us-gaap_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeMember" xlink:to="lab_us-gaap_DerivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_019c9afa-c38f-76d2-b8bf-97552d57aaf6_terseLabel_en-US" xlink:label="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guaranteed Minimum Death Benefits Total Contractholders</link:label>
    <link:label id="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_label_en-US" xlink:label="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Amount At Risk By Product And Guarantee, Number Of Contractholders Estimated</link:label>
    <link:label id="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_documentation_en-US" xlink:label="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Amount At Risk By Product And Guarantee, Number Of Contractholders Estimated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:href="ci-20260331.xsd#ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:to="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_019c9afa-c543-78e0-8c62-62ada60b90bc_negatedTotalLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Investments classified as assets of business held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_019c9afa-c42c-790e-860c-3dc0bf3b5d92_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future policy benefits, current</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Future Policy Benefit, Before Reinsurance, Current</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Future Policy Benefit, Before Reinsurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019c9afa-c38f-7f3a-9b49-d4c9715367bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities_019c9afa-c42c-7c00-81a2-ce9adf169f42_terseLabel_en-US" xlink:label="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities and equity securities</link:label>
    <link:label id="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities_label_en-US" xlink:label="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Debt And Equity Securities</link:label>
    <link:label id="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities_documentation_en-US" xlink:label="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from sales of debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:href="ci-20260331.xsd#ci_ProceedsFromSaleOfDebtAndEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:to="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c4bd-7701-a456-33adaaf338e4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future policy benefits reserve, reinsurance recoverables</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit, Reinsurance Recoverable, after Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember_label_en-US" xlink:label="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Zero PercentTarget Level [Member]</link:label>
    <link:label id="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember_documentation_en-US" xlink:label="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Zero PercentTarget Level</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember" xlink:href="ci-20260331.xsd#ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember" xlink:to="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_019c9afa-c38f-7b69-ba70-a468dd9e8067_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers into / (out of) Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_019c9afa-c42c-7b95-a827-67621af636f1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_019c9afa-c38f-7a74-af46-48448b976faa_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_label_en-US" xlink:label="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees, Indemnifications and Warranties Policies [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_019c9afa-c543-779f-9e56-5d37ec469fe0_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019c9afa-c38f-7c59-9f4f-bd2883495e97_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverablesAllowance_019c9afa-c42c-759d-a34d-27062b28b909_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverablesAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Allowance for uncollectible reinsurance</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverablesAllowance_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverablesAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverablesAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverablesAllowance" xlink:to="lab_us-gaap_ReinsuranceRecoverablesAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy_019c9afa-c38f-72d4-aa74-76896dec3345_terseLabel_en-US" xlink:label="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Policy Benefits</link:label>
    <link:label id="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy_label_en-US" xlink:label="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FuturePolicyBenefitsLiabilityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:to="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c9afa-c542-7302-9b4e-e6300a71722e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrent_019c9afa-c38f-74f2-a7b8-197d1c503a36_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding payment obligations, current</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrent_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c38f-7592-b351-a3a1e151f8dc_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinsurance Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReinsuranceDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract" xlink:to="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_019c9afa-c4bc-7203-8c0b-93ed4ba7f3bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LtvLessThan60PercentMember_019c9afa-c4bd-711f-ba28-585d75cdc830_terseLabel_en-US" xlink:label="lab_ci_LtvLessThan60PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Below 60%</link:label>
    <link:label id="lab_ci_LtvLessThan60PercentMember_label_en-US" xlink:label="lab_ci_LtvLessThan60PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LTV Less Than 60 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvLessThan60PercentMember" xlink:href="ci-20260331.xsd#ci_LtvLessThan60PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LtvLessThan60PercentMember" xlink:to="lab_ci_LtvLessThan60PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019c9afa-c42c-7c2a-8c21-5b9c8a1c9d30_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) included in Shareholders' net income</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c4bc-7cfd-a84e-3dea356015e6_terseLabel_en-US" xlink:label="lab_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax adjustments to reconcile to adjusted income from operations</link:label>
    <link:label id="lab_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_label_en-US" xlink:label="lab_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pretax Adjustments To Reconcile Adjusted Income From Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" xlink:href="ci-20260331.xsd#ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" xlink:to="lab_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-c543-7e8b-af37-13ed8c124232_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Redeemable Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019c9afa-c542-7623-b345-d608af39cb1e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_019c9afa-c4bd-7507-9370-076190494b9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roll forward of Accrued Liability</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_019c9afa-c543-7584-9e6c-b8a2f091102f_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future policy benefit, excluding deferred profit liability</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Future Policy Benefit, Excluding Deferred Profit Liability</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Future Policy Benefit, Excluding Deferred Profit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c9afa-c4bd-7664-b85e-4c40d424ab24_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c42c-76ee-ab20-18d7259d6ad2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_019c9afa-c4bc-7df9-8537-df98df634bde_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019c9afa-c38f-7959-ba42-dd3c28a89f59_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c9afa-c38f-73ae-9dc9-d1689a7fa119_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_019c9afa-c42c-7ac4-be69-4a5e4eeda2cf_terseLabel_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities and derivatives</link:label>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_label_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Parent [Member]</link:label>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_documentation_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:href="ci-20260331.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:to="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_019c9afa-c542-71e8-89c3-0af1312f57db_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_019c9afa-c42c-7997-870f-a694bb26b42c_terseLabel_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net amount at risk</link:label>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_label_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Amount at Risk by Product and Guarantee, Net Amount at Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" xlink:to="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_019c9afa-c38f-7fda-a159-bf57d4d7fccf_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019c9afa-c543-7d5e-90f7-68a9ef096748_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_019c9afa-c38f-7c99-aeb0-58bef21f35d9_terseLabel_en-US" xlink:label="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded commitments, percentage expected to fund in next fiscal year</link:label>
    <link:label id="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_label_en-US" xlink:label="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unfunded Commitments, Percentage Expected To Fund In Next Fiscal Year</link:label>
    <link:label id="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_documentation_en-US" xlink:label="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unfunded Commitments, Percentage Expected To Fund In Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:href="ci-20260331.xsd#ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:to="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_019c9afa-c38f-73d2-8a31-9c6aafe27833_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c4bd-7e45-bf61-c9951ac7ca43_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c4bd-74e8-8e1f-64870c44682d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherPharmacyMember_019c9afa-c543-7715-9e67-dd370115d8d3_terseLabel_en-US" xlink:label="lab_ci_OtherPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_ci_OtherPharmacyMember_label_en-US" xlink:label="lab_ci_OtherPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Pharmacy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherPharmacyMember" xlink:href="ci-20260331.xsd#ci_OtherPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherPharmacyMember" xlink:to="lab_ci_OtherPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c42c-7560-b90d-ce476dfb2dd9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c42c-72e2-87d9-d8aa51f54b74_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Favorable (unfavorable) variance, amount</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_Ltv60To79PercentMember_019c9afa-c542-7880-8b61-271e007c64a7_terseLabel_en-US" xlink:label="lab_ci_Ltv60To79PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">60% to 79%</link:label>
    <link:label id="lab_ci_Ltv60To79PercentMember_label_en-US" xlink:label="lab_ci_Ltv60To79PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LTV 60 to 79 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_Ltv60To79PercentMember" xlink:href="ci-20260331.xsd#ci_Ltv60To79PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_Ltv60To79PercentMember" xlink:to="lab_ci_Ltv60To79PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_019c9afa-c543-7596-be0b-60d35a5181aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_019c9afa-c42c-7fb6-81a5-66fd65467c7d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_019c9afa-c42c-7b96-90cc-5963fa8ef264_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_019c9afa-c5bb-7cad-bf55-699ecd2a7cca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Losses) gains included in Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnearnedPremiums_019c9afa-c4bc-7721-b4b2-fb2b5a1dd96e_totalLabel_en-US" xlink:label="lab_us-gaap_UnearnedPremiums" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unearned premiums</link:label>
    <link:label id="lab_us-gaap_UnearnedPremiums_label_en-US" xlink:label="lab_us-gaap_UnearnedPremiums" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unearned Premiums</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnearnedPremiums"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnearnedPremiums" xlink:to="lab_us-gaap_UnearnedPremiums" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncatastrophicEventAxis_019c9afa-c42c-773e-bbf0-cd2f6fb49d83_terseLabel_en-US" xlink:label="lab_us-gaap_NoncatastrophicEventAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncatastrophic Event [Axis]</link:label>
    <link:label id="lab_us-gaap_NoncatastrophicEventAxis_label_en-US" xlink:label="lab_us-gaap_NoncatastrophicEventAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncatastrophic Event [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncatastrophicEventAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncatastrophicEventAxis" xlink:to="lab_us-gaap_NoncatastrophicEventAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_019c9afa-c4bc-7316-959e-8593d5e31a5d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019c9afa-c543-7316-9e82-204dfb82bda1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Depreciation</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019c9afa-c5bb-75d6-bbec-fc5109811064_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019c9afa-c5bb-7274-a482-419b0f832ba9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share, basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_019c9afa-c542-7520-9ed5-e0f5b4d4a824_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_StopLossMember_019c9afa-c42c-71c7-b723-bef2a2166ab1_terseLabel_en-US" xlink:label="lab_ci_StopLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stop loss</link:label>
    <link:label id="lab_ci_StopLossMember_label_en-US" xlink:label="lab_ci_StopLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stop Loss [Member]</link:label>
    <link:label id="lab_ci_StopLossMember_documentation_en-US" xlink:label="lab_ci_StopLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An insurance product that provides additional coverage on Administrative Services Only plans that provides reimbursement for claims in excess of a predetermined amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StopLossMember" xlink:href="ci-20260331.xsd#ci_StopLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_StopLossMember" xlink:to="lab_ci_StopLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_019c9afa-c4bc-761d-8209-346278cdfd66_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_019c9afa-c38f-7040-a3c2-40d77a5d406a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-c543-7de6-94e1-1f19e2e6305b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-c543-78d7-ac81-078e3b1fb62b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_019c9afa-c38f-7098-a1bd-cac2e8f247be_totalLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total purchases, sales and settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019c9afa-c38f-7e1f-b895-bf84c8c64d84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarized Segment Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_019c9afa-c42c-765a-8188-5c0a6063cd5b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average duration</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit, Weighted-Average Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_019c9afa-c38f-7512-8a92-c602e9164720_terseLabel_en-US" xlink:label="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends Payable, Date to be Paid</link:label>
    <link:label id="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_label_en-US" xlink:label="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable, Date to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:to="lab_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_019c9afa-c542-781b-aa4d-51e28fd681dc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c38f-71b1-8038-76b83819d2a5_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance [Line Items]</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceLineItems_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems" xlink:to="lab_us-gaap_PolicyholderAccountBalanceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_019c9afa-c38f-7f58-b68b-3c77b580ebff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DividendsReceivableImpairmentLoss_019c9afa-c38f-7806-879c-5224fc1caa76_terseLabel_en-US" xlink:label="lab_ci_DividendsReceivableImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of dividend receivable</link:label>
    <link:label id="lab_ci_DividendsReceivableImpairmentLoss_label_en-US" xlink:label="lab_ci_DividendsReceivableImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Receivable, Impairment Loss</link:label>
    <link:label id="lab_ci_DividendsReceivableImpairmentLoss_documentation_en-US" xlink:label="lab_ci_DividendsReceivableImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividends Receivable, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DividendsReceivableImpairmentLoss" xlink:href="ci-20260331.xsd#ci_DividendsReceivableImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DividendsReceivableImpairmentLoss" xlink:to="lab_ci_DividendsReceivableImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_019c9afa-c38f-76b6-8d8e-e147dd6e995b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverables</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:to="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NetInvestmentGainsLossesEquityMethodInvestments_019c9afa-c542-7f3a-8503-9b368beaf3c2_negatedLabel_en-US" xlink:label="lab_ci_NetInvestmentGainsLossesEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net investment results from certain equity method investments</link:label>
    <link:label id="lab_ci_NetInvestmentGainsLossesEquityMethodInvestments_label_en-US" xlink:label="lab_ci_NetInvestmentGainsLossesEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Gains Losses Equity Method Investments</link:label>
    <link:label id="lab_ci_NetInvestmentGainsLossesEquityMethodInvestments_documentation_en-US" xlink:label="lab_ci_NetInvestmentGainsLossesEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains (losses), attributable to equity method investment, based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainsLossesEquityMethodInvestments" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainsLossesEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NetInvestmentGainsLossesEquityMethodInvestments" xlink:to="lab_ci_NetInvestmentGainsLossesEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_019c9afa-c42c-73f6-a37d-efd12370d0ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Renewable energy tax credit equity investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemsAfterTaxAbstract_019c9afa-c543-7703-961d-fc24bec6f52d_terseLabel_en-US" xlink:label="lab_ci_SpecialItemsAfterTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After-tax</link:label>
    <link:label id="lab_ci_SpecialItemsAfterTaxAbstract_label_en-US" xlink:label="lab_ci_SpecialItemsAfterTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Items After Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsAfterTaxAbstract" xlink:href="ci-20260331.xsd#ci_SpecialItemsAfterTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract" xlink:to="lab_ci_SpecialItemsAfterTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_019c9afa-c42c-714d-8d0f-8c9f6f241adf_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_019c9afa-c542-7e44-a77b-ef2fe75d3644_negatedLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Investments classified as assets of business held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Including Discontinued Operation Noncurrent Investments Current</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group Including Discontinued Operation Noncurrent Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019c9afa-c543-7ee7-a3f4-1b2ff6dae1c0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_019c9afa-c4bd-7468-971b-808ce4dce475_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation of Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c9afa-c543-7223-94ac-5b7ff3c7b79b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_019c9afa-c542-7ce5-8a24-4c79a7eef150_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Postretirement benefits liability</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c4bd-79ad-845f-a0e087ff93d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_019c9afa-c42c-741e-ad12-04ec53a84a24_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis points above guaranteed minimum crediting rate</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" xlink:to="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c9afa-c4bd-75f9-99cb-3610690df15c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash January 1, including held for sale assets</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c9afa-c4bd-7a16-bac2-f3cabc47e083_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash December 31, including held for sale assets</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NetworkPharmacyMember_019c9afa-c543-77ee-b477-8faf3c1b9358_terseLabel_en-US" xlink:label="lab_ci_NetworkPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Network revenues</link:label>
    <link:label id="lab_ci_NetworkPharmacyMember_label_en-US" xlink:label="lab_ci_NetworkPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Network Pharmacy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetworkPharmacyMember" xlink:href="ci-20260331.xsd#ci_NetworkPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NetworkPharmacyMember" xlink:to="lab_ci_NetworkPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_019c9afa-c542-740a-8bfd-a5e14b7d4372_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareMember_019c9afa-c42c-7206-87fb-61fa2dacb184_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cigna Healthcare</link:label>
    <link:label id="lab_us-gaap_HealthCareMember_label_en-US" xlink:label="lab_us-gaap_HealthCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareMember" xlink:to="lab_us-gaap_HealthCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c38f-7fcf-8ec7-da1a5f511b71_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderContractDeposits_019c9afa-c38f-7474-9bd3-55f93e79d427_totalLabel_en-US" xlink:label="lab_us-gaap_PolicyholderContractDeposits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Contractholder deposit funds</link:label>
    <link:label id="lab_us-gaap_PolicyholderContractDeposits_019c9afa-c38f-787b-87f6-15d274f23c4a_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderContractDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractholder deposit funds</link:label>
    <link:label id="lab_us-gaap_PolicyholderContractDeposits_label_en-US" xlink:label="lab_us-gaap_PolicyholderContractDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Contract Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderContractDeposits" xlink:to="lab_us-gaap_PolicyholderContractDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_019c9afa-c42c-7450-99ba-dfc94e0bec59_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (primarily short-term and other long-term investments)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_TransactionRelatedCostsAfterTax_019c9afa-c543-7143-a329-bb6067296d71_terseLabel_en-US" xlink:label="lab_ci_TransactionRelatedCostsAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Integration and transaction-related costs, after-tax</link:label>
    <link:label id="lab_ci_TransactionRelatedCostsAfterTax_label_en-US" xlink:label="lab_ci_TransactionRelatedCostsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Related Costs After Tax</link:label>
    <link:label id="lab_ci_TransactionRelatedCostsAfterTax_documentation_en-US" xlink:label="lab_ci_TransactionRelatedCostsAfterTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After-tax transaction-related costs including the impact of tax benefits realized from termination of merger agreement. Transaction-related costs consist primarily of fees for legal, advisory and other professional services as well as employee costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCostsAfterTax" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCostsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_TransactionRelatedCostsAfterTax" xlink:to="lab_ci_TransactionRelatedCostsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_019c9afa-c42c-70c9-9d3e-6dc8b7cc332d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableLineItems_019c9afa-c38f-7d9e-abee-faaa98d6fe1a_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends Payable [Line Items]</link:label>
    <link:label id="lab_us-gaap_DividendsPayableLineItems_label_en-US" xlink:label="lab_us-gaap_DividendsPayableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableLineItems" xlink:to="lab_us-gaap_DividendsPayableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric_019c9afa-c42c-7b2f-8115-0bb0c8a9b3a5_terseLabel_en-US" xlink:label="lab_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric_label_en-US" xlink:label="lab_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General Administrative Expenses Segment Performance Metric</link:label>
    <link:label id="lab_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric_documentation_en-US" xlink:label="lab_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selling, General Administrative Expenses Segment Performance Metric</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" xlink:href="ci-20260331.xsd#ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" xlink:to="lab_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_019c9afa-c42c-70d3-aca2-722c2489b35f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c38f-7440-aab2-c138f8cf3649_negatedLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Risk corridors recovery</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c38f-7c22-bdbc-896da55b94be_negatedTerseLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Risk corridors recovery</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_label_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Before Taxes</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_documentation_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Before Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:to="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_019c9afa-c543-7ae1-9707-074fa0fe1579_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_019c9afa-c4bc-7915-8cf5-6bd106485d2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c542-77cf-a0be-f362b321d8ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_019c9afa-c38f-77bf-ba53-de7797cb07f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax_019c9afa-c38f-754e-a6de-d8ab62b9a86a_terseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expenses (benefits), after-tax</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax_label_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item Charge Benefit Tax Matters After Tax</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax_documentation_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Item Charge Benefit Tax Matters After Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitTaxMattersAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:to="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_019c9afa-c38f-78e1-ae15-a03d45b7ed6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_019c9afa-c38f-7676-a32f-7a03e752f22c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">SHAREHOLDERS' COMPREHENSIVE INCOME</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_019c9afa-c543-702c-9c3a-f41c261e7f0c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c42c-7a89-8056-46c0f1c30911_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceCustomerReceivables_019c9afa-c38f-7ff6-a5f0-3815331383f7_terseLabel_en-US" xlink:label="lab_ci_InsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance customer receivables</link:label>
    <link:label id="lab_ci_InsuranceCustomerReceivables_label_en-US" xlink:label="lab_ci_InsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Customer Receivables</link:label>
    <link:label id="lab_ci_InsuranceCustomerReceivables_documentation_en-US" xlink:label="lab_ci_InsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivables due from customers under insurance contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivables" xlink:href="ci-20260331.xsd#ci_InsuranceCustomerReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceCustomerReceivables" xlink:to="lab_ci_InsuranceCustomerReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MeasurementInputInterVariableCorrelationAssumptionMember_019c9afa-c38f-7b16-a747-b749437a225c_terseLabel_en-US" xlink:label="lab_ci_MeasurementInputInterVariableCorrelationAssumptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Correlation</link:label>
    <link:label id="lab_ci_MeasurementInputInterVariableCorrelationAssumptionMember_label_en-US" xlink:label="lab_ci_MeasurementInputInterVariableCorrelationAssumptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Inter-Variable Correlation Assumption [Member]</link:label>
    <link:label id="lab_ci_MeasurementInputInterVariableCorrelationAssumptionMember_documentation_en-US" xlink:label="lab_ci_MeasurementInputInterVariableCorrelationAssumptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Inter-Variable Correlation Assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputInterVariableCorrelationAssumptionMember" xlink:href="ci-20260331.xsd#ci_MeasurementInputInterVariableCorrelationAssumptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MeasurementInputInterVariableCorrelationAssumptionMember" xlink:to="lab_ci_MeasurementInputInterVariableCorrelationAssumptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c9afa-c4bc-72c7-baf6-8130982dde5c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted_019c9afa-c543-73ba-97fe-70f352ac5e3c_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables collected but not remitted to the financial institution</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facilities, Accounts Receivable Received But Not Remitted</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of, as of the reporting date, of receivables sold to a financial institution under uncommitted Accounts receivable factoring facilities that have been received from the manufacturers but not yet remitted to the financial institution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_019c9afa-c38f-71f5-85f2-d01c080cae5a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IndividualAndFamilyPlansMember_019c9afa-c4bc-7ee0-af50-dea14cadc0b3_terseLabel_en-US" xlink:label="lab_ci_IndividualAndFamilyPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual and Family Plans</link:label>
    <link:label id="lab_ci_IndividualAndFamilyPlansMember_label_en-US" xlink:label="lab_ci_IndividualAndFamilyPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual And Family Plans [Member]</link:label>
    <link:label id="lab_ci_IndividualAndFamilyPlansMember_documentation_en-US" xlink:label="lab_ci_IndividualAndFamilyPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndividualAndFamilyPlansMember" xlink:href="ci-20260331.xsd#ci_IndividualAndFamilyPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IndividualAndFamilyPlansMember" xlink:to="lab_ci_IndividualAndFamilyPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_019c9afa-c38f-7087-8f11-8ea75620eff4_terseLabel_en-US" xlink:label="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and Accrued expenses and other liabilities</link:label>
    <link:label id="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued And Other Operating Liabilities</link:label>
    <link:label id="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_documentation_en-US" xlink:label="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of accounts payable, accrued liabilities and other operating obligations not separately disclosed in the statement of cash flows.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:href="ci-20260331.xsd#ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:to="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue_019c9afa-c38f-752c-9379-c9e1a148987d_terseLabel_en-US" xlink:label="lab_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairments requiring certain assets and liabilities to be measured at fair value</link:label>
    <link:label id="lab_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue_label_en-US" xlink:label="lab_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairments Requiring Certain Assets And Liabilities To Be Measured At Fair Value</link:label>
    <link:label id="lab_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue_documentation_en-US" xlink:label="lab_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impairments requiring certain financial assets and liabilities, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions, to be measured using fair value. These financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue" xlink:href="ci-20260331.xsd#ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue" xlink:to="lab_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_019c9afa-c38f-73ea-9c5d-0c4b2a3f01b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate accounts assets classified in Level 3, period increase (decrease), including transfers in and out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_019c9afa-c543-7b55-ba0e-98ed6d4c0f5a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Appreciation (Depreciation) on Debt Securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019c9afa-c543-7d2a-ae52-0cce2db94ede_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_019c9afa-c42c-7c7f-8791-24b7af01839d_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_019c9afa-c42c-75b9-b918-d37af7c6e22c_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, before Reinsurance and Cumulative Increase (Decrease) from Instrument-Specific Credit Risk Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:to="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_019c9afa-c543-7c70-83a8-cd9cc8ebc66c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c4bd-7b61-8203-3a024839f83a_verboseLabel_en-US" xlink:label="lab_ci_RestructuringChargesNetOfTaxExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic optimization program costs, after-tax</link:label>
    <link:label id="lab_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c4bd-7421-8a35-96e5ea825d56_terseLabel_en-US" xlink:label="lab_ci_RestructuringChargesNetOfTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic optimization program, after-tax</link:label>
    <link:label id="lab_ci_RestructuringChargesNetOfTaxExpense_label_en-US" xlink:label="lab_ci_RestructuringChargesNetOfTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Net Of Tax Expense</link:label>
    <link:label id="lab_ci_RestructuringChargesNetOfTaxExpense_documentation_en-US" xlink:label="lab_ci_RestructuringChargesNetOfTaxExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Net Of Tax Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestructuringChargesNetOfTaxExpense" xlink:href="ci-20260331.xsd#ci_RestructuringChargesNetOfTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RestructuringChargesNetOfTaxExpense" xlink:to="lab_ci_RestructuringChargesNetOfTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnearnedPremiumsNoncurrent_019c9afa-c542-7c80-a699-425f44698683_terseLabel_en-US" xlink:label="lab_ci_UnearnedPremiumsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unearned premiums, non-current</link:label>
    <link:label id="lab_ci_UnearnedPremiumsNoncurrent_label_en-US" xlink:label="lab_ci_UnearnedPremiumsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unearned Premiums, Noncurrent</link:label>
    <link:label id="lab_ci_UnearnedPremiumsNoncurrent_documentation_en-US" xlink:label="lab_ci_UnearnedPremiumsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unearned Premiums, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrent" xlink:href="ci-20260331.xsd#ci_UnearnedPremiumsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnearnedPremiumsNoncurrent" xlink:to="lab_ci_UnearnedPremiumsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c42c-7a07-9da0-c27132082251_periodStartLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c42c-7a3c-88d8-ad775535c753_periodEndLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense Including Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c38f-750a-ae8a-6b5f2877ca50_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EarningsPerShareEffectOfDilution_019c9afa-c543-7d7e-8a94-3e4b70cd308a_terseLabel_en-US" xlink:label="lab_ci_EarningsPerShareEffectOfDilution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share, effect of dilution</link:label>
    <link:label id="lab_ci_EarningsPerShareEffectOfDilution_label_en-US" xlink:label="lab_ci_EarningsPerShareEffectOfDilution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Effect Of Dilution</link:label>
    <link:label id="lab_ci_EarningsPerShareEffectOfDilution_documentation_en-US" xlink:label="lab_ci_EarningsPerShareEffectOfDilution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The decrease in net income (loss) on a per share basis when the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period is assumed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EarningsPerShareEffectOfDilution" xlink:href="ci-20260331.xsd#ci_EarningsPerShareEffectOfDilution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EarningsPerShareEffectOfDilution" xlink:to="lab_ci_EarningsPerShareEffectOfDilution" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OrganizationalEfficiencyPlanMember_019c9afa-c38f-7fd8-8d4b-734c7cf00fc7_terseLabel_en-US" xlink:label="lab_ci_OrganizationalEfficiencyPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organizational Efficiency Plan</link:label>
    <link:label id="lab_ci_OrganizationalEfficiencyPlanMember_label_en-US" xlink:label="lab_ci_OrganizationalEfficiencyPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organizational Efficiency Plan [Member]</link:label>
    <link:label id="lab_ci_OrganizationalEfficiencyPlanMember_documentation_en-US" xlink:label="lab_ci_OrganizationalEfficiencyPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organizational Efficiency Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanMember" xlink:href="ci-20260331.xsd#ci_OrganizationalEfficiencyPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OrganizationalEfficiencyPlanMember" xlink:to="lab_ci_OrganizationalEfficiencyPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NoncontrollingInterestOtherChanges_019c9afa-c38f-7064-85da-fe5f7f6e29a3_verboseLabel_en-US" xlink:label="lab_ci_NoncontrollingInterestOtherChanges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other transactions impacting noncontrolling interests</link:label>
    <link:label id="lab_ci_NoncontrollingInterestOtherChanges_label_en-US" xlink:label="lab_ci_NoncontrollingInterestOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest Other Changes</link:label>
    <link:label id="lab_ci_NoncontrollingInterestOtherChanges_documentation_en-US" xlink:label="lab_ci_NoncontrollingInterestOtherChanges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other activity associated with noncontrolling interest that is not separately disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoncontrollingInterestOtherChanges" xlink:href="ci-20260331.xsd#ci_NoncontrollingInterestOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NoncontrollingInterestOtherChanges" xlink:to="lab_ci_NoncontrollingInterestOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c38f-7ea2-8bfc-874776383e56_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets at fair value:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_019c9afa-c38f-7fb5-be02-98b13da14de3_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends Payable, Date Declared</link:label>
    <link:label id="lab_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_label_en-US" xlink:label="lab_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable, Date Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:to="lab_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_019c9afa-c4bd-7b86-a1b6-f3e96b7fbb79_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019c9afa-c543-7aea-ad4f-8a5ae0b2e669_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c543-7f31-b466-6af5ded4f82f_negatedTotalLabel_en-US" xlink:label="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total impact from special items, after-tax</link:label>
    <link:label id="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item Gain Or Loss Net Of Tax Attributable To Reporting Entity</link:label>
    <link:label id="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_documentation_en-US" xlink:label="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sum of after-tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity" xlink:href="ci-20260331.xsd#ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity" xlink:to="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c4bc-7d12-b558-782a81792077_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_019c9afa-c4bd-7370-8fd2-411a3dd0f278_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_019c9afa-c4bc-7579-a3ea-be9172c851c5_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation_019c9afa-c543-73f7-b0d3-3374c3bc0bb9_verboseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Charges (benefits) associated with litigation matters, after-tax</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation_label_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item Charge (Benefit) After Tax Litigation</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation_documentation_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitAfterTaxLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:to="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_019c9afa-c5bb-7da4-bd86-0d3708586d33_terseLabel_en-US" xlink:label="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Favorable (unfavorable) variance, percentage</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_label_en-US" xlink:label="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Unpaid Medical Claims And Claims Adjustment Expense Incurred Claims Prior Years Percentage</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_documentation_en-US" xlink:label="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of payments made in the reporting period to settle claims incurred in prior periods and related claims settlement costs as a percentage of incurred claims as reported in the prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:to="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilities_019c9afa-c38f-7e45-bcd2-ce73a39c16af_totalLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilities_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilities_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance And Contractholder Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilities" xlink:to="lab_ci_InsuranceAndContractholderLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_019c9afa-c38f-7bbd-9d03-cf7717b938ad_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Measurement Input</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset (Liability) Net, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetLiabilityNetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:to="lab_us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c42c-7652-888c-fb77d12656e3_terseLabel_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt extinguishment costs (gains)</link:label>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_label_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item Charges Debt Extinguishment Costs Before Tax</link:label>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_documentation_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Item Charges Debt Extinguishment Costs Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:to="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_019c9afa-c42c-75a0-8785-0b58cbdc1660_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers into Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_019c9afa-c4bc-7040-a7cf-3e506dee5c73_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_019c9afa-c42c-7677-a18f-666062b6603e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_019c9afa-c38f-7aee-ae98-226c8dafc00b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverablesGross_019c9afa-c4bc-7ec7-9e31-cd17797581ff_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverablesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinsurance recoverables before market risk benefits</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverablesGross_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverablesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverables, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverablesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverablesGross" xlink:to="lab_us-gaap_ReinsuranceRecoverablesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c9afa-c42c-76de-bdb7-63b89377a13c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net changes in assets and liabilities, net of non-operating effects:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold_019c9afa-c4bd-7678-b607-c130ba8b1a28_terseLabel_en-US" xlink:label="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding payment obligations, current, voluntarily elected by suppliers to be sold to the financial institution</link:label>
    <link:label id="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold_label_en-US" xlink:label="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Outstanding Payment Obligation, Current, Voluntarily Elected To Be Sold</link:label>
    <link:label id="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold_documentation_en-US" xlink:label="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Outstanding Payment Obligation, Current, Voluntarily Elected To Be Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:href="ci-20260331.xsd#ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:to="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_019c9afa-c42c-7b65-a815-5316fad91fac_terseLabel_en-US" xlink:label="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable</link:label>
    <link:label id="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_label_en-US" xlink:label="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Secured, Contractually Required Fair Value [Member]</link:label>
    <link:label id="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_documentation_en-US" xlink:label="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Secured, Contractually Required Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:href="ci-20260331.xsd#ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:to="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019c9afa-c42c-7b58-b754-d6466e1a40d3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_019c9afa-c543-7a85-845e-4fcb53eeb8ff_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff_019c9afa-c4bc-7a4c-ba6c-d66eaafd8000_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes due to expected run-off</link:label>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff_label_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) Due to Expected Run-Off</link:label>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) Due to Expected Run-Off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:to="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c9afa-c543-7d28-b3ae-0a947f4a7fcc_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash and cash equivalents January 1,</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c9afa-c543-763b-9482-1bd456e5a53c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year (1)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_019c9afa-c543-7046-8a6c-51da02ceb207_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsMember_019c9afa-c42c-703b-ab12-97ceb28f5939_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and performance guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsMember_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantee Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMember" xlink:to="lab_us-gaap_GuaranteeObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_019c9afa-c542-7d31-b3e5-7e424705e50f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019c9afa-c42c-7283-b536-cd6914459304_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnitedStatesHealthcareMember_019c9afa-c4bc-7b70-934c-c73e2d9893c6_terseLabel_en-US" xlink:label="lab_ci_UnitedStatesHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Healthcare</link:label>
    <link:label id="lab_ci_UnitedStatesHealthcareMember_label_en-US" xlink:label="lab_ci_UnitedStatesHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States Healthcare [Member]</link:label>
    <link:label id="lab_ci_UnitedStatesHealthcareMember_documentation_en-US" xlink:label="lab_ci_UnitedStatesHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnitedStatesHealthcareMember" xlink:href="ci-20260331.xsd#ci_UnitedStatesHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnitedStatesHealthcareMember" xlink:to="lab_ci_UnitedStatesHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MeasurementInputLiquidityMember_019c9afa-c542-7554-84f2-11552981755b_terseLabel_en-US" xlink:label="lab_ci_MeasurementInputLiquidityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_ci_MeasurementInputLiquidityMember_label_en-US" xlink:label="lab_ci_MeasurementInputLiquidityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Liquidity [Member]</link:label>
    <link:label id="lab_ci_MeasurementInputLiquidityMember_documentation_en-US" xlink:label="lab_ci_MeasurementInputLiquidityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputLiquidityMember" xlink:href="ci-20260331.xsd#ci_MeasurementInputLiquidityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MeasurementInputLiquidityMember" xlink:to="lab_ci_MeasurementInputLiquidityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract_019c9afa-c42c-76e7-90ae-5e1c166505e8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from investments sold:</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_019c9afa-c38f-7b4c-80aa-c2c67e23739c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_019c9afa-c543-7779-a07d-2b9bd65c94a0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsurerConcentrationRiskMember_019c9afa-c4bc-75d3-b788-aa4cf0b7fb92_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsurerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinsurer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ReinsurerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ReinsurerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsurerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsurerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsurerConcentrationRiskMember" xlink:to="lab_us-gaap_ReinsurerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock_019c9afa-c38f-74b6-8cb7-1b8e8d687b9b_terseLabel_en-US" xlink:label="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value Information for Other Long-Term Investments</link:label>
    <link:label id="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Other Long-Term Investments [Table Text Block]</link:label>
    <link:label id="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Other Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:href="ci-20260331.xsd#ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:to="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_019c9afa-c38f-757a-813b-02c571e712fd_negatedLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) on sale of businesses, after-tax</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_label_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item, Gain (Loss) On Sale Of Business, Net Of Tax</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_documentation_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Item, Gain (Loss) On Sale Of Business, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:to="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentIncome_019c9afa-c543-7a45-8658-30dc542993b9_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_019c9afa-c543-75ce-8b90-3289cc5e25c6_totalLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net investment income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_019c9afa-c543-7ef2-ac74-0cee53a6a655_verboseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net investment income (loss)</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_label_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentIncome" xlink:to="lab_us-gaap_NetInvestmentIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c542-7ebb-a2de-db2b7525b3be_verboseLabel_en-US" xlink:label="lab_ci_SpecialItemsBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax</link:label>
    <link:label id="lab_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c542-7649-9694-592007b0d158_terseLabel_en-US" xlink:label="lab_ci_SpecialItemsBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special items</link:label>
    <link:label id="lab_ci_SpecialItemsBeforeTaxAbstract_label_en-US" xlink:label="lab_ci_SpecialItemsBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Items Before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsBeforeTaxAbstract" xlink:href="ci-20260331.xsd#ci_SpecialItemsBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract" xlink:to="lab_ci_SpecialItemsBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_019c9afa-c38f-782b-a78a-ff9f31a1ed7e_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends Payable, Date of Record</link:label>
    <link:label id="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_label_en-US" xlink:label="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable, Date of Record</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:to="lab_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_019c9afa-c542-7bb4-b61f-ee56b56ab64f_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_019c9afa-c4bc-74cc-b67b-19a76c83c5cb_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_019c9afa-c4bc-7dbd-8c3d-25b4e63e6696_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_019c9afa-c4bd-7bfb-845e-905d71c711da_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional Value</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c9afa-c5bb-70b6-9fb0-f2876a7d4333_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AssetImpairmentsMember_019c9afa-c38f-7052-98d5-06fc7b5ba05e_terseLabel_en-US" xlink:label="lab_ci_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_ci_AssetImpairmentsMember_label_en-US" xlink:label="lab_ci_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairments [Member]</link:label>
    <link:label id="lab_ci_AssetImpairmentsMember_documentation_en-US" xlink:label="lab_ci_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Impairments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetImpairmentsMember" xlink:href="ci-20260331.xsd#ci_AssetImpairmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AssetImpairmentsMember" xlink:to="lab_ci_AssetImpairmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock_019c9afa-c5bb-7596-98d5-767451109c13_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Security Investments</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI And Equity Securities Without Readily Determinable Fair Value [Table Text Block]</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI And Equity Securities Without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:to="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_019c9afa-c38f-7eb7-b006-070b77330ef9_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain]</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain" xlink:to="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity_019c9afa-c42c-7850-891d-d0d931ee9620_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total capacity, uncommitted factoring facilities</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facilities, Total Capacity</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total amount of certain accounts receivable that may be sold on a non-recourse basis to a financial institution under uncommitted accounts receivable factoring facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019c9afa-c542-70d8-8e6b-bc8f10c468d6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgagesMember_019c9afa-c542-7ffa-bcaa-3dd4b3d977a0_verboseLabel_en-US" xlink:label="lab_us-gaap_MortgagesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial mortgage loans</link:label>
    <link:label id="lab_us-gaap_MortgagesMember_label_en-US" xlink:label="lab_us-gaap_MortgagesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgages [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgagesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgagesMember" xlink:to="lab_us-gaap_MortgagesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_019c9afa-c4bc-7d15-99f7-f304e8796417_terseLabel_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_label_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value [Member]</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_documentation_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:href="ci-20260331.xsd#ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:to="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue2026125Member_019c9afa-c543-798f-be9c-b4fea447e3b7_terseLabel_en-US" xlink:label="lab_ci_NotesDue2026125Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.250% Notes due March 2026</link:label>
    <link:label id="lab_ci_NotesDue2026125Member_label_en-US" xlink:label="lab_ci_NotesDue2026125Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes due 2026, 1.25% [Member]</link:label>
    <link:label id="lab_ci_NotesDue2026125Member_documentation_en-US" xlink:label="lab_ci_NotesDue2026125Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes payable bearing interest at 1.25% due in 2026.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2026125Member" xlink:href="ci-20260331.xsd#ci_NotesDue2026125Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue2026125Member" xlink:to="lab_ci_NotesDue2026125Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-c4bc-7b2a-a97e-f43b7577338b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_019c9afa-c4bd-75a8-94a9-287803f5a677_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c38f-705c-8972-91896dbfdb7b_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c38f-749e-b312-56cd075bf835_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_019c9afa-c4bc-7850-aea4-3532b5eea006_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_019c9afa-c542-7a21-92ce-66ab280d2fe3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShieldsHealthSolutionsMember_019c9afa-c4bd-7a47-ba9c-efb2090e922b_terseLabel_en-US" xlink:label="lab_ci_ShieldsHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shields Health Solutions</link:label>
    <link:label id="lab_ci_ShieldsHealthSolutionsMember_label_en-US" xlink:label="lab_ci_ShieldsHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shields Health Solutions [Member]</link:label>
    <link:label id="lab_ci_ShieldsHealthSolutionsMember_documentation_en-US" xlink:label="lab_ci_ShieldsHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shields Health Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShieldsHealthSolutionsMember" xlink:href="ci-20260331.xsd#ci_ShieldsHealthSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShieldsHealthSolutionsMember" xlink:to="lab_ci_ShieldsHealthSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax_019c9afa-c42c-78e8-90c6-5019398a0723_negatedTerseLabel_en-US" xlink:label="lab_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of dividend receivable, after-tax</link:label>
    <link:label id="lab_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax_label_en-US" xlink:label="lab_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Items. Increase (Decrease) To Revenues After Tax</link:label>
    <link:label id="lab_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax_documentation_en-US" xlink:label="lab_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Items. Increase (Decrease) To Revenues After Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax" xlink:href="ci-20260331.xsd#ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax" xlink:to="lab_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateLoanMember_019c9afa-c4bd-79d7-a689-648003e6a67e_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Real Estate Loan</link:label>
    <link:label id="lab_us-gaap_RealEstateLoanMember_label_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateLoanMember" xlink:to="lab_us-gaap_RealEstateLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_019c9afa-c5bb-7f08-8020-554f8f96c4b8_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_019c9afa-c543-7362-b28b-2b83e88997d4_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_019c9afa-c4bd-7f28-890d-fb108d68d471_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate_019c9afa-c543-7c1d-9d86-9829ee0cb0a5_terseLabel_en-US" xlink:label="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price discount, spread on variable rate</link:label>
    <link:label id="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate_label_en-US" xlink:label="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Discount, Spread On US Treasury Rate</link:label>
    <link:label id="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate_documentation_en-US" xlink:label="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis points added to the most directly comparable U.S. Treasury rate to calculate a "make whole" premium for debt redemptions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate" xlink:href="ci-20260331.xsd#ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate" xlink:to="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_019dd52b-a723-7e15-880d-9f27cbe93229_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_019c9afa-c4bc-7fda-ab72-2521f409e188_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosure of Cash Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c38f-7154-89da-83666c3f74a9_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c38f-7e53-b022-0c73bdf7d429_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_019c9afa-c38f-7d58-bcfe-5184c5be56cf_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal government and agency</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_019c9afa-c543-74a3-a4cf-8790b11c6568_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_019c9afa-c42c-73df-9e08-0c61c1222ea2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption_019c9afa-c38f-734c-b76a-51d3e0864e91_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumption changes</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) from Other Assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" xlink:to="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_019c9afa-c4bc-7d9e-b8ee-a20fc2e3f1c2_terseLabel_en-US" xlink:label="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities and equity securities</link:label>
    <link:label id="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_label_en-US" xlink:label="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Maturities Prepayments And Calls Of Debt And Equity Securities</link:label>
    <link:label id="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_documentation_en-US" xlink:label="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from maturities, repayments and calls of debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:href="ci-20260331.xsd#ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:to="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_019c9afa-c4bd-7404-b8c3-272db411f60c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_019c9afa-c4bd-70aa-bf68-a32b74d8f0ca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_019c9afa-c42c-7fb3-9431-38843ebe9742_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_019c9afa-c5bb-7028-a9ee-6442c67a923b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_019c9afa-c4bd-7870-b0b0-3dd57296866e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other restructuring</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-c543-7e91-89d5-38d021a695ad_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_019c9afa-c5bb-7a42-8b2f-a494aade8cf8_terseLabel_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractholder deposit funds not reinsured externally, percent with guaranteed interest rates of 0300 to 0400</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_label_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Percentage</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_documentation_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of policyholder account balance representing contract with guaranteed interest rates of 3%-4%.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:href="ci-20260331.xsd#ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:to="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_019c9afa-c42c-73b9-a688-898f8ba7cc40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:to="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_019c9afa-c4bc-7079-b104-43a2f6f0e26a_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_019c9afa-c4bc-7d21-8f62-1dc16dc2713a_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_019c9afa-c4bc-7ebd-8695-4edb010c61ce_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019c9afa-c42c-7416-8d9b-a212ded0eed6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateInvestmentMember_019c9afa-c42c-75ff-9528-4fbf564575d6_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Real estate investments</link:label>
    <link:label id="lab_us-gaap_RealEstateInvestmentMember_label_en-US" xlink:label="lab_us-gaap_RealEstateInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate Investment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateInvestmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateInvestmentMember" xlink:to="lab_us-gaap_RealEstateInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019c9afa-c543-7d3e-8f31-745ac9cf83f4_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c9afa-c42c-7791-b7a4-9aecfb535c0a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_019c9afa-c4bc-7fbc-93ec-eb4ca2444e6d_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Operations</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019c9afa-c543-7181-a91b-afce08f8fd98_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_019c9afa-c38f-7e0b-9b81-8524cd2718a7_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_019c9afa-c42c-71c5-8772-1ac69d9a8de1_terseLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid claims and claim expenses, non-current</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Noncurrent</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_019c9afa-c42c-7842-8019-728d4583b4a3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019c9afa-c4bd-7fa4-b172-68417a4a5f2c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c542-7d7d-bdcd-6651279ec6d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-c42c-7990-bb7f-fc6a86de279f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Total Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm_019c9afa-c543-7c99-b1ee-42ecdf4100ea_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Automatic renewal term, uncommitted factoring facilities (in years)</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facilities, Automatic Renewal Term</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Automatic renewal term for uncommitted Accounts receivable factoring facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_019c9afa-c4bc-782c-9f3d-1a9dd13adb66_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average crediting rate</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Weighted Average Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate" xlink:to="lab_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_019c9afa-c42c-7229-95f9-be8023edf7a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases, sales and settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_019c9afa-c543-74f1-8e30-bd860bf7da8c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other debt securities</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c38f-7139-808d-466cb3ae9fd3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_019c9afa-c4bc-73b7-b22e-c17f35c48790_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_019c9afa-c42c-7d98-93f6-8d9ac9e4b5be_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_019c9afa-c42c-77e2-a961-3262da13039e_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_019c9afa-c542-777c-a555-1bfdb11039fa_negatedTerseLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Risk corridors recovery, after-tax</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_label_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Net Of Tax</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_documentation_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:to="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_019c9afa-c4bc-7628-b6f6-d609f114f7e2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_019c9afa-c42c-7fa0-ada3-4c3072856c1c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Adjustment</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_019c9afa-c542-7eec-ba57-3f9bbc9925ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in the Components of AOCI</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_019c9afa-c542-7768-a287-5e11c67bd67d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_R2026Q2DividendsMember_019c9afa-c38f-79d0-bf37-aba101d8a621_terseLabel_en-US" xlink:label="lab_ci_R2026Q2DividendsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R2026Q2 Dividends [Member]</link:label>
    <link:label id="lab_ci_R2026Q2DividendsMember_label_en-US" xlink:label="lab_ci_R2026Q2DividendsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">R2026Q2 Dividends [Member]</link:label>
    <link:label id="lab_ci_R2026Q2DividendsMember_documentation_en-US" xlink:label="lab_ci_R2026Q2DividendsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">R2026Q2 Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_R2026Q2DividendsMember" xlink:href="ci-20260331.xsd#ci_R2026Q2DividendsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_R2026Q2DividendsMember" xlink:to="lab_ci_R2026Q2DividendsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_019dd492-23b7-7178-aa58-7fac8ba9dc0b_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_019c9afa-c543-7d27-b25d-76a611720232_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_019c9afa-c543-7470-aad1-cab170659083_terseLabel_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">A- equivalent and higher current ratings</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_label_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), A- Or Higher [Member]</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_documentation_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), A- Or Higher</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:to="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c38f-794f-8044-acb5ae95d3c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c4bc-75c8-aed5-5c6ba94e38fb_terseLabel_en-US" xlink:label="lab_ci_EmployeeSeveranceAndOtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee severance, asset impairments and other</link:label>
    <link:label id="lab_ci_EmployeeSeveranceAndOtherRestructuringMember_label_en-US" xlink:label="lab_ci_EmployeeSeveranceAndOtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance And Other Restructuring [Member]</link:label>
    <link:label id="lab_ci_EmployeeSeveranceAndOtherRestructuringMember_documentation_en-US" xlink:label="lab_ci_EmployeeSeveranceAndOtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Severance And Other Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmployeeSeveranceAndOtherRestructuringMember" xlink:href="ci-20260331.xsd#ci_EmployeeSeveranceAndOtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EmployeeSeveranceAndOtherRestructuringMember" xlink:to="lab_ci_EmployeeSeveranceAndOtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019c9afa-c4bc-7180-9e98-7a1100564c94_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_019c9afa-c38f-7cde-8cbc-5df583da7d57_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for (Proceeds from) Other Investing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019c9afa-c4bc-7275-85d9-d6a1ca79bd77_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_019c9afa-c38f-7452-a7d7-af5c9ea81097_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTableTextBlock_019c9afa-c42c-775f-9d56-50345cac36ac_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTableTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:to="lab_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_019c9afa-c42c-737d-bcc5-243450a8a816_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_019c9afa-c543-78ca-8b91-a63880edf38b_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_019c9afa-c543-7d43-bb9e-be04fb20ef3c_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, after Increase (Decrease) from Instrument-Specific Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:to="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_019c9afa-c4bc-736a-ad90-5590bb32ff9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-c4bc-7a4e-a59e-7e6afbb4b2b5_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt extinguishment gain</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-c4bc-7f2b-abff-45d07872571b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt extinguishment gain</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_019c9afa-c38f-7527-b9a7-2b00385388c3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_019c9afa-c42c-76cd-8b21-491d27241144_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c4bd-789d-b9cc-402431455d48_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_019c9afa-c543-72b9-8436-f47141a77c60_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_019c9afa-c542-7977-a145-f8373d6c6d09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_019c9afa-c38f-71bc-a274-094663d13e4b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted EBITDA Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_019c9afa-c4bd-7dcd-a7bf-e55244a00a6b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RevolvingCreditAgreementApril2025Member_019c9afa-c38f-7744-b744-889790105fcc_terseLabel_en-US" xlink:label="lab_ci_RevolvingCreditAgreementApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Agreement, April 2025</link:label>
    <link:label id="lab_ci_RevolvingCreditAgreementApril2025Member_label_en-US" xlink:label="lab_ci_RevolvingCreditAgreementApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Agreement April 2025 [Member]</link:label>
    <link:label id="lab_ci_RevolvingCreditAgreementApril2025Member_documentation_en-US" xlink:label="lab_ci_RevolvingCreditAgreementApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revolving credit agreement entered in April 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAgreementApril2025Member" xlink:href="ci-20260331.xsd#ci_RevolvingCreditAgreementApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RevolvingCreditAgreementApril2025Member" xlink:to="lab_ci_RevolvingCreditAgreementApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WithdrawalFromContractHoldersFunds_019c9afa-c42c-739b-a449-e601ca75f1dd_negatedLabel_en-US" xlink:label="lab_us-gaap_WithdrawalFromContractHoldersFunds" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Withdrawals and benefit payments from contractholder deposit funds</link:label>
    <link:label id="lab_us-gaap_WithdrawalFromContractHoldersFunds_label_en-US" xlink:label="lab_us-gaap_WithdrawalFromContractHoldersFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Withdrawal from Contract Holders Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WithdrawalFromContractHoldersFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WithdrawalFromContractHoldersFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WithdrawalFromContractHoldersFunds" xlink:to="lab_us-gaap_WithdrawalFromContractHoldersFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_019c9afa-c42c-7e26-a1fb-38e3b362acd5_terseLabel_en-US" xlink:label="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_label_en-US" xlink:label="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Long-term Debt, Net Of Discounts And Underwriting Fees</link:label>
    <link:label id="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_documentation_en-US" xlink:label="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Long-term Debt, Net Of Discounts And Underwriting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:href="ci-20260331.xsd#ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:to="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019c9afa-c38f-7432-a932-fc7ab09db214_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c543-7b1b-99ae-83e177d9b6fe_terseLabel_en-US" xlink:label="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax adjusted income (loss) from operations</link:label>
    <link:label id="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c543-7208-98e8-ebf011f13931_totalLabel_en-US" xlink:label="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Pre-tax adjusted income (loss) from operations</link:label>
    <link:label id="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted Income (Loss) From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="ci-20260331.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c4bc-7674-a2b6-7b3fa505d4ae_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskCollateralizationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Collateralization [Axis]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskCollateralizationAxis_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskCollateralizationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Collateralization [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis" xlink:to="lab_us-gaap_CededCreditRiskCollateralizationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncatastrophicEventDomain_019c9afa-c38f-7caa-b7b8-50e7c7420ad8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncatastrophicEventDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncatastrophic Event [Domain]</link:label>
    <link:label id="lab_us-gaap_NoncatastrophicEventDomain_label_en-US" xlink:label="lab_us-gaap_NoncatastrophicEventDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncatastrophic Event [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncatastrophicEventDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncatastrophicEventDomain" xlink:to="lab_us-gaap_NoncatastrophicEventDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_019c9afa-c542-794d-96b3-dc2a12b65e4a_terseLabel_en-US" xlink:label="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate amount of options to increase commitments</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_label_en-US" xlink:label="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Accordion Feature, Incremental Increase In Maximum Borrowing Capacity</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Accordion Feature, Incremental Increase In Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:to="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_019c9afa-c38f-71ed-b52a-6fbdc91dd0d6_terseLabel_en-US" xlink:label="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare Advantage and related Cigna Healthcare businesses</link:label>
    <link:label id="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_label_en-US" xlink:label="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare Advantage And Related Cigna Healthcare Businesses [Member]</link:label>
    <link:label id="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_documentation_en-US" xlink:label="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare Advantage And Related Cigna Healthcare Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:href="ci-20260331.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:to="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c4bc-7632-ae61-85086c53b149_periodStartLabel_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, including held for sale assets</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c4bc-7cd9-b2d6-f4f66414a390_periodEndLabel_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, including held for sale assets</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20260331.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_019c9afa-c543-7677-a5a9-d19518b517bc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccruedExpensesAndOtherLiabilities_019c9afa-c543-7a74-9b3c-a0c0964e1ffb_terseLabel_en-US" xlink:label="lab_ci_AccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_ci_AccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_ci_AccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_ci_AccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_ci_AccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of other current liabilities and obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccruedExpensesAndOtherLiabilities" xlink:href="ci-20260331.xsd#ci_AccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccruedExpensesAndOtherLiabilities" xlink:to="lab_ci_AccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_HomeDeliveryAndSpecialtyMember_019c9afa-c42c-7520-9bc9-df31131ebb18_terseLabel_en-US" xlink:label="lab_ci_HomeDeliveryAndSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Home delivery and specialty revenues</link:label>
    <link:label id="lab_ci_HomeDeliveryAndSpecialtyMember_label_en-US" xlink:label="lab_ci_HomeDeliveryAndSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Home Delivery And Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HomeDeliveryAndSpecialtyMember" xlink:href="ci-20260331.xsd#ci_HomeDeliveryAndSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_HomeDeliveryAndSpecialtyMember" xlink:to="lab_ci_HomeDeliveryAndSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019c9afa-c4bc-7e72-82a1-8cfa09e57db5_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Number of Issues</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019c9afa-c5bb-78c3-85da-5f75605bf797_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with no readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_019c9afa-c4bc-7891-8985-478f68f10bc2_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees and other revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_019c9afa-c4bc-7764-a5f3-d2f995dc1c2f_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019c9afa-c543-78b3-9ced-0de6d6bf03bb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of issuing stock for employee benefit plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019c9afa-c4bc-7ffd-b88b-fea1856d568e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019c9afa-c4bd-7d25-b342-d3df47b5065f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payment for) Other Financing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_019c9afa-c542-7556-beb9-57dead75ef35_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on long-term and short-term debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_019c9afa-c542-7b30-a443-eb8ea601e5d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net amounts reclassified from AOCI to net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeparateAccountsLiability_019c9afa-c42c-7693-a813-84d11afae8a6_terseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate account liabilities</link:label>
    <link:label id="lab_us-gaap_SeparateAccountsLiability_label_en-US" xlink:label="lab_us-gaap_SeparateAccountsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Separate Account, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeparateAccountsLiability" xlink:to="lab_us-gaap_SeparateAccountsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_019c9afa-c38f-7c8b-a2f1-2830aff43e35_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c38f-77e6-a5fc-2ea69b2b8edf_terseLabel_en-US" xlink:label="lab_ci_SeniorNotesIssuedSeptember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes Issued September 2025</link:label>
    <link:label id="lab_ci_SeniorNotesIssuedSeptember2025Member_label_en-US" xlink:label="lab_ci_SeniorNotesIssuedSeptember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Issued September 2025 [Member]</link:label>
    <link:label id="lab_ci_SeniorNotesIssuedSeptember2025Member_documentation_en-US" xlink:label="lab_ci_SeniorNotesIssuedSeptember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Issued September 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeniorNotesIssuedSeptember2025Member" xlink:href="ci-20260331.xsd#ci_SeniorNotesIssuedSeptember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SeniorNotesIssuedSeptember2025Member" xlink:to="lab_ci_SeniorNotesIssuedSeptember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c9afa-c5bb-73d7-ab9f-6b6a5bcbc654_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AnnuitizationElectionPeriod_019c9afa-c42c-7a61-ab6f-fd510559bb91_terseLabel_en-US" xlink:label="lab_ci_AnnuitizationElectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annuitization election period</link:label>
    <link:label id="lab_ci_AnnuitizationElectionPeriod_label_en-US" xlink:label="lab_ci_AnnuitizationElectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annuitization Election Period</link:label>
    <link:label id="lab_ci_AnnuitizationElectionPeriod_documentation_en-US" xlink:label="lab_ci_AnnuitizationElectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of time prior to a policy anniversary when an annuitization election must occur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AnnuitizationElectionPeriod" xlink:href="ci-20260331.xsd#ci_AnnuitizationElectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AnnuitizationElectionPeriod" xlink:to="lab_ci_AnnuitizationElectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_019c9afa-c4bd-7d13-ac75-6e4e7c41f346_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange_019c9afa-c543-7d8f-8d44-fcd8ea34ae4d_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes due to capital markets versus expected</link:label>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange_label_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) From Interest Rate Change And Equity Market Change</link:label>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) From Interest Rate Change And Equity Market Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:to="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_019c9afa-c42c-763f-b222-ab64bc1c116f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_019c9afa-c542-798d-bd43-3f5cf2ab3d3b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_019c9afa-c4bc-7145-a5bb-969259df47b0_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_019c9afa-c38f-7902-9b39-6c9d3a5d8b42_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_019c9afa-c42c-7e1e-8af7-1b166d0a5b8d_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_019c9afa-c38f-73e3-8614-01e7cc4861fe_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_019c9afa-c38f-7f51-8fee-b3c0fec27d05_verboseLabel_en-US" xlink:label="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Berkshire Hathway Life Insurance Company Of Nebraska</link:label>
    <link:label id="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_label_en-US" xlink:label="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Berkshire Hathway Life Insurance Company Of Nebraska [Member]</link:label>
    <link:label id="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_documentation_en-US" xlink:label="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Berkshire Hathway Life Insurance Company Of Nebraska</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:href="ci-20260331.xsd#ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:to="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_019c9afa-c42c-7c6b-8db9-59678747d720_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c4bc-7dbc-8e9b-1762a0e79d9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_019c9afa-c543-789a-af08-39117ccf1216_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_019c9afa-c543-78eb-b80e-8cb881ad058f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c38f-74e8-9ff5-016526e4acd3_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale [Abstract]</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:to="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderFunds_019c9afa-c543-776f-a355-d590fbdf9d2b_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractholder deposit funds not reinsured externally</link:label>
    <link:label id="lab_us-gaap_PolicyholderFunds_label_en-US" xlink:label="lab_us-gaap_PolicyholderFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderFunds" xlink:to="lab_us-gaap_PolicyholderFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_019c9afa-c4bd-737d-85c5-cda5e5c41c74_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AllowanceForReceivablesCurrent_019c9afa-c543-7802-904c-c6be9414b5a2_terseLabel_en-US" xlink:label="lab_ci_AllowanceForReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">allowances</link:label>
    <link:label id="lab_ci_AllowanceForReceivablesCurrent_label_en-US" xlink:label="lab_ci_AllowanceForReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Receivables Current</link:label>
    <link:label id="lab_ci_AllowanceForReceivablesCurrent_documentation_en-US" xlink:label="lab_ci_AllowanceForReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of allowance for receivables, classified as current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllowanceForReceivablesCurrent" xlink:href="ci-20260331.xsd#ci_AllowanceForReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AllowanceForReceivablesCurrent" xlink:to="lab_ci_AllowanceForReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_019c9afa-c38f-70bc-9f10-1b278296a8b9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_019c9afa-c543-7422-a5bd-228ff9491a2e_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_019c9afa-c543-7730-bdbc-4ada07b3327c_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local government</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_019c9afa-c5bb-7d5d-862c-1d48a0b40048_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EmployerInsuredMember_019c9afa-c42c-792e-9d66-31fa5175e2c4_terseLabel_en-US" xlink:label="lab_ci_EmployerInsuredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer insured</link:label>
    <link:label id="lab_ci_EmployerInsuredMember_label_en-US" xlink:label="lab_ci_EmployerInsuredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employer Insured [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmployerInsuredMember" xlink:href="ci-20260331.xsd#ci_EmployerInsuredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EmployerInsuredMember" xlink:to="lab_ci_EmployerInsuredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_019c9afa-c5bb-713e-9ece-10250078dae2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c542-731e-b235-e49f3da87264_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_019c9afa-c38f-7ddf-9ff5-e896570ff2cd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_019c9afa-c38f-7a37-9e4f-ee9769350fb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_019c9afa-c4bc-77fc-ab1b-a48205c3ae9d_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding_019c9afa-c38f-7cda-8779-349a0fd67f95_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable sold that remain outstanding, uncommitted factoring facilities</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facilities, Accounts Receivable Sold That Remain Outstanding</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, as of the reporting date, of receivables sold to a financial institution under uncommitted Accounts receivable factoring facilities that have not been collected from the manufacturers and have been removed from the Balance Sheet.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019c9afa-c42c-7c6f-9d57-dbc89d2ff432_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies &#8212; Note 14</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_019c9afa-c4bd-7119-8c7b-95b6a97330ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c38f-7a48-a4f3-bf599a709d98_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c542-70bd-8250-412c09ce8b1e_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Total [Abstract]</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_019c9afa-c38f-7226-8e3a-d6a7d1f5e338_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Non- controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTextBlock_019c9afa-c42c-7e16-8fa2-045aba35ac57_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramTextBlock" xlink:to="lab_us-gaap_SupplierFinanceProgramTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeTextBlock_019c9afa-c543-7e26-8dbe-403833ec845d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Net Investment Income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeTextBlock" xlink:to="lab_us-gaap_InvestmentIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_019c9afa-c543-7b0a-ad56-a0372dee4266_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_019c9afa-c5bb-75b2-a466-70afbf6d5b61_terseLabel_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net translation (depreciation) appreciation on foreign currencies</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_label_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Including Temporary Equity</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_documentation_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Including Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:href="ci-20260331.xsd#ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:to="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_019c9afa-c542-71f0-8af2-0d1e78cc5d45_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMortgageNotesReceivable_019c9afa-c38f-763f-8142-978b55ddfd04_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Commercial mortgage loans</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMortgageNotesReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Mortgage Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMortgageNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:to="lab_us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_019c9afa-c542-71ae-aff8-e6ec2f6682ab_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_019c9afa-c543-7e47-ac28-cc7e1514c89b_terseLabel_en-US" xlink:label="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in short-term debt</link:label>
    <link:label id="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_label_en-US" xlink:label="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From (Repayments Of) Other Short-Term Debt</link:label>
    <link:label id="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_documentation_en-US" xlink:label="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow for principal payment on finance lease and the net proceeds from (repayments of) short-term debt, defined as borrowing having initial term of repayment of one year or less.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:href="ci-20260331.xsd#ci_ProceedsFromRepaymentsOfOtherShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:to="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c42c-748a-8490-d57cbbb8d4c7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_019c9afa-c5bb-7c91-b1fb-0e1fad2e2aef_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance and Contractholder Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InvestmentIncomeAndGainsAndLossesAbstract_label_en-US" xlink:label="lab_ci_InvestmentIncomeAndGainsAndLossesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income And Gains And Losses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentIncomeAndGainsAndLossesAbstract" xlink:href="ci-20260331.xsd#ci_InvestmentIncomeAndGainsAndLossesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InvestmentIncomeAndGainsAndLossesAbstract" xlink:to="lab_ci_InvestmentIncomeAndGainsAndLossesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_019c9afa-c542-76df-92f1-961af9ee06ba_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Postretirement benefits liability adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_019c9afa-c542-7565-9c2c-6d34ba92147f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_019c9afa-c38f-76a6-8380-e8303d344120_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_019c9afa-c543-75c8-929d-fe837e671df5_terseLabel_en-US" xlink:label="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral provisions exist that may mitigate risk of credit loss</link:label>
    <link:label id="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_label_en-US" xlink:label="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Secured, Collateral Provisions Exist That May Mitigate Risk [Member]</link:label>
    <link:label id="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_documentation_en-US" xlink:label="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ceded Credit Risk, Secured, Collateral Provisions Exist That May Mitigate Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:href="ci-20260331.xsd#ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:to="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_019c9afa-c543-77f4-9d37-d7b0bf39fe9f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_019c9afa-c42c-7124-85bb-8460ab44a5e6_totalLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total transfers into / (out of) Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_019c9afa-c42c-799f-b068-3b00f1f89908_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_019c9afa-c42c-7ee7-8f27-7682ed6ded86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EvernorthMember_019c9afa-c42c-7ce6-8f5e-231c71009e7b_terseLabel_en-US" xlink:label="lab_ci_EvernorthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Evernorth Health Services</link:label>
    <link:label id="lab_ci_EvernorthMember_label_en-US" xlink:label="lab_ci_EvernorthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Evernorth [Member]</link:label>
    <link:label id="lab_ci_EvernorthMember_documentation_en-US" xlink:label="lab_ci_EvernorthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Health Services includes pharmacy benefits management (PBM), pharmacy home delivery, and certain medical management services. This segment includes Express Scripts business from the date of acquisition with the exception of Express Scripts Medicare Part D business that is reported in the Government operating segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember" xlink:href="ci-20260331.xsd#ci_EvernorthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EvernorthMember" xlink:to="lab_ci_EvernorthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold_019c9afa-c4bc-71fd-a4f2-57f165dafb62_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable sold, uncommitted factoring facilities</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facilities, Amount Sold</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of receivables sold to a financial institution under uncommitted Accounts receivable factoring facilities during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_019c9afa-c42c-77b8-b3f7-dfdca2182b30_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_019c9afa-c542-7bc1-ab70-b990a62f5d33_terseLabel_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not rated</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_label_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), Not Rated [Member]</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_documentation_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), Not Rated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:to="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LtvGreaterThan100PercentMember_019c9afa-c4bd-79ee-bb49-f206efeca84c_terseLabel_en-US" xlink:label="lab_ci_LtvGreaterThan100PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Greater than 100%</link:label>
    <link:label id="lab_ci_LtvGreaterThan100PercentMember_label_en-US" xlink:label="lab_ci_LtvGreaterThan100PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ltv Greater Than 100 Percent [Member]</link:label>
    <link:label id="lab_ci_LtvGreaterThan100PercentMember_documentation_en-US" xlink:label="lab_ci_LtvGreaterThan100PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt-to-value ratio greater than 100 percent. Element name an standard label in DTV [numeric lower end] to [numeric higher end] Percent [Member] format.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvGreaterThan100PercentMember" xlink:href="ci-20260331.xsd#ci_LtvGreaterThan100PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LtvGreaterThan100PercentMember" xlink:to="lab_ci_LtvGreaterThan100PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_019c9afa-c542-73dc-95b0-a51656885e11_terseLabel_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Account value</link:label>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_label_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Amount at Risk by Product and Guarantee, General Account Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" xlink:to="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_019c9afa-c542-7103-a175-9007f3c181d8_verboseLabel_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized depreciation on securities and derivatives</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_label_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_documentation_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:href="ci-20260331.xsd#ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:to="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_019c9afa-c4bd-7068-8089-301957c91e3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_019c9afa-c543-7d6d-ad89-a76b765b35f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Derivative Instruments Held</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c542-7656-b42f-fc2a43333c76_negatedNetLabel_en-US" xlink:label="lab_ci_SpecialItemsIncreaseDecreaseToRevenues" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Impairment of dividend receivable</link:label>
    <link:label id="lab_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c542-7830-8f10-4cf4220e39c2_negatedLabel_en-US" xlink:label="lab_ci_SpecialItemsIncreaseDecreaseToRevenues" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Special item related to impairment of dividend receivable</link:label>
    <link:label id="lab_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c542-7bff-8fd3-5d74f5866037_negatedTerseLabel_en-US" xlink:label="lab_ci_SpecialItemsIncreaseDecreaseToRevenues" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of dividend receivable</link:label>
    <link:label id="lab_ci_SpecialItemsIncreaseDecreaseToRevenues_label_en-US" xlink:label="lab_ci_SpecialItemsIncreaseDecreaseToRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Items. Increase (Decrease) To Revenues</link:label>
    <link:label id="lab_ci_SpecialItemsIncreaseDecreaseToRevenues_documentation_en-US" xlink:label="lab_ci_SpecialItemsIncreaseDecreaseToRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Items. Increase (Decrease) To Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsIncreaseDecreaseToRevenues" xlink:href="ci-20260331.xsd#ci_SpecialItemsIncreaseDecreaseToRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemsIncreaseDecreaseToRevenues" xlink:to="lab_ci_SpecialItemsIncreaseDecreaseToRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_019c9afa-c42c-7861-b549-09332ae7a68e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds on issuance of term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_019c9afa-c38f-73c2-bdd6-41f90405b090_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit Activity [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit Activity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitActivityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c542-7828-ad0f-4cadb6ed55c5_totalLabel_en-US" xlink:label="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Investments including held for sale assets</link:label>
    <link:label id="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20260331.xsd#ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPortfolioSegmentMember_019c9afa-c543-7f8c-be2e-edcd87c37895_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPortfolioSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Portfolio Segment</link:label>
    <link:label id="lab_us-gaap_CommercialPortfolioSegmentMember_label_en-US" xlink:label="lab_us-gaap_CommercialPortfolioSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Portfolio Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPortfolioSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPortfolioSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPortfolioSegmentMember" xlink:to="lab_us-gaap_CommercialPortfolioSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_019c9afa-c38f-7736-bd4a-9647d2918255_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c4bd-707f-97c1-85c63b967f41_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019c9afa-c4bc-757f-8c1e-f2b0100725fc_verboseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_019c9afa-c38f-7b92-8a9e-e62ad263b3c6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest accretion rate</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit, Weighted-Average Interest Accretion Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c543-7e58-8218-518dbfeaa1d0_totalLabel_en-US" xlink:label="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Investments including held for sale assets</link:label>
    <link:label id="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20260331.xsd#ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceOtherMember_019c9afa-c4bd-760f-b624-5b1493944267_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceOtherMember" xlink:to="lab_us-gaap_ServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019c9afa-c42c-754a-9dc4-686c8ff7c5eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_019c9afa-c42c-7d17-88e7-0e12f80a9dff_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_019c9afa-c38f-774e-93cd-0e8e9c234b59_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c4bc-73c5-a409-c17d9df1b182_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid costs related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019c9afa-c38f-7589-aba6-ba576133c01e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReinsuranceRecoverablesNonCurrent_019c9afa-c38f-7d19-a6da-987b2c4131fd_terseLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinsurance recoverables</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesNonCurrent_label_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance Recoverables, Noncurrent</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesNonCurrent_documentation_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, after valuation allowance, recoverable after one year under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesNonCurrent" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverablesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReinsuranceRecoverablesNonCurrent" xlink:to="lab_ci_ReinsuranceRecoverablesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio_019c9afa-c42c-7639-a37e-2de2f13bb950_terseLabel_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Loan-to-Value Ratio</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio_label_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable Credit Quality Loan To Value Ratio</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio_documentation_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Receivable Credit Quality Loan To Value Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:href="ci-20260331.xsd#ci_FinancingReceivableCreditQualityLoanToValueRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:to="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RetirementAndLifeInsuranceContractsMember_019c9afa-c42c-7d14-82db-2fea236db97f_terseLabel_en-US" xlink:label="lab_ci_RetirementAndLifeInsuranceContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retiree and Life Insurance Benefits</link:label>
    <link:label id="lab_ci_RetirementAndLifeInsuranceContractsMember_label_en-US" xlink:label="lab_ci_RetirementAndLifeInsuranceContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement And Life Insurance Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RetirementAndLifeInsuranceContractsMember" xlink:href="ci-20260331.xsd#ci_RetirementAndLifeInsuranceContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RetirementAndLifeInsuranceContractsMember" xlink:to="lab_ci_RetirementAndLifeInsuranceContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_019c9afa-c5bb-7081-91f7-2df95ed920a7_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c4bc-7093-9585-42b222ceafdc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c42c-78dc-b61b-7a3382c4abb7_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c42c-761b-b16e-5ee08858ea4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_019c9afa-c542-7afe-9c7c-a2c283b143da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) before reclassifications, after-tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_019c9afa-c42c-78cd-9a81-6dcf240f3d4b_terseLabel_en-US" xlink:label="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value</link:label>
    <link:label id="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label id="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_documentation_en-US" xlink:label="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the fair value measurement of assets and liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3, by class of assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="ci-20260331.xsd#ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_019c9afa-c4bd-7975-9c67-69d070375f0b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying value, after allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceTextBlock_019c9afa-c42c-750e-b07b-b6643852db1e_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinsurance</link:label>
    <link:label id="lab_us-gaap_ReinsuranceTextBlock_label_en-US" xlink:label="lab_us-gaap_ReinsuranceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reinsurance [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceTextBlock" xlink:to="lab_us-gaap_ReinsuranceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019c9afa-c38f-71fd-9b6d-001229f3c6c2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">SHAREHOLDERS' NET INCOME</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019c9afa-c38f-7fc3-a9c9-dae3a3a255c6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SHAREHOLDERS' NET INCOME</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountCurrent_019c9afa-c38f-7326-badf-645300bddfd4_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market risk benefits, current</link:label>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountCurrent_label_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Liability, Amount, Current</link:label>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountCurrent_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Liability, Amount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:to="lab_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable_019c9afa-c4bc-7d72-b05d-a384ee301b60_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial mortgage loans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collection of Loans Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c38f-7c05-84f4-647a76e535a7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liability for future policy benefits</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefit, before Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_019c9afa-c38f-78d4-9182-6e1cb309111e_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future policy benefits, non-current</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Future Policy Benefit, Before Reinsurance, Noncurrent</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Future Policy Benefit, Before Reinsurance, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_019c9afa-c4bc-7d85-a547-4619e678f89a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_019c9afa-c38f-7efd-9cfb-10ec3bee84ec_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c543-7868-b792-75d1bf764413_terseLabel_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Amount at Risk by Product and Guarantee [Line Items]</link:label>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_label_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Amount at Risk by Product and Guarantee [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems" xlink:to="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-c42c-7b77-8e9d-3cd6b1edd397_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019c9afa-c38f-740c-a043-8cdd78b34b4a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_019c9afa-c42c-7ec4-b5fb-6dfd797e4151_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019c9afa-c42c-737a-84b9-1b55ef54a145_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_019c9afa-c542-7089-bd1a-dc0accc8dc0f_negatedLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Investments classified as assets of business held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Including Discontinued Operation, Current Investments, Current</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group Including Discontinued Operation, Current Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_019c9afa-c38f-7e1e-9f74-4a19eaf9ae94_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_019c9afa-c543-7655-894b-b9f998137a7b_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, at Guaranteed Minimum Crediting Rate</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, at Guaranteed Minimum Crediting Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember" xlink:to="lab_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_019c9afa-c38f-7d6d-bc01-75e8485bed10_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Issues</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_019c9afa-c543-75a5-a781-575869463301_terseLabel_en-US" xlink:label="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York</link:label>
    <link:label id="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_label_en-US" xlink:label="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York [Member]</link:label>
    <link:label id="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_documentation_en-US" xlink:label="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reinsurance recoverables resulting from the 1998 sale of the Companys individual life insurance and annuity business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:href="ci-20260331.xsd#ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:to="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_019c9afa-c42c-72ce-a06a-6fc2e9ff1ff1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SeparateAccountAssetsMember_019c9afa-c42c-7fda-8520-d88967835379_terseLabel_en-US" xlink:label="lab_ci_SeparateAccountAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate Account Assets</link:label>
    <link:label id="lab_ci_SeparateAccountAssetsMember_label_en-US" xlink:label="lab_ci_SeparateAccountAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Separate Account Assets [Member]</link:label>
    <link:label id="lab_ci_SeparateAccountAssetsMember_documentation_en-US" xlink:label="lab_ci_SeparateAccountAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A separate investment account established and maintained by an insurance entity under relevant state insurance law to which funds have been allocated for certain contracts of the insurance entity. Funds in a separate account are not commingled with other assets of the insurance entity for investment purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsMember" xlink:href="ci-20260331.xsd#ci_SeparateAccountAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SeparateAccountAssetsMember" xlink:to="lab_ci_SeparateAccountAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c9afa-c42c-7ed4-ac08-85482537effe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_019c9afa-c42c-7ef9-93ac-698c67e957a3_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-c4bc-7125-816b-691fe177f37e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense and other</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019c9afa-c543-7bbd-b01b-f6484b6796b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CignaHealthcareMember_019c9afa-c42c-77b1-a5e8-5daea5227642_terseLabel_en-US" xlink:label="lab_ci_CignaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cigna Healthcare</link:label>
    <link:label id="lab_ci_CignaHealthcareMember_label_en-US" xlink:label="lab_ci_CignaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cigna Healthcare [Member]</link:label>
    <link:label id="lab_ci_CignaHealthcareMember_documentation_en-US" xlink:label="lab_ci_CignaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cigna Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CignaHealthcareMember" xlink:to="lab_ci_CignaHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c9afa-c42c-7630-8ce6-336a2a20cbed_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign currency rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c9afa-c543-7294-86c1-7ff5e35ecdd1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_019c9afa-c543-75ad-8d87-ea467ff43ebb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_019c9afa-c4bc-7946-b83c-fab1b8100497_terseLabel_en-US" xlink:label="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage with cash values at more than 110% of guaranteed cash value</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_label_en-US" xlink:label="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Percentage With Cash Values At More Than 110 Percent Of Guaranteed Cash Value</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_documentation_en-US" xlink:label="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Percentage With Cash Values At More Than 110 Percent Of Guaranteed Cash Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:href="ci-20260331.xsd#ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:to="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019c9afa-c543-7edd-a124-052f1d0b1d41_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_019c9afa-c38f-765b-988a-5fd03ab32311_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c4bc-7843-95d6-a5c80b8aad95_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unpaid claims and claim expenses</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c4bc-7df4-9c89-f29a81274279_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c4bc-71d4-8b9d-74cb209755a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c542-7bc1-897a-bb679184e730_totalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_019c9afa-c38f-7286-bc3a-55c12e64d01f_totalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c38f-7207-b1a5-64d503269b2d_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reinsured market risk benefit, end of period</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c38f-749b-8979-ee6a93c6b222_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market risk benefits</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit, Reinsurance Recoverable, after Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:to="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_019c9afa-c38f-7082-8900-3d56713a7342_terseLabel_en-US" xlink:label="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_label_en-US" xlink:label="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest And Dividend Income Operating And Operating Leases Income Statement Lease Revenue</link:label>
    <link:label id="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_documentation_en-US" xlink:label="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein. Also includes the total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:href="ci-20260331.xsd#ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:to="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableTable_019c9afa-c38f-7fcf-877f-38e44dc23dd7_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends Payable [Table]</link:label>
    <link:label id="lab_us-gaap_DividendsPayableTable_label_en-US" xlink:label="lab_us-gaap_DividendsPayableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableTable" xlink:to="lab_us-gaap_DividendsPayableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherHealthcareMember_019c9afa-c5bb-745a-9236-df1359129ca2_terseLabel_en-US" xlink:label="lab_ci_OtherHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ci_OtherHealthcareMember_label_en-US" xlink:label="lab_ci_OtherHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Healthcare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherHealthcareMember" xlink:href="ci-20260331.xsd#ci_OtherHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherHealthcareMember" xlink:to="lab_ci_OtherHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c5bb-7017-9d62-ac281f51cf90_terseLabel_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Domain]</link:label>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_label_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Domain]</link:label>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_documentation_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:href="ci-20260331.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:to="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019c9afa-c5bb-70f0-a4bc-d09a19416492_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_019c9afa-c4bc-7f14-8790-07d0c8bc6a07_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitRollForward_019c9afa-c4bc-7e74-90cf-f7d3218501f9_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Risk Benefit [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitRollForward_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Risk Benefit [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward" xlink:to="lab_us-gaap_MarketRiskBenefitRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_019c9afa-c42c-7209-88e4-1b374ce65dd0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_019c9afa-c542-7599-b52c-4f04bcd9b7f1_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustment, tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_019c9afa-c5bb-7de2-b77f-ffe6468850ff_terseLabel_en-US" xlink:label="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid Claims and Claims Expenses</link:label>
    <link:label id="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:to="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_019c9afa-c38f-789f-9cd1-436585eda308_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guaranteed minimum credit rating</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Credit Rating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating" xlink:to="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c9afa-c38f-7c87-ac3c-0e46e07a7c1a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019c9afa-c543-7da3-aacf-11e4a8d26e69_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InternationalHealthMember_019c9afa-c42c-78d6-ab61-a9b70d085ab2_terseLabel_en-US" xlink:label="lab_ci_InternationalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International Health</link:label>
    <link:label id="lab_ci_InternationalHealthMember_label_en-US" xlink:label="lab_ci_InternationalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">International Health [Member]</link:label>
    <link:label id="lab_ci_InternationalHealthMember_documentation_en-US" xlink:label="lab_ci_InternationalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">International Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalHealthMember" xlink:href="ci-20260331.xsd#ci_InternationalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InternationalHealthMember" xlink:to="lab_ci_InternationalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables_019c9afa-c42c-73d4-bc89-0726a93e1b8a_terseLabel_en-US" xlink:label="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">contractual allowances for certain pharmaceutical manufacturers rebate receivables</link:label>
    <link:label id="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables_label_en-US" xlink:label="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Allowance, Pharmaceutical Manufacturers Receivables</link:label>
    <link:label id="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables_documentation_en-US" xlink:label="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of contractual allowances for certain rebates receivables with pharmaceutical manufacturers, classified as current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:href="ci-20260331.xsd#ci_ContractualAllowancePharmaceuticalManufacturersReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:to="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MedicalCostTrendMember_019c9afa-c4bc-7bbc-9c52-a41cbc5bd41b_terseLabel_en-US" xlink:label="lab_ci_MedicalCostTrendMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical cost trend</link:label>
    <link:label id="lab_ci_MedicalCostTrendMember_label_en-US" xlink:label="lab_ci_MedicalCostTrendMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Cost Trend [Member]</link:label>
    <link:label id="lab_ci_MedicalCostTrendMember_documentation_en-US" xlink:label="lab_ci_MedicalCostTrendMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amounts relating to actual claims emerging differently from assumptions about the level of claims per member used to set reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicalCostTrendMember" xlink:href="ci-20260331.xsd#ci_MedicalCostTrendMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MedicalCostTrendMember" xlink:to="lab_ci_MedicalCostTrendMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember_label_en-US" xlink:label="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At 200 Percent Target Level [Member]</link:label>
    <link:label id="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember_documentation_en-US" xlink:label="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At 200 Percent Target Level</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember" xlink:href="ci-20260331.xsd#ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember" xlink:to="lab_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_019c9afa-c38f-7cba-b91e-701293441956_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_019c9afa-c38f-71b4-8e2c-44e285c353a9_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_019c9afa-c542-727c-a0d4-fb8c5ffa42ca_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_019c9afa-c4bd-70f9-a7e9-267533a3046d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Assets and Financial Liabilities Carried at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_019c9afa-c42c-783c-85f4-e767a1966a90_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReinsuranceRecoverable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reinsurance recoverable and Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReinsuranceRecoverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Reinsurance Recoverable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInReinsuranceRecoverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable" xlink:to="lab_us-gaap_IncreaseDecreaseInReinsuranceRecoverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_019c9afa-c4bd-7e51-954b-0d0dfed1c72f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_019c9afa-c38f-76f9-b520-6b0c1fe630a7_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceLossReservesAbstract_019c9afa-c42c-7fb8-bf65-8764e133b432_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceLossReservesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance Loss Reserves [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceLossReservesAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceLossReservesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Loss Reserves [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract" xlink:to="lab_us-gaap_InsuranceLossReservesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_019c9afa-c42c-7f21-b397-1e8b96fa032a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_019c9afa-c42c-7605-8d80-0cec5a4af0c5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_TradingArrangementStockOptionsMember_label_en-US" xlink:label="lab_ci_TradingArrangementStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Stock Options [Member]</link:label>
    <link:label id="lab_ci_TradingArrangementStockOptionsMember_documentation_en-US" xlink:label="lab_ci_TradingArrangementStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementStockOptionsMember" xlink:href="ci-20260331.xsd#ci_TradingArrangementStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_TradingArrangementStockOptionsMember" xlink:to="lab_ci_TradingArrangementStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderContractDepositNoncurrent_019c9afa-c42c-7ba4-b742-13a00529a6bf_terseLabel_en-US" xlink:label="lab_ci_PolicyholderContractDepositNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractholder deposit funds, non-current</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositNoncurrent_label_en-US" xlink:label="lab_ci_PolicyholderContractDepositNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Contract Deposit, Noncurrent</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositNoncurrent_documentation_en-US" xlink:label="lab_ci_PolicyholderContractDepositNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Policyholder Contract Deposit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrent" xlink:href="ci-20260331.xsd#ci_PolicyholderContractDepositNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderContractDepositNoncurrent" xlink:to="lab_ci_PolicyholderContractDepositNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_019c9afa-c542-70e1-805e-3b6dc8650726_totalLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:to="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderContractBalancePercentReinsuredExternally_019c9afa-c5bb-7ca4-a30d-575ee5e81d1f_terseLabel_en-US" xlink:label="lab_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractholder deposit fund liabilities, approximate percent reinsured externally</link:label>
    <link:label id="lab_ci_PolicyholderContractBalancePercentReinsuredExternally_label_en-US" xlink:label="lab_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Policyholder Contract Balance, Percent Reinsured Externally</link:label>
    <link:label id="lab_ci_PolicyholderContractBalancePercentReinsuredExternally_documentation_en-US" xlink:label="lab_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Policyholder Contract Balance, Percent Reinsured Externally</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:href="ci-20260331.xsd#ci_PolicyholderContractBalancePercentReinsuredExternally"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:to="lab_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c4bd-796c-9ba4-e2d43814e662_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c4bd-72e3-a263-9de48521b9e0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:to="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_019c9afa-c42c-7157-ba80-eac169b1da01_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset-backed</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_019c9afa-c42c-788b-9f9a-f65cbff4191e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c542-7ad1-846a-c305ed69b721_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnearnedPremiumsCurrent_019c9afa-c5bb-7a14-9ac4-632044c5937b_terseLabel_en-US" xlink:label="lab_ci_UnearnedPremiumsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unearned premiums, current</link:label>
    <link:label id="lab_ci_UnearnedPremiumsCurrent_label_en-US" xlink:label="lab_ci_UnearnedPremiumsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unearned Premiums, Current</link:label>
    <link:label id="lab_ci_UnearnedPremiumsCurrent_documentation_en-US" xlink:label="lab_ci_UnearnedPremiumsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unearned Premiums, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrent" xlink:href="ci-20260331.xsd#ci_UnearnedPremiumsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnearnedPremiumsCurrent" xlink:to="lab_ci_UnearnedPremiumsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_019c9afa-c38f-7589-8375-b08977b2d20d_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c9afa-c42c-79a2-a690-2db34e142be2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_019c9afa-c38f-70cf-a909-6b47c2e5548c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019c9afa-c38f-749d-99a1-e51e67485fbf_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_019c9afa-c5bb-7b93-9c08-2a1f71c3fa51_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_A1250Million4.875NotesDueSeptember2032Member_019c9afa-c542-7e6c-aad3-5e43f6f3b189_terseLabel_en-US" xlink:label="lab_ci_A1250Million4.875NotesDueSeptember2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.875% Notes due September 2032</link:label>
    <link:label id="lab_ci_A1250Million4.875NotesDueSeptember2032Member_label_en-US" xlink:label="lab_ci_A1250Million4.875NotesDueSeptember2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$1,250 million, 4.875% Notes Due September 2032 [Member]</link:label>
    <link:label id="lab_ci_A1250Million4.875NotesDueSeptember2032Member_documentation_en-US" xlink:label="lab_ci_A1250Million4.875NotesDueSeptember2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$1,250 million, 4.875% Notes Due September 2032</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A1250Million4.875NotesDueSeptember2032Member" xlink:href="ci-20260331.xsd#ci_A1250Million4.875NotesDueSeptember2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_A1250Million4.875NotesDueSeptember2032Member" xlink:to="lab_ci_A1250Million4.875NotesDueSeptember2032Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>ci-20260331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c9afa-b9b6-7bff-8807-e603b8e89aeb,g:b1b37cb4-a013-41e0-9774-54a06c55ff7f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CoverPage" xlink:type="simple" xlink:href="ci-20260331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019c9afa-bfed-7b6a-95a3-f9edca6067af" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_DocumentType_019c9afa-bfed-7b6a-95a3-f9edca6067af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019c9afa-bfed-7749-b441-1012031faa07" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_DocumentQuarterlyReport_019c9afa-bfed-7749-b441-1012031faa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019c9afa-bfed-700e-bd4f-a9b320e55846" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_DocumentTransitionReport_019c9afa-bfed-700e-bd4f-a9b320e55846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019c9afa-bfed-7b14-8313-b1ebfcdd3f9e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityFileNumber_019c9afa-bfed-7b14-8313-b1ebfcdd3f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019c9afa-bfed-7e9b-a8ba-1c90038ec5df" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityRegistrantName_019c9afa-bfed-7e9b-a8ba-1c90038ec5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019c9afa-bfed-7ee6-9ac3-1dbf6016ad67" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019c9afa-bfed-7ee6-9ac3-1dbf6016ad67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019c9afa-bfed-7145-9e66-c0851cf55754" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityTaxIdentificationNumber_019c9afa-bfed-7145-9e66-c0851cf55754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019c9afa-bfed-7ebd-9abc-c7303b124f14" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityAddressAddressLine1_019c9afa-bfed-7ebd-9abc-c7303b124f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019c9afa-bfed-73a0-94db-697154c124eb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityAddressCityOrTown_019c9afa-bfed-73a0-94db-697154c124eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019c9afa-bfed-75ef-b9ea-7758081dd5e7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityAddressStateOrProvince_019c9afa-bfed-75ef-b9ea-7758081dd5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019c9afa-bfed-705c-97a8-af8a4bd5ddbe" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityAddressPostalZipCode_019c9afa-bfed-705c-97a8-af8a4bd5ddbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019c9afa-bfed-7173-94e8-bd0cb0111594" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_CityAreaCode_019c9afa-bfed-7173-94e8-bd0cb0111594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019c9afa-bfed-72fa-8e8c-329d12a8e863" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_LocalPhoneNumber_019c9afa-bfed-72fa-8e8c-329d12a8e863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019c9afa-bfed-7e5e-aac4-104c548aa622" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_Security12bTitle_019c9afa-bfed-7e5e-aac4-104c548aa622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019c9afa-bfed-7aa3-ba24-71aaaa287ae7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_TradingSymbol_019c9afa-bfed-7aa3-ba24-71aaaa287ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019c9afa-bfed-7282-b0a2-512e91394aa6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_SecurityExchangeName_019c9afa-bfed-7282-b0a2-512e91394aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019c9afa-bfed-7f75-a770-00f786f8ef0a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityCurrentReportingStatus_019c9afa-bfed-7f75-a770-00f786f8ef0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019c9afa-bfed-75ae-bbf5-b4a43f6911dd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityInteractiveDataCurrent_019c9afa-bfed-75ae-bbf5-b4a43f6911dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019c9afa-bfed-7e8f-868f-f642f217380c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityFilerCategory_019c9afa-bfed-7e8f-868f-f642f217380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019c9afa-bfed-709d-836c-769a4dc1395b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntitySmallBusiness_019c9afa-bfed-709d-836c-769a4dc1395b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019c9afa-bfed-7cff-85f8-da097b647da7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityEmergingGrowthCompany_019c9afa-bfed-7cff-85f8-da097b647da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019c9afa-bfed-7a35-8529-17f9bb78eaee" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityShellCompany_019c9afa-bfed-7a35-8529-17f9bb78eaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019c9afa-bfed-7b4f-891d-78b2d7467c0b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019c9afa-bfed-7b4f-891d-78b2d7467c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019c9afa-bfed-75e8-a593-554b6e2ffc52" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019c9afa-bfed-75e8-a593-554b6e2ffc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019c9afa-bfed-7db6-99f1-efa201fea10d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_DocumentFiscalYearFocus_019c9afa-bfed-7db6-99f1-efa201fea10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019c9afa-bfed-796a-9f3d-9b1a33d3e30a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_CurrentFiscalYearEndDate_019c9afa-bfed-796a-9f3d-9b1a33d3e30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019c9afa-bfed-7dbe-8d79-854cb3e1b05f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_AmendmentFlag_019c9afa-bfed-7dbe-8d79-854cb3e1b05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019c9afa-bfed-79aa-bfe9-0c3bfffc87c1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_EntityCentralIndexKey_019c9afa-bfed-79aa-bfe9-0c3bfffc87c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_019c9afa-bfed-7b15-8001-2c9b714afc73" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_019c9afa-bfed-7b15-8001-2c9b714afc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019c9afa-bfed-7ccd-83f8-677a8b512391" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c9afa-bfed-77d3-9c7e-b44eb3f61c10" xlink:to="loc_dei_DocumentPeriodEndDate_019c9afa-bfed-7ccd-83f8-677a8b512391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019c9afa-bfed-7fd0-bc86-b6680f7b04b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019c9afa-bfed-7127-95c4-2ea198e5d1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019c9afa-bfed-7fd0-bc86-b6680f7b04b4" xlink:to="loc_us-gaap_StatementTable_019c9afa-bfed-7127-95c4-2ea198e5d1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-bfed-7565-85e1-ba5b29cb35b1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019c9afa-bfed-7127-95c4-2ea198e5d1e3" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-bfed-7565-85e1-ba5b29cb35b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-bfed-7dcb-9e0d-11e29311f0db" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-bfed-7565-85e1-ba5b29cb35b1" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-bfed-7dcb-9e0d-11e29311f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019c9afa-bfed-7b8d-a42b-eb99c20dbe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-bfed-7dcb-9e0d-11e29311f0db" xlink:to="loc_us-gaap_ProductMember_019c9afa-bfed-7b8d-a42b-eb99c20dbe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_019c9afa-bfed-755e-8ed9-50e00e2bef54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-bfed-7dcb-9e0d-11e29311f0db" xlink:to="loc_us-gaap_ServiceMember_019c9afa-bfed-755e-8ed9-50e00e2bef54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019c9afa-bfed-7127-95c4-2ea198e5d1e3" xlink:to="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-bfed-74fc-8534-492c3229220a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-bfed-74fc-8534-492c3229220a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_019c9afa-bfed-70c7-af09-ba8b87fa5a73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:to="loc_us-gaap_PremiumsEarnedNet_019c9afa-bfed-70c7-af09-ba8b87fa5a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_019c9afa-bfed-74cc-afc3-3659f129a90c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:to="loc_us-gaap_NetInvestmentIncome_019c9afa-bfed-74cc-afc3-3659f129a90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019c9afa-bfed-793b-8ec1-cbd0051c0d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_019c9afa-bfed-764a-9b1c-a7888d7b72d4" xlink:to="loc_us-gaap_Revenues_019c9afa-bfed-793b-8ec1-cbd0051c0d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BenefitsLossesAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-bfed-7716-bb8a-99f13fcb5d85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-bfed-7716-bb8a-99f13fcb5d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-bfed-7723-8b11-578a54c69d74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-bfed-7723-8b11-578a54c69d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c9afa-bfed-79f1-b244-66f55bd1546b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c9afa-bfed-79f1-b244-66f55bd1546b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-bfed-75e0-aaa3-b03abc6a11cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-bfed-75e0-aaa3-b03abc6a11cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-73a5-b3c7-0717a49acfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_019c9afa-bfed-7f23-86e5-4e2e0a3743a4" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_019c9afa-bfed-73a5-b3c7-0717a49acfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019c9afa-bfed-73ba-92d0-fdcf3ebea7de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_OperatingIncomeLoss_019c9afa-bfed-73ba-92d0-fdcf3ebea7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-bfed-7488-834e-a98c98d90b74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-bfed-7488-834e-a98c98d90b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-bfed-78fb-bd35-8b510555b3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-bfed-78fb-bd35-8b510555b3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_019c9afa-bfed-7104-90e3-bf6f65b86508" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_019c9afa-bfed-7104-90e3-bf6f65b86508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLoss_019c9afa-bfed-7199-80cb-8123d4116ef4" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_ci_NetInvestmentGainLoss_019c9afa-bfed-7199-80cb-8123d4116ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-7340-aca8-6fdfa051e76a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-bfed-7340-aca8-6fdfa051e76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c9afa-bfed-78c3-925d-30b71e910da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019c9afa-bfed-78c3-925d-30b71e910da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019c9afa-bfed-7132-9256-f5826941de7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_ProfitLoss_019c9afa-bfed-7132-9256-f5826941de7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019c9afa-bfed-7ace-a987-1af87b71a351" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019c9afa-bfed-7ace-a987-1af87b71a351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c9afa-bfed-7ea7-855c-5fe3c56e7796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_NetIncomeLoss_019c9afa-bfed-7ea7-855c-5fe3c56e7796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c9afa-bfed-76f8-a843-1af789ecf569" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7668-8e05-af823893ad6c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_019c9afa-bfed-76f8-a843-1af789ecf569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019c9afa-bfed-739c-aa87-8283afc116aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-bfed-76f8-a843-1af789ecf569" xlink:to="loc_us-gaap_EarningsPerShareBasic_019c9afa-bfed-739c-aa87-8283afc116aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019c9afa-bfed-7ae3-8da2-7c3b9287a77d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-bfed-76f8-a843-1af789ecf569" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019c9afa-bfed-7ae3-8da2-7c3b9287a77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c9afa-bfed-7b68-9588-4cd98f2834f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019c9afa-bfed-7f5c-a4ae-3dda04d6b3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c9afa-bfed-7b68-9588-4cd98f2834f6" xlink:to="loc_us-gaap_ProfitLoss_019c9afa-bfed-7f5c-a4ae-3dda04d6b3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019c9afa-bfed-7878-bc4b-1b633160155b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c9afa-bfed-7b68-9588-4cd98f2834f6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019c9afa-bfed-7878-bc4b-1b633160155b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_019c9afa-bfed-7ea2-81b3-e45c8c9abad8" xlink:href="ci-20260331.xsd#ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019c9afa-bfed-7878-bc4b-1b633160155b" xlink:to="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_019c9afa-bfed-7ea2-81b3-e45c8c9abad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_019c9afa-bfed-77a6-a804-e14754a053af" xlink:href="ci-20260331.xsd#ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019c9afa-bfed-7878-bc4b-1b633160155b" xlink:to="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_019c9afa-bfed-77a6-a804-e14754a053af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_019c9afa-bfed-7a4a-aa11-215214741a62" xlink:href="ci-20260331.xsd#ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019c9afa-bfed-7878-bc4b-1b633160155b" xlink:to="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_019c9afa-bfed-7a4a-aa11-215214741a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_019c9afa-bfed-7234-b03e-51c4b2431eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019c9afa-bfed-7878-bc4b-1b633160155b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_019c9afa-bfed-7234-b03e-51c4b2431eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7e0b-afc5-76ea286bab75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019c9afa-bfed-7878-bc4b-1b633160155b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7e0b-afc5-76ea286bab75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7007-b0ba-4ca2806afbac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019c9afa-bfed-7878-bc4b-1b633160155b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7007-b0ba-4ca2806afbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_019c9afa-bfed-79f4-876e-c55b974a5a62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c9afa-bfed-7b68-9588-4cd98f2834f6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_019c9afa-bfed-79f4-876e-c55b974a5a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c9afa-bfed-7e92-9250-b9a8a003820f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c9afa-bfed-7b68-9588-4cd98f2834f6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c9afa-bfed-7e92-9250-b9a8a003820f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-bfed-7a67-b5e3-426b9e9d56bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-bfed-7a67-b5e3-426b9e9d56bc" xlink:to="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c9afa-bfed-74eb-86ee-ea9be769ab97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c9afa-bfed-74eb-86ee-ea9be769ab97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_019c9afa-bfed-762f-92e3-4373679e39a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_ShortTermInvestments_019c9afa-bfed-762f-92e3-4373679e39a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfed-7649-9ddc-22d3ab336df0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfed-7649-9ddc-22d3ab336df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019c9afa-bfed-7556-afa1-58d5b08bbfca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_InventoryNet_019c9afa-bfed-7556-afa1-58d5b08bbfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019c9afa-bfed-70ae-8e0c-adbba6c300fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_OtherAssetsCurrent_019c9afa-bfed-70ae-8e0c-adbba6c300fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c9afa-bfed-731a-b2e8-b332c8138200" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c9afa-bfed-731a-b2e8-b332c8138200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019c9afa-bfed-706a-ad3f-7968b8e924eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_AssetsCurrent_019c9afa-bfed-706a-ad3f-7968b8e924eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_019c9afa-bfed-7dda-b9c1-6b38a7421b77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_LongTermInvestments_019c9afa-bfed-7dda-b9c1-6b38a7421b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesNonCurrent_019c9afa-bfed-7703-8b5d-87be2e610340" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverablesNonCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_ci_ReinsuranceRecoverablesNonCurrent_019c9afa-bfed-7703-8b5d-87be2e610340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_019c9afa-bfed-7241-b4eb-ea02b9e260dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_019c9afa-bfed-7241-b4eb-ea02b9e260dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_019c9afa-bfed-7f5b-8eec-3f0f7808468e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_Goodwill_019c9afa-bfed-7f5b-8eec-3f0f7808468e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019c9afa-bfed-7b11-a8b2-c8233f608dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019c9afa-bfed-7b11-a8b2-c8233f608dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019c9afa-bfed-7134-b459-895474137b79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019c9afa-bfed-7134-b459-895474137b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetAtCarryingValue_019c9afa-bfed-785b-86fb-fb0fbad592a4" xlink:href="ci-20260331.xsd#ci_SeparateAccountAssetAtCarryingValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_ci_SeparateAccountAssetAtCarryingValue_019c9afa-bfed-785b-86fb-fb0fbad592a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019c9afa-bfed-7261-9440-d1d20ac39296" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c9afa-bfed-759f-88d2-507e42862889" xlink:to="loc_us-gaap_Assets_019c9afa-bfed-7261-9440-d1d20ac39296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-bfed-7a67-b5e3-426b9e9d56bc" xlink:to="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-bfed-715e-8cdb-61204c2adb8f" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-bfed-715e-8cdb-61204c2adb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyAndServiceCostsPayable_019c9afa-bfed-7eae-a2d7-31cc4cea77c9" xlink:href="ci-20260331.xsd#ci_PharmacyAndServiceCostsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_ci_PharmacyAndServiceCostsPayable_019c9afa-bfed-7eae-a2d7-31cc4cea77c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019c9afa-bfed-711d-bca4-2b74c4e914df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_us-gaap_AccountsPayableCurrent_019c9afa-bfed-711d-bca4-2b74c4e914df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccruedExpensesAndOtherLiabilities_019c9afa-bfed-7506-a401-19e636002c9a" xlink:href="ci-20260331.xsd#ci_AccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_ci_AccruedExpensesAndOtherLiabilities_019c9afa-bfed-7506-a401-19e636002c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_019c9afa-bfed-7a5a-82f3-276821eb599c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_us-gaap_DebtCurrent_019c9afa-bfed-7a5a-82f3-276821eb599c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c9afa-bfed-7602-b4d4-06d829faca73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c9afa-bfed-7602-b4d4-06d829faca73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7cb4-b4d7-1691f8f94957" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_us-gaap_LiabilitiesCurrent_019c9afa-bfed-7cb4-b4d7-1691f8f94957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-bfed-773b-acbd-e6eeb1074612" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-bfed-773b-acbd-e6eeb1074612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019c9afa-bfed-7e3c-96ce-7d063cd22110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019c9afa-bfed-7e3c-96ce-7d063cd22110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019c9afa-bfed-7054-8c26-2ceef556c315" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019c9afa-bfed-7054-8c26-2ceef556c315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_019c9afa-bfed-7858-a901-e5c1cdd70b87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_019c9afa-bfed-7858-a901-e5c1cdd70b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability_019c9afa-bfed-795e-af65-9a1b442d42b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_us-gaap_SeparateAccountsLiability_019c9afa-bfed-795e-af65-9a1b442d42b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019c9afa-bfed-717d-b035-defa6ab3ffce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019c9afa-bfed-7dac-bb39-25fddde54c01" xlink:to="loc_us-gaap_Liabilities_019c9afa-bfed-717d-b035-defa6ab3ffce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019c9afa-bfed-7125-90c1-71f1d2183029" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-bfed-7a67-b5e3-426b9e9d56bc" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019c9afa-bfed-7125-90c1-71f1d2183029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-bfed-7ca0-8a26-75219feee15c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-bfed-7a67-b5e3-426b9e9d56bc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-bfed-7ca0-8a26-75219feee15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019c9afa-bfed-7a2b-bc39-65c74db79018" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-bfed-7ca0-8a26-75219feee15c" xlink:to="loc_us-gaap_CommonStockValue_019c9afa-bfed-7a2b-bc39-65c74db79018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019c9afa-bfed-7906-9d0d-5daef0967961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-bfed-7ca0-8a26-75219feee15c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019c9afa-bfed-7906-9d0d-5daef0967961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7c46-930f-ab2a266b8144" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-bfed-7ca0-8a26-75219feee15c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-7c46-930f-ab2a266b8144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019c9afa-bfed-7df9-a8df-044fbc71e6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-bfed-7ca0-8a26-75219feee15c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019c9afa-bfed-7df9-a8df-044fbc71e6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_019c9afa-bfed-7a33-9486-8cc77a66f2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-bfed-7ca0-8a26-75219feee15c" xlink:to="loc_us-gaap_TreasuryStockValue_019c9afa-bfed-7a33-9486-8cc77a66f2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c9afa-bfed-734b-bf73-e0c7fa6cd540" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-bfed-7ca0-8a26-75219feee15c" xlink:to="loc_us-gaap_StockholdersEquity_019c9afa-bfed-734b-bf73-e0c7fa6cd540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_019c9afa-bfed-76fb-b8a4-c31e83ba99e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-bfed-7ca0-8a26-75219feee15c" xlink:to="loc_us-gaap_MinorityInterest_019c9afa-bfed-76fb-b8a4-c31e83ba99e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7be8-94f8-8a3c89d2991c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019c9afa-bfed-7ca0-8a26-75219feee15c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7be8-94f8-8a3c89d2991c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c9afa-bfed-731b-b5e4-1021c21b157a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-bfed-7a67-b5e3-426b9e9d56bc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c9afa-bfed-731b-b5e4-1021c21b157a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-bfed-7bd7-97b1-85ac0ebb3534" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019c9afa-bfed-70e9-addf-df10d7418e65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-bfed-7bd7-97b1-85ac0ebb3534" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019c9afa-bfed-70e9-addf-df10d7418e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019c9afa-bfed-7fa6-90d3-71458ef0cfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-bfed-7bd7-97b1-85ac0ebb3534" xlink:to="loc_us-gaap_CommonStockSharesIssued_019c9afa-bfed-7fa6-90d3-71458ef0cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019c9afa-bfed-7fbb-9360-8b8d0e5b3863" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019c9afa-bfed-7bd7-97b1-85ac0ebb3534" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019c9afa-bfed-7fbb-9360-8b8d0e5b3863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedStatementsofChangesinTotalEquity"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019c9afa-bfed-7f44-a7d2-48cb19fa0b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019c9afa-bfed-7137-8a4d-59365886fec3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019c9afa-bfed-7f44-a7d2-48cb19fa0b9c" xlink:to="loc_us-gaap_StatementTable_019c9afa-bfed-7137-8a4d-59365886fec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-bfed-7e7e-839a-7535fd753a11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019c9afa-bfed-7137-8a4d-59365886fec3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-bfed-7e7e-839a-7535fd753a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019c9afa-bfed-7f57-821d-940bf2edec96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-bfed-7e7e-839a-7535fd753a11" xlink:to="loc_us-gaap_EquityComponentDomain_019c9afa-bfed-7f57-821d-940bf2edec96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019c9afa-bfed-7f57-821d-940bf2edec96" xlink:to="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019c9afa-bfed-7057-baaa-947ecff0eb58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:to="loc_us-gaap_CommonStockMember_019c9afa-bfed-7057-baaa-947ecff0eb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019c9afa-bfed-7b66-80d8-37f84c5b7854" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019c9afa-bfed-7b66-80d8-37f84c5b7854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-bfed-7b67-b701-f775c90d4ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-bfed-7b67-b701-f775c90d4ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019c9afa-bfed-7426-9a51-85f635e4117c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:to="loc_us-gaap_RetainedEarningsMember_019c9afa-bfed-7426-9a51-85f635e4117c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019c9afa-bfed-7f5b-b53f-2067a93fc35a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019c9afa-bfed-77e0-ba5f-57e05587e3d3" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019c9afa-bfed-7f5b-b53f-2067a93fc35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_019c9afa-bfed-7217-8edd-4fbbea1c08aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019c9afa-bfed-7f57-821d-940bf2edec96" xlink:to="loc_us-gaap_NoncontrollingInterestMember_019c9afa-bfed-7217-8edd-4fbbea1c08aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019c9afa-bfed-7c85-96d6-e53e8d3a5af5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019c9afa-bfed-7137-8a4d-59365886fec3" xlink:to="loc_us-gaap_StatementLineItems_019c9afa-bfed-7c85-96d6-e53e8d3a5af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7c85-96d6-e53e8d3a5af5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7b20-ade2-3559a7856a24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7b20-ade2-3559a7856a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019c9afa-bfed-72aa-83a1-e5a4d5723864" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019c9afa-bfed-72aa-83a1-e5a4d5723864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-78e3-b03b-6db392113e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-bfed-78e3-b03b-6db392113e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_019c9afa-bfed-7ed5-b946-9655d22b4b80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_019c9afa-bfed-7ed5-b946-9655d22b4b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_019c9afa-bfed-796f-b310-8ee2025397b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_DividendsCommonStockCash_019c9afa-bfed-796f-b310-8ee2025397b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c9afa-bfed-72ac-83b3-c79eef640bff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c9afa-bfed-72ac-83b3-c79eef640bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoncontrollingInterestOtherChanges_019c9afa-bfed-7669-bd67-c084c34b98c4" xlink:href="ci-20260331.xsd#ci_NoncontrollingInterestOtherChanges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_ci_NoncontrollingInterestOtherChanges_019c9afa-bfed-7669-bd67-c084c34b98c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7c79-ad4b-41c1268090ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c9afa-bfed-7e29-a1ac-30cb570c3580" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-bfed-7c79-ad4b-41c1268090ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c9afa-bfed-7c85-96d6-e53e8d3a5af5" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_019c9afa-bfed-7005-8610-9c6478fe101f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_019c9afa-bfed-7005-8610-9c6478fe101f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncomeLoss_019c9afa-bfed-7f8c-b04a-beccf4e25a45" xlink:href="ci-20260331.xsd#ci_TemporaryEquityOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:to="loc_ci_TemporaryEquityOtherComprehensiveIncomeLoss_019c9afa-bfed-7f8c-b04a-beccf4e25a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_019c9afa-bfed-7b92-ace3-5595037b9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_019c9afa-bfed-7b92-ace3-5595037b9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_019c9afa-bfed-7428-84ff-ac89cb328497" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_019c9afa-bfed-7b11-8468-06e29158957b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_019c9afa-bfed-7428-84ff-ac89cb328497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedStatementsofChangesinTotalEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019c9afa-bfed-7784-bdf5-2a3467c3a1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_019c9afa-bfed-7277-a6e4-bce3eda16659" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019c9afa-bfed-7784-bdf5-2a3467c3a1c5" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_019c9afa-bfed-7277-a6e4-bce3eda16659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ci-20260331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019c9afa-bfed-72c4-8617-001228ce0498" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019c9afa-bfed-72c4-8617-001228ce0498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019c9afa-bfed-76d8-b48e-cf30080ce56e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019c9afa-bfed-72c4-8617-001228ce0498" xlink:to="loc_us-gaap_ProfitLoss_019c9afa-bfed-76d8-b48e-cf30080ce56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c9afa-bfed-7ee6-9e75-c0fbd44e13f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019c9afa-bfed-72c4-8617-001228ce0498" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c9afa-bfed-7ee6-9e75-c0fbd44e13f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019c9afa-bfed-7840-b550-c98447ff51f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c9afa-bfed-7ee6-9e75-c0fbd44e13f3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019c9afa-bfed-7840-b550-c98447ff51f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLoss_019c9afa-bfed-7d9f-936a-3b97152ed329" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c9afa-bfed-7ee6-9e75-c0fbd44e13f3" xlink:to="loc_ci_NetInvestmentGainLoss_019c9afa-bfed-7d9f-936a-3b97152ed329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_019c9afa-bfed-7b92-9950-d3a387f67351" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c9afa-bfed-7ee6-9e75-c0fbd44e13f3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_019c9afa-bfed-7b92-9950-d3a387f67351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_019c9afa-bfed-7e95-b0d3-0a1193da7318" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c9afa-bfed-7ee6-9e75-c0fbd44e13f3" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_019c9afa-bfed-7e95-b0d3-0a1193da7318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-bfed-7ff5-aa47-d3ed4591c12d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c9afa-bfed-7ee6-9e75-c0fbd44e13f3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019c9afa-bfed-7ff5-aa47-d3ed4591c12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c9afa-bfed-76dc-9eb5-ee18088f5eac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019c9afa-bfed-72c4-8617-001228ce0498" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c9afa-bfed-76dc-9eb5-ee18088f5eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_019c9afa-bfed-7a73-b6ce-c90e83789c22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c9afa-bfed-76dc-9eb5-ee18088f5eac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_019c9afa-bfed-7a73-b6ce-c90e83789c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_019c9afa-bfed-7e29-a3bc-6c5ca27823b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c9afa-bfed-76dc-9eb5-ee18088f5eac" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_019c9afa-bfed-7e29-a3bc-6c5ca27823b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_019c9afa-bfed-7af0-a14c-c54f9764bf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInReinsuranceRecoverable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c9afa-bfed-76dc-9eb5-ee18088f5eac" xlink:to="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_019c9afa-bfed-7af0-a14c-c54f9764bf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_019c9afa-bfed-714f-88d2-280b1dbd8e97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c9afa-bfed-76dc-9eb5-ee18088f5eac" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_019c9afa-bfed-714f-88d2-280b1dbd8e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_019c9afa-bfed-70c7-ba5c-1f1bd43e1156" xlink:href="ci-20260331.xsd#ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c9afa-bfed-76dc-9eb5-ee18088f5eac" xlink:to="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_019c9afa-bfed-70c7-ba5c-1f1bd43e1156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_019c9afa-bfed-707b-85f1-951f9bd35fc6" xlink:href="ci-20260331.xsd#ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c9afa-bfed-76dc-9eb5-ee18088f5eac" xlink:to="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_019c9afa-bfed-707b-85f1-951f9bd35fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_019c9afa-bfed-7bbb-98f7-465230ab0971" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c9afa-bfed-76dc-9eb5-ee18088f5eac" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_019c9afa-bfed-7bbb-98f7-465230ab0971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7918-baaa-9f269620dd66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019c9afa-bfed-72c4-8617-001228ce0498" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c9afa-bfed-7918-baaa-9f269620dd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract_019c9afa-bfed-7b40-9dc8-16a1af302569" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract_019c9afa-bfed-7b40-9dc8-16a1af302569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities_019c9afa-bfed-7d8a-8749-818364d14fa3" xlink:href="ci-20260331.xsd#ci_ProceedsFromSaleOfDebtAndEquitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract_019c9afa-bfed-7b40-9dc8-16a1af302569" xlink:to="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities_019c9afa-bfed-7d8a-8749-818364d14fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_019c9afa-bfed-764b-9eeb-03cb245610f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_019c9afa-bfed-764b-9eeb-03cb245610f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_019c9afa-bfed-7e7b-90b2-b35c85dbfe60" xlink:href="ci-20260331.xsd#ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_019c9afa-bfed-764b-9eeb-03cb245610f5" xlink:to="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_019c9afa-bfed-7e7b-90b2-b35c85dbfe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_019c9afa-bfed-7062-894b-2005f80a8367" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_019c9afa-bfed-764b-9eeb-03cb245610f5" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_019c9afa-bfed-7062-894b-2005f80a8367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_019c9afa-bfed-7a2e-b140-1bccb8d63a57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_019c9afa-bfed-764b-9eeb-03cb245610f5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_019c9afa-bfed-7a2e-b140-1bccb8d63a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract_019c9afa-bfed-76a5-a936-6bb167dddb97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestmentsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:to="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract_019c9afa-bfed-76a5-a936-6bb167dddb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_019c9afa-bfed-7e6e-8a4b-5b124ff4bc5f" xlink:href="ci-20260331.xsd#ci_PaymentsToAcquireDebtAndEquitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract_019c9afa-bfed-76a5-a936-6bb167dddb97" xlink:to="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_019c9afa-bfed-7e6e-8a4b-5b124ff4bc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable_019c9afa-bfed-7cfa-b78b-2b6756629502" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMortgageNotesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract_019c9afa-bfed-76a5-a936-6bb167dddb97" xlink:to="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable_019c9afa-bfed-7cfa-b78b-2b6756629502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_019c9afa-bfed-7f48-afb4-40ac73a70d79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract_019c9afa-bfed-76a5-a936-6bb167dddb97" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_019c9afa-bfed-7f48-afb4-40ac73a70d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_019c9afa-bfed-7b66-b6bf-7121c16a9654" xlink:href="ci-20260331.xsd#ci_PaymentsForProceedsFromPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:to="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_019c9afa-bfed-7b66-b6bf-7121c16a9654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019c9afa-bfed-75f6-9879-656880530585" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019c9afa-bfed-75f6-9879-656880530585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_019c9afa-bfed-7c79-a712-bc39013b1ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_019c9afa-bfed-7c79-a712-bc39013b1ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_019c9afa-bfed-7f55-a52c-67c07432a30b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_019c9afa-bfed-7f55-a52c-67c07432a30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_019c9afa-bfed-75e9-b261-ad2b534faff6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_019c9afa-bfed-75e9-b261-ad2b534faff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7692-b331-959f4bb72746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c9afa-bfed-78ba-b671-cc5717de39c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c9afa-bfed-7692-b331-959f4bb72746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionsToContractHoldersFunds_019c9afa-bfed-7254-a98e-def8b750d557" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionsToContractHoldersFunds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_AdditionsToContractHoldersFunds_019c9afa-bfed-7254-a98e-def8b750d557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WithdrawalFromContractHoldersFunds_019c9afa-bfed-7aa0-88fe-4f3e614a0578" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WithdrawalFromContractHoldersFunds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_WithdrawalFromContractHoldersFunds_019c9afa-bfed-7aa0-88fe-4f3e614a0578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_019c9afa-bfed-7b94-9f0f-e8830e076cf9" xlink:href="ci-20260331.xsd#ci_ProceedsFromRepaymentsOfOtherShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_019c9afa-bfed-7b94-9f0f-e8830e076cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_019c9afa-bfed-7711-b48c-64161ed6feda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_019c9afa-bfed-7711-b48c-64161ed6feda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_019c9afa-bfed-76e7-a099-4d7cd73bb215" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_019c9afa-bfed-76e7-a099-4d7cd73bb215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_019c9afa-bfed-7e0e-80ef-6d6b64689fed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_019c9afa-bfed-7e0e-80ef-6d6b64689fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_019c9afa-bfed-7012-b66a-a6363f2de1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_019c9afa-bfed-7012-b66a-a6363f2de1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019c9afa-bfed-7770-be2e-459705472887" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019c9afa-bfed-7770-be2e-459705472887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c9afa-bfed-71fb-9b72-cd55a8d60e01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c9afa-bfed-71fb-9b72-cd55a8d60e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019c9afa-bfed-7893-b9f4-e55b3a0af945" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019c9afa-bfed-7893-b9f4-e55b3a0af945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_019c9afa-bfed-7855-9a9a-a348b19edddf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_019c9afa-bfed-7855-9a9a-a348b19edddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019c9afa-bfed-7562-889f-41c43fa19f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019c9afa-bfed-7562-889f-41c43fa19f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-766c-b3aa-bb7563cd1d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019c9afa-bfed-7ff4-aba0-36b9c3ef1778" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c9afa-bfed-766c-b3aa-bb7563cd1d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c9afa-bfed-7d75-97ac-cf6cc2319077" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c9afa-bfed-7d75-97ac-cf6cc2319077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c9afa-bfed-7bf9-a210-23ce20a8729f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c9afa-bfed-7bf9-a210-23ce20a8729f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019dd9db-1a99-702a-ac91-2b426d635c37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019dd9db-1a99-702a-ac91-2b426d635c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c9afa-bfed-7198-8b42-6299808aed77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c9afa-bfed-7198-8b42-6299808aed77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019dd98c-ac9b-75d2-b59f-8ada3d52c8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019dd98c-ac9b-75d2-b59f-8ada3d52c8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019dd9db-74b8-74d3-9b0d-152bce318866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019dd9db-74b8-74d3-9b0d-152bce318866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_019c9afa-bfed-7428-ac49-4e0d270096b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c9afa-bfed-7702-b14b-05b5dc644eb3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_019c9afa-bfed-7428-ac49-4e0d270096b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_019c9afa-bfed-7b63-93fd-b8de6773f1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019c9afa-bfed-7428-ac49-4e0d270096b7" xlink:to="loc_us-gaap_InterestPaidNet_019c9afa-bfed-7b63-93fd-b8de6773f1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ci-20260331.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c9afa-bfed-7a64-8aa9-8b7d4e0091b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_019c9afa-bfed-7fc2-b8e7-7f3eb6d8f542" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c9afa-bfed-7a64-8aa9-8b7d4e0091b7" xlink:to="loc_us-gaap_NatureOfOperations_019c9afa-bfed-7fc2-b8e7-7f3eb6d8f542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019c9afa-bfed-7366-b3f1-92d20831e7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019c9afa-bfed-793a-a4cf-327a22e4c682" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c9afa-bfed-7366-b3f1-92d20831e7ab" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019c9afa-bfed-793a-a4cf-327a22e4c682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNet" xlink:type="simple" xlink:href="ci-20260331.xsd#AccountsReceivableNet"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-7df7-a039-8d2545e4951f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_019c9afa-bfee-78a2-8654-1d3fdffdcbee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-7df7-a039-8d2545e4951f" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_019c9afa-bfee-78a2-8654-1d3fdffdcbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SupplierFinanceProgram" xlink:type="simple" xlink:href="ci-20260331.xsd#SupplierFinanceProgram"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SupplierFinanceProgram" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-7d53-8333-a6fe24758663" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTextBlock_019c9afa-bfee-7f91-aed3-32cfb109f1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-7d53-8333-a6fe24758663" xlink:to="loc_us-gaap_SupplierFinanceProgramTextBlock_019c9afa-bfee-7f91-aed3-32cfb109f1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShare" xlink:type="simple" xlink:href="ci-20260331.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-7102-b0b5-5c3b28774479" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_019c9afa-c0ae-7071-bc28-ef7193b598b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-7102-b0b5-5c3b28774479" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_019c9afa-c0ae-7071-bc28-ef7193b598b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/Debt" xlink:type="simple" xlink:href="ci-20260331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019c9afa-c0ae-7cb0-b29e-51b58febad0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_019c9afa-c0ae-7f19-8319-3754fe8a18f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019c9afa-c0ae-7cb0-b29e-51b58febad0a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_019c9afa-c0ae-7f19-8319-3754fe8a18f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilities"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0ae-7009-8da3-f30b8872bfab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_019c9afa-c0ae-7391-8e7f-eee8aeb7a54e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0ae-7009-8da3-f30b8872bfab" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_019c9afa-c0ae-7391-8e7f-eee8aeb7a54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/Reinsurance" xlink:type="simple" xlink:href="ci-20260331.xsd#Reinsurance"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/Reinsurance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c0af-7383-8133-cbb16545c297" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceTextBlock_019c9afa-c0af-75e5-aad2-e06d7d9a7ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c0af-7383-8133-cbb16545c297" xlink:to="loc_us-gaap_ReinsuranceTextBlock_019c9afa-c0af-75e5-aad2-e06d7d9a7ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/Investments" xlink:type="simple" xlink:href="ci-20260331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-703d-b7e1-061cbaf3cbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_019c9afa-c16c-7efe-8c92-5b53cae08b99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-703d-b7e1-061cbaf3cbd5" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_019c9afa-c16c-7efe-8c92-5b53cae08b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-76c1-bd2e-a47126db5559" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_019c9afa-c16c-7c50-9e47-304297e44d68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-76c1-bd2e-a47126db5559" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_019c9afa-c16c-7c50-9e47-304297e44d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ci-20260331.xsd#AccumulatedOtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_019c9afa-c22b-7dfc-8d64-9a468121c4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock_019c9afa-c22b-79cf-846e-607019e4f484" xlink:href="ci-20260331.xsd#ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_019c9afa-c22b-7dfc-8d64-9a468121c4ad" xlink:to="loc_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock_019c9afa-c22b-79cf-846e-607019e4f484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/StrategicOptimizationProgram" xlink:type="simple" xlink:href="ci-20260331.xsd#StrategicOptimizationProgram"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/StrategicOptimizationProgram" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c9afa-c22b-7aae-85f1-72d11c07dc63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019c9afa-c22b-70f4-b237-746dfd87b385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c9afa-c22b-7aae-85f1-72d11c07dc63" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019c9afa-c22b-70f4-b237-746dfd87b385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ci-20260331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019c9afa-c22c-7667-8608-152c809073ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_019c9afa-c22c-7d15-bd34-09206f7d84de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019c9afa-c22c-7667-8608-152c809073ce" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_019c9afa-c22c-7d15-bd34-09206f7d84de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ContingenciesandOtherMatters" xlink:type="simple" xlink:href="ci-20260331.xsd#ContingenciesandOtherMatters"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ContingenciesandOtherMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c9afa-c2d7-7303-ac54-3aa4b470a15e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019c9afa-c2d7-7bf8-9648-092e1520eabb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c9afa-c2d7-7303-ac54-3aa4b470a15e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019c9afa-c2d7-7bf8-9648-092e1520eabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformation" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-7e2b-a0cc-55bfa8a3bc68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019c9afa-c2d7-7f68-8f86-5a50f5e0c3de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-7e2b-a0cc-55bfa8a3bc68" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019c9afa-c2d7-7f68-8f86-5a50f5e0c3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019c9afa-bfed-725a-a118-507ab993a4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019c9afa-bfed-736f-a794-71c514ce098a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c9afa-bfed-725a-a118-507ab993a4f4" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019c9afa-bfed-736f-a794-71c514ce098a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019c9afa-bfed-71e4-af76-662ffe0b813a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c9afa-bfed-725a-a118-507ab993a4f4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019c9afa-bfed-71e4-af76-662ffe0b813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_019c9afa-bfed-71d9-9b86-9755379ed213" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c9afa-bfed-725a-a118-507ab993a4f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_019c9afa-bfed-71d9-9b86-9755379ed213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_019c9afa-bfed-71a6-8c24-39f11b1c51be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c9afa-bfed-725a-a118-507ab993a4f4" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_019c9afa-bfed-71a6-8c24-39f11b1c51be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_019c9afa-bfed-73ed-bef1-7abfe7ed3b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c9afa-bfed-725a-a118-507ab993a4f4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_019c9afa-bfed-73ed-bef1-7abfe7ed3b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_019c9afa-bfed-7e19-899a-112131dae3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c9afa-bfed-725a-a118-507ab993a4f4" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_019c9afa-bfed-7e19-899a-112131dae3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_019c9afa-bfed-7f4f-8fa2-ec5dc19ff630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c9afa-bfed-725a-a118-507ab993a4f4" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_019c9afa-bfed-7f4f-8fa2-ec5dc19ff630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetPolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#AccountsReceivableNetPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-76bc-ad39-42d796e565b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_019c9afa-bfee-7707-be57-96f41f182648" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-76bc-ad39-42d796e565b9" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_019c9afa-bfee-7707-be57-96f41f182648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerSharePolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#EarningsPerSharePolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerSharePolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-7f1a-86b9-be450cabc65f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_019c9afa-c0ae-725e-bb5c-b9e80df96d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-7f1a-86b9-be450cabc65f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_019c9afa-c0ae-725e-bb5c-b9e80df96d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesPolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-760c-8da9-950112a6a7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceUnearnedPremiumsPolicyTextBlock_019c9afa-c0af-7710-823e-4cebe14a502b" xlink:href="ci-20260331.xsd#ci_InsuranceUnearnedPremiumsPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-760c-8da9-950112a6a7d7" xlink:to="loc_ci_InsuranceUnearnedPremiumsPolicyTextBlock_019c9afa-c0af-7710-823e-4cebe14a502b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_019c9afa-c0af-70f3-9e3e-c873fab36fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-760c-8da9-950112a6a7d7" xlink:to="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_019c9afa-c0af-70f3-9e3e-c873fab36fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy_019c9afa-c0af-7d76-a2ab-7ab9b8c6cf99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FuturePolicyBenefitsLiabilityPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-760c-8da9-950112a6a7d7" xlink:to="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy_019c9afa-c0af-7d76-a2ab-7ab9b8c6cf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractholderDepositFundsPolicyPolicyTextBlock_019c9afa-c0af-7f59-a62b-ef4433f363c9" xlink:href="ci-20260331.xsd#ci_ContractholderDepositFundsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-760c-8da9-950112a6a7d7" xlink:to="loc_ci_ContractholderDepositFundsPolicyPolicyTextBlock_019c9afa-c0af-7f59-a62b-ef4433f363c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitPolicyTextBlock_019c9afa-c0af-7742-828c-cb78772c2b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-760c-8da9-950112a6a7d7" xlink:to="loc_us-gaap_MarketRiskBenefitPolicyTextBlock_019c9afa-c0af-7742-828c-cb78772c2b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsurancePolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#ReinsurancePolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ReinsurancePolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c0af-77c5-aeaf-9e7d74d774ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceAccountingPolicy_019c9afa-c0af-701e-a33a-a3c71e98b137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceAccountingPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c0af-77c5-aeaf-9e7d74d774ee" xlink:to="loc_us-gaap_ReinsuranceAccountingPolicy_019c9afa-c0af-701e-a33a-a3c71e98b137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsPolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-75f0-955a-1f368fe897bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_019c9afa-c16c-70cc-8e35-2ffa337541ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-75f0-955a-1f368fe897bf" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_019c9afa-c16c-70cc-8e35-2ffa337541ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_019c9afa-c16c-7eae-8bf0-072bf6136bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-75f0-955a-1f368fe897bf" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_019c9afa-c16c-7eae-8bf0-072bf6136bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasuresandDisclosuresPolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasuresandDisclosuresPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasuresandDisclosuresPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-7d4d-a2da-738e43e34d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_019c9afa-c16c-7ecc-bc33-986d43afdac8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-7d4d-a2da-738e43e34d33" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_019c9afa-c16c-7ecc-bc33-986d43afdac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountsPolicy_019c9afa-c16c-7c6f-9391-00f35d8e11c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-7d4d-a2da-738e43e34d33" xlink:to="loc_us-gaap_PolicyholderAccountsPolicy_019c9afa-c16c-7c6f-9391-00f35d8e11c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossPolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#AccumulatedOtherComprehensiveIncomeLossPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_019c9afa-c22b-7bfa-8599-2a6fd1e6bbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_019c9afa-c22b-7e42-92ef-a745f570fffb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_019c9afa-c22b-7bfa-8599-2a6fd1e6bbdf" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_019c9afa-c22b-7e42-92ef-a745f570fffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesPolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#IncomeTaxesPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019c9afa-c22c-70a1-9798-6486d3c7f52d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_019c9afa-c22c-7ef8-bd9e-f629c6132767" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019c9afa-c22c-70a1-9798-6486d3c7f52d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_019c9afa-c22c-7ef8-bd9e-f629c6132767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CommitmentandContingenciesPolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#CommitmentandContingenciesPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CommitmentandContingenciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c9afa-c2d7-7fac-9e1d-576635fdfd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_019c9afa-c2d7-724b-a554-33eb567b4d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c9afa-c2d7-7fac-9e1d-576635fdfd1d" xlink:to="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_019c9afa-c2d7-724b-a554-33eb567b4d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_019c9afa-c2d7-7a8f-b5e9-8375f030abe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c9afa-c2d7-7fac-9e1d-576635fdfd1d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_019c9afa-c2d7-7a8f-b5e9-8375f030abe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentReportingPolicies" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentReportingPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentReportingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-72d1-ab0b-8e7e52ad4a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_019c9afa-c2d7-76be-8487-83dd22669eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-72d1-ab0b-8e7e52ad4a76" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_019c9afa-c2d7-76be-8487-83dd22669eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetTables" xlink:type="simple" xlink:href="ci-20260331.xsd#AccountsReceivableNetTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-70db-81ac-65e89b37e9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_019c9afa-bfee-7a8b-b4c1-7e3f371c7b93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-70db-81ac-65e89b37e9d3" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_019c9afa-bfee-7a8b-b4c1-7e3f371c7b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SupplierFinanceProgramTables" xlink:type="simple" xlink:href="ci-20260331.xsd#SupplierFinanceProgramTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SupplierFinanceProgramTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-7541-9458-510543c2aeae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTableTextBlock_019c9afa-bfee-704f-95c3-9714eb5d894f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-7541-9458-510543c2aeae" xlink:to="loc_us-gaap_SupplierFinanceProgramTableTextBlock_019c9afa-bfee-704f-95c3-9714eb5d894f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ci-20260331.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-7026-9e83-3e1c98c644fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019c9afa-c0ae-78cd-a563-de596694e36a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-7026-9e83-3e1c98c644fd" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019c9afa-c0ae-78cd-a563-de596694e36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019c9afa-c0ae-7bf9-9f78-df885f4f43cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-7026-9e83-3e1c98c644fd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019c9afa-c0ae-7bf9-9f78-df885f4f43cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7193-a1b6-e5ff479562ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7347-89fc-28d8c758d901" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7193-a1b6-e5ff479562ae" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7347-89fc-28d8c758d901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_019c9afa-c0af-7eb0-956f-f26536328183" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7193-a1b6-e5ff479562ae" xlink:to="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_019c9afa-c0af-7eb0-956f-f26536328183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_019c9afa-c0af-7c31-be2b-c9dec1f2ee59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7193-a1b6-e5ff479562ae" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_019c9afa-c0af-7c31-be2b-c9dec1f2ee59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock_019c9afa-c0af-7fc1-8578-f08a8e4f0bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7193-a1b6-e5ff479562ae" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock_019c9afa-c0af-7fc1-8578-f08a8e4f0bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitActivityTableTextBlock_019c9afa-c0af-70cd-8ff9-99a30c6ac80c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7193-a1b6-e5ff479562ae" xlink:to="loc_us-gaap_MarketRiskBenefitActivityTableTextBlock_019c9afa-c0af-70cd-8ff9-99a30c6ac80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock_019c9afa-c0af-7a5f-8155-571df11a93c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7193-a1b6-e5ff479562ae" xlink:to="loc_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock_019c9afa-c0af-7a5f-8155-571df11a93c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceTables" xlink:type="simple" xlink:href="ci-20260331.xsd#ReinsuranceTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c0af-775f-8840-5340d73afeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_019c9afa-c0af-7bf2-8350-2fb3704c6695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c0af-775f-8840-5340d73afeb3" xlink:to="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_019c9afa-c0af-7bf2-8350-2fb3704c6695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsTables" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7307-8b32-30492d95ed9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_019c9afa-c16c-7abd-88f2-b23cb2d35639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7307-8b32-30492d95ed9e" xlink:to="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_019c9afa-c16c-7abd-88f2-b23cb2d35639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_019c9afa-c16c-72b0-b739-14496bac650d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7307-8b32-30492d95ed9e" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_019c9afa-c16c-72b0-b739-14496bac650d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_019c9afa-c16c-7393-85ff-bf461852cba8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7307-8b32-30492d95ed9e" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_019c9afa-c16c-7393-85ff-bf461852cba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019c9afa-c16c-71fb-9927-613475dd0c88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7307-8b32-30492d95ed9e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019c9afa-c16c-71fb-9927-613475dd0c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock_019c9afa-c16c-789d-8238-52c8bf898177" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7307-8b32-30492d95ed9e" xlink:to="loc_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock_019c9afa-c16c-789d-8238-52c8bf898177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock_019c9afa-c16c-70e9-936c-3df5f27f87ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7307-8b32-30492d95ed9e" xlink:to="loc_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock_019c9afa-c16c-70e9-936c-3df5f27f87ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock_019c9afa-c16c-723a-bf16-e6718491483c" xlink:href="ci-20260331.xsd#ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7307-8b32-30492d95ed9e" xlink:to="loc_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock_019c9afa-c16c-723a-bf16-e6718491483c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_019c9afa-c16c-71e1-906f-28a4d3d41598" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7307-8b32-30492d95ed9e" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_019c9afa-c16c-71e1-906f-28a4d3d41598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeTextBlock_019c9afa-c16c-7b50-9723-dfd3c47fffc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7307-8b32-30492d95ed9e" xlink:to="loc_us-gaap_InvestmentIncomeTextBlock_019c9afa-c16c-7b50-9723-dfd3c47fffc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-72f0-9883-acc8b63f2354" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_019c9afa-c16c-71c1-9eec-6e730f4b4018" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-72f0-9883-acc8b63f2354" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_019c9afa-c16c-71c1-9eec-6e730f4b4018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_019c9afa-c16c-73da-a542-2940d6722cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-72f0-9883-acc8b63f2354" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_019c9afa-c16c-73da-a542-2940d6722cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_019c9afa-c16c-7d77-9d03-4e45434e00b8" xlink:href="ci-20260331.xsd#ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-72f0-9883-acc8b63f2354" xlink:to="loc_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_019c9afa-c16c-7d77-9d03-4e45434e00b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueOfSeparateAccountAssetsTableTextBlock_019c9afa-c16c-7e3c-a30a-064c160dd0f3" xlink:href="ci-20260331.xsd#ci_FairValueOfSeparateAccountAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-72f0-9883-acc8b63f2354" xlink:to="loc_ci_FairValueOfSeparateAccountAssetsTableTextBlock_019c9afa-c16c-7e3c-a30a-064c160dd0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_019c9afa-c16c-7d38-87cc-0d3f06565a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-72f0-9883-acc8b63f2354" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_019c9afa-c16c-7d38-87cc-0d3f06565a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="ci-20260331.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_019c9afa-c22b-72cc-8b26-21380aa7a6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_019c9afa-c22b-741e-aeb6-5e5d3c6c465e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_019c9afa-c22b-72cc-8b26-21380aa7a6d3" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_019c9afa-c22b-741e-aeb6-5e5d3c6c465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/StrategicOptimizationProgramTables" xlink:type="simple" xlink:href="ci-20260331.xsd#StrategicOptimizationProgramTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/StrategicOptimizationProgramTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c9afa-c22b-748c-936b-2cd92972e50d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_019c9afa-c22b-7c5f-aef6-e3dd4e1aa804" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c9afa-c22b-748c-936b-2cd92972e50d" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_019c9afa-c22b-7c5f-aef6-e3dd4e1aa804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-76be-ae3f-fc5336208ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfSpecialItemsTableTextBlock_019c9afa-c2d7-72b0-9688-bac1de44f98d" xlink:href="ci-20260331.xsd#ci_ScheduleOfSpecialItemsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-76be-ae3f-fc5336208ec1" xlink:to="loc_ci_ScheduleOfSpecialItemsTableTextBlock_019c9afa-c2d7-72b0-9688-bac1de44f98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019c9afa-c2d7-745e-abb1-036a1f7b27ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-76be-ae3f-fc5336208ec1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019c9afa-c2d7-745e-abb1-036a1f7b27ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_019c9afa-c2d7-7457-aaf0-f8047542769c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-76be-ae3f-fc5336208ec1" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_019c9afa-c2d7-7457-aaf0-f8047542769c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_019c9afa-c2d7-754a-96ab-8bd0d3f9f9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-76be-ae3f-fc5336208ec1" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_019c9afa-c2d7-754a-96ab-8bd0d3f9f9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DescriptionofBusinessSegmentInformationDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#DescriptionofBusinessSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DescriptionofBusinessSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c9afa-bfed-7f27-b0e7-6fa6a1b22172" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019c9afa-bfed-7136-bbdc-f1e4bc2eed09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c9afa-bfed-7f27-b0e7-6fa6a1b22172" xlink:to="loc_us-gaap_NumberOfReportableSegments_019c9afa-bfed-7136-bbdc-f1e4bc2eed09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#AccountsReceivableNetAmountsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-753d-9dc9-175f27a1b48b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_019c9afa-bfee-7e49-8546-d7b20f740a75" xlink:href="ci-20260331.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-753d-9dc9-175f27a1b48b" xlink:to="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_019c9afa-bfee-7e49-8546-d7b20f740a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturerReceivable_019c9afa-bfee-755d-a9ed-b957258e32f7" xlink:href="ci-20260331.xsd#ci_PharmaceuticalManufacturerReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-753d-9dc9-175f27a1b48b" xlink:to="loc_ci_PharmaceuticalManufacturerReceivable_019c9afa-bfee-755d-a9ed-b957258e32f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivables_019c9afa-bfee-7c4f-b3d9-0807deef9c5c" xlink:href="ci-20260331.xsd#ci_InsuranceCustomerReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-753d-9dc9-175f27a1b48b" xlink:to="loc_ci_InsuranceCustomerReceivables_019c9afa-bfee-7c4f-b3d9-0807deef9c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_019c9afa-bfee-7871-aaae-e8a253373606" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-753d-9dc9-175f27a1b48b" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_019c9afa-bfee-7871-aaae-e8a253373606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfee-7451-8f1c-3495797ba133" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-753d-9dc9-175f27a1b48b" xlink:to="loc_us-gaap_ReceivablesNetCurrent_019c9afa-bfee-7451-8f1c-3495797ba133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAllowancesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#AccountsReceivableNetAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-720a-8374-bfbaa6df0540" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllowanceForReceivablesCurrent_019c9afa-bfee-7f08-8079-6c1e8643f14b" xlink:href="ci-20260331.xsd#ci_AllowanceForReceivablesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-720a-8374-bfbaa6df0540" xlink:to="loc_ci_AllowanceForReceivablesCurrent_019c9afa-bfee-7f08-8079-6c1e8643f14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractualAllowancePharmaceuticalManufacturersReceivables_019c9afa-bfee-79d3-a5c1-1a74ef98036c" xlink:href="ci-20260331.xsd#ci_ContractualAllowancePharmaceuticalManufacturersReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-720a-8374-bfbaa6df0540" xlink:to="loc_ci_ContractualAllowancePharmaceuticalManufacturersReceivables_019c9afa-bfee-79d3-a5c1-1a74ef98036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractualAllowanceNoninsuranceCustomerReceivables_019c9afa-bfee-763f-9ba5-319a273bbaf5" xlink:href="ci-20260331.xsd#ci_ContractualAllowanceNoninsuranceCustomerReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-720a-8374-bfbaa6df0540" xlink:to="loc_ci_ContractualAllowanceNoninsuranceCustomerReceivables_019c9afa-bfee-763f-9ba5-319a273bbaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019c9afa-bfee-77eb-9c2a-bef63cf60a36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-720a-8374-bfbaa6df0540" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019c9afa-bfee-77eb-9c2a-bef63cf60a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#AccountsReceivableNetFactoringFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-7b8f-ae6d-7ae0db2603b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity_019c9afa-bfee-7624-96a2-d0f9dcd16f42" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-7b8f-ae6d-7ae0db2603b4" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity_019c9afa-bfee-7624-96a2-d0f9dcd16f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm_019c9afa-bfee-7f47-9c15-49799f25ccc8" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-7b8f-ae6d-7ae0db2603b4" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm_019c9afa-bfee-7f47-9c15-49799f25ccc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold_019c9afa-bfee-794d-9d1f-62efcd8dfb28" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-7b8f-ae6d-7ae0db2603b4" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold_019c9afa-bfee-794d-9d1f-62efcd8dfb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid_019c9afa-bfee-77e5-bb37-f25ee65c8ada" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-7b8f-ae6d-7ae0db2603b4" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid_019c9afa-bfee-77e5-bb37-f25ee65c8ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding_019c9afa-bfee-7e9d-b3f2-2da438b24f20" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-7b8f-ae6d-7ae0db2603b4" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding_019c9afa-bfee-7e9d-b3f2-2da438b24f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted_019c9afa-bfee-7ab8-a858-51d5874ef014" xlink:href="ci-20260331.xsd#ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_019c9afa-bfee-7b8f-ae6d-7ae0db2603b4" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted_019c9afa-bfee-7ab8-a858-51d5874ef014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SupplierFinanceProgramDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SupplierFinanceProgramDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SupplierFinanceProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-76c4-89ca-5a03528e4e57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_019c9afa-bfee-75b0-8b18-cf22c6b76665" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramPaymentTimingPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-76c4-89ca-5a03528e4e57" xlink:to="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_019c9afa-bfee-75b0-8b18-cf22c6b76665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligation_019c9afa-bfee-7047-9f77-cfbb9cbf4dee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-76c4-89ca-5a03528e4e57" xlink:to="loc_us-gaap_SupplierFinanceProgramObligation_019c9afa-bfee-7047-9f77-cfbb9cbf4dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent_019c9afa-bfee-7c93-8674-e8862d9a8464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-76c4-89ca-5a03528e4e57" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationCurrent_019c9afa-bfee-7c93-8674-e8862d9a8464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_019c9afa-bfee-7383-92c6-4e8844c0e607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-76c4-89ca-5a03528e4e57" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_019c9afa-bfee-7383-92c6-4e8844c0e607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_019c9afa-bfee-7889-b5d5-278dc968b6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-76c4-89ca-5a03528e4e57" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_019c9afa-bfee-7889-b5d5-278dc968b6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold_019c9afa-c0ae-7c2c-a876-946b6972c97f" xlink:href="ci-20260331.xsd#ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c9afa-bfee-76c4-89ca-5a03528e4e57" xlink:to="loc_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold_019c9afa-c0ae-7c2c-a876-946b6972c97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#EarningsPerShareBasicandDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-75cb-b74e-37590d23004c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c9afa-c0ae-7494-88dc-c2c386fa0a66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-75cb-b74e-37590d23004c" xlink:to="loc_us-gaap_NetIncomeLoss_019c9afa-c0ae-7494-88dc-c2c386fa0a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c9afa-c0ae-7370-9b67-d1c58d28e474" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-75cb-b74e-37590d23004c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c9afa-c0ae-7370-9b67-d1c58d28e474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_019c9afa-c0ae-7194-a05f-775419d73f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c9afa-c0ae-7370-9b67-d1c58d28e474" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_019c9afa-c0ae-7194-a05f-775419d73f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c9afa-c0ae-7b1d-aebe-2da4743781f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c9afa-c0ae-7370-9b67-d1c58d28e474" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c9afa-c0ae-7b1d-aebe-2da4743781f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c9afa-c0ae-76f5-b9ce-636fcf9087b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c9afa-c0ae-7370-9b67-d1c58d28e474" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c9afa-c0ae-76f5-b9ce-636fcf9087b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019c9afa-c0ae-7cb1-a2a1-b009bdb9961d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-75cb-b74e-37590d23004c" xlink:to="loc_us-gaap_EarningsPerShareBasic_019c9afa-c0ae-7cb1-a2a1-b009bdb9961d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EarningsPerShareEffectOfDilution_019c9afa-c0ae-795d-84ff-163ed81c1064" xlink:href="ci-20260331.xsd#ci_EarningsPerShareEffectOfDilution"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-75cb-b74e-37590d23004c" xlink:to="loc_ci_EarningsPerShareEffectOfDilution_019c9afa-c0ae-795d-84ff-163ed81c1064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019c9afa-c0ae-7c29-a8fe-98a021b39e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-75cb-b74e-37590d23004c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019c9afa-c0ae-7c29-a8fe-98a021b39e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#EarningsPerShareAntidilutiveOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-7b7b-974c-8a8cf79d890f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c9afa-c0ae-7806-b210-4e88c1b0ca20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-7b7b-974c-8a8cf79d890f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c9afa-c0ae-7806-b210-4e88c1b0ca20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c9afa-c0ae-7327-9c89-6b4560d26485" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c9afa-c0ae-7806-b210-4e88c1b0ca20" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c9afa-c0ae-7327-9c89-6b4560d26485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c9afa-c0ae-739e-b14b-f7ff4534c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c9afa-c0ae-7327-9c89-6b4560d26485" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c9afa-c0ae-739e-b14b-f7ff4534c73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019c9afa-c0ae-7020-9da8-880fb1677b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c9afa-c0ae-739e-b14b-f7ff4534c73f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019c9afa-c0ae-7020-9da8-880fb1677b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c9afa-c0ae-7fc0-b9fe-6b3f3e91889a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c9afa-c0ae-7806-b210-4e88c1b0ca20" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c9afa-c0ae-7fc0-b9fe-6b3f3e91889a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019c9afa-c0ae-75e7-b764-a385b34ad06d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c9afa-c0ae-7fc0-b9fe-6b3f3e91889a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019c9afa-c0ae-75e7-b764-a385b34ad06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#EarningsPerShareDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019dbbc5-3865-7f15-8874-5360016458dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_019dbbc5-3865-76cb-ba3a-784e0d36eb05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019dbbc5-3865-7f15-8874-5360016458dc" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_019dbbc5-3865-76cb-ba3a-784e0d36eb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_019dbbc5-3865-70dc-b6a9-18cc3fa787f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019dbbc5-3865-7f15-8874-5360016458dc" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_019dbbc5-3865-70dc-b6a9-18cc3fa787f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableTable_019dbbc5-3865-7bad-bc71-e367103b972c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019dbbc5-3865-7f15-8874-5360016458dc" xlink:to="loc_us-gaap_DividendsPayableTable_019dbbc5-3865-7bad-bc71-e367103b972c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAxis_019dbbc5-3865-7230-8ba1-2baa71fa48ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_019dbbc5-3865-7bad-bc71-e367103b972c" xlink:to="loc_us-gaap_DividendsAxis_019dbbc5-3865-7230-8ba1-2baa71fa48ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain_019dbbc5-3865-718d-847e-3e55a15087bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAxis_019dbbc5-3865-7230-8ba1-2baa71fa48ff" xlink:to="loc_us-gaap_DividendsDomain_019dbbc5-3865-718d-847e-3e55a15087bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_R2026Q2DividendsMember_019dbbc5-3865-7fb6-9e14-57bd70b867fd" xlink:href="ci-20260331.xsd#ci_R2026Q2DividendsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsDomain_019dbbc5-3865-718d-847e-3e55a15087bf" xlink:to="loc_ci_R2026Q2DividendsMember_019dbbc5-3865-7fb6-9e14-57bd70b867fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019dbbc5-3865-7a04-b184-16c9c70196b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_019dbbc5-3865-7bad-bc71-e367103b972c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019dbbc5-3865-7a04-b184-16c9c70196b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019dbbc5-3865-73fa-8cba-6e81735946df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019dbbc5-3865-7a04-b184-16c9c70196b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019dbbc5-3865-73fa-8cba-6e81735946df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019dbbc5-3865-7457-8f63-8b030da8ab42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019dbbc5-3865-73fa-8cba-6e81735946df" xlink:to="loc_us-gaap_SubsequentEventMember_019dbbc5-3865-7457-8f63-8b030da8ab42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_019dbbc5-3865-7bad-bc71-e367103b972c" xlink:to="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_019dbbc5-3865-7aa2-a9df-94c262af4c97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:to="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_019dbbc5-3865-7aa2-a9df-94c262af4c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_019dbbc5-3865-74ed-855f-95fe9cde6688" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_019dbbc5-3865-74ed-855f-95fe9cde6688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_019dbbc5-3865-7ef5-8b0e-c0c4a6594461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:to="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_019dbbc5-3865-7ef5-8b0e-c0c4a6594461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_019dbbc5-3865-799b-8a21-2259a65ca1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_019dbbc5-3865-7adc-a36e-cc286a64fb0c" xlink:to="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_019dbbc5-3865-799b-8a21-2259a65ca1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#EarningsPerShareSharesofCommonStockHeldinTreasuryDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-710a-afcd-8254446e6359" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c9afa-c0ae-77f6-b4b3-3526488834ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-710a-afcd-8254446e6359" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019c9afa-c0ae-77f6-b4b3-3526488834ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019c9afa-c0ae-7a8c-8033-7ae39ad2c186" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c9afa-c0ae-710a-afcd-8254446e6359" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019c9afa-c0ae-7a8c-8033-7ae39ad2c186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtDebtRepaymentDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#DebtDebtRepaymentDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DebtDebtRepaymentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019c9afa-c0ae-7f52-b8ba-c39a2aa77b00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-7944-9703-b425c6504137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019c9afa-c0ae-7f52-b8ba-c39a2aa77b00" xlink:to="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-7944-9703-b425c6504137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7599-b51d-773888142cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-7944-9703-b425c6504137" xlink:to="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7599-b51d-773888142cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7b1c-b42a-33e0dd29025d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7599-b51d-773888142cf0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7b1c-b42a-33e0dd29025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:href="ci-20260331.xsd#ci_SeniorNotesIssuedSeptember2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7b1c-b42a-33e0dd29025d" xlink:to="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A1000Million4.500NotesDueSeptember2030Member_019c9afa-c0ae-79af-bc31-d62445c15abb" xlink:href="ci-20260331.xsd#ci_A1000Million4.500NotesDueSeptember2030Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:to="loc_ci_A1000Million4.500NotesDueSeptember2030Member_019c9afa-c0ae-79af-bc31-d62445c15abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A1250Million4.875NotesDueSeptember2032Member_019c9afa-c0ae-7598-ad50-cc39313bfd16" xlink:href="ci-20260331.xsd#ci_A1250Million4.875NotesDueSeptember2032Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:to="loc_ci_A1250Million4.875NotesDueSeptember2032Member_019c9afa-c0ae-7598-ad50-cc39313bfd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A1500Million5.250NotesDueJanuary2036Member_019c9afa-c0ae-7fee-8a56-4217389c1fd3" xlink:href="ci-20260331.xsd#ci_A1500Million5.250NotesDueJanuary2036Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:to="loc_ci_A1500Million5.250NotesDueJanuary2036Member_019c9afa-c0ae-7fee-8a56-4217389c1fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A750Million6.000NotesDueJanuary2056Member_019c9afa-c0ae-74ab-bf80-624b49268bee" xlink:href="ci-20260331.xsd#ci_A750Million6.000NotesDueJanuary2056Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SeniorNotesIssuedSeptember2025Member_019c9afa-c0ae-7cee-8487-6dc861985b96" xlink:to="loc_ci_A750Million6.000NotesDueJanuary2056Member_019c9afa-c0ae-74ab-bf80-624b49268bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2026125Member_019d3132-92b8-7e46-a2fa-be8569454569" xlink:href="ci-20260331.xsd#ci_NotesDue2026125Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-7b1c-b42a-33e0dd29025d" xlink:to="loc_ci_NotesDue2026125Member_019d3132-92b8-7e46-a2fa-be8569454569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019c9afa-c0ae-7ed2-9f2a-051a2c64f72a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-7944-9703-b425c6504137" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019c9afa-c0ae-7ed2-9f2a-051a2c64f72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019c9afa-c0ae-760d-b43e-f6de3d3ade2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019c9afa-c0ae-7ed2-9f2a-051a2c64f72a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019c9afa-c0ae-760d-b43e-f6de3d3ade2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_019c9afa-c0ae-7207-be3f-64925c358a61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019c9afa-c0ae-760d-b43e-f6de3d3ade2d" xlink:to="loc_us-gaap_SeniorNotesMember_019c9afa-c0ae-7207-be3f-64925c358a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-7944-9703-b425c6504137" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_019c9afa-c0ae-7e11-81ce-842ac103b279" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_019c9afa-c0ae-7e11-81ce-842ac103b279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_019c9afa-c0ae-71f7-aa6e-b0561bf256cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_019c9afa-c0ae-71f7-aa6e-b0561bf256cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019c9afa-c0ae-76c5-8da3-64a91811453e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019c9afa-c0ae-76c5-8da3-64a91811453e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_019c9afa-c0ae-78a7-b0f6-dcebd1f5e199" xlink:href="ci-20260331.xsd#ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_019c9afa-c0ae-78a7-b0f6-dcebd1f5e199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate_019c9afa-c0ae-73fe-bf79-23870803a069" xlink:href="ci-20260331.xsd#ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-72f6-8ab2-d67b81bf322e" xlink:to="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate_019c9afa-c0ae-73fe-bf79-23870803a069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#DebtRevolvingCreditAgreementandCommercialPaperDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019c9afa-c0ae-73ab-a357-5434edfd4e87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019c9afa-c0ae-73ab-a357-5434edfd4e87" xlink:to="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7092-98ac-224f6a4f0e21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:to="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7092-98ac-224f6a4f0e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-729f-89a2-759e1965bcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c9afa-c0ae-7092-98ac-224f6a4f0e21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-729f-89a2-759e1965bcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAgreementApril2025Member_019c9afa-c0ae-7427-a9cb-64fb85dc6468" xlink:href="ci-20260331.xsd#ci_RevolvingCreditAgreementApril2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c9afa-c0ae-729f-89a2-759e1965bcd7" xlink:to="loc_ci_RevolvingCreditAgreementApril2025Member_019c9afa-c0ae-7427-a9cb-64fb85dc6468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019c9afa-c0ae-7b88-9449-424a683ad749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:to="loc_us-gaap_CreditFacilityAxis_019c9afa-c0ae-7b88-9449-424a683ad749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7f17-8bd4-36fd80a7ad81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_019c9afa-c0ae-7b88-9449-424a683ad749" xlink:to="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7f17-8bd4-36fd80a7ad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_019dd492-23b7-7885-9bde-e0b18181cf47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7f17-8bd4-36fd80a7ad81" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_019dd492-23b7-7885-9bde-e0b18181cf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_019c9afa-c0ae-7673-b457-44eaed3077e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7f17-8bd4-36fd80a7ad81" xlink:to="loc_us-gaap_LetterOfCreditMember_019c9afa-c0ae-7673-b457-44eaed3077e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019c9afa-c0ae-7dfb-9d2f-25c10b3426dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019c9afa-c0ae-7f17-8bd4-36fd80a7ad81" xlink:to="loc_us-gaap_CommercialPaperMember_019c9afa-c0ae-7dfb-9d2f-25c10b3426dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019dd491-7a35-78b9-bbf7-7273abe7292c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019dd491-7a35-78b9-bbf7-7273abe7292c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019dd491-7a35-707b-88fe-ce276497f1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019dd491-7a35-78b9-bbf7-7273abe7292c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019dd491-7a35-707b-88fe-ce276497f1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019dd491-d5bc-7eeb-8ed3-1073b06f4869" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019dd491-7a35-707b-88fe-ce276497f1ea" xlink:to="loc_us-gaap_LineOfCreditMember_019dd491-d5bc-7eeb-8ed3-1073b06f4869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c9afa-c0ae-75c2-9d1f-7df35912feb2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c9afa-c0ae-7cfe-b6e0-31f855124fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c9afa-c0ae-7cfe-b6e0-31f855124fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_019c9afa-c0ae-702a-b115-e0833f419455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_DebtInstrumentTerm_019c9afa-c0ae-702a-b115-e0833f419455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_019dd52b-a723-713d-8dcf-af7a9a065c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_019dd52b-a723-713d-8dcf-af7a9a065c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentExtensionTerm_019c9afa-c0ae-7269-a3a6-1205048bdd5d" xlink:href="ci-20260331.xsd#ci_DebtInstrumentExtensionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_ci_DebtInstrumentExtensionTerm_019c9afa-c0ae-7269-a3a6-1205048bdd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_019c9afa-c0ae-7bbe-a4ce-b597119a898d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_LineOfCredit_019c9afa-c0ae-7bbe-a4ce-b597119a898d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_019c9afa-c0ae-70e1-831f-0e1b500a6655" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_019c9afa-c0ae-70e1-831f-0e1b500a6655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature_019c9afa-c0ae-7b5f-a95c-64fd3f6e753d" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature_019c9afa-c0ae-7b5f-a95c-64fd3f6e753d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_019c9afa-c0ae-75f9-9fca-47ca81dcca51" xlink:href="ci-20260331.xsd#ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_019c9afa-c0ae-75f9-9fca-47ca81dcca51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_019c9afa-c0ae-710c-8b80-8b69aa7abd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_us-gaap_CommercialPaper_019c9afa-c0ae-710c-8b80-8b69aa7abd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CommercialPaperAverageRatePaid_019c9afa-c0ae-70ae-9e4f-60c7571f5b85" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CommercialPaperAverageRatePaid"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c9afa-c0ae-7f1e-a824-1a75e6ee9662" xlink:to="loc_srt_CommercialPaperAverageRatePaid_019c9afa-c0ae-70ae-9e4f-60c7571f5b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019c9afa-c0ae-7c7c-9c55-2ddf1203ddab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_019c9afa-c0ae-7f70-8f61-437f97911626" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019c9afa-c0ae-7c7c-9c55-2ddf1203ddab" xlink:to="loc_us-gaap_InterestExpenseDebt_019c9afa-c0ae-7f70-8f61-437f97911626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7b38-a763-9043ac6b240f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable_019c9afa-c0af-7bbc-a4ec-925c6ea0c7ac" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7b38-a763-9043ac6b240f" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesTable_019c9afa-c0af-7bbc-a4ec-925c6ea0c7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7a87-bc53-df38c3b7b91d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_019c9afa-c0af-7bbc-a4ec-925c6ea0c7ac" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7a87-bc53-df38c3b7b91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-7515-96c3-b4ce35e247dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7a87-bc53-df38c3b7b91d" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-7515-96c3-b4ce35e247dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c0af-780e-8a9c-4ca79fd84385" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-7515-96c3-b4ce35e247dd" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c0af-780e-8a9c-4ca79fd84385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllSegmentsExcludingCignaHealthcareMember_019c9afa-c0af-77b7-a554-c78accd9b150" xlink:href="ci-20260331.xsd#ci_AllSegmentsExcludingCignaHealthcareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-7515-96c3-b4ce35e247dd" xlink:to="loc_ci_AllSegmentsExcludingCignaHealthcareMember_019c9afa-c0af-77b7-a554-c78accd9b150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_019c9afa-c0af-7ff2-a3dd-17af15c2ae62" xlink:href="ci-20260331.xsd#ci_EvernorthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AllSegmentsExcludingCignaHealthcareMember_019c9afa-c0af-77b7-a554-c78accd9b150" xlink:to="loc_ci_EvernorthMember_019c9afa-c0af-7ff2-a3dd-17af15c2ae62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c0af-7fe7-88fd-59a65a3c3bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AllSegmentsExcludingCignaHealthcareMember_019c9afa-c0af-77b7-a554-c78accd9b150" xlink:to="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c0af-7fe7-88fd-59a65a3c3bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c0af-7c28-91ee-0b3d3a34df77" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_019c9afa-c0af-7bbc-a4ec-925c6ea0c7ac" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c0af-7c28-91ee-0b3d3a34df77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c0af-7c28-91ee-0b3d3a34df77" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_019c9afa-c0af-7a7f-99a5-7d6adcd4c8fb" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_019c9afa-c0af-7a7f-99a5-7d6adcd4c8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_019c9afa-c0af-7d78-bde6-5ed503fc69b6" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_019c9afa-c0af-7d78-bde6-5ed503fc69b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrent_019c9afa-c0af-75ca-91a4-45dcadd8fb85" xlink:href="ci-20260331.xsd#ci_PolicyholderContractDepositCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_PolicyholderContractDepositCurrent_019c9afa-c0af-75ca-91a4-45dcadd8fb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_019c9afa-c0af-77a0-9c1c-47d7447fadfe" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_019c9afa-c0af-77a0-9c1c-47d7447fadfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrent_019c9afa-c0af-7c01-ae18-59b649ea5c59" xlink:href="ci-20260331.xsd#ci_UnearnedPremiumsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_UnearnedPremiumsCurrent_019c9afa-c0af-7c01-ae18-59b649ea5c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-7b48-a62e-b676d6f608fc" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_019c9afa-c0af-76fe-bac7-5ec3c2efbe31" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_019c9afa-c0af-7b48-a62e-b676d6f608fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c0af-7c28-91ee-0b3d3a34df77" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_019c9afa-c0af-70f6-904c-f320018dd108" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_019c9afa-c0af-70f6-904c-f320018dd108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_019c9afa-c0af-7884-a32c-02c2944707b5" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_019c9afa-c0af-7884-a32c-02c2944707b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrent_019c9afa-c0af-7297-989e-46723d3b5158" xlink:href="ci-20260331.xsd#ci_PolicyholderContractDepositNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_PolicyholderContractDepositNoncurrent_019c9afa-c0af-7297-989e-46723d3b5158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_019c9afa-c0af-76b1-8638-2758d3727417" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_019c9afa-c0af-76b1-8638-2758d3727417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrent_019c9afa-c0af-7fac-ab12-6a9ea0078ef2" xlink:href="ci-20260331.xsd#ci_UnearnedPremiumsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_UnearnedPremiumsNoncurrent_019c9afa-c0af-7fac-ab12-6a9ea0078ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-73b1-95dc-0d00975dc9c4" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_019c9afa-c0af-7f64-9353-892f37a67f61" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_019c9afa-c0af-73b1-95dc-0d00975dc9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_019c9afa-c0af-7c28-91ee-0b3d3a34df77" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7dd7-91eb-441f06e7224d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7dd7-91eb-441f06e7224d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-72d4-ae64-8e4e3b50e730" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-72d4-ae64-8e4e3b50e730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7995-a3c4-2e24ac13ae80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7995-a3c4-2e24ac13ae80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount_019c9afa-c0af-7eb9-b314-b54f97eaca4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_us-gaap_MarketRiskBenefitLiabilityAmount_019c9afa-c0af-7eb9-b314-b54f97eaca4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums_019c9afa-c0af-7456-8a6f-dcf46c373ace" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnearnedPremiums"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_us-gaap_UnearnedPremiums_019c9afa-c0af-7456-8a6f-dcf46c373ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-7bb7-abe5-7f38de8ffd78" xlink:href="ci-20260331.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_019c9afa-c0af-7b76-81af-0e2353503c1f" xlink:to="loc_ci_InsuranceAndContractholderLiabilities_019c9afa-c0af-7bb7-abe5-7f38de8ffd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-770f-9264-6314ff3699d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-770f-9264-6314ff3699d9" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7aac-b2ca-2c47195f4e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7aac-b2ca-2c47195f4e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-7f7a-ad54-76624ee3dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-7aac-b2ca-2c47195f4e40" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-7f7a-ad54-76624ee3dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c0af-76ce-8ad5-50dc545dcd4a" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-7f7a-ad54-76624ee3dbe2" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c0af-76ce-8ad5-50dc545dcd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c0af-7b89-ba58-29fab8cf4d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c0af-7b89-ba58-29fab8cf4d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c0af-79d1-a43b-c46a09421f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c0af-7b89-ba58-29fab8cf4d7e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c0af-79d1-a43b-c46a09421f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_019c9afa-c0af-76ee-9bc4-ab70dcf7a647" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c0af-79d1-a43b-c46a09421f3a" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_019c9afa-c0af-76ee-9bc4-ab70dcf7a647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c0af-72b7-89b0-ac9d5b69b3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c0af-72b7-89b0-ac9d5b69b3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c0af-736e-b75c-d73c2d42db00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c0af-72b7-89b0-ac9d5b69b3b8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c0af-736e-b75c-d73c2d42db00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_019c9afa-c0af-792f-be02-a88b09f8c271" xlink:href="ci-20260331.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c0af-736e-b75c-d73c2d42db00" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_019c9afa-c0af-792f-be02-a88b09f8c271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-7e44-b682-5601ba61f604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7f5a-aaaa-fb90004f5c63" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-7e44-b682-5601ba61f604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_019c9afa-c0af-7357-b58a-c36998d0b857" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-7e44-b682-5601ba61f604" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_019c9afa-c0af-7357-b58a-c36998d0b857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-7e44-b682-5601ba61f604" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7db8-95f9-35a6648c7367" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7db8-95f9-35a6648c7367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c0af-76ce-880c-0ee9014ed96b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c0af-76ce-880c-0ee9014ed96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c0af-75db-a8d2-b39912560b56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c0af-75db-a8d2-b39912560b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c0af-7850-a559-4b98920565c2" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c0af-7850-a559-4b98920565c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c0af-7f2a-b405-3bed9554ca78" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c0af-7f2a-b405-3bed9554ca78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c0af-7fbe-921f-a77bd1a5443a" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c0af-7fbe-921f-a77bd1a5443a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c0af-79e1-ab2f-defa4cbd9405" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c0af-79e1-ab2f-defa4cbd9405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-79c8-8dfd-d0ee52d8cef2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c0af-79e1-ab2f-defa4cbd9405" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-79c8-8dfd-d0ee52d8cef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-740d-ad89-b95bb8670d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c0af-79e1-ab2f-defa4cbd9405" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-740d-ad89-b95bb8670d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_019c9afa-c0af-7466-820a-1b95f8e5d89b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_019c9afa-c0af-79e1-ab2f-defa4cbd9405" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_019c9afa-c0af-7466-820a-1b95f8e5d89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c0af-798d-aa1a-a14e2ad66824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c0af-798d-aa1a-a14e2ad66824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_019c9afa-c0af-7e20-8257-9cd021d55fde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c0af-798d-aa1a-a14e2ad66824" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_019c9afa-c0af-7e20-8257-9cd021d55fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_019c9afa-c0af-7f20-b2d4-b219be0d75d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c0af-798d-aa1a-a14e2ad66824" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_019c9afa-c0af-7f20-b2d4-b219be0d75d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_019c9afa-c0af-7098-a1f1-d699eb380e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_019c9afa-c0af-798d-aa1a-a14e2ad66824" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_019c9afa-c0af-7098-a1f1-d699eb380e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther_019c9afa-c0af-788e-b703-59cce73bc5f3" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther_019c9afa-c0af-788e-b703-59cce73bc5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c0af-7f33-9c77-fdc041bdf372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_019c9afa-c0af-7f33-9c77-fdc041bdf372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c0af-7aeb-ab3e-b170158bf3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_019c9afa-c0af-7aeb-ab3e-b170158bf3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-76a2-b790-e345fa94d572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-76a2-b790-e345fa94d572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c0af-7154-894d-e02d28631186" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_019c9afa-c0af-7154-894d-e02d28631186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c0af-7ac8-9015-38ab35bdd344" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_019c9afa-c0af-7ac8-9015-38ab35bdd344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c0af-7fe7-a317-ea8bbd2f5765" xlink:href="ci-20260331.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_019c9afa-c0af-7fe7-a317-ea8bbd2f5765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-78dc-81eb-379e8eaa4e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_019c9afa-c0af-731b-b745-ad122704ef95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-78dc-81eb-379e8eaa4e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7daf-a759-58e2ad311a90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7ab9-a0e9-85824da5cf10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7daf-a759-58e2ad311a90" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7ab9-a0e9-85824da5cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-724d-9d0c-797bd30cecbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7ab9-a0e9-85824da5cf10" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-724d-9d0c-797bd30cecbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-72ac-a6d5-d3e308208ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-724d-9d0c-797bd30cecbc" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-72ac-a6d5-d3e308208ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c0af-7b3f-be4e-689b652b987d" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-72ac-a6d5-d3e308208ccf" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c0af-7b3f-be4e-689b652b987d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventAxis_019c9afa-c0af-7bd4-a98a-ce6af6ba0ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncatastrophicEventAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7ab9-a0e9-85824da5cf10" xlink:to="loc_us-gaap_NoncatastrophicEventAxis_019c9afa-c0af-7bd4-a98a-ce6af6ba0ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventDomain_019c9afa-c0af-7ae9-9e72-28758d483c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncatastrophicEventDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncatastrophicEventAxis_019c9afa-c0af-7bd4-a98a-ce6af6ba0ae0" xlink:to="loc_us-gaap_NoncatastrophicEventDomain_019c9afa-c0af-7ae9-9e72-28758d483c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CompletionFactorsAndOtherMember_019c9afa-c0af-74ee-a289-d1afdd297d56" xlink:href="ci-20260331.xsd#ci_CompletionFactorsAndOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncatastrophicEventDomain_019c9afa-c0af-7ae9-9e72-28758d483c6c" xlink:to="loc_ci_CompletionFactorsAndOtherMember_019c9afa-c0af-74ee-a289-d1afdd297d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicalCostTrendMember_019c9afa-c0af-73bf-88ce-5a4ea6978f5e" xlink:href="ci-20260331.xsd#ci_MedicalCostTrendMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncatastrophicEventDomain_019c9afa-c0af-7ae9-9e72-28758d483c6c" xlink:to="loc_ci_MedicalCostTrendMember_019c9afa-c0af-73bf-88ce-5a4ea6978f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-750c-9f0c-1dd02c73c016" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_019c9afa-c0af-7ab9-a0e9-85824da5cf10" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-750c-9f0c-1dd02c73c016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_019c9afa-c0af-774f-9c23-b075ff5ec34b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_019c9afa-c0af-750c-9f0c-1dd02c73c016" xlink:to="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_019c9afa-c0af-774f-9c23-b075ff5ec34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7cb7-a96d-122b4d42cb01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_019c9afa-c0af-774f-9c23-b075ff5ec34b" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_019c9afa-c0af-7cb7-a96d-122b4d42cb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_019c9afa-c0af-7c95-9c83-24502778eb87" xlink:href="ci-20260331.xsd#ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_019c9afa-c0af-774f-9c23-b075ff5ec34b" xlink:to="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_019c9afa-c0af-7c95-9c83-24502778eb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_019c9afa-c0af-7905-82a7-fb74cd6d42f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_019c9afa-c0af-7283-837a-a5d6acf32a74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitActivityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_019c9afa-c0af-7905-82a7-fb74cd6d42f1" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_019c9afa-c0af-7283-837a-a5d6acf32a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-75a2-9839-53c6d3934ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_019c9afa-c0af-7283-837a-a5d6acf32a74" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-75a2-9839-53c6d3934ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c0af-77f5-b565-f90615a4feff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c0af-75a2-9839-53c6d3934ed6" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c0af-77f5-b565-f90615a4feff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c0af-7e53-bc7e-dcdc713c6576" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-77f5-b565-f90615a4feff" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c0af-7e53-bc7e-dcdc713c6576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c0af-715b-ae03-45f2ab5327fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c0af-77f5-b565-f90615a4feff" xlink:to="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c0af-715b-ae03-45f2ab5327fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c0af-70f1-8c99-6848c0f4085c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_019c9afa-c0af-7283-837a-a5d6acf32a74" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c0af-70f1-8c99-6848c0f4085c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a77-8ed8-e7a6695d9fec" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-70f1-8c99-6848c0f4085c" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a77-8ed8-e7a6695d9fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeAndAnnuityInsuranceProductLineMember_019c9afa-c0af-77be-8dc6-c10e26526d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LifeAndAnnuityInsuranceProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a77-8ed8-e7a6695d9fec" xlink:to="loc_us-gaap_LifeAndAnnuityInsuranceProductLineMember_019c9afa-c0af-77be-8dc6-c10e26526d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTable_019c9afa-c0af-7283-837a-a5d6acf32a74" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_019c9afa-c0af-751b-86ae-f1ca8c5d9b98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_019c9afa-c0af-751b-86ae-f1ca8c5d9b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_019c9afa-c0af-7c9e-abb7-97e80f283faa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_019c9afa-c0af-7c9e-abb7-97e80f283faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_019c9afa-c0af-7c85-a120-5a6387da44f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_019c9afa-c0af-7c85-a120-5a6387da44f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_019c9afa-c0af-7033-85fd-640e38c356c2" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_019c9afa-c0af-7033-85fd-640e38c356c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_019c9afa-c0af-744b-b4e6-4998cf325761" xlink:href="ci-20260331.xsd#ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_019c9afa-c0af-744b-b4e6-4998cf325761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-7dfe-99cf-d14772a5b192" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_019c9afa-c0af-7dfe-99cf-d14772a5b192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_019c9afa-c0af-7453-8567-58341531b8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_019c9afa-c0af-7453-8567-58341531b8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-7d7f-83fb-2093d5bb6dea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems_019c9afa-c0af-7088-ba37-f36e2720a157" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-7d7f-83fb-2093d5bb6dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_019c9afa-c0af-7a6b-977b-8ee558513f01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_019c9afa-c0af-7a6b-977b-8ee558513f01" xlink:to="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c9afa-c0af-73da-8604-d30d77793e8a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:to="loc_srt_RangeAxis_019c9afa-c0af-73da-8604-d30d77793e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c9afa-c0af-7ec3-945c-5137149aee57" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019c9afa-c0af-73da-8604-d30d77793e8a" xlink:to="loc_srt_RangeMember_019c9afa-c0af-7ec3-945c-5137149aee57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c9afa-c0af-7d0a-86f1-7d209760f2f7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c9afa-c0af-7ec3-945c-5137149aee57" xlink:to="loc_srt_MinimumMember_019c9afa-c0af-7d0a-86f1-7d209760f2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c9afa-c0af-724c-85d6-cf6a70cf3057" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c9afa-c0af-7ec3-945c-5137149aee57" xlink:to="loc_srt_MaximumMember_019c9afa-c0af-724c-85d6-cf6a70cf3057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_019c9afa-c0af-73c4-b8b5-d7114a1e9973" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_019c9afa-c0af-73c4-b8b5-d7114a1e9973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_019c9afa-c0af-780a-a441-bbb906731dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_019c9afa-c0af-73c4-b8b5-d7114a1e9973" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_019c9afa-c0af-780a-a441-bbb906731dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_019c9afa-c0af-7e1b-b7c7-b60bd3983ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_019c9afa-c0af-780a-a441-bbb906731dae" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_019c9afa-c0af-7e1b-b7c7-b60bd3983ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_019c9afa-c0af-740e-b0e8-51ba71c2f810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_019c9afa-c0af-740e-b0e8-51ba71c2f810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-7487-aafe-751a03645a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_019c9afa-c0af-740e-b0e8-51ba71c2f810" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-7487-aafe-751a03645a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_019c9afa-c0af-7f86-9f96-229304dfe3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-7487-aafe-751a03645a32" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_019c9afa-c0af-7f86-9f96-229304dfe3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_019c9afa-c0af-7335-807d-01973a73dc07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-7487-aafe-751a03645a32" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_019c9afa-c0af-7335-807d-01973a73dc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_019c9afa-c0af-70ba-9f10-c06bc19030ef" xlink:href="ci-20260331.xsd#ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_019c9afa-c0af-7487-aafe-751a03645a32" xlink:to="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_019c9afa-c0af-70ba-9f10-c06bc19030ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceTable_019c9afa-c0af-79c0-a3fb-ae6aafe5e883" xlink:to="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7761-bc60-773645b9f64e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderContractDeposits_019c9afa-c0af-7761-bc60-773645b9f64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractBalancePercentReinsuredExternally_019c9afa-c0af-7e78-95e1-af9a1bfc96bb" xlink:href="ci-20260331.xsd#ci_PolicyholderContractBalancePercentReinsuredExternally"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_ci_PolicyholderContractBalancePercentReinsuredExternally_019c9afa-c0af-7e78-95e1-af9a1bfc96bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_019c9afa-c0af-7c95-88fb-8626651f6954" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_019c9afa-c0af-7c95-88fb-8626651f6954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_019c9afa-c0af-7794-8656-a4c7db0853cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceNetAmountAtRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_019c9afa-c0af-7794-8656-a4c7db0853cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount_019c9afa-c0af-7162-99d3-896ea2dc4c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashSurrenderValueDuePolicyholdersAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount_019c9afa-c0af-7162-99d3-896ea2dc4c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_019c9afa-c0af-778d-be7a-b5a601ef8169" xlink:href="ci-20260331.xsd#ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_019c9afa-c0af-778d-be7a-b5a601ef8169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderFunds_019c9afa-c0af-78f2-8324-0462abfb92bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderFunds"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderFunds_019c9afa-c0af-78f2-8324-0462abfb92bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_019c9afa-c0af-764c-8c38-0d26e516a861" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_019c9afa-c0af-764c-8c38-0d26e516a861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_019c9afa-c0af-7bd4-985f-5f3838ecf866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_019c9afa-c0af-7bd4-985f-5f3838ecf866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_019c9afa-c0af-7bba-8c5f-e024e12dc988" xlink:href="ci-20260331.xsd#ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceLineItems_019c9afa-c0af-79c5-8e00-5213ee4d977a" xlink:to="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_019c9afa-c0af-7bba-8c5f-e024e12dc988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7a8c-b48e-733b9b183c57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AnnuitizationElectionPeriod_019c9afa-c0af-7305-88b0-9c8ac6e830d6" xlink:href="ci-20260331.xsd#ci_AnnuitizationElectionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7a8c-b48e-733b9b183c57" xlink:to="loc_ci_AnnuitizationElectionPeriod_019c9afa-c0af-7305-88b0-9c8ac6e830d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-7a8c-b48e-733b9b183c57" xlink:to="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_019c9afa-c0af-7301-9ce4-1ffa642c7bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:to="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_019c9afa-c0af-7301-9ce4-1ffa642c7bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_019c9afa-c0af-71f9-b02b-032a440d5bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:to="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_019c9afa-c0af-71f9-b02b-032a440d5bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff_019c9afa-c0af-74dc-ac4d-17bb0b7e75cf" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:to="loc_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff_019c9afa-c0af-74dc-ac4d-17bb0b7e75cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange_019c9afa-c0af-7994-abea-92c0e18bc506" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:to="loc_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange_019c9afa-c0af-7994-abea-92c0e18bc506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected_019c9afa-c0af-70ed-9129-e785d6cef002" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:to="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected_019c9afa-c0af-70ed-9129-e785d6cef002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption_019c9afa-c0af-7568-85f2-a6b460c2e95f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:to="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption_019c9afa-c0af-7568-85f2-a6b460c2e95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_019c9afa-c0af-7458-8ddb-b7b65fa16797" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:to="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_019c9afa-c0af-7458-8ddb-b7b65fa16797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_019c9afa-c0af-738a-be6b-6cf07ed944ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:to="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_019c9afa-c0af-738a-be6b-6cf07ed944ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_019c9afa-c0af-7e67-967a-9ce9e5db62ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:to="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_019c9afa-c0af-7e67-967a-9ce9e5db62ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-71e2-9cd5-5df3b73bb569" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_019c9afa-c0af-7cc9-8175-d5ddf60469c7" xlink:to="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-71e2-9cd5-5df3b73bb569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-75c3-a466-785b406dc9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_019c9afa-c0af-7c06-876e-5aedbed65ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_019c9afa-c0af-75c3-a466-785b406dc9a3" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_019c9afa-c0af-7c06-876e-5aedbed65ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7ec3-9c6f-e80cf912c55b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_019c9afa-c0af-7c06-876e-5aedbed65ae8" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7ec3-9c6f-e80cf912c55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7e1b-8ead-25eebac7d949" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7ec3-9c6f-e80cf912c55b" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7e1b-8ead-25eebac7d949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember_019c9afa-c0af-739a-a268-7298e0512fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableAnnuityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7e1b-8ead-25eebac7d949" xlink:to="loc_us-gaap_VariableAnnuityMember_019c9afa-c0af-739a-a268-7298e0512fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_019c9afa-c0af-7c06-876e-5aedbed65ae8" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_019c9afa-c0af-7fe0-aa2f-ac5665ca3137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_019c9afa-c0af-7fe0-aa2f-ac5665ca3137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_019c9afa-c0af-7baf-87b5-254656638b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_019c9afa-c0af-7baf-87b5-254656638b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_019c9afa-c0af-7f54-a1c0-326cc1019523" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_019c9afa-c0af-7f54-a1c0-326cc1019523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_019c9afa-c0af-7315-a998-ece08349ce30" xlink:href="ci-20260331.xsd#ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_019c9afa-c0af-71f9-a7b4-b8906abb48f9" xlink:to="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_019c9afa-c0af-7315-a998-ece08349ce30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#ReinsuranceReinsuranceRecoverablesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c0af-7ad5-b9d8-e429cbcb9b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c0af-7ad5-b9d8-e429cbcb9b3b" xlink:to="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_019c9afa-c0af-7834-a0c7-cfd891a74f4a" xlink:href="ci-20260331.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_019c9afa-c0af-7834-a0c7-cfd891a74f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7666-a3ce-4ee9ac6d383e" xlink:href="ci-20260331.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_019c9afa-c0af-7834-a0c7-cfd891a74f4a" xlink:to="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7666-a3ce-4ee9ac6d383e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_019c9afa-c0af-793d-bc1c-049f5fe59519" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7666-a3ce-4ee9ac6d383e" xlink:to="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_019c9afa-c0af-793d-bc1c-049f5fe59519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_019c9afa-c0af-76d0-86cf-b6c1ed377058" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_019c9afa-c0af-793d-bc1c-049f5fe59519" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_019c9afa-c0af-76d0-86cf-b6c1ed377058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_019c9afa-c0af-7b46-9c62-9377b33f96f5" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7666-a3ce-4ee9ac6d383e" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_019c9afa-c0af-7b46-9c62-9377b33f96f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_019c9afa-c0af-7a4e-aa63-304698cc22c6" xlink:href="ci-20260331.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_019c9afa-c0af-7666-a3ce-4ee9ac6d383e" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_019c9afa-c0af-7a4e-aa63-304698cc22c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7b7b-9edf-c1add3f4226c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7b7b-9edf-c1add3f4226c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-74af-b403-a1d786a76327" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-7b7b-9edf-c1add3f4226c" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-74af-b403-a1d786a76327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OngoingOperationsMember_019c9afa-c0af-78dc-a0a1-cdfa340e07fd" xlink:href="ci-20260331.xsd#ci_OngoingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-74af-b403-a1d786a76327" xlink:to="loc_ci_OngoingOperationsMember_019c9afa-c0af-78dc-a0a1-cdfa340e07fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AcquisitionDispositionRunoffActivitiesMember_019c9afa-c0af-7ec4-ad04-30ef9cc44c34" xlink:href="ci-20260331.xsd#ci_AcquisitionDispositionRunoffActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-74af-b403-a1d786a76327" xlink:to="loc_ci_AcquisitionDispositionRunoffActivitiesMember_019c9afa-c0af-7ec4-ad04-30ef9cc44c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-788b-9c72-42fca8b0ee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-788b-9c72-42fca8b0ee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-778a-88f9-ad87f8e53b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-788b-9c72-42fca8b0ee5a" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-778a-88f9-ad87f8e53b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-7a4e-a2a0-a540229748ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskSecuredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-778a-88f9-ad87f8e53b1b" xlink:to="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-7a4e-a2a0-a540229748ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_019c9afa-c0af-728a-8b75-a6179f17c5ef" xlink:href="ci-20260331.xsd#ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-7a4e-a2a0-a540229748ae" xlink:to="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_019c9afa-c0af-728a-8b75-a6179f17c5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_019c9afa-c0af-7153-a0bc-409325badd9e" xlink:href="ci-20260331.xsd#ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-7a4e-a2a0-a540229748ae" xlink:to="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_019c9afa-c0af-7153-a0bc-409325badd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskUnsecuredMember_019c9afa-c0af-72e9-a858-03735896005f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskUnsecuredMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-778a-88f9-ad87f8e53b1b" xlink:to="loc_us-gaap_CededCreditRiskUnsecuredMember_019c9afa-c0af-72e9-a858-03735896005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-7623-b68e-e3d4871a0e09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-7623-b68e-e3d4871a0e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7496-a49c-662b942fd483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-7623-b68e-e3d4871a0e09" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7496-a49c-662b942fd483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_019c9afa-c0af-7906-a96d-961bca238e04" xlink:href="ci-20260331.xsd#ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7496-a49c-662b942fd483" xlink:to="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_019c9afa-c0af-7906-a96d-961bca238e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76cb-8838-673b951dfe76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76cb-8838-673b951dfe76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-7fa8-b01f-e08588417151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76cb-8838-673b951dfe76" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-7fa8-b01f-e08588417151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsurerConcentrationRiskMember_019c9afa-c0af-7d4e-9148-a7f8eacce2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsurerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-7fa8-b01f-e08588417151" xlink:to="loc_us-gaap_ReinsurerConcentrationRiskMember_019c9afa-c0af-7d4e-9148-a7f8eacce2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_019c9afa-c0af-7a9a-aeef-955077be81a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_019c9afa-c0af-7a9a-aeef-955077be81a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019c9afa-c0af-71ba-a92e-ef64e2dda8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019c9afa-c0af-7a9a-aeef-955077be81a2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019c9afa-c0af-71ba-a92e-ef64e2dda8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_019c9afa-c0af-7a0d-9359-74558fe18d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019c9afa-c0af-71ba-a92e-ef64e2dda8f5" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_019c9afa-c0af-7a0d-9359-74558fe18d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-73eb-958d-67badb4c5ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-73eb-958d-67badb4c5ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7ce7-8753-ab476df27e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-73eb-958d-67badb4c5ee5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7ce7-8753-ab476df27e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember_019c9afa-c0af-77ea-a364-cbcdd9f52bb7" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7ce7-8753-ab476df27e4a" xlink:to="loc_ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember_019c9afa-c0af-77ea-a364-cbcdd9f52bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-7059-ad1c-b302f8f09e75" xlink:to="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesGross_019c9afa-c0af-7aec-b0f6-2dc236bcdb84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverablesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_ReinsuranceRecoverablesGross_019c9afa-c0af-7aec-b0f6-2dc236bcdb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesAllowance_019c9afa-c0af-7b00-a3ef-b53b6acab1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverablesAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_ReinsuranceRecoverablesAllowance_019c9afa-c0af-7b00-a3ef-b53b6acab1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-7d29-a894-8d035a603f92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_019c9afa-c0af-7d29-a894-8d035a603f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables_019c9afa-c0af-7fb4-8487-d88c86457a77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_ReinsuranceRecoverables_019c9afa-c0af-7fb4-8487-d88c86457a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesNumberOfReinsurers_019c9afa-c0af-726d-9f01-4b2e1a363831" xlink:href="ci-20260331.xsd#ci_ReinsuranceRecoverablesNumberOfReinsurers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_ci_ReinsuranceRecoverablesNumberOfReinsurers_019c9afa-c0af-726d-9f01-4b2e1a363831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019c9afa-c0af-7ee7-a3f3-a64dcd91f29f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-704c-b35f-dc0a4e6fef57" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019c9afa-c0af-7ee7-a3f3-a64dcd91f29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#ReinsuranceVariableAnnuityReinsuranceAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c0af-7392-9045-2e0a42c27fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_019c9afa-c0af-7392-9045-2e0a42c27fdd" xlink:to="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c0af-780c-947e-9dc700814fd3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c0af-780c-947e-9dc700814fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a59-aff8-5e7704723ad5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c0af-780c-947e-9dc700814fd3" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a59-aff8-5e7704723ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember_019c9afa-c0af-7d4b-9392-b60cccccd70d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableAnnuityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c0af-7a59-aff8-5e7704723ad5" xlink:to="loc_us-gaap_VariableAnnuityMember_019c9afa-c0af-7d4b-9392-b60cccccd70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-78e7-919a-7113e436999b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-78e7-919a-7113e436999b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7281-9df4-7a3a3f696783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskAxis_019c9afa-c0af-78e7-919a-7113e436999b" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7281-9df4-7a3a3f696783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_019c9afa-c0af-7964-b8b1-ee28ad81fac6" xlink:href="ci-20260331.xsd#ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_019c9afa-c0af-7281-9df4-7a3a3f696783" xlink:to="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_019c9afa-c0af-7964-b8b1-ee28ad81fac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-7cf2-bb5c-4f2b73d48c52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-7cf2-bb5c-4f2b73d48c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-794e-9f1c-705a3627d0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_019c9afa-c0af-7cf2-bb5c-4f2b73d48c52" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-794e-9f1c-705a3627d0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-72c3-b093-98c47fa31356" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskSecuredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_019c9afa-c0af-794e-9f1c-705a3627d0ae" xlink:to="loc_us-gaap_CededCreditRiskSecuredMember_019c9afa-c0af-72c3-b093-98c47fa31356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-79fe-9943-d34aa41cddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-79fe-9943-d34aa41cddc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7684-8b56-878b30c4378f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c9afa-c0af-79fe-9943-d34aa41cddc9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7684-8b56-878b30c4378f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_019c9afa-c0af-7d89-8bf8-2398cf22aaef" xlink:href="ci-20260331.xsd#ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c9afa-c0af-7684-8b56-878b30c4378f" xlink:to="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_019c9afa-c0af-7d89-8bf8-2398cf22aaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76ad-919c-8d9b5dd7f61a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76ad-919c-8d9b5dd7f61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-72c5-a210-caea1627b85a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019c9afa-c0af-76ad-919c-8d9b5dd7f61a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-72c5-a210-caea1627b85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditCollateralizationRiskMember_019c9afa-c0af-716b-95bd-8195ac53aece" xlink:href="ci-20260331.xsd#ci_CededCreditCollateralizationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019c9afa-c0af-72c5-a210-caea1627b85a" xlink:to="loc_ci_CededCreditCollateralizationRiskMember_019c9afa-c0af-716b-95bd-8195ac53aece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-72aa-90ed-c8c37280f8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_019c9afa-c0af-73fa-896b-821850b89c53" xlink:to="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-72aa-90ed-c8c37280f8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage_019c9afa-c0af-7112-a7a7-38f86a4a80cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-72aa-90ed-c8c37280f8b1" xlink:to="loc_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage_019c9afa-c0af-7112-a7a7-38f86a4a80cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_019c9afa-c0af-70af-8857-40dbc027cd56" xlink:href="ci-20260331.xsd#ci_CededReinsuranceAgreementCoverageLimitAmountRemaining"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-72aa-90ed-c8c37280f8b1" xlink:to="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_019c9afa-c0af-70af-8857-40dbc027cd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019c9afa-c0af-7cd4-9814-7173d889f8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_019c9afa-c0af-72aa-90ed-c8c37280f8b1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019c9afa-c0af-7cd4-9814-7173d889f8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsInvestmentsbyCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-73a6-a806-9bc689d4830e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7a90-a507-c7384f1e7d84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-73a6-a806-9bc689d4830e" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7a90-a507-c7384f1e7d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7946-8690-8543557537f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7a90-a507-c7384f1e7d84" xlink:to="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7946-8690-8543557537f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7946-8690-8543557537f7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-763c-acf1-5cdba2114966" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-763c-acf1-5cdba2114966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-7583-8d41-4a96e34cb5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-7583-8d41-4a96e34cb5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_019c9afa-c16c-71c4-aa1d-10ff88fb137e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgagesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_MortgagesMember_019c9afa-c16c-71c4-aa1d-10ff88fb137e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-74be-a52f-a46fb0b521c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyLoansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-74be-a52f-a46fb0b521c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-7d2f-8107-371597b63f93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-7d2f-8107-371597b63f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_019c9afa-c16c-7241-85cc-a1b31b480989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-726d-a127-e7cf15e02619" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_019c9afa-c16c-7241-85cc-a1b31b480989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7eb9-a483-d85ac9f672e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7a90-a507-c7384f1e7d84" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7eb9-a483-d85ac9f672e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-7289-ac21-dcf6e9c6bc60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7eb9-a483-d85ac9f672e7" xlink:to="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-7289-ac21-dcf6e9c6bc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_019c9afa-c16c-76b2-87fc-8e541587533a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7eb9-a483-d85ac9f672e7" xlink:to="loc_us-gaap_LongTermInvestments_019c9afa-c16c-76b2-87fc-8e541587533a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_019c9afa-c16c-7d69-8add-9f39e3c4c9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7eb9-a483-d85ac9f672e7" xlink:to="loc_us-gaap_Investments_019c9afa-c16c-7d69-8add-9f39e3c4c9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7e19-bd68-af2fdbba7550" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7e19-bd68-af2fdbba7550" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c6a-811b-1f2b7381afeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:to="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c6a-811b-1f2b7381afeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c6a-811b-1f2b7381afeb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7804-99eb-b7157c6cccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7804-99eb-b7157c6cccf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-73a9-b495-51d439be7612" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-73a9-b495-51d439be7612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_019c9afa-c16c-7d27-854c-a35163f5a81a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgagesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_MortgagesMember_019c9afa-c16c-7d27-854c-a35163f5a81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-71fb-840b-11d9e4256c75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyLoansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-71fb-840b-11d9e4256c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-76b1-99fe-01d05676677f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-76b1-99fe-01d05676677f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_019c9afa-c16c-73ed-b4ca-6703c853379f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7ea1-adfb-c7be1d9ecdf6" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_019c9afa-c16c-73ed-b4ca-6703c853379f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c16c-74e4-90b9-6df11ec1049e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c16c-74e4-90b9-6df11ec1049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c16c-745a-9a51-064335ca5b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c9afa-c16c-74e4-90b9-6df11ec1049e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c16c-745a-9a51-064335ca5b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_019c9afa-c16c-7bd3-965e-4fb5c3c48707" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019c9afa-c16c-745a-9a51-064335ca5b9b" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_019c9afa-c16c-7bd3-965e-4fb5c3c48707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c16c-7983-9f65-5d7b9966f2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c16c-7983-9f65-5d7b9966f2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c16c-798e-b7e7-0e263cda1811" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c9afa-c16c-7983-9f65-5d7b9966f2ae" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c16c-798e-b7e7-0e263cda1811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_019c9afa-c16c-7c87-8669-4470db6b8c0c" xlink:href="ci-20260331.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c9afa-c16c-798e-b7e7-0e263cda1811" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_019c9afa-c16c-7c87-8669-4470db6b8c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7d80-a499-4c0495bff1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-739b-904a-8fae7112b507" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7d80-a499-4c0495bff1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c16c-7f55-9bcd-0ff0e052e9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7d80-a499-4c0495bff1ed" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c16c-7f55-9bcd-0ff0e052e9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-77c5-8004-bab8bd6d5085" xlink:href="ci-20260331.xsd#ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c16c-7f55-9bcd-0ff0e052e9bb" xlink:to="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-77c5-8004-bab8bd6d5085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_019c9afa-c16c-7cf3-af62-b26736b446fd" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c16c-7f55-9bcd-0ff0e052e9bb" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_019c9afa-c16c-7cf3-af62-b26736b446fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-738c-90c7-46bc5ee8704f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_019c9afa-c16c-7f55-9bcd-0ff0e052e9bb" xlink:to="loc_us-gaap_ShortTermInvestments_019c9afa-c16c-738c-90c7-46bc5ee8704f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_019c9afa-c16c-7052-8c2d-0168a06c13ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7d80-a499-4c0495bff1ed" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_019c9afa-c16c-7052-8c2d-0168a06c13ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-750a-9be3-4a35e7bb66a5" xlink:href="ci-20260331.xsd#ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_019c9afa-c16c-7052-8c2d-0168a06c13ea" xlink:to="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-750a-9be3-4a35e7bb66a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_019c9afa-c16c-7ad1-80de-f9440d58194b" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_019c9afa-c16c-7052-8c2d-0168a06c13ea" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_019c9afa-c16c-7ad1-80de-f9440d58194b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_019c9afa-c16c-7051-84e7-248c978f8d11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_019c9afa-c16c-7052-8c2d-0168a06c13ea" xlink:to="loc_us-gaap_LongTermInvestments_019c9afa-c16c-7051-84e7-248c978f8d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c16c-7415-9133-ccd841465951" xlink:href="ci-20260331.xsd#ci_ShortTermAndLongTermInvestmentsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7d80-a499-4c0495bff1ed" xlink:to="loc_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c16c-7415-9133-ccd841465951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7957-88a3-60d2855bc3f2" xlink:href="ci-20260331.xsd#ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c16c-7415-9133-ccd841465951" xlink:to="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16c-7957-88a3-60d2855bc3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_019c9afa-c16c-7c28-b52d-7c5283fca9e1" xlink:href="ci-20260331.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c16c-7415-9133-ccd841465951" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_019c9afa-c16c-7c28-b52d-7c5283fca9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_019c9afa-c16c-7e07-9b33-f526c6f0f8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_019c9afa-c16c-7415-9133-ccd841465951" xlink:to="loc_us-gaap_Investments_019c9afa-c16c-7e07-9b33-f526c6f0f8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7a28-8eb1-3c5f8512abe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_019c9afa-c16c-7c75-8f5f-8d80935dbec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7a28-8eb1-3c5f8512abe4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_019c9afa-c16c-7c75-8f5f-8d80935dbec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c9afa-c16c-7df1-86fe-5bfcbe050956" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_019c9afa-c16c-7c75-8f5f-8d80935dbec1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c9afa-c16c-7df1-86fe-5bfcbe050956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c9afa-c16c-7c53-9c50-b3af20db9604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_019c9afa-c16c-7c75-8f5f-8d80935dbec1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c9afa-c16c-7c53-9c50-b3af20db9604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_019c9afa-c16c-7bb7-81a6-9672f968a713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_019c9afa-c16c-7c75-8f5f-8d80935dbec1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_019c9afa-c16c-7bb7-81a6-9672f968a713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_019c9afa-c16c-73d1-856d-893dc1f53990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_019c9afa-c16c-7c75-8f5f-8d80935dbec1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_019c9afa-c16c-73d1-856d-893dc1f53990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_019c9afa-c16c-747e-bd50-c8c1c9bce960" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_019c9afa-c16c-7c75-8f5f-8d80935dbec1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_019c9afa-c16c-747e-bd50-c8c1c9bce960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7b40-bb28-582fb0634f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_019c9afa-c16c-7c75-8f5f-8d80935dbec1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7b40-bb28-582fb0634f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_019c9afa-c16c-7557-8681-6547ae7be611" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7a28-8eb1-3c5f8512abe4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_019c9afa-c16c-7557-8681-6547ae7be611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c9afa-c16c-7541-ab94-7788f513a49e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_019c9afa-c16c-7557-8681-6547ae7be611" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c9afa-c16c-7541-ab94-7788f513a49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c9afa-c16c-765c-a79c-c3efdd8533be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_019c9afa-c16c-7557-8681-6547ae7be611" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c9afa-c16c-765c-a79c-c3efdd8533be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_019c9afa-c16c-7980-a5e0-8cb0cafbe05a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_019c9afa-c16c-7557-8681-6547ae7be611" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_019c9afa-c16c-7980-a5e0-8cb0cafbe05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_019c9afa-c16c-71f5-9c17-16b5edc3f3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_019c9afa-c16c-7557-8681-6547ae7be611" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_019c9afa-c16c-71f5-9c17-16b5edc3f3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_019c9afa-c16c-7179-9330-bd0e50668509" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_019c9afa-c16c-7557-8681-6547ae7be611" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_019c9afa-c16c-7179-9330-bd0e50668509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-75d6-bfc4-7a980207496b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_019c9afa-c16c-7557-8681-6547ae7be611" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-75d6-bfc4-7a980207496b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7513-9640-ba4c8d00a672" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-70e2-bbb5-fb3cf191b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7513-9640-ba4c8d00a672" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-70e2-bbb5-fb3cf191b86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-77ef-a20f-b5aec9f05c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-70e2-bbb5-fb3cf191b86d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-77ef-a20f-b5aec9f05c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-77ef-a20f-b5aec9f05c0c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019c9afa-c16c-71d8-81ce-30749f0be3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019c9afa-c16c-71d8-81ce-30749f0be3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_019c9afa-c16c-7518-bd61-576fdac6a208" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_019c9afa-c16c-7518-bd61-576fdac6a208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_019c9afa-c16c-788a-8311-34a851721d72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_019c9afa-c16c-788a-8311-34a851721d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019c9afa-c16c-70c7-b6a8-bf04858da77b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019c9afa-c16c-70c7-b6a8-bf04858da77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7091-ae5b-23102f6d0e94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7625-b6f1-df7ffb605276" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7091-ae5b-23102f6d0e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-70e2-bbb5-fb3cf191b86d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7eca-a4e6-13a75aa1a508" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_019c9afa-c16c-7eca-a4e6-13a75aa1a508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_019c9afa-c16c-7dc1-b8fc-2a0b0478fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_019c9afa-c16c-7dc1-b8fc-2a0b0478fa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019c9afa-c16c-72a3-b452-e29318d48e34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019c9afa-c16c-72a3-b452-e29318d48e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019c9afa-c16c-7372-8d3e-b47a13114de2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019c9afa-c16c-7372-8d3e-b47a13114de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-7bc1-be2a-9de6abe7b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-77fd-a3a6-78ce20f7604f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c9afa-c16c-7bc1-be2a-9de6abe7b9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-732c-8c75-ea08c44d1a49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-7b31-8c10-e31e3cf11efb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-732c-8c75-ea08c44d1a49" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-7b31-8c10-e31e3cf11efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingAxis_019c9afa-c16c-7012-b6bb-ed7b287fda15" xlink:href="ci-20260331.xsd#ci_InvestmentsCreditRatingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-7b31-8c10-e31e3cf11efb" xlink:to="loc_ci_InvestmentsCreditRatingAxis_019c9afa-c16c-7012-b6bb-ed7b287fda15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingDomain_019c9afa-c16c-776f-8e77-7d8af36cf5ae" xlink:href="ci-20260331.xsd#ci_InvestmentsCreditRatingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InvestmentsCreditRatingAxis_019c9afa-c16c-7012-b6bb-ed7b287fda15" xlink:to="loc_ci_InvestmentsCreditRatingDomain_019c9afa-c16c-776f-8e77-7d8af36cf5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentGradeMember_019c9afa-c16c-71c8-9f68-e189bf91819f" xlink:href="ci-20260331.xsd#ci_InvestmentGradeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InvestmentsCreditRatingDomain_019c9afa-c16c-776f-8e77-7d8af36cf5ae" xlink:to="loc_ci_InvestmentGradeMember_019c9afa-c16c-71c8-9f68-e189bf91819f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BelowInvestmentGradeMember_019c9afa-c16c-7fad-afbe-d721ba615127" xlink:href="ci-20260331.xsd#ci_BelowInvestmentGradeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InvestmentsCreditRatingDomain_019c9afa-c16c-776f-8e77-7d8af36cf5ae" xlink:to="loc_ci_BelowInvestmentGradeMember_019c9afa-c16c-7fad-afbe-d721ba615127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7ca5-b7ad-9dfa577091c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-7b31-8c10-e31e3cf11efb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7ca5-b7ad-9dfa577091c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7f57-bc3a-9ce70c0cc813" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7ca5-b7ad-9dfa577091c5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7f57-bc3a-9ce70c0cc813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7633-90f6-587ad97d423d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7f57-bc3a-9ce70c0cc813" xlink:to="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7633-90f6-587ad97d423d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-737a-a06c-951efe8217f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019c9afa-c16c-7b31-8c10-e31e3cf11efb" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-737a-a06c-951efe8217f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-737a-a06c-951efe8217f4" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019c9afa-c16c-7573-a2a4-815669706dec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019c9afa-c16c-7573-a2a4-815669706dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_019c9afa-c16c-7545-bc5a-c786b3ca3dca" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_019c9afa-c16c-7545-bc5a-c786b3ca3dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019c9afa-c16c-7d23-bb87-77fe13fbf035" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019c9afa-c16c-7d23-bb87-77fe13fbf035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_019c9afa-c16c-7c7d-be88-c602e5071a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_019c9afa-c16c-70dc-9613-83bc62d50595" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_019c9afa-c16c-7c7d-be88-c602e5071a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-737a-a06c-951efe8217f4" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019c9afa-c16c-72a8-860d-4b7db0219fee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019c9afa-c16c-72a8-860d-4b7db0219fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_019c9afa-c16c-7e83-91bf-572c6ea4755e" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_019c9afa-c16c-7e83-91bf-572c6ea4755e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019c9afa-c16c-7f0d-a4e1-7602d5b0437d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019c9afa-c16c-7f0d-a4e1-7602d5b0437d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_019c9afa-c16c-7e92-b3e5-5e2ed2747795" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_019c9afa-c16c-7aaa-b86d-9121154b6b0a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_019c9afa-c16c-7e92-b3e5-5e2ed2747795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c9afa-c16c-737a-a06c-951efe8217f4" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c9afa-c16c-7d84-a520-0dab00c9cf64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c9afa-c16c-7d84-a520-0dab00c9cf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c16c-7234-813e-44935b974e60" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_019c9afa-c16c-7234-813e-44935b974e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c9afa-c16c-7124-b1bc-6f2f5becd5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c9afa-c16c-7124-b1bc-6f2f5becd5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019c9afa-c16c-72ff-9a84-d55d75727251" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_019c9afa-c16c-7132-9653-2939b59a0c70" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019c9afa-c16c-72ff-9a84-d55d75727251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c9afa-c16c-70d7-874a-79233446666b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7f77-94e8-958b599814fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c9afa-c16c-70d7-874a-79233446666b" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7f77-94e8-958b599814fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16c-7185-b3f2-bb94eb11e3b8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7f77-94e8-958b599814fb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16c-7185-b3f2-bb94eb11e3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16c-73b8-a3d6-b6a670c87ebe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16c-7185-b3f2-bb94eb11e3b8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16c-73b8-a3d6-b6a670c87ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShieldsHealthSolutionsMember_019c9afa-c16c-7e82-b724-8b9ee941656c" xlink:href="ci-20260331.xsd#ci_ShieldsHealthSolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16c-73b8-a3d6-b6a670c87ebe" xlink:to="loc_ci_ShieldsHealthSolutionsMember_019c9afa-c16c-7e82-b724-8b9ee941656c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-72a2-86ad-e46157e96c34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7f77-94e8-958b599814fb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-72a2-86ad-e46157e96c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-747a-9a05-805dcfcc30b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-72a2-86ad-e46157e96c34" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-747a-9a05-805dcfcc30b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_019c9afa-c16c-7ce4-9488-4ee7158ead99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-747a-9a05-805dcfcc30b3" xlink:to="loc_us-gaap_PreferredStockMember_019c9afa-c16c-7ce4-9488-4ee7158ead99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7ec0-9bcc-463c0ecbd3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7f77-94e8-958b599814fb" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7ec0-9bcc-463c0ecbd3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c16c-7f66-8b2c-5d1b0b635821" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7ec0-9bcc-463c0ecbd3cb" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c16c-7f66-8b2c-5d1b0b635821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_019c9afa-c16c-7269-bc0b-cd9d58ac20e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c16c-7f66-8b2c-5d1b0b635821" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_019c9afa-c16c-7269-bc0b-cd9d58ac20e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_019c9afa-c16c-729e-a719-ca6a01ff84df" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c16c-7f66-8b2c-5d1b0b635821" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_019c9afa-c16c-729e-a719-ca6a01ff84df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_019c9afa-c16c-7d29-8b4a-164c9c2daf98" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_019c9afa-c16c-7f66-8b2c-5d1b0b635821" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_019c9afa-c16c-7d29-8b4a-164c9c2daf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c16c-73e8-9cb7-6f40086cf1b3" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7ec0-9bcc-463c0ecbd3cb" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c16c-73e8-9cb7-6f40086cf1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c16c-7ba9-abf7-419f0c9a83a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c16c-73e8-9cb7-6f40086cf1b3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c16c-7ba9-abf7-419f0c9a83a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019c9afa-c16c-727b-bbe7-4c646304be68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c16c-73e8-9cb7-6f40086cf1b3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019c9afa-c16c-727b-bbe7-4c646304be68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_019c9afa-c16c-7095-914b-f27ddf7435a5" xlink:href="ci-20260331.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_019c9afa-c16c-73e8-9cb7-6f40086cf1b3" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_019c9afa-c16c-7095-914b-f27ddf7435a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsCommercialMortgageLoansDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-758b-8182-26d411b93770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-758b-8182-26d411b93770" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c9afa-c16c-79ea-846c-880e6dea5785" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c9afa-c16c-79ea-846c-880e6dea5785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c9afa-c16c-7cb4-bfac-f913bb7abeed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c9afa-c16c-79ea-846c-880e6dea5785" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c9afa-c16c-7cb4-bfac-f913bb7abeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_019c9afa-c16c-7b0c-9f69-5f1b538c3de8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c9afa-c16c-7cb4-bfac-f913bb7abeed" xlink:to="loc_us-gaap_RealEstateLoanMember_019c9afa-c16c-7b0c-9f69-5f1b538c3de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_019c9afa-c16c-7027-9f67-f66d152abdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_019c9afa-c16c-7027-9f67-f66d152abdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_019c9afa-c16c-7299-a0f3-60c967e55701" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_019c9afa-c16c-7027-9f67-f66d152abdcc" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_019c9afa-c16c-7299-a0f3-60c967e55701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPortfolioSegmentMember_019c9afa-c16c-77d3-9f60-88a1f53579d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPortfolioSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_019c9afa-c16c-7299-a0f3-60c967e55701" xlink:to="loc_us-gaap_CommercialPortfolioSegmentMember_019c9afa-c16c-77d3-9f60-88a1f53579d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueAxis_019c9afa-c16c-7e24-97cf-0078753903c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoanToValueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:to="loc_us-gaap_LoanToValueAxis_019c9afa-c16c-7e24-97cf-0078753903c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7ca5-95f9-bc659dc50f07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoanToValueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoanToValueAxis_019c9afa-c16c-7e24-97cf-0078753903c5" xlink:to="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7ca5-95f9-bc659dc50f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LtvLessThan80PercentMember_019c9afa-c16c-72a1-bc4e-d3902edb589a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LtvLessThan80PercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7ca5-95f9-bc659dc50f07" xlink:to="loc_us-gaap_LtvLessThan80PercentMember_019c9afa-c16c-72a1-bc4e-d3902edb589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvLessThan60PercentMember_019c9afa-c16c-7aba-b164-6b5c2e483bea" xlink:href="ci-20260331.xsd#ci_LtvLessThan60PercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LtvLessThan80PercentMember_019c9afa-c16c-72a1-bc4e-d3902edb589a" xlink:to="loc_ci_LtvLessThan60PercentMember_019c9afa-c16c-7aba-b164-6b5c2e483bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_Ltv60To79PercentMember_019c9afa-c16c-741e-8656-843622f0559a" xlink:href="ci-20260331.xsd#ci_Ltv60To79PercentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LtvLessThan80PercentMember_019c9afa-c16c-72a1-bc4e-d3902edb589a" xlink:to="loc_ci_Ltv60To79PercentMember_019c9afa-c16c-741e-8656-843622f0559a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Ltv80To100PercentMember_019c9afa-c16c-7298-b4fb-179a2bd1646b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Ltv80To100PercentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7ca5-95f9-bc659dc50f07" xlink:to="loc_us-gaap_Ltv80To100PercentMember_019c9afa-c16c-7298-b4fb-179a2bd1646b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvGreaterThan100PercentMember_019c9afa-c16c-77cf-95e8-275354fb0faf" xlink:href="ci-20260331.xsd#ci_LtvGreaterThan100PercentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoanToValueDomain_019c9afa-c16c-7ca5-95f9-bc659dc50f07" xlink:to="loc_ci_LtvGreaterThan100PercentMember_019c9afa-c16c-77cf-95e8-275354fb0faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c9afa-c16c-7471-80d8-19566db04993" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:to="loc_srt_RangeAxis_019c9afa-c16c-7471-80d8-19566db04993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c9afa-c16c-796d-b58b-7d017c278d6b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019c9afa-c16c-7471-80d8-19566db04993" xlink:to="loc_srt_RangeMember_019c9afa-c16c-796d-b58b-7d017c278d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_019c9afa-c16c-7f77-a530-f7505f44267f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c9afa-c16c-796d-b58b-7d017c278d6b" xlink:to="loc_srt_WeightedAverageMember_019c9afa-c16c-7f77-a530-f7505f44267f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7fff-9ddb-1af2c28e7110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_019c9afa-c16c-7528-93c6-c2fea958ab6f" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7fff-9ddb-1af2c28e7110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_019c9afa-c16c-7091-ace4-fdb8d536c7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7fff-9ddb-1af2c28e7110" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_019c9afa-c16c-7091-ace4-fdb8d536c7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_019c9afa-c16c-7d1f-8f0b-60cd38f0bbc0" xlink:href="ci-20260331.xsd#ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7fff-9ddb-1af2c28e7110" xlink:to="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_019c9afa-c16c-7d1f-8f0b-60cd38f0bbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio_019c9afa-c16c-7a33-8d30-767dcc54adab" xlink:href="ci-20260331.xsd#ci_FinancingReceivableCreditQualityLoanToValueRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7fff-9ddb-1af2c28e7110" xlink:to="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio_019c9afa-c16c-7a33-8d30-767dcc54adab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsOtherLongTermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c9afa-c16c-7cf1-b881-59a079ea1c70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7bcb-8b41-e163212742d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c9afa-c16c-7cf1-b881-59a079ea1c70" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7bcb-8b41-e163212742d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c58-8a6a-471cb0485839" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7bcb-8b41-e163212742d6" xlink:to="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c58-8a6a-471cb0485839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d02-a876-a15a3804ad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7c58-8a6a-471cb0485839" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d02-a876-a15a3804ad9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateInvestmentMember_019c9afa-c16c-78ee-acb2-74b7401c7585" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d02-a876-a15a3804ad9c" xlink:to="loc_us-gaap_RealEstateInvestmentMember_019c9afa-c16c-78ee-acb2-74b7401c7585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_019c9afa-c16c-7f0c-96b1-4fced1e3e33e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d02-a876-a15a3804ad9c" xlink:to="loc_srt_PartnershipInterestMember_019c9afa-c16c-7f0c-96b1-4fced1e3e33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_019c9afa-c16c-7810-ac98-6ae2df6b85b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d02-a876-a15a3804ad9c" xlink:to="loc_us-gaap_OtherInvestmentsMember_019c9afa-c16c-7810-ac98-6ae2df6b85b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019c9afa-c16c-7bcb-8b41-e163212742d6" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_019c9afa-c16c-7413-bdd5-e74fd6bafacb" xlink:href="ci-20260331.xsd#ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:to="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_019c9afa-c16c-7413-bdd5-e74fd6bafacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_019c9afa-c16c-7430-8ee2-89533f41f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_019c9afa-c16c-7430-8ee2-89533f41f5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_019c9afa-c16c-7239-834f-9551106fcfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:to="loc_us-gaap_OtherLongTermInvestments_019c9afa-c16c-7239-834f-9551106fcfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital_019c9afa-c16c-7075-8a62-9b2f2926aba8" xlink:href="ci-20260331.xsd#ci_CommitmentsToContributeAdditionalEquityAndCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019c9afa-c16c-7af0-ad82-d5a52407f69b" xlink:to="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital_019c9afa-c16c-7075-8a62-9b2f2926aba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsDerivativeFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7196-885f-79e080a56435" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-7196-885f-79e080a56435" xlink:to="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_019c9afa-c16c-707e-ba08-036db5cda375" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:to="loc_us-gaap_HedgingDesignationAxis_019c9afa-c16c-707e-ba08-036db5cda375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_019c9afa-c16c-70e9-a832-94278f6237dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_019c9afa-c16c-707e-ba08-036db5cda375" xlink:to="loc_us-gaap_HedgingDesignationDomain_019c9afa-c16c-70e9-a832-94278f6237dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_019c9afa-c16c-7339-a70a-708434b2f864" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_019c9afa-c16c-70e9-a832-94278f6237dd" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_019c9afa-c16c-7339-a70a-708434b2f864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_019c9afa-c16c-7c99-ba0a-62985137627f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_019c9afa-c16c-7c99-ba0a-62985137627f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_019c9afa-c16c-7feb-a8d5-ef9c758a441c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_019c9afa-c16c-7c99-ba0a-62985137627f" xlink:to="loc_us-gaap_HedgingRelationshipDomain_019c9afa-c16c-7feb-a8d5-ef9c758a441c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_019c9afa-c16c-7e5a-9282-d40896e91a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_019c9afa-c16c-7feb-a8d5-ef9c758a441c" xlink:to="loc_us-gaap_FairValueHedgingMember_019c9afa-c16c-7e5a-9282-d40896e91a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_019c9afa-c16c-753f-a2e2-c3471a90c845" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_019c9afa-c16c-7feb-a8d5-ef9c758a441c" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_019c9afa-c16c-753f-a2e2-c3471a90c845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_019c9afa-c16c-772e-bbb2-57d4269a715e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_019c9afa-c16c-772e-bbb2-57d4269a715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019c9afa-c16c-7317-b4e5-58f9473158f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019c9afa-c16c-772e-bbb2-57d4269a715e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019c9afa-c16c-7317-b4e5-58f9473158f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_019c9afa-c16c-7cb8-8719-dd18a41fd0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_019c9afa-c16c-7317-b4e5-58f9473158f6" xlink:to="loc_us-gaap_CurrencySwapMember_019c9afa-c16c-7cb8-8719-dd18a41fd0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_019c9afa-c16c-7f26-a9d1-54fe1ac4175f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_019c9afa-c16c-7317-b4e5-58f9473158f6" xlink:to="loc_us-gaap_InterestRateSwapMember_019c9afa-c16c-7f26-a9d1-54fe1ac4175f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_019c9afa-c16c-751b-bc2a-0c57adfb3fa0" xlink:to="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_019c9afa-c16c-72a4-8f7a-f32ab325a36b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_019c9afa-c16c-72a4-8f7a-f32ab325a36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_019c9afa-c16c-7203-bb92-302f65228541" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_019c9afa-c16c-7203-bb92-302f65228541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_019c9afa-c16c-7620-b2b5-4fa7f3bca948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_019c9afa-c16c-7620-b2b5-4fa7f3bca948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_019c9afa-c16c-7821-a1e9-55fedb1c44c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_019c9afa-c16c-761c-8815-3accea68f82a" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_019c9afa-c16c-7821-a1e9-55fedb1c44c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsComponentsofNetInvestmentIncomeLossesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentIncomeAndGainsAndLossesAbstract_019c9afa-c16c-710d-a6a2-1140e18c3ec6" xlink:href="ci-20260331.xsd#ci_InvestmentIncomeAndGainsAndLossesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_019c9afa-c16c-78cc-844a-d6862c0a0e23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InvestmentIncomeAndGainsAndLossesAbstract_019c9afa-c16c-710d-a6a2-1140e18c3ec6" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_019c9afa-c16c-78cc-844a-d6862c0a0e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7695-931a-275c207f5908" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_019c9afa-c16c-78cc-844a-d6862c0a0e23" xlink:to="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7695-931a-275c207f5908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c9afa-c16c-7695-931a-275c207f5908" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-743a-bb37-440a2d9cdcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-743a-bb37-440a2d9cdcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-76fe-b97b-201a95583895" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_us-gaap_EquitySecuritiesMember_019c9afa-c16c-76fe-b97b-201a95583895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_019c9afa-c16c-7318-abd2-2be4cd0f9047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgagesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_us-gaap_MortgagesMember_019c9afa-c16c-7318-abd2-2be4cd0f9047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-7e45-aab4-e283c64f5be1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyLoansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_us-gaap_PolicyLoansMember_019c9afa-c16c-7e45-aab4-e283c64f5be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-751f-9a10-e24cdb538ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_019c9afa-c16c-751f-9a10-e24cdb538ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember_019c9afa-c16c-721d-8f4c-d4140c27d83e" xlink:href="ci-20260331.xsd#ci_CashCashEquivalentsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c9afa-c16c-7d41-be68-5d528ccbf98a" xlink:to="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember_019c9afa-c16c-721d-8f4c-d4140c27d83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_019c9afa-c16c-78cc-844a-d6862c0a0e23" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_019c9afa-c16c-7fa3-957b-f6d6a336a986" xlink:href="ci-20260331.xsd#ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:to="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_019c9afa-c16c-7fa3-957b-f6d6a336a986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_019c9afa-c16c-707c-b3c1-5cac6bb545f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_019c9afa-c16c-707c-b3c1-5cac6bb545f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_019c9afa-c16c-7233-8d33-b701e5afd0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:to="loc_us-gaap_NetInvestmentIncome_019c9afa-c16c-7233-8d33-b701e5afd0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DividendsReceivableImpairmentLoss_019c9afa-c16c-7cfe-a08d-297456baf50a" xlink:href="ci-20260331.xsd#ci_DividendsReceivableImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_019c9afa-c16c-7d8b-ac85-faa4dd00544a" xlink:to="loc_ci_DividendsReceivableImpairmentLoss_019c9afa-c16c-7cfe-a08d-297456baf50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentGainsandLossesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#InvestmentsInvestmentGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-705f-8a42-48fefe82bca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLoss_019c9afa-c16c-7ecb-b573-c2ab4a1250c7" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019c9afa-c16c-705f-8a42-48fefe82bca2" xlink:to="loc_ci_NetInvestmentGainLoss_019c9afa-c16c-7ecb-b573-c2ab4a1250c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-7b6f-9adc-49a8967b0923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-7b6f-9adc-49a8967b0923" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7f83-8702-f8aa4f2d978a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7f83-8702-f8aa4f2d978a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7f83-8702-f8aa4f2d978a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019c9afa-c16c-7fee-bf5c-5269498890f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019c9afa-c16c-7fee-bf5c-5269498890f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_019c9afa-c16c-73bd-96bd-e374b43d6e69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_019c9afa-c16c-73bd-96bd-e374b43d6e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_019c9afa-c16c-7eb7-82aa-f81bab9eae5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_019c9afa-c16c-7eb7-82aa-f81bab9eae5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019c9afa-c16c-7ae9-bdbf-a881f14640ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019c9afa-c16c-7ae9-bdbf-a881f14640ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7368-b831-e1cc0d303cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7368-b831-e1cc0d303cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember_019c9afa-c16c-7675-a4cc-fbd257dde873" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-7927-bc78-cbadcdd5697f" xlink:to="loc_us-gaap_DerivativeMember_019c9afa-c16c-7675-a4cc-fbd257dde873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-7525-a959-1ed7f324ec03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-7525-a959-1ed7f324ec03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7f78-b020-2a1d865f4351" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-7525-a959-1ed7f324ec03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7f78-b020-2a1d865f4351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019c9afa-c16c-7ace-8837-1119e4749002" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7f78-b020-2a1d865f4351" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019c9afa-c16c-7ace-8837-1119e4749002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16c-79c8-9f2c-6ca2aac806fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7f78-b020-2a1d865f4351" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16c-79c8-9f2c-6ca2aac806fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16c-72a7-ad59-08f38a0ef8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-7f78-b020-2a1d865f4351" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16c-72a7-ad59-08f38a0ef8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77c2-8a2e-e30140ca6d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77c2-8a2e-e30140ca6d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-751b-ac21-c73ab35aa415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77c2-8a2e-e30140ca6d0e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-751b-ac21-c73ab35aa415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_019c9afa-c16c-7370-aad0-706f276f77d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-751b-ac21-c73ab35aa415" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_019c9afa-c16c-7370-aad0-706f276f77d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16c-7283-be1a-12715da78c30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16c-70f5-ba8f-a7c6dc71dcf4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16c-7283-be1a-12715da78c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16c-7283-be1a-12715da78c30" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c9afa-c16c-752c-8ba8-bb70f2f3b96d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c9afa-c16c-752c-8ba8-bb70f2f3b96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c16c-74cc-a647-1be230b81d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019c9afa-c16c-74cc-a647-1be230b81d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_019c9afa-c16c-7c20-8fca-8915b1088097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:to="loc_us-gaap_OtherShortTermInvestments_019c9afa-c16c-7c20-8fca-8915b1088097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_019c9afa-c16c-7758-be07-8ec0f6ef9d39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019c9afa-c16c-7669-bdc2-baa95f77c82f" xlink:to="loc_us-gaap_DerivativeAssets_019c9afa-c16c-7758-be07-8ec0f6ef9d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019c9afa-c16c-75f9-9320-797f9ff85db6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16c-7283-be1a-12715da78c30" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019c9afa-c16c-75f9-9320-797f9ff85db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_019c9afa-c16c-7317-be8c-fd102d898271" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019c9afa-c16c-75f9-9320-797f9ff85db6" xlink:to="loc_us-gaap_DerivativeLiabilities_019c9afa-c16c-7317-be8c-fd102d898271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesClassifiedInLevel3Percentage_019c9afa-c16c-707e-8e45-72aee3e5cbc4" xlink:href="ci-20260331.xsd#ci_DebtSecuritiesClassifiedInLevel3Percentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16c-7283-be1a-12715da78c30" xlink:to="loc_ci_DebtSecuritiesClassifiedInLevel3Percentage_019c9afa-c16c-707e-8e45-72aee3e5cbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-77f4-b5cb-bdf44439969f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16c-77f4-b5cb-bdf44439969f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7fee-887f-a81f2a5a4233" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7fee-887f-a81f2a5a4233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-781b-aee3-295548b3007c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c9afa-c16c-7fee-887f-a81f2a5a4233" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-781b-aee3-295548b3007c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7be9-b4e7-1220f91dbb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c9afa-c16c-781b-aee3-295548b3007c" xlink:to="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7be9-b4e7-1220f91dbb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndGovernmentDebtSecuritiesMember_019c9afa-c16c-7fd7-904c-454686fbdd71" xlink:href="ci-20260331.xsd#ci_CorporateAndGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7be9-b4e7-1220f91dbb3d" xlink:to="loc_ci_CorporateAndGovernmentDebtSecuritiesMember_019c9afa-c16c-7fd7-904c-454686fbdd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7ad4-a66b-cb4e4feb89c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7be9-b4e7-1220f91dbb3d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_019c9afa-c16c-7ad4-a66b-cb4e4feb89c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_019c9afa-c16c-748d-9a5a-f5e984040bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_019c9afa-c16c-7be9-b4e7-1220f91dbb3d" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_019c9afa-c16c-748d-9a5a-f5e984040bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16c-74e7-91fa-a0ce10dcb918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16c-74e7-91fa-a0ce10dcb918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16c-7118-a1d7-e13d714ca0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16c-74e7-91fa-a0ce10dcb918" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16c-7118-a1d7-e13d714ca0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnobservableInputsDevelopedByCompanyMember_019c9afa-c16c-7eb0-b233-b6d5d0986db3" xlink:href="ci-20260331.xsd#ci_UnobservableInputsDevelopedByCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16c-7118-a1d7-e13d714ca0bf" xlink:to="loc_ci_UnobservableInputsDevelopedByCompanyMember_019c9afa-c16c-7eb0-b233-b6d5d0986db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77a4-b0e5-d7915fb0237f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77a4-b0e5-d7915fb0237f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-7b63-bdd7-5edffc056dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c9afa-c16c-77a4-b0e5-d7915fb0237f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-7b63-bdd7-5edffc056dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_019c9afa-c16c-7078-b19e-3de249c27ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c9afa-c16c-7b63-bdd7-5edffc056dae" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_019c9afa-c16c-7078-b19e-3de249c27ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-706a-93e6-5320c39655c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-706a-93e6-5320c39655c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-72b5-ab49-2f7ce34141fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16c-706a-93e6-5320c39655c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-72b5-ab49-2f7ce34141fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16c-78b0-8be0-05a7f7958bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16c-72b5-ab49-2f7ce34141fb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16c-78b0-8be0-05a7f7958bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c9afa-c16c-7859-b6a1-9b5a92477476" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_srt_RangeAxis_019c9afa-c16c-7859-b6a1-9b5a92477476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c9afa-c16c-71df-8348-4223050c687f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019c9afa-c16c-7859-b6a1-9b5a92477476" xlink:to="loc_srt_RangeMember_019c9afa-c16c-71df-8348-4223050c687f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c9afa-c16c-7413-986b-d29a5f15fd9c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c9afa-c16c-71df-8348-4223050c687f" xlink:to="loc_srt_MinimumMember_019c9afa-c16c-7413-986b-d29a5f15fd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c9afa-c16c-713c-b79b-a8ed9185cc2c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c9afa-c16c-71df-8348-4223050c687f" xlink:to="loc_srt_MaximumMember_019c9afa-c16c-713c-b79b-a8ed9185cc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_019c9afa-c16c-71ab-ba0e-d7f3cd9b690f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c9afa-c16c-71df-8348-4223050c687f" xlink:to="loc_srt_WeightedAverageMember_019c9afa-c16c-71ab-ba0e-d7f3cd9b690f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16c-7e9e-885e-ee3c3a2b6f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16c-7e9e-885e-ee3c3a2b6f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16c-7f74-86d6-7555c795df9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16c-7e9e-885e-ee3c3a2b6f3d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16c-7f74-86d6-7555c795df9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputLiquidityMember_019c9afa-c16c-7b22-8d36-30fee007d4e6" xlink:href="ci-20260331.xsd#ci_MeasurementInputLiquidityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16c-7f74-86d6-7555c795df9a" xlink:to="loc_ci_MeasurementInputLiquidityMember_019c9afa-c16c-7b22-8d36-30fee007d4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16c-7a4a-9790-009cee6ed01e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16c-76d5-86f7-80a211ed2faa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16c-7a4a-9790-009cee6ed01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_019c9afa-c16c-7e86-831f-1faec1502a71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16c-7a4a-9790-009cee6ed01e" xlink:to="loc_us-gaap_MarketableSecurities_019c9afa-c16c-7e86-831f-1faec1502a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_019c9afa-c16c-7681-b4da-c2dec8c4e56f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16c-7a4a-9790-009cee6ed01e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_019c9afa-c16c-7681-b4da-c2dec8c4e56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7bf4-9ebe-9b570ea7f304" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7bf4-9ebe-9b570ea7f304" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16d-7386-b9f6-abd5385ddfce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:to="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16d-7386-b9f6-abd5385ddfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16d-7143-9b0a-625d28709c90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019c9afa-c16d-7386-b9f6-abd5385ddfce" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16d-7143-9b0a-625d28709c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_019c9afa-c16d-7b98-9c95-7fdb4d928f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_019c9afa-c16d-7143-9b0a-625d28709c90" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_019c9afa-c16d-7b98-9c95-7fdb4d928f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7d8c-9fff-c58121526aff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7d8c-9fff-c58121526aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7726-899a-d603d0f78a68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7d8c-9fff-c58121526aff" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7726-899a-d603d0f78a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7e7d-8ab0-4aa05b7e64b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7726-899a-d603d0f78a68" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7e7d-8ab0-4aa05b7e64b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16d-79c6-a169-c1788ea13213" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16d-79c6-a169-c1788ea13213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019c9afa-c16d-79c6-a169-c1788ea13213" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_019c9afa-c16d-76d8-8821-055a7f75b07f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_019c9afa-c16d-76d8-8821-055a7f75b07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputEquityPriceVolatilityMember_019c9afa-c16d-71d3-97df-12c8c9396f25" xlink:href="ci-20260331.xsd#ci_MeasurementInputEquityPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:to="loc_ci_MeasurementInputEquityPriceVolatilityMember_019c9afa-c16d-71d3-97df-12c8c9396f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputInterVariableCorrelationAssumptionMember_019c9afa-c16d-7746-ab39-fbfecab89ca7" xlink:href="ci-20260331.xsd#ci_MeasurementInputInterVariableCorrelationAssumptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:to="loc_ci_MeasurementInputInterVariableCorrelationAssumptionMember_019c9afa-c16d-7746-ab39-fbfecab89ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputEntityCreditRiskMember_019c9afa-c16d-7db9-923c-8cfb312b64c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputEntityCreditRiskMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:to="loc_us-gaap_MeasurementInputEntityCreditRiskMember_019c9afa-c16d-7db9-923c-8cfb312b64c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019c9afa-c16d-71cb-823e-a1f333233356" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c9afa-c16d-7fb2-b47c-a71c2aead889" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019c9afa-c16d-71cb-823e-a1f333233356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16d-7ae3-99f8-7e55373d1ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019c9afa-c16d-752f-a761-3e716d1504e4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16d-7ae3-99f8-7e55373d1ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_019c9afa-c16d-7825-8f60-9929e1b7c5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetLiabilityNetMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019c9afa-c16d-7ae3-99f8-7e55373d1ddf" xlink:to="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_019c9afa-c16d-7825-8f60-9929e1b7c5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7623-866d-3620a43391d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7623-866d-3620a43391d0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019c9afa-c16d-7c7d-9ff1-6b3fa4808e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019c9afa-c16d-7c7d-9ff1-6b3fa4808e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16d-7ec7-b53f-9b3f7a62baa1" xlink:href="ci-20260331.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16d-7ec7-b53f-9b3f7a62baa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019c9afa-c16d-795d-ba15-ba19be29ac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019c9afa-c16d-795d-ba15-ba19be29ac8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_019c9afa-c16d-72df-9c76-c17bea0bba2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_019c9afa-c16d-72df-9c76-c17bea0bba2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_019c9afa-c16d-7efc-a23d-ea6c6b902ebe" xlink:href="ci-20260331.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_019c9afa-c16d-7efc-a23d-ea6c6b902ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_019c9afa-c16d-7bb2-a503-1e209853806e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_019c9afa-c16d-7bb2-a503-1e209853806e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_019c9afa-c16d-7030-8192-16b963a786d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_019c9afa-c16d-7bb2-a503-1e209853806e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_019c9afa-c16d-7030-8192-16b963a786d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_019c9afa-c16d-7f3b-acc0-f10a574dc854" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_019c9afa-c16d-7bb2-a503-1e209853806e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_019c9afa-c16d-7f3b-acc0-f10a574dc854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_019c9afa-c16d-7895-b20d-d380953a0a38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_019c9afa-c16d-7bb2-a503-1e209853806e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_019c9afa-c16d-7895-b20d-d380953a0a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_019c9afa-c16d-7055-a103-d9b61d61eb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_019c9afa-c16d-7bb2-a503-1e209853806e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_019c9afa-c16d-7055-a103-d9b61d61eb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_019c9afa-c16d-7ddf-831c-025aafece176" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_019c9afa-c16d-7ddf-831c-025aafece176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_019c9afa-c16d-79ac-8427-16095ce96e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_019c9afa-c16d-7ddf-831c-025aafece176" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_019c9afa-c16d-79ac-8427-16095ce96e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_019c9afa-c16d-759d-8ef1-27365f74fc37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_019c9afa-c16d-7ddf-831c-025aafece176" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_019c9afa-c16d-759d-8ef1-27365f74fc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_019c9afa-c16d-7235-a89c-0af4b0f92edc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_019c9afa-c16d-7ddf-831c-025aafece176" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_019c9afa-c16d-7235-a89c-0af4b0f92edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019c9afa-c16d-79ac-8fa6-789a9b9c1c97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019c9afa-c16d-79ac-8fa6-789a9b9c1c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16d-7b0b-9c56-7c22b119085d" xlink:href="ci-20260331.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019c9afa-c16d-7550-8c9d-703c5aacd7e0" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_019c9afa-c16d-7b0b-9c56-7c22b119085d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss_019c9afa-c16d-72c7-b76b-f01261323f66" xlink:href="ci-20260331.xsd#ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7623-866d-3620a43391d0" xlink:to="loc_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss_019c9afa-c16d-72c7-b76b-f01261323f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_019c9afa-c16d-7f24-9226-550466271b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7623-866d-3620a43391d0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_019c9afa-c16d-7f24-9226-550466271b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_019c9afa-c16d-7b05-94f9-d257e6b98aac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7623-866d-3620a43391d0" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_019c9afa-c16d-7b05-94f9-d257e6b98aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList_019c9afa-c16d-7da4-983a-dba29a862f41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7623-866d-3620a43391d0" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList_019c9afa-c16d-7da4-983a-dba29a862f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsSeparateAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7fe4-87d5-56cecdac0fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7fe4-87d5-56cecdac0fbd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7bbd-8133-8efa298bc608" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7bbd-8133-8efa298bc608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7912-a6ab-6b47eebd46ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7bbd-8133-8efa298bc608" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7912-a6ab-6b47eebd46ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c16d-73cb-a368-6f2600936ada" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7912-a6ab-6b47eebd46ac" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c16d-73cb-a368-6f2600936ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019c9afa-c16d-7748-bd02-41be8ab280a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c16d-73cb-a368-6f2600936ada" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019c9afa-c16d-7748-bd02-41be8ab280a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16d-71fe-a4f4-062c0be9010f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c16d-73cb-a368-6f2600936ada" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16d-71fe-a4f4-062c0be9010f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7740-98bf-798efda37c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_019c9afa-c16d-73cb-a368-6f2600936ada" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7740-98bf-798efda37c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_019c9afa-c16d-71b5-bb30-7e5b5dad9382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7912-a6ab-6b47eebd46ac" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_019c9afa-c16d-71b5-bb30-7e5b5dad9382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_019c9afa-c16d-782d-a8d1-e445e5dd02d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_019c9afa-c16d-782d-a8d1-e445e5dd02d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_019c9afa-c16d-7060-b92e-ad0361faafa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_019c9afa-c16d-782d-a8d1-e445e5dd02d7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_019c9afa-c16d-7060-b92e-ad0361faafa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_019c9afa-c16d-710b-98bd-0a7ee18b1149" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_019c9afa-c16d-7060-b92e-ad0361faafa7" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_019c9afa-c16d-710b-98bd-0a7ee18b1149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryAxis_019c9afa-c16d-7746-a7b2-fef8ea42d6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountAssetCategoryAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryAxis_019c9afa-c16d-7746-a7b2-fef8ea42d6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c16d-74df-9814-87687fd34af4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis_019c9afa-c16d-7746-a7b2-fef8ea42d6ae" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c16d-74df-9814-87687fd34af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountGuaranteedSeparateAccountsMember_019c9afa-c16d-743b-a80f-c4dff0710768" xlink:href="ci-20260331.xsd#ci_SeparateAccountGuaranteedSeparateAccountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c16d-74df-9814-87687fd34af4" xlink:to="loc_ci_SeparateAccountGuaranteedSeparateAccountsMember_019c9afa-c16d-743b-a80f-c4dff0710768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountNonGuaranteedSeparateAccountsMember_019c9afa-c16d-7eaf-9c98-6fc1490fbe3d" xlink:href="ci-20260331.xsd#ci_SeparateAccountNonGuaranteedSeparateAccountsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_019c9afa-c16d-74df-9814-87687fd34af4" xlink:to="loc_ci_SeparateAccountNonGuaranteedSeparateAccountsMember_019c9afa-c16d-7eaf-9c98-6fc1490fbe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_019c9afa-c16d-73a6-8e76-378e0af8da2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_019c9afa-c16d-73a6-8e76-378e0af8da2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_019c9afa-c16d-7e68-bac8-aa2b8c3a818b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_019c9afa-c16d-73a6-8e76-378e0af8da2b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_019c9afa-c16d-7e68-bac8-aa2b8c3a818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsMember_019c9afa-c16d-79e1-bb40-6dfa644d5a24" xlink:href="ci-20260331.xsd#ci_SeparateAccountAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_019c9afa-c16d-7e68-bac8-aa2b8c3a818b" xlink:to="loc_ci_SeparateAccountAssetsMember_019c9afa-c16d-79e1-bb40-6dfa644d5a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16d-7d11-bd11-94ea1f1799f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c9afa-c16d-7514-b7cd-d2c983f7250f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16d-7d11-bd11-94ea1f1799f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_019c9afa-c16d-776f-8d2d-d85c7dcf5761" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeparateAccountAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16d-7d11-bd11-94ea1f1799f4" xlink:to="loc_us-gaap_SeparateAccountAssets_019c9afa-c16d-776f-8d2d-d85c7dcf5761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_019c9afa-c16d-7864-8f4f-ed66657badae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c9afa-c16d-7d11-bd11-94ea1f1799f4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_019c9afa-c16d-7864-8f4f-ed66657badae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7261-aaf4-b234f04455f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7318-8090-4774c2946705" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7261-aaf4-b234f04455f5" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7318-8090-4774c2946705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16d-745c-bb80-449343c32bdc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7318-8090-4774c2946705" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16d-745c-bb80-449343c32bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16d-77a9-bcfa-28ce5d0aab5c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c9afa-c16d-745c-bb80-449343c32bdc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16d-77a9-bcfa-28ce5d0aab5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_VillageMDMember_019c9afa-c16d-711e-9178-42d92ca599c6" xlink:href="ci-20260331.xsd#ci_VillageMDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c9afa-c16d-77a9-bcfa-28ce5d0aab5c" xlink:to="loc_ci_VillageMDMember_019c9afa-c16d-711e-9178-42d92ca599c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7318-8090-4774c2946705" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_019c9afa-c16d-7f00-9346-985916049078" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_019c9afa-c16d-7f00-9346-985916049078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue_019c9afa-c16d-717d-b82f-1bc300dcd859" xlink:href="ci-20260331.xsd#ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:to="loc_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue_019c9afa-c16d-717d-b82f-1bc300dcd859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_019c9afa-c16d-7aa5-be16-5f8401c3a8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_019c9afa-c16d-7aa5-be16-5f8401c3a8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_019c9afa-c16d-7489-b989-63e2d1a93a61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7847-809e-e3aa9da8a3c3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_019c9afa-c16d-7489-b989-63e2d1a93a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7c46-8e3c-bde616c3948b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7a4c-b271-4ad7f122315d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c9afa-c16d-7c46-8e3c-bde616c3948b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7a4c-b271-4ad7f122315d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_019c9afa-c16d-7f12-b015-ce73bdc08203" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7a4c-b271-4ad7f122315d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_019c9afa-c16d-7f12-b015-ce73bdc08203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019c9afa-c16d-78a9-94f9-e100bbf35349" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_019c9afa-c16d-7f12-b015-ce73bdc08203" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019c9afa-c16d-78a9-94f9-e100bbf35349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c16d-727d-9e77-7a0344020dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019c9afa-c16d-78a9-94f9-e100bbf35349" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c16d-727d-9e77-7a0344020dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019c9afa-c16d-79a2-8752-0299d1db443f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c16d-727d-9e77-7a0344020dd0" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019c9afa-c16d-79a2-8752-0299d1db443f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_019c9afa-c16d-7587-9f42-5e49b4cf27e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019c9afa-c16d-727d-9e77-7a0344020dd0" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_019c9afa-c16d-7587-9f42-5e49b4cf27e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7e49-be1c-43a8059416df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7a4c-b271-4ad7f122315d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7e49-be1c-43a8059416df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7ef0-a68c-9009293a7e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c9afa-c16d-7e49-be1c-43a8059416df" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7ef0-a68c-9009293a7e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16d-75fe-b96d-b7e679b72513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7ef0-a68c-9009293a7e3a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019c9afa-c16d-75fe-b96d-b7e679b72513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7a09-9294-27b7d823d3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c9afa-c16d-7ef0-a68c-9009293a7e3a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c9afa-c16d-7a09-9294-27b7d823d3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7619-bd7c-61b9354a53f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019c9afa-c16d-7a4c-b271-4ad7f122315d" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7619-bd7c-61b9354a53f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_019c9afa-c16d-75b1-9ab1-d791cda83b28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7619-bd7c-61b9354a53f9" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_019c9afa-c16d-75b1-9ab1-d791cda83b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_019c9afa-c16d-7f46-8835-603c549baf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019c9afa-c16d-7619-bd7c-61b9354a53f9" xlink:to="loc_us-gaap_LongTermDebtFairValue_019c9afa-c16d-7f46-8835-603c549baf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_019c9afa-c22b-78dc-9b1f-160173c41ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019c9afa-c22b-7e6e-a43a-f5c069c5a78c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_019c9afa-c22b-78dc-9b1f-160173c41ac8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019c9afa-c22b-7e6e-a43a-f5c069c5a78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-c22b-7f68-b294-fcecd583166c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019c9afa-c22b-7e6e-a43a-f5c069c5a78c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-c22b-7f68-b294-fcecd583166c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019c9afa-c22b-7fc4-a543-75fc2d18da59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019c9afa-c22b-7f68-b294-fcecd583166c" xlink:to="loc_us-gaap_EquityComponentDomain_019c9afa-c22b-7fc4-a543-75fc2d18da59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019c9afa-c22b-7fc4-a543-75fc2d18da59" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_019c9afa-c22b-7fd1-8625-47df33e51da4" xlink:href="ci-20260331.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:to="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_019c9afa-c22b-7fd1-8625-47df33e51da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7a9a-a909-fec42bacea3e" xlink:href="ci-20260331.xsd#ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:to="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7a9a-a909-fec42bacea3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_019c9afa-c22b-75b9-a57e-cfa2c0dacb63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7a9a-a909-fec42bacea3e" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_019c9afa-c22b-75b9-a57e-cfa2c0dacb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7ac6-bd0d-e8a504596e00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7a9a-a909-fec42bacea3e" xlink:to="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_019c9afa-c22b-7ac6-bd0d-e8a504596e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_019c9afa-c22b-70ca-865e-05913abe83e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_019c9afa-c22b-70ca-865e-05913abe83e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_019c9afa-c22b-72b6-b755-c115a7eeaff9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c9afa-c22b-75ed-8786-3f2dc5d8709b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_019c9afa-c22b-72b6-b755-c115a7eeaff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019c9afa-c22b-7fd4-afc2-46e1dbb8352f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019c9afa-c22b-7e6e-a43a-f5c069c5a78c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019c9afa-c22b-7fd4-afc2-46e1dbb8352f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c22b-7ed8-af59-9f14a3a78f30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019c9afa-c22b-7fd4-afc2-46e1dbb8352f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c22b-7ed8-af59-9f14a3a78f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_019c9afa-c22b-70d4-b0e1-8c0bc8fc3bde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c22b-7ed8-af59-9f14a3a78f30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_019c9afa-c22b-70d4-b0e1-8c0bc8fc3bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_019c9afa-c22b-7107-b666-5cb9ebd64f84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c22b-7ed8-af59-9f14a3a78f30" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_019c9afa-c22b-7107-b666-5cb9ebd64f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_019c9afa-c22b-7876-bce3-c14d25053315" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019c9afa-c22b-7ed8-af59-9f14a3a78f30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_019c9afa-c22b-7876-bce3-c14d25053315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019c9afa-c22b-7fd4-afc2-46e1dbb8352f" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c22b-7b51-bdf7-729682528df9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c22b-7b51-bdf7-729682528df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_019c9afa-c22b-765d-831b-81218ca12554" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_019c9afa-c22b-765d-831b-81218ca12554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_019c9afa-c22b-7864-ab62-535338bfb7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_019c9afa-c22b-7864-ab62-535338bfb7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-c22b-70b6-a9ea-a733450b157a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019c9afa-c22b-70b6-a9ea-a733450b157a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c22b-74c1-a837-c0d452dba039" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_019c9afa-c22b-7192-bd4d-f80397d16af6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019c9afa-c22b-74c1-a837-c0d452dba039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#StrategicOptimizationProgramDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c9afa-c22b-700d-a5d8-a96750228001" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c22b-7682-90ee-beda48cc5521" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c9afa-c22b-700d-a5d8-a96750228001" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c22b-7682-90ee-beda48cc5521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_019c9afa-c22b-7047-988f-c21c05c5ffe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c22b-7682-90ee-beda48cc5521" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_019c9afa-c22b-7047-988f-c21c05c5ffe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_019c9afa-c22b-78f2-a7aa-e3d82e033761" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_019c9afa-c22b-7047-988f-c21c05c5ffe1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_019c9afa-c22b-78f2-a7aa-e3d82e033761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c22b-773a-9eeb-10a35298dc68" xlink:href="ci-20260331.xsd#ci_EmployeeSeveranceAndOtherRestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_019c9afa-c22b-78f2-a7aa-e3d82e033761" xlink:to="loc_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c22b-773a-9eeb-10a35298dc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_019c9afa-c22b-73b9-be76-3ceecb53233d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c22b-773a-9eeb-10a35298dc68" xlink:to="loc_us-gaap_EmployeeSeveranceMember_019c9afa-c22b-73b9-be76-3ceecb53233d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetImpairmentsMember_019c9afa-c22b-768d-9922-f777da80082c" xlink:href="ci-20260331.xsd#ci_AssetImpairmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c22b-773a-9eeb-10a35298dc68" xlink:to="loc_ci_AssetImpairmentsMember_019c9afa-c22b-768d-9922-f777da80082c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_019c9afa-c22b-7b53-97fc-ffa6c4127c43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EmployeeSeveranceAndOtherRestructuringMember_019c9afa-c22b-773a-9eeb-10a35298dc68" xlink:to="loc_us-gaap_OtherRestructuringMember_019c9afa-c22b-7b53-97fc-ffa6c4127c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingResultsOfCertainNonstrategicBusinessesMember_019c9afa-c22b-7b62-a390-bdd74783e35a" xlink:href="ci-20260331.xsd#ci_OperatingResultsOfCertainNonstrategicBusinessesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_019c9afa-c22b-78f2-a7aa-e3d82e033761" xlink:to="loc_ci_OperatingResultsOfCertainNonstrategicBusinessesMember_019c9afa-c22b-7b62-a390-bdd74783e35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_019c9afa-c22b-7fac-aeff-41754864bf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c22b-7682-90ee-beda48cc5521" xlink:to="loc_us-gaap_RestructuringPlanAxis_019c9afa-c22b-7fac-aeff-41754864bf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c9afa-c22b-74b6-9260-d5524762fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c9afa-c22b-7fac-aeff-41754864bf7a" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c9afa-c22b-74b6-9260-d5524762fc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StrategicOptimizationProgramMember_019c9afa-c22b-7b7f-b885-d102266d22db" xlink:href="ci-20260331.xsd#ci_StrategicOptimizationProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c9afa-c22b-74b6-9260-d5524762fc9d" xlink:to="loc_ci_StrategicOptimizationProgramMember_019c9afa-c22b-7b7f-b885-d102266d22db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c22b-7ff1-a184-d7c9c8ed70bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c22b-7682-90ee-beda48cc5521" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c22b-7ff1-a184-d7c9c8ed70bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c22b-7ff1-a184-d7c9c8ed70bf" xlink:to="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019c9afa-c22b-7078-8339-1aafe58f03b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:to="loc_us-gaap_RestructuringReserve_019c9afa-c22b-7078-8339-1aafe58f03b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c9afa-c22b-7eb1-b67e-020f4bf2604c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:to="loc_us-gaap_RestructuringCharges_019c9afa-c22b-7eb1-b67e-020f4bf2604c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_019c9afa-c22b-75a5-917e-7695813b4112" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:to="loc_us-gaap_PaymentsForRestructuring_019c9afa-c22b-75a5-917e-7695813b4112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019c9afa-c22b-7af8-9782-a991743c101e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c9afa-c22b-7631-8023-155dcfe15c3f" xlink:to="loc_us-gaap_RestructuringReserve_019c9afa-c22b-7af8-9782-a991743c101e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c22b-71ea-bbc4-7653b506cd35" xlink:href="ci-20260331.xsd#ci_RestructuringChargesNetOfTaxExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c22b-7ff1-a184-d7c9c8ed70bf" xlink:to="loc_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c22b-71ea-bbc4-7653b506cd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019c9afa-c22c-7352-9b9b-9df7d921cc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c9afa-c22c-7c2f-83d7-3eee26636afc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019c9afa-c22c-7352-9b9b-9df7d921cc2a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c9afa-c22c-7c2f-83d7-3eee26636afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#ContingenciesandOtherMattersDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c9afa-c2d7-7458-9efa-f3e2e63f1c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:href="ci-20260331.xsd#ci_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c9afa-c2d7-7458-9efa-f3e2e63f1c1a" xlink:to="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-7ec0-96cd-87b39060afc8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-7ec0-96cd-87b39060afc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-7c60-9097-1c22f6fb615c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-7ec0-96cd-87b39060afc8" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-7c60-9097-1c22f6fb615c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RetirementAndLifeInsuranceContractsMember_019c9afa-c2d7-7aef-84e1-dcc658750269" xlink:href="ci-20260331.xsd#ci_RetirementAndLifeInsuranceContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-7c60-9097-1c22f6fb615c" xlink:to="loc_ci_RetirementAndLifeInsuranceContractsMember_019c9afa-c2d7-7aef-84e1-dcc658750269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_019c9afa-c2d7-74f1-9700-ba1a72e6f980" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_019c9afa-c2d7-74f1-9700-ba1a72e6f980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c2d7-724e-b63c-b682ababe2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_019c9afa-c2d7-74f1-9700-ba1a72e6f980" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c2d7-724e-b63c-b682ababe2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeMember_019c9afa-c2d7-76dc-a5cc-183ea95be5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c2d7-724e-b63c-b682ababe2a7" xlink:to="loc_us-gaap_FinancialGuaranteeMember_019c9afa-c2d7-76dc-a5cc-183ea95be5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_019c9afa-c2d7-73a1-a176-b128779aa624" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_019c9afa-c2d7-724e-b63c-b682ababe2a7" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_019c9afa-c2d7-73a1-a176-b128779aa624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7524-ab3b-7c31376f3384" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7524-ab3b-7c31376f3384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-78eb-9be0-b516f15d95d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7524-ab3b-7c31376f3384" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-78eb-9be0-b516f15d95d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRelatedAssessmentsMember_019c9afa-c2d7-70ab-8120-d57b0ede1e66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceRelatedAssessmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-78eb-9be0-b516f15d95d8" xlink:to="loc_us-gaap_InsuranceRelatedAssessmentsMember_019c9afa-c2d7-70ab-8120-d57b0ede1e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LitigationMattersAndRegulatoryMattersMember_019c9afa-c2d7-73e8-8957-c1da35f36c21" xlink:href="ci-20260331.xsd#ci_LitigationMattersAndRegulatoryMattersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-78eb-9be0-b516f15d95d8" xlink:to="loc_ci_LitigationMattersAndRegulatoryMattersMember_019c9afa-c2d7-73e8-8957-c1da35f36c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:href="ci-20260331.xsd#ci_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesTable_019c9afa-c2d7-72c9-b034-29ff9d82fa7f" xlink:to="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_019c9afa-c2d7-7baa-ab16-fbd38a1575fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_019c9afa-c2d7-7baa-ab16-fbd38a1575fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLiquidationProceeds_019c9afa-c2d7-7603-8785-1fee90fe7d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsLiquidationProceeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_us-gaap_GuaranteeObligationsLiquidationProceeds_019c9afa-c2d7-7603-8785-1fee90fe7d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_019c9afa-c2d7-7db6-a85d-5da7e5d36d15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_019c9afa-c2d7-7db6-a85d-5da7e5d36d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_019c9afa-c2d7-7e42-9bcf-74df88ffeb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_019c9afa-c2d7-7e42-9bcf-74df88ffeb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c9afa-c2d7-7d0c-bcc8-ef4b4f216127" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_019c9afa-c2d7-7c99-962f-7e03627ae693" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c9afa-c2d7-7d0c-bcc8-ef4b4f216127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationSpecialItemChargesBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-72f8-a8e1-66759e9cdd57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c2d7-7203-9dcd-b497a7fbdbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-72f8-a8e1-66759e9cdd57" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c2d7-7203-9dcd-b497a7fbdbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-71cc-b2b0-121d517e2b26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c2d7-7203-9dcd-b497a7fbdbd0" xlink:to="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-71cc-b2b0-121d517e2b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-7cc5-b914-b43f2a01821d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-71cc-b2b0-121d517e2b26" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-7cc5-b914-b43f2a01821d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StrategicOptimizationProgramMember_019c9afa-c2d7-7d7e-8103-6043b7f6e581" xlink:href="ci-20260331.xsd#ci_StrategicOptimizationProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-7cc5-b914-b43f2a01821d" xlink:to="loc_ci_StrategicOptimizationProgramMember_019c9afa-c2d7-7d7e-8103-6043b7f6e581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanMember_019c9afa-c2d7-796b-a274-5f7644fadbd8" xlink:href="ci-20260331.xsd#ci_OrganizationalEfficiencyPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-7cc5-b914-b43f2a01821d" xlink:to="loc_ci_OrganizationalEfficiencyPlanMember_019c9afa-c2d7-796b-a274-5f7644fadbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c2d7-7431-8a40-52fb2d69cecb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c9afa-c2d7-7203-9dcd-b497a7fbdbd0" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c2d7-7431-8a40-52fb2d69cecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:href="ci-20260331.xsd#ci_SpecialItemsBeforeTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c2d7-7431-8a40-52fb2d69cecb" xlink:to="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-7c28-b63b-b5af2e62da95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-7c28-b63b-b5af2e62da95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-71fa-917b-87a34e9b2fa9" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-71fa-917b-87a34e9b2fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c2d7-779b-ab70-a37aae98aeea" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitTaxMatters"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c2d7-779b-ab70-a37aae98aeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7145-8fb6-652caedddd0f" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7145-8fb6-652caedddd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-7da2-af43-a71b06d84da3" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-7da2-af43-a71b06d84da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7647-8256-9f966cdb5a70" xlink:href="ci-20260331.xsd#ci_SpecialItemsIncreaseDecreaseToRevenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7647-8256-9f966cdb5a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-7f2c-8097-3685237ab577" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-7f2c-8097-3685237ab577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c2d7-7df8-a554-97694996623e" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c2d7-7df8-a554-97694996623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-75ff-9550-021135450cc4" xlink:href="ci-20260331.xsd#ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7263-925c-1156d6a9f0ac" xlink:to="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity_019c9afa-c2d7-75ff-9550-021135450cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:href="ci-20260331.xsd#ci_SpecialItemsAfterTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c9afa-c2d7-7431-8a40-52fb2d69cecb" xlink:to="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c2d7-7e7b-b98c-f98350c70487" xlink:href="ci-20260331.xsd#ci_RestructuringChargesNetOfTaxExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_RestructuringChargesNetOfTaxExpense_019c9afa-c2d7-7e7b-b98c-f98350c70487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCostsAfterTax_019c9afa-c2d7-789d-8827-816d2acc1d7e" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCostsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_TransactionRelatedCostsAfterTax_019c9afa-c2d7-789d-8827-816d2acc1d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax_019c9afa-c2d7-774e-94c7-131224f70a04" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitTaxMattersAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax_019c9afa-c2d7-774e-94c7-131224f70a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_019c9afa-c2d7-77e0-afae-444ca7a7e5f1" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_019c9afa-c2d7-77e0-afae-444ca7a7e5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation_019c9afa-c2d7-701b-a5d4-6b0c63f287cb" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitAfterTaxLitigation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation_019c9afa-c2d7-701b-a5d4-6b0c63f287cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax_019c9afa-c2d7-7012-8657-d874c67595f8" xlink:href="ci-20260331.xsd#ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax_019c9afa-c2d7-7012-8657-d874c67595f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_019c9afa-c2d7-7f7e-bca7-e33322b37a75" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_019c9afa-c2d7-7f7e-bca7-e33322b37a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_019c9afa-c2d7-7987-aec6-b28e6cf72b6c" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_019c9afa-c2d7-7987-aec6-b28e6cf72b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-761f-a700-9762fe856e02" xlink:href="ci-20260331.xsd#ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_019c9afa-c2d7-701b-b788-639f52931e6b" xlink:to="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity_019c9afa-c2d7-761f-a700-9762fe856e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationSummarizedSegmentFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-7e8e-950c-8ba65a601d90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-7e8e-950c-8ba65a601d90" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-7c20-b018-850cd9e88ca8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:to="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-7c20-b018-850cd9e88ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7481-969c-bafe72ae0cb5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-7c20-b018-850cd9e88ca8" xlink:to="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7481-969c-bafe72ae0cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_019c9afa-c2d7-7332-9162-e62cfacbe133" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7481-969c-bafe72ae0cb5" xlink:to="loc_us-gaap_OperatingSegmentsMember_019c9afa-c2d7-7332-9162-e62cfacbe133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-7f16-b731-d2b25d4c3c43" xlink:href="ci-20260331.xsd#ci_CorporateAndEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7481-969c-bafe72ae0cb5" xlink:to="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-7f16-b731-d2b25d4c3c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_019c9afa-c2d7-7983-85b2-5c242828a2df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-7f16-b731-d2b25d4c3c43" xlink:to="loc_us-gaap_CorporateNonSegmentMember_019c9afa-c2d7-7983-85b2-5c242828a2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_019c9afa-c2d7-75d4-8ae4-8b7e94dac30a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-7f16-b731-d2b25d4c3c43" xlink:to="loc_us-gaap_IntersegmentEliminationMember_019c9afa-c2d7-75d4-8ae4-8b7e94dac30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7d45-8168-6cdcc795c618" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7d45-8168-6cdcc795c618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c2d7-796d-a5c2-b636953d96d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7d45-8168-6cdcc795c618" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c2d7-796d-a5c2-b636953d96d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_019c9afa-c2d7-7f07-8744-59e1b989cb07" xlink:href="ci-20260331.xsd#ci_EvernorthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-796d-a5c2-b636953d96d3" xlink:to="loc_ci_EvernorthMember_019c9afa-c2d7-7f07-8744-59e1b989cb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c2d7-7e29-82c5-3e0e3760975a" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-796d-a5c2-b636953d96d3" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c2d7-7e29-82c5-3e0e3760975a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c2d7-7e07-aae0-40441240d2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-796d-a5c2-b636953d96d3" xlink:to="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c2d7-7e07-aae0-40441240d2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-78b2-8f13-f028b7148c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:to="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-78b2-8f13-f028b7148c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-73b0-afe7-1dac786a2f43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c9afa-c2d7-78b2-8f13-f028b7148c8d" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-73b0-afe7-1dac786a2f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StrategicOptimizationProgramMember_019c9afa-c2d7-70cc-9c51-7efd1aa4e6ab" xlink:href="ci-20260331.xsd#ci_StrategicOptimizationProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-73b0-afe7-1dac786a2f43" xlink:to="loc_ci_StrategicOptimizationProgramMember_019c9afa-c2d7-70cc-9c51-7efd1aa4e6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanMember_019c9afa-c2d7-7a24-8bd6-3c38a476cace" xlink:href="ci-20260331.xsd#ci_OrganizationalEfficiencyPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c9afa-c2d7-73b0-afe7-1dac786a2f43" xlink:to="loc_ci_OrganizationalEfficiencyPlanMember_019c9afa-c2d7-7a24-8bd6-3c38a476cace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019c9afa-c2d7-7db9-b6e5-ca221137c76f" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-7168-b71d-8ebf9707de6b" xlink:href="ci-20260331.xsd#ci_NonInvestmentRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-7168-b71d-8ebf9707de6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_019c9afa-c2d7-7571-8aac-a3977bc4b526" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_NetInvestmentIncome_019c9afa-c2d7-7571-8aac-a3977bc4b526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019c9afa-c2d7-76a2-a2b3-fda7f331e746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_Revenues_019c9afa-c2d7-76a2-a2b3-fda7f331e746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainsLossesEquityMethodInvestments_019c9afa-c2d7-7030-b551-a86abbfcaea9" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainsLossesEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_NetInvestmentGainsLossesEquityMethodInvestments_019c9afa-c2d7-7030-b551-a86abbfcaea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7ddc-93ed-29a8f3ca2927" xlink:href="ci-20260331.xsd#ci_SpecialItemsIncreaseDecreaseToRevenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7ddc-93ed-29a8f3ca2927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SegmentRevenues_019c9afa-c2d7-7246-bf84-8b94f24f56be" xlink:href="ci-20260331.xsd#ci_SegmentRevenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_SegmentRevenues_019c9afa-c2d7-7246-bf84-8b94f24f56be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-c2d7-78db-acab-1b3366791e97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019c9afa-c2d7-78db-acab-1b3366791e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-c2d7-7b94-b8ed-04fbb1ae5b23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_019c9afa-c2d7-7b94-b8ed-04fbb1ae5b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric_019c9afa-c2d7-7f94-83cf-420d9757d967" xlink:href="ci-20260331.xsd#ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric_019c9afa-c2d7-7f94-83cf-420d9757d967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-c2d7-7bb4-acc1-69f4116b0099" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019c9afa-c2d7-7bb4-acc1-69f4116b0099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax_019c9afa-c2d7-7785-bdf9-ffe9edd509ae" xlink:href="ci-20260331.xsd#ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax_019c9afa-c2d7-7785-bdf9-ffe9edd509ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7b0d-9c6d-fab12180aff9" xlink:href="ci-20260331.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7b0d-9c6d-fab12180aff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7209-91c6-688c1ab6c044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-7209-91c6-688c1ab6c044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:href="ci-20260331.xsd#ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_019c9afa-c2d7-74d3-90e7-09cef4501354" xlink:href="ci-20260331.xsd#ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:to="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_019c9afa-c2d7-74d3-90e7-09cef4501354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries_019c9afa-c2d7-7125-8357-0fa472f5cc94" xlink:href="ci-20260331.xsd#ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:to="loc_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries_019c9afa-c2d7-7125-8357-0fa472f5cc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-c2d7-7966-8ef9-44c6cab452db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019c9afa-c2d7-7966-8ef9-44c6cab452db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:href="ci-20260331.xsd#ci_SpecialItemsBeforeTaxAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:to="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-7499-ab28-8f11fc1b8eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_us-gaap_RestructuringCharges_019c9afa-c2d7-7499-ab28-8f11fc1b8eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-7044-b18f-d9a6e731f82b" xlink:href="ci-20260331.xsd#ci_TransactionRelatedCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_TransactionRelatedCosts_019c9afa-c2d7-7044-b18f-d9a6e731f82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-732a-a704-f6523cef3e3a" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_019c9afa-c2d7-732a-a704-f6523cef3e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7b4c-879f-211846d53fb1" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_019c9afa-c2d7-7b4c-879f-211846d53fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c2d7-71be-a50f-0fcd0ac9e6ac" xlink:href="ci-20260331.xsd#ci_SpecialItemChargeBenefitTaxMatters"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMatters_019c9afa-c2d7-71be-a50f-0fcd0ac9e6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7ed3-baa9-51018a3454b8" xlink:href="ci-20260331.xsd#ci_SpecialItemsIncreaseDecreaseToRevenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemsIncreaseDecreaseToRevenues_019c9afa-c2d7-7ed3-baa9-51018a3454b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-7544-bca8-1c0aee257a68" xlink:href="ci-20260331.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_019c9afa-c2d7-7544-bca8-1c0aee257a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c2d7-7b4d-a2bb-902678a7b93e" xlink:href="ci-20260331.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_019c9afa-c2d7-7958-9bc5-53dbcf3adff4" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_019c9afa-c2d7-7b4d-a2bb-902678a7b93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-71d1-94e5-8ccf9ad900e4" xlink:href="ci-20260331.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_019c9afa-c2d7-7514-ab17-0badcd9ded80" xlink:to="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019c9afa-c2d7-71d1-94e5-8ccf9ad900e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019c9afa-c2d7-7ea8-a147-b35642d9d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019c9afa-c2d7-72ec-84a6-1e6a542700b8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019c9afa-c2d7-7ea8-a147-b35642d9d6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationRevenuefromExternalCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-740b-a99d-e85d026b6c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-740b-a99d-e85d026b6c91" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-748b-8ef3-925db73be66b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:to="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-748b-8ef3-925db73be66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7ec0-a906-56fce355346e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_019c9afa-c2d7-748b-8ef3-925db73be66b" xlink:to="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7ec0-a906-56fce355346e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_019c9afa-c2d7-75ff-95db-6d6b6c5200c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7ec0-a906-56fce355346e" xlink:to="loc_us-gaap_OperatingSegmentsMember_019c9afa-c2d7-75ff-95db-6d6b6c5200c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-78ee-b176-043ec95d7daf" xlink:href="ci-20260331.xsd#ci_CorporateAndEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_019c9afa-c2d7-7ec0-a906-56fce355346e" xlink:to="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-78ee-b176-043ec95d7daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_019c9afa-c2d7-7687-b134-1b4c984df516" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-78ee-b176-043ec95d7daf" xlink:to="loc_us-gaap_CorporateNonSegmentMember_019c9afa-c2d7-7687-b134-1b4c984df516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_019c9afa-c2d7-70f3-b503-43a3697374b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CorporateAndEliminationsMember_019c9afa-c2d7-78ee-b176-043ec95d7daf" xlink:to="loc_us-gaap_IntersegmentEliminationMember_019c9afa-c2d7-70f3-b503-43a3697374b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7333-9804-dc52d78fd08a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7333-9804-dc52d78fd08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7eaa-8215-6c9656a1776c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-7333-9804-dc52d78fd08a" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7eaa-8215-6c9656a1776c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_019c9afa-c2d7-7a40-baa2-212d94ab3922" xlink:href="ci-20260331.xsd#ci_EvernorthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7eaa-8215-6c9656a1776c" xlink:to="loc_ci_EvernorthMember_019c9afa-c2d7-7a40-baa2-212d94ab3922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_019c9afa-c2d7-79d1-831b-946e3c56f3b0" xlink:href="ci-20260331.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7eaa-8215-6c9656a1776c" xlink:to="loc_ci_CignaHealthcareMember_019c9afa-c2d7-79d1-831b-946e3c56f3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c2d7-7989-931d-a541cd4a66a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7eaa-8215-6c9656a1776c" xlink:to="loc_us-gaap_AllOtherSegmentsMember_019c9afa-c2d7-7989-931d-a541cd4a66a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_019c9afa-c2d7-7ab0-bae8-0373eb4009bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:to="loc_us-gaap_SubsegmentsAxis_019c9afa-c2d7-7ab0-bae8-0373eb4009bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_019c9afa-c2d7-7406-88d5-15ad0b4bea55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_019c9afa-c2d7-7ab0-bae8-0373eb4009bd" xlink:to="loc_us-gaap_SubsegmentsDomain_019c9afa-c2d7-7406-88d5-15ad0b4bea55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnitedStatesHealthcareMember_019c9afa-c2d7-75bc-aae7-fc466244a1e6" xlink:href="ci-20260331.xsd#ci_UnitedStatesHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_019c9afa-c2d7-7406-88d5-15ad0b4bea55" xlink:to="loc_ci_UnitedStatesHealthcareMember_019c9afa-c2d7-75bc-aae7-fc466244a1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalHealthMember_019c9afa-c2d7-7875-bb79-e334b1e1ed5c" xlink:href="ci-20260331.xsd#ci_InternationalHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_019c9afa-c2d7-7406-88d5-15ad0b4bea55" xlink:to="loc_ci_InternationalHealthMember_019c9afa-c2d7-7875-bb79-e334b1e1ed5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-797c-a478-6af969c76ebe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:to="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-797c-a478-6af969c76ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-79c8-8604-527add133736" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c9afa-c2d7-797c-a478-6af969c76ebe" xlink:to="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-79c8-8604-527add133736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019c9afa-c2d7-777e-8ee6-66a75d77c3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-79c8-8604-527add133736" xlink:to="loc_us-gaap_ProductMember_019c9afa-c2d7-777e-8ee6-66a75d77c3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetworkPharmacyMember_019c9afa-c2d7-79fa-a9d5-cd8fac828a24" xlink:href="ci-20260331.xsd#ci_NetworkPharmacyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_019c9afa-c2d7-777e-8ee6-66a75d77c3ff" xlink:to="loc_ci_NetworkPharmacyMember_019c9afa-c2d7-79fa-a9d5-cd8fac828a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HomeDeliveryAndSpecialtyMember_019c9afa-c2d7-7cb5-9269-d98ef58e1f25" xlink:href="ci-20260331.xsd#ci_HomeDeliveryAndSpecialtyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_019c9afa-c2d7-777e-8ee6-66a75d77c3ff" xlink:to="loc_ci_HomeDeliveryAndSpecialtyMember_019c9afa-c2d7-7cb5-9269-d98ef58e1f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherPharmacyMember_019c9afa-c2d7-77b2-8b0e-2daaceb22e39" xlink:href="ci-20260331.xsd#ci_OtherPharmacyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_019c9afa-c2d7-777e-8ee6-66a75d77c3ff" xlink:to="loc_ci_OtherPharmacyMember_019c9afa-c2d7-77b2-8b0e-2daaceb22e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-79c8-8604-527add133736" xlink:to="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmployerInsuredMember_019c9afa-c2d7-7df8-918e-c967c87255c5" xlink:href="ci-20260331.xsd#ci_EmployerInsuredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:to="loc_ci_EmployerInsuredMember_019c9afa-c2d7-7df8-918e-c967c87255c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageMember_019c9afa-c2d7-7a72-a5d4-9ef9b9ca567d" xlink:href="ci-20260331.xsd#ci_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:to="loc_ci_MedicareAdvantageMember_019c9afa-c2d7-7a72-a5d4-9ef9b9ca567d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StopLossMember_019c9afa-c2d7-7fb3-86ab-73f25c2db972" xlink:href="ci-20260331.xsd#ci_StopLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:to="loc_ci_StopLossMember_019c9afa-c2d7-7fb3-86ab-73f25c2db972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndividualAndFamilyPlansMember_019c9afa-c2d7-79e0-b254-6d7718381d96" xlink:href="ci-20260331.xsd#ci_IndividualAndFamilyPlansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:to="loc_ci_IndividualAndFamilyPlansMember_019c9afa-c2d7-79e0-b254-6d7718381d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherHealthcareMember_019c9afa-c2d7-71ce-be03-3628ccdcd6e3" xlink:href="ci-20260331.xsd#ci_OtherHealthcareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareMember_019c9afa-c2d7-7360-b6c9-28ac5ce573e3" xlink:to="loc_ci_OtherHealthcareMember_019c9afa-c2d7-71ce-be03-3628ccdcd6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_019c9afa-c2d7-7353-979a-3005e2490689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c9afa-c2d7-79c8-8604-527add133736" xlink:to="loc_us-gaap_ServiceMember_019c9afa-c2d7-7353-979a-3005e2490689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ServiceFeesAndOtherRevenuesMember_019c9afa-c2d7-779e-babc-d5497da800e1" xlink:href="ci-20260331.xsd#ci_ServiceFeesAndOtherRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_019c9afa-c2d7-7353-979a-3005e2490689" xlink:to="loc_ci_ServiceFeesAndOtherRevenuesMember_019c9afa-c2d7-779e-babc-d5497da800e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ServiceFeesMember_019c9afa-c2d7-7238-a8ff-19ea7a24ea5d" xlink:href="ci-20260331.xsd#ci_ServiceFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ServiceFeesAndOtherRevenuesMember_019c9afa-c2d7-779e-babc-d5497da800e1" xlink:to="loc_ci_ServiceFeesMember_019c9afa-c2d7-7238-a8ff-19ea7a24ea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_019c9afa-c2d7-7c5b-8d58-c6b107fc3ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ServiceFeesAndOtherRevenuesMember_019c9afa-c2d7-779e-babc-d5497da800e1" xlink:to="loc_us-gaap_ServiceOtherMember_019c9afa-c2d7-7c5b-8d58-c6b107fc3ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c2d7-78cf-8e2e-5f58968d41df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_019c9afa-c2d7-739e-a068-22671b57d361" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c2d7-78cf-8e2e-5f58968d41df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-c2d7-7fa3-bca1-706eeab1584e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c2d7-78cf-8e2e-5f58968d41df" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c9afa-c2d7-7fa3-bca1-706eeab1584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_019c9afa-c2d7-7d8f-be47-696a0b6252b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c2d7-78cf-8e2e-5f58968d41df" xlink:to="loc_us-gaap_PremiumsEarnedNet_019c9afa-c2d7-7d8f-be47-696a0b6252b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-7190-aaee-2ccc01ed1f4f" xlink:href="ci-20260331.xsd#ci_NonInvestmentRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_019c9afa-c2d7-78cf-8e2e-5f58968d41df" xlink:to="loc_ci_NonInvestmentRevenue_019c9afa-c2d7-7190-aaee-2ccc01ed1f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails" xlink:type="simple" xlink:href="ci-20260331.xsd#SegmentInformationFinancialandPerformanceGuaranteesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-77fd-9429-a5d7ed0c6078" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_019c9afa-c2d7-70d4-9eb5-55733f03c54f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c9afa-c2d7-77fd-9429-a5d7ed0c6078" xlink:to="loc_us-gaap_LossContingenciesTable_019c9afa-c2d7-70d4-9eb5-55733f03c54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-77f2-a67f-204ed1ec74ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019c9afa-c2d7-70d4-9eb5-55733f03c54f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-77f2-a67f-204ed1ec74ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7b3a-b12f-99e80f04b1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c9afa-c2d7-77f2-a67f-204ed1ec74ae" xlink:to="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7b3a-b12f-99e80f04b1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_019c9afa-c2d7-778e-8570-8d9038ddb856" xlink:href="ci-20260331.xsd#ci_EvernorthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c9afa-c2d7-7b3a-b12f-99e80f04b1ba" xlink:to="loc_ci_EvernorthMember_019c9afa-c2d7-778e-8570-8d9038ddb856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7ccd-b188-633ce98914a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019c9afa-c2d7-70d4-9eb5-55733f03c54f" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7ccd-b188-633ce98914a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-7717-bfed-399fb3ca218e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9afa-c2d7-7ccd-b188-633ce98914a0" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-7717-bfed-399fb3ca218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMember_019c9afa-c2d7-7d7a-a9b2-587f213e14c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_019c9afa-c2d7-7717-bfed-399fb3ca218e" xlink:to="loc_us-gaap_GuaranteeObligationsMember_019c9afa-c2d7-7d7a-a9b2-587f213e14c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_019c9afa-c2d7-76cc-8f4d-47d6414b42ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019c9afa-c2d7-70d4-9eb5-55733f03c54f" xlink:to="loc_us-gaap_LossContingenciesLineItems_019c9afa-c2d7-76cc-8f4d-47d6414b42ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c9afa-c2d7-7582-96f7-5b5a8a593e29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c9afa-c2d7-76cc-8f4d-47d6414b42ed" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c9afa-c2d7-7582-96f7-5b5a8a593e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember" xlink:href="ci-20260331.xsd#ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember" xlink:href="ci-20260331.xsd#ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember" xlink:href="ci-20260331.xsd#ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TradingArrangementStockOptionsMember" xlink:href="ci-20260331.xsd#ci_TradingArrangementStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_ci_TradingArrangementStockOptionsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DavidCordaniMember" xlink:href="ci-20260331.xsd#ci_DavidCordaniMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ci_DavidCordaniMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ci-20260331_g1.jpg
<TEXT>
begin 644 ci-20260331_g1.jpg
M_]C_X0U717AI9@  34T *@    @ # $   ,    ! X0   $!  ,    ! 5P
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ 6XV
M   G$ !;C8   "<0061O8F4@4&AO=&]S:&]P(#(T+C$@*$UA8VEN=&]S:"D
M,C R,SHP-#HP-" Q,SHQ,3HQ,       !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   #P* #  0    !   !F          & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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M @4 '6-I9VYA9W)O=7!?;&]G;U]C;VQO<E]P;W-?<F=B #A"24T$)0
M$/OV!AQI$41.NTUJ)PV%.;LX0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q @L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$1       $     (   )
M   "0      X0DE-!!X       0     .$))300:      -]    !@
M       !F    \     D &, :0!G &X 80!G '( ;P!U '  7P!L &\ 9P!O
M %\ 8P!O &P ;P!R %\ < !O ', 7P!R &< 8@!? #8 ,  P '  < !I
M 0                         !              /    !F
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !F     !29VAT
M;&]N9P   \     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M    5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   9@     4F=H=&QO;F<   /      W5R
M;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53
M;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /
M15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N
M9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO
M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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MO5;\C)P,XC(Z9ELL]+.8&[*VPYU=AMJVU^V-CF6_X1,G.M*U/\AQ,&?.,=1
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M>OU\'J_2;K?\2[W8NZWJH&:X;G15NKW1+F;W6-N?[_\ #?\ @*TQT;KO2/\
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MJ22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]D .$))300A      !7     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #,    ! #A"24T$!@
M    !P (     0$ _^$0W&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M1T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M          #VU@ !     -,M2% @(
M                                $6-P<G0   %0    ,V1E<V,   &$
M    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H
M  (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U
M960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M)'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\
M   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R
M9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M        $G-21T(@245#-C$Y-C8M,BXQ
M                                      !865H@        \U$  0
M  $6S%A96B                      6%E:(        &^B   X]0   Y!8
M65H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M       6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT
M=' Z+R]W=W<N:65C+F-H
M                     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V
M,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                      !D97-C         "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03
M"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                   "CP    )S:6<@     $-25"!C=7)V        !
M   %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M
M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L
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M<: 7<4XK\Y0SS$<*E-J-E5B(Y]S[%KKEOZI!FWF5S_I2"A_FRD^@%>'# O\
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M]??1'V[Y?ON5>1.4^7-S,9W&QV^&&0QDLA>- K:20"148-!CI*QU.3UN3_\
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M&2+#U<]9ZEU4N&KI:?(D<G71J0"18B?D[=3L_,6W75:0L_AO_I7[37Y*:/\
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MP^,I$DJ:[(5U3(J11(I9V( 'O/S<-PL=IL;O<]SNXX-O@C+R2.0J(BBK,S'
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MK^7Y#CUQ"Y@_O%_O![M(YVE=DVJ(' @M#*:8(#-=2SAC04)"(,F@';1/X?\
MFT_,G%U(GK-S;)W%$-/^19G8>%@ICI#7!?;ZX*L]98$_N\6%OS=B+W*YJC8,
M]S"XKP:-1_QP+_AKT3[;_>$?>2L)EENM[VR]CK\$UA"J_P#9OX#?\;\L4Z.K
MT[_.HQU95TN,[WZI_A,$S(D^[>M:V:MI*9W*(9)]G[@G>MCHXKL[R196IF"<
M+"Y'(LVOW81V$>\[9I6OQQ&H^TQMFGV.Q_H]9.^V_P#>:V=S<6]A[K\@_3QL
M0&N]M=G1232K6<[%P@^(E+J1Z86-SU<OU7W'UCW;MF+>'5F],+O3 .ZQ356*
MJ&^YQM4T2R_89G%U*4^5PN1$3!S3UD,,P4AM-B"95V[==OW:W%UMUTDL/J.(
M^3 @%3\F -,]=*.0?<CD;W0V*/F/D+F:UW/:6(#-$W=&Y&KPYHF"RPR4()CE
M1'H0:4()$V_LPZ&_71^GOW6C6AIQZUR/YTO5DN)[.ZO[AI*=AC]Y;3JMEY>6
M*/\ :3/;0KYLC13U<G]FIRF%W"L48OZH\<; :23!/NOMQCW';]T5>R6(H?\
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MW%)./W1<_P#5L],Q_&O7V,[^^+O2WKWOW7NOCE_SB_\ MZE_,$_Q^6'=%O\
MT,\G[[0^R_\ TZ7V\_Z5%M_U:7I%)\;=;87_  B[_P"99_/W_P /KX^?^Z#M
MGWB-]]S_ )*GM[_S0O/^/P=/0<&^WK=R]X+]/]:O'_"N4C_AJW;O_BV/47_O
M&=K_ /%?>57W/"/]=JX%<_NBX_ZN6_34WP=?,O5F1E=&9'1E9'4E65E(*LK
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MD<,4*:(45$J30  5.3@8R34^IR>DEAMNW;3;"SVNP@MK0,S:(D6--3L6=M*
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MW3GJ^F(X^%!%"#CR#O-3.<DU&,'/53/Z+T!66_X6,?S&YJLO@_C]\)\=0>-
MM+E=D]ZYFK$H!\C-6T?R"P,+1L?TK]N"OY+>S^'[EWMLL8%QS%OCR>966U4?
ML-H__'CUKQS_  CIXP__  L>^?D--&NX/C7\/LG5B9C+/AL+W3@J9X"RE8XZ
M6M[BW#+%,J @N9G!-B%%K%F;[EGM\SDV_-&\I'Y!FMG/[1;(/Y=>\<_PCHQ^
MQ?\ A:#V#2U$:=F? ;9V=I'ETRU&Q>_<WM.II('FI1YXZ//]7;TBKY::G6;]
MDSTRS.R#R1!6+AF_^Y%M[J3M?N#-&P'"6T60$T.*K/%I%:9HU!7!QU[Q_5>K
M$>F_^%@7\OC><E)0=O\ 3?R3Z5KIT1JC*4^"V9V9LZB?4%FCER> W5BMX3$:
M@R&/ .& :^DA5>-]Z^YG[C6(:39=YVR^C'!2TD$A^85HVC^1K*/*E>(N)U)H
M01U=O\9OYMO\M[Y?5.-Q70GR_P"GMS;GRS118W8>XLY-UKV-D*B1"QIL9U]V
M91[0WAEY8=!$AI**=%-CJTLI,%\T>T'N9R<))>8.3;V*T3+2H@GA ]3- 9(U
M!\M3 GIP.IX'JQ>X]QM4=6Z]?WNO#KW7O?NO=>]^Z]U[W[KW7O?NO=%'^:'S
M>^.O\O\ Z@I>]?D_NS*;,ZVJ]Y8;84&7Q&U=Q[RJSN;<%#F<EBZ,XC:V.RF2
M6*>DP-4QF,?BC* $@L+B[DCD3F7W#WIM@Y5LTGW,0-*5:1(QH0J&.J1E7!=<
M5J:X\^M,P45)QU5-_P!!1/\ )L_[R"WW_P"B"[G_ /L,]R[_ ,"I[U_],Y;_
M /97;?\ 6WJGBQ_Q=>_Z"B?Y-G_>06^__1!=S_\ V&>_?\"I[U_],Y;_ /97
M;?\ 6WKWBQ_Q=>_Z"B?Y-G_>06^__1!=S_\ V&>_?\"I[U_],Y;_ /97;?\
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M:&\YIV6(#X9A(?\ FU63_GWK(K[I?+<G-'WCO:2PCCU"#=DO#Z!;!6O:D_;
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M0@@@D$&_O%H@@E2"".G>LE_>NO=>]^Z]U[W[KW6KQ_PKE_[=6;=_\6QZB_\
M>,[8]Y5?<\_Z>U<?]*BX_P"KEOTU-\!Z^9;[ZC](^O>_=>Z][]U[KWOW7NOL
MW_RNO^W9O\NO_P 44^(__O@.OO?$SW6_Z>C[D_\ 2_W#_M+FZ,!P'V='J]@'
MK?7O?NO=>]^Z]U[W[KW7O?NO==7'O51U[HO/R:^6/QQ^&_660[?^3?;VSNG]
M@T+/!%E=U9 I7YW(I"]0,'M';E#%6;EWGN.6GC:1,=BJ2LK7C1G$1168"/E?
ME'F7G7=(]FY6V>>]W!LZ8QA16FN1S1(TK0:Y&5*D"M2.M,P45)QUI2?S O\
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MQ"PTFX*;"3232+!3-5R$%L&O<G[KG/W(XNMRV51O.P)4EX%(N(U J3);U9B
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MGEM;F,I<1L58'B"#0@CKYI=]V+=.6M[W7EW>[![;>;*X>&:)\-'+&Q1U/S#
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M! /M/<VT%W#+;7<"2VTBE71U#*RL*,K*:AE()!!K4$BG7A]M.OH__P#">O\
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M4.FNH-Z][=C[;ZQV#C7R&?W'6+#Y&63[#$8V,ALEG<S/$K_:8C%4MY9I#R0
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M>/I(XX(0S-8R/([]:N4^4M@Y)V.RY=Y:VY+;:X!A1\3,?BDD;B\CT&IFR?L
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MNKZZLF>HJZVMJZAY*BJJZJHD9Y)'9G=V+,23[ZKQ1)"D<<486)5  & H
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M:7\#6U[;1S0'BKJ&'Y5KGT/$<1T'N9^4^5^==IGV+F[EZSW+9Y?BAN84F2O
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MC<D2)K>]N]&=L]$;A?;':^QLWL[)%I11S9"F$F(R\4#:):G YZE:?#9ND4D
MR4L\JJ3I;2UQ[@?<]GW/9KCZ;<[1XGS2O!OFI^%OF03^1KUQ8]Q?:OW ]J-X
M.P\_\JW6VWM6\-I%K%,%-"T$Z:H9T]6B=@#AJ,".@E_WW^/^V^OLLJ,]1[0\
M?+KUC_R(@^_5Z]0Y^71WOY;\,LWS8Z'2**25QF]RS%8T9V$5/L/=<\\A502(
MX88F=S]%5238 ^Q=R'GFS9J?Q.?R$;D_RZRB^Y;%)+]Y[VH6-&9A=7)P*FBV
M%TS'@<*H+'T )-*5&X0/K^./Z?[Q?\'CWE%2E/3KZ-\8I_JX]=D7%O?NO==
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M]M_O/_&O?-L#I3UR][Z]U[W[KW7O?NO=>]^Z]UID?\+-/^R9OAA_XG7?W_O
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M?+U.IT :2I<*S %8^:?WS]G6UY_Y;WF-:)=;6(V.>YX)I*G[=$L:T]!\ZE7
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M[$<S7.\;#:3W/M9?3%K:XH6^E=R3]%<,*Z60#]&1](GC%03(DBK7E_OOJ/\
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MQ.76IX]7[>\?.G.O>_=>ZTR/^%FG_9,WPP_\3KO[_P!X"#WFS]R;_E:>=_\
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ML<4DF@112.@CY5Y1YBYWWFWV#EC:I;O<I/PJ.U%J 9)'-$CC4D:G<A02!6I
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MA6JW!F\1@J9M6FIS&2HL9 UFCC:TU;-!&UI)D7@\%E'Y'MJ6:&!2\\RHOJQ
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M@]"WUSWYW3U'4PU'6O:6^=FB%T8T.'W%D8L-4>.Y1*[!232X7(P(22(YZ>1
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M\O67-7)6^V^X[#<#MEB:H#4!9)%-'BE2H#Q2*DB'#*#TNQS]/Z?X?[#^E_\
M#VM^?0K'2-W?UQU]V! E-OS8>S-[4\2-'%3[NVO@]RPQQO?5&D69H:V-4:YN
M +&Y]I+JPL;Y0M[9Q3 ?QHK_ /'@>@SS%R7R=S=$L/-?*>V[I$JD!;NU@N0!
MZ 3(X -3BE.@9E^&/Q.EDDE?XZ=/AI&9V";%P,2:F)8A(H:-8HE!/"JH"C@
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MOKV6Q]K8V*,PU1S[E2H+STHR6K?Z';&A9:/< N5BAJO_ !]?];_D=OQ_O/\
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MGJ[,Q_:37K!+F'FSF?FV];<N:N8[[<MP/&6ZN)9Y#_MI6<_SI_@Z2O\ K?\
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MW[KW7O?NO=>]^Z]UJ\?\*Y?^W5FW?_%L>HO_ 'C.V/>57W//^GM7'_2HN/\
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M&;B9[D\FW7('/',/*EPC>';7#>$Q_' _?#)7@=49753@X9>*GI<C:E!Z.U[
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M3IT__P#8=[]_K@<^?]-MN_\ V67'_6SKU!Z=>_V0GX,?]X7_ !._])TZ?_\
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M[Z,=)>O>_=>Z][]U[KWOW7NON/=6_P#,LNNO_#$VC_[S^/\ ?![=O^2KN?\
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M0U7A@HMOT-2&(D@Q\-,LRA1,92H;W+>P\I;+R\-=C;EKLBAE?N<_82**/4*
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MU[KWOW7NO>_=>Z^X]U;_ ,RRZZ_\,3:/_O/X_P!\'MV_Y*NY_P#/1)_Q\]&
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M=DJR9UI\;AL53R/&M5E<O72)! A95+O=V5 S*AW3<K3:+"XW"\>D$8K\R?(
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MBY5^_GL#NWMYNEWS%R[927'(LSE@45F:S)(_2FI4B($TBE-12B.0]"ZN.0,
M">[K91N/>,E0.G>N_?JCKW75Q[]4=>Z[/OQI2AIU[JC'^:U_/E^)?\L[!9K9
M--EL5WK\K6HG3!=!;-SE/(=L5LT*O2Y/N3<E#'D:7KO%1)-'.*"57SE=%)&U
M/2"!VJXIY]H_8#F_W1N+>_:%[#E*O?=R+_: '*VR-I,S'AK!$2&NI]0T&CR*
ME<]W7S%?F'\Q_D!\[>]=T?(?Y([UGWEO_<OAHZ:&&-Z#;.SMM433-A]E;&P
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MPP"*<"1:P_WW]./Q;_;6]Q;FM3Q_U8'7-PG]O_%?+KH?\5_WKWOJHXCJY_\
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M]OY7??4^X=D8_+;C^'G;^>R55TGOAA79*79=8Z')5?36_LE*LII]T;=A,O\
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M6\>SIJF."ITL\;24FS,!64U6*=PJO%+/E(I"& DIE/'N*-V]UZ,\>R[>"O\
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MMS_WO]P>^Z'*G_*K\M?\\%O_ -64Z0-\3= 5[$/5>O>_=>Z][T>!ZWUNX_\
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MRX :5L1H#0NPI\L*,%CF@\B2 <COO >_'*OL!R1-S3OU+C=IM4=E9!PLMW.
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M7<TA((L8Z-*_HODBG@';@#Y"K4[>LE_NP?=\WCW_ /<*UVIH9(>2;!DFW*Y
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M;V@N-]Y9Y:]X=GM"]SM ^COM()(M)G+P2GT2"X9T;YW0; 5CUKG^X+^77&4
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M /\ 8_[Z9_UKY6_Z:7;_ /LHA_Z#Z2:6_A/7O]E<^3/_ 'CKWK_Z*/?_ /\
M8_[]_6OE;_II=O\ ^RB'_H/KVEOX3U[_ &5SY,_]XZ]Z_P#HH]__ /V/^_?U
MKY6_Z:7;_P#LHA_Z#Z]I;^$]=_[*Y\F?^\=>]?\ T4?8'_V/^_?UKY6_Z:6P
M_P"RB'_H/KVEO0]?8'_EG8O)X/\ EP?R_,+FL=78?,X?X1_%+%Y;$Y2DJ,?D
M\7D\?T1L*DK\=D:"KCBJJ*NHJJ%XIH9462.12K $$>^,_NA+%/[F>XD\$JO
M^^W[*RD%64W4I#*14$$9!&",CI<. Z.Y[ O6^O>_=>Z][]U[KWOW7NO>_=>Z
MZ/\ A_OO]Y'OWY]>ZX/&DBLDB*Z.K*Z.H9'5A8JZGA@P/(^GO6:ZO/KW5"OS
MM_X3C_RWOFS+F=W8[KR?XR=Q90U=4_9'Q^AQFV,;E<K4,)A6[PZPGI)M@;@\
MM67EJYJ6DQ>5K&D8R5VK2RY!<@?>5]S>1A!9R[D-TV9* 0W>IV51Y1S@B9,4
M #-(BT%(Z=-M$K?(]:E7RS_X28?S$^DY\KF/CKG.M/EULNE-1+10;=S%%U1V
MHU#3O([U&1V+V%E8-I^7[4!UI\;N?*54SADCB9_&),O^3_O>^V^]B&+F6"ZV
M:]( 8NIG@K08$L*F2FJN7@0 4)(R0RT+#X<CK7S[S^(GRG^,E?48[Y"_'7NC
MIB:GJ?M/N>Q^M]V;5Q-7*TC1QMB\[E<73X7,4U0ZGQ34E1-#-:Z,P]Y&;#SE
MRES3&DO+G,MC?*16D,T<C#UU*K%E(\PP!'F!TT58<1T77V)*CUZKUZ_OVH>O
M7NO>_5'KU[KWOU0.O=>]^J!6ISUZO0K=4]$=W][YD;<Z0Z<[3[AS[2Q0?P7J
M[K_=F_LJ)9@3%&]!M7$Y6J1I I(NHN 3]/91N_,.P[!;FZWW>K6RMJ5U3RQQ
M+0?.1E'RZWI8\!U>/\8O^$P7\UKY"S8S(;PZPVC\8]GUYCEDW%WWO&AQN96D
MLS5!AZ[V4F\M^TV1C":8X,G0XM9)&6\J)JD6!.:?O4>TG+BS0V6Z3;I> ?V=
MI$2M?G-(8HB/5D=\>1P"X(7-*B@ZV>/AG_PDB^#W2DN)W3\K-^;Y^7.\:-H:
MJ3:]I^HNF8JI!!41QS;9VQF:_?6X6Q]7&5#U6XXJ"MAXGQX5C&,6N=?O@<^;
MV)[3E';K?9K)L"3%Q<TR,.ZK$E0:]L)=3\,E:'IY8%'Q9/6T%U?U-UATELK#
M];=.=>;*ZKZ_V]$8,)LOK[;.'VCMC&1N0931X7!4E#CX9JAQJED$?DED)9RS
M$DXK;KN^[;[?3[GO>Y7%WN,AJTLLC22-]K.22!Y"N/*G3P & ,="#_OO]]_A
M[+NO==^]]>Z][]U[KWOW7NO>_<,GKW6GW_PL ZX[#['^.'P]HNO-A[TWY6XW
MN[?55D:39FULYNBIH*:78<$4536P82AKI:6GEE&E7<*K-P#?WF9]S3<]MVSF
M;G-]RW""W1K&( RNL8)\4F@+$ FGITS."0M!UH/_ .RN?)G_ +QU[U_]%'O_
M /\ L?\ ?0;^M?*W_32[?_V40_\ 0?2;2W\)Z]_LKGR9_P"\=>]?_11[_P#_
M +'_ '[^M?*W_32[?_V40_\ 0?7M+?PGKW^RN?)G_O'7O7_T4>__ /['_?OZ
MU\K?]-+M_P#V40_]!]>TM_">O?[*Y\F?^\=>]?\ T4>__P#['_?OZU\K?]-+
M8?\ 91#_ -!]>TMZ'K[5O644L'6_7T$\<D,\.R-J130RHT<L4L>!H$DBDC<!
MDD1U(*D @CGWP[W1E;=-R*FJF>0U_P!N>EPX#I;^T/6^O>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z^,3\F/C-\D*_Y'_(&NH?C[W=6459W=VM5TE7
M2]4;\J*:JI:C?>>EIZFGGBP+Q3P3Q.&1U)5E(()!]]L^5N:.6H^6N74DYBL5
M=;&W!!N(@01"H((+X((H1Y=(2#5L'H$?]E<^3/\ WCKWK_Z*/?\ _P#8_P"S
M_P#K7RM_TTNW_P#91#_T'UK2W\)Z]_LKGR9_[QU[U_\ 11[_ /\ ['_?OZU\
MK?\ 32[?_P!E$/\ T'U[2W\)Z]_LKGR9_P"\=>]?_11[_P#_ +'_ 'H\U\K4
M/_(EV_\ [*(?^@^O:6]#UN=_\([^J.TNM^R/G;/V)UMO[8,.6V1T+%BIMZ;.
MW%M:+)RTF>[2>KCQ\F<QU"M;)2I41F01EB@=2UM0OA+]\[=]JW/:^05VW<[>
MX9+B[+".1'T@K!0G232M#2O&G3\((+5'6]3[P(Z4=>]^Z]U[W[KW7O?NO=%>
M^67PP^,OSCZPJNH?E'U%MCM79LC3U&*_B\,]'N+:>4GB6$YS9.[<5-0[EV?F
MQ&BJU3CZJ!YHP8I=<3-&PIY/YUYIY#W1=XY4WB6SO10-H(*2*,Z)(V!21/DZ
MFA[A1J$:9584(QUI$?.[_A(+W;LVMSV]_P"7]VUA>Y-JO/65M!TCW#78[8O:
M&,IF9?M,+M_L4_;]=;WJ 68F?*C:BQ1J 6G>[-G3R!]\C8[U+>Q]Q=G>RO*
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M'^]*M?G\NLOON+<RS<N_>7Y$A2?1:;C'=V<N0-:R6TLD:DDBO^,10,!Q)&D
MDCK;B!Y_WQ_K_3WDT/,UZ^AKUQT'?;?9^V>FNM-Z=H[OG:';^R<%5YJM2-D6
MIK98@L6/Q%%Y62)LEF\E-#1TRN55JB= 2 ;^T&Y[C;[5M]WN-T?T84+'YTX
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M]UU?W[KW7=_?NO=>]^Z]UZ_^^_V__%/?NO=>]^Z]U[W[KW75Q_7\7_V']?\
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MGJ*NMK*NI>6>JJZJ>5GDD=F=W8LQ)-_?5*...%$AA14C4!0%H  ,4 & !0
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M+2UV4J(TC6KS&3%(:FLG*AIZJ621O4Q]\8>8=\ON9M]WCF+<W#;A>W,DTE.
M:1BQ"CR5:Z5'DH \NEP%  .A>]D_6^O>_=>Z][]U[K__U-_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[WH]>Z^9'_ ,*KOA1GOC]_,+J/DKB<.\?5
M/S!V]C=V463IH7_A^-[8V-A,)M#L?;L[:6$-?DJ>CQN?N[?Y1)EY_'Q!($ZC
M?=*YX@YB]N%Y8EF!W;9I&C92>YH)6:2!P/X5J\5!2GA+6FH523+1Z^1ZJ)_E
M??S M^?RT/F%U_\ )W9N-DW+A<?3UVS.U=AI6C'KV#U/N>>@?=6UUKM$B4>3
MAJ,929/&3.KQ09?'4LDJ21(\;3'[J>W5A[H<F;CRM?S>%,Q$L$M*^#<)JT2:
M1Q%"T;@$$QNZBC4(;1]# ]?6C^'_ ,VOC/\ .WJ7"]R_&?M';W8&VLC04%1F
M<+35]%%O?8&5K8#*^UNQMHK4S9?9^Y:*1'1H*E?'.$\U-)44SQ3/R$YSY&YI
MY W>?9.:-IEMKE68*Q4^%,H-/$ADIIEC.""IJ/A<*P*A<K!A4'HUO^V''^!'
MUO?_ &-O80\P".M]?-4_X5O=U]0]N_/;IG&]5]E;*[&J^L?CK3[*[!&R=Q8W
M<T&T-X#L_L'*R[4SU;B*BKHJ'<5'CZV&6HHFD^YIA,GE1"R@]._N>;'O.R^W
M^]R[OM=Q;1W6Y&6+Q49#)'X$*^(H8 E"0:-2A(-">DLY!84/ = ]_P )2/\
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=U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@   QT   $I" 8   #V[4\!    "7!(67,  $SE
M  !,Y0%USO"5  !LY$E$051XVNS="7!5U1D'\(][[PO$ %DI"+15H;05A2*T
M15L1%!<&0?+N/0G+H*@=K'5I=4#*",U+6!10VTH9Q-966ZU+JW1JM5*M$<68
MY)[S$E!$RE2MU 5%M@H"5M+ON^\Q6B#A[6'Y_V;./$:3F_-.,IGOG[,1 0
M             !PO.F (       @LUHX:&P8U9&,ZFO[KFL;=XSCA[]#=:H$
M@P,      .FI'>Y0_:2NU.SVMWWO4EM[]W*[VS)>Q(EZYU%]N#?IJ2&*D(7!
M @    " Y$G@,!,&6-J;;_MJ)0>.=[B]RZ'C'[9VEUO&O8:BJANM57D8+
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MXXY0@SLDE4L"C['0D?66Y9F.3+:[NU+54+D$$K_U    X'@/'=OD="<NUG]
M>LP)R<PJD'$'\.?-X6<T9/@&]0]M7SWK-%8,DQF5A/HB%P!*"#+>[[AMS?4=
M* @="!T('0   (#0T7J!+WL[=CK&6Q3<VY',\J!FU<LV[AC;J#_&B_R,[)^P
MM%IC&;68&MW^B78EY+N#'.W5\/OQVV,<$3H0.A Z     *'C</L[C'K(CJJQ
M,F.0\!MY8THG>GEL]^#H7!,<G9N9V04CIU:IB10=WS/1KDCX<7QEXIO'$3H0
M.A Z    X'@/'>I<1_\/  #__^R="914U9G'K^^]:EJ!;AI!9%,T:MP"&C>8
M+.X0X@'INO=V-W"8H)EA,N)&W(/:10ON:QAC,&.,9HR*1D>38-0Q[8A"5;W[
MJFE:Q@6%N.*"HN(" MWS?;=*CTHWU*NUZ?Q_YWSG]8&J^^Z]K[O.]Z_[+6JY
MZZO/7*,ZNH4%:HD3J)@(:@\0V;)0NV+E^%YN(/_5"]23M)ZU><YA(UT_\'QY
MM4C5CA+Q\57;G4/S]$K1(O>EN9]/[WV;QMA0COWS?'5])"$/%T]/["N*2'_1
M-*9&S%E.UM&%;:P1L2OZB:9#!XES>Q?^_G/JZ1Z+Z?KV-N905.LG8HEJT5A7
M+2[>*^S\Z?T3R-XLT5QOK1*-HZO%%34"     *#4D(/^ \^HI\A9?:_;B XC
M7Z7K?WLI/49TB)U"K\=7\VA-S]$86_*8QSH:YUDWT#/$"MU'=)"HV1[+I]2X
M?IVD]]Q)[_^\7/L'T?$U:R?;1+8A1]M4/M'1],7<-^8Q_R_L5R0ZCJP6%T)T
M     *#T1(+H:#=0#Y&S^EKW$1WJ4\?(-M?HDT3S,96AA(>)#O8"_2/75X_P
M2059>TZ.NU'/DEWCI>I^2'/PLII#:W288^HN=XP.:(S-$!WE%AU-F^GZ*=GK
MF7F&-AK[K3*>=+#@6$-S>)&N;;FN@:V?F--8(QI']A>Q*GSJ 0   *#THB.I
M#R%']1:'O]7O/J*#[4T.E6)'/JM3AB]8H2M$0N]%@J&)+)[#B<,FLK4D6O[H
M^G4_%FT-P[.Z[^KIE9$6VDO[/O5NKF('HJ.0HF/.9V1OD/CX"SG;E^5B-/_F
M,HJ.3VB/GZ Y+*"?+\]U#6PD.D[N+V8/'R9F[8Q//0    "4G%YQN:_GR_/(
M47ZRFXF.M20:KN1P*<[5R'I!?"+1.JTWG^"0\WVE&ZCUX7(Y],=T33A&721:
M)O7+5O#L8J*#W:!N@NOK9)YA71 =A1,=Z^C_##G=9]>(*ZMS,7I_4QE%Q[M\
M0M%?-([N*V(#<ET#VS!Q/8F-A?2[W+$3/O4   " GH:9$1$KIU;QM^5\HN E
MU?%=FHD>ZQG]_4BJ?I18.FF$:-9]2C+'5,,0UY>2[/YN)CH^<(V^B^8UF45$
MJ#5Q.%1K[6Y6! 3Z3A(OSV=U3U]]Y!B]W E4(S\+^_RR)&+D49ZO9].]7BSW
MWI'H:!2IZ)XVL?T?7G3$$G3]MUSO0>^=74;1\0[9!;2'!PL1J\ '*@    "V
M)A9S1/+DX>F<"5T;\>4LS\@;NS9UK1/HN>3TGD6.HXX$^C ;VM,V>9#]QIUS
M&Q:&"#/*VD&?U(_F=B@YW+_N9J+C$[)F)ZB;)>)3<XM#CT>'N2D]T37R+AKK
M_6V$6G$HU";'5\\[1MTADNJ?Q!*]<YA<$GYF;B#OL6%AY=NS=C=06QPCS[)"
MK1B_+Q =$!T     Z$8L&M^+0W3<=&6HA&=T&UU?[MKD2_2:%VP"M:]\UY9]
MU?=[@;J*?IY:X=<?;,5'H>%O\XVN)M%S63<3'1LXSX1L7L[K9N&0U+N[05T=
MC?<;LE>ZN!>7"WZ'[&;AZQ.MT OIL#N^G,G/.9.\7JX]XWR4CUU?SK!A82$K
M?T%T0'0     8$>"G=VVAN'D "[,RXFTX3YJ.7^#[B75)21"IGD)]0,^00D=
M<K0]I]G(,^F>:[I1OPYRH/5;M.8%8H7NG]?BELN]2;A%:1_OM*5TTVO<8BU0
MZ^T>&_4[?HV]5XBP*M$1<_CU')+E&/T&BZ4R[MF'9"MM2%H)@.B Z     !
M.4DU#.$\#7*:_YIWN(QOO[W^E*X?DKU,=I^;T+65+0TC"CEE-]#U9(_3^&]U
MH],.$@7Z?I'2 _-:''_KOT3W]WQ]HA>HZS-KY.9_&TDHK'+XA,/(_?G$QX;%
MB3 E>CEO9WP5"9KYF3*Y9:M:16+C5=?(O[@I-1ZB Z(#     #V=>'28EY#C
MR+E]K*#Q^CZ)#V.%QT/< ,]^HYVHW<^6B<TSE(;&.X8<\ANR3KHN77?RA^S)
M#B>'YP.+@V5ZJ)>2)SB!GFU/-HQZ@$3'A5Z@C\NZ >!6X^KJ"A(L--8=Y=XK
M/K%Q2%1YG),"T=$31,=Z6ML#M(8Y-:+I-%Y'(8S&/%&(,WKA@QH   #8T>$&
M=>3$9QK4%<O)_+L;Z(==(W\B6N2^UFG.QS%GQSG0TUVCEW(R<K<1';Y:)%+Z
M0-$ZMC!.ZVMZ9WL2Q0T$$[1WW <D[V<M3V !TPWV:[%CY,_L?D%T] 31P<T!
M7\TT*4R2)0IAW/-C@+BJ+SZH 0  @!T=%@"!WL<VBBMBUVZ;@V%4G*M?1>+1
MT2)1NVM><T[*@TC$/)A)K&[O)J*CF4\GV+DOR+/A!'$N)?M,[6Y6<'#^33[P
M<[9BK:"G6KG:GSU3=RR+*HB.'B$ZVFM$$W=4_XC74BBCYW8[S;L?/J@!  "
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MD=)CW):Z']MQ22#F>D+@F>BQM.]<,&!5F4H*;W",#&QCPZ3>':(#H@.B P
M /A'PLR(V(9[1M]%SN':TG[S;9O>!8Y1YXA 'Q9^[M'!;B GD"/+.2F?N'Z1
MP\-*(3HXU"RE!T:,/(J>RPPG4%?1=8&34F=X*76\6**'<AY.:-&1XB:0ZD]D
MKY1I?U;Q<XHLDX?:4YL2LJNX[ !R8&_M)^8\UIG1_RVJ%G-^6B4:]Q$B5EGH
M^Y/#?PR)BAOH>E]G]^<>%R1ZYM,\3LI==#1.Z6I]Z37&YO<3EQS=6\1""[[^
MHG$TS>V>;8U?'&NZ>*"(]<&'-    - 3Z-"NE]1'9T*LWBR#,_H!"8]ECB]G
MAIX[.Z\K='_'R MIG-<S30EW;-'QZ-C>7J)VC&>B39E3B0\S@NH53OBGYS26
MFSJ&%QWZ:!IG(8G+E\I44OB1"#_C>)[]1G)S^OO5B$N^1\[]N,ZL6C2.[2L:
M]R-A4"7$0K?0]R?'>?<J<<E1Y$@?V_G]+SV>'?O^8O;P7.]1+6)[=[6^M#6.
MYGD,$]>'+KW<1UP^,"V<MC5^X8WN>8@0.5:X P   $ W@W,'6AI&N+X\E1S:
MY\A!_+S$83<;,PG&O_62ZOA0H3<=-'<2'IR0SA6QR%XH8T?R1SC<2SR?1QG8
M9,-P+Z@;1^/]T@UTDJX?9Y+[.1SMD_3Z](-.0,Y[($>*^-2J;(>V.1V^NL$+
M]+(2BXW-7";7"]0UD63TB+SV)_=?\HK>8MX@$A7#.K-=Q=RA->*":B$6D(/;
M4? $]R$BM@L[[@-$XY#.[L__WD<T[C9(7)-S:!<WT>MJ?6P\?EIPQ$(WYAPA
M8I4#Q+S!VQJ_&-977+0KS=?!AS0   #04U@]O=)V)@_4D^0HKBN'TVXK6OGJ
MJDA"'FY#C,+D+J0F#F'A8<.'?)N7LJ7$@H/[3_R1PZ)RVG].&#>ZVDVI\20L
MKMON:82O'G&"NIEBF3Q(/#JM=S9[51%PR5PYNPPE<]?1/?_/=J3G;NUA"@8
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MD90\/.=3(       T(/@$JU&[^$$>F[9\B+XQ,"7#[N!G$&BHW_H-2S4+O>
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MX4/BY7JQG!Q\[E[>&?&I5;T2]?O1:W^;.5%I+U+OE<T<)N;XZC\$YYOP"1H
M      !?8XGN'TG5CB+G\59R'E_+..RE/.W80HXQ=QC_%Q'4'Q!Z_ORM.I_:
M&+V'%^@?T3CW.D:_D<F]*,9\W_:,NH 3\<.<S'BINA/H?3?1^U?F66VK/5-6
M-^X$:I[P];>[%&,<SN7+ZS*)ZIN+E)?#N30W>W[="3:QO@,E3P$     P%9.
M.SNGNMI-JE-<H^]CI[K4G;Z]0+WH^?IJ;FB7\SK,81%.7G:3>KH;Z#N==!G:
M0B>7;[3A8 D])6L'NWEZI8A/'D2"[ER:ERE@B>)WR.'_'S<I)Z3GTGE($^W#
MA?0\5Q6XD2(+G\]M'Q%?W4USJ+/]5DK<>1P      .Q0PB/F5"YM&,$..SG5
MRXN>%[&UO6$%3ZI.YK4.;GSX],2^7HL^D1SR!XJ07+[.\]42[G&2]9Q("-ED
M=R/O*D*(T^M.H'YA\RBZ**/K^OJGM!=/<(GB MYWLSWA"-3=D63]$:A4!0
M    LA =8B=VUB.F_KN>D9>6L,SJ5QK*Z< Q\F=YKF0G>^+!/3P".8[6,L<-
M]..VE&MA&AH^1^+A/VT/BBRI2,J#'-M/1#]=G(I1^G''ES/MB4HG9$+.;B9[
MI5#/*E/J]V9[PL&"HQEY'       (%M:)O6+&'D4.==7VBI)IF3=OC>D<R7T
MA85<#I\ >$EUCANH1US?YJNLMWD(N3>^8P?_=+%<[IV5D.N(>5Y*'4_"X.$"
M.OW?[!FREL9?P(GJG>:8++.BYS2:=YOMI)Y':!G9!^E<$CW?YG!P2)5 I2H
M     ! &#M&)CZ_R GT<.:J7DX/NVV[?09&%1V"3R3E?HJF@ZWEZ8M_*5KT7
MK>-DSU=7.;Y*Y15FQ T!N4)35Q6COB8ZM"L2M;N2()B>#O/2GQ6I>A27WOT3
M";;OB_C$05O-HW5:;Q:2)"+_1J_+9PYK:"W_ZP3J;)&J'27,A '(X0
M +F3:ACB)?71Y,A>FFDNM[84R>4>5V,JAI!:HH=R'H9CZLZU)60#6Q[X=2NH
MLLFSL!6:]$LDQ,X1RZ?49%6UBD..@LDCR4EOI+W[J,A[EZ"YG5$1ER,[?Y[1
M/6V%*2-?"'ERM2%36& )77_C!'*F#2UK/J825:H      $#^<'*Y=5;K?D+.
M:ELIDLN+(CJ^0:1%'\(..HF(QTA,O)UE*=E7W$#?8WMS9$M\:A6]I]8U\O9,
MR=IB=G9?16OY+R^H&]?I7)[2 R.^/)5>^T#(\++W2'@NY=,-*S9B$!H
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M)10=M+\I/GT22VL/P!\%       (!X>\<(*PB0ZV\?8I?2 [MI&6^B-LX[=
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MSABR,KGF@,"!1!2*KG%OG$^&Y5@ZAOSVO 4(8"UT'U%E9.J"/!,1^1/IVA@
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M)"QEH:.3KQ!H'RL/C$[^>N-P AY72CI6KS>7PVE&+\,D5DT.>DO[.K F]RI
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M1F;R,T1QER<^Q\Z7?.H!-/T5D],*;O6@:+9+)^,(&F@?HO,_090]I*N>O?V
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MW>>88^AU. <:M68Y_<\)K+9_-S;UI [I8%QJ7I\)V)#SKSOF2;ZX.8J.M8H
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MCVNX7!E(\H1V=C 7]HZR^#@!@ILEC2E:"'TLRA+'Y]]3 #2T]?@1AEMUMM[
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M7GXCR=#T=QYQ_EN4X2]?A,O=2+$C*LL+HQ']X?3<-X ;!D9AR X$*-P&G0?
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M6-^GX'8ZI^%8MP >_HQ_S]%<\RVQX[.G][%&<ZQW "P$(L]3W0PM98VE71&
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M7.L!Z(MHAS?\'0W'!XW6N9\ 0"A[U[MT7[K''Z:4N'[E\'I^F+_KD:/Q'A1
M3O$<(@WA.DE5F.F<GY$Q6<;L'Y2Q,0>JJ51!1VM#!V5%(E<FW,-DN;"=^#@:
M9"<[OR.+=5;]2T%'&M+D-M%J?)"(H#FGWEWTSB*#'_<X04[2A\2"(,MC[%C5
MV^5+(9M4)HJZSLN\JUUB)?KBG:4L?JZ<0KUID((ZWCWBFB-@;#>)>(KF\"K
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M.^9\P^7C\6S.\EW#LEPP052)VAR?2X(.*H9V3SF+':6F;P4=F8*.0O0WBN?
M=S7*C.4H9;%$$4N<I/J4@HXTNNM-QKS>A5:?<WRGXWS<Z^Q,%PG,;>BP#9%@
MXR#<WW$4( VMP;^'!Y7MXZ/P[SN$=\27>B_^?QH5;(SZ-4SB3^%W?Z+W^C<^
M]Y7B.^Z"QO#S2!ROH0)_E(&JE-7^N(C%3BG$&-H3:%;0L:^2XIU@X'+=-:=1
MW(3(8!5N@]RQ5N):G])3UJ"=WMO\ 84L:?8P7&LR[NMSL8/0G#7J^&E[ZW#]
MM05>33>JIY*EDXNH44#;\'X@MRS#:R;T4LJ@I<P5!1V9@@[*6H678PSZEH3K
MIYV5+6B[9XO9^'/+V 25K4U!1[H*3&ZF@H!D..9ZK1?<:S^,8_+C7Z:@8V^$
MZDK07'Y+<2??)<H^G$ #\](9Q2S.\?.U 1Q0DAD_YG,A_OVO-"7=V"+2S;Z.
M[W1Q_ >>Y0R RSV8D\<1A%"!8'*!I;3/E-&2("0 :=\CHHV"CO3N=A2PNL$5
M>M(:JKO\.<#'^SD#'0 .S;'NT%SNB52UV[,*.H+@_C4"/"89GG5&ED)'NV"U
MUQXKN3;'%,JR$F2M4J*@(S/0008+KOT^'-^3</U;@C@2^Q[*PL/8E+:J3RGH
M2(-NP#SZ$8S%JT7-@)QVV1.U.OXD=NH5=.RA4!'24C;A8 #&.51W!/?V6\Q)
MSXEZ%Q3C^2;-CX$;:/Q3Z!JQ0+DM30LO&X6'Q6>BF.5'F)/)S?MMBO.$>@)V
M[J<=D2BK'4@04L%NZ/#-FA@*.M(D!62@N_RR #S\XGB;0QG3X5FKH0LTU[HI
MTLA/WMD]11SS^,"MRL]2U9S%^A_=X<FO NCW-'.79"$C/YALXG=C8&^4$$2[
M64PX(RGP3%4?5]"18>@8#/V+>*%F^OK7B4*8-^5:X38E4J$#QIO]!NU>YT,[
M!S5V_/I2BQ1T[-9"HU;.)NX?91-[E;#8>8"VGP=SN'T?YO$7<%PBP*(Y1+HI
M@!""C\1#&%>UY!D1U*")G4().$K83<4*.M(E2_JUI<)[6LH:"^,V)=R1PF9\
M;]6"H/<I;.' +KLJHD<N28;'?XW/NUD.'0*X^)-ZBENLD6>5BP2EYRQCB6$8
M,#-H2U["8 5PV.]A\K@@UU?D%'2$$CHN@]%2C^-J"=?_2>"R$!NBDB<HZ$BC
M?HPY]56,R2'YT<YV[U)6&Q/N.0HZ=@T=!;CF,\G]3L3"+ NR1R:V!KL7<A)J
M[,8"Y7:QN[)-9+M<"YU'1?F*6:PZ\-A0T)$>F<YU @^J^JVES!$P<O\"?2=$
M1C>E]9VK.=9HP^6G^P4"=R5-E9WUE-4/QOHT$1^Q-9O!PW#,MVCGQFBL/MN/
M5[&SPXCHS"96B "N6<+=(].#E=Q:GB$W%V6F*.C(-'3@Q3M>;.=+V.6CE[T]
M 7JZ@@X%'6G4%50@K12&6/Y 1YR@PU'0\2WQ:YE0O%@9J_T!YIK+*3X#USPC
MRN))D?'KBW!"QJ[=4W$O*ZB^4M2W7_PZ1^2"M51!1SIE 3_0=[6BPH&.#QYK
M_/@"+\,Q$4'ZV/5!\4+^-\/C8PI<?LQNWP=5]6ZZH+.6JK[:<*W7?=>L[-[M
MV 2 6NJ[636:/9@[/)(=$W;L  R6\4'*4"F%T1HP64PL8[&3E9FBH"-ST$%&
M/M7HL.^4]=*D8,PHLX=1AJ%P[O)Q/^\^^7SG@P;U4=*7LE@B=+Q?ZAN5M0,4
M=.0O=-#8)9=E2F$+ +5PK;?ANN<*M\XM60H:NW+!6B?)CLEAZ"!C'>!AI*QS
M1#&]N8"/]1*JEM/NQ!+ PH-ZBE_@NU3-WHT=CJ_>^7CI+^8%$:_J%,.S1N->
M&K(:.@C"'&NM7R Q95W%ZOIE14 T!9")R>@UL;V:Z<'Z2I3%+RI4J7(5=&00
M.LC [.2_D"EH4MI+\O5B9O^@"[-#F7);I,SL7LS&G9 /6L1B1Z338) %':5!
MX.^4<A8_6T%'_D)'&:OM1N]6Z.]+@Z#P=X4;Z58Y15 SD;6-;!@I[F$Y#!U?
MBMN_/.)6]8:Q?BVY]5#!.MTUE_HK[JT#(-M% /MRP[$<')^@=+&ZQRM9?>7>
M&XQ-E9T-I^HT7/OO_NOZLQ,\ C>Q>LWC8[*E6CD%8&&@_$'X=6Z3,%AGDG\I
M!;8I(UY!1Z:@(\KL*!G4HN_+\$^F%;FY03',< I5LL;8O([J/>2#PFBXA/I%
M#NQT+"YCB5L#MST%'?D#'<UM:,>.4LN*K'RCHT&LYMLB0U0N@D98- ^@(Y V
M@(_O,-<\.N*85\)H?UJX6[6&X4YU--8".&8#-L8:*7ZJ'[M \2;[*@MX>US[
M1;IGS1#7GZT['E\ //ZNN>;5V5*WHXC5'HD!\WS@URECA<!^O)B-[5K.;BU4
M1KR"CDQ!1T<6ZXQK/X/ZGZ27U <P<)\@UX?P[H+&3@E29M*\D ]J4^:>0Q1T
M*.C(3NC@N@BD'EP2U"WY,+Q!X0HZLE=FGV6PAH%12JMK./Q<W>/##->,PP#^
M _1EP^7_A"'\'_R\<0]6[ DP5NM^.EL^7\# %!C3U]'.!J6[I1T*/VZA.0V^
MR+B'MO651^&\%^(\S^)\[V8?<)COHVU>T!SKT@*GIF?VQ'30B]%^69Z/9^*A
M8'5Q:H0I4="1(>@@MT)*MRB2&,AX22VB-)\T_L(/'?EB."04="CHR$KHH-T-
M,G@QI]TFWN?+LCA 7$%'5@E!@,._JSM5 S37N@$&\3V^(4_9I5PK!2#YI^%:
M;[:DFLL;8?2_"@!X <#Q.T#+>-VMOL@O?K=H0(6?OK>UI(D?1KL$NL.?Q/6^
M!UV7%0'D5*O#Y3/1=M>Q.O/(;.HN9<P^&@-FCJ1JS)OQ8IP:5$15HJ C<]!!
M_OM15OMS& RS)+VDYE,"!ZK^JZ!#08>"#@4=>RZV1NY4P>Y&;(AP%7U; 8""
MCLP+N5S55Y:QIJJ#F,>/*' J>T:2O!>!@^Z9/X/^<H?J6I?0;DFD@?>B3%1M
M&VN.8JFJ0]FBP15^C )52&_-5+!+A[6C.A> GI\ D&Z!+LX"Z%@!?5'SK$M9
M'=I[ 6^OH&.WBP)^$F7V[0HZ%'1D?J=C4G=A$,Z3D[DJ\2(,PZMIQT5!AX(.
M!1T*.O90VE ""G+/Q+6,(1?IH,!I8KT"  4=X1$RZ@$1Y,JT0Z55^C#$(J0&
M'6 XUEF&QR=0C 1TF1\O$:)"B%2@47.LUW77?%1SS1$%GGELMG6'"G9#!V%8
M+) P2#?0JDPIL^.J1H&"CDQ#!Z[W&!AFHR7U_6811T6%"0]2T*&@0T&'@H[=
M%ZY39KDHL\^"CA7]:[DR_!5T*-D7F<[U=@L'==%=/@30\:+F6A^(VB#;I5<?
M#^J3O(OKN5M/FOW]G:4LE#(VYL H&U^) >/)J41.YXW=J*!#04?^04?B.>@(
M!1T*.A1T*.C8$Z%TWS1OX-QW!.Y44@J;*E70D6-"L2E4V=RMZ6IX_,> CE&
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MU-.U)A"0O::L/X6"L>6F:[]A^/7UL+3 ]2UL0P?!85 N:+%)T<19%I1K P+
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M]OMJK.=AMG  .&AM. 2':[1'MH3H(%1#QT:M'[ \('/2C)-[L3DG]A4N2@A
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ME;LJ\]8\RW-JD9E,A58E33AHW%"WQ+,OI['\(UVK%K5(E""]GLX9E;N*V62
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M99&!?HX4Y6OOX%FM#[#C/H>LCDA3E-.BL :V+QV)\ZO:/>CSH\V>6V/VX8:
M)C/1C]@TJ5QO?E>?T7OU1"0N P%$/161AT,#.NTQ,NO[<XL^QY&GVMU3?D<]
M3,1P7BM[)X'G*Z2CO?!T[]+BANK#??%@A!SJSUW6<:PFFZ9/_!L'[9KMD"QX
M&'H(-1)M(!R;O7%KIHYR) ;NGPW)0F3&%PO9]-VO"THZ#':(5^]"<SV5OOL,
MW?=G.C4MD2'5BM_?3 3IAN+&_H<0@=E1-JM (!#D"LN+$\\R?>(9N8H<EQ@Y
M'#@]WUP AWX9.3HO,;&Q#^33[^SK#@I,.EH:H@IOT[J,0]H,.\_YBGK8)>5J
M5 4B-W3]B"%GWQ3@'N"H3B?B= E2;#@BT-P&9U)(1Q:&Z,132 4T]2W?RWY!
ME .DEO<T__;\3/9I;6TBH/;C,([ V<O,04#R^G\K5[46"+$3Z>#T1WLR:H2V
MK('],WKO:D.PA71T*(Q.A\^]3L>'Y$#_&0)[NKB9G/ALA\3)O2\1NIFNM3!W
MPA'ZAN;[#S7'.D*KH+L^;#G6I^K[=O?$0R-,RE/!20?6J%-C]1[>!FL@K=W=
MAK1M=$'NOO8D0I?KKEQNTKD$ H% T"J0;D'.RB^Y;D"?SJXPIZP%<> #G'8#
M8C.)4W2N+<]VSNU+.J)-[#C:2".ZN4R-/S(U1:4M0!H;4KAHC(= ;(P#78BU
MWV0<]]>1]@-'GHF'G>._GT(ZLK -9OY/8[W@Z+><2Z6JW8WFT=_,)?G\9]*?
M;T)*%-W?T;!R7:NC(V^+4Z[_!NH_4(/E'.F(?$Q[^"$F^]^N;6_Z\VTF?5)(
M1X<"Q=?U@[M[X\&SR!:14]Q:^L\Z:'@0,9E+KW_1-09NA/C2H'BV=2B<::/:
MG:,">O!]$!<UW]I9=XMR?>!B>]#ERIL(#J#[>=<0 +<U))]Z8\%;:0UZ9TT"
MYELE.S0.VI6^/YBN]82'T]-6.9"/5;ZX]1X^+YM4(! (<CYE]W%*5<UQ. %M
M!^<K:1N9V-CWIJ19;<6D8XLA"D0V 1VBVE)<CA0G+I".7FC2:9:VTSVLH75[
MC^L-[&-WRCE=3$A'MF;2I%"'<39WA=H2\> .92CFCLQMF0Z%?9*,K*%C&UD_
MKK6*S&2S'PCH"&7M'FE(1Q-'3W1JUBNH&4J.S07G.OUNN2&F&U-2(H5TM#N:
M+2]T)7PQ+6;W9>L%U-9,3RQXA6X7BY/W;!S]%NA<7]U#:X/$=3%Y+J1CE584
MCX6&HA#>4:BOU?M511!$1(&W+Q9\+XMQEQ!1&5\<LXYPU2FKQ9B:J,P;W%TU
M#NKE201O\(#$Q4-?.=2K/(SG(AM4(! (<@-2.DPKUNM-T>HW[>CXDE-DCV(G
M<:M/KVKAX$8^).=N6%N*RY%7SUV?=-K-6N/LM<?\-_')NVX.,(W3Q81TM-/:
M)YW_VRO4^%^@2YDSZ8C,IOG]'SJ0F3J<(JR[J;TZKEQ%@K" FG!2N1I_&%KH
MMDXZ=).!)6;OHG:C3W)LU!"A+L0T(=A@/K->2$<' F0"40RHBYO3]R5D<>A$
MT-_=A+:MB%#H@N;F-O;$GF_M6!P+_I2N_121F359MI)%B]RY2(\J:0@>D&O:
M$71%Z!H7T_5FN"_JMA9Y$J$+5,+:)^<UT,7E_?R^!NM71#Q^1VL^A=L.ZW5/
M+>2O)V)T94DB>+#L3H% (,@>5>J:KJ8G?S+"L=YM:A2WQXV^@%QRM,>%D;/S
MJ)_ST><8!W&3@]-.W[<C2.G*-;W'!>E8;Z('\TR+V73VAOE,DG0UN70<KX,S
MF$,+X"+H):#%*ZTANF\M<NFP?IWL2(7.1.9T^QY$BU"K84Z]%YK3;#?7@Y/Y
M#MFU<%2S+R[?KD@'UCUA]DKJWGF5[%^FT]12X]R[6?LW4;^3VLG-M+H]V5QO
M@XF,( VQ@3Y[%Z]AY"(4?=/?G<2D(]P+]X#4+(Z<W%F<)M*!@O-9B+2@FQA2
MM*#!@;T(K9<40K(\P#5%*X5T=""@LDW$8[B.(.@T*R(;B=#U.IHPAYS[? /%
MU;'@G>1P+S8:%JYJ.3PQ'0%XL'A6L%?;QA]<53PS>"2Z7YF"\J8,A=V;=#I6
M(E1-Q"&0=72EU3GTV0%%[2!T.FTM'IH%+1!=6Q,+/>BKMXZ!R*#L3H% (,@>
M+ 86&6Q:PSK5,VPVCC8<J@]-*M"M.*5GQQ^"@5H7 /GH(W RRTZQSA%' :WI
M?*6OLQE.#[W>AQ2/+:>WA2 =T=4XP27[*QPGI)^T9I6J9BSGM-O_I.\M,([>
M-QFZ=:'(]Q%R!(=FV<U*ZW @-]_/HGZ?N.F$9)Q $(1GZ;Y_#RV(<C7A>*P[
M(A704PAP$?HT<CK)V8Q^;HA1AHYC^MF L%RTDQK3/;N(TW9%.D#HIE1J\<LM
M>P<%V'3_$TQ-Q+.F4]@7+CJ.K6+"@BA34KO$[F3J>Q[C5"?4]7RGD<,JLP>F
MTYBWL/Z-?0S2XTRT4"N4IR$=BPS!!2G]B,4DPT=A3.Z4IJ-L*\UO\Q6SUD(Z
M.@QSS^S2:2X1C_KJHU"SX(M5'ZWU-QJK]T";V;R/]]:0"D\\>"'(#=E:%T*
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MAV)^%*$;#88L89?@9)T<\6O0XC?#>(@&Q8T07 XD5N^E+QUT3>A^[3NP%]"
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M! *!0" 0;&5 )Z$ .5*&("QTT3ZVF5-Q(I\'N.4NU*N?,@6VCQB']VE3O['
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MDN)=C+J?AWJAOR(:PT%H'[01L5L$G5-JGQ.2F8@XS$N*_VGQ-MTU<7&;$O)
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>%$51%$51E$CX!\%MX!A.)T%1     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
MB5!.1PT*&@H    -24A$4@   QT   $I" 8   #V[4\!    "7!(67,  $SE
M  !,Y0%USO"5  !LY$E$051XVNS="7!5U1D'\(][[PO$ %DI"+15H;05A2*T
M15L1%!<&0?+N/0G+H*@=K'5I=4#*",U+6!10VTH9Q-966ZU+JW1JM5*M$<68
MY)[S$E!$RE2MU 5%M@H"5M+ON^\Q6B#A[6'Y_V;./$:3F_-.,IGOG[,1 0
M             !PO.F (       @LUHX:&P8U9&,ZFO[KFL;=XSCA[]#=:H$
M@P,      .FI'>Y0_:2NU.SVMWWO4EM[]W*[VS)>Q(EZYU%]N#?IJ2&*D(7!
M @    " Y$G@,!,&6-J;;_MJ)0>.=[B]RZ'C'[9VEUO&O8:BJANM57D8+
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MXXY0@SLDE4L"C['0D?66Y9F.3+:[NU+54+D$$K_U    X'@/'=OD="<NUG]
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MZ^T>&_4[?HV]5XBP*M$1<_CU')+E&/T&BZ4R[MF'9"MM2%H)@.B Z     !
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M<[9BK:"G6KG:GSU3=RR+*HB.'B$ZVFM$$W=4_XC74BBCYW8[S;L?/J@!  "
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MD=)CW):Z']MQ22#F>D+@F>BQM.]<,&!5F4H*;W",#&QCPZ3>':(#H@.B P
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MKMON:82O'G&"NIEBF3Q(/#JM=S9[51%PR5PYNPPE<]?1/?_/=J3G;NUA"@8
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MD90\/.=3(       T(/@$JU&[^$$>F[9\B+XQ,"7#[N!G$&BHW_H-2S4+O>
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MX4/BY7JQG!Q\[E[>&?&I5;T2]?O1:W^;.5%I+U+OE<T<)N;XZC\$YYOP"1H
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M=R/O*D*(T^M.H'YA\RBZ**/K^OJGM!=/<(GB MYWLSWA"-3=D63]$:A4!0
M    LA =8B=VUB.F_KN>D9>6L,SJ5QK*Z< Q\F=YKF0G>^+!/3P".8[6,L<-
M]..VE&MA&AH^1^+A/VT/BBRI2,J#'-M/1#]=G(I1^G''ES/MB4HG9$+.;B9[
MI5#/*E/J]V9[PL&"HQEY'       (%M:)O6+&'D4.==7VBI)IF3=OC>D<R7T
MA85<#I\ >$EUCANH1US?YJNLMWD(N3>^8P?_=+%<[IV5D.N(>5Y*'4_"X.$"
M.OW?[!FREL9?P(GJG>:8++.BYS2:=YOMI)Y':!G9!^E<$CW?YG!P2)5 I2H
M     ! &#M&)CZ_R GT<.:J7DX/NVV[?09&%1V"3R3E?HJF@ZWEZ8M_*5KT7
MK>-DSU=7.;Y*Y15FQ T!N4)35Q6COB8ZM"L2M;N2()B>#O/2GQ6I>A27WOT3
M";;OB_C$05O-HW5:;Q:2)"+_1J_+9PYK:"W_ZP3J;)&J'27,A '(X0
M +F3:ACB)?71Y,A>FFDNM[84R>4>5V,JAI!:HH=R'H9CZLZU)60#6Q[X=2NH
MLLFSL!6:]$LDQ,X1RZ?49%6UBD..@LDCR4EOI+W[J,A[EZ"YG5$1ER,[?Y[1
M/6V%*2-?"'ERM2%36& )77_C!'*F#2UK/J825:H      $#^<'*Y=5;K?D+.
M:ELIDLN+(CJ^0:1%'\(..HF(QTA,O)UE*=E7W$#?8WMS9$M\:A6]I]8U\O9,
MR=IB=G9?16OY+R^H&]?I7)[2 R.^/)5>^T#(\++W2'@NY=,-*S9B$!H
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M)10=M+\I/GT22VL/P!\%       (!X>\<(*PB0ZV\?8I?2 [MI&6^B-LX[=
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MSABR,KGF@,"!1!2*KG%OG$^&Y5@ZAOSVO 4(8"UT'U%E9.J"/!,1^1/IVA@
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M)"QEH:.3KQ!H'RL/C$[^>N-P AY72CI6KS>7PVE&+\,D5DT.>DO[.K F]RI
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M1F;R,T1QER<^Q\Z7?.H!-/T5D],*;O6@:+9+)^,(&F@?HO,_090]I*N>O?V
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MW>>88^AU. <:M68Y_<\)K+9_-S;UI [I8%QJ7I\)V)#SKSOF2;ZX.8J.M8H
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MCVNX7!E(\H1V=C 7]HZR^#@!@ILEC2E:"'TLRA+'Y]]3 #2T]?@1AEMUMM[
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M7GXCR=#T=QYQ_EN4X2]?A,O=2+$C*LL+HQ']X?3<-X ;!D9AR X$*-P&G0?
M> ^Z#KI>K*QO DQL\5U_6E)R^:'/!6X_&Z!?D.N0X?*W "%/&HXY,N(,/)G-
MYAU]T,EO:>-# @$8M3_%8Y [6M,%'8(=$4!$2_HF_I_<WNBSR_!W(8:X<C9Q
M?PJ,"@*D_ E6YLOR/V(5X](@:#9[_(_3"!Y%A?ZN1^*ZTB!P[C(*N U6O&4&
M$><F=)2R6"+H=]*VZ_];Y]"**L68Y%_?_W_PH*#8"C:Y0[ ZGQW!L2&#CN5B
MIYC+VQE-GT29W07P1(L#BR6U)^TX3U$F?QC&V8V%16SLD6)A3M;X>B/*$F?F
M9@LO&5IDU/-3=<>\&* Q&=#QM.%8#0"%CP 1&](0Y-SLPXAG?8Z?WP%TS,<Y
M'C4\R\;OJ@J29@^V=%@[ULS#]0)L]F&@'<6GM'4'=OVFLB9^&*L;7.$;_@J>
M6A0R9,DWD0+ER']:!"PWR]NVC-?A17E-?OI+?@4>!DVL06!_W"3@H.Q*@3$F
M4W(+.HJ875K,)O9&^SXD=M@D]OW$ISB^3EFJRECBI-P+&L\'8R@\T"&2@5R!
M?G5,KAB:F /[B+;]0E*[/DR[<)0Q2O5VF3(\0L\ -L+X4GGNX/\FM\\.;'1%
MML5)M6Q04W W955RS>\926L<@& 6="UT<UI 8]?Z(?2/FF-=REQ^#*L;4,&6
M]&N;X=7Z-GX[T.X"!;Y3D'QRT,&,H**.=V=N56_#,_OJGOFS;ZG+AP#4S@.4
MG,J\RF[L-?-PW,<A04 ][^0'T?LPA;;.8S<R\AFGK#!!S(#TU;G%(DM-KUR/
MX<A.R2WH"-*'UEX1 B-QFX@GF1IE$_JH?J:@8Q_[$HSRQ.-E;&RW(.E$;D@P
M7NT_"_=;&:Z/3T79N#,[,7L_U=OE"Y['+P'7]8'K6\;[P_LX]S7DZB5_,3 =
MXF>4JMI?2U6/T!W^A.'R10" 3X1KU/8,08>?=<EPK7H1+W)!VSKSR(QF7YK.
M]0X C4BRZB1<PV C9=VD>];=T+_J'I^CN^9\_#YIN&;C-U5SK0;=L1SH ES[
M'$J#B_NYWW#X!/S?Y;I7W9]1_$K3CSJ$,[@[4P-WPO<Q>.T@4$[VZIR?UK%O
M1S:J4VZL'BCH"#-TT/8X7AQ/4FI:R4;B>O3])TJ9_?W._LJ9$@4=>Q_TC#DT
MB;X]MI"-*@MK>N&]&Z^4,M6.B[3*VQ5TY#MTU/X(S^5>2?-WCD 'N3#5#2V*
M--2<Y!O&#G\&QQ5^#$9F0&-'2O$B= V/:PZ_,M)H'N\'FK>&D/'OI_&MZ6HT
M6-^GX'8ZI^%8MP >_HQ_S]%<\RVQX[.G][%&<ZQW "P$(L]3W0PM98VE71&
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M7.L!Z(MHAS?\'0W'!XW6N9\ 0"A[U[MT7[K''Z:4N'[E\'I^F+_KD:/Q'A1
M3O$<(@WA.DE5F.F<GY$Q6<;L'Y2Q,0>JJ51!1VM#!V5%(E<FW,-DN;"=^#@:
M9"<[OR.+=5;]2T%'&M+D-M%J?)"(H#FGWEWTSB*#'_<X04[2A\2"(,MC[%C5
MV^5+(9M4)HJZSLN\JUUB)?KBG:4L?JZ<0KUID((ZWCWBFB-@;#>)>(KF\"K
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M.^9\P^7C\6S.\EW#LEPP052)VAR?2X(.*H9V3SF+':6F;P4=F8*.0O0WBN?
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M!1T*.A1T*.C8$Z%TWS1OX-QW!.Y44@J;*E70D6-"L2E4V=RMZ6IX_,> CE&
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MU-.U)A"0O::L/X6"L>6F:[]A^/7UL+3 ]2UL0P?!85 N:+%)T<19%I1K P+
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M]OMJK.=AMG  .&AM. 2':[1'MH3H(%1#QT:M'[ \('/2C)-[L3DG]A4N2@A
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ME;LJ\]8\RW-JD9E,A58E33AHW%"WQ+,OI['\(UVK%K5(E""]GLX9E;N*V62
M3^0)A\%@,!@,!H/1RK!BSDFF[_R5#.#W<T0ZOJ+VOZ!8'QGTX3:P*_>Z[!&J
MKSC:\"HG4-]>L#S[71J/&ZR&\F-$G2Q-G'2(#LK(?WO('F;,*4.H%9&!#[^?
MVM>>0^TQ:H-5&N!4B($G]R1RA)HJ+R-[%YWK4R),L^A93J/_OHM^SQ;3S^ZM
MTBXS& P&@\%@,!BM"=.W*\E(G4(D8%Z6PZFPV[_6\.PFPZ^\.M0D?]3J-__&
MH"ZBT>YK>G*8*O"'ZN5!W8SFC84%(1!/-KN6(E-1N2O&UO*=VZR "'RF/1R+
MZ7J3:3Q^4>#9!Z1,%MW*GT 38P:D9LNQ7D'__QWZ?0R5Y:D/ T53U?Z*W# 8
M# :#P6 P&#D'&=)$ BXD8W@NC-4LDXYFE1G+E<\(EPA'X^#BUKWWL($L6,A^
M123@O]OH\RHB"S.4QP"A2BGJ) J:[(.)!(R&!R6HR2'?-GSG1E173Z<"N>E7
MGJ-3],YO8;S7!-FQ[$?-1OL\,;VB=QZEY&4P& P&@\%@M M@-_ZM826&*Z\A
MX_2;K&>M4KO\\A7#EW]0!G R-33@98"!CMUZU=),BSM'Z2&.( )PJ0[UFKN-
M/J_3!OV#JEIXG4PM%_C4,TH*ZNU#S:@]T(S9(Q2)<2M^DG)8E0:1Q:MT2%Q+
M9+%9$X\/Z?=Y53 1>H\P$P\&@\%@,!@,1LY(!QF]J'?A.3?E0,<!,?7'AN=,
M4(;OW#@&/(QQ] ]"<U0K;[+[6S%Y/+)L":38?5VFGF<>&H=ZNZ\1LT=1GY[3
M(4\MBM[)6)]MN<YMR$R%(HHI7Q>D"8)QM#E*/)]:BEM4+7]A^,X(V]*$8UT"
MA&]9$"XFKQ6N[*<$\@P&@\%@,!@,1O9)ARP*>54_5*+CK*?'E7-,3SYI^?(T
ME8IV>V$^\&K JZ"T%HXT7&<\JHZ;K@V]Q22$*H7<-/0@?M6!=*X12H#MRT5Q
M4@1#AT*DQ/ZOU2!/%%[%;BE?-RP,1:;0TO$VT',K?$/V0WT/[<U8G\ S #'1
MQ,.9$/+LH_@#8# 8# :#P6#D@'0,[:XR5WG.O[*='I?:OR&<%M/E/MOM$Q&2
M0J^J#_UMA>'):U'+ ZE\#<_Y,C#^\2LGT_F&)'V_&\(6A..F6SF4SC.1SOU9
MHO=!??&MJ//[D&OW;PO/+12M&@"A> JZFOD0RQN^\SMZ%OU87,Y@,!@,!H/!
MR++Q6K&;&:NTE0&>'<*!'?C%9+ W0CLAZLNZMJC%T*EF"^OMOF;4KMQ"(+WN
M.V%"T)TLLSQY5=+> H0UH0Y'$):T+"D-B^]\K(Q\WSFSU9];5.YJN<X)U)__
MI/%LZ%C[/.6YR9M*Y@P&@\%@,!B,/"0=<D\R/G^E= V9)QQ(.?NU$FG[<J2(
ME1^VW9H<=;(4(3]:U#[%].2GVK.Q?AL9L+Z%#D55#4]&W!V3!QF^C?._CG,D
M67E]"1&==Q&6U=J/K;"I:O^0;U\ 47X:SV<VPK-H3(Y)J3 A@\%@,!@,!H.1
M"#HVR'W(T!]%AO2+&28<WZJ0*E^^:'B5HT%N6LQ4!6U'X^#BD%]UM"(<OB($
MB63"N@<A1LB^%?=&072F#]\97@HZ[E54 D_AGM;2\=]8KG.UF#FHBQ)S)PN,
M 9&K K?\$%2!UQF\DC;X0PWEAQ'I&DNM/HWTQ:OI^+=,O_(")2QG;P>#P6 P
M& P&(\](QP+3DPWPHB [%AGH'5LT:F>7%2K"X3GC#%^^J\.>$KB&?)P(Q%DB
M-F3W1(S]0C*L#4]>3D3H<T6*4@L5@V?D3S#ZE1@^64PO[VE%Y?&H_FYZ]C],
M5_X2WI=6(1VXGZ 8Y(,H8,AI=!D,!H/!8# 8V4%TR!XZB].S&2(;2RW7>8>,
MV/L-U[Y(1.V#U>Y^2X3#&]BI(Y$2U.T@ _BEI(H3^LXD9;0W#MD[[GW.'-3%
MC#H59.C_DXY;GEZM$?M1.L]@52PP22#[E>56WDAD83JUF1AW53LCYIRD"@5Z
M1R14>P2ZEY OS]=CEL[S6H'BAT3X(J+Q_.*DZJ8P& P&@\%@,!@)@0Q=TY?E
MU!Y-4RS>K,-UR)"V_V+Y]JF)7'ZG.MG+\BM/1>$Z13B2TUA,L:+.%84-Y?O'
MO="T\IY&3-;0,9[*II46Z9 OAJ+VI2!+"8\SO A33K ,U[G2<.4L78@QR(J%
MBN>><[>J/X+:&8F$.4%('JTX3F4$RPQ9?%QX0P_@VAT,!H/!8# 8C,RCH;R;
MY57\C(S7>]/9+=?5O!\D@_IBRY,_%;%!NR=R>:M1_IR._:OEVK.T9F)]QDD'
MQ.N^W(_^_N$@["LI8I,9TD&DQVJL_$F0FE@N_4[6K"6&9[^-L"W3MP<F5&D]
MTZ3#=Z;!,U4 SQ2#P6 P& P&@Y%1S!S4!8)FRW/N2,) 71]D?I*+5 8DWWE5
MD1;?KBR<-KA/0B$Z,*QGG]V5C.U1AN>\ \,[!6/YY9!G7UJ(:N7;P]0S2JQ&
MY\>JGYGQ"DRQ7.?*PKHXU]T"&&.$45$?ZEJJUD[C\);E.S=">Q)7+P(QNF\?
MJHE4!N[)_H#:0RK,B\%@,!@,!H/!R"A $+R!W1'3GU0J7,]9:'GR30N5PETY
M2$RKV$M,'58B)I45)A0>A&Q5KMV?R,J=U%9]KQ9'8D+RR2H5;[QB@_!R^/8Y
M9/"[&3'071E%1>\"O_S 1(<9(61TS%0Z_JL6B!S&="6UJ?#>A!KEX=L]X09I
M(E4P'9>I2O*+J7\S:#RK^*-@,!@,!H/!8&062%<[NZP0U:G)B$=-C=7;(!@+
ML!-.!*.1",+S2%5K^8ILC%2A5*B5D2R(*!BN\VLZ[^0TC/\G3*]R<+SL5:%H
MQ0#+LZ^R H]*)@QTS_+E'PL2R3H%<D!D#)78Z;BY-,:KXIS["WAPS*ASMDJE
M&R<M+S)^T=]_HHE;>E7C?;F(SO=;==V)U&\&@\%@,!@,!B.3(&-X&!GQ=61T
MHNKVXBT:B$B]Z=N/DN%^B^E6#"^H)V,['<'Q!M$!1 "%Z8BTS$J==#CWA%SY
M(X0:;>]REFN?K/02GOP@,YX.QR4"<T.!7Q7?TS'E_(X(EZ(^7)-,9B[#D]>K
M5,/>P$[;?6[(/.8[+VBM2MKW!A*C2"014?XJ& Q&J^/_ 0  ___L70F84]79
M/I-D9D!D)I,9Q 4K+M7ZN[;BTE_;6K4J6A FN6PJXH9+Q165/3>9 =RJ?ZE+
MQ;9NJ'7J5J7NBEMEF"0#B(@6%44*5D00$5D&YO_>\YU('"<W-YED!N1[G^=[
M(B2YY]QS3^1[S[>\2@D$ H'@!X79@WKZ$L&3O/$!_;R)X(!O+6:%? W6R;ZX
M=4QQO758I[G6GBINE:OX\.*<QFE616IA[U)O+'B*)QY,>./6E]YXJ#D7\R5"
MUZM9_2O5?*O$:4AO+#2(/C^=;%FN8WW'8M:KOGAP5&G"VB?C_;[1MZLO%CR!
MYG KV3=9C/&DMW' .:J^NH?3Y7WQT(GT^2ED'^?CWNAZUY4T! ]0<\_L(C\*
M@4 @$ @$ L&VB6;;H^)]JL@!'TI.[M(<G>/U9)][XJ&1;H;TQJK/)0(UD[ZS
M(D^DXX7BAN!EG6+!O3(._OJ0"F_"&NA-A*;1=]>Y=_ZM=^@[?RJ90P3 "?'@
M3V@^PVDMWJ+O;6KSO=&8OGCUKS%OV:P"@4 @$ @$@FT3\>'%)>0HDY-\%3FX
M_\W1.?X,T08B$F=L]:1COA70!"L6^CO=[[HLQOD2]U@<#Q[I>/V%O4N+9P5[
M>>/6RUE%4M*:]7AQ0^AL%:_>13:K0" 0" 0"@6#;!#G)2-4BFTQ.\HH<4X 6
M( W(EPC]HD-(1YP(1,P*J3?Z[IIQ\%G]*[T-U</H\X^8"(U+8A/:2&LTCXC*
M;U7]Z64Z+2TMD;-^Y(N%)M)G8WF(=DPG$G.A>M/:33:K0" 0" 0"@6#;1+S/
M#N2 ]R4'>2K9RNRC#*$F^MXKN(9J&+1[!Y&..XH;@[W4['[^@I$.M@_)SNLT
MR]I3V;;'@724^V+6;[QQZW;Z/*(=FX5T" 0"P5:-(J5L'UE)#W5SY^YJ9)=N
MRMXQH.RREH;W\)F>RNZ$SRM5Y^7OYQO-17QMS MUF_DRJT#S;<M]XAY'E.ZJ
M[!VZJQN_M_95ZOJN^#N\OV7=V^4^,#>/\S/0^\;3MKDDU\!I#+T7//F??S:6
MG$>;USTY+_J]7=$9OR<\VZ299^SC=<GFGM+NB33K^^VS$[0+GCNQ"Z($Y-S>
M2P0BVR+RC:9@>FIIS-H/!*8C2(<O'IRLYI!3OFA8IP*3CD\\B="8XH1UF*K3
M&SL-Z:"-W&#M[(F%+O#$0_]N2W&^D Z!0"!H#]@E?F7W) ?W?P.J)A10D7,#
M*GJY7T7&T]_5),VOHN/H[\^A]X,5*M*G7(5[T=_W8"<IOX"3C3EU5>/VJU#V
M@?DRNN[.</2V%F<+3F:9"N]#:_NK"A4=1&M[/JWQE?0:YG6/1&FMQ^)YT/MG
MT/,Y&>M>I<*[&N>T4/=!CNJ4TJ[*KNJJ:M(^@THU;O\=U:1N2L^E.2=G'*3*
M>8R:_;'/*M1UY=G=KUU2H:XM+U?V7OG8.UU5>-_\['>[TXYJ=+=R5=O+KVKZ
MFM_<P*15J)K?EJF:'X-PMB01/?5W)W5K[9ZJU)A=6MO;^$[+SV--R]6XO?%\
MY?]_[86Y9W;1W:0:@@_HN@7WSO F_KSU3T_<NDAWT'*)O)&.F"8]7Y%C?ZTF
M/$Y$(#^D8YDO;OW>UQ@Z7LTXUI=I*%]LP-$TMZD>I&4A(I13Q,-ZW)NPADE-
MAT @$.33F:SSPH&#(U*IHH=7J/ IY-A>1,[(1')L[Z7_?H+L97* XO3Z5M+H
MSS%Z_W%ZO8=>[_2S8WP>OD_7^EE U>X.LI"/29:KFCT#*CR YQ6^)E]&<SZ;
M[+1R%3F>'/=>W<CA+U>3*_C4M]"1 S[1+U-VH)MV*L-'82YD(^@^;Z#U?X!>
MGR1[A:S1K/M<6N\&?A[1A^GU5E[WR+F\[M'#L.[L;-9Y\S=7VP.'E C1$33F
M[]*O9_12FM?/F7CD-CX]Z[WIWB]./X9-A,O^+1QEI>YTW:T4>[Q2V3^A]3HS
M3WOG,I!"$&Z:SS'T=P=7J8F[*-?DS_9AK]&:'4+?'0123]>::GYSTU+L3QB+
M7D^EW]?_\/YD[*C".^%P(,T]G8*U1.1DRYB6%P35K\)#6ZXI7>.L2GJ^\K_$
MK9UT<!'V1[Z$=75)W#HH4YO<@I".N/4E.?3O(N7),=TI?Z3C,[*[:+U.<T,Z
M5'QPE4I8A^DH4CRTAJPIA^Y5]Q/IZ*\:K6ZR604"@2 _SB1.U^'X5&IG,O(@
M.5 +Z/43LN5DJ\@)6DVVAO[[&[)U*88_TWN1E?3^%_3Z&=EB.,CDP/R5_FX(
M3FCS0SKLX\BY^CM=>PY=^[_Y,KK>?\@^,(1J&KU> <<+:4TF/:6 J/-RZE3T
MYV0C0>[(^7O/S.ES6C]:^\A79%]_=^VC:\WS^)(LN>Y+L>X!=EJ'5*JQN^&Y
MYG&?^$ST@<A 9%ZZ]:3Q_TT.[95PCI$BELM(1+Y.!+ER>&;OTSSNH/W:/YM[
MI._\"*2.OO]LGO;/IW2M)7AF=-\OTCW_ =='] Q1H4SSP1XS)&ZL(91+^+>D
M?W.IAF>\C%YG(-)5J:)'IMS3@8B$I;FG/_M5336(2?+SB'+@^S3G%UJLZ8<T
M_Q=HC(O55I5N^$/&FU9GZ'YHW8JX^YH.7SPT'PXX-"_46T,J=.M=MZ0C$3J=
MOOL\V7_;F%KU =D]OL2 DUS?;_WI9424<+]_,O46V8RWG+[W5V]#J%K%#\M\
MT@ B-GN8G^]7DSJDHFW(OF7N &F9*Q (!'D IW0@(F$/)Z=C"CDOS\$!-\[M
M)K+F'&R3<93?Y0B)CI8,@A.*U)9<'1KZ_LEP[.A:2W*<EY,U&?*T$!$$LMMQ
MF@_GK(N:V#W_*]]<!,>T0HT_FAST2W&2#8?2$+;U9)MSO ^L^WP3F;J.;#!.
MW[][TITKAA?3_CC D*-E#G-8B;0[C.O&\6Z='"!RH(E7NC% @A$%&IQ-)(VC
M99&!?HX4Y6OOX%FM#[#C/H>LCDA3E-.BL :V+QV)\ZO:/>CSH\V>6V/VX8:
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M.@QSS^S2:2X1C_KJHU"SX(M5'ZWU-QJK]T";V;R/]]:0"D\\>"'(#=E:%T*
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MAV)^%*$;#88L89?@9)T<\6O0XC?#>(@&Q8T07 XD5N^E+QUT3>A^[3NP%]"
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M! *!0" 0;&5 )Z$ .5*&("QTT3ZVF5-Q(I\'N.4NU*N?,@6VCQB']VE3O['
MG+*O[RA%<G>D0ZF=U,3N2%_B>W!TTI'B,P_%PI5J[&ZY1 62A \I4&;^CQ@'
MW&U7I%5F;5\W:_V$G^LI7C8I;(LR"#^F1AZ6&C' \VGM]\FU44"RA@1BDB;%
MZHL,8S>9J-+[M.:S_/H9VL^8CFJO&;*Z(K.@I":SJ,>Y =&27-H+"^D0" 0"
M@4 @: <8[8BS^=19IU"M*Z!(6FO$X!M33U%;H<8?E(WCF"_2H;3 '=+"HB/Y
M=%VG 3G-^VEHC^1RLIX*%.97JNBEIJ9DI7N"UF;;R)VF=+W'>&XSVW:0X_YK
M>B9_ #'C>\D896FK%@;V33W:$.>^_X5T" 0"@4 @$+0#AA>C+B"@:I 6A6Y6
M'[0GZ3!%ZJCYZ,.$H\[[_P   /__[9Q[B)15&,;?V<TMV]VY?;MNZE9:271#
M$8N%J(2VI="P4I%:*A$SQ&Y6IJU;WV5FMR*QRS^51DI%Q$91$%T--C*Z8OW3
MA5HK+XNE*Y12)J73\\PY2^LVCN[,]^T:O#]X../.S+F\YR#O\YUS1N3H2(MW
M>5K\#2D)MJ?$SPT6WOLY+<%:1_Q9(E[%X6OR*AIEZ6A',LWXSM/0-X7J&Z#-
M4%="_$NE#":(=T)*O%/0QP6H[RUH^Q':#4E!'\INC/.NA'BGU8M7(R$P1CH:
MDN)=C+J?AWJAOR(:PT%H'[01L5L$G5-JGQ.2F8@XS$N*_VGQ-MTU<7&;$O)
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>%$51%$51E$CX!\%MX!A.)T%1     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Apr. 24, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">The Cigna Group<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4991898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">900 Cottage Grove Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bloomfield<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">226-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,532,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001739940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">$ 9,812<span></span>
</td>
<td class="nump">$ 12,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="nump">68,494<span></span>
</td>
<td class="nump">65,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpensesAbstract', window );"><strong>Benefits and expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Pharmacy and other service costs</a></td>
<td class="nump">54,100<span></span>
</td>
<td class="nump">48,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet', window );">Medical costs and other benefit expenses</a></td>
<td class="nump">7,924<span></span>
</td>
<td class="nump">10,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">3,722<span></span>
</td>
<td class="nump">4,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">TOTAL BENEFITS AND EXPENSES</a></td>
<td class="nump">66,136<span></span>
</td>
<td class="nump">63,531<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">2,358<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest expense and other</a></td>
<td class="num">(357)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of businesses</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainLoss', window );">Net investment gains (losses)</a></td>
<td class="nump">258<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TOTAL INCOME TAXES</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">SHAREHOLDERS' NET INCOME</a></td>
<td class="nump">$ 1,654<span></span>
</td>
<td class="nump">$ 1,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Shareholders' net income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Pharmacy revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 54,037<span></span>
</td>
<td class="nump">$ 48,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Fees and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 4,443<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NetInvestmentGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (losses) based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NetInvestmentGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BenefitsLossesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BenefitsLossesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BenefitsLossesAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BenefitsLossesAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 220<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479868/944-20-45-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-15<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479838/944-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477965/944-235-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479032/944-605-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -SubTopic 220<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -SubTopic 220<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,861<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax', window );">Net unrealized depreciation on securities and derivatives</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent', window );">Net long-duration insurance and contractholder liabilities measurement adjustments</a></td>
<td class="num">(635)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity', window );">Net translation (depreciation) appreciation on foreign currencies</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Postretirement benefits liability adjustment</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(792)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income</a></td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest', window );">Less: Net income attributable to other noncontrolling interests</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">SHAREHOLDERS' COMPREHENSIVE INCOME</a></td>
<td class="nump">$ 862<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Including Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of net income (loss) attributable to nonredeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,040<span></span>
</td>
<td class="nump">$ 7,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">812<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,607<span></span>
</td>
<td class="nump">28,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,831<span></span>
</td>
<td class="nump">7,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,742<span></span>
</td>
<td class="nump">2,976<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,032<span></span>
</td>
<td class="nump">47,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,902<span></span>
</td>
<td class="nump">18,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesNonCurrent', window );">Reinsurance recoverables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,073<span></span>
</td>
<td class="nump">4,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,704<span></span>
</td>
<td class="nump">3,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,534<span></span>
</td>
<td class="nump">44,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,318<span></span>
</td>
<td class="nump">28,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,253<span></span>
</td>
<td class="nump">2,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SeparateAccountAssetAtCarryingValue', window );">Separate account assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,450<span></span>
</td>
<td class="nump">7,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">153,266<span></span>
</td>
<td class="nump">157,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrent', window );">Current insurance and contractholder liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,455<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PharmacyAndServiceCostsPayable', window );">Pharmacy and other service costs payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,763<span></span>
</td>
<td class="nump">30,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,879<span></span>
</td>
<td class="nump">10,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccruedExpensesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,980<span></span>
</td>
<td class="nump">9,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,529<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,606<span></span>
</td>
<td class="nump">56,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrent', window );">Non-current insurance and contractholder liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,777<span></span>
</td>
<td class="nump">9,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,851<span></span>
</td>
<td class="nump">7,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,769<span></span>
</td>
<td class="nump">4,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,371<span></span>
</td>
<td class="nump">30,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountsLiability', window );">Separate account liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,450<span></span>
</td>
<td class="nump">7,511<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110,824<span></span>
</td>
<td class="nump">116,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingencies &#8212; Note 14</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,914<span></span>
</td>
<td class="nump">31,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,598)<span></span>
</td>
<td class="num">(2,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,106<span></span>
</td>
<td class="nump">47,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: Treasury stock, at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(35,216)<span></span>
</td>
<td class="num">(35,140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,210<span></span>
</td>
<td class="nump">41,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">232<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,442<span></span>
</td>
<td class="nump">41,874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 153,266<span></span>
</td>
<td class="nump">$ 157,919<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Par value per share, $0.01; shares issued, 406&#160;million as of March&#160;31, 2026 and 405 million as of December&#160;31, 2025; authorized shares, 600 million.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of other current liabilities and obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PharmacyAndServiceCostsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects amounts due to pharmacies for prescriptions filled through our retail network of pharmacies. Also includes amounts due to clients for their portion of rebates that must be contractually shared.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PharmacyAndServiceCostsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReinsuranceRecoverablesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable after one year under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReinsuranceRecoverablesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SeparateAccountAssetAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Separate Account Asset, At Carrying Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SeparateAccountAssetAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for variable contract in which all or portion of contract holder's funds is allocated to specific separate account and supported by assets held in separate account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480141/944-80-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480109/944-80-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480109/944-80-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480141/944-80-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">406,000,000<span></span>
</td>
<td class="nump">405,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Total Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Shareholders' Equity</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss)</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Other Non- controlling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 41,243<span></span>
</td>
<td class="nump">$ 41,033<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 31,288<span></span>
</td>
<td class="num">$ (2,341)<span></span>
</td>
<td class="nump">$ 43,519<span></span>
</td>
<td class="num">$ (31,437)<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Total Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Effect of issuing stock for employee benefit plans</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">1,409<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common dividends declared</a></td>
<td class="num">(408)<span></span>
</td>
<td class="num">(408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(1,521)<span></span>
</td>
<td class="num">(1,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NoncontrollingInterestOtherChanges', window );">Other transactions impacting noncontrolling interests</a></td>
<td class="num">(108)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">40,414<span></span>
</td>
<td class="nump">40,226<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">31,443<span></span>
</td>
<td class="num">(2,590)<span></span>
</td>
<td class="nump">44,434<span></span>
</td>
<td class="num">(33,065)<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2025</a></td>
<td class="nump">41,874<span></span>
</td>
<td class="nump">41,713<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">31,790<span></span>
</td>
<td class="num">(2,806)<span></span>
</td>
<td class="nump">47,865<span></span>
</td>
<td class="num">(35,140)<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Total Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Effect of issuing stock for employee benefit plans</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(792)<span></span>
</td>
<td class="num">(792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common dividends declared</a></td>
<td class="num">(413)<span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NoncontrollingInterestOtherChanges', window );">Other transactions impacting noncontrolling interests</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2026</a></td>
<td class="nump">$ 42,442<span></span>
</td>
<td class="nump">$ 42,210<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 31,914<span></span>
</td>
<td class="num">$ (3,598)<span></span>
</td>
<td class="nump">$ 49,106<span></span>
</td>
<td class="num">$ (35,216)<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NoncontrollingInterestOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other activity associated with noncontrolling interest that is not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NoncontrollingInterestOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Total Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common dividends declared (in dollars per share)</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,861<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">650<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainLoss', window );">Investment (gains) losses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(258)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities, net of non-operating effects:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,152<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,507<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReinsuranceRecoverable', window );">Reinsurance recoverable and Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">104<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities', window );">Insurance liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">739<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable', window );">Pharmacy and other service costs payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,570)<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities', window );">Accounts payable and Accrued expenses and other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(988)<span></span>
</td>
<td class="num">(1,174)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH PROVIDED BY OPERATING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">1,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract', window );"><strong>Proceeds from investments sold:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromSaleOfDebtAndEquitySecurities', window );">Debt securities and equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract', window );"><strong>Investment maturities and repayments:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities', window );">Debt securities and equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">185<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLoansReceivable', window );">Commercial mortgage loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Other sales, maturities and repayments (primarily short-term and other long-term investments)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">426<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestmentsAbstract', window );"><strong>Investments purchased or originated:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PaymentsToAcquireDebtAndEquitySecurities', window );">Debt securities and equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(362)<span></span>
</td>
<td class="num">(952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMortgageNotesReceivable', window );">Commercial mortgage loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Other (primarily short-term and other long-term investments)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(557)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PaymentsForProceedsFromPropertyPlantAndEquipment', window );">Property and equipment purchases, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(267)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Divestitures, net of cash sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20<span></span>
</td>
<td class="nump">2,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Renewable energy tax credit equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(637)<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionsToContractHoldersFunds', window );">Deposits and interest credited to contractholder deposit funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WithdrawalFromContractHoldersFunds', window );">Withdrawals and benefit payments from contractholder deposit funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromRepaymentsOfOtherShortTermDebt', window );">Net change in short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(550)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Common stock dividend paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(417)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED IN FINANCING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,141)<span></span>
</td>
<td class="num">(3,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of foreign currency rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(656)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash January 1, including held for sale assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents January 1,</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 7,080<span></span>
</td>
<td class="nump">$ 8,376<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Restricted cash and cash equivalents were reported in other long-term investments and Other assets.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of accounts payable, accrued liabilities and other operating obligations not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NetInvestmentGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (losses) based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NetInvestmentGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PaymentsForProceedsFromPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Property, Plant, And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PaymentsForProceedsFromPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PaymentsToAcquireDebtAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Debt And Equity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PaymentsToAcquireDebtAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturities, repayments and calls of debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ProceedsFromRepaymentsOfOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease and the net proceeds from (repayments of) short-term debt, defined as borrowing having initial term of repayment of one year or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ProceedsFromRepaymentsOfOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ProceedsFromSaleOfDebtAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sales of debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ProceedsFromSaleOfDebtAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionsToContractHoldersFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a segregated fund account during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionsToContractHoldersFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReinsuranceRecoverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of benefits the ceding insurer expects to recover on insurance policies ceded to other insurance entities as of the balance sheet date for all guaranteed benefit types.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReinsuranceRecoverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMortgageNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the purchase of receivables arising from the mortgage note on real estate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMortgageNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WithdrawalFromContractHoldersFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a segregated fund account during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WithdrawalFromContractHoldersFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="ib641022b45dc4b2381a2a2ff76bff34d_3012"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8211; Description of Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Powered by our dedicated people and valued brands, we advance our mission to improve the health and vitality of those we serve. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. The majority of these products and services are offered through employers and other entities, such as governmental and nongovernmental organizations, unions and associations. Certain subsidiaries also offer health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A full description of our segments follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Evernorth Health Services</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services, such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cigna Healthcare</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:700;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as for individual and family plan customers. International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare also included the Medicare Advantage and related businesses until the divestiture of such businesses to Health Care Services Corporation ("HCSC") on March 19, 2025 ("HCSC transaction").</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> comprises the remainder of our business operations, which includes certain continuing business (corporate-owned life insurance ("COLI")), as well as run-off and other non-strategic businesses. Our run-off businesses include the (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013; (ii) settlement annuity business; and (iii) individual life insurance and annuity and retirement benefits businesses, which were sold through reinsurance agreements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span id="iad4ff92f8b8243cd96f4a641a7625340_743"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8211; Summary of Significant Accounting Policies</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain goodwill and other intangible assets amounts in the Consolidated Balance Sheet have been reclassified as of March 31, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">These interim Consolidated Financial Statements are unaudited but include all adjustments (including normal recurring adjustments) necessary, in the opinion of management, for a fair statement of financial position and results of operations for the periods reported. The interim Consolidated Financial Statements and Notes should be read in conjunction with the Consolidated Financial Statements and Notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K"). The Company has not included certain footnote disclosures that would substantially duplicate the disclosures contained in its 2025 Form </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">10-K, unless the information in those disclosures materially changed or is required by GAAP. The preparation of interim Consolidated Financial Statements necessarily relies heavily on estimates. This and other factors, including the seasonal nature of portions of the health care and related benefits business, as well as competitive and other market conditions, call for caution in estimating full-year results based on interim results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">The Company's 2025 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. There are no updates to significant accounting pronouncements recently adopted that have occurred since the Company filed its 2025 Form 10-K. There are no incremental significant accounting pronouncements recently issued and not yet adopted that are expected to impact our operations or financial statements beyond those described in the Company's 2025 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"> The Company continues to progress with its adoption plans, with no significant updates since the 2025 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Accounts Receivable, Net</a></td>
<td class="text"><div><span id="iab9e5d6c7f8041278eb36290adebc81f_13"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8211; Accounts Receivable, Net</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included within Accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Noninsurance customer receivables</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">13,797</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,707&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical manufacturers receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10,914</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Insurance customer receivables</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,652</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">244</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">26,607</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">28,768&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These accounts receivable are reported net of our allowances of $7.7 billion and $6.8 billion as of March&#160;31, 2026 and December&#160;31, 2025, respectively. These allowances include contractual allowances for certain rebates receivable with pharmaceutical manufacturers and certain accounts receivable from third-party payors, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses, and other non-credit adjustments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's allowance for current expected credit losses was $228 million and $199 million as of March&#160;31, 2026 and December&#160;31, 2025, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Accounts Receivable Factoring Facilities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company maintains uncommitted factoring facilities with a total capacity of $2.0 billion under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. In the first quarter of 2026, the Company entered into a new accounts receivable factoring facility with an initial two-year term, in addition to the previously established accounts receivable factoring facility outlined in Note 3 to the Consolidated Financial Statements included in the Company's 2025 Form 10-K (together, the "Facilities"). The Facilities automatically renew and are subject to automatic one-year renewal terms following the expiration of the initial term unless terminated by either party. The transactions under the Facilities are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with the Facilities are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under the Facilities are reflected in Interest expense and other in the Consolidated Statements of Income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We sold receivables under the Facilities of $0.3 billion and $1.4 billion for the three months ended March&#160;31, 2026 and 2025, respectively. For the three months ended March&#160;31, 2026 and 2025, factoring fees paid were not material. As of March&#160;31, 2026 and December&#160;31, 2025, all sold accounts receivable had been collected. As of March&#160;31, 2026, all collections have been remitted to the financial institution. As of December&#160;31, 2025, there were $0.4 billion of collections that had not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplier Finance Program<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramTextBlock', window );">Supplier Finance Program</a></td>
<td class="text"><div style="margin-top:10pt"><span id="ia7fc84917c564cad9c9383247302640f_12"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8211; Supplier Finance Program</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require. </span></div>As of March&#160;31, 2026 and December&#160;31, 2025, $1.3&#160;billion and $1.6&#160;billion, respectively, of the Company's outstanding payment obligations were confirmed as valid within the Program by the financial institution and are reflected in <span style="-sec-ix-hidden:f-378"><span style="-sec-ix-hidden:f-379"><span style="-sec-ix-hidden:f-380"><span style="-sec-ix-hidden:f-381">Accounts payable</span></span></span></span> in the Consolidated Balance Sheets. The amounts confirmed as valid for both periods are predominately associated with one supplier.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-50/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt"><span id="i70b43112ac3247a498e319c771b05e87_13"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 &#8211; Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted earnings per share were computed as follows:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.238%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands, dollars in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' net income</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,654</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,654</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">262,746</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">262,746</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">270,867&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">270,867&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Common stock equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,271</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,271</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total shares</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">262,746</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,271</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">264,017</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">270,867&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">272,953&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Earnings per share</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6.30</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6.26</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4.88&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4.85&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.955%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.096%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On April&#160;22, 2026, the Board of Directors of The Cigna Group (the "Board") declared the second quarter cash dividend of $1.56 per share of The Cigna Group common stock to be paid on June&#160;18, 2026 to shareholders of record on June&#160;4, 2026. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by the Board and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company held approximately 141.4 million shares of common stock in treasury as of March&#160;31, 2026, 141.1 million shares as of December&#160;31, 2025 and 134.1 million shares as of March&#160;31, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span id="i94555fdb495846a18fe0238b309c6410_11"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8211; Debt</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term and Long-Term Debt. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026, the Company repaid $550 million 1.250% senior notes that matured in March 2026. For more information regarding our short-term and long-term debt, see Note 7 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revolving Credit Agreement.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> The Company maintains a $6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for additional one-year periods, subject to consent of the banks (the "Credit Agreement"). Our Credit Agreement provides us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of March&#160;31, 2026, there was no outstanding balance under the Credit Agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Paper. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper balance as of March&#160;31, 2026.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Expense. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense on long-term and short-term debt was $357 million for the three months ended March&#160;31, 2026 and $362 million for the three months ended March&#160;31, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceLossReservesAbstract', window );"><strong>Insurance Loss Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Insurance and Contractholder Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8211; <span id="i360bb05418cb4cd3be784b1eac3699f5_700"></span>Insurance and Contractholder Liabilities</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Account Balances &#8211; Insurance and Contractholder Liabilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance and contractholder liabilities were comprised of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unpaid claims and claim expenses</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,856</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,920</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">316</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Future policy benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">139</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,008</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,147</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Contractholder deposit funds</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,701</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,030</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,778&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,251&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">675</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Unearned premiums</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">914</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">959</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total insurance and contractholder liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,455</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">9,777</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">16,232</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,710&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">9,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">15,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">16,293&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Insurance and contractholder liabilities expected to be paid within one year are classified as current. </span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Unpaid Claims and Claim Expenses &#8211; Cigna Healthcare</span><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $4.7 billion as of March&#160;31, 2026 and $4.4 billion as of March&#160;31, 2025.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:74.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,241</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,018&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, net</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,094</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,859&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,852</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10,606&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,664</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10,384&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Paid costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,119</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,078&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,859</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,978</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">9,550&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Divestiture and other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance, net</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,780</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Add: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">140</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,920</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes unpaid claims amounts classified as liabilities of businesses held for sale prior to the completion of the HCSC transaction. As of December&#160;31, 2024, includes $983 million classified as liabilities of businesses held for sale.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 8 to the Consolidated Financial Statements for additional information on reinsurance.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:53.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Actual completion factors and other</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical cost trend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total favorable variance</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2025.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Favorable prior year development in both years primarily reflects lower than expected utilization of medical services as compared to our assumptions.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Future Policy Benefits</span><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest accretion rate </span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5.64</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current discount rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5.39</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average duration </span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10.5 years</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10.8 years</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">'</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Future policy benefits include deferred profit liability of $348 million as of March&#160;31, 2026 and $359&#160;million as of March&#160;31, 2025. Future policy benefits excluding deferred profit liability were $2.8&#160;billion as of March&#160;31, 2026, $2.9&#160;billion as of December&#160;31, 2025, $3.0&#160;billion as of March&#160;31, 2025, and $2.9&#160;billion as of December&#160;31, 2024. Undiscounted expected future policy benefits were $4.1&#160;billion as of March&#160;31, 2026 and $4.3&#160;billion as of March&#160;31, 2025. As of March&#160;31, 2026 and March&#160;31, 2025, $0.8&#160;billion and $0.9&#160;billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Contractholder Deposit Funds</span><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Contractholder deposit fund liabilities within Other Operations were $6.0 billion as of March&#160;31, 2026, $6.1 billion as of December&#160;31, 2025 and $6.3 billion as of both March&#160;31, 2025 and December&#160;31, 2024. Approximately 37% of the balance is reinsured externally. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2026, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were 3.19%, $2.4 billion and $2.8 billion, respectively. The comparative amounts as of March&#160;31, 2025 were 3.20%, $2.8 billion and $2.8 billion, respectively. More than 99% of the $3.8 billion liability as of March&#160;31, 2026 and the $4.0 billion liability as of March&#160;31, 2025 not reinsured externally is for contracts with guaranteed interest rates of 3% - 4%, and approximately $1.2 billion as of both period ends represented contracts with policies at the guarantee. At these same period ends, $1.0 billion and $1.2 billion was 50 - 150 basis points ("bps") above the guarantee, and the remaining $1.6 billion as of both March&#160;31, 2026 and March&#160;31, 2025 represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. As of both March&#160;31, 2026 and March&#160;31, 2025, more than 90% of these contracts have actual cash values of at least 110% of the guaranteed cash value.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Market Risk Benefits</span><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities for market risk benefits ("MRBs") consist of variable annuity reinsurance contracts in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within 30 days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Market risk benefits activity was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:74.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">674</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">785&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">714</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to expected run-off</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">(6)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">(4)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to capital markets versus expected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">13</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to policyholder behavior versus expected</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">(5)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">716</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Nonperformance risk (own credit risk), end of period</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">(41)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">(48)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">675</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">830&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Reinsured market risk benefit, end of period</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">715</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">876&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 8 to the Consolidated Financial Statements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions, excludes impact of reinsurance ceded)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net amount at risk</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,194</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Average attained age of contractholders (weighted by exposure)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">77.6 years</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">77.0 years</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceLossReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceLossReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/944-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceTextBlock', window );">Reinsurance</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="id20be86505734bd88680a83a2a1e6585_624"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 8 &#8211; Reinsurance</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables primarily for expected credit losses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's reinsurance recoverables as of March&#160;31, 2026 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Collateral Provisions Exist That May Mitigate Risk of Credit Loss </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">No Collateral</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Ongoing operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">A- equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">227</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">BBB- to BBB+ equivalent current credit ratings</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition, disposition or run-off activities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">BBB+ equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">280</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,810</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,116</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables before market risk benefits</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">361</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,822</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,502</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for uncollectible reinsurance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">715</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,195</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Certified by a nationally recognized statistical ratings organization ("NRSRO").</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Comprised of six reinsurers, of which 77%</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes $122 million of current reinsurance recoverables that are reported in Other current assets.</span></div>The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 7 to the Consolidated Financial Statements. Berkshire reinsured 100% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit, with approximately $3.0 billion remaining as of March&#160;31, 2026. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit. As of both March&#160;31, 2026 and 2025, market risk benefits (shown in the table net of nonperformance risk as of March&#160;31, 2026) were predominantly reinsured by Berkshire, which is rated AA+ by an NRSRO. As of March&#160;31, 2026, approximately 100% of the Berkshire recoverable is secured by assets in a trust.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479838/944-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479032/944-605-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479838/944-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="iffda1ddb399742d1a8a04892fba27ddb_14"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 &#8211; Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's investments by category and current or long-term classification:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,859</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,671&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,641</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,669</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,220</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,272</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Policy loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,158</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,158</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,037&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,037&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">812</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">18,902</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">19,714</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18,471&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">19,527&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Investment Portfolio</span><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of March&#160;31, 2026:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">566</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,842</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,783</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,017</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,969</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,956</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,766</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">228</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,739</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Appreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">452</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">452</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,793</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(402)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,377</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">228</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,739</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(437)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,704&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,410&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">8,660&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Review of Declines in Fair Value. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">One year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,674</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,700</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">609</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">276</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">632</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">More than one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,757</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,146</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(389)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">743</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,382&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,835</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,272</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(437)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,066</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,733&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,100&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the values of the Company's equity security investments: </span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,893</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,584</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,994</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,669</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,870&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,556&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Mortgage Loans</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high-quality, primarily completed and substantially leased operating properties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company regularly evaluates and monitors credit risk from the initial mortgage loan underwriting and throughout the investment holding period. The annual portfolio review performed in the second quarter of 2025 confirmed ongoing strong overall credit quality in line with the previous year's results. For more information on the Company's accounting policies and methodologies regarding these investments, see Note 11 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Below 60%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">393</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2.13</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2.13</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">60% to 79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">694</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">80% to 100%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.92</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.79</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,272</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.74</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1.72</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Long-Term Investments</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,993</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,961</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,158</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,037&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Derivative Financial Instruments</span><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt. The Company also has derivative instruments associated with certain equity securities; see Note 12A to the Consolidated Financial Statements in the Company&#8217;s 2025 Form 10-K for further information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2026, the notional value of interest rate swap contracts increased to $3.5 billion compared with $3.2 billion as of December&#160;31, 2025. There were no other material changes to the Company's individual derivative hedging strategies during the three months ended March&#160;31, 2026. Please refer to the Company's 2025 Form 10-K for further discussion of the types of derivative financial instruments and associated accounting policies. The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of March&#160;31, 2026 and December&#160;31, 2025. The gross fair values of our derivative financial instruments are presented in Note 10 to the Consolidated Financial Statements. </span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Investment Gains and Losses</span>Net investment gains (losses) before income taxes were $258&#160;million for the three months ended March&#160;31, 2026 versus $(2)&#160;million for the three months ended March&#160;31, 2025. Investment results increased primarily due to fair value changes of derivative instruments associated with certain equity securities. These amounts exclude investment gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span id="i1597debdc6cf41409a9c5b168712b46e_14"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 &#8211; Fair Value Measurements </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For a description of the policies, methods and assumptions that are used to estimate fair value and determine the fair value hierarchy for each class of financial instruments, see Note 12 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Financial Assets and Financial Liabilities Carried at Fair Value</span><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides information about the Company's investment and derivative financial assets and liabilities carried at fair value on a recurring basis. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets at fair value</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">122</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">452</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,106</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,377</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">195</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">228</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,890</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,173</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,270</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities at fair value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">343</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Excludes certain equity securities that have no readily determinable fair value.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 3 Financial Assets and Financial Liabilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Information about Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The significant unobservable input used to value our corporate and government debt securities, and mortgage and other asset-backed securities, is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Adjustment Range (Weighted Average by Quantity) as of</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Fair value in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">280</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10 - 920 (135)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">60 - 920 (175)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">115 - 340 (160) </span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">105 - 350 (160)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Level 3 debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Information about Derivative Instruments. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">See Note 12A to the Consolidated Financial Statements in the Company&#8217;s 2025 Form 10-K for further information regarding our Level 3 derivative instruments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">896</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) included in Shareholders' net income</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Losses) gains included in Other comprehensive loss</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Purchases, sales and settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total purchases, sales and settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Transfers into / (out of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total transfers into / (out of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,146</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Total gains and losses included in Shareholders' net income in the table above are reflected in the Consolidated Statements of Income as <span style="-sec-ix-hidden:f-979">Net investment gains/losses</span> and as <span style="-sec-ix-hidden:f-980">Net investment income/losses</span>. Gains and losses included in Other comprehensive loss, net of tax, in the table above are reflected in <span style="-sec-ix-hidden:f-981">Net unrealized depreciation on securities and derivatives</span> in the Consolidated Statements of Comprehensive Income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2026 and 2025 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Level 3 Financial Assets and Financial Liabilities above for more information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. The separate account activity for the three months ended March&#160;31, 2026 and 2025 was primarily driven by changes in the market values of the underlying separate account investments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Fair values of Separate account assets were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Guaranteed separate accounts (see Note 14)</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">332</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">570</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">262</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,766</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,195</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,098</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,099&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,765</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,826&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts priced at net asset value as a practical expedient </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">662</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,427</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,487&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Non-guaranteed separate accounts include $3.7 billion as of March&#160;31, 2026 and $3.8 billion</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">as of December&#160;31, 2025 in assets supporting the Company's pension plans, including $0.1 billion classified in Level 3 as of March&#160;31, 2026 and $0.2 billion</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">as of December&#160;31, 2025. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the three months ended March&#160;31, 2026 or 2025. </span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Assets and Liabilities Measured at Fair Value under Certain Conditions</span><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">For the three months ended March&#160;31, 2026 and 2025, impairments recognized requiring the assets and liabilities described above to be measured at fair value were not material. Observable price changes for equity securities with no readily determinable fair value were not material for the three months ended March&#160;31, 2026 or March&#160;31, 2025.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Fair Value Disclosures for Financial Instruments Not Carried at Fair Value</span><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.045%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Fair Value Hierarchy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,227</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,272</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, including current maturities, excluding finance leases</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">28,838</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">30,783</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">29,907&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">31,352&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="i863307f831dc42769ca918fef181998a_940"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 11 &#8211; Accumulated Other Comprehensive Income (Loss)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Accumulated Other Comprehensive Income (Loss) ("AOCI") includes net unrealized appreciation/depreciation on securities and derivatives, change in discount rate and instrument-specific credit risk for certain long-duration insurance contractholder liabilities (see Note 7 to the Consolidated Financial Statements), foreign currency translation, and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Shareholders' other comprehensive loss, net of tax, for the three months ended March 31, 2026 and March 31, 2025 is primarily attributable to the change in discount rates for certain long-duration liabilities and unrealized changes in the market values of securities and derivatives, including the impacts from unconsolidated entities reported on the equity method. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the components of AOCI were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:81.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.790%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Securities and derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">594</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (depreciation) on securities and derivatives, before reclassification, net of tax benefit of $44 and $49, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(133)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(1) and $(9), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss), net of tax</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(129)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">465</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net long-duration insurance and contractholder liabilities measurement adjustments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(2,329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit of $214 and $33, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(636)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to Shareholders' net income, net of tax expense of $&#8212; and $16, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in discount rate for certain long-duration liabilities, net of tax benefit of $214 and $49, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(636)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $&#8212; and $1, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss), net of tax</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(635)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(2,964)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,206)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net translation of foreign currencies, before reclassification, net of tax benefit (expense) of $2 and $(6), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(162)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Postretirement benefits liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(944)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(2) and $(2), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(937)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(931)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(2,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive (loss), net of tax benefit of $257 and $82, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(792)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3,598)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,590)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclousre of the changes in the componenets of other comprehensive income/loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Optimization Program<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Strategic Optimization Program</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="ida55c25e8fb54e10816a26583a743776_1349"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 12 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Strategic Optimization Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2025, the Company commenced an enterprise-wide initiative to evolve our business and deliver a more efficient and improved experience for our patients, providers and customers. The Company expects that the program will continue through 2028 and is continuing to evaluate additional opportunities to improve the overall efficiency and effectiveness of our operations. The program includes severance and other employee costs, asset impairments and accelerated asset amortization, and the operating results of certain small non-strategic businesses that we plan to discontinue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2026, we reported total costs of $380 million pre-tax ($290 million after-tax) associated with this initiative, compared with $215 million ($163 million after-tax) for the three months ended March&#160;31, 2025. The total costs for the three months ended March&#160;31, 2026 included $377 million, pre-tax in Selling, general and administrative expenses, which was primarily associated with severance ($337 million). The total costs for the three months ended March&#160;31, 2025 included $198 million, pre-tax in Selling, general and administrative expenses, which was primarily associated with severance ($171 million). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Program-to-date total costs of $1,129 million pre-tax ($855 million after-tax) included $993 million in Selling, general and administrative expenses, which were primarily associated with severance ($715 million) and asset impairments ($101 million). The remainder of the total program costs reflects the operating results of certain non-strategic businesses. We expect substantially all of the accrued liability to be paid by the end of 2026. See Note 15 to the Consolidated Financial Statements for further details of the strategic optimization program by segment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2025</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">140</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2026 charges</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">337</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2026 payments</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(75)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2026</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span id="if8a7d32f2f9a48df9d2560389dd78819_12"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 13 &#8211; Income Taxes</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense. </span>The 18.0% effective tax rate for the three months ended March&#160;31, 2026 was higher than the 14.5% rate for the three months ended March&#160;31, 2025 primarily due to the absence of a benefit related to the<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Other Matters<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Other Matters</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="iac22c09659494a23aa923ff1c0be1036_2784"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 14 &#8211; Contingencies and Other Matters</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Financial Guarantees: Retiree and Life Insurance Benefits</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of March&#160;31, 2026, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $390 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of March&#160;31, 2026. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Certain Other Guarantees</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company had indemnification obligations as of March&#160;31, 2026 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no recorded liabilities for these indemnification obligations as of March&#160;31, 2026.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Guaranty Fund Assessments</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the three months ended March&#160;31, 2026.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Legal and Regulatory Matters</span><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="ia0e64411f920407abbeb7bfa2e95bbb4_620"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 15 &#8211; Segment Information</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chair and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to each segment and assessing its performance.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not report total assets by segment because this is not a metric used by the CODM to allocate resources or evaluate segment performance.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:65.427%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Strategic optimization program</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(primarily Selling, general and administrative expenses)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">380</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">290</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Integration and transaction-related costs</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(Selling, general and administrative expenses)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Deferred tax expenses, net</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(Income taxes, less amount attributable to noncontrolling interests)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Gain) on sale of businesses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Benefits) associated with litigation matters</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(Selling, general and administrative expenses)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total impact from special items</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">322</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Integration and Transaction-Related Costs. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March&#160;31, 2026 and March&#160;31, 2025 the Company incurred transaction-related costs, as shown in the table above, associated with the HCSC transaction. These costs incurred consisted primarily of post-closing technology activities to separate the divested systems; fees for legal, advisory and other professional services; and certain employment-related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Summarized segment financial information was as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2026</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,206</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10,039</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,292</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,526)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">11,454</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,522)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,494</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net investment results from certain equity method investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">11,477</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,522)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,517</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">55,700</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,664</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,301</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">226</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,466</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,514</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(404)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,603</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,561</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,481</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,270</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(261)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(235)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">388</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">390</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Strategic optimization program</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">380</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Benefits) associated with litigation matters</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,466</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,514</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(404)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,603</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other segment information</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">560</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">650</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">52,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,891)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">53,681&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,532&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,886)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,502&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">53,681&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,482&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,886)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,452&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">51,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10,385&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Integration and transaction-related costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Strategic optimization program</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Gain) on sale of businesses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other segment information</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from external customers includes Pharmacy revenues, Premiums, and Fees and other revenues. The following table presents these revenues by product, premium and service type:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.011%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Products (Pharmacy revenues) (ASC 606)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Network revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">31,080</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">28,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Home delivery and specialty revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">19,788</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18,937&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,426</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Evernorth Health Services</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">54,294</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">50,226&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(257)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Pharmacy revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">54,037</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">48,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Insurance premiums (ASC 944)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Employer insured</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,996</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,363&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Stop loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,116</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Individual and Family Plans</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">873</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">507</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,492</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">11,650&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">International Health</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,113</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Cigna Healthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">9,605</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12,628&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">154</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Premiums</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">9,812</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Services (Fees) (ASC 606) and other revenues</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,123</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,746</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,423)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Fees and other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,443</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from external customers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,292</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,264&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other revenues for the three months ended March&#160;31, 2026 and 2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">were $159 million and $162 million, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial and performance guarantees. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Evernorth Health Services may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period, and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. This guarantee liability was $2.0 billion as of March&#160;31, 2026 and $1.8 billion as of December&#160;31, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ci_DavidCordaniMember', window );">David Cordani [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">On February&#160;6, 2026, David Cordani, Chair and Chief Executive Officer of The Cigna Group, adopted a 10b5-1 plan. Mr. Cordani's plan provides for (i) the sale of shares of The Cigna Group common stock issuable upon vesting of performance awards (the actual number of shares depends on actual performance achieved and may range from 0% to 200% of the 62,366 shares subject to the awards at the target level of performance), net of shares withheld to satisfy applicable tax obligations; and (ii) the exercise of up to 212,543 vested stock options and the associated sale of shares of The Cigna Group common stock acquired upon exercise to cover the exercise price, applicable tax obligations and fees and 50% of the resulting net shares acquired upon exercise (such limitation reflecting The Cigna Group stock ownership guidelines), through April&#160;30, 2027.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">David Cordani<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chair and Chief Executive Officer of The Cigna Group<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">February&#160;6, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">April&#160;30, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">448 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember', window );">Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Zero PercentTarget Level [Member] | David Cordani [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember', window );">Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At 200 Percent Target Level [Member] | David Cordani [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">124,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember', window );">Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Target Level [Member] | David Cordani [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">62,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=ci_TradingArrangementStockOptionsMember', window );">Trading Arrangement, Stock Options [Member] | David Cordani [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">212,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ci_DavidCordaniMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ci_DavidCordaniMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=ci_TradingArrangementStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=ci_TradingArrangementStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain goodwill and other intangible assets amounts in the Consolidated Balance Sheet have been reclassified as of March 31, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">These interim Consolidated Financial Statements are unaudited but include all adjustments (including normal recurring adjustments) necessary, in the opinion of management, for a fair statement of financial position and results of operations for the periods reported. The interim Consolidated Financial Statements and Notes should be read in conjunction with the Consolidated Financial Statements and Notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K"). The Company has not included certain footnote disclosures that would substantially duplicate the disclosures contained in its 2025 Form </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">10-K, unless the information in those disclosures materially changed or is required by GAAP. The preparation of interim Consolidated Financial Statements necessarily relies heavily on estimates. This and other factors, including the seasonal nature of portions of the health care and related benefits business, as well as competitive and other market conditions, call for caution in estimating full-year results based on interim results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">The Company's 2025 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. There are no updates to significant accounting pronouncements recently adopted that have occurred since the Company filed its 2025 Form 10-K. There are no incremental significant accounting pronouncements recently issued and not yet adopted that are expected to impact our operations or financial statements beyond those described in the Company's 2025 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"> The Company continues to progress with its adoption plans, with no significant updates since the 2025 Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Evernorth Health Services may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period, and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceLossReservesAbstract', window );"><strong>Insurance Loss Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy', window );">Unpaid Claims and Claims Expenses</a></td>
<td class="text">This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FuturePolicyBenefitsLiabilityPolicy', window );">Future Policy Benefits</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">'</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FuturePolicyBenefitsLiabilityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liability for future benefit to be paid to or on behalf of policyholder. Includes, but is not limited to, input, judgment, assumption, and method used in measuring liability and change in input, judgment, and assumption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FuturePolicyBenefitsLiabilityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceLossReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceLossReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceAccountingPolicy', window );">Reinsurance</a></td>
<td class="text">The Company reviews its reinsurance arrangements and establishes reserves against the recoverables primarily for expected credit losses.Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 7 to the Consolidated Financial Statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479838/944-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479032/944-605-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479032/944-605-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479032/944-605-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Review of Declines in Fair Value. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company regularly evaluates and monitors credit risk from the initial mortgage loan underwriting and throughout the investment holding period. The annual portfolio review performed in the second quarter of 2025 confirmed ongoing strong overall credit quality in line with the previous year's results. For more information on the Company's accounting policies and methodologies regarding these investments, see Note 11 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. </span></div>Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">Please refer to the Company's 2025 Form 10-K for further discussion of the types of derivative financial instruments and associated accounting policies.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measures and Disclosures (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For a description of the policies, methods and assumptions that are used to estimate fair value and determine the fair value hierarchy for each class of financial instruments, see Note 12 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 3 Financial Assets and Financial Liabilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Information about Debt Securities. </span>The significant unobservable input used to value our corporate and government debt securities, and mortgage and other asset-backed securities, is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Total gains and losses included in Shareholders' net income in the table above are reflected in the Consolidated Statements of Income as <span style="-sec-ix-hidden:f-979">Net investment gains/losses</span> and as <span style="-sec-ix-hidden:f-980">Net investment income/losses</span>. Gains and losses included in Other comprehensive loss, net of tax, in the table above are reflected in <span style="-sec-ix-hidden:f-981">Net unrealized depreciation on securities and derivatives</span> in the Consolidated Statements of Comprehensive Income.</span></div>Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads.<span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Assets and Liabilities Measured at Fair Value under Certain Conditions</span><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountsPolicy', window );">Separate Accounts</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts</span></div>The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows.Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contracts reported in separate accounts, including the extent and terms of minimum guarantees, basis of presentation for separate account assets and liabilities and related separate account activity, the liability valuation method and assumptions used in valuing each type of policyholder and contract holder account maintained by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">AOCI</a></td>
<td class="text">Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guarantees</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Financial Guarantees: Retiree and Life Insurance Benefits</span>The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.<span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Certain Other Guarantees</span><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company had indemnification obligations as of March&#160;31, 2026 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. </span></div>The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/460/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chair and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to each segment and assessing its performance.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. </span></div>The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Accounts Receivable, Net</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included within Accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Noninsurance customer receivables</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">13,797</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,707&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical manufacturers receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10,914</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Insurance customer receivables</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,652</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">244</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">26,607</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">28,768&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted earnings per share were computed as follows:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.238%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands, dollars in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' net income</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,654</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,654</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">262,746</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">262,746</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">270,867&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">270,867&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Common stock equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,271</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,271</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total shares</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">262,746</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,271</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">264,017</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">270,867&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">272,953&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Earnings per share</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6.30</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6.26</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4.88&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4.85&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.955%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.096%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceLossReservesAbstract', window );"><strong>Insurance Loss Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Insurance and Contractholder Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance and contractholder liabilities were comprised of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unpaid claims and claim expenses</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,856</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,920</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">316</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Future policy benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">139</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,008</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,147</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Contractholder deposit funds</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,701</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,030</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,778&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,251&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">675</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Unearned premiums</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">914</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">959</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total insurance and contractholder liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,455</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">9,777</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">16,232</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,710&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">9,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">15,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">16,293&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:74.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,241</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,018&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, net</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,094</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,859&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,852</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10,606&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,664</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10,384&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Paid costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,119</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,078&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,859</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,978</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">9,550&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Divestiture and other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance, net</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,780</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Add: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">140</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,920</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock', window );">Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:53.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Actual completion factors and other</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical cost trend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total favorable variance</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2025.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock', window );">Future Policy Benefit Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest accretion rate </span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5.64</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current discount rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5.39</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average duration </span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10.5 years</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10.8 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitActivityTableTextBlock', window );">Summary of Market Risk Benefit</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Market risk benefits activity was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:74.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">674</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">785&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">714</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to expected run-off</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">(6)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">(4)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to capital markets versus expected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">13</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to policyholder behavior versus expected</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">(5)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">716</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Nonperformance risk (own credit risk), end of period</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">(41)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">(48)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">675</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">830&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Reinsured market risk benefit, end of period</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">715</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">876&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock', window );">Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 8 to the Consolidated Financial Statements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions, excludes impact of reinsurance ceded)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net amount at risk</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,194</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Average attained age of contractholders (weighted by exposure)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">77.6 years</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">77.0 years</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceLossReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceLossReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of beginning balance to ending balance for liability for future policy benefit, with separate presentation of expected future net premium and expected future benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29E<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of beginning balance to ending balance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reasons for the change in incurred claims and claim adjustment expenses recognized in the income statement attributable to insured events of prior fiscal years. Also includes disclosures of additional premiums or return premiums accrued as a result of changes in incurred claims and claim adjustment expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.W)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the guaranteed benefits in excess of the current account balance, quantifies such excesses (the net amounts at risk) and includes other relevant, pertinent information as of the most recent balance sheet date by product type.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480109/944-80-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479808/944-20-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock', window );">Reinsurance Recoverables</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company's reinsurance recoverables as of March&#160;31, 2026 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Collateral Provisions Exist That May Mitigate Risk of Credit Loss </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">No Collateral</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Ongoing operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">A- equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">227</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">BBB- to BBB+ equivalent current credit ratings</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition, disposition or run-off activities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">BBB+ equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">280</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,810</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,116</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables before market risk benefits</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">361</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,822</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,502</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for uncollectible reinsurance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">715</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,195</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Certified by a nationally recognized statistical ratings organization ("NRSRO").</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Comprised of six reinsurers, of which 77%</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes $122 million of current reinsurance recoverables that are reported in Other current assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reinsurer or group of reinsurers for whom the entity has a concentration of credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -SubTopic 825<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477351/944-825-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock', window );">Investments by category and current or long-term classification</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's investments by category and current or long-term classification:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,859</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,671&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,641</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,669</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,220</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,272</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Policy loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,158</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,158</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,037&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,037&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">812</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">18,902</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">19,714</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18,471&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">19,527&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Debt Securities by Contractual Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of March&#160;31, 2026:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">566</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,842</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,783</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,017</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,969</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,956</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,766</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">228</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,739</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Gross Unrealized Appreciation (Depreciation) on Debt Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Appreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">452</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">452</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,793</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(402)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,377</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">228</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,739</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(437)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,704&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,410&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">8,660&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Summary of Debt Securities with a Decline in Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">One year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,674</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,700</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">609</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">276</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">632</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">More than one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,757</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,146</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(389)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">743</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,382&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,835</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,272</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(437)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,066</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,733&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,100&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock', window );">Equity Security Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the values of the Company's equity security investments: </span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,893</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,584</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,994</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,669</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,870&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,556&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock', window );">Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Below 60%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">393</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2.13</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2.13</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">60% to 79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">694</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">80% to 100%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">0.92</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">0.79</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,272</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1.74</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1.72</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock', window );">Carrying Value Information for Other Long-Term Investments</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,993</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,961</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,158</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,037&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI And Equity Securities Without Readily Determinable Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Other Long-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financing receivables by credit quality indicator. The credit quality indicator is a statistic about the credit quality of financing receivables. Examples include, but not limited to, consumer credit risk scores, credit-rating-agency ratings, an entity's internal credit risk grades, loan-to-value ratios, collateral, collection experience and other internal metrics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Financial Assets and Financial Liabilities Carried at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides information about the Company's investment and derivative financial assets and liabilities carried at fair value on a recurring basis. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets at fair value</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">122</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">452</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,106</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,377</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">195</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">228</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,890</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,173</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,270</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities at fair value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">343</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Excludes certain equity securities that have no readily determinable fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Adjustment Range (Weighted Average by Quantity) as of</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Fair value in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">280</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10 - 920 (135)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">60 - 920 (175)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">115 - 340 (160) </span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">105 - 350 (160)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Level 3 debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">896</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) included in Shareholders' net income</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Losses) gains included in Other comprehensive loss</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Purchases, sales and settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total purchases, sales and settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Transfers into / (out of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total transfers into / (out of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,146</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueOfSeparateAccountAssetsTableTextBlock', window );">Fair Values of Separate Account Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Fair values of Separate account assets were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Guaranteed separate accounts (see Note 14)</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">332</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">570</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">262</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5,766</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,195</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,098</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,099&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">6,765</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,826&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts priced at net asset value as a practical expedient </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">662</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,427</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,487&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Non-guaranteed separate accounts include $3.7 billion as of March&#160;31, 2026 and $3.8 billion</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">as of December&#160;31, 2025 in assets supporting the Company's pension plans, including $0.1 billion classified in Level 3 as of March&#160;31, 2026 and $0.2 billion</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">as of December&#160;31, 2025. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value Disclosures for Financial Instruments Not Carried at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.045%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Fair Value Hierarchy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,227</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,272</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, including current maturities, excluding finance leases</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">28,838</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">30,783</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">29,907&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">31,352&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets and liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3, by class of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueOfSeparateAccountAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclose the aggregate fair value of separate account assets, by fair value level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueOfSeparateAccountAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in the Components of AOCI</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the components of AOCI were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:81.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.790%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Securities and derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">594</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (depreciation) on securities and derivatives, before reclassification, net of tax benefit of $44 and $49, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(133)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(1) and $(9), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss), net of tax</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(129)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">465</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net long-duration insurance and contractholder liabilities measurement adjustments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(2,329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit of $214 and $33, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(636)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to Shareholders' net income, net of tax expense of $&#8212; and $16, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in discount rate for certain long-duration liabilities, net of tax benefit of $214 and $49, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(636)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $&#8212; and $1, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss), net of tax</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(635)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(2,964)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,206)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net translation of foreign currencies, before reclassification, net of tax benefit (expense) of $2 and $(6), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(162)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Postretirement benefits liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(944)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(2) and $(2), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(937)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(931)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(2,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive (loss), net of tax benefit of $257 and $82, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(792)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3,598)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,590)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Optimization Program (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Roll forward of Accrued Liability</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2025</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">140</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2026 charges</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">337</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2026 payments</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(75)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2026</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfSpecialItemsTableTextBlock', window );">Summary of Special Items</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:65.427%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Strategic optimization program</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(primarily Selling, general and administrative expenses)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">380</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">290</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Integration and transaction-related costs</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(Selling, general and administrative expenses)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Deferred tax expenses, net</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(Income taxes, less amount attributable to noncontrolling interests)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Gain) on sale of businesses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Benefits) associated with litigation matters</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;(Selling, general and administrative expenses)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total impact from special items</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">322</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summarized Segment Financial Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Summarized segment financial information was as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2026</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,206</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10,039</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,292</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,526)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">11,454</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,522)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,494</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net investment results from certain equity method investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">11,477</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,522)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,517</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">55,700</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,664</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,301</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">226</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,466</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,514</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(404)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,603</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,561</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,481</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,270</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(261)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(235)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">388</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">390</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Strategic optimization program</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">380</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Benefits) associated with litigation matters</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,466</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,514</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(404)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,603</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other segment information</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">560</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">650</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">52,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,891)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">53,681&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,532&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,886)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,502&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">53,681&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,482&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,886)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,452&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">51,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10,385&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Integration and transaction-related costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Strategic optimization program</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Gain) on sale of businesses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other segment information</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span>Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2026</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,206</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">10,039</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,292</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,312</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,526)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">11,454</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,522)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,494</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net investment results from certain equity method investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">58,442</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">11,477</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,522)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,517</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">55,700</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">7,664</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,301</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">226</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,466</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,514</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(404)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,603</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,561</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,481</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,270</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(261)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(235)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">388</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">390</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Strategic optimization program</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">380</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Benefits) associated with litigation matters</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,466</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,514</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(404)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,603</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other segment information</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">560</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">650</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">52,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,891)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">53,681&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,532&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,886)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,502&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">53,681&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14,482&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,886)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,452&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">51,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10,385&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: Income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net investment (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Integration and transaction-related costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Strategic optimization program</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;(Gain) on sale of businesses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other segment information</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span>Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Revenue from External Customers</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from external customers includes Pharmacy revenues, Premiums, and Fees and other revenues. The following table presents these revenues by product, premium and service type:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.011%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Products (Pharmacy revenues) (ASC 606)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Network revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">31,080</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">28,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Home delivery and specialty revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">19,788</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18,937&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3,426</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Evernorth Health Services</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">54,294</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">50,226&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(257)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Pharmacy revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">54,037</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">48,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Insurance premiums (ASC 944)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Employer insured</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,996</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,363&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Stop loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2,116</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Individual and Family Plans</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">873</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">507</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">8,492</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">11,650&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">International Health</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,113</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Cigna Healthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">9,605</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12,628&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">154</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Premiums</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">9,812</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Services (Fees) (ASC 606) and other revenues</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,123</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1,746</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1,423)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total Fees and other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">4,443</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">3,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from external customers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">68,292</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">65,264&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Other revenues for the three months ended March&#160;31, 2026 and 2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">were $159 million and $162 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ScheduleOfSpecialItemsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of pre- and after-tax amounts reported as special items, attributable to the parent. Special items are amounts that management does not believe are representative of underlying results of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ScheduleOfSpecialItemsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net - Amounts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable', window );">Noninsurance customer receivables</a></td>
<td class="nump">$ 13,797<span></span>
</td>
<td class="nump">$ 14,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PharmaceuticalManufacturerReceivable', window );">Pharmaceutical manufacturer receivables</a></td>
<td class="nump">10,914<span></span>
</td>
<td class="nump">12,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceCustomerReceivables', window );">Insurance customer receivables</a></td>
<td class="nump">1,652<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total</a></td>
<td class="nump">$ 26,607<span></span>
</td>
<td class="nump">$ 28,768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceCustomerReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables due from customers under insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceCustomerReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables due from customers that are not under insurance contracts. These include pharmacy sales and fees due from employer clients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PharmaceuticalManufacturerReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables due from pharmaceutical manufacturers related to rebate contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PharmaceuticalManufacturerReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net - Allowances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AllowanceForReceivablesCurrent', window );">allowances</a></td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">allowances for current expected credit losses</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AllowanceForReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for receivables, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AllowanceForReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net - Factoring Facility (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity', window );">Total capacity, uncommitted factoring facilities</a></td>
<td class="nump">$ 2,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm', window );">Automatic renewal term, uncommitted factoring facilities (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold', window );">Accounts receivable sold, uncommitted factoring facilities</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid', window );">Factoring fees paid, uncommitted factoring facilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding', window );">Accounts receivable sold that remain outstanding, uncommitted factoring facilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted', window );">Receivables collected but not remitted to the financial institution</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of, as of the reporting date, of receivables sold to a financial institution under uncommitted Accounts receivable factoring facilities that have been received from the manufacturers but not yet remitted to the financial institution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, as of the reporting date, of receivables sold to a financial institution under uncommitted Accounts receivable factoring facilities that have not been collected from the manufacturers and have been removed from the Balance Sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables sold to a financial institution under uncommitted Accounts receivable factoring facilities during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Automatic renewal term for uncommitted Accounts receivable factoring facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Factoring fees paid under uncommitted Account Receivable factoring facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of certain accounts receivable that may be sold on a non-recourse basis to a financial institution under uncommitted accounts receivable factoring facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplier Finance Program (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligation', window );">Outstanding payment obligations, supplier finance program</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationCurrent', window );">Outstanding payment obligations, current</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration', window );">Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accounts payable<span></span>
</td>
<td class="text">Accounts payable<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accounts payable<span></span>
</td>
<td class="text">Accounts payable<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for supplier finance program, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes obligation for supplier finance program, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes obligation for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Basic and Diluted Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">SHAREHOLDERS' NET INCOME</a></td>
<td class="nump">$ 1,654<span></span>
</td>
<td class="nump">$ 1,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average</a></td>
<td class="nump">262,746<span></span>
</td>
<td class="nump">270,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Common stock equivalents</a></td>
<td class="nump">1,271<span></span>
</td>
<td class="nump">2,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total shares</a></td>
<td class="nump">264,017<span></span>
</td>
<td class="nump">272,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EarningsPerShareEffectOfDilution', window );">Earnings per share, effect of dilution</a></td>
<td class="num">(0.04)<span></span>
</td>
<td class="num">(0.03)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted</a></td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EarningsPerShareEffectOfDilution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in net income (loss) on a per share basis when the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period is assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EarningsPerShareEffectOfDilution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Anti-dilutive Options (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive options</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Dividends (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 22, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Total amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common dividends declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsAxis=ci_R2026Q2DividendsMember', window );">R2026Q2 Dividends [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear', window );">Dividends Payable, Date Declared</a></td>
<td class="text">Apr. 22,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common dividends declared (in dollars per share)</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear', window );">Dividends Payable, Date to be Paid</a></td>
<td class="text">Jun. 18,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear', window );">Dividends Payable, Date of Record</a></td>
<td class="text">Jun.  04,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the declared dividend will be paid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendPayableDateToBePaidDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the dividend to be paid was declared, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateDeclaredDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateOfRecordDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=ci_R2026Q2DividendsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=ci_R2026Q2DividendsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Earnings Per Share - Shares of Common Stock Held in Treasury (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Shares of common stock held in treasury</a></td>
<td class="nump">141.4<span></span>
</td>
<td class="nump">141.1<span></span>
</td>
<td class="nump">134.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Debt Repayment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2026125Member', window );">1.250% Notes due March 2026 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2026125Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue2026125Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Revolving Credit Agreement and Commercial Paper (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAgreementApril2025Member', window );">Revolving Credit Agreement, April 2025 | Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 6,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Apr. 30,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtInstrumentExtensionTerm', window );">Credit agreement term extension</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtInstrumentExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtInstrumentExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAgreementApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAgreementApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on long-term and short-term debt</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Account Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractDepositCurrent', window );">Contractholder deposit funds, current</a></td>
<td class="nump">$ 329<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitLiabilityAmountCurrent', window );">Market risk benefits, current</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_UnearnedPremiumsCurrent', window );">Unearned premiums, current</a></td>
<td class="nump">914<span></span>
</td>
<td class="nump">822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrent', window );">Current insurance and contractholder liabilities</a></td>
<td class="nump">6,455<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractDepositNoncurrent', window );">Contractholder deposit funds, non-current</a></td>
<td class="nump">5,701<span></span>
</td>
<td class="nump">5,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitLiabilityAmountNoncurrent', window );">Market risk benefits, non-current</a></td>
<td class="nump">647<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_UnearnedPremiumsNoncurrent', window );">Unearned premiums, non-current</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrent', window );">Non-current insurance and contractholder liabilities</a></td>
<td class="nump">9,777<span></span>
</td>
<td class="nump">9,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderContractDeposits', window );">Contractholder deposit funds</a></td>
<td class="nump">6,030<span></span>
</td>
<td class="nump">6,114<span></span>
</td>
<td class="nump">$ 6,251<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitLiabilityAmount', window );">Market risk benefits</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnearnedPremiums', window );">Unearned premiums</a></td>
<td class="nump">959<span></span>
</td>
<td class="nump">862<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilities', window );">Total insurance and contractholder liabilities</a></td>
<td class="nump">16,232<span></span>
</td>
<td class="nump">15,648<span></span>
</td>
<td class="nump">16,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent', window );">Unpaid claims and claim expenses, current</a></td>
<td class="nump">4,856<span></span>
</td>
<td class="nump">4,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent', window );">Future policy benefits, current</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent', window );">Unpaid claims and claim expenses, non-current</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent', window );">Future policy benefits, non-current</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Unpaid claims and claim expenses</a></td>
<td class="nump">4,920<span></span>
</td>
<td class="nump">4,241<span></span>
</td>
<td class="nump">4,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Total liability for future policy benefits</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_AllSegmentsExcludingCignaHealthcareMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent', window );">Unpaid claims and claim expenses, current</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent', window );">Unpaid claims and claim expenses, non-current</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Unpaid claims and claim expenses</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent', window );">Future policy benefits, current</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent', window );">Future policy benefits, non-current</a></td>
<td class="nump">3,008<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Total liability for future policy benefits</a></td>
<td class="nump">$ 3,147<span></span>
</td>
<td class="nump">$ 3,223<span></span>
</td>
<td class="nump">$ 3,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Before Reinsurance, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Before Reinsurance, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MarketRiskBenefitLiabilityAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market Risk Benefit, Liability, Amount, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MarketRiskBenefitLiabilityAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MarketRiskBenefitLiabilityAmountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market Risk Benefit, Liability, Amount, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MarketRiskBenefitLiabilityAmountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderContractDepositCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Contract Deposit, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderContractDepositCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderContractDepositNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Contract Deposit, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderContractDepositNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_UnearnedPremiumsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unearned Premiums, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_UnearnedPremiumsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_UnearnedPremiumsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unearned Premiums, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_UnearnedPremiumsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-9E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability position for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29G<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderContractDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability due to policyholder for deposit held under long-duration contract issued by insurance entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479250/944-40-25-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderContractDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnearnedPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(2))<br> -SubTopic 210<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnearnedPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_AllSegmentsExcludingCignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_AllSegmentsExcludingCignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Paid costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Unpaid claims classified as liabilities of business held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses', window );">Total of incurred but not reported liabilities plus expected claim development on reported claims and reported claims in process</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">4,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Less: Reinsurance and other amounts recoverable</a></td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Beginning balance, net</a></td>
<td class="nump">4,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups', window );">Beginning balance, including held for sale liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups', window );">Less: Reinsurance, including held for sale liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups', window );">Beginning balance, net, including held for sale liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Incurred costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">7,852<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(188)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total incurred</a></td>
<td class="nump">7,664<span></span>
</td>
<td class="nump">10,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Paid costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">4,119<span></span>
</td>
<td class="nump">6,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">2,859<span></span>
</td>
<td class="nump">3,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">6,978<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther', window );">Less: Divestiture and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Ending balance, net</a></td>
<td class="nump">4,780<span></span>
</td>
<td class="nump">4,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Add: Reinsurance and other amounts recoverable</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">$ 4,920<span></span>
</td>
<td class="nump">$ 4,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total liability for incurred but not reported claims plus expected claim development on reported claims, including reported claims in process. Excludes amounts due for physician incentives and other medical care expenses and services payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the divesture and/or re-segmentation of business unit(s). Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for unpaid claims and claims adjustment expense attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-9E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479838/944-20-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477363/944-310-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477409/944-310-45-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-9E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details) - Cigna Healthcare - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Favorable (unfavorable) variance, amount</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage', window );">Favorable (unfavorable) variance, percentage</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Actual completion factors and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Favorable (unfavorable) variance, amount</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage', window );">Favorable (unfavorable) variance, percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Medical cost trend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Favorable (unfavorable) variance, amount</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage', window );">Favorable (unfavorable) variance, percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments made in the reporting period to settle claims incurred in prior periods and related claims settlement costs as a percentage of incurred claims as reported in the prior year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncatastrophicEventAxis=ci_CompletionFactorsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncatastrophicEventAxis=ci_CompletionFactorsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncatastrophicEventAxis=ci_MedicalCostTrendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncatastrophicEventAxis=ci_MedicalCostTrendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Future Policy Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems', window );"><strong>Liability for Future Policy Benefit Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Total liability for future policy benefits</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems', window );"><strong>Liability for Future Policy Benefit Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability', window );">Deferred profit liability included in future policy benefits</a></td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability', window );">Future policy benefit, excluding deferred profit liability</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Total liability for future policy benefits</a></td>
<td class="nump">3,147<span></span>
</td>
<td class="nump">$ 3,223<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance', window );">Undiscounted expected future policy benefits</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance', window );">Future policy benefits reserve, reinsurance recoverables</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operations | Life and annuity insurance products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems', window );"><strong>Liability for Future Policy Benefit Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate', window );">Interest accretion rate</a></td>
<td class="nump">5.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate', window );">Current discount rate</a></td>
<td class="nump">5.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration', window );">Weighted average duration</a></td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Excluding Deferred Profit Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits, Deferred Profit Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29E<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current weighted-average discount rate used to measure liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of undiscounted balance for expected future policy benefit and expense component of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, recoverable under reinsurance of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average duration of liability for future policy benefit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Original weighted-average discount rate at contract issue date used to measure liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LifeAndAnnuityInsuranceProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LifeAndAnnuityInsuranceProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceLineItems', window );"><strong>Policyholder Account Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderContractDeposits', window );">Contractholder deposit funds</a></td>
<td class="nump">$ 6,030<span></span>
</td>
<td class="nump">$ 6,114<span></span>
</td>
<td class="nump">$ 6,251<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractBalancePercentReinsuredExternally', window );">Contractholder deposit fund liabilities, approximate percent reinsured externally</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate', window );">Weighted average crediting rate</a></td>
<td class="nump">3.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk', window );">Net amount at risk</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashSurrenderValueDuePolicyholdersAmount', window );">Cash surrender value</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis=us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member', window );">Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceLineItems', window );"><strong>Policyholder Account Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage', window );">Contractholder deposit funds not reinsured externally, percent with guaranteed interest rates of 0300 to 0400</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderFunds', window );">Contractholder deposit funds not reinsured externally</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis=us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member', window );">Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 | Policyholder Account Balance, at Guaranteed Minimum Crediting Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceLineItems', window );"><strong>Policyholder Account Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderFunds', window );">Contractholder deposit funds not reinsured externally</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis=us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member', window );">Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 | Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceLineItems', window );"><strong>Policyholder Account Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderFunds', window );">Contractholder deposit funds not reinsured externally</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis=us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member', window );">Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 | Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceLineItems', window );"><strong>Policyholder Account Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderFunds', window );">Contractholder deposit funds not reinsured externally</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue', window );">Percentage with cash values at more than 110% of guaranteed cash value</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceLineItems', window );"><strong>Policyholder Account Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate', window );">Basis points above guaranteed minimum crediting rate</a></td>
<td class="nump">0.0050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceLineItems', window );"><strong>Policyholder Account Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating', window );">Guaranteed minimum credit rating</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceLineItems', window );"><strong>Policyholder Account Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate', window );">Basis points above guaranteed minimum crediting rate</a></td>
<td class="nump">0.0150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceLineItems', window );"><strong>Policyholder Account Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating', window );">Guaranteed minimum credit rating</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of policyholder account balance representing contract with guaranteed interest rates of 3%-4%.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Account Balance, Percentage With Cash Values At More Than 110 Percent Of Guaranteed Cash Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderContractBalancePercentReinsuredExternally">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Contract Balance, Percent Reinsured Externally</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderContractBalancePercentReinsuredExternally</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashSurrenderValueDuePolicyholdersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash to be paid to policyholder upon termination and surrender of long-duration contract issued by insurance entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashSurrenderValueDuePolicyholdersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value above guaranteed minimum crediting rate on policyholder account balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29F<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guaranteed minimum crediting rate on policyholder account balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29F<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of guaranteed benefit in excess of current account balance of policyholder account balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceNetAmountAtRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average crediting rate for liability for policyholder account balance, calculated at a point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderContractDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability due to policyholder for deposit held under long-duration contract issued by insurance entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479250/944-40-25-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderContractDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due to policyholder. Includes, but is not limited to, unpaid policy dividend, retrospective refund, and undistributed earnings on participating business. Excludes future policy benefit and claim expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis=us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis=us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Market Risk Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceLossReservesAbstract', window );"><strong>Insurance Loss Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AnnuitizationElectionPeriod', window );">Annuitization election period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitRollForward', window );"><strong>Market Risk Benefit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk', window );">Balance, beginning of year</a></td>
<td class="nump">$ 674<span></span>
</td>
<td class="nump">$ 785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange', window );">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff', window );">Changes due to expected run-off</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange', window );">Changes due to capital markets versus expected</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected', window );">Changes due to policyholder behavior versus expected</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange', window );">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax', window );">Nonperformance risk (own credit risk), end of period</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk', window );">Balance, end of period</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance', window );">Reinsured market risk benefit, end of period</a></td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">$ 876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AnnuitizationElectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time prior to a policy anniversary when an annuitization election must occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AnnuitizationElectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market Risk Benefit, Increase (Decrease) Due to Expected Run-Off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market Risk Benefit, Increase (Decrease) From Interest Rate Change And Equity Market Change</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in instrument-specific credit risk on contract or contract feature in long-duration contract issued by insurance entity protecting contract holder from other-than-nominal capital market risk and exposing insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29G<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13K<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-13K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceLossReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceLossReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance and after accumulated increase (decrease) in instrument-specific credit risk, of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29G<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480112/944-40-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance and cumulative increase (decrease) in instrument-specific credit risk, of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29G<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk from change associated with actual policyholder behavior different from expected.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29G<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13K<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-13K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, recoverable under reinsurance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29G<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details) - Variable Annuity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems', window );"><strong>Net Amount at Risk by Product and Guarantee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk', window );">Net amount at risk</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1', window );">Average attained age of contractholders (weighted by exposure)</a></td>
<td class="text">77 years 7 months 6 days<span></span>
</td>
<td class="text">77 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479808/944-20-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount at risk, representing the guaranteed benefit in excess of the current account balance corresponding to the specified product, guarantee type and subset of the guarantee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480109/944-80-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479808/944-20-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average attained age of policyholders or contract holders in the specified guarantee type and subset of guarantee class, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480109/944-80-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479808/944-20-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance - Reinsurance Recoverables (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>reinsurer</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">$ 3,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesAllowance', window );">Allowance for uncollectible reinsurance</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance', window );">Market risk benefits</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">$ 876<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverables', window );">Total reinsurance recoverables</a></td>
<td class="nump">4,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverables', window );">Total reinsurance recoverables</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember', window );">Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember', window );">Collateral provisions exist that may mitigate risk of credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">2,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskCollateralizationAxis=us-gaap_CededCreditRiskUnsecuredMember', window );">No Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember', window );">BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">$ 3,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesNumberOfReinsurers', window );">Number of reinsurers | reinsurer</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember', window );">BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities | The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesNumberOfReinsurers', window );">Number of reinsurers | reinsurer</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember', window );">BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities | The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York | Reinsurer Concentration Risk | Reinsurance Recoverables, Gross, Acquisition Disposition Runoff Activities, Nationally Recognized Statistical Rating Organizations, BBB+ Or Higher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember', window );">BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember', window );">BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">2,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember', window );">BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities | No Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember', window );">A- equivalent and higher current ratings | Ongoing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember', window );">A- equivalent and higher current ratings | Ongoing operations | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember', window );">A- equivalent and higher current ratings | Ongoing operations | Collateral provisions exist that may mitigate risk of credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember', window );">A- equivalent and higher current ratings | Ongoing operations | No Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember', window );">BBB- to BBB+ equivalent current credit ratings | Ongoing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember', window );">BBB- to BBB+ equivalent current credit ratings | Ongoing operations | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember', window );">BBB- to BBB+ equivalent current credit ratings | Ongoing operations | Collateral provisions exist that may mitigate risk of credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember', window );">BBB- to BBB+ equivalent current credit ratings | Ongoing operations | No Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember', window );">Not rated | Ongoing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember', window );">Not rated | Ongoing operations | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember', window );">Not rated | Ongoing operations | Collateral provisions exist that may mitigate risk of credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember', window );">Not rated | Ongoing operations | No Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember', window );">Not rated | Acquisition, disposition or run-off activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember', window );">Not rated | Acquisition, disposition or run-off activities | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember', window );">Not rated | Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember', window );">Not rated | Acquisition, disposition or run-off activities | No Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesGross', window );">Reinsurance recoverables before market risk benefits</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReinsuranceRecoverablesNumberOfReinsurers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reinsurance Recoverables, Number Of Reinsurers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReinsuranceRecoverablesNumberOfReinsurers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477351/944-825-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477351/944-825-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, recoverable under reinsurance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29G<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479838/944-20-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477363/944-310-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477409/944-310-45-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477409/944-310-45-5<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverablesAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on reinsurance recoverable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477363/944-310-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477409/944-310-45-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479838/944-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477409/944-310-45-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverablesAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverablesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation allowance recoverable under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477363/944-310-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477409/944-310-45-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479838/944-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477409/944-310-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverablesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskCollateralizationAxis=us-gaap_CededCreditRiskUnsecuredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskCollateralizationAxis=us-gaap_CededCreditRiskUnsecuredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ReinsurerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ReinsurerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_OngoingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance - Variable Annuity Reinsurance Agreement (Details) - Variable Annuity - Berkshire Hathway Life Insurance Company Of Nebraska - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage', window );">Reinsurance, Reinsured Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining', window );">Remaining overall limit under reinsurance agreement</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember', window );">Secured | Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due | Collateralization risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of overall limit to claims covered under ceded reinsurance agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CededReinsuranceAgreementCoverageLimitAmountRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477351/944-825-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477351/944-825-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of risk undertaken originally by insurer ceded to reinsurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479838/944-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskCollateralizationAxis=us-gaap_CededCreditRiskSecuredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskCollateralizationAxis=us-gaap_CededCreditRiskSecuredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=ci_CededCreditCollateralizationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=ci_CededCreditCollateralizationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Investments by Category (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">$ 1,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">18,902<span></span>
</td>
<td class="nump">18,471<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">19,714<span></span>
</td>
<td class="nump">19,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">7,859<span></span>
</td>
<td class="nump">7,671<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">8,312<span></span>
</td>
<td class="nump">8,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">3,641<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">3,669<span></span>
</td>
<td class="nump">3,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember', window );">Commercial mortgage loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember', window );">Policy loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Other long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">5,158<span></span>
</td>
<td class="nump">5,037<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">5,158<span></span>
</td>
<td class="nump">5,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Investments by Category, Including Disposal Groups (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">$ 1,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="nump">18,902<span></span>
</td>
<td class="nump">18,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">19,714<span></span>
</td>
<td class="nump">19,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="nump">7,859<span></span>
</td>
<td class="nump">7,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">8,312<span></span>
</td>
<td class="nump">8,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="nump">3,641<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">3,669<span></span>
</td>
<td class="nump">3,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember', window );">Commercial mortgage loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember', window );">Policy loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Other long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="nump">5,158<span></span>
</td>
<td class="nump">5,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">5,158<span></span>
</td>
<td class="nump">5,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShortTermAndLongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term And Long-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShortTermAndLongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Debt Securities by Contractual Maturity Periods (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">3,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Due after ten years</a></td>
<td class="nump">1,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost', window );">Mortgage and other asset-backed securities</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Total</a></td>
<td class="nump">8,739<span></span>
</td>
<td class="nump">$ 8,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">3,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">1,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after ten years</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Mortgage and other asset-backed securities</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="nump">$ 8,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 8,739<span></span>
</td>
<td class="nump">$ 8,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="num">(437)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">8,312<span></span>
</td>
<td class="nump">8,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">7,793<span></span>
</td>
<td class="nump">7,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">7,377<span></span>
</td>
<td class="nump">7,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Debt Securities with a Decline in Fair Value (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 4,835<span></span>
</td>
<td class="nump">$ 3,733<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost', window );">Total Amortized Cost</a></td>
<td class="nump">5,272<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Depreciation</a></td>
<td class="num">$ (437)<span></span>
</td>
<td class="num">$ (367)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Issues | position</a></td>
<td class="nump">2,066<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsCreditRatingAxis=ci_InvestmentGradeMember', window );">Investment grade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract', window );"><strong>One year or less</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">$ 1,674<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Depreciation</a></td>
<td class="num">$ (26)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Issues | position</a></td>
<td class="nump">609<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract', window );"><strong>More than one year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value</a></td>
<td class="nump">$ 2,757<span></span>
</td>
<td class="nump">$ 3,044<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">3,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Depreciation</a></td>
<td class="num">$ (389)<span></span>
</td>
<td class="num">$ (338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Issues | position</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsCreditRatingAxis=ci_BelowInvestmentGradeMember', window );">Below investment grade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract', window );"><strong>One year or less</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Depreciation</a></td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Issues | position</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract', window );"><strong>More than one year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Depreciation</a></td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Issues | position</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months Or Longer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less Than 12 Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InvestmentsCreditRatingAxis=ci_InvestmentGradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InvestmentsCreditRatingAxis=ci_InvestmentGradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InvestmentsCreditRatingAxis=ci_BelowInvestmentGradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InvestmentsCreditRatingAxis=ci_BelowInvestmentGradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities with readily determinable fair values</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost', window );">Equity securities with no readily determinable fair value</a></td>
<td class="nump">6,893<span></span>
</td>
<td class="nump">6,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost', window );">Total</a></td>
<td class="nump">6,994<span></span>
</td>
<td class="nump">6,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract', window );"><strong>Carrying Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities with readily determinable fair values</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities with no readily determinable fair value</a></td>
<td class="nump">3,584<span></span>
</td>
<td class="nump">3,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount', window );">Total</a></td>
<td class="nump">$ 3,669<span></span>
</td>
<td class="nump">$ 3,556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Commercial Mortgage Loans (Details) - Real Estate Loan - Commercial Portfolio Segment<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Carrying value, after allowance for credit loss</a></td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio', window );">Average Debt Service Coverage Ratio</a></td>
<td class="nump">1.74<span></span>
</td>
<td class="nump">1.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityLoanToValueRatio', window );">Average Loan-to-Value Ratio</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">Below 60%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Carrying value, after allowance for credit loss</a></td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">Below 60% | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio', window );">Average Debt Service Coverage Ratio</a></td>
<td class="nump">2.13<span></span>
</td>
<td class="nump">2.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">60% to 79%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Carrying value, after allowance for credit loss</a></td>
<td class="nump">$ 694<span></span>
</td>
<td class="nump">$ 694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">60% to 79% | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio', window );">Average Debt Service Coverage Ratio</a></td>
<td class="nump">1.79<span></span>
</td>
<td class="nump">1.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">80% to 100%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Carrying value, after allowance for credit loss</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">80% to 100% | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio', window );">Average Debt Service Coverage Ratio</a></td>
<td class="nump">0.92<span></span>
</td>
<td class="nump">0.79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Credit Quality Debt Service Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FinancingReceivableCreditQualityLoanToValueRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable Credit Quality Loan To Value Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FinancingReceivableCreditQualityLoanToValueRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePortfolioSegmentAxis=us-gaap_CommercialPortfolioSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePortfolioSegmentAxis=us-gaap_CommercialPortfolioSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanToValueAxis=ci_LtvLessThan60PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanToValueAxis=ci_LtvLessThan60PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanToValueAxis=ci_Ltv60To79PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanToValueAxis=ci_Ltv60To79PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanToValueAxis=us-gaap_Ltv80To100PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanToValueAxis=us-gaap_Ltv80To100PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Other Long-Term Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other long-term investments</a></td>
<td class="nump">$ 5,158<span></span>
</td>
<td class="nump">$ 5,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RealEstateInvestmentMember', window );">Real estate investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other long-term investments</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember', window );">Securities partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other long-term investments</a></td>
<td class="nump">2,961<span></span>
</td>
<td class="nump">2,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other long-term investments</a></td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RealEstateInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RealEstateInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Derivative Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Derivative gain (loss) reclassified from other comprehensive income into shareholders' net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Derivative gain (loss) recognized in other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative gain (loss) recognized in the income statement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Value</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480682/815-20-25-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 181<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-181<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Components of Net Investment Income/Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 220<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Investment Gains and Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainLoss', window );">Net investment gains (losses)</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NetInvestmentGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (losses) based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NetInvestmentGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">8,312<span></span>
</td>
<td class="nump">8,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">7,890<span></span>
</td>
<td class="nump">7,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">7,377<span></span>
</td>
<td class="nump">7,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">7,106<span></span>
</td>
<td class="nump">7,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivatives | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1,270<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivatives | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivatives | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivatives | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">$ 354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details) - Recurring - Significant Unobservable Inputs (Level 3)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="nump">$ 314<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember', window );">Corporate | Securities Priced by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember', window );">Corporate | Securities Priced by the Company | Minimum | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="nump">0.0010<span></span>
</td>
<td class="nump">0.0060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember', window );">Corporate | Securities Priced by the Company | Maximum | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="nump">0.0920<span></span>
</td>
<td class="nump">0.0920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember', window );">Corporate | Securities Priced by the Company | Weighted Average | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="nump">0.0135<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed securities | Securities Priced by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed securities | Securities Priced by the Company | Minimum | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="nump">0.0115<span></span>
</td>
<td class="nump">0.0105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed securities | Securities Priced by the Company | Maximum | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="nump">0.0340<span></span>
</td>
<td class="nump">0.0350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed securities | Securities Priced by the Company | Weighted Average | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="nump">0.0160<span></span>
</td>
<td class="nump">0.0160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=ci_UnobservableInputsDevelopedByCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=ci_UnobservableInputsDevelopedByCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ci_MeasurementInputLiquidityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ci_MeasurementInputLiquidityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">$ 896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Beginning balance, including held for sale assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Gains (losses) included in Shareholders' net income</a></td>
<td class="nump">258<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">(Losses) gains included in Other comprehensive loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract', window );"><strong>Purchases, sales and settlements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements', window );">Total purchases, sales and settlements</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract', window );"><strong>Transfers into / (out of) Level 3</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers into Level 3</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level 3</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Total transfers into / (out of) Level 3</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss', window );">Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date</a></td>
<td class="nump">258<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Net investment income, Net investment gains (losses)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList', window );">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents total gains or losses for the period (realized and unrealized), arising from assets included in income attributable to instruments held at the reporting date, measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in earnings or resulted in a change in asset value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-102<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-102<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from asset measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which other comprehensive income (OCI) is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Separate Accounts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">$ 7,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=ci_SeparateAccountAssetsMember', window );">Separate Account Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Separate accounts assets classified in Level 3, period increase (decrease), including transfers in and out of Level 3</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plans | Separate Account, Non-Guaranteed Separate Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">6,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member', window );">Total | Separate Account, Guaranteed Separate Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member', window );">Total | Separate Account, Non-Guaranteed Separate Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">6,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Separate Account, Guaranteed Separate Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Separate Account, Non-Guaranteed Separate Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">6,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Separate Account, Guaranteed Separate Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Separate Account, Non-Guaranteed Separate Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">5,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Separate Account, Guaranteed Separate Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Separate Account, Non-Guaranteed Separate Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">$ 662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset at fair value held for benefit of separate account policyholder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480109/944-80-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480141/944-80-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480141/944-80-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ci_SeparateAccountAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ci_SeparateAccountAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssetCategoryAxis=ci_SeparateAccountNonGuaranteedSeparateAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssetCategoryAxis=ci_SeparateAccountNonGuaranteedSeparateAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssetCategoryAxis=ci_SeparateAccountGuaranteedSeparateAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssetCategoryAxis=ci_SeparateAccountGuaranteedSeparateAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue', window );">Impairments requiring certain assets and liabilities to be measured at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairments requiring certain financial assets and liabilities, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions, to be measured using fair value. These financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, including current maturities, excluding finance leases</a></td>
<td class="nump">$ 28,838<span></span>
</td>
<td class="nump">$ 29,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet', window );">Commercial mortgage loans</a></td>
<td class="nump">1,227<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet', window );">Commercial mortgage loans</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, including current maturities, excluding finance leases</a></td>
<td class="nump">$ 30,783<span></span>
</td>
<td class="nump">$ 31,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The balance represents the amount of loans that are secured by real estate mortgages, offset by the reserve to cover probable credit losses on the loan portfolio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="nump">$ 41,874<span></span>
</td>
<td class="nump">$ 41,243<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(792)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="nump">42,442<span></span>
</td>
<td class="nump">40,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other Comprehensive Income (Loss), Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other Comprehensive Income (Loss), Tax</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(2,806)<span></span>
</td>
<td class="num">(2,341)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(792)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(3,598)<span></span>
</td>
<td class="num">(2,590)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember', window );">Securities and derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other Comprehensive Income (Loss), Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), before reclassifications, tax</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassification adjustment, tax</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, after-tax</a></td>
<td class="num">(133)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amounts reclassified from AOCI to net income</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember', window );">Net long-duration insurance and contractholder liabilities measurement adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(2,329)<span></span>
</td>
<td class="num">(2,038)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(635)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(2,964)<span></span>
</td>
<td class="num">(2,206)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociLiabilityForFuturePolicyBenefitParentMember', window );">Change in discount rate for certain long-duration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other Comprehensive Income (Loss), Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), before reclassifications, tax</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassification adjustment, tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other Comprehensive Income (Loss), Tax</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, after-tax</a></td>
<td class="num">(636)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amounts reclassified from AOCI to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(636)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember', window );">Change in instrument-specific credit risk for market risk benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other Comprehensive Income (Loss), Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), before reclassifications, tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Translation of foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other Comprehensive Income (Loss), Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), before reclassifications, tax</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, after-tax</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(162)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Postretirement benefits liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other Comprehensive Income (Loss), Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassification adjustment, tax</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(944)<span></span>
</td>
<td class="num">(937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amounts reclassified from AOCI to net income</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">$ (937)<span></span>
</td>
<td class="num">$ (931)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociLiabilityForFuturePolicyBenefitParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociLiabilityForFuturePolicyBenefitParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Optimization Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ci_StrategicOptimizationProgramMember', window );">Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">$ 1,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RestructuringChargesNetOfTaxExpense', window );">Strategic optimization program costs, after-tax</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ci_EmployeeSeveranceAndOtherRestructuringMember', window );">Employee severance, asset impairments and other | Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="nump">377<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee severance | Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve, Beginning Balance</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve, Ending Balance</a></td>
<td class="nump">402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ci_AssetImpairmentsMember', window );">Asset impairments | Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ci_OperatingResultsOfCertainNonstrategicBusinessesMember', window );">Operating results of certain non-strategic businesses | Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RestructuringChargesNetOfTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Net Of Tax Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RestructuringChargesNetOfTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ci_StrategicOptimizationProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ci_StrategicOptimizationProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ci_EmployeeSeveranceAndOtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ci_EmployeeSeveranceAndOtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ci_AssetImpairmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ci_AssetImpairmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ci_OperatingResultsOfCertainNonstrategicBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ci_OperatingResultsOfCertainNonstrategicBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Consolidated effective tax rate</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Other Matters (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_InsuranceRelatedAssessmentsMember', window );">Guaranty Fund Assessments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">Loss contingency accrual, period increase (decrease)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification obligations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Liability for guarantees</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_RetirementAndLifeInsuranceContractsMember', window );">Retiree and Life Insurance Benefits | Financial Guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Maximum guarantee exposure</a></td>
<td class="nump">390,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLiquidationProceeds', window );">Assets maintained by employers (minimum)</a></td>
<td class="nump">390,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Liability for guarantees</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsLiquidationProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates, if estimable, the approximate extent to which the proceeds from liquidation of any assets held either as collateral or by third parties would be expected to cover the maximum potential amount of future payments under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsLiquidationProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_InsuranceRelatedAssessmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_InsuranceRelatedAssessmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_RetirementAndLifeInsuranceContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_RetirementAndLifeInsuranceContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Special Item Charges (Benefits) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Pre-tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitTaxMatters', window );">Deferred tax expenses (benefits)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) on sale of businesses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">Charges (benefits) associated with litigation matters</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity', window );">Total impact from special items, pre-tax</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsAfterTaxAbstract', window );"><strong>After-tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCostsAfterTax', window );">Integration and transaction-related costs, after-tax</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitTaxMattersAfterTax', window );">Deferred tax expenses (benefits), after-tax</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax', window );">(Gain) on sale of businesses, after-tax</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitAfterTaxLitigation', window );">Charges (benefits) associated with litigation matters, after-tax</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity', window );">Total impact from special items, after-tax</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ci_StrategicOptimizationProgramMember', window );">Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Pre-tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">$ 1,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsAfterTaxAbstract', window );"><strong>After-tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RestructuringChargesNetOfTaxExpense', window );">Strategic optimization program, after-tax</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RestructuringChargesNetOfTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Net Of Tax Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RestructuringChargesNetOfTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitAfterTaxLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitAfterTaxLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitBeforeTaxLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitTaxMatters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item Charge Benefit Tax Matters</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitTaxMatters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitTaxMattersAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item Charge Benefit Tax Matters After Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitTaxMattersAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item, Gain (Loss) On Sale Of Business, Before Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item, Gain (Loss) On Sale Of Business, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of before-tax tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of after-tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemsAfterTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemsAfterTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemsBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemsBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TransactionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-tax transaction-related costs primarily consisting of fees for legal, advisory and other professional services, as well as employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TransactionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TransactionRelatedCostsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After-tax transaction-related costs including the impact of tax benefits realized from termination of merger agreement. Transaction-related costs consist primarily of fees for legal, advisory and other professional services as well as employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TransactionRelatedCostsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ci_StrategicOptimizationProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ci_StrategicOptimizationProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summarized Segment Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="nump">$ 68,292<span></span>
</td>
<td class="nump">$ 65,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="nump">68,494<span></span>
</td>
<td class="nump">65,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainsLossesEquityMethodInvestments', window );">Net investment results from certain equity method investments</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SegmentRevenues', window );">Adjusted revenues</a></td>
<td class="nump">68,517<span></span>
</td>
<td class="nump">65,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Pharmacy and other service costs</a></td>
<td class="nump">54,100<span></span>
</td>
<td class="nump">48,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet', window );">Medical costs and other benefit expenses</a></td>
<td class="nump">7,924<span></span>
</td>
<td class="nump">10,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest expense and other</a></td>
<td class="num">(357)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="nump">2,603<span></span>
</td>
<td class="nump">2,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract', window );"><strong>Pre-tax adjustments to reconcile to adjusted income from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax', window );">(Income) loss attributable to noncontrolling interests</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries', window );">Net realized investment (gains) losses</a></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) on sale of businesses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitTaxMatters', window );">Deferred tax expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="nump">2,603<span></span>
</td>
<td class="nump">2,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ci_StrategicOptimizationProgramMember', window );">Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">$ 1,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember', window );">Evernorth Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="nump">58,206<span></span>
</td>
<td class="nump">52,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="nump">10,039<span></span>
</td>
<td class="nump">13,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evernorth Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="nump">58,442<span></span>
</td>
<td class="nump">53,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainsLossesEquityMethodInvestments', window );">Net investment results from certain equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SegmentRevenues', window );">Adjusted revenues</a></td>
<td class="nump">58,442<span></span>
</td>
<td class="nump">53,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Pharmacy and other service costs</a></td>
<td class="nump">55,700<span></span>
</td>
<td class="nump">51,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet', window );">Medical costs and other benefit expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric', window );">Selling, general and administrative expenses</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest expense and other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax', window );">Less: Income attributable to noncontrolling interests</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract', window );"><strong>Pre-tax adjustments to reconcile to adjusted income from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax', window );">(Income) loss attributable to noncontrolling interests</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries', window );">Net realized investment (gains) losses</a></td>
<td class="num">(261)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) on sale of businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evernorth Health Services | Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="nump">11,454<span></span>
</td>
<td class="nump">14,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainsLossesEquityMethodInvestments', window );">Net investment results from certain equity method investments</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SegmentRevenues', window );">Adjusted revenues</a></td>
<td class="nump">11,477<span></span>
</td>
<td class="nump">14,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Pharmacy and other service costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet', window );">Medical costs and other benefit expenses</a></td>
<td class="nump">7,664<span></span>
</td>
<td class="nump">10,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric', window );">Selling, general and administrative expenses</a></td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest expense and other</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax', window );">Less: Income attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract', window );"><strong>Pre-tax adjustments to reconcile to adjusted income from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax', window );">(Income) loss attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries', window );">Net realized investment (gains) losses</a></td>
<td class="nump">29<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) on sale of businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare | Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainsLossesEquityMethodInvestments', window );">Net investment results from certain equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SegmentRevenues', window );">Adjusted revenues</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract', window );"><strong>Pre-tax adjustments to reconcile to adjusted income from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax', window );">(Income) loss attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries', window );">Net realized investment (gains) losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) on sale of businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other Operations | Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember', window );">Corporate and Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="num">(1,522)<span></span>
</td>
<td class="num">(2,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SegmentRevenues', window );">Adjusted revenues</a></td>
<td class="num">(1,522)<span></span>
</td>
<td class="num">(2,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainsLossesEquityMethodInvestments', window );">Net investment results from certain equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="num">(404)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="num">(796)<span></span>
</td>
<td class="num">(804)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract', window );"><strong>Pre-tax adjustments to reconcile to adjusted income from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax', window );">(Income) loss attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries', window );">Net realized investment (gains) losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) on sale of businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="num">(404)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate | Strategic Optimization Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Strategic optimization program costs</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="num">(1,526)<span></span>
</td>
<td class="num">(2,891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Evernorth Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(1,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="num">(1,312)<span></span>
</td>
<td class="num">(1,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of pre-tax income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (losses), including those from equity method subsidiaries, based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NetInvestmentGainsLossesEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (losses), attributable to equity method investment, based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NetInvestmentGainsLossesEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NonInvestmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue excluding net investment income and realized investment results.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NonInvestmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Segment Items, Income (Loss) Attributable To Noncontrolling Interests, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SegmentRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total revenues less realized investment gains from equity method subsidiaries, special items and other reconciling items determined by management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SegmentRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling, General Administrative Expenses Segment Performance Metric</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitBeforeTaxLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitTaxMatters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item Charge Benefit Tax Matters</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitTaxMatters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item, Gain (Loss) On Sale Of Business, Before Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemsBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemsBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TransactionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-tax transaction-related costs primarily consisting of fees for legal, advisory and other professional services, as well as employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TransactionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 220<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479868/944-20-45-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ci_StrategicOptimizationProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ci_StrategicOptimizationProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Revenue from External Customers (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">$ 9,812<span></span>
</td>
<td class="nump">$ 12,736<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="nump">68,292<span></span>
</td>
<td class="nump">65,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Pharmacy revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">54,037<span></span>
</td>
<td class="nump">48,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">4,443<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_ServiceFeesAndOtherRevenuesMember', window );">Service, Fees And Other Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">4,443<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember', window );">Evernorth Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="nump">58,206<span></span>
</td>
<td class="nump">52,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="nump">10,039<span></span>
</td>
<td class="nump">13,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evernorth Health Services | Pharmacy revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">54,294<span></span>
</td>
<td class="nump">50,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evernorth Health Services | Network revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">31,080<span></span>
</td>
<td class="nump">28,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evernorth Health Services | Home delivery and specialty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">19,788<span></span>
</td>
<td class="nump">18,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evernorth Health Services | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">3,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evernorth Health Services | Service, Fees And Other Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">4,123<span></span>
</td>
<td class="nump">3,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">9,605<span></span>
</td>
<td class="nump">12,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare | Service, Fees And Other Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">1,746<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare | U.S. Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">8,492<span></span>
</td>
<td class="nump">11,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare | U.S. Healthcare | Employer insured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">4,996<span></span>
</td>
<td class="nump">4,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare | U.S. Healthcare | Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare | U.S. Healthcare | Stop loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">2,116<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare | U.S. Healthcare | Individual and Family Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare | U.S. Healthcare | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare | International Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other Operations | Pharmacy revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other Operations | Service, Fees And Other Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember', window );">Corporate and Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember', window );">Corporate and Eliminations | Pharmacy revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="num">(257)<span></span>
</td>
<td class="num">(1,606)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember', window );">Corporate and Eliminations | Service, Fees And Other Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="num">(1,423)<span></span>
</td>
<td class="num">(1,312)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="num">(1,526)<span></span>
</td>
<td class="num">(2,891)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Evernorth Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(1,648)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="num">(1,312)<span></span>
</td>
<td class="num">(1,231)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NonInvestmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue excluding net investment income and realized investment results.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NonInvestmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-15<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479838/944-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477965/944-235-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479032/944-605-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -SubTopic 220<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -SubTopic 220<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_ServiceFeesAndOtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_ServiceFeesAndOtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_NetworkPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_NetworkPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_HomeDeliveryAndSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_HomeDeliveryAndSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_OtherPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_OtherPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ci_UnitedStatesHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ci_UnitedStatesHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_EmployerInsuredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_EmployerInsuredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_StopLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_StopLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_IndividualAndFamilyPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_IndividualAndFamilyPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_OtherHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_OtherHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ci_InternationalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ci_InternationalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Financial and Performance Guarantees (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember', window );">Evernorth Health Services | Financial and performance guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Guarantee liability</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_GuaranteeObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_GuaranteeObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>409</ContextCount>
  <ElementCount>404</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>131</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Changes in Total Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity</Role>
      <ShortName>Consolidated Statements of Changes in Total Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Changes in Total Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Total Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Accounts Receivable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccountsReceivableNet</Role>
      <ShortName>Accounts Receivable, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Supplier Finance Program</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SupplierFinanceProgram</Role>
      <ShortName>Supplier Finance Program</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Insurance and Contractholder Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities</Role>
      <ShortName>Insurance and Contractholder Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Reinsurance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/Reinsurance</Role>
      <ShortName>Reinsurance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Strategic Optimization Program</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/StrategicOptimizationProgram</Role>
      <ShortName>Strategic Optimization Program</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Contingencies and Other Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ContingenciesandOtherMatters</Role>
      <ShortName>Contingencies and Other Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Insurance and Contractholder Liabilities (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesPolicies</Role>
      <ShortName>Insurance and Contractholder Liabilities (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Reinsurance (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ReinsurancePolicies</Role>
      <ShortName>Reinsurance (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Investments (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsPolicies</Role>
      <ShortName>Investments (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Fair Value Measures and Disclosures (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasuresandDisclosuresPolicies</Role>
      <ShortName>Fair Value Measures and Disclosures (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossPolicies</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Commitment and Contingencies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CommitmentandContingenciesPolicies</Role>
      <ShortName>Commitment and Contingencies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Segment Reporting (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentReportingPolicies</Role>
      <ShortName>Segment Reporting (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Accounts Receivable, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccountsReceivableNetTables</Role>
      <ShortName>Accounts Receivable, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/AccountsReceivableNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/EarningsPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Insurance and Contractholder Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables</Role>
      <ShortName>Insurance and Contractholder Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Reinsurance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ReinsuranceTables</Role>
      <ShortName>Reinsurance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/Reinsurance</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/Investments</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/FairValueMeasurements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Strategic Optimization Program (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/StrategicOptimizationProgramTables</Role>
      <ShortName>Strategic Optimization Program (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/StrategicOptimizationProgram</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SegmentInformation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Description of Business - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DescriptionofBusinessSegmentInformationDetails</Role>
      <ShortName>Description of Business - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Accounts Receivable, Net - Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails</Role>
      <ShortName>Accounts Receivable, Net - Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Accounts Receivable, Net - Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccountsReceivableNetAllowancesDetails</Role>
      <ShortName>Accounts Receivable, Net - Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Accounts Receivable, Net - Factoring Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails</Role>
      <ShortName>Accounts Receivable, Net - Factoring Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Supplier Finance Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SupplierFinanceProgramDetails</Role>
      <ShortName>Supplier Finance Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SupplierFinanceProgram</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Earnings Per Share - Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share - Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Earnings Per Share - Anti-dilutive Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails</Role>
      <ShortName>Earnings Per Share - Anti-dilutive Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Earnings Per Share - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails</Role>
      <ShortName>Earnings Per Share - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Earnings Per Share - Shares of Common Stock Held in Treasury (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails</Role>
      <ShortName>Earnings Per Share - Shares of Common Stock Held in Treasury (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Debt - Debt Repayment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DebtDebtRepaymentDetails</Role>
      <ShortName>Debt - Debt Repayment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Debt - Revolving Credit Agreement and Commercial Paper (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails</Role>
      <ShortName>Debt - Revolving Credit Agreement and Commercial Paper (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Insurance and Contractholder Liabilities - Account Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Account Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Insurance and Contractholder Liabilities - Future Policy Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Future Policy Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Insurance and Contractholder Liabilities - Market Risk Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Market Risk Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails</Role>
      <ShortName>Reinsurance - Reinsurance Recoverables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Reinsurance - Variable Annuity Reinsurance Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails</Role>
      <ShortName>Reinsurance - Variable Annuity Reinsurance Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Investments - Investments by Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails</Role>
      <ShortName>Investments - Investments by Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Investments - Investments by Category, Including Disposal Groups (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails</Role>
      <ShortName>Investments - Investments by Category, Including Disposal Groups (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Investments - Debt Securities by Contractual Maturity Periods (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails</Role>
      <ShortName>Investments - Debt Securities by Contractual Maturity Periods (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails</Role>
      <ShortName>Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Investments - Summary of Debt Securities with a Decline in Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails</Role>
      <ShortName>Investments - Summary of Debt Securities with a Decline in Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Investments - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails</Role>
      <ShortName>Investments - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Investments - Commercial Mortgage Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails</Role>
      <ShortName>Investments - Commercial Mortgage Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Investments - Other Long-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails</Role>
      <ShortName>Investments - Other Long-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Investments - Derivative Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails</Role>
      <ShortName>Investments - Derivative Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Investments - Components of Net Investment Income/Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails</Role>
      <ShortName>Investments - Components of Net Investment Income/Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Investments - Investment Gains and Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsInvestmentGainsandLossesDetails</Role>
      <ShortName>Investments - Investment Gains and Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Fair Value Measurements - Separate Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails</Role>
      <ShortName>Fair Value Measurements - Separate Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Strategic Optimization Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails</Role>
      <ShortName>Strategic Optimization Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/StrategicOptimizationProgramTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Contingencies and Other Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails</Role>
      <ShortName>Contingencies and Other Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/ContingenciesandOtherMatters</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Segment Information - Special Item Charges (Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails</Role>
      <ShortName>Segment Information - Special Item Charges (Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Segment Information - Summarized Segment Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails</Role>
      <ShortName>Segment Information - Summarized Segment Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Segment Information - Revenue from External Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails</Role>
      <ShortName>Segment Information - Revenue from External Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ci-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Segment Information - Financial and Performance Guarantees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails</Role>
      <ShortName>Segment Information - Financial and Performance Guarantees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ci-20260331.htm">ci-20260331.htm</File>
    <File>ci-20260331.xsd</File>
    <File>ci-20260331_cal.xml</File>
    <File>ci-20260331_def.xml</File>
    <File>ci-20260331_lab.xml</File>
    <File>ci-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ci-20260331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1040">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ci-20260331.htm": {
   "nsprefix": "ci",
   "nsuri": "http://www.thecignagroup.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "ci-20260331.htm"
     ]
    },
    "schema": {
     "local": [
      "ci-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ci-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ci-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ci-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ci-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 311,
   "keyCustom": 93,
   "axisStandard": 44,
   "axisCustom": 2,
   "memberStandard": 73,
   "memberCustom": 57,
   "hidden": {
    "total": 38,
    "http://fasb.org/us-gaap/2025": 23,
    "http://xbrl.sec.gov/ecd/2025": 3,
    "http://www.thecignagroup.com/20260331": 7,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 409,
   "entityCount": 1,
   "segmentCount": 131,
   "elementCount": 931,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1040,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 14
   },
   "report": {
    "R1": {
     "role": "http://www.thecignagroup.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
     "longName": "9952151 - Statement - Consolidated Statements of Income",
     "shortName": "Consolidated Statements of Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PremiumsEarnedNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "9952152 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
     "longName": "9952153 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952154 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "link:footnote",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "link:footnote",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
     "longName": "9952155 - Statement - Consolidated Statements of Changes in Total Equity",
     "shortName": "Consolidated Statements of Changes in Total Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-37",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical",
     "longName": "9952156 - Statement - Consolidated Statements of Changes in Total Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Total Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952157 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncreaseDecreaseInDeferredIncomeTaxes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.thecignagroup.com/role/DescriptionofBusiness",
     "longName": "9952158 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952159 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.thecignagroup.com/role/AccountsReceivableNet",
     "longName": "9952160 - Disclosure - Accounts Receivable, Net",
     "shortName": "Accounts Receivable, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.thecignagroup.com/role/SupplierFinanceProgram",
     "longName": "9952161 - Disclosure - Supplier Finance Program",
     "shortName": "Supplier Finance Program",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplierFinanceProgramTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplierFinanceProgramTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShare",
     "longName": "9952162 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.thecignagroup.com/role/Debt",
     "longName": "9952163 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities",
     "longName": "9952164 - Disclosure - Insurance and Contractholder Liabilities",
     "shortName": "Insurance and Contractholder Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.thecignagroup.com/role/Reinsurance",
     "longName": "9952165 - Disclosure - Reinsurance",
     "shortName": "Reinsurance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReinsuranceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReinsuranceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.thecignagroup.com/role/Investments",
     "longName": "9952166 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurements",
     "longName": "9952167 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss",
     "longName": "9952168 - Disclosure - Accumulated Other Comprehensive Income (Loss)",
     "shortName": "Accumulated Other Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:AccumulatedOtherComprehensiveIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:AccumulatedOtherComprehensiveIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.thecignagroup.com/role/StrategicOptimizationProgram",
     "longName": "9952169 - Disclosure - Strategic Optimization Program",
     "shortName": "Strategic Optimization Program",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.thecignagroup.com/role/IncomeTaxes",
     "longName": "9952170 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.thecignagroup.com/role/ContingenciesandOtherMatters",
     "longName": "9952171 - Disclosure - Contingencies and Other Matters",
     "shortName": "Contingencies and Other Matters",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.thecignagroup.com/role/SegmentInformation",
     "longName": "9952172 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesPolicies",
     "longName": "9955514 - Disclosure - Insurance and Contractholder Liabilities (Policies)",
     "shortName": "Insurance and Contractholder Liabilities (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.thecignagroup.com/role/ReinsurancePolicies",
     "longName": "9955515 - Disclosure - Reinsurance (Policies)",
     "shortName": "Reinsurance (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReinsuranceAccountingPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReinsuranceAccountingPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.thecignagroup.com/role/InvestmentsPolicies",
     "longName": "9955516 - Disclosure - Investments (Policies)",
     "shortName": "Investments (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasuresandDisclosuresPolicies",
     "longName": "9955517 - Disclosure - Fair Value Measures and Disclosures (Policies)",
     "shortName": "Fair Value Measures and Disclosures (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossPolicies",
     "longName": "9955518 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Policies)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.thecignagroup.com/role/CommitmentandContingenciesPolicies",
     "longName": "9955520 - Disclosure - Commitment and Contingencies (Policies)",
     "shortName": "Commitment and Contingencies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.thecignagroup.com/role/SegmentReportingPolicies",
     "longName": "9955521 - Disclosure - Segment Reporting (Policies)",
     "shortName": "Segment Reporting (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.thecignagroup.com/role/AccountsReceivableNetTables",
     "longName": "9955522 - Disclosure - Accounts Receivable, Net (Tables)",
     "shortName": "Accounts Receivable, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShareTables",
     "longName": "9955524 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables",
     "longName": "9955525 - Disclosure - Insurance and Contractholder Liabilities (Tables)",
     "shortName": "Insurance and Contractholder Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.thecignagroup.com/role/ReinsuranceTables",
     "longName": "9955526 - Disclosure - Reinsurance (Tables)",
     "shortName": "Reinsurance (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.thecignagroup.com/role/InvestmentsTables",
     "longName": "9955527 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsTables",
     "longName": "9955528 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "longName": "9955529 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.thecignagroup.com/role/StrategicOptimizationProgramTables",
     "longName": "9955530 - Disclosure - Strategic Optimization Program (Tables)",
     "shortName": "Strategic Optimization Program (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationTables",
     "longName": "9955531 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:ScheduleOfSpecialItemsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:ScheduleOfSpecialItemsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.thecignagroup.com/role/DescriptionofBusinessSegmentInformationDetails",
     "longName": "9955532 - Disclosure - Description of Business - Segment Information (Details)",
     "shortName": "Description of Business - Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails",
     "longName": "9955533 - Disclosure - Accounts Receivable, Net - Amounts (Details)",
     "shortName": "Accounts Receivable, Net - Amounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.thecignagroup.com/role/AccountsReceivableNetAllowancesDetails",
     "longName": "9955534 - Disclosure - Accounts Receivable, Net - Allowances (Details)",
     "shortName": "Accounts Receivable, Net - Allowances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ci:AllowanceForReceivablesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "ci:AllowanceForReceivablesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails",
     "longName": "9955535 - Disclosure - Accounts Receivable, Net - Factoring Facility (Details)",
     "shortName": "Accounts Receivable, Net - Factoring Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ci:AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "ci:AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails",
     "longName": "9955536 - Disclosure - Supplier Finance Program (Details)",
     "shortName": "Supplier Finance Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:SupplierFinanceProgramObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:SupplierFinanceProgramObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails",
     "longName": "9955537 - Disclosure - Earnings Per Share - Basic and Diluted Earnings Per Share (Details)",
     "shortName": "Earnings Per Share - Basic and Diluted Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails",
     "longName": "9955538 - Disclosure - Earnings Per Share - Anti-dilutive Options (Details)",
     "shortName": "Earnings Per Share - Anti-dilutive Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails",
     "longName": "9955539 - Disclosure - Earnings Per Share - Dividends (Details)",
     "shortName": "Earnings Per Share - Dividends (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsOfDividendsCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails",
     "longName": "9955540 - Disclosure - Earnings Per Share - Shares of Common Stock Held in Treasury (Details)",
     "shortName": "Earnings Per Share - Shares of Common Stock Held in Treasury (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails",
     "longName": "9955541 - Disclosure - Debt - Debt Repayment (Details)",
     "shortName": "Debt - Debt Repayment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails",
     "longName": "9955542 - Disclosure - Debt - Revolving Credit Agreement and Commercial Paper (Details)",
     "shortName": "Debt - Revolving Credit Agreement and Commercial Paper (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.thecignagroup.com/role/DebtInterestExpenseDetails",
     "longName": "9955543 - Disclosure - Debt - Interest Expense (Details)",
     "shortName": "Debt - Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
     "longName": "9955544 - Disclosure - Insurance and Contractholder Liabilities - Account Balances (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Account Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ci:PolicyholderContractDepositCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "ci:PolicyholderContractDepositCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
     "longName": "9955545 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails",
     "longName": "9955546 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-78",
      "name": "ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails",
     "longName": "9955547 - Disclosure - Insurance and Contractholder Liabilities - Future Policy Benefits (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Future Policy Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-68",
      "name": "us-gaap:LiabilityForFuturePolicyBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
     "longName": "9955548 - Disclosure - Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:PolicyholderContractDeposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "ci:PolicyholderContractBalancePercentReinsuredExternally",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails",
     "longName": "9955549 - Disclosure - Insurance and Contractholder Liabilities - Market Risk Benefits (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Market Risk Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:AnnuitizationElectionPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:AnnuitizationElectionPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails",
     "longName": "9955550 - Disclosure - Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-104",
      "name": "us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-104",
      "name": "us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
     "longName": "9955551 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)",
     "shortName": "Reinsurance - Reinsurance Recoverables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ReinsuranceRecoverablesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ReinsuranceRecoverablesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails",
     "longName": "9955552 - Disclosure - Reinsurance - Variable Annuity Reinsurance Agreement (Details)",
     "shortName": "Reinsurance - Variable Annuity Reinsurance Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-134",
      "name": "us-gaap:ReinsuranceRetentionPolicyReinsuredRiskPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-134",
      "name": "us-gaap:ReinsuranceRetentionPolicyReinsuredRiskPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
     "longName": "9955553 - Disclosure - Investments - Investments by Category (Details)",
     "shortName": "Investments - Investments by Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails",
     "longName": "9955554 - Disclosure - Investments - Investments by Category, Including Disposal Groups (Details)",
     "shortName": "Investments - Investments by Category, Including Disposal Groups (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails",
     "longName": "9955555 - Disclosure - Investments - Debt Securities by Contractual Maturity Periods (Details)",
     "shortName": "Investments - Debt Securities by Contractual Maturity Periods (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails",
     "longName": "9955556 - Disclosure - Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer (Details)",
     "shortName": "Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails",
     "longName": "9955557 - Disclosure - Investments - Summary of Debt Securities with a Decline in Fair Value (Details)",
     "shortName": "Investments - Summary of Debt Securities with a Decline in Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails",
     "longName": "9955558 - Disclosure - Investments - Equity Securities (Details)",
     "shortName": "Investments - Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails",
     "longName": "9955559 - Disclosure - Investments - Commercial Mortgage Loans (Details)",
     "shortName": "Investments - Commercial Mortgage Loans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails",
     "longName": "9955560 - Disclosure - Investments - Other Long-Term Investments (Details)",
     "shortName": "Investments - Other Long-Term Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OtherLongTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:ScheduleOfOtherLongTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OtherLongTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:ScheduleOfOtherLongTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails",
     "longName": "9955561 - Disclosure - Investments - Derivative Financial Instruments (Details)",
     "shortName": "Investments - Derivative Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-185",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-185",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails",
     "longName": "9955562 - Disclosure - Investments - Components of Net Investment Income/Losses (Details)",
     "shortName": "Investments - Components of Net Investment Income/Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetInvestmentIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://www.thecignagroup.com/role/InvestmentsInvestmentGainsandLossesDetails",
     "longName": "9955563 - Disclosure - Investments - Investment Gains and Losses (Details)",
     "shortName": "Investments - Investment Gains and Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:NetInvestmentGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
     "longName": "9955564 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-233",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
     "longName": "9955565 - Disclosure - Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details)",
     "shortName": "Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-261",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-261",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails",
     "longName": "9955567 - Disclosure - Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails",
     "longName": "9955568 - Disclosure - Fair Value Measurements - Separate Accounts (Details)",
     "shortName": "Fair Value Measurements - Separate Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:SeparateAccountAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ci:FairValueOfSeparateAccountAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:SeparateAccountAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ci:FairValueOfSeparateAccountAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
     "longName": "9955569 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details)",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R79": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
     "longName": "9955570 - Disclosure - Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "longName": "9955571 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-20",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails",
     "longName": "9955572 - Disclosure - Strategic Optimization Program (Details)",
     "shortName": "Strategic Optimization Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-329",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.thecignagroup.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955573 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
     "longName": "9955574 - Disclosure - Contingencies and Other Matters (Details)",
     "shortName": "Contingencies and Other Matters (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-341",
      "name": "us-gaap:GuaranteeObligationsCurrentCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-341",
      "name": "us-gaap:GuaranteeObligationsCurrentCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
     "longName": "9955575 - Disclosure - Segment Information - Special Item Charges (Benefits) (Details)",
     "shortName": "Segment Information - Special Item Charges (Benefits) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ci:ScheduleOfSpecialItemsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
     "longName": "9955576 - Disclosure - Segment Information - Summarized Segment Financial Information (Details)",
     "shortName": "Segment Information - Summarized Segment Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:NonInvestmentRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:NetInvestmentGainsLossesEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
     "longName": "9955577 - Disclosure - Segment Information - Revenue from External Customers (Details)",
     "shortName": "Segment Information - Revenue from External Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PremiumsEarnedNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-402",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
     "longName": "9955578 - Disclosure - Segment Information - Financial and Performance Guarantees (Details)",
     "shortName": "Segment Information - Financial and Performance Guarantees (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-406",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-406",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20260331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ci_A1000Million4.500NotesDueSeptember2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "A1000Million4.500NotesDueSeptember2030Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.500% Notes due September 2030",
        "label": "$1,000 million, 4.500% Notes Due September 2030 [Member]",
        "documentation": "$1,000 million, 4.500% Notes Due September 2030"
       }
      }
     },
     "auth_ref": []
    },
    "ci_A1250Million4.875NotesDueSeptember2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "A1250Million4.875NotesDueSeptember2032Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.875% Notes due September 2032",
        "label": "$1,250 million, 4.875% Notes Due September 2032 [Member]",
        "documentation": "$1,250 million, 4.875% Notes Due September 2032"
       }
      }
     },
     "auth_ref": []
    },
    "ci_A1500Million5.250NotesDueJanuary2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "A1500Million5.250NotesDueJanuary2036Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.250% Notes due January 2036",
        "label": "$1,500 million, 5.250% Notes Due January 2036 [Member]",
        "documentation": "$1,500 million, 5.250% Notes Due January 2036"
       }
      }
     },
     "auth_ref": []
    },
    "ci_A750Million6.000NotesDueJanuary2056Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "A750Million6.000NotesDueJanuary2056Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.000% Notes due January 2056",
        "label": "$750 million, 6.000% Notes Due January 2056 [Member]",
        "documentation": "$750 million, 6.000% Notes Due January 2056"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities and derivatives",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Parent [Member]",
        "documentation": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net long-duration insurance and contractholder liabilities measurement adjustments",
        "label": "AOCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Parent [Member]",
        "documentation": "AOCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Parent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Accounts and Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r1220"
     ]
    },
    "ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables collected but not remitted to the financial institution",
        "label": "Accounts Receivable, Uncommitted Factoring Facilities, Accounts Receivable Received But Not Remitted",
        "documentation": "Amount of, as of the reporting date, of receivables sold to a financial institution under uncommitted Accounts receivable factoring facilities that have been received from the manufacturers but not yet remitted to the financial institution."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable sold that remain outstanding, uncommitted factoring facilities",
        "label": "Accounts Receivable, Uncommitted Factoring Facilities, Accounts Receivable Sold That Remain Outstanding",
        "documentation": "Amount, as of the reporting date, of receivables sold to a financial institution under uncommitted Accounts receivable factoring facilities that have not been collected from the manufacturers and have been removed from the Balance Sheet."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsReceivableUncommittedFactoringFacilitiesAmountSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AccountsReceivableUncommittedFactoringFacilitiesAmountSold",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable sold, uncommitted factoring facilities",
        "label": "Accounts Receivable, Uncommitted Factoring Facilities, Amount Sold",
        "documentation": "Amount of receivables sold to a financial institution under uncommitted Accounts receivable factoring facilities during the period."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Automatic renewal term, uncommitted factoring facilities (in years)",
        "label": "Accounts Receivable, Uncommitted Factoring Facilities, Automatic Renewal Term",
        "documentation": "Automatic renewal term for uncommitted Accounts receivable factoring facilities."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Factoring fees paid, uncommitted factoring facilities",
        "label": "Accounts Receivable, Uncommitted Factoring Facilities, Factoring Fees Paid",
        "documentation": "Factoring fees paid under uncommitted Account Receivable factoring facilities."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetFactoringFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total capacity, uncommitted factoring facilities",
        "label": "Accounts Receivable, Uncommitted Factoring Facilities, Total Capacity",
        "documentation": "Total amount of certain accounts receivable that may be sold on a non-recourse basis to a financial institution under uncommitted accounts receivable factoring facilities."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccruedExpensesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AccruedExpensesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Accrued Expenses And Other Liabilities",
        "documentation": "Carrying value as of the balance sheet date of other current liabilities and obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Postretirement benefits liability",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r15",
      "r22",
      "r88",
      "r1387",
      "r1388",
      "r1389"
     ]
    },
    "ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AccumulatedOtherComprehensiveIncomeDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "Accumulated Other Comprehensive Income (Loss) [Text Block]",
        "documentation": "Disclousre of the changes in the componenets of other comprehensive income/loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r709",
      "r710",
      "r711",
      "r712",
      "r757",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r89",
      "r187",
      "r843",
      "r922",
      "r924",
      "r1573"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r709",
      "r710",
      "r711",
      "r712",
      "r757",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss)",
        "verboseLabel": "AOCI Attributable to Parent",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r15",
      "r22",
      "r704",
      "r707",
      "r770",
      "r917",
      "r918",
      "r1387",
      "r1388",
      "r1389",
      "r1443",
      "r1444",
      "r1445",
      "r1446"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation of foreign currencies",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15",
      "r22",
      "r86",
      "r87",
      "r208",
      "r209",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r1387"
     ]
    },
    "ci_AcquisitionDispositionRunoffActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AcquisitionDispositionRunoffActivitiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition, disposition or run-off activities",
        "label": "Acquisition Disposition Runoff Activities [Member]",
        "documentation": "Products related to acquisition, disposition or runoff activities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1298"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1443",
      "r1444",
      "r1445",
      "r1446",
      "r1574",
      "r1677"
     ]
    },
    "us-gaap_AdditionsToContractHoldersFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionsToContractHoldersFunds",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and interest credited to contractholder deposit funds",
        "label": "Additions to Contract Holders Funds",
        "documentation": "The cash inflow from a segregated fund account during the period."
       }
      }
     },
     "auth_ref": [
      "r1433"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax adjusted income (loss) from operations",
        "totalLabel": "Pre-tax adjusted income (loss) from operations",
        "label": "Adjusted Income (Loss) From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1345"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1269",
      "r1280",
      "r1290",
      "r1323"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1272",
      "r1283",
      "r1293",
      "r1326"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1346"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1273",
      "r1284",
      "r1294",
      "r1318",
      "r1327",
      "r1331",
      "r1339"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operations",
        "label": "Other Operating Segment [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r1134",
      "r1135"
     ]
    },
    "ci_AllSegmentsExcludingCignaHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AllSegmentsExcludingCignaHealthcareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "All Segments Excluding Cigna Healthcare [Member]",
        "documentation": "All Segments Excluding Cigna Healthcare"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "allowances for current expected credit losses",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r317",
      "r363"
     ]
    },
    "ci_AllowanceForReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AllowanceForReceivablesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "allowances",
        "label": "Allowance For Receivables Current",
        "documentation": "Amount of allowance for receivables, classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "verboseLabel": "Amortization of acquired intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r218",
      "r397",
      "r398",
      "r1106",
      "r1115",
      "r1117",
      "r1119",
      "r1121"
     ]
    },
    "ci_AnnuitizationElectionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AnnuitizationElectionPeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annuitization election period",
        "label": "Annuitization Election Period",
        "documentation": "The period of time prior to a policy anniversary when an annuitization election must occur."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive options",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_AociLiabilityForFuturePolicyBenefitParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AociLiabilityForFuturePolicyBenefitParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in discount rate for certain long-duration liabilities",
        "label": "AOCI, Liability for Future Policy Benefit, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in liability for future policy benefit from change in discount rate, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r198",
      "r208",
      "r209",
      "r658",
      "r1387"
     ]
    },
    "us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails": {
       "parentTag": "us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Nonperformance risk (own credit risk), end of period",
        "label": "AOCI, Market Risk Benefit, Instrument-Specific Credit Risk, before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in instrument-specific credit risk on contract or contract feature in long-duration contract issued by insurance entity protecting contract holder from other-than-nominal capital market risk and exposing insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r1225",
      "r1228",
      "r1657",
      "r1660"
     ]
    },
    "us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in instrument-specific credit risk for market risk benefits",
        "label": "AOCI, Market Risk Benefit, Instrument-Specific Credit Risk, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in instrument-specific credit risk on contract or contract feature in long-duration contract issued by insurance entity protecting contract holder from other-than-nominal capital market risk and exposing insurance entity to other-than-nominal capital market risk, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r198",
      "r208",
      "r209",
      "r658",
      "r1387"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage and other asset-backed",
        "verboseLabel": "Mortgage and other asset-backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1184",
      "r1221",
      "r1467",
      "r1472",
      "r1473"
     ]
    },
    "ci_AssetImpairmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "AssetImpairmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairments",
        "label": "Asset Impairments [Member]",
        "documentation": "Asset Impairments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r135",
      "r183",
      "r228",
      "r231",
      "r232",
      "r269",
      "r278",
      "r303",
      "r307",
      "r360",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r654",
      "r660",
      "r753",
      "r813",
      "r814",
      "r837",
      "r983",
      "r1134",
      "r1135",
      "r1178",
      "r1220",
      "r1234",
      "r1237",
      "r1258",
      "r1516",
      "r1517",
      "r1603"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r192",
      "r228",
      "r231",
      "r232",
      "r360",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r654",
      "r660",
      "r753",
      "r1220",
      "r1516",
      "r1517",
      "r1603"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets at fair value:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets of businesses held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r62",
      "r63",
      "r108",
      "r109",
      "r174",
      "r175"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Appreciation",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Depreciation",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1470"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r821"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1469"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r820"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after ten years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1471"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after ten years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r822"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1468"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r819"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage and other asset-backed securities",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping."
       }
      }
     },
     "auth_ref": [
      "r1466",
      "r1467"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage and other asset-backed securities",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r818",
      "r1466"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r375",
      "r718",
      "r744",
      "r746",
      "r748",
      "r749",
      "r808",
      "r1104",
      "r1207",
      "r1211",
      "r1218",
      "r1465",
      "r1578",
      "r1579",
      "r1580"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1334"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1333"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1332"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r663",
      "r666",
      "r667",
      "r668",
      "r669",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r752",
      "r1205",
      "r1206",
      "r1359",
      "r1628"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r663",
      "r666",
      "r667",
      "r668",
      "r669",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r752",
      "r1205",
      "r1206",
      "r1359",
      "r1628"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1436"
     ]
    },
    "ci_BelowInvestmentGradeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "BelowInvestmentGradeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Below investment grade",
        "label": "Below Investment Grade [Member]",
        "documentation": "External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments that connote non-investment grade."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BenefitsLossesAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BenefitsLossesAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL BENEFITS AND EXPENSES",
        "label": "Benefits, Losses and Expenses",
        "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r1234",
      "r1237"
     ]
    },
    "us-gaap_BenefitsLossesAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BenefitsLossesAndExpensesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits and expenses",
        "label": "Benefits, Losses and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Berkshire Hathway Life Insurance Company Of Nebraska",
        "label": "Berkshire Hathway Life Insurance Company Of Nebraska [Member]",
        "documentation": "Berkshire Hathway Life Insurance Company Of Nebraska"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value",
        "label": "Reported Value Measurement [Member]",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r751",
      "r1104",
      "r1595"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r179",
      "r1108"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ci_CashCashEquivalentsAndShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments and cash",
        "label": "Cash Cash Equivalents And Short Term Investments [Member]",
        "documentation": "Aggregate of cash, cash equivalents and short-term investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash and cash equivalents January 1,",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year (1)",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r104",
      "r225"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash January 1, including held for sale assets",
        "periodEndLabel": "Cash, cash equivalents and restricted cash December 31, including held for sale assets",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r104",
      "r225"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r104"
     ]
    },
    "us-gaap_CashSurrenderValueDuePolicyholdersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashSurrenderValueDuePolicyholdersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash surrender value",
        "label": "Policyholder Account Balance, Cash Surrender Value",
        "documentation": "Amount of cash to be paid to policyholder upon termination and surrender of long-duration contract issued by insurance entity."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r1227"
     ]
    },
    "us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]",
        "label": "Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CededCreditCollateralizationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CededCreditCollateralizationRiskMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateralization risk",
        "label": "Ceded Credit Collateralization Risk [Member]",
        "documentation": "Concentration risk related to collateralization of a specified benchmark, such as reinsurance recoverables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CededCreditRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CededCreditRiskAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk, Reinsurer [Axis]",
        "label": "Reinsurer, Name [Axis]",
        "documentation": "Information by name of reinsurer or group of reinsurers in reinsurance contract."
       }
      }
     },
     "auth_ref": [
      "r1614",
      "r1666",
      "r1667"
     ]
    },
    "us-gaap_CededCreditRiskCollateralizationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CededCreditRiskCollateralizationAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk, Collateralization [Axis]",
        "label": "Ceded Credit Risk, Collateralization [Axis]",
        "documentation": "Information by collateralization of reinsurance recoverable."
       }
      }
     },
     "auth_ref": [
      "r1666",
      "r1667"
     ]
    },
    "us-gaap_CededCreditRiskCollateralizationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CededCreditRiskCollateralizationDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk, Collateralization [Domain]",
        "label": "Ceded Credit Risk, Collateralization [Domain]",
        "documentation": "Collateralization of reinsurance recoverable."
       }
      }
     },
     "auth_ref": [
      "r1666",
      "r1667"
     ]
    },
    "us-gaap_CededCreditRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CededCreditRiskLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk [Line Items]",
        "label": "Ceded Credit Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936"
     ]
    },
    "us-gaap_CededCreditRiskReinsurerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CededCreditRiskReinsurerDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk, Reinsurer [Domain]",
        "label": "Reinsurer, Name [Domain]",
        "documentation": "Name of reinsurer or group of reinsurers in reinsurance contract."
       }
      }
     },
     "auth_ref": [
      "r1614",
      "r1666",
      "r1667"
     ]
    },
    "ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateral provisions exist that may mitigate risk of credit loss",
        "label": "Ceded Credit Risk, Secured, Collateral Provisions Exist That May Mitigate Risk [Member]",
        "documentation": "Ceded Credit Risk, Secured, Collateral Provisions Exist That May Mitigate Risk"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CededCreditRiskSecuredContractuallyRequiredFairValueMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable",
        "label": "Ceded Credit Risk, Secured, Contractually Required Fair Value [Member]",
        "documentation": "Ceded Credit Risk, Secured, Contractually Required Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CededCreditRiskSecuredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CededCreditRiskSecuredMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured",
        "label": "Ceded Credit Risk, Secured [Member]",
        "documentation": "Reinsurance recoverable that is secured by collateral."
       }
      }
     },
     "auth_ref": [
      "r1666",
      "r1667"
     ]
    },
    "us-gaap_CededCreditRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CededCreditRiskTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk [Table]",
        "label": "Ceded Credit Risk [Table]",
        "documentation": "Disclosure of information about reinsurer or group of reinsurers for whom the entity has a concentration of credit risk."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936"
     ]
    },
    "us-gaap_CededCreditRiskUnsecuredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CededCreditRiskUnsecuredMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Collateral",
        "label": "Ceded Credit Risk, Unsecured [Member]",
        "documentation": "Reinsurance recoverable that is not secured by collateral."
       }
      }
     },
     "auth_ref": [
      "r1666",
      "r1667"
     ]
    },
    "ci_CededReinsuranceAgreementCoverageLimitAmountRemaining": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CededReinsuranceAgreementCoverageLimitAmountRemaining",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining overall limit under reinsurance agreement",
        "label": "Ceded Reinsurance Agreement, Coverage Limit, Amount Remaining",
        "documentation": "Amount remaining of overall limit to claims covered under ceded reinsurance agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1309"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1306"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1304"
     ]
    },
    "ci_CignaHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CignaHealthcareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cigna Healthcare",
        "label": "Cigna Healthcare [Member]",
        "documentation": "Cigna Healthcare"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "us-gaap_CommercialPaper": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaper",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper",
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r121",
      "r1618"
     ]
    },
    "srt_CommercialPaperAverageRatePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CommercialPaperAverageRatePaid",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper average interest rate",
        "label": "Commercial Paper, Average Rate Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r445",
      "r1247",
      "r1248",
      "r1249",
      "r1252"
     ]
    },
    "us-gaap_CommercialPortfolioSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPortfolioSegmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Portfolio Segment",
        "label": "Commercial Portfolio Segment [Member]",
        "documentation": "Portfolio segment of the company's total financing receivables related to commercial receivables."
       }
      }
     },
     "auth_ref": [
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1486"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies \u2014 Note 14",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r124",
      "r841",
      "r970"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMatters"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies and Other Matters",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r431",
      "r432",
      "r1100",
      "r1501",
      "r1508"
     ]
    },
    "ci_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "documentation": "Commitments And Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/CommitmentandContingenciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r1101"
     ]
    },
    "ci_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Table]",
        "label": "Commitments And Contingencies [Table]",
        "documentation": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CommitmentsToContributeAdditionalEquityAndCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CommitmentsToContributeAdditionalEquityAndCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfunded commitments",
        "label": "Commitments To Contribute Additional Equity And Capital",
        "documentation": "Investment commitments of estimated payments required under contractual arrangements diversified by issuer, property type and geographic regions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount per share (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical",
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common dividends declared (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1243",
      "r1244",
      "r1245",
      "r1247",
      "r1248",
      "r1249",
      "r1252",
      "r1443",
      "r1444",
      "r1446",
      "r1574",
      "r1668",
      "r1677"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r971"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r488",
      "r495",
      "r842",
      "r1220"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1315"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1313"
     ]
    },
    "ci_CompletionFactorsAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CompletionFactorsAndOtherMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual completion factors and other",
        "label": "Completion Factors And Other [Member]",
        "documentation": "Amounts relating to actual claims emerging differently from assumptions about claim payment speed used to set reserves, as well as other factors impacting prior year reserves."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "SHAREHOLDERS' COMPREHENSIVE INCOME",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r203",
      "r205",
      "r213",
      "r811",
      "r857",
      "r858"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r117",
      "r203",
      "r205",
      "r212",
      "r810",
      "r857"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r314",
      "r935",
      "r936",
      "r1099",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r314",
      "r935",
      "r936",
      "r1099",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r314",
      "r935",
      "r936",
      "r1099",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r314",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r314",
      "r935",
      "r936",
      "r1099",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r133",
      "r228",
      "r229",
      "r234",
      "r236",
      "r269",
      "r280",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r816",
      "r1134",
      "r1135",
      "r1516",
      "r1517"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r133",
      "r228",
      "r229",
      "r234",
      "r236",
      "r269",
      "r280",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r816",
      "r1134",
      "r1135",
      "r1516",
      "r1517"
     ]
    },
    "ci_ContractholderDepositFundsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ContractholderDepositFundsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder Deposit Funds",
        "label": "Contractholder Deposit Funds, Policy [Policy Text Block]",
        "documentation": "Describes an entity's accounting policy for contractholder deposit funds."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ContractualAllowanceNoninsuranceCustomerReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ContractualAllowanceNoninsuranceCustomerReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "contractual allowances for third-party payor noninsurance customer receivables",
        "label": "Contractual Allowance, Noninsurance Customer Receivables",
        "documentation": "Amount of contractual allowances from third-party payors based upon the contractual payment terms."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ContractualAllowancePharmaceuticalManufacturersReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ContractualAllowancePharmaceuticalManufacturersReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "contractual allowances for certain pharmaceutical manufacturers rebate receivables",
        "label": "Contractual Allowance, Pharmaceutical Manufacturers Receivables",
        "documentation": "Amount of contractual allowances for certain rebates receivables with pharmaceutical manufacturers, classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "ci_CorporateAndEliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CorporateAndEliminationsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate and Eliminations",
        "label": "Corporate And Eliminations [Member]",
        "documentation": "Reflects amounts not allocated to other segments, such as net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment operations), interest on uncertain tax positions, certain litigation matters, intersegment eliminations, compensation cost for stock options, expense associated with its frozen pension plans, certain corporate project and overhead costs."
       }
      }
     },
     "auth_ref": []
    },
    "ci_CorporateAndGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CorporateAndGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate",
        "label": "Corporate And Government Debt Securities [Member]",
        "documentation": "This category includes information about debt securities that are issued by either a domestic or foreign corporate business entity with a promise of repayment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1184",
      "r1186",
      "r1207",
      "r1221",
      "r1240",
      "r1662"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate",
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r1456"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmacy and other service costs",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r805",
      "r1117",
      "r1122",
      "r1204",
      "r1427"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Goods and Service",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1361"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r1515"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r1515"
     ]
    },
    "ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Axis]",
        "label": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Axis]",
        "documentation": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO)"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Domain]",
        "label": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Domain]",
        "documentation": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrencySwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrencySwapMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency Swap",
        "label": "Currency Swap [Member]",
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency."
       }
      }
     },
     "auth_ref": [
      "r1567"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DavidCordaniMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DavidCordaniMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "David Cordani [Member]",
        "documentation": "David Cordani"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt",
        "label": "Debt, Current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r228",
      "r230",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r444",
      "r445",
      "r457",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r473",
      "r480",
      "r481",
      "r483",
      "r700",
      "r765"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails",
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r67",
      "r68",
      "r122",
      "r123",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1219",
      "r1437",
      "r1438",
      "r1439",
      "r1442",
      "r1502",
      "r1503",
      "r1504",
      "r1601",
      "r1602",
      "r1612"
     ]
    },
    "ci_DebtInstrumentExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DebtInstrumentExtensionTerm",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit agreement term extension",
        "label": "Debt Instrument, Extension Term",
        "documentation": "Debt Instrument, Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r765",
      "r766",
      "r1174",
      "r1175",
      "r1219"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r459"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails",
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r700",
      "r816",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1219",
      "r1437",
      "r1438",
      "r1439",
      "r1442",
      "r1601",
      "r1602"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r1173",
      "r1579",
      "r1580"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails",
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1219",
      "r1437",
      "r1438",
      "r1439",
      "r1442",
      "r1502",
      "r1503",
      "r1504",
      "r1601",
      "r1602",
      "r1612"
     ]
    },
    "ci_DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DebtInstrumentRedemptionPriceDiscountSpreadOnUSTreasuryRate",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price discount, spread on variable rate",
        "label": "Debt Instrument, Redemption Price, Discount, Spread On US Treasury Rate",
        "documentation": "Basis points added to the most directly comparable U.S. Treasury rate to calculate a \"make whole\" premium for debt redemptions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails",
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r51",
      "r52",
      "r61",
      "r114",
      "r115",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r700",
      "r816",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1219",
      "r1437",
      "r1438",
      "r1439",
      "r1442",
      "r1601",
      "r1602"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit agreement term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Allowance for Credit Loss",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r380",
      "r1163"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than one year",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months Or Longer [Abstract]",
        "documentation": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months Or Longer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Depreciation",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r380"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails_1": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Amortized Cost",
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Issues",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r1494"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Amortized Cost",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Amortized Cost",
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r380",
      "r1163"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One year or less",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less Than 12 Months [Abstract]",
        "documentation": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less Than 12 Months"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Depreciation",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r380"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails_1": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Amortized Cost",
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Issues",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r1494"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Total [Abstract]",
        "documentation": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleMeasurementInput",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable Adjustment",
        "label": "Debt Securities, Available-for-Sale, Measurement Input",
        "documentation": "Value of input used to measure investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r722",
      "r1211"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails",
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r377",
      "r1163"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Unrealized Depreciation",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r378"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Debt Securities with a Decline in Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r1163",
      "r1492"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Number of Issues",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r379"
     ]
    },
    "ci_DebtSecuritiesClassifiedInLevel3Percentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DebtSecuritiesClassifiedInLevel3Percentage",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of debt securities classified in Level 3",
        "label": "Debt Securities Classified In Level 3 Percentage",
        "documentation": "Debt Securities Classified In Level 3 Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails",
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r1245",
      "r1678"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities, net",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r623",
      "r838"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r219",
      "r269",
      "r283",
      "r307",
      "r1115",
      "r1134",
      "r1135"
     ]
    },
    "us-gaap_DerivativeAssetLiabilityNetMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeAssetLiabilityNetMeasurementInput",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Measurement Input",
        "label": "Derivative Asset (Liability) Net, Measurement Input",
        "documentation": "Value of input used to measure net derivative asset (liability)."
       }
      }
     },
     "auth_ref": [
      "r1578",
      "r1579",
      "r1580"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative assets",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r696",
      "r718",
      "r719",
      "r734",
      "r746",
      "r748",
      "r749",
      "r951",
      "r952",
      "r953",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r961",
      "r962",
      "r977",
      "r978",
      "r1062",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1104",
      "r1110",
      "r1112",
      "r1113",
      "r1114",
      "r1207",
      "r1211",
      "r1218",
      "r1245",
      "r1578",
      "r1579",
      "r1580",
      "r1672"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r959",
      "r962",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985",
      "r986",
      "r987",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1062",
      "r1063",
      "r1066",
      "r1068",
      "r1110",
      "r1111",
      "r1114",
      "r1205",
      "r1206",
      "r1243",
      "r1245",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1568",
      "r1569",
      "r1570",
      "r1571",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1588",
      "r1589"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative gain (loss) recognized in the income statement",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1104",
      "r1564"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r959",
      "r962",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985",
      "r986",
      "r987",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1062",
      "r1063",
      "r1066",
      "r1068",
      "r1110",
      "r1111",
      "r1114",
      "r1205",
      "r1206",
      "r1243",
      "r1245",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1568",
      "r1569",
      "r1570",
      "r1571",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1588",
      "r1589"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liabilities",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r696",
      "r718",
      "r719",
      "r734",
      "r746",
      "r748",
      "r749",
      "r951",
      "r952",
      "r953",
      "r955",
      "r957",
      "r958",
      "r959",
      "r961",
      "r962",
      "r984",
      "r986",
      "r987",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1110",
      "r1112",
      "r1113",
      "r1114",
      "r1578",
      "r1579",
      "r1580",
      "r1672"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r1572"
     ]
    },
    "us-gaap_DerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives",
        "label": "Derivative [Member]",
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)."
       }
      }
     },
     "auth_ref": [
      "r1209"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Value",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1205",
      "r1562",
      "r1563"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r1572"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Financial Instruments",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r235",
      "r252",
      "r662",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r701",
      "r702"
     ]
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated as Hedging Instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held-for-Sale",
        "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r17",
      "r174"
     ]
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails": {
       "parentTag": "ci_DisposalGroupIncludingDiscontinuedOperationInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments classified as assets of business held for sale",
        "label": "Disposal Group Including Discontinued Operation, Current Investments, Current",
        "documentation": "Disposal Group Including Discontinued Operation, Current Investments, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails_1": {
       "parentTag": "ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Investments classified as assets of business held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Investments",
        "documentation": "Disposal Group, Including Discontinued Operation, Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid claims classified as liabilities of business held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Liability for Unpaid Claims and Claims Adjustment Expense",
        "documentation": "Amount of liability for unpaid claims and claims adjustment expense attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1372",
      "r1373",
      "r1374",
      "r1500"
     ]
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails": {
       "parentTag": "ci_DisposalGroupIncludingDiscontinuedOperationInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments classified as assets of business held for sale",
        "label": "Disposal Group Including Discontinued Operation Noncurrent Investments Current",
        "documentation": "Disposal Group Including Discontinued Operation Noncurrent Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r1188",
      "r1191"
     ]
    },
    "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendPayableDateToBePaidDayMonthAndYear",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends Payable, Date to be Paid",
        "label": "Dividends Payable, Date to be Paid",
        "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_DividendsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends [Axis]",
        "label": "Dividends [Axis]",
        "documentation": "Information by event wherein earnings are distributed to shareholder."
       }
      }
     },
     "auth_ref": [
      "r1523",
      "r1524"
     ]
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common dividends declared",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_DividendsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends [Domain]",
        "label": "Dividends [Domain]",
        "documentation": "Event wherein earnings are distributed to shareholder."
       }
      }
     },
     "auth_ref": [
      "r1523",
      "r1524"
     ]
    },
    "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableDateDeclaredDayMonthAndYear",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends Payable, Date Declared",
        "label": "Dividends Payable, Date Declared",
        "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableDateOfRecordDayMonthAndYear",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends Payable, Date of Record",
        "label": "Dividends Payable, Date of Record",
        "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends Payable [Line Items]",
        "label": "Dividends Payable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableTable",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends Payable [Table]",
        "label": "Dividends Payable [Table]",
        "documentation": "Disclosure of information about distribution of earnings to shareholder declared but not yet paid. Includes, but is not limited to, total amount and amount per share of distribution, declaration date, and date to be paid."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ci_DividendsReceivableImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "DividendsReceivableImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of dividend receivable",
        "label": "Dividends Receivable, Impairment Loss",
        "documentation": "Dividends Receivable, Impairment Loss"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1262",
      "r1264",
      "r1276",
      "r1319"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r1263"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1297"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1308"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' net income per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in dollars per share)",
        "terseLabel": "Earnings per share, basic",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r214",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r254",
      "r256",
      "r261",
      "r262",
      "r263",
      "r268",
      "r486",
      "r617",
      "r647",
      "r652",
      "r715",
      "r716",
      "r812",
      "r859",
      "r1124"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "totalLabel": "Earnings per share, diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r214",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r256",
      "r261",
      "r262",
      "r263",
      "r268",
      "r486",
      "r617",
      "r647",
      "r652",
      "r715",
      "r716",
      "r812",
      "r859",
      "r1124"
     ]
    },
    "ci_EarningsPerShareEffectOfDilution": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "EarningsPerShareEffectOfDilution",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share, effect of dilution",
        "label": "Earnings Per Share Effect Of Dilution",
        "documentation": "The decrease in net income (loss) on a per share basis when the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period is assumed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerSharePolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r265"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r264",
      "r266",
      "r267"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign currency rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1598"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r1195"
     ]
    },
    "ci_EmployeeSeveranceAndOtherRestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "EmployeeSeveranceAndOtherRestructuringMember",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee severance, asset impairments and other",
        "label": "Employee Severance And Other Restructuring [Member]",
        "documentation": "Employee Severance And Other Restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee severance",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1531",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1536",
      "r1537",
      "r1538",
      "r1539",
      "r1540",
      "r1541",
      "r1542",
      "r1543",
      "r1544",
      "r1545",
      "r1546",
      "r1547",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556"
     ]
    },
    "ci_EmployerInsuredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "EmployerInsuredMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer insured",
        "label": "Employer Insured [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1348"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customer [Line Items]",
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1302"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r169",
      "r171",
      "r172",
      "r207",
      "r208",
      "r209",
      "r237",
      "r238",
      "r239",
      "r241",
      "r248",
      "r250",
      "r252",
      "r270",
      "r361",
      "r362",
      "r400",
      "r485",
      "r498",
      "r617",
      "r634",
      "r635",
      "r644",
      "r645",
      "r646",
      "r648",
      "r651",
      "r652",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r757",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r767",
      "r769",
      "r770",
      "r853",
      "r917",
      "r918",
      "r919",
      "r948",
      "r1008"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r643",
      "r753",
      "r1350",
      "r1351",
      "r1352",
      "r1557",
      "r1558",
      "r1559",
      "r1560"
     ]
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income distributions",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r13",
      "r91",
      "r848"
     ]
    },
    "ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Security Investments",
        "label": "Equity Securities, FV-NI And Equity Securities Without Readily Determinable Fair Value [Table Text Block]",
        "documentation": "Equity Securities, FV-NI And Equity Securities Without Readily Determinable Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost",
        "documentation": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost [Abstract]",
        "documentation": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount",
        "documentation": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value",
        "label": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale [Abstract]",
        "documentation": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with readily determinable fair values",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity securities with readily determinable fair values",
        "terseLabel": "Equity securities",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r718",
      "r744",
      "r746",
      "r748",
      "r749",
      "r829",
      "r830",
      "r1207",
      "r1239",
      "r1242",
      "r1578",
      "r1579",
      "r1580"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r1221",
      "r1253",
      "r1254",
      "r1255",
      "r1678"
     ]
    },
    "ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with no readily determinable fair value",
        "label": "Equity Securities Without Readily Determinable Fair Value, Amortized Cost",
        "documentation": "Equity Securities Without Readily Determinable Fair Value, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with no readily determinable fair value",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount",
        "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1269",
      "r1280",
      "r1290",
      "r1323"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1266",
      "r1277",
      "r1287",
      "r1320"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r746",
      "r748",
      "r751",
      "r1104",
      "r1174",
      "r1175"
     ]
    },
    "ci_EvernorthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "EvernorthMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Evernorth Health Services",
        "label": "Evernorth [Member]",
        "documentation": "Health Services includes pharmacy benefits management (PBM), pharmacy home delivery, and certain medical management services. This segment includes Express Scripts business from the date of acquisition with the exception of Express Scripts Medicare Part D business that is reported in the Government operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "ci_FairValueAssetRecurringBasisStillHeldRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "FairValueAssetRecurringBasisStillHeldRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date",
        "label": "Fair Value, Asset, Recurring Basis, Still Held, Realized Gain (Loss)",
        "documentation": "This element represents total gains or losses for the period (realized and unrealized), arising from assets included in income attributable to instruments held at the reporting date, measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in earnings or resulted in a change in asset value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r734",
      "r1207"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r734",
      "r1207"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets and Financial Liabilities Carried at Fair Value",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r1207",
      "r1576",
      "r1577",
      "r1588"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r722",
      "r1196",
      "r1199",
      "r1211"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r722",
      "r1196",
      "r1199",
      "r1211"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r1211"
     ]
    },
    "ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value",
        "label": "Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets and liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3, by class of assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period",
        "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r735",
      "r1209",
      "r1210"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r735",
      "r1104",
      "r1209",
      "r1218"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r748",
      "r749",
      "r1104",
      "r1218",
      "r1595"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r735",
      "r1104",
      "r1209",
      "r1218"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r749",
      "r1104",
      "r1218",
      "r1593",
      "r1595"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures for Financial Instruments Not Carried at Fair Value",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r750",
      "r1104",
      "r1218",
      "r1595"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r555",
      "r556",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r731",
      "r734",
      "r736",
      "r746",
      "r775",
      "r776",
      "r777",
      "r1104",
      "r1174",
      "r1175",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1207",
      "r1211",
      "r1218"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r746",
      "r748",
      "r749",
      "r751",
      "r753",
      "r754",
      "r1104",
      "r1174",
      "r1175",
      "r1595"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r722",
      "r1207",
      "r1579",
      "r1590"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r1174",
      "r1175"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r727",
      "r729",
      "r730",
      "r731",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r806",
      "r1207",
      "r1212"
     ]
    },
    "us-gaap_FairValueHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueHedgingMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hedging",
        "label": "Fair Value Hedging [Member]",
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel12And3Member",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]",
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)."
       }
      }
     },
     "auth_ref": [
      "r1207",
      "r1528",
      "r1530",
      "r1577",
      "r1588",
      "r1592"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r526",
      "r531",
      "r555",
      "r719",
      "r734",
      "r746",
      "r775",
      "r1104",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1207",
      "r1218"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r526",
      "r531",
      "r555",
      "r557",
      "r719",
      "r720",
      "r734",
      "r746",
      "r776",
      "r1104",
      "r1174",
      "r1175",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1207",
      "r1218"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r555",
      "r556",
      "r719",
      "r720",
      "r721",
      "r722",
      "r734",
      "r746",
      "r777",
      "r1104",
      "r1174",
      "r1175",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1207",
      "r1211",
      "r1218"
     ]
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NAV",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "documentation": "Fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r555",
      "r717",
      "r736",
      "r1207"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r722",
      "r1207",
      "r1579",
      "r1590"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gains (losses) included in Shareholders' net income",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r1209",
      "r1210"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Losses) gains included in Other comprehensive loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r725",
      "r735",
      "r1209"
     ]
    },
    "ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) required to adjust future policy benefits for settlement annuities",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Required To Adjust Future Policy Benefits",
        "documentation": "This element represents total gains or losses for the period (realized and unrealized), arising from assets measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in gains or losses required to adjust future policy benefits for settlement annuities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate accounts assets classified in Level 3, period increase (decrease), including transfers in and out of Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1581",
      "r1589"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r732",
      "r735",
      "r1209"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total purchases, sales and settlements",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)",
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1584",
      "r1589"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases, sales and settlements",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sales",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales",
        "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r735",
      "r1209"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r735",
      "r1209"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers into Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r733",
      "r735",
      "r1209"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total transfers into / (out of) Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r1585",
      "r1589"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers into / (out of) Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Transfers out of Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r733",
      "r735",
      "r1209"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r735",
      "r1209"
     ]
    },
    "ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, including held for sale assets",
        "periodEndLabel": "Ending balance, including held for sale assets",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r555",
      "r556",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r731",
      "r734",
      "r736",
      "r746",
      "r775",
      "r776",
      "r777",
      "r1104",
      "r1174",
      "r1175",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1207",
      "r1211",
      "r1218"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1207",
      "r1576",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1590"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasuresandDisclosuresPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1591"
     ]
    },
    "ci_FairValueOfSeparateAccountAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "FairValueOfSeparateAccountAssetsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values of Separate Account Assets",
        "label": "Fair Value Of Separate Account Assets [Table Text Block]",
        "documentation": "Disclose the aggregate fair value of separate account assets, by fair value level."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from asset measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which other comprehensive income (OCI) is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r725",
      "r735"
     ]
    },
    "us-gaap_FinancialGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialGuaranteeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Guarantees",
        "label": "Financial Guarantee [Member]",
        "documentation": "An agreement (contract) that requires the guarantor to make payments to the guaranteed party based on another entity's failure to pay specified obligations, such as debt, to a lender."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails",
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r364",
      "r365",
      "r372",
      "r373",
      "r374",
      "r376",
      "r381",
      "r382",
      "r482",
      "r497",
      "r700",
      "r713",
      "r741",
      "r752",
      "r755",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r824",
      "r854",
      "r1163",
      "r1207",
      "r1209",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1221",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1575",
      "r1578",
      "r1579",
      "r1580",
      "r1587",
      "r1590",
      "r1592",
      "r1593"
     ]
    },
    "ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "FinancingReceivableCreditQualityDebtServiceCoverageRatio",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Debt Service Coverage Ratio",
        "label": "Financing Receivable, Credit Quality Debt Service Coverage Ratio",
        "documentation": "Financing Receivable, Credit Quality Debt Service Coverage Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableCreditQualityIndicatorsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio",
        "label": "Financing Receivable Credit Quality Indicators [Table Text Block]",
        "documentation": "Tabular disclosure of financing receivables by credit quality indicator. The credit quality indicator is a statistic about the credit quality of financing receivables. Examples include, but not limited to, consumer credit risk scores, credit-rating-agency ratings, an entity's internal credit risk grades, loan-to-value ratios, collateral, collection experience and other internal metrics."
       }
      }
     },
     "auth_ref": [
      "r1487"
     ]
    },
    "ci_FinancingReceivableCreditQualityLoanToValueRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "FinancingReceivableCreditQualityLoanToValueRatio",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Loan-to-Value Ratio",
        "label": "Financing Receivable Credit Quality Loan To Value Ratio",
        "documentation": "Financing Receivable Credit Quality Loan To Value Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value, after allowance for credit loss",
        "label": "Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r1479"
     ]
    },
    "us-gaap_FinancingReceivablePortfolioSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivablePortfolioSegmentAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Receivable Portfolio Segment [Axis]",
        "label": "Financing Receivable Portfolio Segment [Axis]",
        "documentation": "Information by the level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r1141",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371"
     ]
    },
    "us-gaap_FinancingReceivablePortfolioSegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivablePortfolioSegmentDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Receivable Portfolio Segment [Domain]",
        "label": "Financing Receivable Portfolio Segment [Domain]",
        "documentation": "Level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371"
     ]
    },
    "us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Financing Receivable [Axis]",
        "label": "Class of Financing Receivable [Axis]",
        "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r165",
      "r166",
      "r167",
      "r168",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r372",
      "r373",
      "r374",
      "r1140",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1161",
      "r1162",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1463"
     ]
    },
    "us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Financing Receivable [Domain]",
        "label": "Class of Financing Receivable [Domain]",
        "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r165",
      "r166",
      "r167",
      "r168",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r1140",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1463"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation of Foreign Currencies",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign government",
        "label": "Debt Security, Government, Non-US [Member]",
        "documentation": "Debt security issued by government not domiciled in United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1221",
      "r1527",
      "r1529",
      "r1662"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1273",
      "r1284",
      "r1294",
      "r1327"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1273",
      "r1284",
      "r1294",
      "r1327"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1273",
      "r1284",
      "r1294",
      "r1327"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1273",
      "r1284",
      "r1294",
      "r1327"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1273",
      "r1284",
      "r1294",
      "r1327"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1307"
     ]
    },
    "us-gaap_FuturePolicyBenefitsLiabilityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FuturePolicyBenefitsLiabilityPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Policy Benefits",
        "label": "Liability for Future Policy Benefit [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for liability for future benefit to be paid to or on behalf of policyholder. Includes, but is not limited to, input, judgment, assumption, and method used in measuring liability and change in input, judgment, and assumption."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r902",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of businesses",
        "negatedLabel": "Gain on sale of businesses",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r1435"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt extinguishment gain",
        "negatedTerseLabel": "Debt extinguishment gain",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r49",
      "r50"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r386",
      "r807",
      "r1135",
      "r1165",
      "r1196",
      "r1197",
      "r1198",
      "r1201",
      "r1208",
      "r1220",
      "r1495",
      "r1496",
      "r1561"
     ]
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantor Obligations, Nature [Axis]",
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_GuaranteeObligationsCurrentCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsCurrentCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for guarantees",
        "label": "Guarantor Obligations, Current Carrying Value",
        "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_GuaranteeObligationsLiquidationProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsLiquidationProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets maintained by employers (minimum)",
        "label": "Guarantor Obligations, Liquidation Proceeds, Monetary Amount",
        "documentation": "Indicates, if estimable, the approximate extent to which the proceeds from liquidation of any assets held either as collateral or by third parties would be expected to cover the maximum potential amount of future payments under the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsMaximumExposure",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum guarantee exposure",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_GuaranteeObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial and performance guarantees",
        "label": "Guarantee Obligations [Member]",
        "documentation": "A written or oral contract that obligates the guarantor to either pay cash or perform services if another party fails to perform specified actions or achieve specified results."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantor Obligations, Nature [Domain]",
        "label": "Guarantor Obligations, Nature [Domain]",
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "presentation": [
      "http://www.thecignagroup.com/role/CommitmentandContingenciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantees",
        "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_HealthCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HealthCareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cigna Healthcare",
        "label": "Health Care [Member]",
        "documentation": "Service provided for prevention, maintenance, diagnosis or treatment of physical and mental health."
       }
      }
     },
     "auth_ref": [
      "r1525",
      "r1526"
     ]
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r1564",
      "r1565"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r1564",
      "r1565"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": []
    },
    "ci_HomeDeliveryAndSpecialtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "HomeDeliveryAndSpecialtyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Home delivery and specialty revenues",
        "label": "Home Delivery And Specialty [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairments requiring certain assets and liabilities to be measured at fair value",
        "label": "Impairments Requiring Certain Assets And Liabilities To Be Measured At Fair Value",
        "documentation": "Impairments requiring certain financial assets and liabilities, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions, to be measured using fair value. These financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "IncomeLossAttributableToNoncontrollingInterestBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Income) loss attributable to noncontrolling interests",
        "label": "Income Loss Attributable To Noncontrolling Interest Before Tax",
        "documentation": "Amount of pre-tax income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r129",
      "r134",
      "r813",
      "r815",
      "r849",
      "r1118",
      "r1120",
      "r1122",
      "r1128",
      "r1134",
      "r1448",
      "r1455",
      "r1457",
      "r1458",
      "r1459"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r1188",
      "r1191"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r233",
      "r619",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r632",
      "r636",
      "r638",
      "r641",
      "r642",
      "r823",
      "r929",
      "r945",
      "r1195"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "TOTAL INCOME TAXES",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r160",
      "r228",
      "r251",
      "r252",
      "r269",
      "r286",
      "r307",
      "r624",
      "r625",
      "r637",
      "r862",
      "r1118",
      "r1120",
      "r1122",
      "r1195"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r620",
      "r621",
      "r629",
      "r630",
      "r631",
      "r633",
      "r941"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and Accrued expenses and other liabilities",
        "label": "Increase Decrease In Accounts Payable Accrued And Other Operating Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of accounts payable, accrued liabilities and other operating obligations not separately disclosed in the statement of cash flows."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred income tax benefit",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInInsuranceLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInsuranceLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance liabilities",
        "label": "Increase (Decrease) in Insurance Liabilities",
        "documentation": "The increase (decrease) in insurance liability balances during the period."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net changes in assets and liabilities, net of non-operating effects:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other, net",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "IncreaseDecreaseInPharmacyAndServiceCostsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmacy and other service costs payable",
        "label": "Increase Decrease In Pharmacy And Service Costs Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInReinsuranceRecoverable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInReinsuranceRecoverable",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reinsurance recoverable and Other assets",
        "label": "Increase (Decrease) in Reinsurance Recoverable",
        "documentation": "The increase (decrease) during the reporting period in the amount of benefits the ceding insurer expects to recover on insurance policies ceded to other insurance entities as of the balance sheet date for all guaranteed benefit types."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Total Equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Redeemable Noncontrolling Interests",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock equivalents",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r263",
      "r588"
     ]
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndemnificationGuaranteeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indemnification obligations",
        "label": "Indemnification Agreement [Member]",
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor."
       }
      }
     },
     "auth_ref": [
      "r1514"
     ]
    },
    "ci_IndividualAndFamilyPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "IndividualAndFamilyPlansMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual and Family Plans",
        "label": "Individual And Family Plans [Member]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1273",
      "r1284",
      "r1294",
      "r1318",
      "r1327",
      "r1331",
      "r1339"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1265",
      "r1343"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1265",
      "r1343"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1265",
      "r1343"
     ]
    },
    "us-gaap_InsuranceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InsuranceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InsuranceAndContractholderLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total insurance and contractholder liabilities",
        "label": "Insurance And Contractholder Liabilities",
        "documentation": "Insurance And Contractholder Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InsuranceAndContractholderLiabilitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Insurance And Contractholder Liabilities [Abstract]",
        "documentation": "Insurance And Contractholder Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InsuranceAndContractholderLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current insurance and contractholder liabilities",
        "totalLabel": "Current insurance and contractholder liabilities",
        "label": "Insurance And Contractholder Liabilities Current",
        "documentation": "The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InsuranceAndContractholderLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Insurance And Contractholder Liabilities, Current [Abstract]",
        "documentation": "Insurance And Contractholder Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InsuranceAndContractholderLiabilitiesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance and Contractholder Liabilities [Line Items]",
        "label": "Insurance and Contractholder Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InsuranceAndContractholderLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current insurance and contractholder liabilities",
        "totalLabel": "Non-current insurance and contractholder liabilities",
        "label": "Insurance And Contractholder Liabilities Noncurrent",
        "documentation": "The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InsuranceAndContractholderLiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current",
        "label": "Insurance And Contractholder Liabilities, Noncurrent [Abstract]",
        "documentation": "Insurance And Contractholder Liabilities, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InsuranceAndContractholderLiabilitiesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance And Contractholder Liabilities [Table]",
        "label": "Insurance And Contractholder Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceCustomerReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InsuranceCustomerReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance customer receivables",
        "label": "Insurance Customer Receivables",
        "documentation": "Receivables due from customers under insurance contracts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceLossReservesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InsuranceLossReservesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance Loss Reserves [Abstract]",
        "label": "Insurance Loss Reserves [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceRelatedAssessmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InsuranceRelatedAssessmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranty Fund Assessments",
        "label": "Insurance-related Assessments [Member]",
        "documentation": "Any funding mandated by statute or regulatory authority that is related directly or indirectly to underwriting activities, including pools for self-insurance and excluding premium taxes and income taxes. The funds derived from the assessments generally enable a government guarantor to pay insurance claims in the event that the underwriting insurer is insolvent or otherwise unable to meet its payment obligations."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ci_InsuranceUnearnedPremiumsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InsuranceUnearnedPremiumsPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned Premium",
        "label": "Insurance, Unearned Premiums [Policy Text Block]",
        "documentation": "Insurance, Unearned Premiums"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r1497",
      "r1498"
     ]
    },
    "ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails": {
       "parentTag": "us-gaap_NetInvestmentIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income",
        "label": "Interest And Dividend Income Operating And Operating Leases Income Statement Lease Revenue",
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein. Also includes the total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on long-term and short-term debt",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r477",
      "r484",
      "r1176",
      "r1177",
      "r1676"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r223",
      "r224"
     ]
    },
    "us-gaap_InterestRateSwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestRateSwapMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swap",
        "label": "Interest Rate Swap [Member]",
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period."
       }
      }
     },
     "auth_ref": [
      "r1205",
      "r1250",
      "r1251",
      "r1566"
     ]
    },
    "ci_InternationalHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InternationalHealthMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International Health",
        "label": "International Health [Member]",
        "documentation": "International Health"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntersegmentEliminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntersegmentEliminationMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intersegment Eliminations",
        "label": "Intersegment Eliminations [Member]",
        "documentation": "Eliminating entries used in operating segment consolidation."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r269",
      "r280",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r1134"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r1109",
      "r1220"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r178",
      "r189",
      "r383",
      "r384",
      "r385",
      "r804",
      "r1123"
     ]
    },
    "ci_InvestmentGradeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InvestmentGradeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment grade",
        "label": "Investment Grade [Member]",
        "documentation": "External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments that connote investment grade."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments by category and current or long-term classification",
        "label": "Investment Holdings, Schedule of Investments [Table Text Block]",
        "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments."
       }
      }
     },
     "auth_ref": [
      "r1669",
      "r1670",
      "r1671",
      "r1672",
      "r1673",
      "r1674"
     ]
    },
    "ci_InvestmentIncomeAndGainsAndLossesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InvestmentIncomeAndGainsAndLossesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income And Gains And Losses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInvestmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails": {
       "parentTag": "us-gaap_NetInvestmentIncome",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less investment expenses",
        "label": "Investment Income, Investment Expense",
        "documentation": "Amount of expenses related to the generation of investment income."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r1256",
      "r1621"
     ]
    },
    "us-gaap_InvestmentIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Net Investment Income",
        "label": "Investment Income [Table Text Block]",
        "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r1622"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r937",
      "r938",
      "r939",
      "r940",
      "r1032",
      "r1034"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails",
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r954",
      "r955",
      "r957",
      "r960",
      "r1012",
      "r1021",
      "r1037",
      "r1045",
      "r1058",
      "r1070",
      "r1086",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1245"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails",
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r954",
      "r955",
      "r957",
      "r960",
      "r1012",
      "r1021",
      "r1037",
      "r1045",
      "r1058",
      "r1070",
      "r1086",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1245"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Investments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails_1": {
       "parentTag": "ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total investments",
        "terseLabel": "Total investments",
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r834",
      "r1234",
      "r1237",
      "r1239",
      "r1242"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Abstract]",
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments including held for sale assets",
        "label": "Investments Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Investments Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities by Contractual Maturity",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InvestmentsCreditRatingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InvestmentsCreditRatingAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Credit Rating [Axis]",
        "label": "Investments Credit Rating [Axis]",
        "documentation": "Information by credit rating of debt and securities investments."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InvestmentsCreditRatingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "InvestmentsCreditRatingDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Credit Rating [Domain]",
        "label": "Investments Credit Rating [Domain]",
        "documentation": "External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r164",
      "r322",
      "r323",
      "r742",
      "r743",
      "r1611"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r67",
      "r68",
      "r69",
      "r72",
      "r73",
      "r74",
      "r75",
      "r228",
      "r231",
      "r232",
      "r360",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r655",
      "r660",
      "r661",
      "r753",
      "r969",
      "r1127",
      "r1178",
      "r1258",
      "r1516",
      "r1603",
      "r1604"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r126",
      "r846",
      "r1220",
      "r1234",
      "r1237",
      "r1437",
      "r1441",
      "r1478",
      "r1597"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r177",
      "r228",
      "r231",
      "r232",
      "r360",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r655",
      "r660",
      "r661",
      "r753",
      "r1220",
      "r1516",
      "r1603",
      "r1604"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, Fair Value Disclosure [Abstract]",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities of businesses held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r62",
      "r63",
      "r108",
      "r109",
      "r174",
      "r175"
     ]
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unpaid claims and claim expenses",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r1229",
      "r1233",
      "r1234",
      "r1616",
      "r1632"
     ]
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid claims and claim expenses, current",
        "label": "Liability For Claims And Claims Adjustment Expense, Current",
        "documentation": "Liability For Claims And Claims Adjustment Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total of incurred but not reported liabilities plus expected claim development on reported claims and reported claims in process",
        "label": "Liability For Claims And Claims Adjustment Expense Excluding Physician Incentives And Other Expenses",
        "documentation": "Represents the total liability for incurred but not reported claims plus expected claim development on reported claims, including reported claims in process. Excludes amounts due for physician incentives and other medical care expenses and services payable."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, including held for sale liabilities",
        "periodEndLabel": "Ending balance, including held for sale liabilities",
        "label": "Liability For Claims And Claims Adjustment Expense Including Disposal Groups",
        "documentation": "Liability For Claims And Claims Adjustment Expense Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "label": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid claims and claim expenses, non-current",
        "label": "Liability For Claims And Claims Adjustment Expense, Noncurrent",
        "documentation": "Liability For Claims And Claims Adjustment Expense, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]",
        "label": "Liability for Claims and Claims Adjustment Expense [Table]",
        "documentation": "Disclosure of information about the liability for claims and claims adjustment expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefitActivityLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Future Policy Benefit Activity [Line Items]",
        "label": "Liability for Future Policy Benefit, Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r920",
      "r1226"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitActivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefitActivityTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Future Policy Benefit Activity [Table]",
        "label": "Liability for Future Policy Benefit Activity [Table]",
        "documentation": "Disclosure of information about activity for liability for future policy benefit. Includes, but is not limited to, beginning and ending balance, issuance, interest income (expense), net premium collected, benefit payment, derecognition, experience adjustment, change in cash flow assumption, and change in discount rate assumption."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r920",
      "r1226"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefitActivityTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Policy Benefit Activity",
        "label": "Liability for Future Policy Benefit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of beginning balance to ending balance for liability for future policy benefit, with separate presentation of expected future net premium and expected future benefit."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r920",
      "r1226"
     ]
    },
    "ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits, current",
        "label": "Liability For Future Policy Benefit, Before Reinsurance, Current",
        "documentation": "Liability For Future Policy Benefit, Before Reinsurance, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits, non-current",
        "label": "Liability For Future Policy Benefit, Before Reinsurance, Noncurrent",
        "documentation": "Liability For Future Policy Benefit, Before Reinsurance, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current discount rate",
        "label": "Liability for Future Policy Benefit, Current Weighted-Average Discount Rate",
        "documentation": "Current weighted-average discount rate used to measure liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r1226"
     ]
    },
    "ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails": {
       "parentTag": "us-gaap_LiabilityForFuturePolicyBenefits",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefit, excluding deferred profit liability",
        "label": "Liability For Future Policy Benefit, Excluding Deferred Profit Liability",
        "documentation": "Liability For Future Policy Benefit, Excluding Deferred Profit Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undiscounted expected future policy benefits",
        "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Undiscounted, before Reinsurance",
        "documentation": "Amount, before effect of reinsurance, of undiscounted balance for expected future policy benefit and expense component of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r1226"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits reserve, reinsurance recoverables",
        "label": "Liability for Future Policy Benefit, Reinsurance Recoverable, after Allowance",
        "documentation": "Amount, after allowance for credit loss, recoverable under reinsurance of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r920",
      "r1226",
      "r1643"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefitWeightedAverageDuration",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average duration",
        "label": "Liability for Future Policy Benefit, Weighted-Average Duration",
        "documentation": "Weighted-average duration of liability for future policy benefit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accretion rate",
        "label": "Liability for Future Policy Benefit, Weighted-Average Interest Accretion Rate",
        "documentation": "Original weighted-average discount rate at contract issue date used to measure liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r1226"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liability for future policy benefits",
        "label": "Liability for Future Policy Benefit, before Reinsurance",
        "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r903",
      "r920",
      "r1226",
      "r1237",
      "r1616"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance and Contractholder Liabilities",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r886"
     ]
    },
    "ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForFuturePolicyBenefitsDeferredProfitLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails": {
       "parentTag": "us-gaap_LiabilityForFuturePolicyBenefits",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred profit liability included in future policy benefits",
        "label": "Liability For Future Policy Benefits, Deferred Profit Liability",
        "documentation": "Liability For Future Policy Benefits, Deferred Profit Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid costs related to:",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r889",
      "r1229"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior years",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r889",
      "r1229"
     ]
    },
    "ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Divestiture and other",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Divestiture and Other",
        "documentation": "Amount of decrease (increase) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the divesture and/or re-segmentation of business unit(s). Includes, but is not limited to, claims which have been incurred but not reported."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total incurred",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process."
       }
      }
     },
     "auth_ref": [
      "r1229",
      "r1630"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred costs related to:",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, net",
        "periodEndLabel": "Ending balance, net",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net",
        "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890",
      "r1616"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, net, including held for sale liabilities",
        "periodEndLabel": "Ending balance, net, including held for sale liabilities",
        "label": "Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups",
        "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Favorable (unfavorable) variance, percentage",
        "label": "Liability For Unpaid Medical Claims And Claims Adjustment Expense Incurred Claims Prior Years Percentage",
        "documentation": "Amount of payments made in the reporting period to settle claims incurred in prior periods and related claims settlement costs as a percentage of incurred claims as reported in the prior year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LifeAndAnnuityInsuranceProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LifeAndAnnuityInsuranceProductLineMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Life and annuity insurance products",
        "label": "Life and Annuity Insurance Product Line [Member]",
        "documentation": "Contract providing periodic payment upon death of insured."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York",
        "label": "The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York [Member]",
        "documentation": "Reinsurance recoverables resulting from the 1998 sale of the Companys individual life insurance and annuity business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding balances",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r123",
      "r1619"
     ]
    },
    "ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails": {
       "parentTag": "ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount of options to increase commitments",
        "label": "Line Of Credit Facility, Accordion Feature, Incremental Increase In Maximum Borrowing Capacity",
        "documentation": "Line Of Credit Facility, Accordion Feature, Incremental Increase In Maximum Borrowing Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leverage ratio covenant",
        "label": "Line Of Credit Facility Debt To Adjusted Capital Ratio Covenant",
        "documentation": "The debt-to adjusted capital ratio which the Company must not exceed in accordance with the terms of the line of credit facility agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails": {
       "parentTag": "ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r71"
     ]
    },
    "ci_LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncludingAccordionFeature",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Maximum total commitment",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity Including Accordion Feature",
        "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity Including Accordion Feature"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LitigationMattersAndRegulatoryMattersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LitigationMattersAndRegulatoryMattersMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Matters and Regulatory Matters",
        "label": "Litigation Matters And Regulatory Matters [Member]",
        "documentation": "Litigation Matters And Regulatory Matters"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoanToValueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoanToValueAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt-to-Value [Axis]",
        "label": "Debt-to-Value [Axis]",
        "documentation": "Information by debt-to-value ratio, for example, but not limited to, 80 percent to 100 percent. Element name and standard label in Debt-to-Value [numeric lower end] to [numeric higher end] Percent [Member] or Debt-to-Value Greater Than [low end numeric value] Percent [Member] or Debt-to-Value Less Than [high end numeric value] Percent [Member] formats."
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1488"
     ]
    },
    "us-gaap_LoanToValueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoanToValueDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt-to-Value [Domain]",
        "label": "Debt-to-Value [Domain]",
        "documentation": "Debt-to-value (DTV) ratio, for example, but not limited to, 80 percent to 100 percent. Element name and standard label in DTV [numeric lower end] to [numeric higher end] Percent [Member] or DTV Greater Than [low end numeric value] Percent [Member] or DTV Less Than [high end numeric value] Percent [Member] formats."
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1488"
     ]
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Net",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r1460"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r839"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, including current maturities, excluding finance leases",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": [
      "r1104",
      "r1218",
      "r1576",
      "r1578",
      "r1579",
      "r1580",
      "r1592",
      "r1593",
      "r1594",
      "r1596"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": "us-gaap_Investments",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails": {
       "parentTag": "ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term investments",
        "terseLabel": "Investments per Consolidated Balance Sheets",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermInvestmentsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term",
        "label": "Long-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails": {
       "parentTag": "ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments including held for sale assets",
        "label": "Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails",
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r1502",
      "r1503",
      "r1504"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails",
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r48",
      "r1502",
      "r1503",
      "r1504"
     ]
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency Nature [Axis]",
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r433",
      "r434",
      "r435",
      "r439",
      "r618",
      "r925",
      "r1172",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r433",
      "r434",
      "r435",
      "r439",
      "r618",
      "r1172",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r433",
      "r434",
      "r435",
      "r439",
      "r618",
      "r1172",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantee liability",
        "netLabel": "Guarantee liability",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r1349"
     ]
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrual, period increase (decrease)",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r1509"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Nature [Domain]",
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r433",
      "r434",
      "r435",
      "r439",
      "r618",
      "r925",
      "r1172",
      "r1510",
      "r1511"
     ]
    },
    "ci_Ltv60To79PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "Ltv60To79PercentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "60% to 79%",
        "label": "LTV 60 to 79 Percent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Ltv80To100PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Ltv80To100PercentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "80% to 100%",
        "label": "Debt-to-Value Ratio, 80 to 100 Percent [Member]",
        "documentation": "Debt-to-value (DTV) ratio from 80 percent to 100 percent. Element name and standard label in DTV [numeric lower end] to [numeric higher end] Percent [Member] format."
       }
      }
     },
     "auth_ref": [
      "r1488",
      "r1489"
     ]
    },
    "ci_LtvGreaterThan100PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LtvGreaterThan100PercentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Greater than 100%",
        "label": "Ltv Greater Than 100 Percent [Member]",
        "documentation": "Debt-to-value ratio greater than 100 percent. Element name an standard label in DTV [numeric lower end] to [numeric higher end] Percent [Member] format."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LtvLessThan60PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "LtvLessThan60PercentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Below 60%",
        "label": "LTV Less Than 60 Percent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LtvLessThan80PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LtvLessThan80PercentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 80 percent",
        "label": "Debt-to-Value Ratio, Less than 80 Percent [Member]",
        "documentation": "Debt-to-value (DTV) ratio less than 80 percent. Element name and standard label in DTV Greater Than [low end numeric value] Percent [Member] or DTV Less Than [high end numeric value] Percent [Member] formats."
       }
      }
     },
     "auth_ref": [
      "r1488",
      "r1489"
     ]
    },
    "us-gaap_MarketRiskBenefitActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketRiskBenefitActivityTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Market Risk Benefit",
        "label": "Market Risk Benefit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of beginning balance to ending balance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r1228"
     ]
    },
    "us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails": {
       "parentTag": "us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of year",
        "periodEndLabel": "Balance, end of period",
        "label": "Market Risk Benefit, after Increase (Decrease) from Instrument-Specific Credit Risk",
        "documentation": "Amount, before effect of reinsurance and after accumulated increase (decrease) in instrument-specific credit risk, of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r913",
      "r923",
      "r1228"
     ]
    },
    "us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of year, before the effect of nonperformance risk (own credit risk)",
        "periodEndLabel": "Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)",
        "label": "Market Risk Benefit, before Reinsurance and Cumulative Increase (Decrease) from Instrument-Specific Credit Risk Change",
        "documentation": "Amount, before effect of reinsurance and cumulative increase (decrease) in instrument-specific credit risk, of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r923",
      "r1228"
     ]
    },
    "ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes due to expected run-off",
        "label": "Market Risk Benefit, Increase (Decrease) Due to Expected Run-Off",
        "documentation": "Market Risk Benefit, Increase (Decrease) Due to Expected Run-Off"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes due to policyholder behavior versus expected",
        "label": "Market Risk Benefit, Increase (Decrease) from Actual Policyholder Behavior Different from Expected",
        "documentation": "Amount of increase (decrease) in contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk from change associated with actual policyholder behavior different from expected."
       }
      }
     },
     "auth_ref": [
      "r1223",
      "r1228",
      "r1657",
      "r1660"
     ]
    },
    "ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes due to capital markets versus expected",
        "label": "Market Risk Benefit, Increase (Decrease) From Interest Rate Change And Equity Market Change",
        "documentation": "Market Risk Benefit, Increase (Decrease) From Interest Rate Change And Equity Market Change"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketRiskBenefitIncreaseDecreaseFromOtherAssumption",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumption changes",
        "label": "Market Risk Benefit, Increase (Decrease) from Other Assumption",
        "documentation": "Amount of increase (decrease) in contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk from change in assumption, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1228",
      "r1657",
      "r1660"
     ]
    },
    "us-gaap_MarketRiskBenefitLiabilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketRiskBenefitLiabilityAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Market risk benefits",
        "label": "Market Risk Benefit, Liability, Amount",
        "documentation": "Amount of liability position for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r1228",
      "r1578",
      "r1579",
      "r1580"
     ]
    },
    "ci_MarketRiskBenefitLiabilityAmountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MarketRiskBenefitLiabilityAmountCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market risk benefits, current",
        "label": "Market Risk Benefit, Liability, Amount, Current",
        "documentation": "Market Risk Benefit, Liability, Amount, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_MarketRiskBenefitLiabilityAmountNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MarketRiskBenefitLiabilityAmountNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "us-gaap_MarketRiskBenefitLiabilityAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market risk benefits, non-current",
        "label": "Market Risk Benefit, Liability, Amount, Noncurrent",
        "documentation": "Market Risk Benefit, Liability, Amount, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketRiskBenefitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketRiskBenefitPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Risk Benefits",
        "label": "Market Risk Benefit [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk. Includes, but is not limited to, input, judgment, assumption and method used in measuring market risk benefit, and change in input, judgment, and assumption."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r916"
     ]
    },
    "us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketRiskBenefitReinsuranceRecoverableAfterAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails": {
       "parentTag": "us-gaap_ReinsuranceRecoverables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reinsured market risk benefit, end of period",
        "terseLabel": "Market risk benefits",
        "label": "Market Risk Benefit, Reinsurance Recoverable, after Allowance",
        "documentation": "Amount, after allowance for credit loss, recoverable under reinsurance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r1228",
      "r1657"
     ]
    },
    "ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due",
        "label": "Market Risk Benefit Reinsurance Recoverable After Allowance And Related Balances [Member]",
        "documentation": "Market risk benefit reinsurance recoverable, including IBNR and outstanding claims, less premiums due."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketRiskBenefitRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketRiskBenefitRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesMarketRiskBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Risk Benefit [Roll Forward]",
        "label": "Market Risk Benefit [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r1376"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r434",
      "r435",
      "r436",
      "r437",
      "r586",
      "r612",
      "r613",
      "r614",
      "r618",
      "r722",
      "r803",
      "r895",
      "r912",
      "r925",
      "r961",
      "r962",
      "r1015",
      "r1036",
      "r1041",
      "r1042",
      "r1080",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1102",
      "r1103",
      "r1140",
      "r1179",
      "r1194",
      "r1196",
      "r1199",
      "r1200",
      "r1211",
      "r1212",
      "r1216",
      "r1217",
      "r1227",
      "r1518",
      "r1605",
      "r1606",
      "r1607",
      "r1608",
      "r1609",
      "r1610"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Cost of Capital",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1196",
      "r1199",
      "r1200",
      "r1578",
      "r1579",
      "r1580"
     ]
    },
    "us-gaap_MeasurementInputEntityCreditRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputEntityCreditRiskMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchaser credit spread",
        "label": "Measurement Input, Entity Credit Risk [Member]",
        "documentation": "Measurement input using risk of default, credit spread risk and downgrade risk."
       }
      }
     },
     "auth_ref": [
      "r1211",
      "r1578",
      "r1579",
      "r1580"
     ]
    },
    "ci_MeasurementInputEquityPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MeasurementInputEquityPriceVolatilityMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Volatility",
        "label": "Measurement Input, Equity Price Volatility [Member]",
        "documentation": "Measurement Input, Equity Price Volatility"
       }
      }
     },
     "auth_ref": []
    },
    "ci_MeasurementInputInterVariableCorrelationAssumptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MeasurementInputInterVariableCorrelationAssumptionMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Correlation",
        "label": "Measurement Input, Inter-Variable Correlation Assumption [Member]",
        "documentation": "Measurement Input, Inter-Variable Correlation Assumption"
       }
      }
     },
     "auth_ref": []
    },
    "ci_MeasurementInputLiquidityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MeasurementInputLiquidityMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity",
        "label": "Measurement Input, Liquidity [Member]",
        "documentation": "Measurement Input, Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted EBITDA Volatility",
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1578",
      "r1579",
      "r1580"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r720",
      "r721",
      "r722",
      "r1196",
      "r1199",
      "r1200",
      "r1211"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r722",
      "r1196",
      "r1199",
      "r1200",
      "r1211"
     ]
    },
    "ci_MedicalCostTrendMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MedicalCostTrendMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical cost trend",
        "label": "Medical Cost Trend [Member]",
        "documentation": "Amounts relating to actual claims emerging differently from assumptions about the level of claims per member used to set reserves."
       }
      }
     },
     "auth_ref": []
    },
    "ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Advantage and related Cigna Healthcare businesses",
        "label": "Medicare Advantage And Related Cigna Healthcare Businesses [Member]",
        "documentation": "Medicare Advantage And Related Cigna Healthcare Businesses"
       }
      }
     },
     "auth_ref": []
    },
    "ci_MedicareAdvantageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "MedicareAdvantageMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Advantage",
        "label": "Medicare Advantage [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r434",
      "r435",
      "r436",
      "r437",
      "r586",
      "r612",
      "r613",
      "r614",
      "r618",
      "r722",
      "r803",
      "r895",
      "r912",
      "r925",
      "r961",
      "r962",
      "r1015",
      "r1036",
      "r1041",
      "r1042",
      "r1080",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1102",
      "r1103",
      "r1140",
      "r1179",
      "r1194",
      "r1196",
      "r1199",
      "r1200",
      "r1211",
      "r1212",
      "r1216",
      "r1227",
      "r1518",
      "r1605",
      "r1606",
      "r1607",
      "r1608",
      "r1609",
      "r1610"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r125",
      "r228",
      "r231",
      "r232",
      "r360",
      "r446",
      "r449",
      "r450",
      "r451",
      "r455",
      "r456",
      "r845",
      "r973",
      "r1597"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MortgageLoansOnRealEstateCommercialAndConsumerNet",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial mortgage loans",
        "label": "Mortgage Loans on Real Estate, Commercial and Consumer, Net",
        "documentation": "The balance represents the amount of loans that are secured by real estate mortgages, offset by the reserve to cover probable credit losses on the loan portfolio."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r831",
      "r1239",
      "r1242"
     ]
    },
    "us-gaap_MortgagesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MortgagesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commercial mortgage loans",
        "label": "Mortgages [Member]",
        "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A- equivalent and higher current ratings",
        "label": "Nationally Recognized Statisical Rating Organizations (NRSRO), A- Or Higher [Member]",
        "documentation": "Nationally Recognized Statisical Rating Organizations (NRSRO), A- Or Higher"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BBB- to BBB+ equivalent current credit ratings",
        "label": "Nationally Recognized Statisical Rating Organizations (NRSRO), BBB- To BBB+ Rating [Member]",
        "documentation": "Nationally Recognized Statisical Rating Organizations (NRSRO), BBB- To BBB+ Rating"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not rated",
        "label": "Nationally Recognized Statisical Rating Organizations (NRSRO), Not Rated [Member]",
        "documentation": "Nationally Recognized Statisical Rating Organizations (NRSRO), Not Rated"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BBB+ equivalent and higher current ratings",
        "label": "Nationally Recognized Statistical Rating Organizations (NRSRO), BBB+ Or Higher [Member]",
        "documentation": "Nationally Recognized Statistical Rating Organizations (NRSRO), BBB+ Or Higher"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.thecignagroup.com/role/DescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r271",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Account value",
        "label": "Net Amount at Risk by Product and Guarantee, General Account Value",
        "documentation": "Value of the general accounts corresponding to the specified product, guarantee type and subset of the guarantee."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150"
     ]
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetAmountAtRiskByProductAndGuaranteeLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Amount at Risk by Product and Guarantee [Line Items]",
        "label": "Net Amount at Risk by Product and Guarantee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net amount at risk",
        "label": "Net Amount at Risk by Product and Guarantee, Net Amount at Risk",
        "documentation": "Net amount at risk, representing the guaranteed benefit in excess of the current account balance corresponding to the specified product, guarantee type and subset of the guarantee."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r154"
     ]
    },
    "ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed Minimum Death Benefits Total Contractholders",
        "label": "Net Amount At Risk By Product And Guarantee, Number Of Contractholders Estimated",
        "documentation": "Net Amount At Risk By Product And Guarantee, Number Of Contractholders Estimated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetAmountAtRiskByProductAndGuaranteeTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Amount at Risk, by Product and Guarantee [Table]",
        "label": "Net Amount at Risk, by Product and Guarantee [Table]",
        "documentation": "For contracts with guaranteed benefits in excess of the current account balance, sets forth the amounts of such excesses (the net amounts at risk) and other pertinent information by type of guarantee by type of insurance product), as of the most recent balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r151",
      "r152",
      "r153"
     ]
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average attained age of contractholders (weighted by exposure)",
        "label": "Net Amount at Risk by Product and Guarantee, Weighted Average Attained Age",
        "documentation": "Weighted average attained age of policyholders or contract holders in the specified guarantee type and subset of guarantee class, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r154"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Operating Activities",
        "label": "Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "SHAREHOLDERS' NET INCOME",
        "terseLabel": "SHAREHOLDERS' NET INCOME",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r106",
      "r130",
      "r172",
      "r175",
      "r201",
      "r204",
      "r209",
      "r228",
      "r231",
      "r232",
      "r234",
      "r240",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r252",
      "r260",
      "r360",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r486",
      "r489",
      "r492",
      "r496",
      "r617",
      "r647",
      "r652",
      "r716",
      "r753",
      "r852",
      "r990",
      "r1006",
      "r1007",
      "r1118",
      "r1120",
      "r1122",
      "r1256",
      "r1516"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Net income attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r118",
      "r201",
      "r204",
      "r248",
      "r251",
      "r252",
      "r851",
      "r1389"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Net income attributable to other noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest",
        "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119"
     ]
    },
    "ci_NetInvestmentGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NetInvestmentGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net investment gains (losses)",
        "negatedLabel": "Investment (gains) losses, net",
        "label": "Net Investment Gain Loss",
        "documentation": "Gains (losses) based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NetInvestmentGainLossIncludingEquityMethodSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NetInvestmentGainLossIncludingEquityMethodSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net realized investment (gains) losses",
        "label": "Net Investment Gain Loss Including Equity Method Subsidiaries",
        "documentation": "Gains (losses), including those from equity method subsidiaries, based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investment"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NetInvestmentGainsLossesEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NetInvestmentGainsLossesEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net investment results from certain equity method investments",
        "label": "Net Investment Gains Losses Equity Method Investments",
        "documentation": "Gains (losses), attributable to equity method investment, based on specifically identified assets and resulting from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetInvestmentHedgingMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Hedging",
        "label": "Net Investment Hedging [Member]",
        "documentation": "Hedges of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetInvestmentIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetInvestmentIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails_1": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net investment income",
        "totalLabel": "Net investment income",
        "verboseLabel": "Net investment income (loss)",
        "label": "Net Investment Income",
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r855",
      "r856",
      "r993",
      "r1234",
      "r1237",
      "r1256"
     ]
    },
    "ci_NetworkPharmacyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NetworkPharmacyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Network revenues",
        "label": "Network Pharmacy [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "ci_NonInvestmentRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NonInvestmentRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails_1": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues from customers",
        "totalLabel": "Total revenues from external customers",
        "label": "Non Investment Revenue",
        "documentation": "Revenue excluding net investment income and realized investment results."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1273",
      "r1284",
      "r1294",
      "r1318",
      "r1327"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1301"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1300"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "us-gaap_NoncatastrophicEventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncatastrophicEventAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncatastrophic Event [Axis]",
        "label": "Noncatastrophic Event [Axis]",
        "documentation": "Information by type of noncatastrophic event causing change in the insurer's provision."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncatastrophicEventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncatastrophicEventDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncatastrophic Event [Domain]",
        "label": "Noncatastrophic Event [Domain]",
        "documentation": "Noncatastrophic event causing change in the insurer's provision."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non- controlling Interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r498",
      "r1443",
      "r1444",
      "r1445",
      "r1446",
      "r1677"
     ]
    },
    "ci_NoncontrollingInterestOtherChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NoncontrollingInterestOtherChanges",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other transactions impacting noncontrolling interests",
        "label": "Noncontrolling Interest Other Changes",
        "documentation": "Other activity associated with noncontrolling interest that is not separately disclosed."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noninsurance customer receivables",
        "label": "Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable",
        "documentation": "Receivables due from customers that are not under insurance contracts. These include pharmacy sales and fees due from employer clients."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue2026125Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "NotesDue2026125Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.250% Notes due March 2026",
        "label": "Notes due 2026, 1.25% [Member]",
        "documentation": "Notes payable bearing interest at 1.25% due in 2026."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.thecignagroup.com/role/DescriptionofBusinessSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Reportable Segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1139",
      "r1454"
     ]
    },
    "ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net long-duration insurance and contractholder liabilities measurement adjustments",
        "label": "OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent",
        "documentation": "OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OngoingOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "OngoingOperationsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ongoing operations",
        "label": "Ongoing Operations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r1118",
      "r1122",
      "r1128",
      "r1448",
      "r1455",
      "r1457",
      "r1458",
      "r1459"
     ]
    },
    "ci_OperatingResultsOfCertainNonstrategicBusinessesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "OperatingResultsOfCertainNonstrategicBusinessesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating results of certain non-strategic businesses",
        "label": "Operating Results Of Certain Nonstrategic Businesses [Member]",
        "documentation": "Operating Results Of Certain Non-strategic Businesses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r1134",
      "r1135"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OrganizationalEfficiencyPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "OrganizationalEfficiencyPlanMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organizational Efficiency Plan",
        "label": "Organizational Efficiency Plan [Member]",
        "documentation": "Organizational Efficiency Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r1220"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net unrealized depreciation on securities and derivatives",
        "label": "Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax",
        "documentation": "Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss) before reclassifications, after-tax",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r22",
      "r208",
      "r710",
      "r757",
      "r760",
      "r763",
      "r853",
      "r1387"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other comprehensive income (loss), before reclassifications, tax",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r207",
      "r853"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative gain (loss) recognized in other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r197",
      "r853"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative gain (loss) reclassified from other comprehensive income into shareholders' net income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r199"
     ]
    },
    "ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net translation (depreciation) appreciation on foreign currencies",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Including Temporary Equity",
        "documentation": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Including Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r19",
      "r202",
      "r205",
      "r211",
      "r248",
      "r757",
      "r758",
      "r763",
      "r809",
      "r853",
      "r1387",
      "r1388"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Postretirement benefits liability adjustment",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r88",
      "r89",
      "r853"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Other Comprehensive Income (Loss), Tax",
        "label": "Other Comprehensive Income (Loss), Tax",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r207",
      "r211",
      "r624",
      "r639",
      "r640",
      "r757",
      "r761",
      "r763",
      "r809",
      "r853"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherDebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other debt securities",
        "label": "Other Debt Obligations [Member]",
        "documentation": "Investments in debt securities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1493",
      "r1527",
      "r1529"
     ]
    },
    "ci_OtherHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "OtherHealthcareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Healthcare [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherInvestmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Investments [Member]",
        "documentation": "Primary financial statement caption encompassing other investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_OtherLongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term investments",
        "label": "Other Long-Term Investments",
        "documentation": "Amount of long-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r832",
      "r1375"
     ]
    },
    "us-gaap_OtherLongTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLongTermInvestmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term investments",
        "verboseLabel": "Other long-term investments",
        "label": "Other Long-Term Investments [Member]",
        "documentation": "Long-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1662"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense and other",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r1204"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "ci_OtherPharmacyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "OtherPharmacyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other Pharmacy [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherRestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherRestructuringMember",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other restructuring",
        "label": "Other Restructuring [Member]",
        "documentation": "Restructuring and related activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1116",
      "r1168",
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "ci_OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Income attributable to noncontrolling interests",
        "label": "Other Segment Items, Income (Loss) Attributable To Noncontrolling Interests, Before Tax",
        "documentation": "Other Segment Items, Income (Loss) Attributable To Noncontrolling Interests, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Other Short-Term Investments",
        "documentation": "Amount of short-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r829",
      "r833",
      "r1377"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1271",
      "r1282",
      "r1292",
      "r1325"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1274",
      "r1285",
      "r1295",
      "r1328"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1274",
      "r1285",
      "r1295",
      "r1328"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "srt_PartnershipInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "PartnershipInterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities partnerships",
        "label": "Partnership Interest [Member]"
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total paid",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r1229",
      "r1631"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other, net",
        "label": "Payment for (Proceeds from) Other Investing Activity",
        "documentation": "Amount of cash (inflow) outflow from investing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1355",
      "r1432"
     ]
    },
    "ci_PaymentsForProceedsFromPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PaymentsForProceedsFromPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment purchases, net",
        "label": "Payments For (Proceeds From) Property, Plant, And Equipment",
        "documentation": "Payments For (Proceeds From) Property, Plant, And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r1434"
     ]
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments for debt extinguishment",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common stock dividend paid",
        "terseLabel": "Total amount paid",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ci_PaymentsToAcquireDebtAndEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PaymentsToAcquireDebtAndEquitySecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt securities and equity securities",
        "label": "Payments To Acquire Debt And Equity Securities",
        "documentation": "Payments To Acquire Debt And Equity Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Renewable energy tax credit equity investments",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInvestmentsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments purchased or originated:",
        "label": "Payments to Acquire Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMortgageNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMortgageNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Commercial mortgage loans",
        "label": "Payments to Acquire Mortgage Notes Receivable",
        "documentation": "The cash outflow from the purchase of receivables arising from the mortgage note on real estate."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other (primarily short-term and other long-term investments)",
        "label": "Payments to Acquire Other Investments",
        "documentation": "Amount of cash outflow to acquire investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1309"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1309"
     ]
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionPlansDefinedBenefitMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Plans",
        "label": "Pension Plan [Member]",
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r587",
      "r1186",
      "r1187",
      "r1191",
      "r1192",
      "r1193"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1301"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1300"
     ]
    },
    "ci_PharmaceuticalManufacturerReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PharmaceuticalManufacturerReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmaceutical manufacturer receivables",
        "label": "Pharmaceutical Manufacturer Receivable",
        "documentation": "Receivables due from pharmaceutical manufacturers related to rebate contracts."
       }
      }
     },
     "auth_ref": []
    },
    "ci_PharmacyAndServiceCostsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PharmacyAndServiceCostsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmacy and other service costs payable",
        "label": "Pharmacy And Service Costs Payable",
        "documentation": "Reflects amounts due to pharmacies for prescriptions filled through our retail network of pharmacies. Also includes amounts due to clients for their portion of rebates that must be contractually shared."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1302"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1347"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1301"
     ]
    },
    "us-gaap_PolicyLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyLoansMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policy loans",
        "verboseLabel": "Policy loans",
        "label": "Policy Loans [Member]",
        "documentation": "Loan issued by an insurance company, collateralized by the cash value of the borrower's life insurance policy."
       }
      }
     },
     "auth_ref": [
      "r1662"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis points above guaranteed minimum crediting rate",
        "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate",
        "documentation": "Value above guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r1227"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis]",
        "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis]",
        "documentation": "Information by range above guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r1227"
     ]
    },
    "ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value",
        "label": "Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value [Member]",
        "documentation": "Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]",
        "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]",
        "documentation": "Range above guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r1227"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150",
        "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150 [Member]",
        "documentation": "Range from 51 basis points to 150 basis points above guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1227",
      "r1656"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, at Guaranteed Minimum Crediting Rate",
        "label": "Policyholder Account Balance, at Guaranteed Minimum Crediting Rate [Member]",
        "documentation": "Range at zero basis point above guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1227",
      "r1656"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditRating",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed minimum credit rating",
        "label": "Policyholder Account Balance, Guaranteed Minimum Credit Rating",
        "documentation": "Guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r1227"
     ]
    },
    "ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds not reinsured externally, percent with guaranteed interest rates of 0300 to 0400",
        "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Percentage",
        "documentation": "Percentage of policyholder account balance representing contract with guaranteed interest rates of 3%-4%."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis]",
        "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis]",
        "documentation": "Information by range of guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r1227"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain]",
        "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain]",
        "documentation": "Range of guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r1227"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400",
        "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 to 0399 [Member]",
        "documentation": "Range of guaranteed minimum crediting rate on policyholder account balance from 3.00 percent to 3.99 percent."
       }
      }
     },
     "auth_ref": [
      "r1656"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance [Line Items]",
        "label": "Policyholder Account Balance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r1227"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceNetAmountAtRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceNetAmountAtRisk",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net amount at risk",
        "label": "Policyholder Account Balance, Net Amount at Risk",
        "documentation": "Amount of guaranteed benefit in excess of current account balance of policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r1227"
     ]
    },
    "ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage with cash values at more than 110% of guaranteed cash value",
        "label": "Policyholder Account Balance, Percentage With Cash Values At More Than 110 Percent Of Guaranteed Cash Value",
        "documentation": "Policyholder Account Balance, Percentage With Cash Values At More Than 110 Percent Of Guaranteed Cash Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderAccountBalanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance [Table]",
        "label": "Policyholder Account Balance [Table]",
        "documentation": "Disclosure of information about policyholder account balance, including, but not limited to change in liability and related cash surrender value."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r1227"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountBalanceWeightedAverageCreditingRate",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average crediting rate",
        "label": "Policyholder Account Balance, Weighted Average Crediting Rate",
        "documentation": "Weighted-average crediting rate for liability for policyholder account balance, calculated at a point in time."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r1227"
     ]
    },
    "us-gaap_PolicyholderAccountsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderAccountsPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasuresandDisclosuresPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate Accounts",
        "label": "Policyholder Accounts, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for contracts reported in separate accounts, including the extent and terms of minimum guarantees, basis of presentation for separate account assets and liabilities and related separate account activity, the liability valuation method and assumptions used in valuing each type of policyholder and contract holder account maintained by the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderBenefitsAndClaimsIncurredNet",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical costs and other benefit expenses",
        "label": "Policyholder Benefits and Claims Incurred, Net",
        "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred."
       }
      }
     },
     "auth_ref": [
      "r1234",
      "r1235",
      "r1237",
      "r1613",
      "r1623"
     ]
    },
    "ci_PolicyholderContractBalancePercentReinsuredExternally": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PolicyholderContractBalancePercentReinsuredExternally",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit fund liabilities, approximate percent reinsured externally",
        "label": "Policyholder Contract Balance, Percent Reinsured Externally",
        "documentation": "Policyholder Contract Balance, Percent Reinsured Externally"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PolicyholderContractDepositCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PolicyholderContractDepositCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "us-gaap_PolicyholderContractDeposits",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds, current",
        "label": "Policyholder Contract Deposit, Current",
        "documentation": "Policyholder Contract Deposit, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PolicyholderContractDepositNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PolicyholderContractDepositNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds, non-current",
        "label": "Policyholder Contract Deposit, Noncurrent",
        "documentation": "Policyholder Contract Deposit, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderContractDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderContractDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Contractholder deposit funds",
        "terseLabel": "Contractholder deposit funds",
        "label": "Policyholder Contract Deposit",
        "documentation": "Amount of liability due to policyholder for deposit held under long-duration contract issued by insurance entity."
       }
      }
     },
     "auth_ref": [
      "r1237",
      "r1629"
     ]
    },
    "us-gaap_PolicyholderFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyholderFunds",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds not reinsured externally",
        "label": "Policyholder Account Balance",
        "documentation": "Amount due to policyholder. Includes, but is not limited to, unpaid policy dividend, retrospective refund, and undistributed earnings on participating business. Excludes future policy benefit and claim expense."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r911",
      "r912",
      "r1227",
      "r1617"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion at Fair Value Measurement",
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r746",
      "r748",
      "r749",
      "r751",
      "r753",
      "r754",
      "r1104",
      "r1595"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r1243",
      "r1244",
      "r1247",
      "r1248",
      "r1249",
      "r1252",
      "r1668",
      "r1677"
     ]
    },
    "us-gaap_PremiumsEarnedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PremiumsEarnedNet",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails": {
       "parentTag": "ci_NonInvestmentRevenue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums",
        "label": "Premiums Earned, Net",
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r825",
      "r878",
      "r927",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238"
     ]
    },
    "ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax adjustments to reconcile to adjusted income from operations",
        "label": "Pretax Adjustments To Reconcile Adjusted Income From Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollectionOfLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromCollectionOfLoansReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial mortgage loans",
        "label": "Proceeds from Collection of Loans Receivable",
        "documentation": "The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestitures, net of cash sold",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds on issuance of long-term debt",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r942"
     ]
    },
    "ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Proceeds From Issuance Of Long-term Debt, Net Of Discounts And Underwriting Fees",
        "documentation": "Proceeds From Issuance Of Long-term Debt, Net Of Discounts And Underwriting Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities and equity securities",
        "label": "Proceeds From Maturities Prepayments And Calls Of Debt And Equity Securities",
        "documentation": "Proceeds from maturities, repayments and calls of debt and equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds on issuance of term loan",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Proceeds from (Payment for) Other Financing Activity",
        "documentation": "Amount of cash inflow (outflow) from financing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1356",
      "r1433"
     ]
    },
    "ci_ProceedsFromRepaymentsOfOtherShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ProceedsFromRepaymentsOfOtherShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in short-term debt",
        "label": "Proceeds From (Repayments Of) Other Short-Term Debt",
        "documentation": "Amount of cash outflow for principal payment on finance lease and the net proceeds from (repayments of) short-term debt, defined as borrowing having initial term of repayment of one year or less."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from investments sold:",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment maturities and repayments:",
        "label": "Proceeds from Sale and Maturity of Held-to-Maturity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other sales, maturities and repayments (primarily short-term and other long-term investments)",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ci_ProceedsFromSaleOfDebtAndEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ProceedsFromSaleOfDebtAndEquitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities and equity securities",
        "label": "Proceeds From Sale Of Debt And Equity Securities",
        "documentation": "Proceeds from sales of debt and equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Pharmacy revenues",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r1117",
      "r1122",
      "r1180",
      "r1181"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r805",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r894",
      "r1105",
      "r1117",
      "r1120",
      "r1122",
      "r1180",
      "r1181",
      "r1222",
      "r1227",
      "r1231",
      "r1233",
      "r1241",
      "r1358",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1512",
      "r1513",
      "r1624",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1664",
      "r1665"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r805",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r894",
      "r1105",
      "r1117",
      "r1120",
      "r1122",
      "r1180",
      "r1181",
      "r1222",
      "r1227",
      "r1231",
      "r1233",
      "r1241",
      "r1358",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1512",
      "r1513",
      "r1624",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1664",
      "r1665"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r175",
      "r201",
      "r204",
      "r221",
      "r228",
      "r231",
      "r232",
      "r234",
      "r240",
      "r248",
      "r251",
      "r252",
      "r360",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r486",
      "r617",
      "r647",
      "r652",
      "r653",
      "r656",
      "r657",
      "r716",
      "r753",
      "r813",
      "r815",
      "r850",
      "r947",
      "r990",
      "r1006",
      "r1007",
      "r1202",
      "r1203",
      "r1257",
      "r1389",
      "r1516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1360",
      "r1499"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "ci_R2026Q2DividendsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "R2026Q2DividendsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R2026Q2 Dividends [Member]",
        "label": "R2026Q2 Dividends [Member]",
        "documentation": "R2026Q2 Dividends"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r434",
      "r435",
      "r436",
      "r437",
      "r524",
      "r586",
      "r612",
      "r613",
      "r614",
      "r616",
      "r618",
      "r722",
      "r778",
      "r787",
      "r803",
      "r895",
      "r912",
      "r925",
      "r961",
      "r962",
      "r1015",
      "r1036",
      "r1041",
      "r1042",
      "r1080",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1102",
      "r1103",
      "r1140",
      "r1179",
      "r1194",
      "r1196",
      "r1199",
      "r1200",
      "r1211",
      "r1212",
      "r1216",
      "r1217",
      "r1227",
      "r1245",
      "r1506",
      "r1518",
      "r1579",
      "r1606",
      "r1607",
      "r1608",
      "r1609",
      "r1610"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r434",
      "r435",
      "r436",
      "r437",
      "r524",
      "r586",
      "r612",
      "r613",
      "r614",
      "r616",
      "r618",
      "r722",
      "r778",
      "r787",
      "r803",
      "r895",
      "r912",
      "r925",
      "r961",
      "r962",
      "r1015",
      "r1036",
      "r1041",
      "r1042",
      "r1080",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1102",
      "r1103",
      "r1140",
      "r1179",
      "r1194",
      "r1196",
      "r1199",
      "r1200",
      "r1211",
      "r1212",
      "r1216",
      "r1217",
      "r1227",
      "r1245",
      "r1506",
      "r1518",
      "r1579",
      "r1606",
      "r1607",
      "r1608",
      "r1609",
      "r1610"
     ]
    },
    "us-gaap_RealEstateInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealEstateInvestmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real estate investments",
        "label": "Real Estate Investment [Member]",
        "documentation": "This element represents direct equity investments in real estate projects (Land, buildings and improvements owned for income production and capital accretion potential) and certain loans accounted for as real estate investments. For loans accounted for as real estate investments, the entity (lender) has virtually the same risks and rewards as those of owners or joint venture participants. Such arrangements are treated as if the entity actually has an ownership interest in the property. In such arrangements, the entity (lender) participates in expected residual profits, which may be in the form of an equity kicker or a higher than usual effective interest rate. At the outset and during the construction and development of the property, the borrower generally has little or no equity in the property and the entity's (lender's) only source of repayment is the property. The entity (lender) generally (a) agrees to provide substantially all funds to acquire, develop, and construct the property, (b) funds the commitment or origination fees or both, and (c) funds interest during the development and construction of the property."
       }
      }
     },
     "auth_ref": [
      "r1091",
      "r1092",
      "r1093",
      "r1107"
     ]
    },
    "us-gaap_RealEstateLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealEstateLoanMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Estate Loan",
        "label": "Real Estate Loan [Member]",
        "documentation": "Loan to finance the purchase of real estate, including but not limited to, land or building."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables [Abstract]",
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsDetails",
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Total",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r1220"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net amounts reclassified from AOCI to net income",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r22",
      "r208",
      "r711",
      "r757",
      "r762",
      "r763",
      "r853",
      "r1387"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification adjustment, tax",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r200",
      "r207",
      "r853"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1266",
      "r1277",
      "r1287",
      "r1320"
     ]
    },
    "us-gaap_ReinsuranceAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReinsuranceAccountingPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsurancePolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance",
        "label": "Reinsurance Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r926",
      "r1236",
      "r1238",
      "r1353",
      "r1354"
     ]
    },
    "us-gaap_ReinsuranceDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReinsuranceDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance Disclosures [Abstract]",
        "label": "Reinsurance Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Less: Reinsurance and other amounts recoverable",
        "periodEndLabel": "Add: Reinsurance and other amounts recoverable",
        "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments",
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890",
      "r893",
      "r1229",
      "r1233",
      "r1615",
      "r1626",
      "r1627"
     ]
    },
    "ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Less: Reinsurance, including held for sale liabilities",
        "periodEndLabel": "Add: Reinsurance, including held for sale liabilities",
        "label": "Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups",
        "documentation": "Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReinsuranceRecoverables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReinsuranceRecoverables",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total reinsurance recoverables",
        "label": "Reinsurance Recoverables, Including Reinsurance Premium Paid",
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves."
       }
      }
     },
     "auth_ref": [
      "r1615",
      "r1620",
      "r1625",
      "r1626",
      "r1627"
     ]
    },
    "us-gaap_ReinsuranceRecoverablesAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReinsuranceRecoverablesAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails": {
       "parentTag": "us-gaap_ReinsuranceRecoverables",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Allowance for uncollectible reinsurance",
        "label": "Reinsurance Recoverable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on reinsurance recoverable."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r366",
      "r371",
      "r828",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_ReinsuranceRecoverablesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReinsuranceRecoverablesGross",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails": {
       "parentTag": "us-gaap_ReinsuranceRecoverables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance recoverables before market risk benefits",
        "label": "Reinsurance Recoverables, Gross",
        "documentation": "Amount before valuation allowance recoverable under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r372",
      "r828",
      "r847",
      "r880",
      "r881",
      "r882",
      "r1236",
      "r1237"
     ]
    },
    "ci_ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance Recoverables, Gross, Acquisition Disposition Runoff Activities, Nationally Recognized Statistical Rating Organizations, BBB+ Or Higher",
        "label": "Reinsurance Recoverables, Gross, Acquisition Disposition Runoff Activities, Nationally Recognized Statistical Rating Organizations, BBB+ Or Higher [Member]",
        "documentation": "Reinsurance Recoverables, Gross, Acquisition Disposition Runoff Activities, Nationally Recognized Statistical Rating Organizations, BBB+ Or Higher"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ReinsuranceRecoverablesNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ReinsuranceRecoverablesNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance recoverables",
        "label": "Reinsurance Recoverables, Noncurrent",
        "documentation": "Amount, after valuation allowance, recoverable after one year under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ReinsuranceRecoverablesNumberOfReinsurers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ReinsuranceRecoverablesNumberOfReinsurers",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reinsurers",
        "label": "Reinsurance Recoverables, Number Of Reinsurers",
        "documentation": "Reinsurance Recoverables, Number Of Reinsurers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReinsuranceRetentionPolicyReinsuredRiskPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReinsuranceRetentionPolicyReinsuredRiskPercentage",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance, Reinsured Risk, Percentage",
        "label": "Reinsurance, Reinsured Risk, Percentage",
        "documentation": "Percentage of risk undertaken originally by insurer ceded to reinsurer."
       }
      }
     },
     "auth_ref": [
      "r1614"
     ]
    },
    "us-gaap_ReinsuranceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReinsuranceTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/Reinsurance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance",
        "label": "Reinsurance [Text Block]",
        "documentation": "The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827",
      "r928",
      "r1236",
      "r1238"
     ]
    },
    "us-gaap_ReinsurerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReinsurerConcentrationRiskMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurer Concentration Risk",
        "label": "Reinsurer Concentration Risk [Member]",
        "documentation": "Concentration risk of a reinsurer to a specified benchmark, such as reinsurance recoverables."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of long-term debt",
        "terseLabel": "Repayment of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r943"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of term loan",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1267",
      "r1278",
      "r1288",
      "r1321"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1268",
      "r1279",
      "r1289",
      "r1322"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1275",
      "r1286",
      "r1296",
      "r1329"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Activities [Abstract]",
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgram"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic Optimization Program",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r422",
      "r425",
      "r430"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Strategic optimization program costs",
        "terseLabel": "Strategic optimization program",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r215",
      "r217",
      "r426",
      "r427",
      "r1119",
      "r1507"
     ]
    },
    "ci_RestructuringChargesNetOfTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "RestructuringChargesNetOfTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Strategic optimization program costs, after-tax",
        "terseLabel": "Strategic optimization program, after-tax",
        "label": "Restructuring Charges, Net Of Tax Expense",
        "documentation": "Restructuring Charges, Net Of Tax Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r217",
      "r421",
      "r422",
      "r427",
      "r428",
      "r1119"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restructuring Reserve, Beginning Balance",
        "periodEndLabel": "Restructuring Reserve, Ending Balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r428"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r116",
      "r844",
      "r921",
      "r924",
      "r944",
      "r972",
      "r1220"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r171",
      "r172",
      "r237",
      "r238",
      "r239",
      "r241",
      "r248",
      "r250",
      "r252",
      "r361",
      "r362",
      "r400",
      "r485",
      "r617",
      "r634",
      "r635",
      "r644",
      "r645",
      "r646",
      "r648",
      "r651",
      "r652",
      "r703",
      "r705",
      "r706",
      "r708",
      "r714",
      "r767",
      "r769",
      "r917",
      "r919",
      "r948",
      "r1677"
     ]
    },
    "ci_RetirementAndLifeInsuranceContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "RetirementAndLifeInsuranceContractsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retiree and Life Insurance Benefits",
        "label": "Retirement And Life Insurance Contracts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails": {
       "parentTag": "ci_NonInvestmentRevenue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from contract with customer",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r269",
      "r279",
      "r280",
      "r301",
      "r307",
      "r311",
      "r313",
      "r314",
      "r499",
      "r500",
      "r501",
      "r805",
      "r1118",
      "r1122"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL REVENUES",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r210",
      "r228",
      "r231",
      "r232",
      "r269",
      "r279",
      "r280",
      "r301",
      "r307",
      "r311",
      "r313",
      "r314",
      "r360",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r753",
      "r813",
      "r815",
      "r1134",
      "r1204",
      "r1234",
      "r1237",
      "r1516"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_RevolvingCreditAgreementApril2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "RevolvingCreditAgreementApril2025Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Agreement, April 2025",
        "label": "Revolving Credit Agreement April 2025 [Member]",
        "documentation": "Revolving credit agreement entered in April 2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtRevolvingCreditAgreementandCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Net",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r85"
     ]
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in the Components of AOCI",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r1599",
      "r1600"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareAntidilutiveOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails",
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses",
        "label": "Schedule of Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the reasons for the change in incurred claims and claim adjustment expenses recognized in the income statement attributable to insured events of prior fiscal years. Also includes disclosures of additional premiums or return premiums accrued as a result of changes in incurred claims and claim adjustment expenses."
       }
      }
     },
     "auth_ref": [
      "r1661"
     ]
    },
    "us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCededCreditRiskByReinsurerTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance Recoverables",
        "label": "Ceded Credit Risk [Table Text Block]",
        "documentation": "Tabular disclosure of reinsurer or group of reinsurers for whom the entity has a concentration of credit risk."
       }
      }
     },
     "auth_ref": [
      "r1357"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Derivative Instruments Held",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computation of Basic and Diluted Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1447"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers by Products and Services [Table]",
        "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]",
        "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r643",
      "r753",
      "r1350",
      "r1351",
      "r1352",
      "r1557",
      "r1558",
      "r1559",
      "r1560"
     ]
    },
    "us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Receivable, Credit Quality Indicator [Table]",
        "label": "Financing Receivable, Credit Quality Indicator [Table]",
        "documentation": "Disclosure of information about credit quality indicator for financing receivable."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1487",
      "r1490"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Income [Line Items]",
        "label": "Net Investment Income [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Income [Table]",
        "label": "Investment Income [Table]",
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r854"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails",
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Line Items]",
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1033",
      "r1035",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails",
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1033",
      "r1035",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1071",
      "r1072",
      "r1073",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Insurance and Contractholder Liabilities",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death",
        "label": "Schedule of Net Amount of Risk by Product and Guarantee [Table Text Block]",
        "documentation": "Tabular disclosure of the guaranteed benefits in excess of the current account balance, quantifies such excesses (the net amounts at risk) and includes other relevant, pertinent information as of the most recent balance sheet date by product type."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147"
     ]
    },
    "ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ScheduleOfOtherLongTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value Information for Other Long-Term Investments",
        "label": "Schedule Of Other Long-Term Investments [Table Text Block]",
        "documentation": "Schedule Of Other Long-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Roll forward of Accrued Liability",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r110"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summarized Segment Financial Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ]
    },
    "ci_ScheduleOfSpecialItemsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ScheduleOfSpecialItemsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Special Items",
        "label": "Schedule Of Special Items [Table Text Block]",
        "documentation": "Schedule of pre- and after-tax amounts reported as special items, attributable to the parent. Special items are amounts that management does not believe are representative of underlying results of operations."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1259"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r269",
      "r275",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r314",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r399",
      "r424",
      "r429",
      "r649",
      "r650",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r1131",
      "r1134",
      "r1135",
      "r1165",
      "r1232",
      "r1624",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1664",
      "r1665"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r269",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r290",
      "r292",
      "r293",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r314",
      "r1129",
      "r1132",
      "r1133",
      "r1134",
      "r1136",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentReportingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r310",
      "r313",
      "r1130",
      "r1131",
      "r1137"
     ]
    },
    "ci_SegmentRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SegmentRevenues",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted revenues",
        "label": "Segment Revenues",
        "documentation": "Total revenues less realized investment gains from equity method subsidiaries, special items and other reconciling items determined by management."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SellingGeneralAdministrativeExpensesSegmentPerformanceMetric": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SellingGeneralAdministrativeExpensesSegmentPerformanceMetric",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General Administrative Expenses Segment Performance Metric",
        "documentation": "Selling, General Administrative Expenses Segment Performance Metric"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r1117",
      "r1118",
      "r1119",
      "r1122",
      "r1427"
     ]
    },
    "ci_SeniorNotesIssuedSeptember2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SeniorNotesIssuedSeptember2025Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes Issued September 2025",
        "label": "Senior Notes Issued September 2025 [Member]",
        "documentation": "Senior Notes Issued September 2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtRepaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SeparateAccountAssetAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SeparateAccountAssetAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate account assets",
        "label": "Separate Account Asset, At Carrying Value",
        "documentation": "Separate Account Asset, At Carrying Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeparateAccountAssetCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeparateAccountAssetCategoryAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate Account Asset Category [Axis]",
        "label": "Separate Account Asset Category [Axis]",
        "documentation": "Information by separate account asset investment."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r1240"
     ]
    },
    "us-gaap_SeparateAccountAssetCategoryDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeparateAccountAssetCategoryDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate Account Asset Category [Domain]",
        "label": "Separate Account Asset Category [Domain]",
        "documentation": "Separate account asset investment."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r1240"
     ]
    },
    "us-gaap_SeparateAccountAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeparateAccountAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate account assets",
        "label": "Separate Account Asset",
        "documentation": "Amount of asset at fair value held for benefit of separate account policyholder."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r930",
      "r931",
      "r932",
      "r1239",
      "r1240",
      "r1242"
     ]
    },
    "ci_SeparateAccountAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SeparateAccountAssetsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate Account Assets",
        "label": "Separate Account Assets [Member]",
        "documentation": "A separate investment account established and maintained by an insurance entity under relevant state insurance law to which funds have been allocated for certain contracts of the insurance entity. Funds in a separate account are not commingled with other assets of the insurance entity for investment purposes."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SeparateAccountGuaranteedSeparateAccountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SeparateAccountGuaranteedSeparateAccountsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate Account, Guaranteed Separate Accounts",
        "label": "Separate Account, Guaranteed Separate Accounts [Member]",
        "documentation": "Separate Account, Guaranteed Separate Accounts"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SeparateAccountNonGuaranteedSeparateAccountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SeparateAccountNonGuaranteedSeparateAccountsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsSeparateAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate Account, Non-Guaranteed Separate Accounts",
        "label": "Separate Account, Non-Guaranteed Separate Accounts [Member]",
        "documentation": "Separate Account, Non-Guaranteed Separate Accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeparateAccountsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeparateAccountsLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate account liabilities",
        "label": "Separate Account, Liability",
        "documentation": "Amount of liability for variable contract in which all or portion of contract holder's funds is allocated to specific separate account and supported by assets held in separate account."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r930",
      "r931",
      "r933",
      "r934",
      "r1241",
      "r1242"
     ]
    },
    "ci_ServiceFeesAndOtherRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ServiceFeesAndOtherRevenuesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service, Fees And Other Revenues [Member]",
        "label": "Service, Fees And Other Revenues [Member]",
        "documentation": "Service, Fees And Other Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ServiceFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ServiceFeesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees",
        "label": "Service, Fees [Member]",
        "documentation": "Service, Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees and other revenues",
        "verboseLabel": "Service",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r1117",
      "r1122",
      "r1180",
      "r1181"
     ]
    },
    "us-gaap_ServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceOtherMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "label": "Service, Other [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1525",
      "r1526"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615"
     ]
    },
    "ci_ShieldsHealthSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ShieldsHealthSolutionsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shields Health Solutions",
        "label": "Shields Health Solutions [Member]",
        "documentation": "Shields Health Solutions"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShortTermAndLongTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ShortTermAndLongTermInvestmentsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Short-Term And Long-Term Investments [Abstract]",
        "documentation": "Short-Term And Long-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": "us-gaap_Investments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails": {
       "parentTag": "ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments",
        "terseLabel": "Current investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r1377"
     ]
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestmentsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Short-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails": {
       "parentTag": "ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments including held for sale assets",
        "label": "Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryIncludingDisposalGroupsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r1091",
      "r1092",
      "r1093",
      "r1107"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred and Paid Claims Development",
        "label": "Short-Duration Insurance Contracts, Claims Development [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r1233",
      "r1636",
      "r1637"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227"
     ]
    },
    "ci_SpecialItemChargeBenefitAfterTaxLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemChargeBenefitAfterTaxLitigation",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Charges (benefits) associated with litigation matters, after-tax",
        "label": "Special Item Charge (Benefit) After Tax Litigation",
        "documentation": "After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargeBenefitBeforeTaxLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemChargeBenefitBeforeTaxLitigation",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Charges (benefits) associated with litigation matters",
        "terseLabel": "(Benefits) charges associated with litigation matters",
        "label": "Special Item Charge (Benefit) Before Tax Litigation",
        "documentation": "After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargeBenefitTaxMatters": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemChargeBenefitTaxMatters",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax expenses (benefits)",
        "verboseLabel": "Deferred tax expenses",
        "label": "Special Item Charge Benefit Tax Matters",
        "documentation": "Special Item Charge Benefit Tax Matters"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargeBenefitTaxMattersAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemChargeBenefitTaxMattersAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax expenses (benefits), after-tax",
        "label": "Special Item Charge Benefit Tax Matters After Tax",
        "documentation": "Special Item Charge Benefit Tax Matters After Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemChargesDebtExtinguishmentCostsBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 8.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt extinguishment costs (gains)",
        "label": "Special Item Charges Debt Extinguishment Costs Before Tax",
        "documentation": "Special Item Charges Debt Extinguishment Costs Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemChargesDebtExtinguishmentCostsNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt extinguishment costs (gains), after-tax",
        "label": "Special Item Charges Debt Extinguishment Costs Net Of Tax",
        "documentation": "Special Item Charges Debt Extinguishment Costs Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Risk corridors recovery",
        "negatedTerseLabel": "Risk corridors recovery",
        "label": "Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Before Taxes",
        "documentation": "Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Before Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Risk corridors recovery, after-tax",
        "label": "Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Net Of Tax",
        "documentation": "Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemGainLossOnSaleOfBusinessBeforeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) on sale of businesses",
        "label": "Special Item, Gain (Loss) On Sale Of Business, Before Taxes",
        "documentation": "Special Item, Gain (Loss) On Sale Of Business, Before Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemGainLossOnSaleOfBusinessNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) on sale of businesses, after-tax",
        "label": "Special Item, Gain (Loss) On Sale Of Business, Net Of Tax",
        "documentation": "Special Item, Gain (Loss) On Sale Of Business, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total impact from special items, pre-tax",
        "label": "Special Item Gain Or Loss Before Tax Attributable To Reporting Entity",
        "documentation": "Sum of before-tax tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total impact from special items, after-tax",
        "label": "Special Item Gain Or Loss Net Of Tax Attributable To Reporting Entity",
        "documentation": "Sum of after-tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItems.IncreaseDecreaseToRevenuesAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItems.IncreaseDecreaseToRevenuesAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment of dividend receivable, after-tax",
        "label": "Special Items. Increase (Decrease) To Revenues After Tax",
        "documentation": "Special Items. Increase (Decrease) To Revenues After Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemsAfterTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemsAfterTaxAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After-tax",
        "label": "Special Items After Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemsBeforeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemsBeforeTaxAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Pre-tax",
        "terseLabel": "Special items",
        "label": "Special Items Before Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemsIncreaseDecreaseToRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SpecialItemsIncreaseDecreaseToRevenues",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedNetLabel": "Impairment of dividend receivable",
        "negatedLabel": "Special item related to impairment of dividend receivable",
        "negatedTerseLabel": "Impairment of dividend receivable",
        "label": "Special Items. Increase (Decrease) To Revenues",
        "documentation": "Special Items. Increase (Decrease) To Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r173",
      "r269",
      "r275",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r314",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r399",
      "r401",
      "r424",
      "r429",
      "r649",
      "r650",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r1131",
      "r1134",
      "r1135",
      "r1165",
      "r1232",
      "r1624",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1664",
      "r1665"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r78",
      "r82",
      "r83",
      "r169",
      "r171",
      "r172",
      "r207",
      "r208",
      "r209",
      "r237",
      "r238",
      "r239",
      "r241",
      "r248",
      "r250",
      "r252",
      "r270",
      "r361",
      "r362",
      "r400",
      "r485",
      "r498",
      "r617",
      "r634",
      "r635",
      "r644",
      "r645",
      "r646",
      "r648",
      "r651",
      "r652",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r757",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r767",
      "r769",
      "r770",
      "r853",
      "r917",
      "r918",
      "r919",
      "r948",
      "r1008"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r270",
      "r487",
      "r488",
      "r490",
      "r493",
      "r769",
      "r805",
      "r937",
      "r949",
      "r950",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r971",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r991",
      "r992",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1008",
      "r1120",
      "r1122",
      "r1246",
      "r1675"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r270",
      "r315",
      "r487",
      "r488",
      "r490",
      "r493",
      "r769",
      "r805",
      "r937",
      "r949",
      "r950",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r971",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r991",
      "r992",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1008",
      "r1120",
      "r1122",
      "r1246",
      "r1675"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1270",
      "r1281",
      "r1291",
      "r1324"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1531",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1536",
      "r1537",
      "r1538",
      "r1539",
      "r1540",
      "r1541",
      "r1542",
      "r1543",
      "r1544",
      "r1545",
      "r1546",
      "r1547",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of issuing stock for employee benefit plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r77",
      "r78",
      "r116"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82",
      "r83",
      "r107",
      "r973",
      "r989",
      "r1009",
      "r1010",
      "r1220",
      "r1258",
      "r1437",
      "r1440",
      "r1441",
      "r1478",
      "r1597",
      "r1677"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r169",
      "r170",
      "r171",
      "r172",
      "r208",
      "r237",
      "r238",
      "r239",
      "r241",
      "r248",
      "r250",
      "r361",
      "r362",
      "r400",
      "r485",
      "r498",
      "r617",
      "r634",
      "r635",
      "r644",
      "r645",
      "r646",
      "r648",
      "r651",
      "r652",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r714",
      "r757",
      "r759",
      "r763",
      "r768",
      "r770",
      "r918",
      "r919",
      "r946",
      "r973",
      "r989",
      "r1009",
      "r1010",
      "r1094",
      "r1234",
      "r1237",
      "r1257",
      "r1437",
      "r1440",
      "r1441",
      "r1478",
      "r1597",
      "r1677"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' equity",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r1011"
     ]
    },
    "ci_StopLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "StopLossMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stop loss",
        "label": "Stop Loss [Member]",
        "documentation": "An insurance product that provides additional coverage on Administrative Services Only plans that provides reimbursement for claims in excess of a predetermined amount."
       }
      }
     },
     "auth_ref": []
    },
    "ci_StrategicOptimizationProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "StrategicOptimizationProgramMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic Optimization Program",
        "label": "Strategic Optimization Program [Member]",
        "documentation": "Strategic Optimization Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Axis]",
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Domain]",
        "label": "Subsegments [Domain]",
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r771"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r771"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r771"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of Cash Information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r1229"
     ]
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior years",
        "negatedTerseLabel": "Favorable (unfavorable) variance, amount",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r1229"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding payment obligations, supplier finance program",
        "label": "Supplier Finance Program, Obligation",
        "documentation": "Amount of obligation for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r1167"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramObligationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding payment obligations, current",
        "label": "Supplier Finance Program, Obligation, Current",
        "documentation": "Amount of obligation for supplier finance program, classified as current."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r418"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program, classified as current."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]",
        "label": "Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding payment obligations, current, voluntarily elected by suppliers to be sold to the financial institution",
        "label": "Supplier Finance Program, Outstanding Payment Obligation, Current, Voluntarily Elected To Be Sold",
        "documentation": "Supplier Finance Program, Outstanding Payment Obligation, Current, Voluntarily Elected To Be Sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramPaymentTimingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramPaymentTimingPeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment term (in months)",
        "label": "Supplier Finance Program, Payment Timing, Period",
        "documentation": "Period when payment is expected to be made to finance provider or intermediary in supplier finance program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_SupplierFinanceProgramTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program",
        "label": "Supplier Finance Program [Table Text Block]",
        "documentation": "Tabular disclosure of supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1505"
     ]
    },
    "us-gaap_SupplierFinanceProgramTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgram"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program",
        "label": "Supplier Finance Program [Text Block]",
        "documentation": "The entire disclosure for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r1166"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1317"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Temporary Equity, Including Noncontrolling Interest",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r228",
      "r232",
      "r360",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r1440",
      "r1522",
      "r1597"
     ]
    },
    "us-gaap_TemporaryEquityOtherChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityOtherChanges",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other transactions impacting noncontrolling interests",
        "label": "Temporary Equity, Other Changes",
        "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other."
       }
      }
     },
     "auth_ref": [
      "r1519",
      "r1520",
      "r1521",
      "r1522"
     ]
    },
    "ci_TemporaryEquityOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "TemporaryEquityOtherComprehensiveIncomeLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Other comprehensive loss",
        "label": "Temporary Equity Other Comprehensive Income (Loss)",
        "documentation": "The portion of other comprehensive income or(loss) attributable to temporary equity interest."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1309"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1461",
      "r1462",
      "r1464"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At 200 Percent Target Level [Member]",
        "documentation": "Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At 200 Percent Target Level"
       }
      }
     },
     "auth_ref": []
    },
    "ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Target Level [Member]",
        "documentation": "Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Target Level"
       }
      }
     },
     "auth_ref": []
    },
    "ci_TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Zero PercentTarget Level [Member]",
        "documentation": "Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Zero PercentTarget Level"
       }
      }
     },
     "auth_ref": []
    },
    "ci_TradingArrangementStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "TradingArrangementStockOptionsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Stock Options [Member]",
        "documentation": "Trading Arrangement, Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ci_TransactionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "TransactionRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Integration and transaction-related costs",
        "terseLabel": "Integration and transaction-related costs",
        "label": "Transaction Related Costs",
        "documentation": "Pre-tax transaction-related costs primarily consisting of fees for legal, advisory and other professional services, as well as employee costs."
       }
      }
     },
     "auth_ref": []
    },
    "ci_TransactionRelatedCostsAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "TransactionRelatedCostsAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSpecialItemChargesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Integration and transaction-related costs, after-tax",
        "label": "Transaction Related Costs After Tax",
        "documentation": "After-tax transaction-related costs including the impact of tax benefits realized from termination of merger agreement. Transaction-related costs consist primarily of fees for legal, advisory and other professional services as well as employee costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecuritiesDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails",
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r482",
      "r497",
      "r700",
      "r713",
      "r741",
      "r752",
      "r755",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r824",
      "r854",
      "r1207",
      "r1209",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1221",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1575",
      "r1578",
      "r1579",
      "r1580",
      "r1587",
      "r1590",
      "r1592",
      "r1593"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1340"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1341"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1341"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1342"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1340"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock held in treasury",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repurchased",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r78",
      "r116"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Treasury stock, at cost",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r78",
      "r82"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r53",
      "r116"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/StrategicOptimizationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r217",
      "r421",
      "r422",
      "r427",
      "r428",
      "r1119"
     ]
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local government",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1184",
      "r1221",
      "r1240",
      "r1662"
     ]
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesbyTypeofIssuerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal government and agency",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r1182",
      "r1184",
      "r1221",
      "r1240",
      "r1662"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1336"
     ]
    },
    "us-gaap_UnearnedPremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnearnedPremiums",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unearned premiums",
        "label": "Unearned Premiums",
        "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r1234"
     ]
    },
    "ci_UnearnedPremiumsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "UnearnedPremiumsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned premiums, current",
        "label": "Unearned Premiums, Current",
        "documentation": "Unearned Premiums, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnearnedPremiumsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "UnearnedPremiumsNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned premiums, non-current",
        "label": "Unearned Premiums, Noncurrent",
        "documentation": "Unearned Premiums, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfunded commitments, percentage expected to fund in next fiscal year",
        "label": "Unfunded Commitments, Percentage Expected To Fund In Next Fiscal Year",
        "documentation": "Unfunded Commitments, Percentage Expected To Fund In Next Fiscal Year"
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnitedStatesHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "UnitedStatesHealthcareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Healthcare",
        "label": "United States Healthcare [Member]",
        "documentation": "United States Healthcare"
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnobservableInputsDevelopedByCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "UnobservableInputsDevelopedByCompanyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Priced by the Company",
        "label": "Unobservable Inputs Developed By Company [Member]",
        "documentation": "Significant unobservable inputs used in pricing Level 3 securities that were developed directly by the Company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid Claims and Claims Expenses",
        "label": "Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r891",
      "r1230"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Appreciation (Depreciation) on Debt Securities",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "documentation": "Tabular disclosure of unrealized gains and losses on investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r1196",
      "r1200",
      "r1211",
      "r1580"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted Cash Flow",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1164",
      "r1165",
      "r1211",
      "r1578",
      "r1579",
      "r1580"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsInformationaboutDerivativeInstrumentsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r1196",
      "r1200",
      "r1211",
      "r1580"
     ]
    },
    "us-gaap_VariableAnnuityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableAnnuityMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails",
      "http://www.thecignagroup.com/role/ReinsuranceVariableAnnuityReinsuranceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Annuity",
        "label": "Variable Annuity [Member]",
        "documentation": "Contract providing periodic payment that varies according to investment experience of separate account in which amount paid to provide for annuity is allocated."
       }
      }
     },
     "auth_ref": [
      "r1228",
      "r1241",
      "r1663"
     ]
    },
    "ci_VillageMDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20260331",
     "localname": "VillageMDMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VillageMD",
        "label": "VillageMD [Member]",
        "documentation": "VillageMD"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1305"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r722",
      "r787",
      "r1102",
      "r1103",
      "r1211",
      "r1605",
      "r1607",
      "r1610"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shares",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r263"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WithdrawalFromContractHoldersFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WithdrawalFromContractHoldersFunds",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Withdrawals and benefit payments from contractholder deposit funds",
        "label": "Withdrawal from Contract Holders Funds",
        "documentation": "The cash outflow for a segregated fund account during the period."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1303"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "405",
   "SubTopic": "30",
   "Section": "15",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482578/405-30-15-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481774/310-40-40-7A"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479808/944-20-55-15"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(2)(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(2)(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(2)(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(n)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "220",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(2))",
   "SubTopic": "210",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(1))",
   "SubTopic": "220",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "SubTopic": "220",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "44",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-44"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-50/tableOfContent"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/460/tableOfContent"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479838/944-20-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479838/944-20-50-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479838/944-20-50-4"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479838/944-20-50-5"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477409/944-310-45-5"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477409/944-310-45-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/944-40/tableOfContent"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480112/944-40-45-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7C"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7C"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480141/944-80-45-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480141/944-80-45-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-10"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-15"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-15"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-15"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-15"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "79",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "80",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-80"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-3"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-5"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13K",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13K"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13K",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13K"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13K",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13K"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29E"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29G"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-7"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-12"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-15"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-2"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-2"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-15"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-15"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-15"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r1596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479868/944-20-45-2"
  },
  "r1614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479838/944-20-50-3"
  },
  "r1615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479838/944-20-50-5"
  },
  "r1616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477409/944-310-45-5"
  },
  "r1626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477409/944-310-45-6"
  },
  "r1627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-2"
  },
  "r1628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479250/944-40-25-14"
  },
  "r1630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r1631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r1632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r1633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r1638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r1662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001739940-26-000043-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001739940-26-000043-xbrl.zip
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M"]4VP)#R:7/OL)LW_?-YYKC#8=L(K!=Z_#@O2-KQ\Z4KQ%P:MA FK<I7TDI
M7MBZ*3, 7_DWP0#""$Z.;;YR;P+;;*.)K]Q6L=#$7JB@\)8Q7QDP 7=A%:<(
M?KYR> +\PB).AFN^,G@"U^PBB;D<F3#?-NC#7 )(V!N[J:4QEWGYH I2$_F
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MFLIKU"!_BK!@K:F\A@T8(U].5IM:H+A!?O(P5>NM0/&#/&V&%"G";!SA&9,
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MF)>'C/1TP[+G]N/ MD:4N/[U_ &1.NTW_9TL!T9@(7OY$V[(7V4N2"G(O]=
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M>$1RQWXKP=PKL1?\"3 0O,6+I ZL^ 3F/R\3106/ ^E.I,=(&GGNSV <7;X
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MZJQL(RMVX5G7><'[^A/Q6WV3N2KJC5TOZ&-OLK:.,9!62ZV&PFD2EIV35@L
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MG\X&)!&IE.M*6J>"9 K(8AOD9,\QW.2Y-EP;218 P<-^\''BV2DJB&^6XWK
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MN6Q_M,?]J)5:S9A&YHR4%'\T+)WG\.9TL'2@C4'[7"@QNT89@9KP$'8#D*)
ME%NQEXK89,\;-"7],!]PW)$5M4:IM6VR<1%F$KX%V[Y%)G!MEEIJS*8XEJ!S
M7A\C_>ZH9RXB[_2EFW;O=^GI^?$?W=O.K73];^GQJ?/<[G<?ODKMFW[W']U^
MM],[Q<<XODMG J/QM'-N"J.=-KD<V)>T7GU:=+>ZGG_WR3[&)9>ONJ\>:C+6
M96HR:GRW(LSA)!C!';D'VL[ '0KACJ9ZLHK,#Z>,]+CF1'^^;7 =-O_@O<'U
MAW@X'PU.S@MG$(D&QN8"S-:RDXU/EM@4VP690167$:M;/ !>Q<;,HW*1)C,P
M/6YP[5L1S#J?NV!85Q''WP'#A_OG"97:CAF> ]E;TB7.VE%++5U4T@J 9ID:
M/PF@6JG5/+DE9H'"57Q8(6M-+\'W6M<6'IZB.35(A"TB;!%AB[#"L>G;(M^6
MC/^T8GJ0^C?(MOV#=  ]%5XDV01TSV6EI ==O=125=$FEM>2OAMW,L$>/;6<
M]&X?H1&6;!<YHF OG].WEAQZX]HVID]\'-X3@JS:B,2Q82VN5S,7^D/4 ?*@
M/U* :+W4BK%Q6$*+:$1[5($?;4/KEW<[PM*GJ0>(\N#-DC\&-5,)L#=9+Q1W
M81+TN[5X_JJ^4_2RS5$1D8 6V((+BW'^.*0T7\4_8JW"1JE55;<;3G.AD(1#
MPZM".@JJS5)+BRD58@DT(@#[7@#6EZ8SSQ@C'X,Z\>"_ULAR4(!%+EC$7T7\
ME1GS)*63K9X6-F7?;1M "P\GCU4U9!#UM6TW66Q69L@T2*.WT8DP44JM9DSW
M8$9@(J*9(IK)MI1>FN9O>?#;@B8/;H#?#Q8U5!#5IW06$U%%+B1U&E#1 "IB
M=W#!0HHB8LB[L$\0>VE42RU=W^Y#S(BE]=% DH.83P(2<B!679R P&1L;D=C
M.(\<XQ3,EQ&3*2V4C,)T_O$=(8IM9YTE<'+G>NLQ\XA63S9R(@>9DBN.%4F5
M0>T4>2W,<B[D=4IPJ8-EKC(+%W&6(:?>RIFS !;=+AO,O+6C"@VRIY;L-Q3A
M_WRK$]:HLSI6%?L/.'@<DHW/X75LQHFG!FBS[5WPHD;AHP'VK#4*R0%[6%N'
M!NE[5-:JVT4W+$%+>$MQI_DX^"=MIPI_>*.Y%*!7R?"P:051NGDMQB7<)A:"
M6V$:\1L.QJ[Y?OBB*<?N[V3$!OYH4,DAQ'4 5$CB^92\,W_N$N>^@>AORH18
M?A.C6 LJO^F4M<UR:EQS4T9"RQ\-,.<3SB< AIQ:PRI@1%_1H_J*?OK>Z]Q*
MW8?/&QU&NP__Z/1$AU&^],..CL([NBDF9/EJJ5734@ACBXZ>#*,QKXZ>L1@\
M+/33U&F_VV9:!SJ+CIZ,:ZZW'3WO+ <YANCHR<'#10 T;I_-U/6M(-Q@8X%(
M]4 B+B*@V)0"EPI:(M/&K@T4 #%+?R -8<8B()I#!JX-TR;/\/ONS8(TOU/2
M^'>$)'$ZJA9;T,U%LDU$8'FRLX[ )JE3.3EO)H*O9\;,/ZU@;'KH)^" :HX!
M=O 0M,*RZP2UC5)7'<6.P64?M%V1+>PADXQ%&Z56\Y3]0")0RU6@]CB0-$NM
MVBFIU@(%9_D0X0\8[/PQ<D88[/[UC3XF'H@"\;R.C%U/C3POFS@MNJGT")'Z
M0".RH7J;"369'+ZDL9K$_FB .<^YL*<!1BFU&LU3<FK\6=[YUVPS5R6>_P#%
MDC!P5[%=UJ5P)'L(5EN8C[9VBNUF9.^+KBNK>R#'>VJ*5 KIV]L%&/$N/AHV
MLG=!#\&&5FH!6%G%AE!.PAE/IIP6&[3I#C=W,G')VUWCA_#$<]CDMBI57!'F
M<7A#R=(C5-DL$QE:K]BL_(4]-TY 54G2JZ$JZA>1@OOPV#UKG6TB\.ZM<=)D
M6N.DRXT/%2?@W-WI^OX,.48Z^J38]NQ9-TU'='G#D=M,5P.?9[NJD N-(;PM
MGHHVCD)GO=2J;>>$6<*)<#/B>[1&BD R+5(,[9C2%%G']=(HMJEVOCUTC\/;
M!2W\/6Q'SO90F.WJ\]$0<CYC/CE"F@0A8B,S1Y:ZV,C,QD:UC59K*R>:DF>Y
MR^.]W6J:0NHO]%/<9&$Y,RZ>L\..4FJIBMC>_/XN..9$^I[MS8O=S=)=]Z']
M<",V-!=!3^S83!K+YH<%6A65;B:MIE"0)?8[,PS6,RJF#,%*SGXHUQI\@E5L
M>CX$FIWA$!NT< HP A<<R9AY'G:,N>2A "_JR'T)0$NZLY;#'JVD@=X+H,8)
MHD-I_<"S#+*OE%[/9YMT GN61YER1@48HN%QV'D-Z?X,$'ATB)@A_^NLJ/Z\
M)#BYT';,S2_6[NPZACTCRWH+'.?ZR/X*=)G"+^ S&:3ES+#Y.,6 -K*],$X<
M54NM%#8I,:$W!<9S2H6PB6P]#MG'I5J*JVF/,"485;9D8Q: U,.D&LPZ1*,*
MCY)/A7J2@'F">9#NIB%@;A? 68J==5$6BK<X$5,KM6KZ]C9\'BQY@6@&W<[\
M$5TG6P9.:2_Z47S3$\XM/'OY0G+?\O\@9X:\N:24TZZ8TB_4!(/]0EM= .*N
M/&R#:?>"OQ (5=0+,M6W:PKP)@\HM:1/BCA(,;LZO>;[YO])4NO@^%FCU*J7
MZS'-;T2-WT=#]NF.K5;/$-H'^[ '<D*SU&J4F]IV))DE3.;BQX:#>ALT3C^<
MS+8R_X8\8RQI2EGB2IF?ILO3 <*ZH#P#YF)E*D.)^?\^TOP_:4WRUR^G6TX-
MABPG52:6D]S@]/RX5"7\F8(H0ORD@I0/*GY2R-OLJ:0_K_PA79/*6CVMMJ5,
M20+1L$ LB5@2L20Y+\EE0$[EC!PG^">Z>R'U*D2K7S4C36\Y)DCRJPI\D:(>
M6_,.Z=.NK "$J/&^;E/T%/Q%T"M#UPT<-\"AUG$J*E%3X5?/+IG9. BF5Y>7
M/W_^O'@=>/:%ZXTN55G6+CVX?!G=FX5:/W QUBFF7C2KA$;/;UQ\XO9OQ0)^
M8@]+'IZZ'KG/<B27U-.O->]:.YN5/H'6VTO(]W'@7RS5\-IBQ@!J@KR1Y2RU
MK[Q$4.O7@7?9VO3@D_PNOZ4NM?IC+"'#<"<PCCDYE.0!)NV38QQ@9:0;UZ'V
M R++N2@!1;;4"^"+<!$_S1PTHT<_?)80+#[,AAP*,?+@MBGR: D@/,G',,GH
M1VD[760I$TSU8B=E%K=5FQ<Z/&F;%W]:9C".C-"UWRU(*:]^@@:P7K-@]T^V
M0;!N@!F8'*B1(BP2+DW]3=AI[5\R=B)0K*9:4W'-1(WA0*T.&[C9&*HR&I@U
MK*M-%=7_T+1Z*?K5V%N)WQ&N##R,?E30$"9WA>R?:.X3N;V^++ FBQ'IP.Y;
MR[>;P?:PF7KV%=X*G:AD$OW?.])-]^M#6_KZ_/C]Z0 AL7OTE"R:436&M:'2
M'!K5JFSBAE&3M;JN#)IUK:[@^A\ZI4K&'!<_Z8?'?J<G]1\E.OO'A][C??>V
MW>_<1MM;VO=2KP]??.L\]'O2I^\/[>^W7;C^64IE@<Y(WO;U?4=ZO".S[)/)
M)!S_3GA2:V8E9ZA+!_.PT=3'5]$?7R)+R'+HD.B/OFR^0=\V(.C[PLL+1FN
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M+MADLA$?T'B6A3DT,!- EP=6\HZ-T"5/7>KU1TS!_(S/E,SPU1U&MP'8@XU
M;1IE=.!=V%G>IL^8:! AJ@II",:,6N:'L-D1E3:MP[WKK:)LKO"J]_?['_>]
MUP+\_=GP8 !QW!>DH:1&7X&I@'UG8.2]U[L1,L^D0BOJ,79(G:8&+Z42J)Q:
M?J0 /+(TT#/TXF HWK2-2)%)>J(YXOAP1D_B0]0*R6.O9M&6DAOWV0%VL:TY
MR02YKWKW7S]][+U^O<'S<:29RC0$X#=^4DR>LM) P%1$_/L,BT6SHZMZ9;VF
MGA95?(8#4PPP 97.(IENL# "X1EFD#AN(&/D%XVT8[.>?9 FP-X2[Z>_L("1
M_V[  ,_&6OB$JTP;*D6)+23J%S+U#/^G 2M/G@,F!_))0U%^ W.%R?K@9=BQ
MV\6F&T_Q#24*_,IZG=5.6V2ESEKT)!/6P&+7@U/MF!(KWE$*00R*IGBMQJ-'
MV WCKLE:K%9.Z<;LE3*/S#$U [IYR9KN.R[LK&V[+*>(_G2!064LC)^!C\\L
M!2A58$>(VWS@:A/V$47*\-,O713#>+5SAGH, ]C(W&R4N&\$#H\.O.ML($OC
MS-!+!C\A,YN,)*:* &0V%GT,"Q^9WEZRNIM^,L\X(P8SI>*":F7NN?\ACH _
MP&>H!8?1P'.WF'N"NB1VZN&;+'G MT)^3%^.B3FPDLRJTY,MJM%NGM$/ 3/\
M+\R*83CFLQ0CN&++R!XR:UJ</J2" /[^,X&9QKNRQ?J_;QP(53O%4GM'G2IE
MX%Q2-)<8S.4!'GP+;/4S/6D:]V+%3,R[(/H,AZUR_A0#LZ*/FSN/,DQE/A]+
M<WVJ2XH\,\?:7#$T131&FJ3*RO#/D2)?]CA*2HZCJN#B9#>ZTA:]-7S+_SK?
MVIXU^]_\%JG#_!:IPZI;=&[@X'VXFI0 2.-OH)0PK\TJ(2Z=P7DH!0N?]1R,
M&"4%UI++CX.R0#LZRXZ83?1'@4%\1)5Q5_TXF\(&7Q@TLP!J)E9-,!)SJ**1
MX1EZ]N&760 UXQ!\K0PO&0=3.N@,4 ULI-P.FA*>7X%]$![!,?!H4(%IGE4T
MA_Q1 Y#BCHH!^C!_N[O[!LYW<M#QZ+KFLV7;&8,!MLEP'BWJ>X&WD;&"T? ;
M*WIKV-3;^+$@8*Y2RGAD9L/C(+#,XL$L6%0@BS0JT-J>/KR+%NVAQ)@I<0_O
MIT,PZP8LQ8Y-Z2%/FIC["SBK$&HMDV,@H%*X7$5L-G7#( F4(QN8FON^$!A1
M=BU! :+'FK&GG_@5Z$]$YI/MZAPXV<7@-ZM&,Q-AR3H(DOW4=<:YL',GU,K@
MRB[<9S3G,.XL0"\67@6Q*HI4"+:7G26BK[",SD>3\=E!H 6"-:.)0@-]!^<1
M7>#D1WA<G/)T$M+B+^(N_]$6@'-AN28=Q_Q7R$ASP- 7&/[]^;RR7H&>]0HB
MJ\ <J\1:H&4HL!=8\K'C&6;P"]P Z>15L3LUL4\8=UG+$B* [!0Z!GC#+.60
MY*W0B\[L&@2<&:\9:_"0J6:AY]%R@/1WKQ.I6O=C-G!7EA/ED%/QZE,/T0!^
MM[#6*)H1_F:>3#3.!4:2Q'C8S1Z4)NEMQFI^E(DC9L3(Y0D!;Z#"(_@+*B13
M#-J-6,W_*W2H@6%ZOIQZ28?,R@A[EEHNT#!W$$O"4]_IK#%D^ "T%<3AS?]+
M5K8&J1+P0,D4W@%I$2\]ULV8L:'_29Y"D_&0OH$>,V/DD<P@]NWG$1PY52:V
MB\FZ.$JGRT=["^8EL*B0F^'*IG4:41(J?01YWZ#1$@R*5CN=3U[0LR)4] DO
MZ(OE>+Q%O,S_7J T;X>ZW*\8I4+%*%](,:)P8#V)S;)1J!J24F(FEF@'LYR-
MILYC[,]LH(DE4Q:JF'^'5E3#A&X:DSCF%QKQ85EYS;/IA> A&J:FG_"?KK-I
MF2T_[RADTQFX+CS'H_EHQXBSQ#3G@,J2U?5L),XW,L[;&:S-TSQ0*00+>IY(
M9A8LLXX[S4I@,-N I@.UU\P(8_)&R\!)8GG(#55JL4;'4QR3Y4L8T0I5?8'C
M4$:?E/0/-/&XK %P9B8<]5P'_IRQG3T0G!8Y&V)!<+I;PN1""5,*]=MV@J$-
MT2PB9&[E"#8(6&;#3^$KCH8'?47<J'U;HYQ?S0U'220>>Q>;OD%ZL! %$)&J
M\C.!AL>V9".0S6X)<Q&B.E0:1+)8@2G'I;%.8@=,1B;JSL]F :@.8H6C5'6B
M%H+_=UPA7)DTR G<C4GMG@V;+D;6IKMB9PE&%-RZ,_1.,7-@8=B;<;M@7C8Q
MMYP5)-#6;. YEMK'!52;C@6A8G0:BM[7&C3DQ@SQ#9C&G459Z@S1,KZMNX.$
M4[)V::T2-5FTT&Y:Y%QNKNX"E0;%/#HX_V$!?>^&8QPK3LILM#X%'8.D[IKN
M5B:#3K]P-MDRYM:4P;;8Z2B#U8@&TX_,@7]R8;4T9GGP#)/<.28]3DVAC/UW
MB8=48-(*7#Y5*LZW;N2YIV.BFMIL-->'BBB-=#*5-6D\A!E,9[HX_U.\<)I;
M3M+<N]&=#YQ>-+*MXR.=E!^S!3%#FR2I<[;'=+=ACS_$QUGIH@HV5R[KF; M
M+V"$"R1%Z!ZBW+.:8YJLB/*%-)N;Q,4HX*! D_WU,OOKD*"H5CFJ]XDC3P_\
MFAN\BF&L?'(;__$F;LYB.71B]*$WFT%G06$3]9K8UVG -ABRH"VZ21N].?IZ
M %_]GO]\I ^&FE;XU7 @%GZ^:ZCQ8"CKE4;:_;FLJDW-2=G_[F;O'B< *DVQ
ML'Z$$44F>/71$> 5-CTOKG<UF>4XSK?2O5?--\\>*BPLN6S>[?7G4GP;)#C
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MWG:Y-_F_H4/8KHMZ\:[C]/T,D"<N%S;>]>JL)LO%7^??Z7"UEZ-DEZ,4KV;
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M&NWDED$K81GR=7_XJ=(:RW"?LM$W9*-+^(5T(G\<Y&Q03(3F3RQLG97Q.?K
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M6;TC>TXDQQ?U3Q442E'/"R47CQ8P$A>/AL1COZ>(5V[R[2FX!+2 5[@$[)*
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M&_N2VI8:L6NYZEG,!9\-[R<)!,_R?QZ^Z-G=C.8IXV1&PN] P2A[F20W[Y9
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M1]MVG_W;G$,'X0/5BW$$P6(!(()MK'QR&__Q)B[KM!RZ'OK0FTUB(M#G5BA
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MP3)^\]P5+'=];_BA80?KI'3\#ZSR??:L@'CQU>+_!?(W?ERA]28CL)0=[7G
M.Z6VRQT\$#BU6 Y&O8DX[&O#=D/1M\J6[4D1M=>6??,LUZ.6[.6@!;^J9\M\
MF#K\U; PTXTH)\IY:=5!6O7\J5JN.HVGS"\G:=6X+F<Y6LAU"(I9@ C1$JYK
ME6TX-G'27L,1=_EED31/JC<=(U7/%\99#?:U6-'E4X=##'TTC2?8>8*]LQ'5
M^:5&I(&2K-<&<GV1N?5#31VZ<?Q<; V^T4MM36:8CU<HUS!XJ]B4)Z[;9U[:
MZ)2QCU$59+)UU:V,A >XHLCA('E:NHU.5$-<+B.0QG#4%ERP#I@AGG-NG7RV
MVPHE";\C0AVE-Y$*JX@Z881XBOO%&*$Z3*[V)G)?&=4&+>6Y[:[GMI'G>%Z[
M:>/US5C3&QP@UI]<WZ>=E/"/NB4+ZE!#[W%<X#UVPCSQ_'7[I>/T5N]TTC'"
MKOJJVA1(.T]3[\]KMBY'O>]>[COL:!=80>AE[N76"<UJ-!:X-KMWU-6/S(;$
MC08W!7YN_2+FS7^(YQ;)NH[61Y=$Z4TW;6%5X3I3I_ZJ7:NN45!.9P)/(R@E
M+..X-Q'[LM1P._J7V93B2IIJO7?,LUP;;JN4-W!GN/$<9O4[PZI(FT^-]+S3
MVPDSV.WF4U<M( V8P6$;!$1$ 9%')X\*7X+M:^D5V&)6O3--WH_IM":NP7Y,
MJDC[,774CO&3MTY9GD;Y%KLO-0;E^0*,R*8AK0]:VE+SLQE@'>EF7 UZ<;,M
MC;N/7GS>\+/AN].J2#M5C:6.6NNF-="9HM)3PR9?J>IIMJ5R]U7/>0/[QE4/
M;?2E#AMNL-P:)5##5<LCM6X!/=8 O-.&V#?F(.*=6HAXI_4RR*1-L'0&[H..
M5@K91E0;  !I7"@KS;\W$5B_/!A\$U(LSFALXL9F ?K<N3 -?1@0:RZ$!;%-
MBC[F@WPA/","D;D4BPR!S&Q"-S8"K?S[_8_[+*[90+BCX[TC,[*<$F\#VDU!
MT+-HCI4@[?0#6F6C06"V;6#"<5]7A"&F5L\L%FD:8-NQGC\SBY&1CJ/U%O!=
ML4Q&#!;MO(J8L'G.30#9?MN$^(E4V3!]Q)B"V@J#W8\48%">$BBH),Z>*&W1
M*O._%327B(5!T6,++Y[_RG@D-U./&#]OC#DL[]:PGXVUC\HT2QB@2G87M@FX
M&VSYD*;4"C7EJ/W8H*4SJC$*;O*=&1)A[KE+^((.03R&!+JBZ+H,+-M'+42'
MV(,[2A\B++Z.]!\BZ8+Z-BPGD3PJ<L\+:[9@$(L1/J-APJ9:?D#?!9^#'85G
MB$/F%LP1L;A=>!_^DMIO'-F=SWT2#(0?A A?W( (>JPK[UV'>@3TZNL'RP&J
M6(8M_ C@ YHPHI- 1R&@&+6PJ*2!"0-&38A92C&41:=52MCJ42$'ZE5QE'_,
M%L0,;?)U?F^$H.Z^SD$W@USY!,P#_>_'(_3Q [SQK>W.?J;J. >ZW*Q/49+]
M_V%X%FX7!:RU=G79C"PJO0#TEVU3[41_IN#)%"?9(WYHX^-41I"[3&L^)QZA
M;YN2X!GQF\$(A<!'^*AGD5@(,PS^%U_X28#-?3]<KB@*J?!,L.KMI:"(JO)@
MJ&F- ':.!T-9;QF(:'-S$@>ZW@S:ZO73:;SWB=,CK4I*;TLZ"R/6?;EQCL-:
M3%I1*D?:HPXD6D7T#1S3[7/N%T4&E6/])DW[WJ%U]Z@_<W+,WU;Q02X%?-0J
M"W6*5H],W4'S_>UZH7PY@W,&[QZ#2T4,WK52^$8#^Y+5@BRNSB2_YQ!JNU&*
M:O.ZV(;F.)HZ[3TQ/37^= L/1>O78^ABZ_L9JZ+>FXSS_>X[6+3!;X^WL7*S
MHA0Y(9X>[A<D>>_EN<_$Q/55ZX":]D[Y1CQT*XS'5%ANI%1:QKW)<) _ .3B
M<D)Q:;<-_.UT-K UUO_4$/0MM/[U2Z)TJ?W67QH66O\7HEA>DAVNR,\[[+#4
M$CLLB<5V^(4P;KOMPF_-9]([?N\PD@5:$R $'G&.:['6[CM:#<3+<@<LI@06
MLZ- B?Q*8NL"6[DM!E7N<&#+^;I=@8_2 36N8#%Q[<B'<U[K0A2E+1I5;21$
M:0F'->+%\U\U<*6+W[ZOU=]Z;CRY["["4U2VS>_A\\NPS<:Q'4!/5B6M&#VY
M$PY_2R_JGNFV_A&IZE,HJTY(9[&3N"F@EW021^@D7D7YQ4N0PG:;[&-/HJ_&
MD^%M/4[?MKJ%GHS>FTA2;>BBEZ?-N$_19.)I4U0NZ5.,BWT*+@\=L>ZE3]4W
MN_MD[DA$*[K!Z=^.XR59H'"=X/9FW&B/B)?:>.?-!I&EP5A!LJ:B2?M/9*"G
MMSL#&'[:O0([0N!]??H[0J^^%C;24;<Z0KR0+9=>\)8K!4U TDX<!SK.7*(;
MQH<DP9HVO ##^$1L=X6V#2^5@@I=L$X8^*.EX<$,XMXPOF"[SP2) ]/&GA8S
M)%<8@ 7]CQ&WH%I&!34PQR<+>V$ :?&>CN&Q7AMNZ&7;791II+*7BF6[K.C#
MWB'9%/5MX<1/3MFT)Q<MTGVZ3XBRNQ^,7M@/9GSNR6[*G3Z0$A*"P^6R_EZW
M(8833&%\""FHUS?:1$AX&S7R238UWP5O4UAJ\L!8+=%I9UQ(683NJ-9J)^M;
MLF6S54>+O@/7[PF^?4"!S#?0D8>M:*#S 'J0_0 [.6&O*-"E%M[M)'X@P/ZB
M@$-\:46-GLR0[3E5HG.VV:QC5-JU";0,!482D@YP?A^)Z5M^@$VB0(D8CA,"
M;>B0MC7'5\9=K%:>:X:@B_I=:)03O7E_[Y,1&&V]6O.374.)PX$BC5K6VP4G
M)1=_5;(ER]ZP>%RFJ4.K;GK3?HQ5*G'WKO^:[L G766$O=U/:E^(OUJ:56J5
M<LV5[A]C&V7,9AZ[(H[62CBJNKO#ETN:J855LPDTI:*G\\_(?[AC[D.\,W?Q
MQGR'?2G*ELEB;Z(.-.4:CN!.<('EXF=8_-+7I1/;NG81N91VR.7+D9 &;E=U
M_-[4?91,,[&C=^@$-:QKNTN?6V! (UIOR>N[B/([Q51&,97'W32?3117=\-"
M\IL#)[9S1XJ/0L6G-A)INQGY)(:LQ+%O1ZQ<S#-)ZC/);S;@#%<F3)MTW=Y<
M.)J[.J[HNXC*&W!#-SZ9W0+]\7 JE5*U-Q&' W7[\(T=89U\DPXEEZZ# _;J
M\!T<L!=FJE$.T"@'Z"4X8 ?N4NDSVTK'/P5K]!,:L(_3-;0#+>'K%/B)'<@P
M) QZ"H,0.1Y906B8]?<)@GIXEFL")9*3G<"%OP4*GP!_&@BY .NP3.S5"..A
M**PH^D?Z.?SSB1XI$\N#URP-R\$S(-MZ(OX@=TY4Y+KN-+EGH-A?FO:E2[X7
M\9TR*"7QV1BR)+HI>#A&H50,#X_.!"]T;MSYO"\LP(X)#@)>D*45+C,$9UN'
M1V+T5/\-[HA'@ M(O_@<#Q$PB/>TP1P4H27Z^\FP0UIVD10*%!\']K,LA6 P
MCPS7JBB^["?P&>G$C:4+VO _]*#/)'-"BSI6GHM3C%&>U@<J-4Y7=3#62YPX
MB\/B(V?Q$+[0^?&$/NPZTJ488KLW !FA$K[8*'=3O;!HLTC+OHLF\8W.(?EU
M07VR#+LC*_F;5@EHF$&U%3UAV2C]T2@C5EN0=HX%C6%!:C[D9Y,_M"IU(.S8
M7_(K G#;L\/T.+[.'NOE2?(^GL\ATHP3TBC#WD0:[ *BG![:\'[%I:GG7)J(
M2]NUZYM+*RY>K+HZ[9RKDX"G![OB\$,;I_:KBZH^.N?RY)J;IPR$/YR,#3U@
M;QN4TY*N_?MH0@5?92?^EGH;&<"Z(F(AE/5 /%:(:VOM2RX=H71W-JTX* 8Q
M"N@NJA1*SCFY)+/Z[RDLX1VB/=YA?=<NLFAXI>*@6C_SOA^[&'KG]( NZ*/G
MC6P%(9*][L>PKWN==.'9V$1[#!80,3TNL..=02,\A%($U0$3Q) BQ7QL$.A0
MRT![5H+-?-.V*ET)\Q_O2E3I@@M?Z-E+YYYNU3K=^RB29#B?8'CH_0!P#QVS
M3+5N:;17N4QX)!434;Y0FF2+-F9$FWE(BU537&$4J8):UR,,L+Y?&7W+0++&
MDXMVS"_2,A#U: 4.E="T$SQN=MKC:A=DFWV[.D2BY3V/0U0L]K>K&R15;'8Y
M8C5BRCM<XF-?+R$UBWH:[J<FO9U2X*I0>N[RCN]6$*O^@JD'8"^%JD>/V75+
MF4B@:,5O#1LM>W3M*'("B/D^,JOVNNB@404])H]R*_\M-NQ3-JA@^8E9-A-+
M;:]A?=%- LSTP0,^V=!"EA^GY. QAU"(Y R0<?30)C9R!A$9?GUO^ OA Y;8
MG^NRCH9@#H?M@EQL%Y3VI<UV^MY]2OS<#8L9[+%%+T.PM"?N&P/F%A![V/)_
M,F!BW!F?9DK1$K&4*V;N9R5-% )UD_D\=B:!K2P*B1QYAUD^H5:KCO#DCNVS
M$G0WHZ%0)$!;AT'W,35VG=6K"J8(Q+SC_%M%BU7!T&[.^ L)[NC^W 7?87>*
M5)Z*<7Z^:$XX.D8Y,%D4VQ\Q;_P#6>-=2+(K\-F,B^:J%>?*A,(09"#@+2%V
MQX]>'4TPY'=&HT=QTZ8)/"4[C9"=I+R'5)6=JACMRORD[]^CYEV,.@PUKL90
MGUV/L&NF535.*7N]2>N_A<"W, @Q/UN.M0R7&PRROZ.#-JQ>S#0^\Q3!U1L7
M50'N<CBJ*:$**I-&CP7<H=$,[QY63@\9]J?VJL^^0I"P<_8R)N;VA%.'9Z]2
M0USDW:'[EC7H4:+F,>&'[<N8,'Y%?AP/"_GQL([:P93 D<"7A9RH5!:6L7BV
MR8%]+A&0_";<5":P=+8U:-4)+)]M<F!5B^[RY&TLBK*Q$;152SL<2$27$FJ]
M8K)AQWE?I7>"D10'10 6)8)B5HR#[2HR!1FTO<6&XJ#I8?3\#5:MD2@2"".#
M*'KT8>;9\:IF?0ZDSLN08C1$4NQ+455U;L85$A@[9R46;U R*\RR5Y6_XGZ7
MA^7O;NH^'? +4BE4TC5(U55$<?NLTTT1+R[D]SY/]LJ:6!P.S[R4ZA9/'!8C
M:IYNCEA"6XK>4\/';))K86SWJC==^;W7@H%OW=0E165:E815'$H-2.L^8UCX
M4KF!EXY0111UC3TJL;GS;':'CB_8# RC F%EK%EU7F8-N)_PM,L2@(]X$@@?
M8O>-K'^Y9&S$<DU141_KCV1$(-S)%_$9<]7%](7EL?'>%J>4BZ;2>.F?8!,Q
MK*71K'\78-SY -,0Q6'THZ_S5**27Q:Y-Z-]'L.NR1<[7Q>8/+@>XQ(J((X1
M_4RM*2LJS3$#Y03@/)L8$)S G)+X,L-<&=XI<\X<)6RCU*JJX-%PKF]9THOE
MM\T\<)0 'J:/&%/?M<-@]R,%1].Y+A#G3R:+\A:M,O];(<<NI<V0%E[::>21
MW$Q!%?R\,;!:X=:PGXVUCU<<LG0!HF0W89M^N\\ KN;T_WV9TW^E^(!"O?3I
MOZ[L/_T''?V3! )F'DOWZ-I#!K68#-J%SN\_90Y ,+>R9*NEIRI)E=RKWN?O
M;]&_B1I3H?*BL"18/1.WI\J>CZ3ZL.#,GZ;(MP[F8##XA%(]<],"3:1G83*5
M7:&(/\=NS %QA.E:F!%:B4L3[@Y^1RU\UN"33/W/C(!2-%$3FV#@%_B"/KO=
M(?CAU&<'@G%8")Z;[>/U /<)YK!UC.33D5W:MZ\?5S>4NQ0#%NV.+84U"GR/
MMPS@O]]HE%EXR<<TTOLQV+LOO8F9W/"!GS K$U<] ;E@L9YO>/ WJB_FIV J
M805;%V =%#M68^%M'VE,<"Z)FV,Y0%>\P[*FYY_L;..>DGK]%Q\,U@H[4F[P
M#/D%%@5KKX#K2[((W7O8U 5Q(C\Y3OT5>%[Q7I)?,_B8[<+FSL#$#.8D1!Z:
M%0]KT_-<)MIK7/@RI'8:3P*3)$  @D7_2*<:OQ/]?6--5\0XE0T;Y^J3>6S0
M*>8ZQLTKW*7XPDE\9XCF-C?\3]BMI1^["%FJ&>"9LL/HLQT_8^>98^Y\,;V)
M:K-<DS]=S-W[VJ-&M6(U.KJ0&OU<I#:-N!8!4R$%O?G.VY!O/!XHBE*Y'Y\R
MT$?5FNCM:7TW%JOUW=L[E'2R+GI:Y[KH/2Q +PB?X7<+7WA/V_0FK=".::YW
M\9OHY1L>T_6_^NC$]Y3\UV5N.G>^TUUC/0$[L- 3-_*KVG\!1CCG!7-4=),H
MX=$'ZP**WXE:P^*U[L9:3!V'EG-:8N3;+$LUH')J0^%<8K''E_GFV@[D73*,
M"SXZ,X^ ]_F.L/]^\-SE1\<''PP=S1_@W5IS:Q:=:&;K;]*KECJ6L(Y:T)R0
M4JSAUFM'MJM!7OG]^B2RF.17*I'%BZU1*WY&D91[DY&NYD2R5<)QIK: [3+8
M^-&<G?&0J. 8OX)-6A&/)G\PTJ>AY"OWV8GJG^D'NUW;DS5%NS:3E[M>BKA6
MX3)D!R95!>]^83B/16AON@+B)W;4(M9JTY;:O:XSYP6T_[FX4^U-='G71>&S
M\LFQT=PA$Y ]%M,*\F,7X!RV';Y@AH3FVN/>!%%'HCK=V-LH/L6Z_56E,I0#
ML)XS*R]"VT+R+B0/;MQ[X'OH?)W/BR1"@P@F)P\Y>UN1*T^C,EN\Y\6,7VG/
MU?/M>6$1[GGW_%0></O5W^;IH2_@667H)UJ1>[H'E6%Y>6". KL;@:6/;"O
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MA6[Z:8Q52VK/ZE:#5EMS*PW *>.'IDK/QGB6.LHGFGB <'426;<:M%,2>8$
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MGKD\7T">&^MQ=]AXRR*>M*I#;KR;K9;>.:,NY"WN$#B$YBL0,2ATX(TV :Y
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M3%E,[4VTX7BG)7C9X0D'4=ZA*;%J_9SA25XU:KV)K+>E00P7$"X@Y03DU)%
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MK,^C,QJW)MI(E8SOS>.4!^.KSZ.C=Q&GE7,U)6($XVS</#KE1"7V)A^U>SF
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MIJ:9W?%P,.Z/^X;6,XRQUIO/5;,[)6JW-_R'-M+[5V;S_2V;W]DKZN:B*<2
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M_7V0;D:O6(X9LK).AZKITG[U_M)]A8-WV.=I?21CZKZ0=B9@'Q_X^^/S8WK
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M5Y9?% R8PW.!65+N#-361&WWU(:*'8E;P7 [XLA0<[NN2%A*6):NI-WK9TS
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M4PM?#WXU#83EN:#<9 <U[',-S@M0_.JYX>(7/Y)>DUC;IMZ<PBK2V)^H533
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M;%],84DYPX GSK984-/"IE<!G>]G,UUXD.P(,+KTYVO(\P<>#LH6^N<:X#'
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M0LY%N69WUR:8BL,*0-50;=TK#0B>.!NCK#)X%V\WE0>C2W^^ACQ_X#&A;(<
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MR48(";SUZ3!"X<4:G&A#0E+Z:-29[M3A<%O ^TR4BOQ<'+@M-QHA%Y'](X?
MP#:8[:]\WN2:'DO97.W>:LZ</JC"%L'^1T;OMA*IOIS?IG>:781 #'G&HX)C
MM6O&1QZ=4,_CW@3Q-=#/MJ@I\DHX&DPY@Y8'3#!1CTD3H%(7C%0%UT\LV^:\
MZ%'P%&UMP5]I);EB#@V8 F>I&):/$8C<V9BT@6=F*'O&%+6YQPG#C\DD>4,#
M)((+4S%7E8>[^$1-+7OGEK\D/AP .I<:8.=X\-^4.):92!41L@]FGAM.9SR?
M[@=@-3K0I3\LGP<@DTG2@U'9L40_,2$G^"C>E!]M4M1=B+I%2E.L=1#2G(Y$
M/ Q<:A.$N(7I*CS-Z&4APA]>. 7RX39RE"LYMWZDYB!S)*T1N->8C<3,SNB8
M#613FB#99%%:%.,G]GZ@),Q"LF!Y  L"2L$& ]:)M-Z_X(7$P;,%0= T9#FT
M^&F(LA2,+"^.$S!N8F_V8Q(#UIQZ9,Y,76OJ\%?#"D*3LC7A$AT68$!#G?$<
M ]53%&;U42$ANPGZ;? _EJ@UA*7>B[@13"^  Z!:@MX*7,<8?\2JRH@6GGL*
MGV[:I]C:=3+G%/.O'&9L11OEZ5PI,,+J4N]-!WM1YX8VSU[#>LZ6PV,K(]"\
M&D++FL B8&Z>_(5SX&-%3"#A3I@A2$^8@#I/EN>RA3;SLR0N/8&UO0R9]+\5
MIJ(J05M8T$9:*^8F[KJ#8@4VA#6,>709.=>F4\OGE-W -$W@0S ,7QII*WW\
MXL!#YI(,1@:,7S-W0?UK"YNPH('CAH[)7?G/8&6.J"<20K\EJ?7:#,T8#&P%
MY#MUXMAU44<DBFN(P E*'<*#Q<#G]!F,)I3G0!^4&0!,[H"$P:Q3OB=6-Q[%
M:B-URLW Y(<+S.A@<@/L??C8?DGMRJ,C,+=N)CP'%O;-004"++# ;87=\)Q+
MYBOP=R"\Z 2D7+ D- E^-.;1E9>;*%X</10? .#L8'XM7'8BB IK7=C"HO%R
M %><#\[$YB[,5RHB!]J=&;R*W*P4&)F;A67SF=Y,;1Y-M1O@ZKFPJQJ1KN(G
M=MP.Q$,[OGOJS%@\@@6X4;,ZXG :Y\>#+%.$PH6KD9/^5U/'27E%QQ-G][E1
M@P9W6"-' +]''R$22IPP,:3 CE=!S)G<54)*FUF+V.79%-&()5QBI*820I-T
MAR*F2*8GQ[?"6!/]G2@,+#8Z!TX7V3=LJ6M^%<CIE&F;-N2B;*6&!A9/$.(9
M.\N2%L=3OK!GYU$@>$1GY,ER\6 ZB@/'CC\F5G-G:KPD]S<=PJ?L&(PJ6I.7
M+9>'"I[B#/0K:4*/[%SK:W(++*,U>[)0WK0DMA79!4P3+SLL?/HF^N4VNHQH
M.>Q-[*';93.QNWZ'CP&;?YU86,T6M[)$;1CQ9O%U$[YZO?YYK]?4#2/SJU93
M_UGRRB%'J$*R&5S]IM%N;X-6H<^-9FL[W$^\)KTY&&R=J6+,Y.^IW>U*!D^C
MV=>'\L'S5)6H9+M7GEUG)G5V$,Y!\+X<[9YYO49MK"=0L(#%.<UQ>@P47%BY
MPV0EQUVKX%73LN]8HW2CB%3E\4-)Y.KZK6OF!\0WKZ44LP>33?43R$6X]3<>
MBJ<-\>JS[]A]=A8N@%?9Z!RN5:.5$B''Y1O9Q156/RA2_?OX_%T#2'5/ :E3
M4?&P=JJ5G_B>D5#9H@NJ7Z :I5"E1DDXZL!BZ+NIX>J*G>>T&EO+[C[;9J;5
M4]IQ@MH'$J@\99'++6J^;=O55YG-WF]WT.ATC+*Y\ 15R[<+PA/5KRWH+YP;
M^Y1;55Q^]LG>;[?=Z WTBR)D*?13V7LI7G9\'P:5B6*'9T^L<DO(XU4%KX$O
ML[TUM6P>RY><FZ>KJ7/*CZG+J%V(4QYSZU!O)6MSU:NH[%WIC4ZO5PN71)YF
M??6DZD.="#FI.J_!4*>MFD&6;/5?8KM8HU9$)+>HN6AK/+L#?!VL<7[=H'9&
M][5QP7;W+K$62>5Q3GI)LUL+8S6;W8\=KY%-#V3C,%\/U)=:<ZR'9E_1S9G;
M#UN!NF\,O%:4?FVTUO)8%9'O <C1PI>2S%4^F!JE1LG,3+G1@4+WV_9P2*,7
M+]]'-THM5+%5:/)B^J),?E0D7V,G156XK >TVVTK?[50_+ P.4MD-.6<O30'
MM7!F]Y CQXYX'D6FU<$-KC$3Y!S5-'?-DE'D>,G>]2X0W_>(ZGRXZUK?P2]7
MC*4\^D).R&M6B&I;%;OA:A&[8:FN0<H:9[,5;=YP>!Y7Z?2SX_K30#::PPZ"
M-:Z!KW>+%\''4O6L+J5IV1:)"C'OUA9B-3D/7O[-A9TL/_W !X\HO))&C\)T
M6)$.JUGRUD[VRX8RO.=,6X;4M+5R$FSY&FS"#'F!4N(7)@U IC7FY=O7:&R7
M_GVWYTP*;:E)(2?2LD824;]TOT";P[B]Y4;ZT/:6<%&WD#'K<I!%:46+37:.
M76QR8Y3KP8GZBMB\@.XDWG&J44D#JW-B@P96RG.C*,]A4P _EO4,GMW,#E)[
MMP3)D.U;"OK6HDAFO]74N]E?[5H2L%"90BG-PN/DC9^J%*.,Y2%/3@LGWA^6
M$^V=;']UJ2>U,6+X& G^1-4])(*_@),I;;)Q!8$E20I'RC+'.<+V(%$1?2TX
MT-"95[%QL1=0UT^5FMP/;KTKS7.?5P/0=0'AD4N*97.<;FS@.&D4=G&?>KD
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M5:..E<Q<VXR>N]7CJMK9]^6%RX]10DVB,/%/QZF?5CB7[N3IWD8]+N?5K_U
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M2L)"2QG\6B-[GNW]:VP=W'/KX&X*8@G%8!56?6R3K1DM)%H6&C8HAGTP\I/
M''?FF7@:N9[G/L==-3:+IG1#C4@PB^]8&("]BS7+B*_(B$88F@7..Z@!WR>@
M=9A(V&B(12%,M M'[A-M:H\@_C^YL)A>)%7O06=AT)@)^%2%\@ ^2 )0D]!C
M4:+T'2?\#U^^"JSH<DK6BB2_E'27QV*@KJ@V(V/MIUY*K<)80()'GAVV82M
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M$?#&99+$0>Q7SZ@.5OW@I"Z[5^]HQ3O4S;NQL7;L&?+(:='-6*A(HAM<$)P
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M)+",S<9("B)*<N*"2^HCSPJ9/OLAVX<\XNF2IP/UH%'GZG;43IK_F0GG.I=
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M$W.Z&(CE5A+C@1N?&*,*VR\Z$&)O3"4V@SK4%.+YB8EOAI!J&7-QWL:/0+^
MW,35OI#:U0J!"(1;$64T+ABKT8\:[$+5F\UL9-(@ZP.-)^];\.-I^WFSF?14
ME1 P9"*%2B89!EIB=V1:17'@N:T.=Y.0B7"BP+L(J>9E1ZNQ?P)BR]#%[LGR
M;Q0@>8>YKP4*!#LZFI; ]8W_7!,=&^86A" A"DYXELY;Z9U!WZI9CZ0WWO:)
M!%AC%4^5.QJWZ['%#0!D*GZ<]K&HRX/3B06.GM!]-'QOO&AD;1\K88Q*PU?#
MLG[6?8)%;JJ>UYNOS[LG:2(C3C%';$XB>L,9%4OGW=?4_ATR8F^\7B2-=REP
M##:\N?'MK8^?OS1-K9U4[Y>AE9Y?41%7^$ABE-XHQ6(68:?^MX_1&Y<53^.(
M0L70<;$M[10>FAG>5_UOR5+2%(B75M5+=03/$%Q:;INW1L^[Q^E-.P$\72,+
MMPL']3J_:,9WH[$?_%PWCQ\VMLIOX[R10@G%[_LH;! '!5:\:I9(UE8":.Z%
MZ-";/0;R/N323XA<E] D7CYNUMQT P3F<GD#4FV$X9AV()1#[T+Q%0"4NJ2M
M4_):$ _9$*J4TEYIR]&CO544O8F&CE?WVHJAXT6-V"?R8QE[U'Y>T\,@,4JL
M"($ Q"!IS+FLZ<C*?CQ^;\(@/#4?+5Z\/=*;43MY#^WMEP8&*Z9:*UM34YY
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MU/;J5 OF!/J9X]VH#MS4??H$0E84.H%J#_TJ@,+D+9@H.!*H V)BX(ZGJ)G
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MF3%98B-W)*B0 E"=BW=XL3BSQXF(DWB"II%>^#52:.+*5\*"5;7):!(9N['
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MQ6\U?P*LQ67 90A<02_P[[0/60MB=8D@L_?6%.IYAIXC0@-_\>O6GPJ!T1B
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M]2(BFJS)4CGFE[Q/A"9BG4WGA.5T'EE".J.PQ>P6#^,),"NT5)Z#8CL7X#,
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MM _IIED830$MU3Q.L)3G[HR^.[IST4PA/@J$+DV3X?OPT=OX@"U0E3) :HP
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M/9U42*CB,*2V &,:N*8!>IP]O?Z44B&[>=T[%;+3OB-FOC7B^IX*N0-G!Z;
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M6^N400QNI7+GQYTHO67,F?=-_2D&O+-JOKQJ1A("!IHX!Y#0 3&+M=]L[]!
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MPW+#$>DM 8HR"Q@B E&EO=^M?&-L CL2$(KRUVFPS+S]&BUUO;IN!N)@&DQ
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M@!;>+Z_B2K:^R&EYL5CX94L"G88Q0B9Q:A24,1D\DD[D/C]IPS*\[Y"+KZJ
ML8?9DWCA9_;J6L\;=_V(-U'VTD5'VFAGJ&4^>__/;9C.QH7(:OP"-]'4\=VA
M:WXC&O$-M4^Q@>UH-BMZ,+I5+AGH&&+;8@M.ZP60(N40&"JX"UCXS<8_)RJ7
M_3<PQE-+)PMY#UU:>K;]/*\6B]U2_?<OI-]:0R]\7,X)I\ :ZYP*#!NS44C5
M<%YS%$,Y@AV67N*J3E@9!7RR+B/4_$4?70T8.,#.8L(C0"-SW\+=A6?T4\:W
M6;KR93/Y<'*XF$ZK/])?UFHA(8QRC>&I8<1P;;5!.G?*PC9,YRV+PTQ?P-/Z
M-4ZX?GD[_T8C+YL!7X2EG[>"=CBEYJ6KO1TDZ1I=$E3NW>"#@)Z)B,J35"#%
MMD7YM>,3$Q%1*8"3TDI.F= B=XO;%BAGHHX<ALY8G-CN@]TUOKX_!*MAQ"F5
M)D $J,$^3GR<2((.]:#KCSMQPHM9MD0>[:9[_W!Q:*V)OH^NO28ANO:<.NL4
M"EAE3Z_OP'/BLLAN\M94I:(]Y3>N-GKTDXO+N5]WGL[17WZ/QQ3H-7_H( ?N
M.X^U!@IZ!ZRT1& )@S39<X%&[#M/XE=2<0,D1I)!(Y5EA7.RC[+O?"?/A_2=
M[S3LV'WG=VT%)*$%B@H/E+,"0HEH<#NIX\P:GW63N6?CLTZCCM7ZJA'4\VU\
MULW1(3VP=C+P6.SK=-(:@@3,B^AJ"4RTV^DD^KA8[]GX+#_IG78=Z]I11PU0
M1&%@.+3I?YR N?-83^G:T6Z2#KEVM-/")1)/ME>8R1CF**0T$ @13PE72A7N
M3G,6BWHN$Y>OW-]2(M:([GN![NX$]JK"W,GZHQ?H8HGBVA=HG!.))H$K+KX7
MZ):61J?1\^:*O/#SWQ=7D[G_12^O_M#?FNH_4YVGF>O%[[JET).GJQ\- MYC
MJ9U$0>_05OV0)X^^&=F+N&HXJY?W*';JYF9#='@,LX &;$0J9+<L]]GGJ3?>
M[.-S]"?A:!IO-J+\WG@S \-9FB;N1,_1--Y4J3(P()L2QC7A6#A8NHWBJ3?>
M'$!#G:R,W'@36P(,5 0H::D(FB#"LG>$.(/&F]T<]FB\V4G $53FJ! 'KB@!
MCE"M*;+.V>SMS$ZX,F<_-R:G\8=(T-B2?]V([WMESL&,]JRUV(F.(ZC,X9("
M:1@'4DA#H*5$R.*Y/:=8F5-4+9TLY-UM.2A7]6+F/OJT-KO;XMF6VE8G51Q'
MD "3N(8&C+7>H0MT5DC'7RG3379U!$R-W!E-N[2K:8%TRC#G1."H?+'@271&
MZ^OA'&3RD3NC-4'[WAEM3PI[=$;;Q?[C=D;#E@&-$016>XUB0&AD_KN53K@S
M6B%E=)J]V)4#M4V"CJ;U/!53&P<D4DS'F5)[N]>% AW/.@(WXU!F&F\+R&76
MTM61RVB"B.Y#-9W8N_1L[YYFT]< (PRTT (0&2375$MH<\<X>X,<?;?M;9:D
MX[+D%+CMIBFE_^7:E[[T;R?7D^7%=;6:15\[V70RNZR5?,0_I&0"4.B,A5A8
MM[E+VS:I[/OH$Y?((!8?PO/HJ-.QC@(E$8TZ%L1)J8+TV4]Y3K(T:K_2A5PF
M;TUHRU\:]6;VU2^62<R+1U^:;R_C,GI9S;\=7 RUZP?G*G\Z:""9"IX^V2OO
M5E/_/CQZ=).F$+= >*. II( %_T9JP(7V.>N1>Y&U'=N:?STS5!_/5:MTF5/
M4  KB*0!>>&RM_UH1S-4(51&_C?GE$RF'KLHZFXX#X-HB//6PU"4 \GC6"2C
MA#'!B BYWXXZBK&VRW+16V4U<P%WY"FBVTGY-DBK!6CM" MMF6U'-\[.65\>
M.V61C82CD$MJ/: 1%L +&Q#ST1=!N=,*QI+)EEVTT572:?L"ZGCES7*= [/N
MI-:,B1,+=$0#F'5&8X2HXKGSD)IP#!_+Y.:KRFSL IMI/_TK%8AM0\6BCR4=
M18!JQ3VAUK#LCG8SDK,300:#EV@K5LV7ES&Z;H&#+ 5:(P<0#$'*8! 1N;<U
M-B"<'?%]3%R@+N]F4_9MI6<M@&CTNS7#(498/!AH&$8V=T^1&HBS8[V?F0N4
M0JS;TK^M9I>?_?SZ4:C4C,Y%8!+%6(D(Q)0PG 25N]:N&]'9*2(C 0723#]=
MQ6EJ)V0XKDZ2V>BN($.0H1(JF3M,:$=S=K+(9/@"R3E-R&J8I(IN*T; V<"]
MLMQ8#@<0P_ R*+E#V=?0!>*#AHFJ%K(8#*0(%DC/*&*IZ3?)G6[3 ..LJ.]K
MYJ(;1S4HCBL@M4L=*HGRQ-(XO-R,GRO3AYKUB$XRW\SL=.4FL\N;IOQZ^G/Z
M]XMB!YQ;GC?4N><^PQ[E.-1)F.[75H!:2!4S(:#L5W\>RW$H408H2#600?N4
M-&08'.3H]XB/0SOY/_PXM-/4IW,<:GD< 4(&H'4UL40Z^-R]I4[Q.+2;WKV/
M0SO-?!3G6XT(OQ^'[L5C[X.NG4@X"KEXC8!VP0 KC$=.>>M"[N.ODST.+:R2
M3MN/=!PJ(05*>0.,0"P:P%H;<N^+G^IQ:#=?!QR'=AI[M.-0HA4PT<,"##D:
MUT\O.,K=0^ITCT/W$D$&@P]_'.JP2/D?%FC"$">!:9F](O4$CT/W(KZ/B<<X
M#D5Q7)+"N-*ED5',N!6YKT$^R>/0O5CO9^;1CT.Y07$Y"AY Y"#C@G-1YF+T
MDSX.W4L1&0D8]3B4>!>7**L!%Y!8R0@1V2]%.NWCT+UDD<GP!8Y#G^S^OISJ
MQ6(2)K:IB=U-?H>/'BPT"G 7$/(60:IRITYM@71F>U Y"2C@273 JU5GMP,L
MM!^U%=PXVU%9*=U=+CWX*+'YL#=0IH'2# '(*2',:F:RWY8PDF"V;$P=EUZZ
M:"BMDU_\U(5J'K_U[ZIE_%$Z7YG,5MZ]CS/US77GS>NF<00HSCR@P3!++)4B
M^PG:@5"']V8RD]XEJ4*,%=@,>S.SU;7_M(R^75JZ;QN(?;KR?GDQ<Q?.K4G1
MTS2&:95Z.RQ>?'MZ./[XS+QAG(T5-C*.,G &F!-&*<X#SMXH>9B1G9G?=81R
M*+ AL!?@=_JZWG*G'?803MWND,<Z>3P^%75-UX4E4-H_Z /? R.\ -!C3JS3
M2*+LYUS'I-RMAZ'/1[@=S&?N/NM==+/F_L)]U>OV+@_]2E^F%+U?O)XNK])O
MO%@M)C._6+0=&%@I@.1< 4H%=(8;::'MSCOL]?R1?=12[%9#4U/ ;VW:.[PP
MB^5<V^4FML 84,8Z $. 'C+LE<D=0W?A.?;<YOUR"G,9/F^?MR98+WR,P5+;
MY">QWN?JR4MV$36]7*2 [74U_Z3K_K.P#$@(*3#:2..X8U"RK9-./CPCJ"<;
MQ=78_.1=R9X ZYZ<7Z[F\SC&1Z.]_9O:Q!D(T(%C8# 7A!M*>7!;Y94#R7D(
M:W!."APG[%(41J2-8;P5@')CF?=20#K$V>,9J"2;F0ML132<BK>--8X.2(OC
M6!&7&G*+B!^@!N\LO9A<9L^[OC2@RK-&,JCC:^()H)HP+XSA7&_W8;+!&5XZ
MV?BM1B9G- ?F736SNZZ7VJ'H@CD/@J(4.B:1HB:G#],%YBS$-08Q!1R9'4J<
M(8N0J!< 4VF5D$&Z[%N.1U%)GELEN6R<T8EY'-==S-P>(Z8H^FV($&"MDQ11
MSA1#6V>,'1]V%IY*(=MF?.DCPNQKH6("2*D)X-!AR9BQ)."MNC@A!Z44K=5(
MG(SFGW1,?Q9+8%B<3H5E6))@M?+;)Y?#GGU.RAG ^@5\C@XH'HKH6<>!!X:Y
MY2'=1W 6/4P*:Z&O:5M=C*)]3*)L%XO?9G.?[C/R[N++EWG\)S?Y7?[AZ_3=
MXZ)$L[Y$JPIO%HN5G^=H<)(52('.)^4,E;TERL77^)"4U72[-CV@:?6N1'!
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MJ_=?--WY975][>=IJ_W7&+9<ZDO_MM*S+%G/6SZZ0/+S/H,9)0<ZI'QWYPQ
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M(:1 #ZI'<)K?AD9 A9R:&IAQG)=>%+73W<.^!1:1K<#2+;:*A93,SIEREL$
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M]4-Z10S[<O^QM(M5GE,6Y/-CRIY)DO]DB')(*\MX-(XFVY])U?+P"V<22&J
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M1DL*"6R38+S4A78.G-@:FPKHH-!P 64)*7&8E)24@**RA*NSG+,B7![N=D1
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M'&)^-8&*!<89C<'ZFJ)1;@AOT# V<)<_$GQO0@NLR_=6-#1'N2"00@*@+51
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M7JXK&"S<TRT^%SMS]M43E/G+%HZ4&;;B?(@S>ZZ@Z4F(H,?AZ:X;VKP>YTF
M%GPSB00\?3^1M@6 ,\-& \&/H$$"/G6/XM9= EG6FE@,B?=( *?5V\U6S6&U
MVJ;-0@WY#V?CA]($UYM*GV"WDLO6WRITM?9NY++<OH''?%94L&=\:#66$2)K
M>)SO(P8#==AG>0.R>B#48C6Z1[US+'(T&I\P-ROJ8"?:+1);?/-ZE/6UI+C/
MD:.=IX4BS)!EQ+X[B$"^X6>S$P=N)'FO>'%>OIQNY19%A[[]P;1!+BJU_(;H
M/5G(6VA,,!M6J:R\LDK@=O2^*WS.VB+AF$QCB#F-PPUP1MV7=@!/D%T'YS0M
MOF=@I+N(BUD&1R]GITUNG@( &B?9L#D0N3DT.DD",C5?=5[$B;5\.]$0@I.,
M24UA75@-VDR>0C[O"],GWM*\,K-54AIX65(QD4@",-TNV&C^'AOX?D]:S<AN
M@D%.Q@*+I91*85:,7W>-9HCXM7XGU"K1N'@TM,8KN84B3BVVN/"2/^/8 [2G
MD-BA,?U$:X.H)Y[+E=U/)2:)I='@&C8=]Z[D&Q6XONI^H[DUOIX\B-EZ@_^2
M.\>YN=B+:YA3<<%="A\L4R>>Q*\L2XZN@LX*:P,;JF=$?;2[5G-I,NR5YM*5
M*M!W?=JE-[U6EE?D5E_5QYJ]>%1+'GZ=>/#CG"0 94X\@_]6KMY* FH33(8\
MPA)!Q0UGQ[?$Q/%3;4M1)K/<^4_PPYRXQ2/$<!(PO#H/KM(QO"4$UKJ-M 7+
ME56BQVE<PZ?)"27%OJZYTU^=,M<[1X@<320 F=='KAA<,3YU]PYM+*P:WU+/
MC5FW/(7K; I/2OZD?K:MO(YMHZFJ?*Y_(ZV8J)GRTEEC\<6J)F+31M!$9U43
M-1HQI\879B__N,;!M+;!I%!TW>%X;ESU4Z6>;'L;@P.WFP\;^4X*< A@GX*K
MT(O6N$^-#> (.7,/%TD4MWG*1 (BSEGCIYWC28"A9 GQ5(C9$@EH)SJ&$L_E
MDH#ZVR!I,@E8[P2#$QXHN)0$G;XJ<:L22X"NXYH*<1\X8,05&W!-A"(!T^9A
MTT3F7<?4GY" ZN\TCLC,#RFG0G0>JC@](@$W<,%@M,-B@6T!68)QEQD/]FOV
M,Z5%]J8U:$;@=C7A:(GBFZ(M*T.!5I\6/!;>9CJ<60'K"M\:6FU>G-SDSWN:
M%,95YC'OBI#S3)]JSTDJS4?8T[<_@I[C93C=&/+O]>'@WP5!ZO[?[LKU+$P/
M(%"+9@-$^[-1$N_&MR10>C5%+I3!25=&3$U4S.4A^A\D^6."'C3?)I80,DA
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M^7'\FJO:?1I?60A5)&"_"0HW=FE\,YSY5GU]W6 %>O7"EF97(?_7 J<-K-L
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MRV\*'RQ_G!? /%R=GB1M5(MNXUHGI[E[#E?S.1;W\)7,WY&%=>,Z3^Q/'%5
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M9".O)V_E:6T%8C,P>,W=\_-#R<V%2(66[/OJ"J_/C"&Y]'UGI.U(R"(>OTT
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M7337<*HV[Z/?4ZX%MP"9GSFJ/<VGN#ZN")CXGC%P,15X>%Z-_33-6IW*>4P
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M4'5)G3\$T"J:11;GEV45?:5*?3"J,_(F@7RT0]7I/:N0? GP-YA.$0-O>JC
MJNEQ=!KQ_KJ#\0=.A5]K$A,?\?2E>A>P<[7U.>4WP>,-F/FS2Z^2Q<TUV< #
MY)!Y<*YYFBY;O9?)Y2=DY6U-]+.H3\]IQF1=V4B+<KYX[MYRX8'6<CN=,[5"
M5]N7/ ,1A[I/SJX6 [KK&2XK7P385J7/P-3\%*]"F(DJ$KCORIXHB\C,UVB+
MW1\&H\Q6,.>5#> *46\'4%0;_;?I]-!)7"AUHZC-=INE^]ZJU\YRZUBNBX!
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M!<'5!QJRU:Z/':BH:)#4' GO*]Z0D]H85KF^!XS4MXE\7J7 ZY)KH$]T7?\
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MK[>UP H3@YEF3YH'XT)>TJH[D01J^>6V?_RX5N$9AXZVK+MA6 .4XJJL4"(
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M&QJ!9M4YY%NJ.. ;(L_L%JB267^)S>LV%!)-3!>%@HH^TI2PD8<T/ MO!\@
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M)2*V8Z6=N?%BUZ_>>)SD<>@_7-7S:&C@X7[THP/\(;!M0OYBY#1151?7@5.
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MZXPR-L3O$@ @<:0K-MAQ9=YLG:ZG,ZGTF,<F<7Y^RRXK=LE@Q[B7^557V9+
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M#@658Y_UIZA9U=5J=;WT&A/ZO,"@;S"J2+!E!#6B15:;DF.;SJ]F>9S+_\^
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MI4((!75Z<_3]5GA\>Q>$?B$3!(5&O9O%^DP>VD2UN1YNQIBE7#Z0^*,.!HS
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MFJV)4N0  [&HP&H$D>*$+.G*5L2/A$\S'>P.;_)6?_8^EM.V%X0R4NI*A%1
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M&:"$TB2U]<-#=S%JV=/N]P9E3MF#=W9.KHQOR2[-;-?&:^\AU"*3Q0Z+'3:
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MEJ]/\*:^?C71HRBZ^T:!R6CESCB=ZUX:<G#>:RBWD3->Q["GMK+F7!'.4O/
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MEMWBI3[-M>^#<]>*K&O/GV S)GNN6%Z+[:Q#E90.:5K-6R\BQT3_L6X8?AR
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MG4XV ]6DE#=6I[;?@5JAEQJ1/<TO\48*+P[^WB]5('/)-H[M2UT.QC(:7N$
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M:.L*55?)T?\8](IO.4CMX;+7%AK& >J'/!H')[WH30;];LEEJ;5KJFD"2 "
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M7*A% *&D\D1OKWM<MV7@[RQ PF>Q:D$K3KZ;)_,T8%_$^2!U.=M&E\U16LE
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M9GY;W&QZH?SC&X 1#W@OFX-9P-+XI/ZU?/5G%3;XHM[TT<39O-X%# ](Y?-
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M+=)MPE=1\1O.^=)=1P.74&=.>7CGG<H-E^#$">/%BL2,3Z?/0R&MA;5TYHI
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M,;2< SNU#@J^^FA8H_0OZ+(7#FAQ-<J(XM:%[YV<L&@?F')[D'?1WWU[-'1
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M&+$][:8]]T4(*\ZWR'2TZ!$(<SQ !RBMR>> F,RRC8/PT4GJVPH(Y.NM<=A
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M3P"DIO(CYPHP;,Q(/P/&Z!8>@!KU+&]U"CC! S;\-TPOM<'S@UCVCRLR0*-
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M[!E@4K/7X,&NIHF4TVVPSZ')M_^S1/&_JQP]>8<'_.%,@*MW,(1IZJH@P-T
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M==!(<OE+GNGSH*-D7^T>]0\$,KAP_\+HI<[ZF9H[<+46/JIS+!$<3Q6J>B?
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M.,UO'@Z?6\W+R<[)"RTH@D"*TN-('!Q\R#,4O73DM90!#Y .D9Q<KD7VU!\
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M-SCLG(CJM+6DD"Z>[R\E1NRR.>R96K-^]E$\MQ6[5UHFV9"W?-I^T-'=Z!J
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M[JO0]62C'6W!G&>E3[YSEP/Z/[&4H#TD>S"R?9W=(68Q;<A5]&P0@=FEEVK
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MU!RNV-%TSAI92V:J0\4[EXR'JX3D./RM7J&-/:T%>\4C8_(*X90>78'O5FS
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M>(S,[U8<7O4">515;DZ[BC<\R>=G-EJ&P8: ._<2*.[? $@R=MJ=7@ /A(D
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MW3K!A?)4A)_3H7PQ.4?W)5Y.>,* 1]%$0"K,P7F[+@MXDIDGJBL04X2ML%Z
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M)0,JNW(O.\0Y:,N9'<^ 8>47(T3 +\[2:0=#$!'PMG5GI:;?<C[]8ISN]?R
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M@ERY1)LP@'9RKQB(.V;W']-I3B*@[1-+UP#V/A&@XGWU\%_J5N-\+V6V$RC
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M.P%Z"FS,K.S-M'-NE8>G<<TJOM%023M\PTHY]-9!.G$].M9%NV0M](%?&]\
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M'?AZ'$7:7A'"A/[,0>.;5=_%%D@?(V.PV$&JYZ+'7#SZ<@ON&:)4MIF.@9[
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MS8\Q+,_#Q"(4>S%E/YN!9412X14I:E-_O+:T$2>.F;_<D(<YR<.(R;G"VG
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MD[L(/:_MXD29MRXLWE\!#3'WI!Q6P+,$A*E:OVS:=*Y7&K7&EWLKS=?P\I0
M>XTN3UX UX;/9$7CZZ\TVE1L0WB;)&G$WM@/&;C[Q>A"$VN-H(^V#*"6@POT
M(<\K/NQ:7GG&01E7**UX0'<[8U"@W[0WS9"65TD-QU>?336E!>VJJ_Q-BEYK
MG<"9/?&2QE1TGKK+BRK)EVG^0)^XP7V?KTB:[85S;;R(31^'D>U@:KEQM+ L
M([!!X5QIRA/K_Y8/M&,$;3E!#2OHMYH9J(,K#:^DJSL%:# CH0LON"\,E5V7
M5RQ-=U[_& K'D:<,7@#>J"-?K=(Z9Z29^L'(44:4EA_3C/(YBN6A84E,$Y/
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M,[$\&L.F2Q<0P%V@%@Q@LV5&A%0;*=.WZ'R39$;$VAL@,W:M^K[K)BNK0N3
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M4KS66_7;ZID6_)2OH,^4.8<O='<:?ZB7KN?@,+0I=@W/M4+"VWXYOV=TQ-&
M$95Z=[<CXX$NAR",HBYEM&1$I0?70- ;UM\)4%'2Z"T3;<2MQFB/C_UF7I.
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M7?Y0PV#;X^J")Q2\4+1C$C5<HBV;B/.IM#<]_UG)[4MG?0*PS\$LX(/WKMH
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MS<.%02\XO#/FX^WCY4=T?_WK]>=?KA^@(9A&=MG("EPB:,"DIJ S(K+/L[9
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MJ)@QB0C;M?@^)H%)J4UXDIA4,^F>]:=6E;K"3Y!$+4UH'>,^(,-JHT%,F.[
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MGU&(HAZR"TV:@NV%IG\H;A#C(&1NJV4$YH(FS&FU%\U#N<[B?YY'TC+[3_=
MY':U;PLQ['.]Y;6)F8E^>S6#:)\9U'*C;Y,\'5":=M<3,#CKMGPZ@ _W\Q-2
M4DUMR)X>:;':G2.>.D<599A!1#%Q X\95QHNB!W%<0#*[1V@-?&>@U/&?,@:
M-,.A'QPY&Z=)9)BQ$M)RJJA#=I+#20GQM&5"]%.:.2=B5.3C[(CQ6\[I,]0Z
MS>W<W],1@R@,L4], \<D\HAGA9$3R'88&24VL?[N-^_9;91;)L[JY],#WVCL
M0"LH, U_"SQ4^AV=CXN&_D<G\-'=$FE83ID623TKO$'+I&%93K=0&KD';-QN
MLG)3\*T,+V#:J[-NNQZGM.0.D9A)<YSQ%5-FZA8V=D++BP+?LF(B-= .3GIB
MP\<(X882[_!2<R8"I0?EY\L=<](Z?R;*CD\PVV#;.#"2A#JAYX8\K7W\7'=B
ME.$'O=\4RJ/?G0FQ@WV%MHS49;O[4'5X03MF)D--^NLT(7JJ?:0HBII](")-
M^)N4[6RGL*FY*T5E(N_AQ/]"EDL$?6/U!*L5\>O]!D+7F^N+J"AGY_NHNH)B
M>Y:(O7R;):__%I]B'EHOZ#/-RO2%=_[/5WUE?HL !U8<8SLQ ]<)V<-9F*!&
M+;*4)S]8W/+1N'M[G("ZVIV-*C%,'+K4PP8-DM#V[,1PDM]?:!'F;XIKEP-Y
M9&^O;M#E0<.Y.R)OT.%PRH57)H$(]A$<P&:">91@@?]_\MZU.6X<21?^*_AP
M3JP[WL(L[Y?])LMVKT[8EM96[\1&?^@ 25#BF1*I(5GNUO[Z X"7HJJ*120*
MH+SQ1LRX;8F%S'Q82 ")S"=U$>%(RUV7$@<*QQ$Y#G@ 1>^\W59_\K7@4U5_
MJ'9)F^^V3+98[">]YHXWVIPGQTTH)DG,_O"2D'INE&<1S$-#I!OVTF30I>/$
M'#8Q]*]GFG+/W5%L];290.\" EG2PYB"#NAE>I&3_I0;-.HFD.S;5?)%;H.N
M%[;;<,>C@H,NYP.2O:X#4H'ER DI#:+FB/8Q:$X+V-/=%_\MCBQ'.QGF:7"8
MQ.R$'R4)MMW(\AW'SFT75#ZW+-*PRWEU"Z)4ZBJ!FIP[T8L%]+@.@ 'L(.0M
MT^05) 2NZ@KD 3B<_X!/JDWZ;W2,$3!_P@MZN$-9[AO7'.Y$<L]AIQHOP[9C
M42?/0W9<=.#Y3LKZK)+6])DVS;^AB8[[Q-0Q/E/OU89Y$FVOPO=S'/G$PWY$
M?.I&@1/9,33+:<47 4YFNLJRG_ MR+GY57"%>?\IDA.=9!N-:JSYN1@<30N(
MNAZKKBL7PW6XW%P^H %2!W'ZGNQ0#K,7J.MA0G(;DS3.HR"DH><"XVD@^<9C
M:EV$LF%ZL./:+'4#>O=<%T^D+K8OJ'FLZE9D,4U<X7;(;$+%7GE@D!/V8N0\
MH#&P85Y/@M"A>Q$3;5;B;I@#80VNAB/9/P\WPQPL("Z&V4'@S9TZ/LSR87(0
M%X&6_]@1WGR9,PSUB1"B4IX\T&]\XWYXBG9L"R<.C7$:1V'J9V',MFRR_9T4
M=3!]W]*)0EP\ZN6C00$D-)!O(:0*\^)M^1K@P7S2J-&K8%X?ONNU>EM0Y5LS
MK0"NVJVZ,9!!_8@NA&>^)9'JP*MU);K0\FECHDN'@O/M"$(408?"25/&SDB@
MQM#''S?LCB?4+EWVB-! T+X VT6?L/R\F]5D-/!*1#20WALYX;;1V$=ZWB+U
MAM(GQERWL_2\44<MIL\\JG8*[ I?]O18GWY\+:ZKYBB[,,IS'%MVAC,_LTF0
M9XZ?2Q6X+PDR/ U[3J5FSPKW9]$^LB,=R?@A+J/\L,9<FHB]C/WW@#>=LR#*
M'<YT0 .;K#TJ>Y$;].D_\=<;MB17.DOEEBS3=+B:%;/J.6K)V,,CT^+S"D4H
MSZ1FSJ&_K?Q:E;_NB* 1H]G![TY4I0AN[-S#B9OF.*!9[&:V$_B>+#<V7+KA
MN3\(1;W4#<]\Q7NET.$#D.;:8*07CT9F\8,Y"#AT*C4N8 P!12\FL52M@M'V
M=835Q:A"<:90!CSD>I4SJM:^*J51'D1M%_:A:)ZKAFQ_K:O=,V<NS:N:QZ*_
M5BW[%<\A+\H=S6Z?V7E*$*H<>6_?<]DF+<MP8A$79VZ41"[U:1:"<D,4]3#L
MQP7'+],$\\ B;&>F"JS<QFT%N&!N>U ("8TVZ!5RW-^PL]E$,;37S$!R[(7H
M:-H;JFJQZM;Q0J@.=Y:7#@?>>%[9EF5]*;9;-ICW-]^RF"3:?-A1YBU;,;9C
MN=;I+6<6.#B* QL[:41CZOJV[<J&XB%R#3LI(?Y_(Z$ RG84C2H@KH/TK@@$
MY>*>TA1 ,+?TO^P-4P,]=7ILT"NL/AQA!=]*@D"3WD2: D]M^P@$4<O>406!
MV5TC:+"U]HLJ%DYVBDH?5Z2&Z:O47CY5]:==NZOI7;4MTI>>D[;/1_X[+1X>
M6YKUMX'"W;-MZC>V8SW,X0AB@HGM4.RF*<E<PH[Z 2BD=[%&AEURKP#*>I&H
ME@Z^ZP-=;B>Y*I0PYSVJ)G+3.N50IQWJU1L+'-"@(1YOHP?LOYW#'LYTHPLO
M77PX%^NS+FN.+OB.N'6T#:SF),=KD9OR>=<VG^D/NK6=JS)S3V\^W=CC)%H9
M]G,OMETGS$@@Q:DM*]"PB[NOI%MS2T,DY[%T&@YS2/N+14[[QX5OD!"/[.$O
MSD;DE77_< V<;66MU^1>%L6MZCUDC3]T#M*? Y\_[VO"B?JN]DW4>4?NJOS>
M5ND_;IIFQ^_W?GNNRK[[RFU^1VNVG#T)/@!^L7K5WI/Z@;9"*=G3E1&QYB9.
MKRZ:Z,LO_+C&2*B,!IT15QH-K6IN<S31N^M/@ZY:U*G>SS+PF<W,.Y,^W+WY
MNU.D)S'X#K4<&8WB.GNV-"-UK4.H4<PFIU6S<E0K8--:J$*VO3*/A'W_7Y.M
MBI^])PW-[KI,_(D)S6%NK\NV<XE+?1S$GI\'*4G"$'2NO5PETP?;;KXW8K[3
M?^Z*'V1[-E7>%/)R6\5U\82MB1/=1C<JM#LB$?E0;'<M)Z[YF.<T;7E*GW@2
M"Z51K_74,6LL7= 'H;9RWXL56KD<6!> Q^7"VD96N'?QQ_"C_S?''\./_X>4
M.U*_.)8;S"3Z^!F.XS3';IRG3IH[)'-BZ5L76:F&_: 0/KUSZ17@ ?  <'D@
M#:+$?8L):,"W+?[THN 52A\.4%*Y:Y&&"W#38@(VY7L6>?@TW;) K3]SQR(]
MU'HW+%#K7MVO@#\,[\#WH?^>_ <;D7FA[<LW^ES51RG001C@R*<9CAS?L5W+
M)J$O581P1H9A!SE(1:-8U,F5;[LW!\YY5ZC)9)CC@UL+ZK6W8(]2I[VY,5?K
ML[=@U+3+WM*CBJEOHEYH[,[]@Q3;OOZ=YRQ==[DJU:[YK:PIV1;_33-.J757
M-07WZIP<Y/Z1E+;SA3WYV!QFQ'E>A),T<W 6):E+<LO*J!3+OAGU#$]WB9*;
M-=Z!W*GP[9 %>I6N*G%?*3&J.LFLVZN+]OH*\C<T:,SO)M@_6Z8TLAW4J:TQ
MV\X(G+J2\/0JMVYNGA%@CU+VS$C1D(X\MD$ZF3HXO?!=("SI>R4?NN@X93LJ
MDK@XLS/B4CM*O$0J_V\5;0U[[)[JI^^ER?[3-$5>,-=!FBE7. \V);NF*+D'
M>:3;3.1B-)>E0VM_L9)^_V=Y7<!EX""U>M]P[G1&]0:]3IR1('4:&KH;2L$V
MA;6)1&WMNKY=.K<IV,\F?1L3>EE;.[[*[:O8#SFEJ(U):,68Q&[@Q[F79+%4
M[>%9*88=^-C*#F5,Z@85HUL8J)3W9%(;1/\:?IL+&@6*MI2 B95/HRGG?2_&
M".8U][WO/@AX=)("2)FDN=_=:QEOTNGNI)ES/>Y./WQA;MU5T]"6.XM)XXPO
M['N\JYF/*;_Q76S-KYG+[&O%MJO]/]^3IFCXYX4+NJ?I8UG\<T>;>W%#0O]J
MWS-K_W'4/=A/V &>L"VB[]M9$CF1%8*<PBI:KW:N%QN'[\5#R7:)*:?:^*VL
M$M[\7-Q2=GE5Z#=^'UF4Z*XN!.7.P0E6,5W0Z%N7<UX_W;N$.</):^R5%;N^
M_JWQ-SLJA_;:H=^%?H@KB(2&)O(8UT!4=S*D49W?)J-RC=<PFY:YBG X_=/U
M([\IS^XHK<7>]E.Y]QN2%%!GAC"=JM-)1EST<'3\5%5M64%XH,Y!<-YU:K0>
MYNS.&<Y<FDYG)FFC$D/4N7%78XF2,&[*%"7SN (+6_9_[ZL[6O&>/ I3<.;C
MAJ??)+AR7Z&[C[>B"1D[T?8Q&OA4G(-A>1IJ0  V!66--S =%VQ5(VN;&7,]
MLK;S1KTB:UMX%)SIU:>--9^J>DJUR_[^3.OVY8Z]^)8MS)Q3ZOF)'G>'M>R(
M%WOZ[$3%?I[FA'JQ^T=)'WBOK?.S5T&ZU'<Z[K[34QVDO]J#9+%KIH-8],P>
M?^0!E0TJJ7QW4S"XYR>[*<#4*+<'ZG*F"GHW$G!S;7Y!@SX;)#3:B,ZQHU+F
M\)-.##.)HUIZF D\(<EBJHC,IHR!!UPK<4S5TDGZF/(0.KIY7?U5'-4F1)F%
M(SNPL4=IX"1N[*0!J'?@L0C#.ZB]0,0EHM^YS(OZ=0E<Y (^EUD+<Y1 0R_L
MR#6UQ4@'+B'@#3MN30T\WV'KU9.73KRC3B6I:^'8B5SL)ZF3!&[N43?Y8]^5
M'O =A$TU>-][4<P];1RB.LN.V[58(4Y2/\))GD<!"6V29Z T.%40%"O:]8
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M1]+F'SH7^0^J>8HO15FQ/=_+3<EV(_1$W_$LQ7'(_@BB( JC($U="\0.<RC
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M5J2<&*!EE;OLJS*[T"D.N]9:=YG5D^7NPH%4KTU_T')'3P9M>/E$G'DX#M,
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MX8;MH=EWHCVL_LFL&$>IYV/'MT+7]SW']HE,0TF]:H'\&[R!Y#W_B"#\:E^
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MJV[S:UJWI"B_5KR+).\T4:3O=TU14A[(/'W-$%/>Q=EW<90YQ$H=)R.!5-!
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M$[%CNR(2=3@/YTZ6[6J=*%L*2ZX=_?NB B1!B;LR26V2J;+ZZ7\ ')(YD 1
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M%T-V\C#$<6(A/X[E3MQK2Z+9OK 2?]JD_9'U;!^V:F\"-O&0+;"=BB/_9)^
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MO3VP1I/;+C47'3XA<L>HLJHOR0-95>U9%@3-;"EV._(T>ZZBA7O[/*LK=OM
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MX^2HSS0C+5BO)Z!/OF"[)BT)QN ."F)<@'<]'[_0O->-@-[$2_C$-:"JA$^
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M3X"RP+V#7%;,['E@L;ABV_1!1$IP ZCD_R&^75X6EGL76RRTW.;2"/_<8'"
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M?)HQA4.3EDZYY R=&):)O-!%R9]U0?9ROM7+3UIH/?<,<'_=7SX^@.NK^W^
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MM[=I6J!3K8/-#;0242U..ZT(YJC.-31%61\6;_,M0U7Z@0I\>JP+0P-&D9_
M)/90X&%"3;A4<VU)^DM'E.I6@JR(_YY!4S;MH63+W.14*F8]%U24G'T< #WH
M<O,?;5NM/QA'H&%)*RBTDC*TU<_)45^YODY)->?U=VK#2$><FDSDDEH[0@^T
MT9;\SA((G]*J(O@KBNF'0&T>_:&QCQ>[*F?GL_B69.0'VMZ3XNDT7R@.&60
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MHXCS\FNIMU5A5KH1TXL7E&[9]=O7O& 9$9T$"YY0<7H<39 !$48V=&+;\*W
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MR4,)+4GQTK,3 <=7ZCS9Y)8CFUG>$E!&/*F2L'Y)E$J^3H9:K:2K7X1NR=;
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M1&%B]D*/&B2O[KHH(@T</]KNNX+O=;(!K:[T6XQIN369AQ%"J]J":8%/%[[
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MCR@S#>.&T(\SJ\ZO?B,,_9 0&$5."!/+\$A"8A0XL> F,DYIX>VAH<SNT3)
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MOS7,ULEL]9W^5H'6U:U;[2"\VAA\([A>W0H>!O;53DDZV^26I%FY*QB 7I-
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M?_AE1T#P&5&I6)8+/?=23=1Q4O%H\_)3/1E>>E\3*&>V#RIO9^KBN , : 4
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M1@DF:X9NA8]\Z^A8[12XI*YE3H;S=31X6)PQ]%KGQ_G2=XZ4&@93[1WVP#[
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MW6E&O$\/(US4GQO';WG(^.&8)1*Q1VM_NIZ6 V)+/27=#^$IS=*GW5/]EW;
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M(O&T1H=J5((UFA^/" ]]8__ZFF\VB*G$"UH!(X"GC8\<Q<QF=1@):3?XZ)2
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M;AYH0;T($Q+;V*6.G7B)'9I^('F]")&K>7X4XO^.!  4[WB%L 8"XABD[^)
MINSG (T&@K'!W\P%@X&V-8X%.K'5IPM;P6M0@8PF?:NIRWCCKCJ!1E1R_SG&
M IV7HJ"/S753.D;#UO7IJ->[Z+4]9'?LI]]_V_\+^R,D)?W]M_\#4$L#!!0
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M3RV0VRB+8 D@G*F L-)J;XGZ*1C90L8XK?P&04E?(1> DR=YM,XRB8G;ND7
M&@<A0Q8ZN:]NJ(^K,TY;OR'WGN/$>3H,ZKF>9('!.S_UH9K/OM1I4XQ1X\<?
M]WXZVRV5@ F0W#- /?90$T&)SNT*'R2JD- ICV^<5P4%F);W]6Q^&?Y4UVX]
M#7%=3USK#!5Q8(S4R\(Z$JQA3K+,8-I-S;BN;V:UUX/HH  T7=63RC[<1LI]
M\R2SR-+[B:[N9G'O375ZVQPUD<1E$ ),2,VHY<J)W(:J*VWCVJMAD3:(?@K
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MN" <T42*P 5AN6U;)\+&/< I!H[#*;,(C#ZMKLOIM9[XR_!N,:NFOKW:O&+
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M^?@H1L!<<0R=X[D?,.I.W;B>8 &YP8$46<";[SLX6YVK=SH%D"9^X@(!:YE
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M0Y;=5!ZFJLBJQG/B,+/B1L^DK_G.7Y\+X1ZK.*YOZV8>(ZZ[;3VOC*) !1B
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M-_O+/DIL70LKS;3.?8,"&B,(,+$>0RT%5KG=]?-R..[!V& +JV"8%+"+G=O
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M;,7N!__=3^K[Q.^> "!R:PD")KT'9I7S%@7L8R"0&_>]*'Y#?7F.@_7Y]%@
M:M<7Z):.1(^O?3_L9S)8!"2+#GR 4DM/ S0N]U6<DPA]0QU_CL+H\%HK )JM
MAC/=V(+6 1E22*DT@99K*X?O =0#?F6T CH*?D-HI@# O3@TO_KYQ5TZ_[P,
M2RX?KIK:+>P\NBW/A8T[V=0L (D8 TP@%Q#2BMCL54.GD3KN6R#G<$6'TUS1
MB:BUICFGIIO:0PS2KFK0>IJCFA(E94L* 2,4.D%TR%_K-FRSJK4 S$?IO8^
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M"05LM8]E'+-T?/7(TAJ;F]Q 9X'A6@$DK25!"RE"[GLV^RD:N0@R'Y@R"KX
M&+VLA]55C&??=YT)HQTP5B#@"1<($I/N/&1&SU9"1BY,R >:_F(N"2M/::1U
MXC%)?0@T MAH+5#05(;<.;M7!(R[.V50Z"Z('"W=DJ#QDA):)Q_)5$DA/"">
M,8U8*L\:#!PEY&][*',7+$Z0[+@E3%]3X/*?^)F!E[S>*S-J.% >13,JC!/0
M2"["1G2_I7!I^]B%Z/P43=4YQ5: 0;A>F)G_^R**[>/WU,$F_K-M2T%#"@R2
M%"!NE17QI]SD[RRTE91Q'=+\^T<.B9<)G.WK*3K30%JC ?<2"<(4Y2[WGK*3
MF)%/N7.H^C!\3I![>0#:;CXI$T &3N(^# ET6FJSV5@^-WA*V*(R*7D_=$Z0
M> &PV33(K_+AKU95C.@UX1Y8BR77G :3_3+?3F+&#8@'#'IZ2;U ^'S0<__!
MVTF4J_N@'WZII_/;BZG[;Z];*T-K#+1R 2AJ,<<Z4*MR]WTZ@KQ"G.A^@#@
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M7LW4 +.^\0I86Z"Y8\ 13Z#$4%J;VR:_UE$C_8H]9]1(KY2O8-2((:D9)O6
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MSE]J:K?4%OXVY0B_Y)Z_L5/(3QOP>)W+HX8,#]G*CWZ91C;HVT-A*!8U)@G
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M+KU/4UUS]$ ^XS&3]$,>RF:1WLA$8: @90#[B%ALL0ANHC*7@KV12?Q.*FZ
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M:(O:;[GQ1L4M-QIX3C)M5> "9S>L^RDJ:V!/%"O*J(0:(-6R. Z6A8P\6(R
MLX%[9;FQ'%Y@;ZHPU#A0SR?L2&<)O0+@M)S1!_$)@X$4P0+I&44L=6@GN>L?
M6\BH<-?) YNQ(J_"0^LAWG$%I':I/2)1GE@:!9(;+^?B9#)/?D*<#!5QMK:E
M)1+N;Q=VOG&SQ>UN>H.>_Y;^?C59'O[(\RZ7GC^'\<ME[3U2P#@N@0XX.&.T
M8"RWS5 T:T^428WQ-)!!^U1Q9Z(!^7]9^Y/T/SQKWROU"JRBXPE%RR/Q"!F
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M.3U_-.GJQ8^GB=+'^=,6N;1>"I-1*H$SP)PP2G$></;^T9?AK,(:B!QYH>I
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MN+I2OGX]MO:\'R74*J'1GE81/ #IA4BC*'0@W :FCQQEQQY1;")"-O4=1<0
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M 2O,M=''&[B?_=A:"D1SGI;3ROY:LH"O_'+V/7[J=]\Z%RQ#+O"T)TR2$1S
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MHWH><MWJF-#K!$\\)YK-8NW=2[VZ>S-O_FP)[J7#0DD0?\#2A?QH12LL [W
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MSJK1RUD8JVAA;AEY*HK/Z]E\GEC[Y/5\]E_O?I:/'9S3Z7:"X 8$B#!'!)/
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MJ+#E<O8DPY,W]96+FHFS7Y,(K4 "S-)4<4DL,,YSQ"U1=+JBUDH28)I&=K%
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MD!=!0$), &+,V> 1L]G']QTAJ:)M+ L&^D V4B&5XNL@PB\DD(0H@+0.GLD
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M=Q,:/)QS%9G+:KDPQ!Y<=GU<4[V,6LH+EF<W.\_^W>:<FJ8"31]6HD) TB
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M;+_7G#Q9'UT[.WKY.OQYJZ@G/5]?P 'C' .I$KV<*$1A9/MR<M#$W%1 =Z>
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M5<D Z/\G09(DG*;F\90:D/(U?$ O8M0+:(]5H#TZ5+WX*AYP:P^:&N0H% E
M+. H5A%.#W-\1AB?X_&\B$XO;7QFPNQ3;/H?[<'3-L,:A!' "*9 X#3AYL$
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MP82SH#_#]D"H%T&^*<R45F!R?"8R8?Q_2IK7W[C&JWG^,B( 1QR"6 8R3E%
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M"*+/FX*@ 8[1C!FX>7'\.KOC*_'B@>7;)A2<ET7Y\")C%[]H*=;'6 ),'3:
MB$K"$#'MUA'+]JY[1L."D,&;4[L%^'!\>_8L4^7AX*$78@ZP+U_PZ\7RLJCU
MR/EVN7ITV55K.\40,*$(4$H2*00,"!UPR69K.L,4\$V&P=U0YE9-=U5+I'A:
MZ@>-^:E>75:L]>+V+]7*8K^ZW>]M"W&?_=![@B8\*VBUV>+5C,O11QL(0#@2
M0%$61B$.J%+]0;%7F.@PU7Y[<7H/:?9@YW]%***  !)R!!#&/*0,\2!)++L-
MSK^+MWLOX8LFN+WJN*QD37\\5;%:F<BH7A+/<OG2?!B4GK!IJ^0!0^V;L3 %
M :.""R*DP/W=?.;.8IBNOLG;D%<ER*U7,L[Q:O6[$A$#$DB]0L*E2F!@NC7T
MJN#$P9V]*'Y=O2A?E237URQ'-Y!FN7KA^5J8FFO/[B&OUFR5B8Q664.WOP@"
M'$.]1$63-%*0<]*OA]/&=O8:V94:O@)%3K7P\?7+K=E2=GFC%TI_5K2XR?0'
M=[):R>.[;X(0P%(?.9.$(TY9 B-ANYM]]XR<%>)WHH@+L.13H>S>-DP$8D 8
MAP#&@G$54Z'4J+8.$WO:+U&+WY4ELP>X!\?K(9W7$T(T,!$V+V]"Q4.&)0LM
M&ZFWV^B^F^$)C>X[X79M;08V:M?'9<!"K( @%,DT#A6.^M.YWW2K^T%Z8 E!
M;^J>CVV''$?4%#I.@$(PBO5!(I;Q]([W4QM/+]U7R)JN+(6T-_HSH2<[2SC
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M0W,ALZMK>R,UT"T>;;"]>&,00)C&L0IB#@\-U.P5-L_$=3S+@@8<[F86(/?
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MGZYJ2^PV"G7IV0TDL0L,UX<?VSQ-YFB9#ZT/_7(8%)ZP=%E5UHDZE.GN>YK
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M&08,AB9$)LJ[6HH/.;V914^;3&>E=\;QU .)^]R0)3CK$.NLULXXVOJ!\<(
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MCXJ3NR*@D\<7S%9KH T@8EV>/%&Z,5&*B=C.NU"&!(?PE^5&@Z,_ HSRXQL
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MR8_DY/+R9_CG].JGZ_/+FY/^Q=4EN;J^OOK2__GRHO^+S;#)C@*9=SN)[R"
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MA[PW3@[>^64BT;T$%A%* QV<+A82),U'\U[-FZPL341>! MQ+9TTBIW_>,A
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M<%(5'A#9 DG8J3P;QAYM ,7X<&UXR)9@<3H*NH#!+=/9CVMRA6OCD<Q1IM1
MUZB_3*WE@ -ZZ8H-$X]V!E2_=H/*);-U 6O> -,[#T@H!QX<4Q@.F,ZZP61%
M01U.$PQZ%PPE&P(7P0)KE769VRD/5OKNO#K2IS+ZL46!&7ZLA6U4+I1M)P_*
M!5;7@WR3E"Z(A;[H K9IQD8/ 0-@R07A*K_!ZF L@R9%$MT3K))POF2:H\L!
MVPTQ!7.AT$%PT9B@\&G:$^8U&H\UAS\C&K6 ID=>H#5I[\IKMZW!PEC8$XR^
M*M)MJS[[-"MDYZFFQY/MF1!K@ %(.";\J .]KC2^S<M"3C<KVI\<5BZQ70=(
M#TEP4;\[GVMOSSD(R:KN(^T?W=#2A_N3#]900-BC#3J::C' @5?N^T:XGB1F
M>N C)JLNMS;** N,:FZYYYIW@M^TI+ VL0[F4A9-1]9W4-<]$^EZ2>0=O1(Y
M@"F?KFHNPG90HN\ZDUAY1 Q!^^U<\JH;B5ZFIN2_S51JM/[N>9K(4*CO6I;'
M]:?Y^RJE%CUSE)/JL%;SVP(]]QTQTWB1OBL3YU-:8$@'?VXNSATBI1WE8SV$
MV$17MVTF],-1.]MS_>GP8]&_:GVS?YX6F8U?;G^B%=/='G40H9&ZL<*\\L5"
MX_!;"FWQ(#VV48C3U^.O89\>;V.SE%+13ORHJTX0,)( 0S$(+&*J.TII0@K-
M( C)&HET%KNY5<2>.)7,.KQOY*+PXAA8^O&9*'O;=D([:3T;/O779_Y2S<'N
M0/W>.0Z_8@R?TO^-HGW-<Y"==,?$7OAM-]W_G:X>DU%QD=YB4P_$M9MJ68]5
M/Z.0^V-HP=EM2+C^RJ:0%,%A1CM574Y$40CL.M15D-J 6C3"P"N5B09[U'^I
ML3P-+ >5,3$5SJ;AWR6HYZ@;V [-CP/VQWVPWU)"%]C=:FK$YM:F)ADS@C@0
M6A)Z.I4TNVHA,Q*QKJ+=9B8!)M6MBK'%@W8M>98SE4C'LQII4ZE.]]'Q)PME
MM%XB,6^VR#I)@QQ_CT2+0(ID5;3I.JQC%M=<*.HS,;CVD?#&_,)R,%TC;6K^
M^)"3<VPF,*/>EN)3T)5(@')!".H*3RY2*O[8BGTW#=3O14_S[[R"B)WG(2<#
MY"'HPT^TL>Y=>B)^L'Q\6^16]>T-7197E<$5UO884)">8QG(+'),E317$G$U
M.,C(3<NK!2#TQG8)6\*2Z:_0=G:VA1[DYLN9GK/[K<GKO?84XZ-:L\9: GQW
MEXF'-\O>TB%_TGG(T4V.Z;3I-?8^-JTE,?WVEIPF:'1RS*S6F+6/'+O=6]]:
M+LNSQYC+\O6I%[V,I(50@PQ.L$2%*C#C:&1+4S5..:AFN:UWBWJ&TUTX!6X.
MYSY3P+]\AS&PM3)B.X1J7TQN/"UL>$,S0U_F.;(_7"B3^]ZF;!\F"02I*G]D
ME=**^:(F/S_/=:1(;+A>/=XC,DFS<O &6SE+D8>.U/^':"?;:=4FEH)=6V]-
MZX!%F>6E:01/*'RC4^S$IJ;*II'4)[W7&B4Y)/#PP0[=L+L]7]5]A1?':\Q-
M/99KE>&Z+05*1MC,$"4TO>S6^C'> 6&>4\AYC-P9-V$9"I5]&5R%)G&?%3N,
M!H!B<!W8-B.P@3QL;8:5<_]GD3?UN)!=R7-C;KBDD$X=T*B[928K=Q&_(G *
M&SN*M%[8=O?L&"DD.3M*XC?X(]HL.38AK=IYP4>>F^6M_*#@]7;8__H@!\\J
M:,-[1XNS",B,AS&2SD,@=^T /1FS-)(%8XEL""Y=,SQLX8K#!XB/4T<QI#,7
MY.,2JRV=^ZHL/8B T&[<G';VA$Q*0.S69ED3-[I)]3*1\;7TY;A>QV+OS,H=
M\8\'V$AC\($)SUF]\\Z,_DPIS V:6!Y)]+<P/CLD3?[6Y0!P3A^>;RX[5WZ'
M9Y1'5=DFF/VJP![_EB]GKDU_;+L0$K7CU(0RRRQWGI;88MR+%IAA)_XIX6 W
M98J [I@"KU_J[(:] F4QTR;NYPH4J3[2=5P1"?5CRH+_QH"FK8$DV9:/K.^,
MLIHC$"#.>]:6U>AD"C]+L+ J0 !1NLH$=:W%BJ/V^*-QO/-NYR*F^JI@AK-Y
M[+@=SW0TV_B0*DX.IJ'19V[!TZAX["E7CA5B9VJ<-F$4_9A16K6M!%"".@5F
MN"4E#@?G85#-E/)*V-RO8.EC;D1^(PM0A5ALQ9E8LH:#] 14YC$#2TU>BVOG
MER/-Q[L6=KK$BF%X-,6ZW?0<4.ES:?? X6F>I4'H=FJ++3ZN3MWNH[L[. .V
M@0% !*<MWWSN6$4&].H,*U;)!7.986MZAP/D.[JE^1*>/X0S&+-F&3:-FTQ.
MH"8J/P(!Y:#D@L:K5R(I5OO3#/F= DJ[U928%J++#%1=4#M#7#V)EVAJ@*P!
M?8H(N#2.V^8.1>X,;,V37W6:2CO@P-BZ_GX/J#\!7'CRI%EZ:\>HD-[@QY;M
M*?+#4-_'<WV.\5PF1;&!U;S2GUW6+4E2X@5M7=4Q]+W[I[L[;&($7P4A*^[F
M4I!95RD#RET3]LKW$.3DK4STPC0L@(.#^CQR<X$9<=RI "7 G'JZF<N*3-!$
M ZR'X*RX7 $81-9N/*(ES&H#]K[4F !<P$(D=#3:/==@2V;TD1%;"7QOZ40L
MJ9Q?%";^$;3Q)3?OT HQ3(2%?7!# 5-O']:X0<Z;R*7(4/] Z54!Q=. .&,S
M8V&#)2')RM> "';$XLSM:-VCJX^G0*#K.^(9'E/UT88,>KGS[A-S=WC I4_4
M#WV#I+\R*7\KE&Q)-79 PS^96F.?7 VU4@BFZDMW!RT>(S;L8<.2]YTWN'LZ
M2 S&W':ALUT']L:*/B^F:*U!]_*6@6!WQ1ALPJA@+HW!9/[$^EP]+HG+3LLD
MF.-( (S/%&Q#MK:#H62QL4T6TQE776(PC<<"U!,*OD<M+5Z?/[:HY>!\45MR
M#O_)IV=;[M\MO?4?CE=LZ<4?3\^$7M\J:MWUAOPJ!;8G3!E%LU3:]A2KF'QL
M7 +$UDGKJE).N(N SO/@UF6>> WKSG1,WH!S,#4C]FR!QII&:I%P M696;::
MN5AI0PL*R3VH,'8X2/JU%TDQZ:\4U QDDDN3X"K2*DAIK/PZLKAZ/B=5VAO'
M8V9WV:NXAUK'C 0.RMELHM ?K@LXIBQ8F583,TUB![<[,\5UYL&KD'N04R?!
MJ6YYUM18?W55(:SK"M3@_&$9$H/ >+=7>4L,][**J9Q2^)F=>Y=D@G&?2&=M
MO3.66&V6R3;X\U:>W><+? S,Z'2T';#6VP4?'CP[P=='!NAH$SA1>"?G#OOJ
M6GE:6 U&X#R+IE,]M'D+E$E@NYC2@N9:YSR0'Q?H/N=NJ-A^59J8HTD+J_*.
MS80$<X+@&>S;L#X2;"N65W*N/4N$;QVAP"5/!$I4=@,TJI=L/J@-7F(M8D9O
M5NUGLGI0$=?XY&0@Y*HZ.:F)>]5JQ,^JT E !N$**V+Z68I)QY70BT4A7-[P
M(P!2-Y0DE^LCB>*1X%8&QB58Y275B!.;:O*7J8QD3LW<T<E&Q=U<FH.Y-84)
M&.;2I4F:Y*;KU'106@O;W['*OE>.#[[J^_E.U+UVU3*P970IF-%:%&Y);;F'
MO/WZ>+[ 3L4X@I9!=E6/J#VWNKFUAVC$#TV\-*>H@KEKMD"-,J1D9YB=F0E"
M@AMD8R7'OTO%+G->R>?Y3:];1[7;CC6ZZ"YG-MF\=6]D5011ZV?.X"6U@*<M
MTF_K[8JK8!6B;B6KWD,MXQAWLE;_WLW&7>LAOQR'.[ZCJ]8PB@Y_[W,<FNOD
M@"%*V&@JL^Y;XM%#>] .QA#LSWWSG?'_\GTH;:6L%#5K)"O7ZJP[1]=O[&>[
M*]#L3]9JA^:&0,3>ND]B9$>>L4+DE57)@^L#GJEL<Z[J%@J(U2F7L K,VJIT
M3GCT;1._ZWC:6M&@QRJW9._W^'R&R2][VN)[7-$;:6'':+(>8*PZ%$!Y70*1
M%PZP$58Y/*XDR:N5/#K9K]5*+B@9P"QK$[$Z''XRDV0\@]IA4PEXO_4, LI1
MGU-+<$QNQ/+W?J;\E68-#88==3-WXM^E'3+7,ABFKV?:AAKV0<*B.U6E_;_S
M,BD4G@=R6'^GJ,U]6\SLWIS8!?;*QF]^$RH+_J"F]<&_1%+61[)TT%> #OL
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MV_5T6P?%[V(Y#&KZA/$F(67B+JC/E;:.Z&I<7&?I7?@)LQ(H";/N4:6^S=5
MNTVC-QJ/OTPP3<@<>MCVE=N.-PS5^DRI;_8B,_J/?2+VX',"O#"QQM<@JY?
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M.MA.Y@AHI@88MGM(S7UHW[CMK="N\=PZS6%BU= %,F-L=BFG#KA601/YL(:
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MV>:N_+08X-\G.E[!/[-BGOSR/U!+ P04    " #@79Y<><5Z'8@H  #=* $
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M$C_[.RPEC> %7FB>Z-G/ZH 0OK"O;5R.(\'/[ GV)@+H.U0)L .U[,TT3@)
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M/Z<54/-<]4.FL)(8->(K*@-LJR35XHO2>;')>VU'9UNY2?GFV/#)S%>ZI=S
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M.F:W>SFZQ'3O*FLLM(%BJ,L-"'YK*?XI6HJ;[-$J5+-2^S93>%GR$H^HZR6
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M 27])MX:8D88IJMBOLE?6*UOIR4X-=O:V>8#MZ2T^_" ?2^[K!#"K4?=;#@
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MD6ZZ4:IP))5*K"@Q@LKK.\UJL==VOD\^^8*ZM( ,BXCHF;>432HH&E.#ZC4
M[B8X@Q82-_$,!)\3\G6E&$TEV3;>[[H/F/B$FU5@.A=4QXRUZB"UU;KKF[3<
M'/;M0>MNXK"YAN:8(U<E!BOQJ$HX"L/#-AIEPD$F7DCTC]./3-Z0W]IHM#8\
MV=QC]<773S+H)+Y^^O'%X-4G)5/XC\-7XN.%.+_X==EV]UA_G29S<P?ZHPXT
M#+XLT/#WH0X7\*])/HW?_#]02P,$%     @ X%V>7!C?%Q9A.P  7E8!  X
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M#I-$+:PN-=ZN>+R!6\&G#N%P["+&0L!>-&PDLMOB[R&;LYL<2'7<P#YBNR)
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M/^$I4<BYY]XQB&<;F#FR>?32SZ=%\!;PYM@)B\1D@;LD\RE\G)8)%:$IRC1
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ML-2.=V^(Y,J)Y1KY+H<X468Z59*C2-TK11QY9+DS^WWP@V'+*<MTVMQ+S/]
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M7/QZ6B)$-4Z[A$V(N-9EDV$5./DJ=5"JYE6O^ +B6G@9MK@&*-;"7*HV4+3
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M#. EQ:^I+J;K+WD3B^6%_D,G-[O7*IV(MTD %!?=*7$1R^3[[XY?G@AQE:=
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MCABEB!1R=J5 +TBZL(E4Y3*="Q.M4/?P11(6JQ;4<>R]K:,X%/J%E?9X4OJ
M$\*R)52#6V1X8QTC#J]4>A<AVH88N9-1#"RBU5FK#@_4X$MLBLV"4 6:C^IK
M"I+A7<]^RLH59V;!WW_W_.A$@>F08%+"7J G&XO1I@B\Z1A9,0#O8'"\]P)D
M_^'QX'EW]8=5LORS )"L@#5 >/#0Y*=O2;VI-TK>.ID(=@F<APT1_]II5 UA
MR;9HV2>='6-DLA4[>&F]#: ^P1M?[^(O7]6Y0%#Z><[Q3!0\)A:UH7@8A\ V
MQ2DY\M87;RMV]"-PN(6T<+J0EY J3#=2B9=)0ZK86Q+N?+[6V^'A\V[L<+#W
M_7>#Y_LGR_\T\>QPO5!ZO]51L%XTOCD "I!]M28)=@6P!RV Q7PFV*N76 3;
MCM*&O(\.QWZ_2.B7D$V7MPOCAZN/$I@Q,T YY0TD<\\80 82&I/ 2S!9=:96
MG1NQBK:8JCQ/@DG9JZ>H3\I@Z8@1=A6DFKPKL\0E"%V?7_Y^)4[?O1%G[]^]
M>7O]]OV[J[79U5_FPGJG8NO-A:\"SO4TPEJ"??^+^/C^PZ7X_KM7@Y./YZ>7
M\!^')^+7R]-WUXUTV('-P+JOKB]/K\]_?7LF+LXO?WE_^?OIN[-S<?7;Z>7Y
MU2<=KVI4_?DFQ,#U&#3$>JY-F62)YR*=8O3'!E+84XN)^,VL)V//V5(!"?UA
MBR6<.WEE?,8XA^&_(E-DTY,['$Q"T9WJ!!Y[2-$(1;+ZHC>DMS3!H5>*'1<)
M&^S 8\%.8P8<OJ(7[JQ51T*>^.:$X:]9UV2<HS.=AIDKPW'^=(JPC2)0 D6L
M\AQ5@T!.0?^*X1LA(294(PJ,&:_^)R"C!1$@!T\QG _P/_ K6XB0(E-^A.'#
M.QV%UG-N,YP!TDYWA&<9*?!&*:Z*81:%$?IR>[):<;!C;>HR=^K3!.G223]9
MH10>?F%N4,_DFNVK+V?7T\M>$Q4%:RRQC=VP+N[_#O\=Z;#+#/A<@MG3=DYZ
M2S_ME)8]G)%20P;3A6MC<^WRNRF(1^]Q1(_!:2#KJUP'MZ+';^POU9"5'^V[
M,#B>QZGD AS/M@I5%J31L%J<MHP%7V&'KY2Q!#RR_RN3 D_@H,^:P;_@?ZP9
MP*UO8#-427BX?+F7UWYLIT;[WPC6ZZGX8&]3CK+.'_!++\C7#10V1#F7M1T\
M9MXYLK%&?T=E++$4*:( =8 +QB[,Z:*?RW,%+P'E2X* FX[%D5&<*J^%3Z]P
MZ'5.!-6#%56Z)AK%@KM )BC.,X65#";Z.S(5NS4H8=\%<$&6#5L/G6$S=#XD
ML<HHX4K=4_V'3ICEPI=[3;2T@T L^$GRTLVBK"[%R64T>75$ .N1BG+1BW6F
M3%FAD3\[_&>1H.B M]0=EH3K),F7 +?0HZ!U3B8JQ.R0>"Z*J0WR7]-RR%_G
M'&Y;C\M@IPF5[T=-]$P"DY-L$ \]\_,I_[S37ZB[7WY#'Q5C.!+],MU'R92]
MH.AI8O\M_CR1<Z=&6*EOOW<.C\#GZHK/O2\"Q5%23I63E494)XP>:U(,!I5J
M>;ODS%@D%6X+NYAH,G> P<>8Z[B8$K;X"!^;20&V$R5VH8$!%$XFU5K5PC<K
MG*</]'9V2!=J]D1W1B?QCM$&UM2@R74&.A6>L/TB5C:RY9)S"<P#C$81LX=Z
MIE=C[E2Y]9XX)T&-42^7\5P5SWU!7F1V<I4]%Y;MG7Y52J/-A_$#*\>!K2N*
MP1$#T=P( &!-P6%B5K5;H"2PH5*8:#V.% :%4$9,BW0*(I^8D_V$C<K8I'%8
M%KJYY(VJ T2-9*N*%N_Y!YER':6I82--G2;S!;)@P6S]5E6H,#7<1'<(8C4:
M>8+7X1X[5 Q>G&0.-28]U7:VP?QZ1V&'AE+LG<HTE #YA'H$7,&_V:'F:68C
M'8.ECXN@L&WU2\LNLLZBJYZA@875>9%T'D<WW+UC3F?26([; _H'<]^26389
M,V@=(;EZ*JE_-=@Q'BQ'_,PU+Q?2BAM4;[)YD GWFE@8W8$6C_,;KV//'_<Q
M>PDSX.?6:9UBOFQ"N;514N@"6P89[S599+*9(WYS(=NC)Q.R7>.(?OT#6>W
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MUUSDW_4QO-.Y\M[>-VW>RP'V9E(?8 I$>!*V-!_X2E9O5YH8/.^^DGDM[[V
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M=9P7_2A381NB]-03IA3E0.W&/6FMA*6T'#U37!6XT._8"YQ7FIQ57PI/.W6
M+4"\G.@$#3,>:83\+37\+%0CE6+6#SF3DDQ:;Q*?R2EVZ\=EI"E.]& _Q"-4
M]NY@K#FEZGKY]'YZ(DE7SF_S9K&G-Q[%ZK!W8K F]\NQ0&E+K*=E$)$J([&+
MV[IS,;L"D18EW),JF>(^E+!WK+P%MF;;AW(=R(0*SW7MQ(<E(C+EE(?[?CDE
M.W=XZ IQA*7W<UX.>=F7/.O6>_XY@/\DAI+V5"-:5VLM,Y52WN32C'L_PNC[
M<PZ.JFXT+QADE88:YWU=FYWJD#D>F&"G]BQJICB-1.+J>&RIZYR"%[B*G8F1
M!4/9<LX23:]M"/&K'=MG(9I@552E@Y"IZL"/IT^ *[9H-88B:.I2(L[@WT %
M/R-DG@MJO'!#]6I)S30Z1#QJA9M)]&EM(;RI,@>_?;/O9U 49C$3FFT^Q:77
M3LH=E4MN6?37$>F.F'R?FW'H)>JN5()QA-\*^"3B$8"/B4B&B_;YY% ZV5CY
M#6"^+#(?CZQNHJ:YV/V-RDN.Y 5_*S/JUSIGA+/UT$NC@&K0N]-WJ1@CJC-&
M? PC&@E/*(BY,VIMF<T3FL RV'\"^8-O"*G5(BMTE9S>V)-V"EA($S4':._^
M(@-N;UMF8G<C\:_^1'D-@D 3?Q*#5]J3ZI9RL5,LL;?CWDT6+W%=QCH:?X9I
M5C.!5<ANA[J,_Y6Y^7Z/W*4Y).1;P5 7/+3U)=@K,JEL1S4>H;;<)(C#[]@Z
MK8CGIDL#?!T;>1('IH%MW"+XAA##M1E\'@D1(\E*F#V7E*QM4#Q48QF/3+/H
M@#J%HW'+M61S$>K H)O6@7+7.FY-VT8W/*S,#'>MK;UM^&2B77[X URD&V#=
M@^ZS[E.O%>QIE@&NQ&64W38SW&\NC#?8?[IQO*_/R^A8]T6$K7XIL$/.8AG"
M]KG\S[ 7O,'-)22^9 (V7#@R334R"R-EZ$5Y.2_05IF9"!+Z7RC!%'-$62R,
M]0P;=/5=L.Y687J^[45)VNA-(;%'F5*V/?Z2-)IPY&>:1HOMZD69%T7>GXC'
MTN9FA" R4LM ;45<S61!(1;&O:WH!$\]U9ZZ E+;G).[[1+N&5$,4X2Y&7.-
MDB16G*B-_ND,\8_)$56G:E8,,3H2H>?U"73*:=<<7.,]R9R?QV8"]_=#UO;'
M$M M9(\ #VB.>]^?F4.C-1M;N P&./5BJ/(9UGV[,T.>-/BNC6B5XY*'9.V'
MKN6TO=T-B>66YYC\@F-.X=9NZPD'6Z GN$#LIFN_-@Z*?\A9-ZBIV1QM'$S3
M!RV=)^QEK(>C)ZZ<9==8)M9?/2!@]8@26T8=5OU,5&E3CN!;_9Z%5>%P^+[E
M!;";:[=*;S2L]2519^AIJLJ*'7P%=H%SG"PW,9@WP+1F-.'=1LY3=8-S6M K
MF-/ S!%0##D.Z05I$:N'9)U_?=KXA=MH"WFGH]".@@EU,5R)X-J^_NLAM.;!
M9FQX"1\9(0(@B\2Z,#2I?E)C-T#?P.0/MX#)I\/(M.#H""SKR?C\$WE85$DS
M8[9HZ!$(BTT!U(8,&)37 6/7:C-AE$T+:M9=:5T,6H>.3?::O67!7EB+1]KD
M6UFBHN-T?;0%=.U&7W49DB9X#-3#5$5$6?8P;)!L?3,:X8&\NR\^OO\@?O]P
M=2W>O;\6IV=GYQ?7XOJW<W%U?7EZ??[KVS-Q<7[YR_O+WT_?G<&OOYU>GHM?
M+T_?7>]M:K"6'3)FNT&LMH4=<.H @&:%9T<N#DDKV_23%6&SVSATZ7K>#-7C
MDG,[8RG*YNDIIPOCHE91VTJT^&.D:OETQ?A<;Y2[4T86QLL^KN*E,^AI&6[S
M!^59NN%>J<(I@"JQ@L>(-:_A.RO+WKR'/CGY"^IP!!(O(GPQ^RD;O%!XIP;K
M3P3 00O]FY ) M0I"75E!$V5,3:7P/7R,"$0-S;$] &ICGULU6%J*Y-7MVKH
M)NR;ZS9..:A50KX2JJI$JC!R; -5)E)D0HE$R3@_S.02^0V^1BLCE\VMAP?[
M:R90M@*Z/DMA [F^KP8G'Y5,X3\.3\2'*W%U<;5H<'N<N487^2MF5$;^/BUF
M],-0AW/XUSB?Q#_]/U!+ 0(4 Q0    ( .!=GEP0!E>1AM ! %V:'@ /
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M,#(V,#,S,5]G,2YJ<&=02P$"% ,4    " #@79Y<CH<FR^*K 0!M$!$ $P
M            @ 'CC00 8VDM,C R-C S,S%?;&%B+GAM;%!+ 0(4 Q0    (
M .!=GERI2!C)9=   (N:"P 3              "  ?8Y!@!C:2TR,#(V,#,S
M,5]P<F4N>&UL4$L! A0#%     @ X%V>7/'1I=-U!P  TB,   \
M     ( !C H' &5X:%\S,3$R-G$Q+FAT;5!+ 0(4 Q0    ( .!=GEP#YA?A
M90<  *@B   /              "  2X2!P!E>&A?,S$R,C9Q,2YH=&U02P$"
M% ,4    " #@79Y<.[I*.JX#   L#@  #P              @ ' &0< 97AH
M7S,R,3(V<3$N:'1M4$L! A0#%     @ X%V>7"6P(%2X P  *@X   \
M         ( !FQT' &5X:%\S,C(R-G$Q+FAT;5!+ 0(4 Q0    ( .!=GES[
MNH<(+08  )4>   .              "  8 A!P!E>&AI8FET,3 Q+FAT;5!+
M 0(4 Q0    ( .!=GER[4Y-CQ0@  #HQ   .              "  =DG!P!E
M>&AI8FET,3 R+FAT;5!+ 0(4 Q0    ( .!=GEP 3>"K@"@  -<G 0 .
M          "  <HP!P!E>&AI8FET,3 S+FAT;5!+ 0(4 Q0    ( .!=GEQY
MQ7H=B"@  -TH 0 .              "  799!P!E>&AI8FET,3 T+FAT;5!+
M 0(4 Q0    ( .!=GER.X>/;A"4  #H0 0 .              "  2J"!P!E
M>&AI8FET,3 U+FAT;5!+ 0(4 Q0    ( .!=GEP8WQ<683L  %Y6 0 .
M          "  =JG!P!E>&AI8FET,3 V+FAT;5!+ 0(4 Q0    ( .!=GES,
MW;1R#2<  )<= 0 .              "  6?C!P!E>&AI8FET,3 W+FAT;5!+
4!08     $@ 2 %8$  "@"@@    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>ci-20260331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ci="http://www.thecignagroup.com/20260331"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ci-20260331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2026-04-24</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ci:OperatingResultsOfCertainNonstrategicBusinessesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceRelatedAssessmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ci:DavidCordaniMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ci:DavidCordaniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">ci:TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtZeroPercentTargetLevelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ci:DavidCordaniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">ci:TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAt200PercentTargetLevelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">ci:R2026Q2DividendsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-22</startDate>
            <endDate>2026-04-22</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2026125Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2026125Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:AllSegmentsExcludingCignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:AllSegmentsExcludingCignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:AllSegmentsExcludingCignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:CompletionFactorsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:CompletionFactorsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:MedicalCostTrendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:MedicalCostTrendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LifeAndAnnuityInsuranceProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LifeAndAnnuityInsuranceProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">ci:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">ci:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:ReinsuranceRecoverablesGrossAcquisitionDispositionRunoffActivitiesNationallyRecognizedStatisticalRatingOrganizationsBBBOrHigherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ReinsurerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskSecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ci:CededCreditCollateralizationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:InvestmentGradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:InvestmentGradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:BelowInvestmentGradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:BelowInvestmentGradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">ci:SeparateAccountNonGuaranteedSeparateAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociLiabilityForFuturePolicyBenefitParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociLiabilityForFuturePolicyBenefitParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ci:EmployeeSeveranceAndOtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ci:EmployeeSeveranceAndOtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ci:EmployeeSeveranceAndOtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ci:AssetImpairmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:RetirementAndLifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:RetirementAndLifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ci:StrategicOptimizationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:NetworkPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:NetworkPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:HomeDeliveryAndSpecialtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:HomeDeliveryAndSpecialtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:EmployerInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:EmployerInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:StopLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:StopLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:IndividualAndFamilyPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:IndividualAndFamilyPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatesHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:InternationalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:InternationalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesAndOtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:GuaranteeObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:GuaranteeObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ci:DavidCordaniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">ci:TradingArrangementCommonStockIssuableUponVestingOfPerformanceAwardAtTargetLevelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ci:DavidCordaniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">ci:TradingArrangementStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ci:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="reinsurer">
        <measure>ci:reinsurer</measure>
    </unit>
    <unit id="position">
        <measure>ci:position</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-2">2026</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="c-1" id="f-4">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-5">0001739940</dei:EntityCentralIndexKey>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-322"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <ci:AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid contextRef="c-1" id="f-323" unitRef="usd" xsi:nil="true"/>
    <ci:AccountsReceivableUncommittedFactoringFacilitiesFactoringFeesPaid contextRef="c-5" id="f-324" unitRef="usd" xsi:nil="true"/>
    <ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding contextRef="c-8" decimals="INF" id="f-325" unitRef="usd">0</ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding>
    <ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding contextRef="c-9" decimals="INF" id="f-326" unitRef="usd">0</ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableSoldThatRemainOutstanding>
    <ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted contextRef="c-8" decimals="INF" id="f-327" unitRef="usd">0</ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-52" id="f-328">2030-04-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RestructuringCharges contextRef="c-53" decimals="-6" id="f-329" unitRef="usd">3000000</us-gaap:RestructuringCharges>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease contextRef="c-54" id="f-330" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-1" id="f-331" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-5" id="f-332" unitRef="usd" xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" id="f-333" unitRef="usd" xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-5" id="f-334" unitRef="usd" xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-1" id="f-335" unitRef="usd" xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-5" id="f-336" unitRef="usd" xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="c-55" id="f-337" unitRef="usd" xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="c-56" id="f-338" unitRef="usd" xsi:nil="true"/>
    <ci:ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue contextRef="c-1" id="f-339" unitRef="usd" xsi:nil="true"/>
    <ci:ImpairmentsRequiringCertainAssetsAndLiabilitiesToBeMeasuredAtFairValue contextRef="c-5" id="f-340" unitRef="usd" xsi:nil="true"/>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount contextRef="c-1" id="f-341" unitRef="usd" xsi:nil="true"/>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount contextRef="c-5" id="f-342" unitRef="usd" xsi:nil="true"/>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount contextRef="c-1" id="f-343" unitRef="usd" xsi:nil="true"/>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount contextRef="c-5" id="f-344" unitRef="usd" xsi:nil="true"/>
    <ecd:TrdArrDuration contextRef="c-57" id="f-345">P448D</ecd:TrdArrDuration>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-58"
      decimals="INF"
      id="f-346"
      unitRef="shares">0</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-59"
      decimals="INF"
      id="f-347"
      unitRef="shares">124732</ecd:TrdArrSecuritiesAggAvailAmt>
    <us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-8" id="f-378">http://fasb.org/us-gaap/2025#AccountsPayableCurrent</us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration contextRef="c-9" id="f-379">http://fasb.org/us-gaap/2025#AccountsPayableCurrent</us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-9" id="f-380">http://fasb.org/us-gaap/2025#AccountsPayableCurrent</us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration contextRef="c-8" id="f-381">http://fasb.org/us-gaap/2025#AccountsPayableCurrent</us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-979">http://fasb.org/us-gaap/2025#NetInvestmentIncome http://www.thecignagroup.com/20260331#NetInvestmentGainLoss</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-980">http://fasb.org/us-gaap/2025#NetInvestmentIncome http://www.thecignagroup.com/20260331#NetInvestmentGainLoss</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList contextRef="c-1" id="f-981">http://www.thecignagroup.com/20260331#OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-7">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-8">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-10">001-38769</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-11">The Cigna Group</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-12">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-13">82-4991898</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-14">900 Cottage Grove Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-15">Bloomfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-16">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-17">06002</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-18">860</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-19">226-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-20">Common Stock, Par Value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-21">CI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-22">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-23">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-24">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-25">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-26">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-27">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-29" unitRef="shares">264532404</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-3" decimals="-6" id="f-30" unitRef="usd">54037000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-6" id="f-31" unitRef="usd">48633000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PremiumsEarnedNet contextRef="c-1" decimals="-6" id="f-32" unitRef="usd">9812000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-5" decimals="-6" id="f-33" unitRef="usd">12736000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-6" id="f-34" unitRef="usd">4443000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-6" id="f-35" unitRef="usd">3895000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetInvestmentIncome contextRef="c-1" decimals="-6" id="f-36" unitRef="usd">202000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-5" decimals="-6" id="f-37" unitRef="usd">238000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-38" unitRef="usd">68494000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-6" id="f-39" unitRef="usd">65502000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-6" id="f-40" unitRef="usd">54100000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="-6" id="f-41" unitRef="usd">48398000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet contextRef="c-1" decimals="-6" id="f-42" unitRef="usd">7924000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet contextRef="c-5" decimals="-6" id="f-43" unitRef="usd">10498000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-44" unitRef="usd">3722000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-6" id="f-45" unitRef="usd">4213000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-6" id="f-46" unitRef="usd">390000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-6" id="f-47" unitRef="usd">422000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-1" decimals="-6" id="f-48" unitRef="usd">66136000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-5" decimals="-6" id="f-49" unitRef="usd">63531000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-50" unitRef="usd">2358000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-6" id="f-51" unitRef="usd">1971000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-52" unitRef="usd">-357000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-6" id="f-53" unitRef="usd">-362000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-6" id="f-54" unitRef="usd">11000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-5" decimals="-6" id="f-55" unitRef="usd">41000000</us-gaap:GainLossOnSaleOfBusiness>
    <ci:NetInvestmentGainLoss contextRef="c-1" decimals="-6" id="f-56" unitRef="usd">258000000</ci:NetInvestmentGainLoss>
    <ci:NetInvestmentGainLoss contextRef="c-5" decimals="-6" id="f-57" unitRef="usd">-2000000</ci:NetInvestmentGainLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-58" unitRef="usd">2270000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-59" unitRef="usd">1648000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-60" unitRef="usd">409000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-6" id="f-61" unitRef="usd">239000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-62" unitRef="usd">1861000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-6" id="f-63" unitRef="usd">1409000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-64" unitRef="usd">207000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-65" unitRef="usd">86000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-66" unitRef="usd">1654000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-6" id="f-67" unitRef="usd">1323000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-68"
      unitRef="usdPerShare">6.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-69"
      unitRef="usdPerShare">4.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-70"
      unitRef="usdPerShare">6.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-71"
      unitRef="usdPerShare">4.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-72" unitRef="usd">1861000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-6" id="f-73" unitRef="usd">1409000000</us-gaap:ProfitLoss>
    <ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-74" unitRef="usd">-129000000</ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax>
    <ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax contextRef="c-5" decimals="-6" id="f-75" unitRef="usd">-100000000</ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax>
    <ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-76" unitRef="usd">-635000000</ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent>
    <ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent contextRef="c-5" decimals="-6" id="f-77" unitRef="usd">-168000000</ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent>
    <ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity contextRef="c-1" decimals="-6" id="f-78" unitRef="usd">-35000000</ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity contextRef="c-5" decimals="-6" id="f-79" unitRef="usd">13000000</ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-80" unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-5" decimals="-6" id="f-81" unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-82" unitRef="usd">-792000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-6" id="f-83" unitRef="usd">-249000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-84" unitRef="usd">1069000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-85" unitRef="usd">1160000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-86" unitRef="usd">207000000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-87" unitRef="usd">86000000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-6" id="f-88" unitRef="usd">862000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-6" id="f-89" unitRef="usd">1074000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-6" id="f-90" unitRef="usd">7040000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-9" decimals="-6" id="f-91" unitRef="usd">7676000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-8" decimals="-6" id="f-92" unitRef="usd">812000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-9" decimals="-6" id="f-93" unitRef="usd">1056000000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent contextRef="c-8" decimals="-6" id="f-94" unitRef="usd">26607000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-9" decimals="-6" id="f-95" unitRef="usd">28768000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet contextRef="c-8" decimals="-6" id="f-96" unitRef="usd">5831000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-9" decimals="-6" id="f-97" unitRef="usd">7338000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-8" decimals="-6" id="f-98" unitRef="usd">2742000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-9" decimals="-6" id="f-99" unitRef="usd">2976000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-8" decimals="-6" id="f-100" unitRef="usd">43032000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-9" decimals="-6" id="f-101" unitRef="usd">47814000000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments contextRef="c-8" decimals="-6" id="f-102" unitRef="usd">18902000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-9" decimals="-6" id="f-103" unitRef="usd">18471000000</us-gaap:LongTermInvestments>
    <ci:ReinsuranceRecoverablesNonCurrent contextRef="c-8" decimals="-6" id="f-104" unitRef="usd">4073000000</ci:ReinsuranceRecoverablesNonCurrent>
    <ci:ReinsuranceRecoverablesNonCurrent contextRef="c-9" decimals="-6" id="f-105" unitRef="usd">4103000000</ci:ReinsuranceRecoverablesNonCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-8" decimals="-6" id="f-106" unitRef="usd">3704000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-9" decimals="-6" id="f-107" unitRef="usd">3651000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Goodwill contextRef="c-8" decimals="-6" id="f-108" unitRef="usd">45534000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-9" decimals="-6" id="f-109" unitRef="usd">44924000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-8" decimals="-6" id="f-110" unitRef="usd">27318000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-9" decimals="-6" id="f-111" unitRef="usd">28560000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-8" decimals="-6" id="f-112" unitRef="usd">3253000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-9" decimals="-6" id="f-113" unitRef="usd">2885000000</us-gaap:OtherAssetsNoncurrent>
    <ci:SeparateAccountAssetAtCarryingValue contextRef="c-8" decimals="-6" id="f-114" unitRef="usd">7450000000</ci:SeparateAccountAssetAtCarryingValue>
    <ci:SeparateAccountAssetAtCarryingValue contextRef="c-9" decimals="-6" id="f-115" unitRef="usd">7511000000</ci:SeparateAccountAssetAtCarryingValue>
    <us-gaap:Assets contextRef="c-8" decimals="-6" id="f-116" unitRef="usd">153266000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-9" decimals="-6" id="f-117" unitRef="usd">157919000000</us-gaap:Assets>
    <ci:InsuranceAndContractholderLiabilitiesCurrent contextRef="c-8" decimals="-6" id="f-118" unitRef="usd">6455000000</ci:InsuranceAndContractholderLiabilitiesCurrent>
    <ci:InsuranceAndContractholderLiabilitiesCurrent contextRef="c-9" decimals="-6" id="f-119" unitRef="usd">5710000000</ci:InsuranceAndContractholderLiabilitiesCurrent>
    <ci:PharmacyAndServiceCostsPayable contextRef="c-8" decimals="-6" id="f-120" unitRef="usd">25763000000</ci:PharmacyAndServiceCostsPayable>
    <ci:PharmacyAndServiceCostsPayable contextRef="c-9" decimals="-6" id="f-121" unitRef="usd">30333000000</ci:PharmacyAndServiceCostsPayable>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-6" id="f-122" unitRef="usd">9879000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-9" decimals="-6" id="f-123" unitRef="usd">10659000000</us-gaap:AccountsPayableCurrent>
    <ci:AccruedExpensesAndOtherLiabilities contextRef="c-8" decimals="-6" id="f-124" unitRef="usd">8980000000</ci:AccruedExpensesAndOtherLiabilities>
    <ci:AccruedExpensesAndOtherLiabilities contextRef="c-9" decimals="-6" id="f-125" unitRef="usd">9048000000</ci:AccruedExpensesAndOtherLiabilities>
    <us-gaap:DebtCurrent contextRef="c-8" decimals="-6" id="f-126" unitRef="usd">1529000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-9" decimals="-6" id="f-127" unitRef="usd">592000000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-8" decimals="-6" id="f-128" unitRef="usd">52606000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-9" decimals="-6" id="f-129" unitRef="usd">56342000000</us-gaap:LiabilitiesCurrent>
    <ci:InsuranceAndContractholderLiabilitiesNoncurrent contextRef="c-8" decimals="-6" id="f-130" unitRef="usd">9777000000</ci:InsuranceAndContractholderLiabilitiesNoncurrent>
    <ci:InsuranceAndContractholderLiabilitiesNoncurrent contextRef="c-9" decimals="-6" id="f-131" unitRef="usd">9938000000</ci:InsuranceAndContractholderLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-8" decimals="-6" id="f-132" unitRef="usd">6851000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-9" decimals="-6" id="f-133" unitRef="usd">7145000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-8" decimals="-6" id="f-134" unitRef="usd">4769000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-9" decimals="-6" id="f-135" unitRef="usd">4238000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-8" decimals="-6" id="f-136" unitRef="usd">29371000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-9" decimals="-6" id="f-137" unitRef="usd">30871000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:SeparateAccountsLiability contextRef="c-8" decimals="-6" id="f-138" unitRef="usd">7450000000</us-gaap:SeparateAccountsLiability>
    <us-gaap:SeparateAccountsLiability contextRef="c-9" decimals="-6" id="f-139" unitRef="usd">7511000000</us-gaap:SeparateAccountsLiability>
    <us-gaap:Liabilities contextRef="c-8" decimals="-6" id="f-140" unitRef="usd">110824000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-9" decimals="-6" id="f-141" unitRef="usd">116045000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-8" id="f-142" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-9" id="f-143" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockValue contextRef="c-8" decimals="-6" id="f-144" unitRef="usd">4000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-9" decimals="-6" id="f-145" unitRef="usd">4000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-8" decimals="-6" id="f-146" unitRef="usd">31914000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-9" decimals="-6" id="f-147" unitRef="usd">31790000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-8" decimals="-6" id="f-148" unitRef="usd">-3598000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-9" decimals="-6" id="f-149" unitRef="usd">-2806000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-6" id="f-150" unitRef="usd">49106000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-9" decimals="-6" id="f-151" unitRef="usd">47865000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue contextRef="c-8" decimals="-6" id="f-152" unitRef="usd">35216000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-9" decimals="-6" id="f-153" unitRef="usd">35140000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-6" id="f-154" unitRef="usd">42210000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-6" id="f-155" unitRef="usd">41713000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-8" decimals="-6" id="f-156" unitRef="usd">232000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-9" decimals="-6" id="f-157" unitRef="usd">161000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-158" unitRef="usd">42442000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-6" id="f-159" unitRef="usd">41874000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-8" decimals="-6" id="f-160" unitRef="usd">153266000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-9" decimals="-6" id="f-161" unitRef="usd">157919000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-162"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-163"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="-6" id="f-164" unitRef="shares">406000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-9" decimals="-6" id="f-165" unitRef="shares">405000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-166" unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-9" decimals="INF" id="f-167" unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-6" id="f-168" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-6" id="f-169" unitRef="usd">31790000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-170" unitRef="usd">-2806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-171" unitRef="usd">47865000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-6" id="f-172" unitRef="usd">-35140000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-6" id="f-173" unitRef="usd">41713000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-6" id="f-174" unitRef="usd">161000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-6" id="f-175" unitRef="usd">41874000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-17" decimals="-6" id="f-176" unitRef="usd">127000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-18" decimals="-6" id="f-177" unitRef="usd">-76000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-19" decimals="-6" id="f-178" unitRef="usd">51000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-6" id="f-179" unitRef="usd">51000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-20" decimals="-6" id="f-180" unitRef="usd">-792000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-6" id="f-181" unitRef="usd">-792000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-182" unitRef="usd">-792000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-21" decimals="-6" id="f-183" unitRef="usd">1654000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-19" decimals="-6" id="f-184" unitRef="usd">1654000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-22" decimals="-6" id="f-185" unitRef="usd">207000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-186" unitRef="usd">1861000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-187"
      unitRef="usdPerShare">1.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-21" decimals="-6" id="f-188" unitRef="usd">413000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-19" decimals="-6" id="f-189" unitRef="usd">413000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-1" decimals="-6" id="f-190" unitRef="usd">413000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-17" decimals="-6" id="f-191" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-18" decimals="-6" id="f-192" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-19" decimals="-6" id="f-193" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-6" id="f-194" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-17" decimals="-6" id="f-195" unitRef="usd">-3000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-19" decimals="-6" id="f-196" unitRef="usd">-3000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-22" decimals="-6" id="f-197" unitRef="usd">-136000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-1" decimals="-6" id="f-198" unitRef="usd">-139000000</ci:NoncontrollingInterestOtherChanges>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-6" id="f-199" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-6" id="f-200" unitRef="usd">31914000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-201" unitRef="usd">-3598000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-202" unitRef="usd">49106000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-6" id="f-203" unitRef="usd">-35216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-6" id="f-204" unitRef="usd">42210000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-6" id="f-205" unitRef="usd">232000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-206" unitRef="usd">42442000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-6" id="f-207" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-6" id="f-208" unitRef="usd">31288000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-6" id="f-209" unitRef="usd">-2341000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-6" id="f-210" unitRef="usd">43519000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-6" id="f-211" unitRef="usd">-31437000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-6" id="f-212" unitRef="usd">41033000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-6" id="f-213" unitRef="usd">210000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-6" id="f-214" unitRef="usd">41243000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-38" decimals="-6" id="f-215" unitRef="usd">155000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-39" decimals="-6" id="f-216" unitRef="usd">-107000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-40" decimals="-6" id="f-217" unitRef="usd">48000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-5" decimals="-6" id="f-218" unitRef="usd">48000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-41" decimals="-6" id="f-219" unitRef="usd">-249000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-40" decimals="-6" id="f-220" unitRef="usd">-249000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-6" id="f-221" unitRef="usd">-249000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-42" decimals="-6" id="f-222" unitRef="usd">1323000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-40" decimals="-6" id="f-223" unitRef="usd">1323000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-43" decimals="-6" id="f-224" unitRef="usd">86000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-225" unitRef="usd">1409000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-5"
      decimals="INF"
      id="f-226"
      unitRef="usdPerShare">1.51</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-42" decimals="-6" id="f-227" unitRef="usd">408000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-40" decimals="-6" id="f-228" unitRef="usd">408000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-5" decimals="-6" id="f-229" unitRef="usd">408000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-38" decimals="-6" id="f-230" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-39" decimals="-6" id="f-231" unitRef="usd">1521000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-40" decimals="-6" id="f-232" unitRef="usd">1521000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-5" decimals="-6" id="f-233" unitRef="usd">1521000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-38" decimals="-6" id="f-234" unitRef="usd">0</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-40" decimals="-6" id="f-235" unitRef="usd">0</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-43" decimals="-6" id="f-236" unitRef="usd">-108000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-5" decimals="-6" id="f-237" unitRef="usd">-108000000</ci:NoncontrollingInterestOtherChanges>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-6" id="f-238" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-6" id="f-239" unitRef="usd">31443000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-6" id="f-240" unitRef="usd">-2590000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-6" id="f-241" unitRef="usd">44434000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-6" id="f-242" unitRef="usd">-33065000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-6" id="f-243" unitRef="usd">40226000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-6" id="f-244" unitRef="usd">188000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-6" id="f-245" unitRef="usd">40414000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-246" unitRef="usd">1861000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-6" id="f-247" unitRef="usd">1409000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-248" unitRef="usd">650000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-6" id="f-249" unitRef="usd">674000000</us-gaap:DepreciationDepletionAndAmortization>
    <ci:NetInvestmentGainLoss contextRef="c-1" decimals="-6" id="f-250" unitRef="usd">258000000</ci:NetInvestmentGainLoss>
    <ci:NetInvestmentGainLoss contextRef="c-5" decimals="-6" id="f-251" unitRef="usd">-2000000</ci:NetInvestmentGainLoss>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-1" decimals="-6" id="f-252" unitRef="usd">60000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-5" decimals="-6" id="f-253" unitRef="usd">216000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-6" id="f-254" unitRef="usd">11000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-5" decimals="-6" id="f-255" unitRef="usd">41000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c-1" decimals="-6" id="f-256" unitRef="usd">-2152000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c-5" decimals="-6" id="f-257" unitRef="usd">2205000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-6" id="f-258" unitRef="usd">-1507000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-5" decimals="-6" id="f-259" unitRef="usd">-1517000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInReinsuranceRecoverable contextRef="c-1" decimals="-6" id="f-260" unitRef="usd">-104000000</us-gaap:IncreaseDecreaseInReinsuranceRecoverable>
    <us-gaap:IncreaseDecreaseInReinsuranceRecoverable contextRef="c-5" decimals="-6" id="f-261" unitRef="usd">219000000</us-gaap:IncreaseDecreaseInReinsuranceRecoverable>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities contextRef="c-1" decimals="-6" id="f-262" unitRef="usd">739000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities contextRef="c-5" decimals="-6" id="f-263" unitRef="usd">1778000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable contextRef="c-1" decimals="-6" id="f-264" unitRef="usd">-4570000000</ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable>
    <ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable contextRef="c-5" decimals="-6" id="f-265" unitRef="usd">135000000</ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable>
    <ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities contextRef="c-1" decimals="-6" id="f-266" unitRef="usd">-988000000</ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities>
    <ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities contextRef="c-5" decimals="-6" id="f-267" unitRef="usd">-1174000000</ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-6" id="f-268" unitRef="usd">-5000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-5" decimals="-6" id="f-269" unitRef="usd">-260000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-270" unitRef="usd">1131000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-6" id="f-271" unitRef="usd">1920000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <ci:ProceedsFromSaleOfDebtAndEquitySecurities contextRef="c-1" decimals="-6" id="f-272" unitRef="usd">54000000</ci:ProceedsFromSaleOfDebtAndEquitySecurities>
    <ci:ProceedsFromSaleOfDebtAndEquitySecurities contextRef="c-5" decimals="-6" id="f-273" unitRef="usd">94000000</ci:ProceedsFromSaleOfDebtAndEquitySecurities>
    <ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities contextRef="c-1" decimals="-6" id="f-274" unitRef="usd">185000000</ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities>
    <ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities contextRef="c-5" decimals="-6" id="f-275" unitRef="usd">222000000</ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities>
    <us-gaap:ProceedsFromCollectionOfLoansReceivable contextRef="c-1" decimals="-6" id="f-276" unitRef="usd">2000000</us-gaap:ProceedsFromCollectionOfLoansReceivable>
    <us-gaap:ProceedsFromCollectionOfLoansReceivable contextRef="c-5" decimals="-6" id="f-277" unitRef="usd">85000000</us-gaap:ProceedsFromCollectionOfLoansReceivable>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-1" decimals="-6" id="f-278" unitRef="usd">426000000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-5" decimals="-6" id="f-279" unitRef="usd">331000000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <ci:PaymentsToAcquireDebtAndEquitySecurities contextRef="c-1" decimals="-6" id="f-280" unitRef="usd">362000000</ci:PaymentsToAcquireDebtAndEquitySecurities>
    <ci:PaymentsToAcquireDebtAndEquitySecurities contextRef="c-5" decimals="-6" id="f-281" unitRef="usd">952000000</ci:PaymentsToAcquireDebtAndEquitySecurities>
    <us-gaap:PaymentsToAcquireMortgageNotesReceivable contextRef="c-1" decimals="-6" id="f-282" unitRef="usd">39000000</us-gaap:PaymentsToAcquireMortgageNotesReceivable>
    <us-gaap:PaymentsToAcquireMortgageNotesReceivable contextRef="c-5" decimals="-6" id="f-283" unitRef="usd">34000000</us-gaap:PaymentsToAcquireMortgageNotesReceivable>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-1" decimals="-6" id="f-284" unitRef="usd">557000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-5" decimals="-6" id="f-285" unitRef="usd">475000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <ci:PaymentsForProceedsFromPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-286" unitRef="usd">267000000</ci:PaymentsForProceedsFromPropertyPlantAndEquipment>
    <ci:PaymentsForProceedsFromPropertyPlantAndEquipment contextRef="c-5" decimals="-6" id="f-287" unitRef="usd">327000000</ci:PaymentsForProceedsFromPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-1" decimals="-6" id="f-288" unitRef="usd">20000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-5" decimals="-6" id="f-289" unitRef="usd">2346000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-290" unitRef="usd">94000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-5" decimals="-6" id="f-291" unitRef="usd">92000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-6" id="f-292" unitRef="usd">5000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-5" decimals="-6" id="f-293" unitRef="usd">1000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-294" unitRef="usd">-637000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-6" id="f-295" unitRef="usd">1197000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:AdditionsToContractHoldersFunds contextRef="c-1" decimals="-6" id="f-296" unitRef="usd">39000000</us-gaap:AdditionsToContractHoldersFunds>
    <us-gaap:AdditionsToContractHoldersFunds contextRef="c-5" decimals="-6" id="f-297" unitRef="usd">36000000</us-gaap:AdditionsToContractHoldersFunds>
    <us-gaap:WithdrawalFromContractHoldersFunds contextRef="c-1" decimals="-6" id="f-298" unitRef="usd">99000000</us-gaap:WithdrawalFromContractHoldersFunds>
    <us-gaap:WithdrawalFromContractHoldersFunds contextRef="c-5" decimals="-6" id="f-299" unitRef="usd">64000000</us-gaap:WithdrawalFromContractHoldersFunds>
    <ci:ProceedsFromRepaymentsOfOtherShortTermDebt contextRef="c-1" decimals="-6" id="f-300" unitRef="usd">-13000000</ci:ProceedsFromRepaymentsOfOtherShortTermDebt>
    <ci:ProceedsFromRepaymentsOfOtherShortTermDebt contextRef="c-5" decimals="-6" id="f-301" unitRef="usd">-891000000</ci:ProceedsFromRepaymentsOfOtherShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-6" id="f-302" unitRef="usd">550000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-5" decimals="-6" id="f-303" unitRef="usd">700000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-6" id="f-304" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-5" decimals="-6" id="f-305" unitRef="usd">1508000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-6" id="f-306" unitRef="usd">57000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-5" decimals="-6" id="f-307" unitRef="usd">69000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-1" decimals="-6" id="f-308" unitRef="usd">417000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-5" decimals="-6" id="f-309" unitRef="usd">412000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-6" id="f-310" unitRef="usd">-158000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-5" decimals="-6" id="f-311" unitRef="usd">-211000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-312" unitRef="usd">-1141000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-6" id="f-313" unitRef="usd">-3681000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-314" unitRef="usd">-9000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-6" id="f-315" unitRef="usd">9000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-316" unitRef="usd">-656000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-6" id="f-317" unitRef="usd">-555000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-6" id="f-318" unitRef="usd">7736000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-37" decimals="-6" id="f-319" unitRef="usd">8931000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-6" id="f-320" unitRef="usd">7080000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-51" decimals="-6" id="f-321" unitRef="usd">8376000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-348">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="ib641022b45dc4b2381a2a2ff76bff34d_3012"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 1 &#x2013; Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Cigna Group&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Powered by our dedicated people and valued brands, we advance our mission to improve the health and vitality of those we serve. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. The majority of these products and services are offered through employers and other entities, such as governmental and nongovernmental organizations, unions and associations. Certain subsidiaries also offer health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A full description of our segments follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Evernorth Health Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services, such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cigna Healthcare&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:700;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as for individual and family plan customers. International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare also included the Medicare Advantage and related businesses until the divestiture of such businesses to Health Care Services Corporation ("HCSC") on March 19, 2025 ("HCSC transaction").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; comprises the remainder of our business operations, which includes certain continuing business (corporate-owned life insurance ("COLI")), as well as run-off and other non-strategic businesses. Our run-off businesses include the (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013; (ii) settlement annuity business; and (iii) individual life insurance and annuity and retirement benefits businesses, which were sold through reinsurance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-349">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span id="iad4ff92f8b8243cd96f4a641a7625340_743"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 2 &#x2013; Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain goodwill and other intangible assets amounts in the Consolidated Balance Sheet have been reclassified as of March 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These interim Consolidated Financial Statements are unaudited but include all adjustments (including normal recurring adjustments) necessary, in the opinion of management, for a fair statement of financial position and results of operations for the periods reported. The interim Consolidated Financial Statements and Notes should be read in conjunction with the Consolidated Financial Statements and Notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K"). The Company has not included certain footnote disclosures that would substantially duplicate the disclosures contained in its 2025 Form &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10-K, unless the information in those disclosures materially changed or is required by GAAP. The preparation of interim Consolidated Financial Statements necessarily relies heavily on estimates. This and other factors, including the seasonal nature of portions of the health care and related benefits business, as well as competitive and other market conditions, call for caution in estimating full-year results based on interim results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company's 2025 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. There are no updates to significant accounting pronouncements recently adopted that have occurred since the Company filed its 2025 Form 10-K. There are no incremental significant accounting pronouncements recently issued and not yet adopted that are expected to impact our operations or financial statements beyond those described in the Company's 2025 Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"&gt; The Company continues to progress with its adoption plans, with no significant updates since the 2025 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-350">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain goodwill and other intangible assets amounts in the Consolidated Balance Sheet have been reclassified as of March 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These interim Consolidated Financial Statements are unaudited but include all adjustments (including normal recurring adjustments) necessary, in the opinion of management, for a fair statement of financial position and results of operations for the periods reported. The interim Consolidated Financial Statements and Notes should be read in conjunction with the Consolidated Financial Statements and Notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K"). The Company has not included certain footnote disclosures that would substantially duplicate the disclosures contained in its 2025 Form &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10-K, unless the information in those disclosures materially changed or is required by GAAP. The preparation of interim Consolidated Financial Statements necessarily relies heavily on estimates. This and other factors, including the seasonal nature of portions of the health care and related benefits business, as well as competitive and other market conditions, call for caution in estimating full-year results based on interim results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-351">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company's 2025 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. There are no updates to significant accounting pronouncements recently adopted that have occurred since the Company filed its 2025 Form 10-K. There are no incremental significant accounting pronouncements recently issued and not yet adopted that are expected to impact our operations or financial statements beyond those described in the Company's 2025 Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"&gt; The Company continues to progress with its adoption plans, with no significant updates since the 2025 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c-1" id="f-352">&lt;div&gt;&lt;span id="iab9e5d6c7f8041278eb36290adebc81f_13"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 3 &#x2013; Accounts Receivable, Net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts were included within Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noninsurance customer receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13,797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical manufacturers receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,914&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance customer receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;244&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26,607&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These accounts receivable are reported net of our allowances of $7.7 billion and $6.8 billion as of March&#160;31, 2026 and December&#160;31, 2025, respectively. These allowances include contractual allowances for certain rebates receivable with pharmaceutical manufacturers and certain accounts receivable from third-party payors, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses, and other non-credit adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's allowance for current expected credit losses was $228 million and $199 million as of March&#160;31, 2026 and December&#160;31, 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;Accounts Receivable Factoring Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company maintains uncommitted factoring facilities with a total capacity of $2.0 billion under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. In the first quarter of 2026, the Company entered into a new accounts receivable factoring facility with an initial two-year term, in addition to the previously established accounts receivable factoring facility outlined in Note 3 to the Consolidated Financial Statements included in the Company's 2025 Form 10-K (together, the "Facilities"). The Facilities automatically renew and are subject to automatic one-year renewal terms following the expiration of the initial term unless terminated by either party. The transactions under the Facilities are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with the Facilities are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under the Facilities are reflected in Interest expense and other in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We sold receivables under the Facilities of $0.3 billion and $1.4 billion for the three months ended March&#160;31, 2026 and 2025, respectively. For the three months ended March&#160;31, 2026 and 2025, factoring fees paid were not material. As of March&#160;31, 2026 and December&#160;31, 2025, all sold accounts receivable had been collected. As of March&#160;31, 2026, all collections have been remitted to the financial institution. As of December&#160;31, 2025, there were $0.4 billion of collections that had not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c-1" id="f-353">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts were included within Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noninsurance customer receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13,797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical manufacturers receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,914&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance customer receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;244&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26,607&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable contextRef="c-8" decimals="-6" id="f-354" unitRef="usd">13797000000</ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable>
    <ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable contextRef="c-9" decimals="-6" id="f-355" unitRef="usd">14707000000</ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable>
    <ci:PharmaceuticalManufacturerReceivable contextRef="c-8" decimals="-6" id="f-356" unitRef="usd">10914000000</ci:PharmaceuticalManufacturerReceivable>
    <ci:PharmaceuticalManufacturerReceivable contextRef="c-9" decimals="-6" id="f-357" unitRef="usd">12437000000</ci:PharmaceuticalManufacturerReceivable>
    <ci:InsuranceCustomerReceivables contextRef="c-8" decimals="-6" id="f-358" unitRef="usd">1652000000</ci:InsuranceCustomerReceivables>
    <ci:InsuranceCustomerReceivables contextRef="c-9" decimals="-6" id="f-359" unitRef="usd">1385000000</ci:InsuranceCustomerReceivables>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-8" decimals="-6" id="f-360" unitRef="usd">244000000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-9" decimals="-6" id="f-361" unitRef="usd">239000000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-8" decimals="-6" id="f-362" unitRef="usd">26607000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-9" decimals="-6" id="f-363" unitRef="usd">28768000000</us-gaap:ReceivablesNetCurrent>
    <ci:AllowanceForReceivablesCurrent contextRef="c-8" decimals="-8" id="f-364" unitRef="usd">7700000000</ci:AllowanceForReceivablesCurrent>
    <ci:AllowanceForReceivablesCurrent contextRef="c-9" decimals="-8" id="f-365" unitRef="usd">6800000000</ci:AllowanceForReceivablesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-8" decimals="-6" id="f-366" unitRef="usd">228000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-9" decimals="-6" id="f-367" unitRef="usd">199000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <ci:AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity contextRef="c-8" decimals="-8" id="f-368" unitRef="usd">2000000000.0</ci:AccountsReceivableUncommittedFactoringFacilitiesTotalCapacity>
    <ci:AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm contextRef="c-1" id="f-369">P1Y</ci:AccountsReceivableUncommittedFactoringFacilitiesAutomaticRenewalTerm>
    <ci:AccountsReceivableUncommittedFactoringFacilitiesAmountSold contextRef="c-1" decimals="-8" id="f-370" unitRef="usd">300000000</ci:AccountsReceivableUncommittedFactoringFacilitiesAmountSold>
    <ci:AccountsReceivableUncommittedFactoringFacilitiesAmountSold contextRef="c-5" decimals="-8" id="f-371" unitRef="usd">1400000000</ci:AccountsReceivableUncommittedFactoringFacilitiesAmountSold>
    <ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted contextRef="c-9" decimals="-8" id="f-372" unitRef="usd">400000000</ci:AccountsReceivableUncommittedFactoringFacilitiesAccountsReceivableReceivedButNotRemitted>
    <us-gaap:SupplierFinanceProgramTextBlock contextRef="c-1" id="f-373">&lt;div style="margin-top:10pt"&gt;&lt;span id="ia7fc84917c564cad9c9383247302640f_12"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 4 &#x2013; Supplier Finance Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require. &lt;/span&gt;&lt;/div&gt;As of March&#160;31, 2026 and December&#160;31, 2025, $1.3&#160;billion and $1.6&#160;billion, respectively, of the Company's outstanding payment obligations were confirmed as valid within the Program by the financial institution and are reflected in &lt;span style="-sec-ix-hidden:f-378"&gt;&lt;span style="-sec-ix-hidden:f-379"&gt;&lt;span style="-sec-ix-hidden:f-380"&gt;&lt;span style="-sec-ix-hidden:f-381"&gt;Accounts payable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; in the Consolidated Balance Sheets. The amounts confirmed as valid for both periods are predominately associated with one supplier.</us-gaap:SupplierFinanceProgramTextBlock>
    <us-gaap:SupplierFinanceProgramObligation contextRef="c-8" decimals="-8" id="f-374" unitRef="usd">1300000000</us-gaap:SupplierFinanceProgramObligation>
    <us-gaap:SupplierFinanceProgramObligationCurrent contextRef="c-8" decimals="-8" id="f-375" unitRef="usd">1300000000</us-gaap:SupplierFinanceProgramObligationCurrent>
    <us-gaap:SupplierFinanceProgramObligation contextRef="c-9" decimals="-8" id="f-376" unitRef="usd">1600000000</us-gaap:SupplierFinanceProgramObligation>
    <us-gaap:SupplierFinanceProgramObligationCurrent contextRef="c-9" decimals="-8" id="f-377" unitRef="usd">1600000000</us-gaap:SupplierFinanceProgramObligationCurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-top:10pt"&gt;&lt;span id="i70b43112ac3247a498e319c771b05e87_13"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 5 &#x2013; Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic and diluted earnings per share were computed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.238%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in thousands, dollars in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of&lt;br/&gt;Dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of&lt;br/&gt;Dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,654&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,654&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;262,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;262,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;262,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;264,017&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;272,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Anti-dilutive options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April&#160;22, 2026, the Board of Directors of The Cigna Group (the "Board") declared the second quarter cash dividend of $1.56 per share of The Cigna Group common stock to be paid on June&#160;18, 2026 to shareholders of record on June&#160;4, 2026. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by the Board and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company held approximately 141.4 million shares of common stock in treasury as of March&#160;31, 2026, 141.1 million shares as of December&#160;31, 2025 and 134.1 million shares as of March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-383">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic and diluted earnings per share were computed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.238%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in thousands, dollars in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of&lt;br/&gt;Dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of&lt;br/&gt;Dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,654&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,654&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;262,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;262,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;262,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;264,017&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;272,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-384" unitRef="usd">1654000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-385" unitRef="usd">1654000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-6" id="f-386" unitRef="usd">1323000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-6" id="f-387" unitRef="usd">1323000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-1" decimals="-3" id="f-388" unitRef="shares">262746000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-1" decimals="-3" id="f-389" unitRef="shares">262746000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-5" decimals="-3" id="f-390" unitRef="shares">270867000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-5" decimals="-3" id="f-391" unitRef="shares">270867000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-392" unitRef="shares">1271000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-393" unitRef="shares">1271000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-5" decimals="-3" id="f-394" unitRef="shares">2086000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-5" decimals="-3" id="f-395" unitRef="shares">2086000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-1" decimals="-3" id="f-396" unitRef="shares">262746000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-397" unitRef="shares">1271000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-398" unitRef="shares">264017000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-5" decimals="-3" id="f-399" unitRef="shares">270867000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-5" decimals="-3" id="f-400" unitRef="shares">2086000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-401" unitRef="shares">272953000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-402"
      unitRef="usdPerShare">6.30</us-gaap:EarningsPerShareBasic>
    <ci:EarningsPerShareEffectOfDilution
      contextRef="c-1"
      decimals="2"
      id="f-403"
      unitRef="usdPerShare">-0.04</ci:EarningsPerShareEffectOfDilution>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-404"
      unitRef="usdPerShare">6.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-405"
      unitRef="usdPerShare">4.88</us-gaap:EarningsPerShareBasic>
    <ci:EarningsPerShareEffectOfDilution
      contextRef="c-5"
      decimals="2"
      id="f-406"
      unitRef="usdPerShare">-0.03</ci:EarningsPerShareEffectOfDilution>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-407"
      unitRef="usdPerShare">4.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Anti-dilutive options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-60" decimals="-5" id="f-409" unitRef="shares">2300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="-5" id="f-410" unitRef="shares">2300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DividendsPayableDateDeclaredDayMonthAndYear contextRef="c-62" id="f-411">2026-04-22</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-62"
      decimals="INF"
      id="f-412"
      unitRef="usdPerShare">1.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear contextRef="c-62" id="f-413">2026-06-18</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear contextRef="c-62" id="f-414">2026-06-04</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:TreasuryStockCommonShares contextRef="c-8" decimals="-5" id="f-415" unitRef="shares">141400000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-9" decimals="-5" id="f-416" unitRef="shares">141100000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-51" decimals="-5" id="f-417" unitRef="shares">134100000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-418">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span id="i94555fdb495846a18fe0238b309c6410_11"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 6 &#x2013; Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term and Long-Term Debt. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2026, the Company repaid $550 million 1.250% senior notes that matured in March 2026. For more information regarding our short-term and long-term debt, see Note 7 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revolving Credit Agreement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company maintains a $6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for additional one-year periods, subject to consent of the banks (the "Credit Agreement"). Our Credit Agreement provides us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of March&#160;31, 2026, there was no outstanding balance under the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Commercial Paper. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper balance as of March&#160;31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Interest Expense. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest expense on long-term and short-term debt was $357 million for the three months ended March&#160;31, 2026 and $362 million for the three months ended March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-63" decimals="-6" id="f-419" unitRef="usd">550000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-64"
      decimals="INF"
      id="f-420"
      unitRef="number">0.01250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-65" decimals="INF" id="f-421" unitRef="usd">6500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-52" id="f-422">P5Y</us-gaap:DebtInstrumentTerm>
    <ci:DebtInstrumentExtensionTerm contextRef="c-52" id="f-423">P1Y</ci:DebtInstrumentExtensionTerm>
    <us-gaap:LineOfCredit contextRef="c-66" decimals="INF" id="f-424" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-67" decimals="INF" id="f-425" unitRef="usd">6500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommercialPaper contextRef="c-67" decimals="INF" id="f-426" unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-6" id="f-427" unitRef="usd">357000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-5" decimals="-6" id="f-428" unitRef="usd">362000000</us-gaap:InterestExpenseDebt>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock contextRef="c-1" id="f-429">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 7 &#x2013; &lt;span id="i360bb05418cb4cd3be784b1eac3699f5_700"&gt;&lt;/span&gt;Insurance and Contractholder Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline"&gt;Account Balances &#x2013; Insurance and Contractholder Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's insurance and contractholder liabilities were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.048%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unpaid claims and claim expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,856&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Future policy benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;139&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,008&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contractholder deposit funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,701&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unearned premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;914&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;959&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total insurance and contractholder liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Insurance and contractholder liabilities expected to be paid within one year are classified as current. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline"&gt;Unpaid Claims and Claim Expenses &#x2013; Cigna Healthcare&lt;/span&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $4.7 billion as of March&#160;31, 2026 and $4.4 billion as of March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Reinsurance and other amounts recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurred costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Paid costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,859&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Divestiture and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Add: Reinsurance and other amounts recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;140&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes unpaid claims amounts classified as liabilities of businesses held for sale prior to the completion of the HCSC transaction. As of December&#160;31, 2024, includes $983 million classified as liabilities of businesses held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 8 to the Consolidated Financial Statements for additional information on reinsurance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.889%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;% &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;% &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual completion factors and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical cost trend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total favorable variance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Percentage of current year incurred costs as reported for the year ended December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Percentage of current year incurred costs as reported for the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Favorable prior year development in both years primarily reflects lower than expected utilization of medical services as compared to our assumptions.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Future Policy Benefits&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest accretion rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current discount rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average duration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;'&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future policy benefits include deferred profit liability of $348 million as of March&#160;31, 2026 and $359&#160;million as of March&#160;31, 2025. Future policy benefits excluding deferred profit liability were $2.8&#160;billion as of March&#160;31, 2026, $2.9&#160;billion as of December&#160;31, 2025, $3.0&#160;billion as of March&#160;31, 2025, and $2.9&#160;billion as of December&#160;31, 2024. Undiscounted expected future policy benefits were $4.1&#160;billion as of March&#160;31, 2026 and $4.3&#160;billion as of March&#160;31, 2025. As of March&#160;31, 2026 and March&#160;31, 2025, $0.8&#160;billion and $0.9&#160;billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline"&gt;Contractholder Deposit Funds&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractholder deposit fund liabilities within Other Operations were $6.0 billion as of March&#160;31, 2026, $6.1 billion as of December&#160;31, 2025 and $6.3 billion as of both March&#160;31, 2025 and December&#160;31, 2024. Approximately 37% of the balance is reinsured externally. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2026, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were 3.19%, $2.4 billion and $2.8 billion, respectively. The comparative amounts as of March&#160;31, 2025 were 3.20%, $2.8 billion and $2.8 billion, respectively. More than 99% of the $3.8 billion liability as of March&#160;31, 2026 and the $4.0 billion liability as of March&#160;31, 2025 not reinsured externally is for contracts with guaranteed interest rates of 3% - 4%, and approximately $1.2 billion as of both period ends represented contracts with policies at the guarantee. At these same period ends, $1.0 billion and $1.2 billion was 50 - 150 basis points ("bps") above the guarantee, and the remaining $1.6 billion as of both March&#160;31, 2026 and March&#160;31, 2025 represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. As of both March&#160;31, 2026 and March&#160;31, 2025, more than 90% of these contracts have actual cash values of at least 110% of the guaranteed cash value.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline"&gt;Market Risk Benefits&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities for market risk benefits ("MRBs") consist of variable annuity reinsurance contracts in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within 30 days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Market risk benefits activity was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, beginning of year, before the effect of nonperformance risk (own credit risk)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to expected run-off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to capital markets versus expected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to policyholder behavior versus expected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;716&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Nonperformance risk (own credit risk), end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Reinsured market risk benefit, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;715&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 8 to the Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions, excludes impact of reinsurance ceded)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amount at risk&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Average attained age of contractholders (weighted by exposure)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense contextRef="c-1" id="f-430">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's insurance and contractholder liabilities were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.048%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unpaid claims and claim expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,856&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Future policy benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;139&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,008&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contractholder deposit funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,701&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unearned premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;914&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;959&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total insurance and contractholder liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Reinsurance and other amounts recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurred costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Paid costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,859&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Divestiture and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Add: Reinsurance and other amounts recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;140&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent contextRef="c-68" decimals="-6" id="f-431" unitRef="usd">4856000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent contextRef="c-68" decimals="-6" id="f-432" unitRef="usd">64000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-68" decimals="-6" id="f-433" unitRef="usd">4920000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent contextRef="c-69" decimals="-6" id="f-434" unitRef="usd">4180000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent contextRef="c-69" decimals="-6" id="f-435" unitRef="usd">61000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-69" decimals="-6" id="f-436" unitRef="usd">4241000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-70" decimals="-6" id="f-437" unitRef="usd">4508000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent contextRef="c-71" decimals="-6" id="f-438" unitRef="usd">152000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent contextRef="c-71" decimals="-6" id="f-439" unitRef="usd">164000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-71" decimals="-6" id="f-440" unitRef="usd">316000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent contextRef="c-72" decimals="-6" id="f-441" unitRef="usd">167000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent contextRef="c-72" decimals="-6" id="f-442" unitRef="usd">176000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-72" decimals="-6" id="f-443" unitRef="usd">343000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-73" decimals="-6" id="f-444" unitRef="usd">366000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent contextRef="c-68" decimals="-6" id="f-445" unitRef="usd">37000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent contextRef="c-68" decimals="-6" id="f-446" unitRef="usd">148000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-68" decimals="-6" id="f-447" unitRef="usd">185000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent contextRef="c-69" decimals="-6" id="f-448" unitRef="usd">38000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent contextRef="c-69" decimals="-6" id="f-449" unitRef="usd">153000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-69" decimals="-6" id="f-450" unitRef="usd">191000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-70" decimals="-6" id="f-451" unitRef="usd">192000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent contextRef="c-74" decimals="-6" id="f-452" unitRef="usd">139000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent contextRef="c-74" decimals="-6" id="f-453" unitRef="usd">3008000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-74" decimals="-6" id="f-454" unitRef="usd">3147000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent contextRef="c-75" decimals="-6" id="f-455" unitRef="usd">142000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent contextRef="c-75" decimals="-6" id="f-456" unitRef="usd">3081000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-75" decimals="-6" id="f-457" unitRef="usd">3223000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-76" decimals="-6" id="f-458" unitRef="usd">3308000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <ci:PolicyholderContractDepositCurrent contextRef="c-8" decimals="-6" id="f-459" unitRef="usd">329000000</ci:PolicyholderContractDepositCurrent>
    <ci:PolicyholderContractDepositNoncurrent contextRef="c-8" decimals="-6" id="f-460" unitRef="usd">5701000000</ci:PolicyholderContractDepositNoncurrent>
    <us-gaap:PolicyholderContractDeposits contextRef="c-8" decimals="-6" id="f-461" unitRef="usd">6030000000</us-gaap:PolicyholderContractDeposits>
    <ci:PolicyholderContractDepositCurrent contextRef="c-9" decimals="-6" id="f-462" unitRef="usd">336000000</ci:PolicyholderContractDepositCurrent>
    <ci:PolicyholderContractDepositNoncurrent contextRef="c-9" decimals="-6" id="f-463" unitRef="usd">5778000000</ci:PolicyholderContractDepositNoncurrent>
    <us-gaap:PolicyholderContractDeposits contextRef="c-9" decimals="-6" id="f-464" unitRef="usd">6114000000</us-gaap:PolicyholderContractDeposits>
    <us-gaap:PolicyholderContractDeposits contextRef="c-51" decimals="-6" id="f-465" unitRef="usd">6251000000</us-gaap:PolicyholderContractDeposits>
    <ci:MarketRiskBenefitLiabilityAmountCurrent contextRef="c-8" decimals="-6" id="f-466" unitRef="usd">28000000</ci:MarketRiskBenefitLiabilityAmountCurrent>
    <ci:MarketRiskBenefitLiabilityAmountNoncurrent contextRef="c-8" decimals="-6" id="f-467" unitRef="usd">647000000</ci:MarketRiskBenefitLiabilityAmountNoncurrent>
    <us-gaap:MarketRiskBenefitLiabilityAmount contextRef="c-8" decimals="-6" id="f-468" unitRef="usd">675000000</us-gaap:MarketRiskBenefitLiabilityAmount>
    <ci:MarketRiskBenefitLiabilityAmountCurrent contextRef="c-9" decimals="-6" id="f-469" unitRef="usd">25000000</ci:MarketRiskBenefitLiabilityAmountCurrent>
    <ci:MarketRiskBenefitLiabilityAmountNoncurrent contextRef="c-9" decimals="-6" id="f-470" unitRef="usd">649000000</ci:MarketRiskBenefitLiabilityAmountNoncurrent>
    <us-gaap:MarketRiskBenefitLiabilityAmount contextRef="c-9" decimals="-6" id="f-471" unitRef="usd">674000000</us-gaap:MarketRiskBenefitLiabilityAmount>
    <us-gaap:MarketRiskBenefitLiabilityAmount contextRef="c-51" decimals="-6" id="f-472" unitRef="usd">830000000</us-gaap:MarketRiskBenefitLiabilityAmount>
    <ci:UnearnedPremiumsCurrent contextRef="c-8" decimals="-6" id="f-473" unitRef="usd">914000000</ci:UnearnedPremiumsCurrent>
    <ci:UnearnedPremiumsNoncurrent contextRef="c-8" decimals="-6" id="f-474" unitRef="usd">45000000</ci:UnearnedPremiumsNoncurrent>
    <us-gaap:UnearnedPremiums contextRef="c-8" decimals="-6" id="f-475" unitRef="usd">959000000</us-gaap:UnearnedPremiums>
    <ci:UnearnedPremiumsCurrent contextRef="c-9" decimals="-6" id="f-476" unitRef="usd">822000000</ci:UnearnedPremiumsCurrent>
    <ci:UnearnedPremiumsNoncurrent contextRef="c-9" decimals="-6" id="f-477" unitRef="usd">40000000</ci:UnearnedPremiumsNoncurrent>
    <us-gaap:UnearnedPremiums contextRef="c-9" decimals="-6" id="f-478" unitRef="usd">862000000</us-gaap:UnearnedPremiums>
    <us-gaap:UnearnedPremiums contextRef="c-51" decimals="-6" id="f-479" unitRef="usd">838000000</us-gaap:UnearnedPremiums>
    <ci:InsuranceAndContractholderLiabilitiesCurrent contextRef="c-8" decimals="-6" id="f-480" unitRef="usd">6455000000</ci:InsuranceAndContractholderLiabilitiesCurrent>
    <ci:InsuranceAndContractholderLiabilitiesNoncurrent contextRef="c-8" decimals="-6" id="f-481" unitRef="usd">9777000000</ci:InsuranceAndContractholderLiabilitiesNoncurrent>
    <ci:InsuranceAndContractholderLiabilities contextRef="c-8" decimals="-6" id="f-482" unitRef="usd">16232000000</ci:InsuranceAndContractholderLiabilities>
    <ci:InsuranceAndContractholderLiabilitiesCurrent contextRef="c-9" decimals="-6" id="f-483" unitRef="usd">5710000000</ci:InsuranceAndContractholderLiabilitiesCurrent>
    <ci:InsuranceAndContractholderLiabilitiesNoncurrent contextRef="c-9" decimals="-6" id="f-484" unitRef="usd">9938000000</ci:InsuranceAndContractholderLiabilitiesNoncurrent>
    <ci:InsuranceAndContractholderLiabilities contextRef="c-9" decimals="-6" id="f-485" unitRef="usd">15648000000</ci:InsuranceAndContractholderLiabilities>
    <ci:InsuranceAndContractholderLiabilities contextRef="c-51" decimals="-6" id="f-486" unitRef="usd">16293000000</ci:InsuranceAndContractholderLiabilities>
    <us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy contextRef="c-1" id="f-487">This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.</us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses contextRef="c-68" decimals="-8" id="f-488" unitRef="usd">4700000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses contextRef="c-70" decimals="-8" id="f-489" unitRef="usd">4400000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-69" decimals="-6" id="f-490" unitRef="usd">4241000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups contextRef="c-77" decimals="-6" id="f-491" unitRef="usd">5018000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments contextRef="c-69" decimals="-6" id="f-492" unitRef="usd">147000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <ci:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups contextRef="c-77" decimals="-6" id="f-493" unitRef="usd">159000000</ci:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet contextRef="c-69" decimals="-6" id="f-494" unitRef="usd">4094000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups contextRef="c-77" decimals="-6" id="f-495" unitRef="usd">4859000000</ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-78" decimals="-6" id="f-496" unitRef="usd">7852000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-79" decimals="-6" id="f-497" unitRef="usd">10606000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-78" decimals="-6" id="f-498" unitRef="usd">-188000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-79" decimals="-6" id="f-499" unitRef="usd">-222000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-78" decimals="-6" id="f-500" unitRef="usd">7664000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-79" decimals="-6" id="f-501" unitRef="usd">10384000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-78" decimals="-6" id="f-502" unitRef="usd">4119000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-79" decimals="-6" id="f-503" unitRef="usd">6078000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-78" decimals="-6" id="f-504" unitRef="usd">2859000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-79" decimals="-6" id="f-505" unitRef="usd">3472000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-78" decimals="-6" id="f-506" unitRef="usd">6978000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-79" decimals="-6" id="f-507" unitRef="usd">9550000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther contextRef="c-78" decimals="-6" id="f-508" unitRef="usd">0</ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther>
    <ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther contextRef="c-79" decimals="-6" id="f-509" unitRef="usd">1323000000</ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDivestitureAndOther>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet contextRef="c-68" decimals="-6" id="f-510" unitRef="usd">4780000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet contextRef="c-70" decimals="-6" id="f-511" unitRef="usd">4370000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments contextRef="c-68" decimals="-6" id="f-512" unitRef="usd">140000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments contextRef="c-70" decimals="-6" id="f-513" unitRef="usd">138000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-68" decimals="-6" id="f-514" unitRef="usd">4920000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-70" decimals="-6" id="f-515" unitRef="usd">4508000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense contextRef="c-80" decimals="-6" id="f-516" unitRef="usd">983000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock contextRef="c-1" id="f-517">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.889%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;% &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;% &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual completion factors and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical cost trend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total favorable variance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Percentage of current year incurred costs as reported for the year ended December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Percentage of current year incurred costs as reported for the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-81" decimals="-6" id="f-518" unitRef="usd">-96000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage contextRef="c-81" decimals="3" id="f-519" unitRef="number">0.003</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-82" decimals="-6" id="f-520" unitRef="usd">-96000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage contextRef="c-82" decimals="3" id="f-521" unitRef="number">0.003</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-83" decimals="-6" id="f-522" unitRef="usd">-92000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage contextRef="c-83" decimals="3" id="f-523" unitRef="number">0.003</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-84" decimals="-6" id="f-524" unitRef="usd">-126000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage contextRef="c-84" decimals="3" id="f-525" unitRef="number">0.003</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-78" decimals="-6" id="f-526" unitRef="usd">-188000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage contextRef="c-78" decimals="3" id="f-527" unitRef="number">0.006</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-79" decimals="-6" id="f-528" unitRef="usd">-222000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage contextRef="c-79" decimals="3" id="f-529" unitRef="number">0.006</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:LiabilityForFuturePolicyBenefitActivityTableTextBlock contextRef="c-1" id="f-530">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest accretion rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current discount rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average duration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitActivityTableTextBlock>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate contextRef="c-85" decimals="4" id="f-531" unitRef="number">0.0564</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate contextRef="c-86" decimals="4" id="f-532" unitRef="number">0.0564</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate>
    <us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate contextRef="c-85" decimals="4" id="f-533" unitRef="number">0.0539</us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate>
    <us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate contextRef="c-86" decimals="4" id="f-534" unitRef="number">0.0530</us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration contextRef="c-85" id="f-535">P10Y6M</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration contextRef="c-86" id="f-536">P10Y9M18D</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration>
    <us-gaap:FuturePolicyBenefitsLiabilityPolicy contextRef="c-1" id="f-537">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;'&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:FuturePolicyBenefitsLiabilityPolicy>
    <ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability contextRef="c-74" decimals="-6" id="f-538" unitRef="usd">348000000</ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability>
    <ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability contextRef="c-76" decimals="-6" id="f-539" unitRef="usd">359000000</ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability>
    <ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability contextRef="c-74" decimals="-8" id="f-540" unitRef="usd">2800000000</ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability>
    <ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability contextRef="c-75" decimals="-8" id="f-541" unitRef="usd">2900000000</ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability>
    <ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability contextRef="c-76" decimals="-8" id="f-542" unitRef="usd">3000000000.0</ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability>
    <ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability contextRef="c-87" decimals="-8" id="f-543" unitRef="usd">2900000000</ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance contextRef="c-74" decimals="-8" id="f-544" unitRef="usd">4100000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance contextRef="c-76" decimals="-8" id="f-545" unitRef="usd">4300000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance contextRef="c-74" decimals="-8" id="f-546" unitRef="usd">800000000</us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance contextRef="c-76" decimals="-8" id="f-547" unitRef="usd">900000000</us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:PolicyholderContractDeposits contextRef="c-8" decimals="-8" id="f-548" unitRef="usd">6000000000.0</us-gaap:PolicyholderContractDeposits>
    <us-gaap:PolicyholderContractDeposits contextRef="c-9" decimals="-8" id="f-549" unitRef="usd">6100000000</us-gaap:PolicyholderContractDeposits>
    <us-gaap:PolicyholderContractDeposits contextRef="c-9" decimals="-8" id="f-550" unitRef="usd">6100000000</us-gaap:PolicyholderContractDeposits>
    <us-gaap:PolicyholderContractDeposits contextRef="c-51" decimals="-8" id="f-551" unitRef="usd">6300000000</us-gaap:PolicyholderContractDeposits>
    <us-gaap:PolicyholderContractDeposits contextRef="c-37" decimals="-8" id="f-552" unitRef="usd">6300000000</us-gaap:PolicyholderContractDeposits>
    <ci:PolicyholderContractBalancePercentReinsuredExternally contextRef="c-8" decimals="2" id="f-553" unitRef="number">0.37</ci:PolicyholderContractBalancePercentReinsuredExternally>
    <us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate contextRef="c-8" decimals="4" id="f-554" unitRef="number">0.0319</us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate>
    <us-gaap:PolicyholderAccountBalanceNetAmountAtRisk contextRef="c-8" decimals="-8" id="f-555" unitRef="usd">2400000000</us-gaap:PolicyholderAccountBalanceNetAmountAtRisk>
    <us-gaap:CashSurrenderValueDuePolicyholdersAmount contextRef="c-8" decimals="-8" id="f-556" unitRef="usd">2800000000</us-gaap:CashSurrenderValueDuePolicyholdersAmount>
    <us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate contextRef="c-51" decimals="4" id="f-557" unitRef="number">0.0320</us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate>
    <us-gaap:PolicyholderAccountBalanceNetAmountAtRisk contextRef="c-51" decimals="-8" id="f-558" unitRef="usd">2800000000</us-gaap:PolicyholderAccountBalanceNetAmountAtRisk>
    <us-gaap:CashSurrenderValueDuePolicyholdersAmount contextRef="c-51" decimals="-8" id="f-559" unitRef="usd">2800000000</us-gaap:CashSurrenderValueDuePolicyholdersAmount>
    <ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage contextRef="c-88" decimals="2" id="f-560" unitRef="number">0.99</ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage>
    <ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage contextRef="c-89" decimals="2" id="f-561" unitRef="number">0.99</ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage>
    <us-gaap:PolicyholderFunds contextRef="c-88" decimals="-8" id="f-562" unitRef="usd">3800000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderFunds contextRef="c-89" decimals="-8" id="f-563" unitRef="usd">4000000000.0</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating contextRef="c-90" decimals="2" id="f-564" unitRef="number">0.03</us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating>
    <us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating contextRef="c-91" decimals="2" id="f-565" unitRef="number">0.03</us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating>
    <us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating contextRef="c-92" decimals="2" id="f-566" unitRef="number">0.04</us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating>
    <us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating contextRef="c-93" decimals="2" id="f-567" unitRef="number">0.04</us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating>
    <us-gaap:PolicyholderFunds contextRef="c-94" decimals="-8" id="f-568" unitRef="usd">1200000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderFunds contextRef="c-95" decimals="-8" id="f-569" unitRef="usd">1200000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderFunds contextRef="c-96" decimals="-8" id="f-570" unitRef="usd">1000000000.0</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderFunds contextRef="c-97" decimals="-8" id="f-571" unitRef="usd">1200000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate contextRef="c-98" decimals="3" id="f-572" unitRef="number">0.0050</us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate>
    <us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate contextRef="c-99" decimals="3" id="f-573" unitRef="number">0.0050</us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate>
    <us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate contextRef="c-100" decimals="3" id="f-574" unitRef="number">0.0150</us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate>
    <us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate contextRef="c-101" decimals="3" id="f-575" unitRef="number">0.0150</us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate>
    <us-gaap:PolicyholderFunds contextRef="c-102" decimals="-8" id="f-576" unitRef="usd">1600000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderFunds contextRef="c-103" decimals="-8" id="f-577" unitRef="usd">1600000000</us-gaap:PolicyholderFunds>
    <ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue contextRef="c-102" decimals="2" id="f-578" unitRef="number">0.90</ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue>
    <ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue contextRef="c-103" decimals="2" id="f-579" unitRef="number">0.90</ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue>
    <ci:AnnuitizationElectionPeriod contextRef="c-1" id="f-580">P30D</ci:AnnuitizationElectionPeriod>
    <us-gaap:MarketRiskBenefitActivityTableTextBlock contextRef="c-1" id="f-581">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Market risk benefits activity was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, beginning of year, before the effect of nonperformance risk (own credit risk)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to expected run-off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to capital markets versus expected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to policyholder behavior versus expected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;716&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Nonperformance risk (own credit risk), end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Reinsured market risk benefit, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%"&gt;715&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketRiskBenefitActivityTableTextBlock>
    <us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk contextRef="c-9" decimals="-6" id="f-582" unitRef="usd">674000000</us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk>
    <us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk contextRef="c-37" decimals="-6" id="f-583" unitRef="usd">785000000</us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk>
    <us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange contextRef="c-9" decimals="-6" id="f-584" unitRef="usd">714000000</us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange>
    <us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange contextRef="c-37" decimals="-6" id="f-585" unitRef="usd">838000000</us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange>
    <ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff contextRef="c-1" decimals="-6" id="f-586" unitRef="usd">-6000000</ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff>
    <ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff contextRef="c-5" decimals="-6" id="f-587" unitRef="usd">-4000000</ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff>
    <ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange contextRef="c-1" decimals="-6" id="f-588" unitRef="usd">13000000</ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange>
    <ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange contextRef="c-5" decimals="-6" id="f-589" unitRef="usd">44000000</ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange>
    <us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected contextRef="c-1" decimals="-6" id="f-590" unitRef="usd">-5000000</us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected>
    <us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected contextRef="c-5" decimals="-6" id="f-591" unitRef="usd">0</us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected>
    <us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange contextRef="c-8" decimals="-6" id="f-592" unitRef="usd">716000000</us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange>
    <us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange contextRef="c-51" decimals="-6" id="f-593" unitRef="usd">878000000</us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange>
    <us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax contextRef="c-8" decimals="-6" id="f-594" unitRef="usd">41000000</us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax>
    <us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax contextRef="c-51" decimals="-6" id="f-595" unitRef="usd">48000000</us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax>
    <us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk contextRef="c-8" decimals="-6" id="f-596" unitRef="usd">675000000</us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk>
    <us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk contextRef="c-51" decimals="-6" id="f-597" unitRef="usd">830000000</us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk>
    <us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance contextRef="c-8" decimals="-6" id="f-598" unitRef="usd">715000000</us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance contextRef="c-51" decimals="-6" id="f-599" unitRef="usd">876000000</us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock contextRef="c-1" id="f-600">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 8 to the Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions, excludes impact of reinsurance ceded)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amount at risk&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Average attained age of contractholders (weighted by exposure)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk contextRef="c-104" decimals="-6" id="f-601" unitRef="usd">1194000000</us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk contextRef="c-105" decimals="-6" id="f-602" unitRef="usd">1412000000</us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1 contextRef="c-106" id="f-603">P77Y7M6D</us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1 contextRef="c-107" id="f-604">P77Y</us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1>
    <us-gaap:ReinsuranceTextBlock contextRef="c-1" id="f-605">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="id20be86505734bd88680a83a2a1e6585_624"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 8 &#x2013; Reinsurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables primarily for expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's reinsurance recoverables as of March&#160;31, 2026 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.903%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collateral Provisions Exist That May Mitigate Risk of Credit Loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;No Collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ongoing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt;A- equivalent and higher current ratings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;227&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt;BBB- to BBB+ equivalent current credit ratings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not rated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition, disposition or run-off activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BBB+ equivalent and higher current ratings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;280&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not rated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reinsurance recoverables before market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allowance for uncollectible reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;715&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reinsurance recoverables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Certified by a nationally recognized statistical ratings organization ("NRSRO").&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Comprised of six reinsurers, of which 77%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes $122 million of current reinsurance recoverables that are reported in Other current assets.&lt;/span&gt;&lt;/div&gt;The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 7 to the Consolidated Financial Statements. Berkshire reinsured 100% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit, with approximately $3.0 billion remaining as of March&#160;31, 2026. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit. As of both March&#160;31, 2026 and 2025, market risk benefits (shown in the table net of nonperformance risk as of March&#160;31, 2026) were predominantly reinsured by Berkshire, which is rated AA+ by an NRSRO. As of March&#160;31, 2026, approximately 100% of the Berkshire recoverable is secured by assets in a trust.</us-gaap:ReinsuranceTextBlock>
    <us-gaap:ReinsuranceAccountingPolicy contextRef="c-1" id="f-606">The Company reviews its reinsurance arrangements and establishes reserves against the recoverables primarily for expected credit losses.Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 7 to the Consolidated Financial Statements.</us-gaap:ReinsuranceAccountingPolicy>
    <us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock contextRef="c-1" id="f-607">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's reinsurance recoverables as of March&#160;31, 2026 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.903%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collateral Provisions Exist That May Mitigate Risk of Credit Loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;No Collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ongoing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt;A- equivalent and higher current ratings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;227&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt;BBB- to BBB+ equivalent current credit ratings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not rated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition, disposition or run-off activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BBB+ equivalent and higher current ratings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;280&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not rated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reinsurance recoverables before market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allowance for uncollectible reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;715&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reinsurance recoverables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Certified by a nationally recognized statistical ratings organization ("NRSRO").&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Comprised of six reinsurers, of which 77%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes $122 million of current reinsurance recoverables that are reported in Other current assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-108" decimals="-6" id="f-608" unitRef="usd">0</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-109" decimals="-6" id="f-609" unitRef="usd">5000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-110" decimals="-6" id="f-610" unitRef="usd">227000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-111" decimals="-6" id="f-611" unitRef="usd">232000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-112" decimals="-6" id="f-612" unitRef="usd">0</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-113" decimals="-6" id="f-613" unitRef="usd">0</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-114" decimals="-6" id="f-614" unitRef="usd">64000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-115" decimals="-6" id="f-615" unitRef="usd">64000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-116" decimals="-6" id="f-616" unitRef="usd">81000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-117" decimals="-6" id="f-617" unitRef="usd">3000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-118" decimals="-6" id="f-618" unitRef="usd">1000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-119" decimals="-6" id="f-619" unitRef="usd">85000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-120" decimals="-6" id="f-620" unitRef="usd">280000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-121" decimals="-6" id="f-621" unitRef="usd">2810000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-122" decimals="-6" id="f-622" unitRef="usd">26000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-123" decimals="-6" id="f-623" unitRef="usd">3116000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-124" decimals="-6" id="f-624" unitRef="usd">0</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-125" decimals="-6" id="f-625" unitRef="usd">4000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-126" decimals="-6" id="f-626" unitRef="usd">1000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-127" decimals="-6" id="f-627" unitRef="usd">5000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-128" decimals="-6" id="f-628" unitRef="usd">361000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-129" decimals="-6" id="f-629" unitRef="usd">2822000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-130" decimals="-6" id="f-630" unitRef="usd">319000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesGross contextRef="c-8" decimals="-6" id="f-631" unitRef="usd">3502000000</us-gaap:ReinsuranceRecoverablesGross>
    <us-gaap:ReinsuranceRecoverablesAllowance contextRef="c-8" decimals="-6" id="f-632" unitRef="usd">22000000</us-gaap:ReinsuranceRecoverablesAllowance>
    <us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance contextRef="c-8" decimals="-6" id="f-633" unitRef="usd">715000000</us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:ReinsuranceRecoverables contextRef="c-8" decimals="-6" id="f-634" unitRef="usd">4195000000</us-gaap:ReinsuranceRecoverables>
    <ci:ReinsuranceRecoverablesNumberOfReinsurers
      contextRef="c-123"
      decimals="INF"
      id="f-635"
      unitRef="reinsurer">6</ci:ReinsuranceRecoverablesNumberOfReinsurers>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-131" decimals="2" id="f-636" unitRef="number">0.77</us-gaap:ConcentrationRiskPercentage1>
    <ci:ReinsuranceRecoverablesNumberOfReinsurers
      contextRef="c-132"
      decimals="INF"
      id="f-637"
      unitRef="reinsurer">2</ci:ReinsuranceRecoverablesNumberOfReinsurers>
    <us-gaap:ReinsuranceRecoverables contextRef="c-133" decimals="-6" id="f-638" unitRef="usd">122000000</us-gaap:ReinsuranceRecoverables>
    <us-gaap:ReinsuranceRetentionPolicyReinsuredRiskPercentage
      contextRef="c-134"
      decimals="INF"
      id="f-639"
      unitRef="number">1</us-gaap:ReinsuranceRetentionPolicyReinsuredRiskPercentage>
    <ci:CededReinsuranceAgreementCoverageLimitAmountRemaining contextRef="c-135" decimals="-8" id="f-640" unitRef="usd">3000000000.0</ci:CededReinsuranceAgreementCoverageLimitAmountRemaining>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-136" decimals="2" id="f-641" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-642">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="iffda1ddb399742d1a8a04892fba27ddb_14"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 9 &#x2013; Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company's investments by category and current or long-term classification:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,859&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,641&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,669&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Policy loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;812&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline"&gt;Investment Portfolio&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of March&#160;31, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;566&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,017&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,766&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,739&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Appreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,793&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,739&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Review of Declines in Fair Value. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Issues&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;One year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;609&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;276&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;632&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;743&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,835&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,066&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides the values of the Company's equity security investments: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.044%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with no readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,893&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,669&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Commercial Mortgage Loans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high-quality, primarily completed and substantially leased operating properties.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company regularly evaluates and monitors credit risk from the initial mortgage loan underwriting and throughout the investment holding period. The annual portfolio review performed in the second quarter of 2025 confirmed ongoing strong overall credit quality in line with the previous year's results. For more information on the Company's accounting policies and methodologies regarding these investments, see Note 11 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Debt Service Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Debt Service Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below 60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;393&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60% to 79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;694&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80% to 100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other Long-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real estate investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,961&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt. The Company also has derivative instruments associated with certain equity securities; see Note 12A to the Consolidated Financial Statements in the Company&#x2019;s 2025 Form 10-K for further information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March&#160;31, 2026, the notional value of interest rate swap contracts increased to $3.5 billion compared with $3.2 billion as of December&#160;31, 2025. There were no other material changes to the Company's individual derivative hedging strategies during the three months ended March&#160;31, 2026. Please refer to the Company's 2025 Form 10-K for further discussion of the types of derivative financial instruments and associated accounting policies. The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of March&#160;31, 2026 and December&#160;31, 2025. The gross fair values of our derivative financial instruments are presented in Note 10 to the Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline"&gt;Investment Gains and Losses&lt;/span&gt;Net investment gains (losses) before income taxes were $258&#160;million for the three months ended March&#160;31, 2026 versus $(2)&#160;million for the three months ended March&#160;31, 2025. Investment results increased primarily due to fair value changes of derivative instruments associated with certain equity securities. These amounts exclude investment gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock contextRef="c-1" id="f-643">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company's investments by category and current or long-term classification:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,859&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,641&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,669&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Policy loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;812&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock>
    <us-gaap:ShortTermInvestments contextRef="c-137" decimals="-6" id="f-644" unitRef="usd">453000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-137" decimals="-6" id="f-645" unitRef="usd">7859000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-137" decimals="-6" id="f-646" unitRef="usd">8312000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-138" decimals="-6" id="f-647" unitRef="usd">691000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-138" decimals="-6" id="f-648" unitRef="usd">7671000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-138" decimals="-6" id="f-649" unitRef="usd">8362000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-139" decimals="-6" id="f-650" unitRef="usd">28000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-139" decimals="-6" id="f-651" unitRef="usd">3641000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-139" decimals="-6" id="f-652" unitRef="usd">3669000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-140" decimals="-6" id="f-653" unitRef="usd">22000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-140" decimals="-6" id="f-654" unitRef="usd">3534000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-140" decimals="-6" id="f-655" unitRef="usd">3556000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-141" decimals="-6" id="f-656" unitRef="usd">52000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-141" decimals="-6" id="f-657" unitRef="usd">1220000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-141" decimals="-6" id="f-658" unitRef="usd">1272000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-142" decimals="-6" id="f-659" unitRef="usd">86000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-142" decimals="-6" id="f-660" unitRef="usd">1147000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-142" decimals="-6" id="f-661" unitRef="usd">1233000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-143" decimals="-6" id="f-662" unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-143" decimals="-6" id="f-663" unitRef="usd">1024000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-143" decimals="-6" id="f-664" unitRef="usd">1024000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-144" decimals="-6" id="f-665" unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-144" decimals="-6" id="f-666" unitRef="usd">1082000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-144" decimals="-6" id="f-667" unitRef="usd">1082000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-145" decimals="-6" id="f-668" unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-145" decimals="-6" id="f-669" unitRef="usd">5158000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-145" decimals="-6" id="f-670" unitRef="usd">5158000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-146" decimals="-6" id="f-671" unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-146" decimals="-6" id="f-672" unitRef="usd">5037000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-146" decimals="-6" id="f-673" unitRef="usd">5037000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-147" decimals="-6" id="f-674" unitRef="usd">279000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-147" decimals="-6" id="f-675" unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-147" decimals="-6" id="f-676" unitRef="usd">279000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-148" decimals="-6" id="f-677" unitRef="usd">257000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-148" decimals="-6" id="f-678" unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-148" decimals="-6" id="f-679" unitRef="usd">257000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-8" decimals="-6" id="f-680" unitRef="usd">812000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-8" decimals="-6" id="f-681" unitRef="usd">18902000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-8" decimals="-6" id="f-682" unitRef="usd">19714000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-9" decimals="-6" id="f-683" unitRef="usd">1056000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-9" decimals="-6" id="f-684" unitRef="usd">18471000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-9" decimals="-6" id="f-685" unitRef="usd">19527000000</us-gaap:Investments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-686">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of March&#160;31, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;566&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,017&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,766&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,739&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-8" decimals="-6" id="f-687" unitRef="usd">674000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-8" decimals="-6" id="f-688" unitRef="usd">566000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-8" decimals="-6" id="f-689" unitRef="usd">3842000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-8" decimals="-6" id="f-690" unitRef="usd">3783000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost contextRef="c-8" decimals="-6" id="f-691" unitRef="usd">2017000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c-8" decimals="-6" id="f-692" unitRef="usd">1969000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost contextRef="c-8" decimals="-6" id="f-693" unitRef="usd">1956000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue contextRef="c-8" decimals="-6" id="f-694" unitRef="usd">1766000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost contextRef="c-8" decimals="-6" id="f-695" unitRef="usd">250000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue contextRef="c-8" decimals="-6" id="f-696" unitRef="usd">228000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-8" decimals="-6" id="f-697" unitRef="usd">8739000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-8" decimals="-6" id="f-698" unitRef="usd">8312000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock contextRef="c-1" id="f-699">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Appreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,793&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,739&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-149" decimals="-6" id="f-700" unitRef="usd">220000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-149" decimals="-6" id="f-701" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-149" decimals="-6" id="f-702" unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-149" decimals="-6" id="f-703" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-149" decimals="-6" id="f-704" unitRef="usd">230000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-150" decimals="-6" id="f-705" unitRef="usd">24000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-150" decimals="-6" id="f-706" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-150" decimals="-6" id="f-707" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-150" decimals="-6" id="f-708" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-150" decimals="-6" id="f-709" unitRef="usd">25000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-151" decimals="-6" id="f-710" unitRef="usd">452000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-151" decimals="-6" id="f-711" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-151" decimals="-6" id="f-712" unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-151" decimals="-6" id="f-713" unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-151" decimals="-6" id="f-714" unitRef="usd">452000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-152" decimals="-6" id="f-715" unitRef="usd">7793000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-152" decimals="-6" id="f-716" unitRef="usd">135000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-152" decimals="-6" id="f-717" unitRef="usd">121000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-152" decimals="-6" id="f-718" unitRef="usd">402000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-152" decimals="-6" id="f-719" unitRef="usd">7377000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-153" decimals="-6" id="f-720" unitRef="usd">250000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-153" decimals="-6" id="f-721" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-153" decimals="-6" id="f-722" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-153" decimals="-6" id="f-723" unitRef="usd">23000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-153" decimals="-6" id="f-724" unitRef="usd">228000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-8" decimals="-6" id="f-725" unitRef="usd">8739000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-8" decimals="-6" id="f-726" unitRef="usd">135000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-8" decimals="-6" id="f-727" unitRef="usd">145000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-8" decimals="-6" id="f-728" unitRef="usd">437000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-8" decimals="-6" id="f-729" unitRef="usd">8312000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-154" decimals="-6" id="f-730" unitRef="usd">215000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-154" decimals="-6" id="f-731" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-154" decimals="-6" id="f-732" unitRef="usd">15000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-154" decimals="-6" id="f-733" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-154" decimals="-6" id="f-734" unitRef="usd">227000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-155" decimals="-6" id="f-735" unitRef="usd">24000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-155" decimals="-6" id="f-736" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-155" decimals="-6" id="f-737" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-155" decimals="-6" id="f-738" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-155" decimals="-6" id="f-739" unitRef="usd">25000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-156" decimals="-6" id="f-740" unitRef="usd">450000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-156" decimals="-6" id="f-741" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-156" decimals="-6" id="f-742" unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-156" decimals="-6" id="f-743" unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-156" decimals="-6" id="f-744" unitRef="usd">456000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-157" decimals="-6" id="f-745" unitRef="usd">7704000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-157" decimals="-6" id="f-746" unitRef="usd">137000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-157" decimals="-6" id="f-747" unitRef="usd">175000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-157" decimals="-6" id="f-748" unitRef="usd">332000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-157" decimals="-6" id="f-749" unitRef="usd">7410000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-158" decimals="-6" id="f-750" unitRef="usd">267000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-158" decimals="-6" id="f-751" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-158" decimals="-6" id="f-752" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-158" decimals="-6" id="f-753" unitRef="usd">26000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-158" decimals="-6" id="f-754" unitRef="usd">244000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-9" decimals="-6" id="f-755" unitRef="usd">8660000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-9" decimals="-6" id="f-756" unitRef="usd">137000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-9" decimals="-6" id="f-757" unitRef="usd">206000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-9" decimals="-6" id="f-758" unitRef="usd">367000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-9" decimals="-6" id="f-759" unitRef="usd">8362000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-760">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Review of Declines in Fair Value. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company regularly evaluates and monitors credit risk from the initial mortgage loan underwriting and throughout the investment holding period. The annual portfolio review performed in the second quarter of 2025 confirmed ongoing strong overall credit quality in line with the previous year's results. For more information on the Company's accounting policies and methodologies regarding these investments, see Note 11 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. &lt;/span&gt;&lt;/div&gt;Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-761">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Issues&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;One year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;609&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;276&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;632&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;743&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,835&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,066&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-159" decimals="-6" id="f-762" unitRef="usd">1674000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost contextRef="c-159" decimals="-6" id="f-763" unitRef="usd">1700000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-159" decimals="-6" id="f-764" unitRef="usd">26000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c-159"
      decimals="INF"
      id="f-765"
      unitRef="position">609</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-160" decimals="-6" id="f-766" unitRef="usd">384000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost contextRef="c-160" decimals="-6" id="f-767" unitRef="usd">386000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-160" decimals="-6" id="f-768" unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c-160"
      decimals="INF"
      id="f-769"
      unitRef="position">149</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-161" decimals="-6" id="f-770" unitRef="usd">276000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost contextRef="c-161" decimals="-6" id="f-771" unitRef="usd">283000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-161" decimals="-6" id="f-772" unitRef="usd">7000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c-161"
      decimals="INF"
      id="f-773"
      unitRef="position">632</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-162" decimals="-6" id="f-774" unitRef="usd">120000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost contextRef="c-162" decimals="-6" id="f-775" unitRef="usd">125000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-162" decimals="-6" id="f-776" unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c-162"
      decimals="INF"
      id="f-777"
      unitRef="position">239</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-159" decimals="-6" id="f-778" unitRef="usd">2757000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost contextRef="c-159" decimals="-6" id="f-779" unitRef="usd">3146000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-159" decimals="-6" id="f-780" unitRef="usd">389000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="c-159"
      decimals="INF"
      id="f-781"
      unitRef="position">743</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-160" decimals="-6" id="f-782" unitRef="usd">3044000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost contextRef="c-160" decimals="-6" id="f-783" unitRef="usd">3382000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-160" decimals="-6" id="f-784" unitRef="usd">338000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="c-160"
      decimals="INF"
      id="f-785"
      unitRef="position">799</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-161" decimals="-6" id="f-786" unitRef="usd">128000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost contextRef="c-161" decimals="-6" id="f-787" unitRef="usd">143000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-161" decimals="-6" id="f-788" unitRef="usd">15000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="c-161"
      decimals="INF"
      id="f-789"
      unitRef="position">82</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-162" decimals="-6" id="f-790" unitRef="usd">185000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost contextRef="c-162" decimals="-6" id="f-791" unitRef="usd">207000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-162" decimals="-6" id="f-792" unitRef="usd">22000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="c-162"
      decimals="INF"
      id="f-793"
      unitRef="position">86</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-8" decimals="-6" id="f-794" unitRef="usd">4835000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost contextRef="c-8" decimals="-6" id="f-795" unitRef="usd">5272000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-8" decimals="-6" id="f-796" unitRef="usd">437000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-8"
      decimals="INF"
      id="f-797"
      unitRef="position">2066</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-9" decimals="-6" id="f-798" unitRef="usd">3733000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost contextRef="c-9" decimals="-6" id="f-799" unitRef="usd">4100000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-9" decimals="-6" id="f-800" unitRef="usd">367000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-9"
      decimals="INF"
      id="f-801"
      unitRef="position">1273</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock contextRef="c-1" id="f-802">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides the values of the Company's equity security investments: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.044%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with no readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,893&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,669&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-8" decimals="-6" id="f-803" unitRef="usd">101000000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-8" decimals="-6" id="f-804" unitRef="usd">85000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-9" decimals="-6" id="f-805" unitRef="usd">78000000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-9" decimals="-6" id="f-806" unitRef="usd">92000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost contextRef="c-8" decimals="-6" id="f-807" unitRef="usd">6893000000</ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-8" decimals="-6" id="f-808" unitRef="usd">3584000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost contextRef="c-9" decimals="-6" id="f-809" unitRef="usd">6792000000</ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-9" decimals="-6" id="f-810" unitRef="usd">3464000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost contextRef="c-8" decimals="-6" id="f-811" unitRef="usd">6994000000</ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost>
    <ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount contextRef="c-8" decimals="-6" id="f-812" unitRef="usd">3669000000</ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount>
    <ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost contextRef="c-9" decimals="-6" id="f-813" unitRef="usd">6870000000</ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost>
    <ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount contextRef="c-9" decimals="-6" id="f-814" unitRef="usd">3556000000</ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount>
    <us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock contextRef="c-1" id="f-815">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Debt Service Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Debt Service Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below 60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;393&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60% to 79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;694&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80% to 100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-163" decimals="-6" id="f-816" unitRef="usd">393000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio contextRef="c-164" decimals="2" id="f-817" unitRef="number">2.13</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-165" decimals="-6" id="f-818" unitRef="usd">355000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio contextRef="c-166" decimals="2" id="f-819" unitRef="number">2.13</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-167" decimals="-6" id="f-820" unitRef="usd">694000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio contextRef="c-168" decimals="2" id="f-821" unitRef="number">1.79</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-169" decimals="-6" id="f-822" unitRef="usd">694000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio contextRef="c-170" decimals="2" id="f-823" unitRef="number">1.81</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-171" decimals="-6" id="f-824" unitRef="usd">185000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio contextRef="c-172" decimals="2" id="f-825" unitRef="number">0.92</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-173" decimals="-6" id="f-826" unitRef="usd">184000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio contextRef="c-174" decimals="2" id="f-827" unitRef="number">0.79</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-175" decimals="-6" id="f-828" unitRef="usd">1272000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio contextRef="c-176" decimals="2" id="f-829" unitRef="number">1.74</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <ci:FinancingReceivableCreditQualityLoanToValueRatio contextRef="c-176" decimals="2" id="f-830" unitRef="number">0.71</ci:FinancingReceivableCreditQualityLoanToValueRatio>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-177" decimals="-6" id="f-831" unitRef="usd">1233000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio contextRef="c-178" decimals="2" id="f-832" unitRef="number">1.72</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <ci:FinancingReceivableCreditQualityLoanToValueRatio contextRef="c-178" decimals="2" id="f-833" unitRef="number">0.71</ci:FinancingReceivableCreditQualityLoanToValueRatio>
    <ci:ScheduleOfOtherLongTermInvestmentsTableTextBlock contextRef="c-1" id="f-834">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real estate investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,961&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:ScheduleOfOtherLongTermInvestmentsTableTextBlock>
    <us-gaap:OtherLongTermInvestments contextRef="c-179" decimals="-6" id="f-835" unitRef="usd">1993000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-180" decimals="-6" id="f-836" unitRef="usd">1895000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-181" decimals="-6" id="f-837" unitRef="usd">2961000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-182" decimals="-6" id="f-838" unitRef="usd">2948000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-183" decimals="-6" id="f-839" unitRef="usd">204000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-184" decimals="-6" id="f-840" unitRef="usd">194000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-8" decimals="-6" id="f-841" unitRef="usd">5158000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-9" decimals="-6" id="f-842" unitRef="usd">5037000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:DerivativeNotionalAmount contextRef="c-185" decimals="-6" id="f-843" unitRef="usd">3500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-186" decimals="-6" id="f-844" unitRef="usd">3200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-845">Please refer to the Company's 2025 Form 10-K for further discussion of the types of derivative financial instruments and associated accounting policies.</us-gaap:DerivativesPolicyTextBlock>
    <ci:NetInvestmentGainLoss contextRef="c-1" decimals="-6" id="f-846" unitRef="usd">258000000</ci:NetInvestmentGainLoss>
    <ci:NetInvestmentGainLoss contextRef="c-5" decimals="-6" id="f-847" unitRef="usd">-2000000</ci:NetInvestmentGainLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-848">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span id="i1597debdc6cf41409a9c5b168712b46e_14"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 10 &#x2013; Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For a description of the policies, methods and assumptions that are used to estimate fair value and determine the fair value hierarchy for each class of financial instruments, see Note 12 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Financial Assets and Financial Liabilities Carried at Fair Value&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides information about the Company's investment and derivative financial assets and liabilities carried at fair value on a recurring basis. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.770%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,890&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;314&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,173&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,270&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial liabilities at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Excludes certain equity securities that have no readily determinable fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Level 3 Financial Assets and Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Information about Debt Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The significant unobservable input used to value our corporate and government debt securities, and mortgage and other asset-backed securities, is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Adjustment Range (Weighted Average by Quantity) as of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Fair value in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;280&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10 - 920 (135)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60 - 920 (175)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115 - 340 (160) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105 - 350 (160)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Level 3 debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;314&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Information about Derivative Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;See Note 12A to the Consolidated Financial Statements in the Company&#x2019;s 2025 Form 10-K for further information regarding our Level 3 derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;896&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) included in Shareholders' net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Losses) gains included in Other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Transfers into / (out of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers into Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total transfers into / (out of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total gains and losses included in Shareholders' net income in the table above are reflected in the Consolidated Statements of Income as &lt;span style="-sec-ix-hidden:f-979"&gt;Net investment gains/losses&lt;/span&gt; and as &lt;span style="-sec-ix-hidden:f-980"&gt;Net investment income/losses&lt;/span&gt;. Gains and losses included in Other comprehensive loss, net of tax, in the table above are reflected in &lt;span style="-sec-ix-hidden:f-981"&gt;Net unrealized depreciation on securities and derivatives&lt;/span&gt; in the Consolidated Statements of Comprehensive Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2026 and 2025 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Level 3 Financial Assets and Financial Liabilities above for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separate Accounts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. The separate account activity for the three months ended March&#160;31, 2026 and 2025 was primarily driven by changes in the market values of the underlying separate account investments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair values of Separate account assets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Guaranteed separate accounts (see Note 14)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;570&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-guaranteed separate accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;262&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,766&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,098&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,765&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-guaranteed separate accounts priced at net asset value as a practical expedient &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;662&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,427&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Non-guaranteed separate accounts include $3.7 billion as of March&#160;31, 2026 and $3.8 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;as of December&#160;31, 2025 in assets supporting the Company's pension plans, including $0.1 billion classified in Level 3 as of March&#160;31, 2026 and $0.2 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;as of December&#160;31, 2025. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the three months ended March&#160;31, 2026 or 2025. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Assets and Liabilities Measured at Fair Value under Certain Conditions&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"&gt;For the three months ended March&#160;31, 2026 and 2025, impairments recognized requiring the assets and liabilities described above to be measured at fair value were not material. Observable price changes for equity securities with no readily determinable fair value were not material for the three months ended March&#160;31, 2026 or March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Fair Value Disclosures for Financial Instruments Not Carried at Fair Value&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,227&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt, including current maturities, excluding finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,838&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-849">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For a description of the policies, methods and assumptions that are used to estimate fair value and determine the fair value hierarchy for each class of financial instruments, see Note 12 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Level 3 Financial Assets and Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Information about Debt Securities. &lt;/span&gt;The significant unobservable input used to value our corporate and government debt securities, and mortgage and other asset-backed securities, is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total gains and losses included in Shareholders' net income in the table above are reflected in the Consolidated Statements of Income as &lt;span style="-sec-ix-hidden:f-979"&gt;Net investment gains/losses&lt;/span&gt; and as &lt;span style="-sec-ix-hidden:f-980"&gt;Net investment income/losses&lt;/span&gt;. Gains and losses included in Other comprehensive loss, net of tax, in the table above are reflected in &lt;span style="-sec-ix-hidden:f-981"&gt;Net unrealized depreciation on securities and derivatives&lt;/span&gt; in the Consolidated Statements of Comprehensive Income.&lt;/span&gt;&lt;/div&gt;Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads.&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Assets and Liabilities Measured at Fair Value under Certain Conditions&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-850">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides information about the Company's investment and derivative financial assets and liabilities carried at fair value on a recurring basis. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.770%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,890&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;314&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,173&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,270&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial liabilities at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Excludes certain equity securities that have no readily determinable fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-187" decimals="-6" id="f-851" unitRef="usd">108000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-188" decimals="-6" id="f-852" unitRef="usd">105000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-189" decimals="-6" id="f-853" unitRef="usd">122000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-190" decimals="-6" id="f-854" unitRef="usd">122000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-191" decimals="-6" id="f-855" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-192" decimals="-6" id="f-856" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-193" decimals="-6" id="f-857" unitRef="usd">230000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-194" decimals="-6" id="f-858" unitRef="usd">227000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-195" decimals="-6" id="f-859" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-196" decimals="-6" id="f-860" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-197" decimals="-6" id="f-861" unitRef="usd">25000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-198" decimals="-6" id="f-862" unitRef="usd">25000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-199" decimals="-6" id="f-863" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-200" decimals="-6" id="f-864" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-201" decimals="-6" id="f-865" unitRef="usd">25000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-202" decimals="-6" id="f-866" unitRef="usd">25000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-203" decimals="-6" id="f-867" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-204" decimals="-6" id="f-868" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-205" decimals="-6" id="f-869" unitRef="usd">442000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-206" decimals="-6" id="f-870" unitRef="usd">446000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-207" decimals="-6" id="f-871" unitRef="usd">10000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-208" decimals="-6" id="f-872" unitRef="usd">10000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-209" decimals="-6" id="f-873" unitRef="usd">452000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-210" decimals="-6" id="f-874" unitRef="usd">456000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-211" decimals="-6" id="f-875" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-212" decimals="-6" id="f-876" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-213" decimals="-6" id="f-877" unitRef="usd">7106000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-214" decimals="-6" id="f-878" unitRef="usd">7133000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-215" decimals="-6" id="f-879" unitRef="usd">271000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-216" decimals="-6" id="f-880" unitRef="usd">277000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-217" decimals="-6" id="f-881" unitRef="usd">7377000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-218" decimals="-6" id="f-882" unitRef="usd">7410000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-219" decimals="-6" id="f-883" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-220" decimals="-6" id="f-884" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-221" decimals="-6" id="f-885" unitRef="usd">195000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-222" decimals="-6" id="f-886" unitRef="usd">206000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-223" decimals="-6" id="f-887" unitRef="usd">33000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-224" decimals="-6" id="f-888" unitRef="usd">38000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-225" decimals="-6" id="f-889" unitRef="usd">228000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-226" decimals="-6" id="f-890" unitRef="usd">244000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-227" decimals="-6" id="f-891" unitRef="usd">108000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-228" decimals="-6" id="f-892" unitRef="usd">105000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-229" decimals="-6" id="f-893" unitRef="usd">7890000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-230" decimals="-6" id="f-894" unitRef="usd">7932000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-231" decimals="-6" id="f-895" unitRef="usd">314000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-232" decimals="-6" id="f-896" unitRef="usd">325000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-233" decimals="-6" id="f-897" unitRef="usd">8312000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-234" decimals="-6" id="f-898" unitRef="usd">8362000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-227" decimals="-6" id="f-899" unitRef="usd">44000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-228" decimals="-6" id="f-900" unitRef="usd">54000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-229" decimals="-6" id="f-901" unitRef="usd">39000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-230" decimals="-6" id="f-902" unitRef="usd">36000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-231" decimals="-6" id="f-903" unitRef="usd">2000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-232" decimals="-6" id="f-904" unitRef="usd">2000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-233" decimals="-6" id="f-905" unitRef="usd">85000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-234" decimals="-6" id="f-906" unitRef="usd">92000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:OtherShortTermInvestments contextRef="c-227" decimals="-6" id="f-907" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-228" decimals="-6" id="f-908" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-229" decimals="-6" id="f-909" unitRef="usd">279000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-230" decimals="-6" id="f-910" unitRef="usd">257000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-231" decimals="-6" id="f-911" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-232" decimals="-6" id="f-912" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-233" decimals="-6" id="f-913" unitRef="usd">279000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-234" decimals="-6" id="f-914" unitRef="usd">257000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:DerivativeAssets contextRef="c-235" decimals="-6" id="f-915" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-236" decimals="-6" id="f-916" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-237" decimals="-6" id="f-917" unitRef="usd">97000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-238" decimals="-6" id="f-918" unitRef="usd">68000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-239" decimals="-6" id="f-919" unitRef="usd">1173000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-240" decimals="-6" id="f-920" unitRef="usd">923000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-241" decimals="-6" id="f-921" unitRef="usd">1270000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-242" decimals="-6" id="f-922" unitRef="usd">991000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-235" decimals="-6" id="f-923" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-236" decimals="-6" id="f-924" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-237" decimals="-6" id="f-925" unitRef="usd">8000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-238" decimals="-6" id="f-926" unitRef="usd">22000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-239" decimals="-6" id="f-927" unitRef="usd">343000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-240" decimals="-6" id="f-928" unitRef="usd">354000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-241" decimals="-6" id="f-929" unitRef="usd">351000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-242" decimals="-6" id="f-930" unitRef="usd">376000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-931">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Adjustment Range (Weighted Average by Quantity) as of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Fair value in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;280&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10 - 920 (135)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60 - 920 (175)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115 - 340 (160) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105 - 350 (160)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Level 3 debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;314&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:MarketableSecurities contextRef="c-243" decimals="-6" id="f-932" unitRef="usd">280000000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-244" decimals="-6" id="f-933" unitRef="usd">286000000</us-gaap:MarketableSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-245" decimals="4" id="f-934" unitRef="number">0.0010</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-246" decimals="4" id="f-935" unitRef="number">0.0920</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-247" decimals="4" id="f-936" unitRef="number">0.0135</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-248" decimals="4" id="f-937" unitRef="number">0.0060</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-249" decimals="4" id="f-938" unitRef="number">0.0920</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-250" decimals="4" id="f-939" unitRef="number">0.0175</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:MarketableSecurities contextRef="c-251" decimals="-6" id="f-940" unitRef="usd">33000000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-252" decimals="-6" id="f-941" unitRef="usd">38000000</us-gaap:MarketableSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-253" decimals="4" id="f-942" unitRef="number">0.0115</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-254" decimals="4" id="f-943" unitRef="number">0.0340</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-255" decimals="4" id="f-944" unitRef="number">0.0160</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-256" decimals="4" id="f-945" unitRef="number">0.0105</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-257" decimals="4" id="f-946" unitRef="number">0.0350</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput contextRef="c-258" decimals="4" id="f-947" unitRef="number">0.0160</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:MarketableSecurities contextRef="c-259" decimals="-6" id="f-948" unitRef="usd">1000000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-260" decimals="-6" id="f-949" unitRef="usd">1000000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-261" decimals="-6" id="f-950" unitRef="usd">314000000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-262" decimals="-6" id="f-951" unitRef="usd">325000000</us-gaap:MarketableSecurities>
    <ci:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="c-1" id="f-952">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;896&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) included in Shareholders' net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Losses) gains included in Other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Transfers into / (out of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers into Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total transfers into / (out of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-9" decimals="-6" id="f-953" unitRef="usd">896000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-37" decimals="-6" id="f-954" unitRef="usd">417000000</ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-1" decimals="-6" id="f-955" unitRef="usd">258000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-5" decimals="-6" id="f-956" unitRef="usd">-10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-1" decimals="-6" id="f-957" unitRef="usd">-3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-5" decimals="-6" id="f-958" unitRef="usd">7000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-1" decimals="-6" id="f-959" unitRef="usd">15000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-5" decimals="-6" id="f-960" unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales contextRef="c-1" decimals="-6" id="f-961" unitRef="usd">6000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales contextRef="c-5" decimals="-6" id="f-962" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-1" decimals="-6" id="f-963" unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-5" decimals="-6" id="f-964" unitRef="usd">31000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements contextRef="c-1" decimals="-6" id="f-965" unitRef="usd">7000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements contextRef="c-5" decimals="-6" id="f-966" unitRef="usd">-29000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 contextRef="c-1" decimals="-6" id="f-967" unitRef="usd">26000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 contextRef="c-5" decimals="-6" id="f-968" unitRef="usd">18000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 contextRef="c-1" decimals="-6" id="f-969" unitRef="usd">38000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 contextRef="c-5" decimals="-6" id="f-970" unitRef="usd">30000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet contextRef="c-1" decimals="-6" id="f-971" unitRef="usd">-12000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet contextRef="c-5" decimals="-6" id="f-972" unitRef="usd">-12000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-8" decimals="-6" id="f-973" unitRef="usd">1146000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-51" decimals="-6" id="f-974" unitRef="usd">373000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <ci:FairValueAssetRecurringBasisStillHeldRealizedGainLoss contextRef="c-1" decimals="-6" id="f-975" unitRef="usd">258000000</ci:FairValueAssetRecurringBasisStillHeldRealizedGainLoss>
    <ci:FairValueAssetRecurringBasisStillHeldRealizedGainLoss contextRef="c-5" decimals="-6" id="f-976" unitRef="usd">-13000000</ci:FairValueAssetRecurringBasisStillHeldRealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="c-1" decimals="-6" id="f-977" unitRef="usd">-3000000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="c-5" decimals="-6" id="f-978" unitRef="usd">3000000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:PolicyholderAccountsPolicy contextRef="c-1" id="f-982">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separate Accounts&lt;/span&gt;&lt;/div&gt;The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows.Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans.</us-gaap:PolicyholderAccountsPolicy>
    <ci:FairValueOfSeparateAccountAssetsTableTextBlock contextRef="c-1" id="f-983">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair values of Separate account assets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Guaranteed separate accounts (see Note 14)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;570&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-guaranteed separate accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;262&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,766&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,098&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,765&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-guaranteed separate accounts priced at net asset value as a practical expedient &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;662&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,427&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Non-guaranteed separate accounts include $3.7 billion as of March&#160;31, 2026 and $3.8 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;as of December&#160;31, 2025 in assets supporting the Company's pension plans, including $0.1 billion classified in Level 3 as of March&#160;31, 2026 and $0.2 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;as of December&#160;31, 2025. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.&lt;/span&gt;&lt;/div&gt;</ci:FairValueOfSeparateAccountAssetsTableTextBlock>
    <us-gaap:SeparateAccountAssets contextRef="c-263" decimals="-6" id="f-984" unitRef="usd">238000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-264" decimals="-6" id="f-985" unitRef="usd">247000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-265" decimals="-6" id="f-986" unitRef="usd">332000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-266" decimals="-6" id="f-987" unitRef="usd">330000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-267" decimals="-6" id="f-988" unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-268" decimals="-6" id="f-989" unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-269" decimals="-6" id="f-990" unitRef="usd">570000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-270" decimals="-6" id="f-991" unitRef="usd">577000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-271" decimals="-6" id="f-992" unitRef="usd">262000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-272" decimals="-6" id="f-993" unitRef="usd">271000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-273" decimals="-6" id="f-994" unitRef="usd">5766000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-274" decimals="-6" id="f-995" unitRef="usd">5769000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-275" decimals="-6" id="f-996" unitRef="usd">167000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-276" decimals="-6" id="f-997" unitRef="usd">209000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-277" decimals="-6" id="f-998" unitRef="usd">6195000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-278" decimals="-6" id="f-999" unitRef="usd">6249000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-279" decimals="-6" id="f-1000" unitRef="usd">500000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-280" decimals="-6" id="f-1001" unitRef="usd">518000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-281" decimals="-6" id="f-1002" unitRef="usd">6098000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-282" decimals="-6" id="f-1003" unitRef="usd">6099000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-283" decimals="-6" id="f-1004" unitRef="usd">167000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-284" decimals="-6" id="f-1005" unitRef="usd">209000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-285" decimals="-6" id="f-1006" unitRef="usd">6765000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-286" decimals="-6" id="f-1007" unitRef="usd">6826000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-287" decimals="-6" id="f-1008" unitRef="usd">662000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-288" decimals="-6" id="f-1009" unitRef="usd">661000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-8" decimals="-6" id="f-1010" unitRef="usd">7427000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-9" decimals="-6" id="f-1011" unitRef="usd">7487000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-289" decimals="-8" id="f-1012" unitRef="usd">3700000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-290" decimals="-8" id="f-1013" unitRef="usd">3800000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-291" decimals="-8" id="f-1014" unitRef="usd">100000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-292" decimals="-8" id="f-1015" unitRef="usd">200000000</us-gaap:SeparateAccountAssets>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="c-1" id="f-1016">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,227&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt, including current maturities, excluding finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,838&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet contextRef="c-293" decimals="-6" id="f-1017" unitRef="usd">1227000000</us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet>
    <us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet contextRef="c-294" decimals="-6" id="f-1018" unitRef="usd">1272000000</us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet>
    <us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet contextRef="c-295" decimals="-6" id="f-1019" unitRef="usd">1195000000</us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet>
    <us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet contextRef="c-296" decimals="-6" id="f-1020" unitRef="usd">1233000000</us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet>
    <us-gaap:LongTermDebtFairValue contextRef="c-297" decimals="-6" id="f-1021" unitRef="usd">28838000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-294" decimals="-6" id="f-1022" unitRef="usd">30783000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-298" decimals="-6" id="f-1023" unitRef="usd">29907000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-296" decimals="-6" id="f-1024" unitRef="usd">31352000000</us-gaap:LongTermDebtFairValue>
    <ci:AccumulatedOtherComprehensiveIncomeDisclosureTextBlock contextRef="c-1" id="f-1025">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="i863307f831dc42769ca918fef181998a_940"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 11 &#x2013; Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accumulated Other Comprehensive Income (Loss) ("AOCI") includes net unrealized appreciation/depreciation on securities and derivatives, change in discount rate and instrument-specific credit risk for certain long-duration insurance contractholder liabilities (see Note 7 to the Consolidated Financial Statements), foreign currency translation, and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shareholders' other comprehensive loss, net of tax, for the three months ended March 31, 2026 and March 31, 2025 is primarily attributable to the change in discount rates for certain long-duration liabilities and unrealized changes in the market values of securities and derivatives, including the impacts from unconsolidated entities reported on the equity method. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the components of AOCI were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities and derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (depreciation) on securities and derivatives, before reclassification, net of tax benefit of $44 and $49, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(1) and $(9), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss), net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net long-duration insurance and contractholder liabilities measurement adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit of $214 and $33, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to Shareholders' net income, net of tax expense of $&#x2014; and $16, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period change in discount rate for certain long-duration liabilities, net of tax benefit of $214 and $49, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $&#x2014; and $1, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss), net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Translation of foreign currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net translation of foreign currencies, before reclassification, net of tax benefit (expense) of $2 and $(6), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Postretirement benefits liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(2) and $(2), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' other comprehensive (loss), net of tax benefit of $257 and $82, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:AccumulatedOtherComprehensiveIncomeDisclosureTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-1026">Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1027">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the components of AOCI were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities and derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (depreciation) on securities and derivatives, before reclassification, net of tax benefit of $44 and $49, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(1) and $(9), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss), net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net long-duration insurance and contractholder liabilities measurement adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit of $214 and $33, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to Shareholders' net income, net of tax expense of $&#x2014; and $16, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period change in discount rate for certain long-duration liabilities, net of tax benefit of $214 and $49, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $&#x2014; and $1, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss), net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Translation of foreign currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net translation of foreign currencies, before reclassification, net of tax benefit (expense) of $2 and $(6), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Postretirement benefits liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(2) and $(2), respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' other comprehensive (loss), net of tax benefit of $257 and $82, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-299" decimals="-6" id="f-1028" unitRef="usd">594000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-300" decimals="-6" id="f-1029" unitRef="usd">832000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-301" decimals="-6" id="f-1030" unitRef="usd">-44000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-302" decimals="-6" id="f-1031" unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-301" decimals="-6" id="f-1032" unitRef="usd">-133000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-302" decimals="-6" id="f-1033" unitRef="usd">-134000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-301" decimals="-6" id="f-1034" unitRef="usd">-1000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-302" decimals="-6" id="f-1035" unitRef="usd">-9000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-301" decimals="-6" id="f-1036" unitRef="usd">-4000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-302" decimals="-6" id="f-1037" unitRef="usd">-34000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-301" decimals="-6" id="f-1038" unitRef="usd">-129000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-302" decimals="-6" id="f-1039" unitRef="usd">-100000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-303" decimals="-6" id="f-1040" unitRef="usd">465000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-304" decimals="-6" id="f-1041" unitRef="usd">732000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-305" decimals="-6" id="f-1042" unitRef="usd">-2329000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-306" decimals="-6" id="f-1043" unitRef="usd">-2038000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-307" decimals="-6" id="f-1044" unitRef="usd">-214000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-308" decimals="-6" id="f-1045" unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-307" decimals="-6" id="f-1046" unitRef="usd">-636000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-308" decimals="-6" id="f-1047" unitRef="usd">-108000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-307" decimals="-6" id="f-1048" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-308" decimals="-6" id="f-1049" unitRef="usd">16000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-307" decimals="-6" id="f-1050" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-308" decimals="-6" id="f-1051" unitRef="usd">56000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c-307" decimals="-6" id="f-1052" unitRef="usd">-214000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c-308" decimals="-6" id="f-1053" unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-307" decimals="-6" id="f-1054" unitRef="usd">-636000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-308" decimals="-6" id="f-1055" unitRef="usd">-164000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-309" decimals="-6" id="f-1056" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-310" decimals="-6" id="f-1057" unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-309" decimals="-6" id="f-1058" unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-310" decimals="-6" id="f-1059" unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-311" decimals="-6" id="f-1060" unitRef="usd">-635000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-312" decimals="-6" id="f-1061" unitRef="usd">-168000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-313" decimals="-6" id="f-1062" unitRef="usd">-2964000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-314" decimals="-6" id="f-1063" unitRef="usd">-2206000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-315" decimals="-6" id="f-1064" unitRef="usd">-127000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-316" decimals="-6" id="f-1065" unitRef="usd">-198000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-317" decimals="-6" id="f-1066" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-318" decimals="-6" id="f-1067" unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-317" decimals="-6" id="f-1068" unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-318" decimals="-6" id="f-1069" unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-319" decimals="-6" id="f-1070" unitRef="usd">-162000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-320" decimals="-6" id="f-1071" unitRef="usd">-185000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-321" decimals="-6" id="f-1072" unitRef="usd">-944000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-322" decimals="-6" id="f-1073" unitRef="usd">-937000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-323" decimals="-6" id="f-1074" unitRef="usd">-2000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-324" decimals="-6" id="f-1075" unitRef="usd">-2000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-323" decimals="-6" id="f-1076" unitRef="usd">-7000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-324" decimals="-6" id="f-1077" unitRef="usd">-6000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-325" decimals="-6" id="f-1078" unitRef="usd">-937000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-326" decimals="-6" id="f-1079" unitRef="usd">-931000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-1080" unitRef="usd">-2806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-6" id="f-1081" unitRef="usd">-2341000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c-20" decimals="-6" id="f-1082" unitRef="usd">-257000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c-41" decimals="-6" id="f-1083" unitRef="usd">-82000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-20" decimals="-6" id="f-1084" unitRef="usd">-792000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-41" decimals="-6" id="f-1085" unitRef="usd">-249000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-1086" unitRef="usd">-3598000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-6" id="f-1087" unitRef="usd">-2590000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-1088">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="ida55c25e8fb54e10816a26583a743776_1349"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 12 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Strategic Optimization Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the first quarter of 2025, the Company commenced an enterprise-wide initiative to evolve our business and deliver a more efficient and improved experience for our patients, providers and customers. The Company expects that the program will continue through 2028 and is continuing to evaluate additional opportunities to improve the overall efficiency and effectiveness of our operations. The program includes severance and other employee costs, asset impairments and accelerated asset amortization, and the operating results of certain small non-strategic businesses that we plan to discontinue. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the three months ended March&#160;31, 2026, we reported total costs of $380 million pre-tax ($290 million after-tax) associated with this initiative, compared with $215 million ($163 million after-tax) for the three months ended March&#160;31, 2025. The total costs for the three months ended March&#160;31, 2026 included $377 million, pre-tax in Selling, general and administrative expenses, which was primarily associated with severance ($337 million). The total costs for the three months ended March&#160;31, 2025 included $198 million, pre-tax in Selling, general and administrative expenses, which was primarily associated with severance ($171 million). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Program-to-date total costs of $1,129 million pre-tax ($855 million after-tax) included $993 million in Selling, general and administrative expenses, which were primarily associated with severance ($715 million) and asset impairments ($101 million). The remainder of the total program costs reflects the operating results of certain non-strategic businesses. We expect substantially all of the accrued liability to be paid by the end of 2026. See Note 15 to the Consolidated Financial Statements for further details of the strategic optimization program by segment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.789%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;140&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026 charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;337&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026 payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March&#160;31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-327" decimals="-6" id="f-1089" unitRef="usd">380000000</us-gaap:RestructuringCharges>
    <ci:RestructuringChargesNetOfTaxExpense contextRef="c-327" decimals="-6" id="f-1090" unitRef="usd">290000000</ci:RestructuringChargesNetOfTaxExpense>
    <us-gaap:RestructuringCharges contextRef="c-328" decimals="-6" id="f-1091" unitRef="usd">215000000</us-gaap:RestructuringCharges>
    <ci:RestructuringChargesNetOfTaxExpense contextRef="c-328" decimals="-6" id="f-1092" unitRef="usd">163000000</ci:RestructuringChargesNetOfTaxExpense>
    <us-gaap:RestructuringCharges contextRef="c-329" decimals="-6" id="f-1093" unitRef="usd">377000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-330" decimals="-6" id="f-1094" unitRef="usd">337000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-331" decimals="-6" id="f-1095" unitRef="usd">198000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-332" decimals="-6" id="f-1096" unitRef="usd">171000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-333" decimals="-6" id="f-1097" unitRef="usd">1129000000</us-gaap:RestructuringCharges>
    <ci:RestructuringChargesNetOfTaxExpense contextRef="c-333" decimals="-6" id="f-1098" unitRef="usd">855000000</ci:RestructuringChargesNetOfTaxExpense>
    <us-gaap:RestructuringCharges contextRef="c-334" decimals="-6" id="f-1099" unitRef="usd">993000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-335" decimals="-6" id="f-1100" unitRef="usd">715000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-336" decimals="-6" id="f-1101" unitRef="usd">101000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-1102">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.789%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;140&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026 charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;337&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026 payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March&#160;31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-337" decimals="-6" id="f-1103" unitRef="usd">140000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-330" decimals="-6" id="f-1104" unitRef="usd">337000000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-330" decimals="-6" id="f-1105" unitRef="usd">75000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-338" decimals="-6" id="f-1106" unitRef="usd">402000000</us-gaap:RestructuringReserve>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1107">&lt;div&gt;&lt;span id="if8a7d32f2f9a48df9d2560389dd78819_12"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 13 &#x2013; Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Tax Expense. &lt;/span&gt;The 18.0% effective tax rate for the three months ended March&#160;31, 2026 was higher than the 14.5% rate for the three months ended March&#160;31, 2025 primarily due to the absence of a benefit related to the</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1108" unitRef="number">0.180</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="3" id="f-1109" unitRef="number">0.145</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1110">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="iac22c09659494a23aa923ff1c0be1036_2784"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 14 &#x2013; Contingencies and Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Financial Guarantees: Retiree and Life Insurance Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of March&#160;31, 2026, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $390 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of March&#160;31, 2026. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;B.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Certain Other Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company had indemnification obligations as of March&#160;31, 2026 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no recorded liabilities for these indemnification obligations as of March&#160;31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;C.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Guaranty Fund Assessments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the three months ended March&#160;31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline"&gt;Legal and Regulatory Matters&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies contextRef="c-1" id="f-1111">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Financial Guarantees: Retiree and Life Insurance Benefits&lt;/span&gt;The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Certain Other Guarantees&lt;/span&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company had indemnification obligations as of March&#160;31, 2026 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. &lt;/span&gt;&lt;/div&gt;The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <us-gaap:GuaranteeObligationsMaximumExposure contextRef="c-339" decimals="-6" id="f-1112" unitRef="usd">390000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:GuaranteeObligationsLiquidationProceeds contextRef="c-340" decimals="-6" id="f-1113" unitRef="usd">390000000</us-gaap:GuaranteeObligationsLiquidationProceeds>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue contextRef="c-339" decimals="INF" id="f-1114" unitRef="usd">0</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue contextRef="c-341" decimals="INF" id="f-1115" unitRef="usd">0</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1116">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="ia0e64411f920407abbeb7bfa2e95bbb4_620"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 15 &#x2013; Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chair and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to each segment and assessing its performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not report total assets by segment because this is not a metric used by the CODM to allocate resources or evaluate segment performance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;After-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;After-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Strategic optimization program&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;(primarily Selling, general and administrative expenses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Integration and transaction-related costs&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;(Selling, general and administrative expenses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Deferred tax expenses, net&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;(Income taxes, less amount attributable to noncontrolling interests)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;(Gain) on sale of businesses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;(Benefits) associated with litigation matters&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;(Selling, general and administrative expenses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total impact from special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Integration and Transaction-Related Costs. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the three months ended March&#160;31, 2026 and March&#160;31, 2025 the Company incurred transaction-related costs, as shown in the table above, associated with the HCSC transaction. These costs incurred consisted primarily of post-closing technology activities to separate the divested systems; fees for legal, advisory and other professional services; and certain employment-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Summarized segment financial information was as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;58,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;58,442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,454&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net investment results from certain equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;58,442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,517&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmacy and other service costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;55,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest (expense) and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,561&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,270&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;388&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Strategic optimization program&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Benefits) associated with litigation matters&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other segment information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;560&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment results from certain equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmacy and other service costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest (expense) and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Integration and transaction-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Strategic optimization program&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;(Gain) on sale of businesses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other segment information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue from external customers includes Pharmacy revenues, Premiums, and Fees and other revenues. The following table presents these revenues by product, premium and service type:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Products (Pharmacy revenues) (ASC 606)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Network revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31,080&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Home delivery and specialty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,788&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,426&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;54,294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Pharmacy revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;54,037&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance premiums (ASC 944)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employer insured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stop loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Individual and Family Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;873&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,113&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Cigna Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Premiums&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,812&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Services (Fees) (ASC 606) and other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fees and other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,443&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Other revenues for the three months ended March&#160;31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;were $159 million and $162 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Financial and performance guarantees. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Evernorth Health Services may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period, and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. This guarantee liability was $2.0 billion as of March&#160;31, 2026 and $1.8 billion as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-1117">Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chair and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to each segment and assessing its performance.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. &lt;/span&gt;&lt;/div&gt;The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <ci:ScheduleOfSpecialItemsTableTextBlock contextRef="c-1" id="f-1118">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;After-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;After-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Strategic optimization program&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;(primarily Selling, general and administrative expenses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Integration and transaction-related costs&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;(Selling, general and administrative expenses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Deferred tax expenses, net&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;(Income taxes, less amount attributable to noncontrolling interests)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;(Gain) on sale of businesses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;(Benefits) associated with litigation matters&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;(Selling, general and administrative expenses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total impact from special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:ScheduleOfSpecialItemsTableTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-327" decimals="-6" id="f-1119" unitRef="usd">380000000</us-gaap:RestructuringCharges>
    <ci:RestructuringChargesNetOfTaxExpense contextRef="c-327" decimals="-6" id="f-1120" unitRef="usd">290000000</ci:RestructuringChargesNetOfTaxExpense>
    <us-gaap:RestructuringCharges contextRef="c-328" decimals="-6" id="f-1121" unitRef="usd">215000000</us-gaap:RestructuringCharges>
    <ci:RestructuringChargesNetOfTaxExpense contextRef="c-328" decimals="-6" id="f-1122" unitRef="usd">163000000</ci:RestructuringChargesNetOfTaxExpense>
    <ci:TransactionRelatedCosts contextRef="c-1" decimals="-6" id="f-1123" unitRef="usd">35000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCostsAfterTax contextRef="c-1" decimals="-6" id="f-1124" unitRef="usd">27000000</ci:TransactionRelatedCostsAfterTax>
    <ci:TransactionRelatedCosts contextRef="c-5" decimals="-6" id="f-1125" unitRef="usd">216000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCostsAfterTax contextRef="c-5" decimals="-6" id="f-1126" unitRef="usd">164000000</ci:TransactionRelatedCostsAfterTax>
    <ci:SpecialItemChargeBenefitTaxMatters contextRef="c-1" decimals="-6" id="f-1127" unitRef="usd">0</ci:SpecialItemChargeBenefitTaxMatters>
    <ci:SpecialItemChargeBenefitTaxMattersAfterTax contextRef="c-1" decimals="-6" id="f-1128" unitRef="usd">16000000</ci:SpecialItemChargeBenefitTaxMattersAfterTax>
    <ci:SpecialItemChargeBenefitTaxMatters contextRef="c-5" decimals="-6" id="f-1129" unitRef="usd">0</ci:SpecialItemChargeBenefitTaxMatters>
    <ci:SpecialItemChargeBenefitTaxMattersAfterTax contextRef="c-5" decimals="-6" id="f-1130" unitRef="usd">17000000</ci:SpecialItemChargeBenefitTaxMattersAfterTax>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-1" decimals="-6" id="f-1131" unitRef="usd">0</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax contextRef="c-1" decimals="-6" id="f-1132" unitRef="usd">3000000</ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-5" decimals="-6" id="f-1133" unitRef="usd">41000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax contextRef="c-5" decimals="-6" id="f-1134" unitRef="usd">115000000</ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-1" decimals="-6" id="f-1135" unitRef="usd">-11000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitAfterTaxLitigation contextRef="c-1" decimals="-6" id="f-1136" unitRef="usd">-8000000</ci:SpecialItemChargeBenefitAfterTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-5" decimals="-6" id="f-1137" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitAfterTaxLitigation contextRef="c-5" decimals="-6" id="f-1138" unitRef="usd">0</ci:SpecialItemChargeBenefitAfterTaxLitigation>
    <ci:SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity contextRef="c-1" decimals="-6" id="f-1139" unitRef="usd">-404000000</ci:SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity>
    <ci:SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-6" id="f-1140" unitRef="usd">-322000000</ci:SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity>
    <ci:SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity contextRef="c-5" decimals="-6" id="f-1141" unitRef="usd">-390000000</ci:SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity>
    <ci:SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity contextRef="c-5" decimals="-6" id="f-1142" unitRef="usd">-229000000</ci:SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1143">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Summarized segment financial information was as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;58,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;58,442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,454&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net investment results from certain equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;58,442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,517&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmacy and other service costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;55,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest (expense) and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,561&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,270&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;388&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Strategic optimization program&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Benefits) associated with litigation matters&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other segment information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;560&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment results from certain equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmacy and other service costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest (expense) and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Integration and transaction-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Strategic optimization program&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;(Gain) on sale of businesses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other segment information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-1144">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;58,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;58,442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,454&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net investment results from certain equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;58,442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,517&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmacy and other service costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;55,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest (expense) and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,561&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,270&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;388&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Strategic optimization program&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Benefits) associated with litigation matters&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other segment information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;560&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment results from certain equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmacy and other service costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest (expense) and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Integration and transaction-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Strategic optimization program&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;(Gain) on sale of businesses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other segment information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <ci:NonInvestmentRevenue contextRef="c-342" decimals="-6" id="f-1145" unitRef="usd">58206000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-78" decimals="-6" id="f-1146" unitRef="usd">10039000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-343" decimals="-6" id="f-1147" unitRef="usd">47000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-344" decimals="-6" id="f-1148" unitRef="usd">0</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-1" decimals="-6" id="f-1149" unitRef="usd">68292000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-345" decimals="-6" id="f-1150" unitRef="usd">-211000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-346" decimals="-6" id="f-1151" unitRef="usd">-1312000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-347" decimals="-6" id="f-1152" unitRef="usd">-3000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-348" decimals="-6" id="f-1153" unitRef="usd">-1526000000</ci:NonInvestmentRevenue>
    <us-gaap:NetInvestmentIncome contextRef="c-349" decimals="-6" id="f-1154" unitRef="usd">25000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-350" decimals="-6" id="f-1155" unitRef="usd">103000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-351" decimals="-6" id="f-1156" unitRef="usd">70000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-344" decimals="-6" id="f-1157" unitRef="usd">4000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-1" decimals="-6" id="f-1158" unitRef="usd">202000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues contextRef="c-349" decimals="-6" id="f-1159" unitRef="usd">58442000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-350" decimals="-6" id="f-1160" unitRef="usd">11454000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-351" decimals="-6" id="f-1161" unitRef="usd">120000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-352" decimals="-6" id="f-1162" unitRef="usd">-1522000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-1163" unitRef="usd">68494000000</us-gaap:Revenues>
    <ci:NetInvestmentGainsLossesEquityMethodInvestments contextRef="c-349" decimals="-6" id="f-1164" unitRef="usd">0</ci:NetInvestmentGainsLossesEquityMethodInvestments>
    <ci:NetInvestmentGainsLossesEquityMethodInvestments contextRef="c-350" decimals="-6" id="f-1165" unitRef="usd">-23000000</ci:NetInvestmentGainsLossesEquityMethodInvestments>
    <ci:NetInvestmentGainsLossesEquityMethodInvestments contextRef="c-351" decimals="-6" id="f-1166" unitRef="usd">0</ci:NetInvestmentGainsLossesEquityMethodInvestments>
    <ci:NetInvestmentGainsLossesEquityMethodInvestments contextRef="c-344" decimals="-6" id="f-1167" unitRef="usd">0</ci:NetInvestmentGainsLossesEquityMethodInvestments>
    <ci:NetInvestmentGainsLossesEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-1168" unitRef="usd">-23000000</ci:NetInvestmentGainsLossesEquityMethodInvestments>
    <ci:SegmentRevenues contextRef="c-349" decimals="-6" id="f-1169" unitRef="usd">58442000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-350" decimals="-6" id="f-1170" unitRef="usd">11477000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-351" decimals="-6" id="f-1171" unitRef="usd">120000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-352" decimals="-6" id="f-1172" unitRef="usd">-1522000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-1" decimals="-6" id="f-1173" unitRef="usd">68517000000</ci:SegmentRevenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-349" decimals="-6" id="f-1174" unitRef="usd">55700000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-350" decimals="-6" id="f-1175" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet contextRef="c-349" decimals="-6" id="f-1176" unitRef="usd">0</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet contextRef="c-350" decimals="-6" id="f-1177" unitRef="usd">7664000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric contextRef="c-349" decimals="-6" id="f-1178" unitRef="usd">1049000000</ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric>
    <ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric contextRef="c-350" decimals="-6" id="f-1179" unitRef="usd">2301000000</ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-349" decimals="-6" id="f-1180" unitRef="usd">-1000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-350" decimals="-6" id="f-1181" unitRef="usd">2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax contextRef="c-349" decimals="-6" id="f-1182" unitRef="usd">226000000</ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax>
    <ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax contextRef="c-350" decimals="-6" id="f-1183" unitRef="usd">0</ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-349" decimals="-6" id="f-1184" unitRef="usd">1466000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-350" decimals="-6" id="f-1185" unitRef="usd">1514000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-351" decimals="-6" id="f-1186" unitRef="usd">27000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-344" decimals="-6" id="f-1187" unitRef="usd">-404000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-1188" unitRef="usd">2603000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-349" decimals="-6" id="f-1189" unitRef="usd">1561000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-350" decimals="-6" id="f-1190" unitRef="usd">1481000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-351" decimals="-6" id="f-1191" unitRef="usd">24000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-344" decimals="-6" id="f-1192" unitRef="usd">-796000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-1193" unitRef="usd">2270000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-349" decimals="-6" id="f-1194" unitRef="usd">226000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-350" decimals="-6" id="f-1195" unitRef="usd">0</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-351" decimals="-6" id="f-1196" unitRef="usd">0</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-344" decimals="-6" id="f-1197" unitRef="usd">0</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-1" decimals="-6" id="f-1198" unitRef="usd">226000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-349" decimals="-6" id="f-1199" unitRef="usd">261000000</ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-350" decimals="-6" id="f-1200" unitRef="usd">-29000000</ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-351" decimals="-6" id="f-1201" unitRef="usd">0</ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-344" decimals="-6" id="f-1202" unitRef="usd">3000000</ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-1" decimals="-6" id="f-1203" unitRef="usd">235000000</ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-349" decimals="-6" id="f-1204" unitRef="usd">388000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-350" decimals="-6" id="f-1205" unitRef="usd">2000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-351" decimals="-6" id="f-1206" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-344" decimals="-6" id="f-1207" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-6" id="f-1208" unitRef="usd">390000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:RestructuringCharges contextRef="c-353" decimals="-6" id="f-1209" unitRef="usd">4000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-354" decimals="-6" id="f-1210" unitRef="usd">13000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-355" decimals="-6" id="f-1211" unitRef="usd">3000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-356" decimals="-6" id="f-1212" unitRef="usd">360000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-327" decimals="-6" id="f-1213" unitRef="usd">380000000</us-gaap:RestructuringCharges>
    <ci:TransactionRelatedCosts contextRef="c-349" decimals="-6" id="f-1214" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-350" decimals="-6" id="f-1215" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-351" decimals="-6" id="f-1216" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-344" decimals="-6" id="f-1217" unitRef="usd">35000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-1" decimals="-6" id="f-1218" unitRef="usd">35000000</ci:TransactionRelatedCosts>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-349" decimals="-6" id="f-1219" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-350" decimals="-6" id="f-1220" unitRef="usd">-11000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-351" decimals="-6" id="f-1221" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-344" decimals="-6" id="f-1222" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-1" decimals="-6" id="f-1223" unitRef="usd">-11000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-349" decimals="-6" id="f-1224" unitRef="usd">1466000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-350" decimals="-6" id="f-1225" unitRef="usd">1514000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-351" decimals="-6" id="f-1226" unitRef="usd">27000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-344" decimals="-6" id="f-1227" unitRef="usd">-404000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-1228" unitRef="usd">2603000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-349" decimals="-6" id="f-1229" unitRef="usd">560000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-350" decimals="-6" id="f-1230" unitRef="usd">83000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-351" decimals="-6" id="f-1231" unitRef="usd">2000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-352" decimals="-6" id="f-1232" unitRef="usd">5000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-1233" unitRef="usd">650000000</us-gaap:DepreciationDepletionAndAmortization>
    <ci:NonInvestmentRevenue contextRef="c-357" decimals="-6" id="f-1234" unitRef="usd">52002000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-79" decimals="-6" id="f-1235" unitRef="usd">13168000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-358" decimals="-6" id="f-1236" unitRef="usd">94000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-359" decimals="-6" id="f-1237" unitRef="usd">0</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-5" decimals="-6" id="f-1238" unitRef="usd">65264000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-360" decimals="-6" id="f-1239" unitRef="usd">-1648000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-361" decimals="-6" id="f-1240" unitRef="usd">-1231000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-362" decimals="-6" id="f-1241" unitRef="usd">-12000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-363" decimals="-6" id="f-1242" unitRef="usd">-2891000000</ci:NonInvestmentRevenue>
    <us-gaap:NetInvestmentIncome contextRef="c-364" decimals="-6" id="f-1243" unitRef="usd">31000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-365" decimals="-6" id="f-1244" unitRef="usd">133000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-366" decimals="-6" id="f-1245" unitRef="usd">69000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-359" decimals="-6" id="f-1246" unitRef="usd">5000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-5" decimals="-6" id="f-1247" unitRef="usd">238000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues contextRef="c-364" decimals="-6" id="f-1248" unitRef="usd">53681000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-365" decimals="-6" id="f-1249" unitRef="usd">14532000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-366" decimals="-6" id="f-1250" unitRef="usd">175000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-367" decimals="-6" id="f-1251" unitRef="usd">-2886000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-6" id="f-1252" unitRef="usd">65502000000</us-gaap:Revenues>
    <ci:NetInvestmentGainsLossesEquityMethodInvestments contextRef="c-364" decimals="-6" id="f-1253" unitRef="usd">0</ci:NetInvestmentGainsLossesEquityMethodInvestments>
    <ci:NetInvestmentGainsLossesEquityMethodInvestments contextRef="c-365" decimals="-6" id="f-1254" unitRef="usd">50000000</ci:NetInvestmentGainsLossesEquityMethodInvestments>
    <ci:NetInvestmentGainsLossesEquityMethodInvestments contextRef="c-366" decimals="-6" id="f-1255" unitRef="usd">0</ci:NetInvestmentGainsLossesEquityMethodInvestments>
    <ci:NetInvestmentGainsLossesEquityMethodInvestments contextRef="c-359" decimals="-6" id="f-1256" unitRef="usd">0</ci:NetInvestmentGainsLossesEquityMethodInvestments>
    <ci:NetInvestmentGainsLossesEquityMethodInvestments contextRef="c-5" decimals="-6" id="f-1257" unitRef="usd">50000000</ci:NetInvestmentGainsLossesEquityMethodInvestments>
    <ci:SegmentRevenues contextRef="c-364" decimals="-6" id="f-1258" unitRef="usd">53681000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-365" decimals="-6" id="f-1259" unitRef="usd">14482000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-366" decimals="-6" id="f-1260" unitRef="usd">175000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-367" decimals="-6" id="f-1261" unitRef="usd">-2886000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-5" decimals="-6" id="f-1262" unitRef="usd">65452000000</ci:SegmentRevenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-364" decimals="-6" id="f-1263" unitRef="usd">51121000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-365" decimals="-6" id="f-1264" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet contextRef="c-364" decimals="-6" id="f-1265" unitRef="usd">0</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet contextRef="c-365" decimals="-6" id="f-1266" unitRef="usd">10385000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric contextRef="c-364" decimals="-6" id="f-1267" unitRef="usd">1024000000</ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric>
    <ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric contextRef="c-365" decimals="-6" id="f-1268" unitRef="usd">2812000000</ci:SellingGeneralAdministrativeExpensesSegmentPerformanceMetric>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-364" decimals="-6" id="f-1269" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-365" decimals="-6" id="f-1270" unitRef="usd">2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax contextRef="c-364" decimals="-6" id="f-1271" unitRef="usd">102000000</ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax>
    <ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax contextRef="c-365" decimals="-6" id="f-1272" unitRef="usd">0</ci:OtherSegmentItemsIncomeLossAttributableToNoncontrollingInterestsBeforeTax>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-364" decimals="-6" id="f-1273" unitRef="usd">1434000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-365" decimals="-6" id="f-1274" unitRef="usd">1287000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-366" decimals="-6" id="f-1275" unitRef="usd">0</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-359" decimals="-6" id="f-1276" unitRef="usd">-411000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-1277" unitRef="usd">2310000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-364" decimals="-6" id="f-1278" unitRef="usd">1108000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-365" decimals="-6" id="f-1279" unitRef="usd">1364000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-366" decimals="-6" id="f-1280" unitRef="usd">-20000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-359" decimals="-6" id="f-1281" unitRef="usd">-804000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-1282" unitRef="usd">1648000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-364" decimals="-6" id="f-1283" unitRef="usd">102000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-365" decimals="-6" id="f-1284" unitRef="usd">0</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-366" decimals="-6" id="f-1285" unitRef="usd">0</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-359" decimals="-6" id="f-1286" unitRef="usd">0</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-5" decimals="-6" id="f-1287" unitRef="usd">102000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-364" decimals="-6" id="f-1288" unitRef="usd">4000000</ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-365" decimals="-6" id="f-1289" unitRef="usd">47000000</ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-366" decimals="-6" id="f-1290" unitRef="usd">-3000000</ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-359" decimals="-6" id="f-1291" unitRef="usd">0</ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-5" decimals="-6" id="f-1292" unitRef="usd">48000000</ci:NetInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-364" decimals="-6" id="f-1293" unitRef="usd">415000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-365" decimals="-6" id="f-1294" unitRef="usd">7000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-366" decimals="-6" id="f-1295" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-359" decimals="-6" id="f-1296" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-6" id="f-1297" unitRef="usd">422000000</us-gaap:AmortizationOfIntangibleAssets>
    <ci:TransactionRelatedCosts contextRef="c-364" decimals="-6" id="f-1298" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-365" decimals="-6" id="f-1299" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-366" decimals="-6" id="f-1300" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-359" decimals="-6" id="f-1301" unitRef="usd">216000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-5" decimals="-6" id="f-1302" unitRef="usd">216000000</ci:TransactionRelatedCosts>
    <us-gaap:RestructuringCharges contextRef="c-364" decimals="-6" id="f-1303" unitRef="usd">21000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-365" decimals="-6" id="f-1304" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-366" decimals="-6" id="f-1305" unitRef="usd">17000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-359" decimals="-6" id="f-1306" unitRef="usd">177000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-5" decimals="-6" id="f-1307" unitRef="usd">215000000</us-gaap:RestructuringCharges>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-364" decimals="-6" id="f-1308" unitRef="usd">4000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-365" decimals="-6" id="f-1309" unitRef="usd">37000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-366" decimals="-6" id="f-1310" unitRef="usd">0</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-359" decimals="-6" id="f-1311" unitRef="usd">0</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-5" decimals="-6" id="f-1312" unitRef="usd">41000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-364" decimals="-6" id="f-1313" unitRef="usd">1434000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-365" decimals="-6" id="f-1314" unitRef="usd">1287000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-366" decimals="-6" id="f-1315" unitRef="usd">0</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-359" decimals="-6" id="f-1316" unitRef="usd">-411000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-1317" unitRef="usd">2310000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-364" decimals="-6" id="f-1318" unitRef="usd">584000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-365" decimals="-6" id="f-1319" unitRef="usd">83000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-366" decimals="-6" id="f-1320" unitRef="usd">2000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-367" decimals="-6" id="f-1321" unitRef="usd">5000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-6" id="f-1322" unitRef="usd">674000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-1323">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue from external customers includes Pharmacy revenues, Premiums, and Fees and other revenues. The following table presents these revenues by product, premium and service type:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Products (Pharmacy revenues) (ASC 606)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Network revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31,080&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Home delivery and specialty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,788&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,426&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;54,294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Pharmacy revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;54,037&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance premiums (ASC 944)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employer insured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stop loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Individual and Family Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;873&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,113&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Cigna Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Premiums&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,812&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Services (Fees) (ASC 606) and other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fees and other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,443&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Other revenues for the three months ended March&#160;31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;were $159 million and $162 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-368" decimals="-6" id="f-1324" unitRef="usd">31080000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-369" decimals="-6" id="f-1325" unitRef="usd">28212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-370" decimals="-6" id="f-1326" unitRef="usd">19788000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-371" decimals="-6" id="f-1327" unitRef="usd">18937000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-372" decimals="-6" id="f-1328" unitRef="usd">3426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-373" decimals="-6" id="f-1329" unitRef="usd">3077000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-374" decimals="-6" id="f-1330" unitRef="usd">54294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-375" decimals="-6" id="f-1331" unitRef="usd">50226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-376" decimals="-6" id="f-1332" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-377" decimals="-6" id="f-1333" unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-378" decimals="-6" id="f-1334" unitRef="usd">-257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-379" decimals="-6" id="f-1335" unitRef="usd">-1606000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-3" decimals="-6" id="f-1336" unitRef="usd">54037000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-6" id="f-1337" unitRef="usd">48633000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PremiumsEarnedNet contextRef="c-380" decimals="-6" id="f-1338" unitRef="usd">4996000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-381" decimals="-6" id="f-1339" unitRef="usd">4688000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-382" decimals="-6" id="f-1340" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-383" decimals="-6" id="f-1341" unitRef="usd">2363000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-384" decimals="-6" id="f-1342" unitRef="usd">2116000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-385" decimals="-6" id="f-1343" unitRef="usd">1868000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-386" decimals="-6" id="f-1344" unitRef="usd">873000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-387" decimals="-6" id="f-1345" unitRef="usd">859000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-388" decimals="-6" id="f-1346" unitRef="usd">507000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-389" decimals="-6" id="f-1347" unitRef="usd">1872000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-390" decimals="-6" id="f-1348" unitRef="usd">8492000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-391" decimals="-6" id="f-1349" unitRef="usd">11650000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-392" decimals="-6" id="f-1350" unitRef="usd">1113000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-393" decimals="-6" id="f-1351" unitRef="usd">978000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-350" decimals="-6" id="f-1352" unitRef="usd">9605000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-365" decimals="-6" id="f-1353" unitRef="usd">12628000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-351" decimals="-6" id="f-1354" unitRef="usd">53000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-366" decimals="-6" id="f-1355" unitRef="usd">81000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-352" decimals="-6" id="f-1356" unitRef="usd">154000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-367" decimals="-6" id="f-1357" unitRef="usd">27000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-1" decimals="-6" id="f-1358" unitRef="usd">9812000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-5" decimals="-6" id="f-1359" unitRef="usd">12736000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-394" decimals="-6" id="f-1360" unitRef="usd">4123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-395" decimals="-6" id="f-1361" unitRef="usd">3424000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-396" decimals="-6" id="f-1362" unitRef="usd">1746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-397" decimals="-6" id="f-1363" unitRef="usd">1771000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-398" decimals="-6" id="f-1364" unitRef="usd">-3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-399" decimals="-6" id="f-1365" unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-400" decimals="-6" id="f-1366" unitRef="usd">-1423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-401" decimals="-6" id="f-1367" unitRef="usd">-1312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-402" decimals="-6" id="f-1368" unitRef="usd">4443000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-403" decimals="-6" id="f-1369" unitRef="usd">3895000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ci:NonInvestmentRevenue contextRef="c-1" decimals="-6" id="f-1370" unitRef="usd">68292000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-5" decimals="-6" id="f-1371" unitRef="usd">65264000000</ci:NonInvestmentRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-404" decimals="-6" id="f-1372" unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-405" decimals="-6" id="f-1373" unitRef="usd">162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-1374">Evernorth Health Services may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period, and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-406" decimals="-8" id="f-1375" unitRef="usd">2000000000.0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-407" decimals="-8" id="f-1376" unitRef="usd">1800000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-1377">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-1378">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-1379">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-57" id="f-1380">On February&#160;6, 2026, David Cordani, Chair and Chief Executive Officer of The Cigna Group, adopted a 10b5-1 plan. Mr. Cordani's plan provides for (i) the sale of shares of The Cigna Group common stock issuable upon vesting of performance awards (the actual number of shares depends on actual performance achieved and may range from 0% to 200% of the 62,366 shares subject to the awards at the target level of performance), net of shares withheld to satisfy applicable tax obligations; and (ii) the exercise of up to 212,543 vested stock options and the associated sale of shares of The Cigna Group common stock acquired upon exercise to cover the exercise price, applicable tax obligations and fees and 50% of the resulting net shares acquired upon exercise (such limitation reflecting The Cigna Group stock ownership guidelines), through April&#160;30, 2027.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-57" id="f-1381">February&#160;6, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-57" id="f-1382">David Cordani</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-57" id="f-1383">Chair and Chief Executive Officer of The Cigna Group</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-57" id="f-1384">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-408"
      decimals="INF"
      id="f-1385"
      unitRef="shares">62366</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-409"
      decimals="INF"
      id="f-1386"
      unitRef="shares">212543</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-57" id="f-1387">April&#160;30, 2027</ecd:TrdArrExpirationDate>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-144"
          xlink:label="f-144"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-145"
          xlink:label="f-145"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Par value per share, $0.01; shares issued, 406&#160;million as of March&#160;31, 2026 and 405 million as of December&#160;31, 2025; authorized shares, 600 million.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-144"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-145"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-320"
          xlink:label="f-320"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-318"
          xlink:label="f-318"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-319"
          xlink:label="f-319"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-321"
          xlink:label="f-321"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Restricted cash and cash equivalents were reported in other long-term investments and Other assets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-320"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-318"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-319"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-321"
          xlink:to="fn-2"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
